<SEC-DOCUMENT>0001770787-25-000032.txt : 20250509
<SEC-HEADER>0001770787-25-000032.hdr.sgml : 20250509
<ACCEPTANCE-DATETIME>20250508173537
ACCESSION NUMBER:		0001770787-25-000032
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		62
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250509
DATE AS OF CHANGE:		20250508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			10x Genomics, Inc.
		CENTRAL INDEX KEY:			0001770787
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				455614458
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39035
		FILM NUMBER:		25927587

	BUSINESS ADDRESS:	
		STREET 1:		6230 STONERIDGE MALL ROAD
		CITY:			PLEASANTON
		STATE:			CA
		ZIP:			94588
		BUSINESS PHONE:		(925) 401-7300

	MAIL ADDRESS:	
		STREET 1:		6230 STONERIDGE MALL ROAD
		CITY:			PLEASANTON
		STATE:			CA
		ZIP:			94588

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	10X Genomics, Inc.
		DATE OF NAME CHANGE:	20190315
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>txg-20250331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:3ecddcae-0640-4c17-b64e-2ecf664c9fd0,g:adbdc3ab-11fd-421c-ac99-3782b4f382a6,d:ded02fd2e98d499fb2d5119ce560145c-->
<html xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:txg="http://www.10xgenomics.com/20250331" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2024" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>txg-20250331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-26">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-27">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-28">Q1</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-29">12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-30">0001770787</ix:nonNumeric><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-252">one</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="txg-20250331.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>txg:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:ProductAndServiceRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:ProductAndServiceRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:LicensingAndRoyaltyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:LicensingAndRoyaltyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">txg:CostOfRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:ProductsAndServicesExcludingGrantRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:ChromiumInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:ChromiumInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:SpatialInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:SpatialInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:InstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:InstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:ChromiumConsumablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:ChromiumConsumablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:SpatialConsumablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:SpatialConsumablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:ConsumablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:ConsumablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">txg:AmericasExcludingUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">txg:AmericasExcludingUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">txg:AsiaPacificExcludingChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">txg:AsiaPacificExcludingChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">txg:VizgenInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">txg:VizgenInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:LicensingAndRoyaltyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-17</xbrli:startDate><xbrli:endDate>2023-11-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txg:TwoThousandsNineteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txg:CompoundAnnualGrowthRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txg:CompoundAnnualGrowthRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txg:CompoundAnnualGrowthRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txg:TotalShareholderReturnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txg:TotalShareholderReturnMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txg:TotalShareholderReturnMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txg:CompoundAnnualGrowthRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txg:MarketBasedPerformanceAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txg:TotalShareholderReturnMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txg:MarketBasedPerformanceAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txg:MarketBasedPerformanceAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txg:TwoThousandsNineteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txg:TwoThousandsNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txg:TwoThousandsNineteenPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txg:TwoThousandsNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txg:TwoThousandsNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txg:TwoThousandsNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">txg:SharesUnderEsppPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">txg:SharesUnderEsppPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-06</xbrli:startDate><xbrli:endDate>2025-05-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-06</xbrli:startDate><xbrli:endDate>2025-05-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-06</xbrli:startDate><xbrli:endDate>2025-05-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">txg:SergeSaxonovMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:TradingArrAxis">txg:SergeSaxonovCommonStockPlusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">txg:SergeSaxonovMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001770787</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:TradingArrAxis">txg:SergeSaxonovCarryoverSharesFromPrior10b51PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:IndividualAxis">txg:SergeSaxonovMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ided02fd2e98d499fb2d5119ce560145c_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">_____________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">_____________________</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">March&#160;31, 2025</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from ___________ to ___________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number:&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-39035</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><img src="txg-20250331_g1.jpg" alt="Logo-10x.jpg" style="height:54px;margin-bottom:5pt;vertical-align:text-bottom;width:80px" id="i-1"/></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">10x Genomics, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">45-5614458</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State&#160;or&#160;other&#160;jurisdiction&#160;of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification&#160;No.)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">6230 Stoneridge Mall Road</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Pleasanton</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-11">California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">94588</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principle executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">925</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">401-7300</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">_____________________</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"/><td style="width:31.753%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.753%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.754%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title&#160;of&#160;each&#160;class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading<br/>Symbol</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name&#160;of&#160;each&#160;exchange<br/>on&#160;which&#160;registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Class&#160;A common stock, par value $0.00001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">TXG</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T&#160;(&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2&#160;of the&#160;Exchange Act.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"/><td style="width:22.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.854%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-22">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2&#160;of the&#160;Exchange Act).&#160;Yes&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-23">&#9744;</ix:nonNumeric>&#160;     &#160;No&#160;&#160;&#9746;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&#160;30, 2025, the registrant had <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">111,092,774</ix:nonFraction> shares of Class A common stock, $0.00001 par value per share, outstanding and <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-25">12,040,976</ix:nonFraction> shares of Class B common stock, $0.00001 par value per share, outstanding.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ided02fd2e98d499fb2d5119ce560145c_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:75.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Page</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#ided02fd2e98d499fb2d5119ce560145c_13">PART&#160;I.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_13">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ided02fd2e98d499fb2d5119ce560145c_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_16">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ided02fd2e98d499fb2d5119ce560145c_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_19">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ided02fd2e98d499fb2d5119ce560145c_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_22">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ided02fd2e98d499fb2d5119ce560145c_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_25">Condensed Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ided02fd2e98d499fb2d5119ce560145c_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_28">Condensed Consolidated Statements of Stockholders&#8217;&#160;Equity </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ided02fd2e98d499fb2d5119ce560145c_28">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_31">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ided02fd2e98d499fb2d5119ce560145c_31">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_34">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ided02fd2e98d499fb2d5119ce560145c_34">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ided02fd2e98d499fb2d5119ce560145c_58">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_58">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ided02fd2e98d499fb2d5119ce560145c_58">19</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ided02fd2e98d499fb2d5119ce560145c_73">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_73">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ided02fd2e98d499fb2d5119ce560145c_73">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ided02fd2e98d499fb2d5119ce560145c_76">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_76">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ided02fd2e98d499fb2d5119ce560145c_76">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#ided02fd2e98d499fb2d5119ce560145c_79">PART&#160;II.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_79">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ided02fd2e98d499fb2d5119ce560145c_79">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ided02fd2e98d499fb2d5119ce560145c_82">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_82">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ided02fd2e98d499fb2d5119ce560145c_82">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;1A.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risk Factors</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ided02fd2e98d499fb2d5119ce560145c_842">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ided02fd2e98d499fb2d5119ce560145c_88">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_88">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ided02fd2e98d499fb2d5119ce560145c_88">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ided02fd2e98d499fb2d5119ce560145c_94">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_94">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ided02fd2e98d499fb2d5119ce560145c_94">71</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_97">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ided02fd2e98d499fb2d5119ce560145c_97">72</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ided02fd2e98d499fb2d5119ce560145c_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10x Genomics, Inc.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q (this &#8220;Quarterly Report&#8221;) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), which are subject to those sections&#8217; &#8220;safe harbor.&#8221; All statements, other than historical facts, may be forward-looking statements. Forward-looking terminology such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;see,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;would,&#8221; &#8220;likely,&#8221; &#8220;seek&#8221; or &#8220;continue&#8221; or variations of these terms or similar terminology generally can identify forward-looking statements, but the absence of these words is not determinative. These forward-looking statements include statements regarding 10x Genomics, Inc.&#8217;s expectations regarding our plans, objectives, goals, beliefs, business strategies, results of operations, financial position, sufficiency of our capital resources, business outlook, future events, business conditions, factors affecting our performance, revenues, gross margin, expenses, organization, business and other trends, expected future investments including anticipated capital expenditures, anticipated size of market opportunities and our ability to capture them, expected uses, performance and benefits of our products and services, business trends and other information. These statements are based on management&#8217;s expectations, forecasts, beliefs, opinions, assumptions and information available at the time of filing and should not be relied upon as 10x Genomics, Inc.&#8217;s views as of any subsequent date. Actual outcomes and results could differ materially from these statements due to several factors. 10x Genomics, Inc. disclaims any obligation to update any published forward-looking statements except as required by law.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The material risks, uncertainties and other factors that could affect 10x Genomics, Inc.&#8217;s financial and operating results and cause actual results to differ from those indicated by the forward-looking statements made include those described in the sections titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in this Quarterly Report and Part I, Item 1A of our Annual Report on Form 10-K for the year ended December&#160;31, 2024. Our periodic filings are accessible on the U.S. Securities and Exchange Commission's (&#8220;SEC&#8221;) website at www.sec.gov. Although we believe the expectations reflected in the forward-looking statements are reasonable, new risks and uncertainties may emerge, and it is not possible for us to predict their impact on the forward-looking statements contained in this Quarterly Report. Moreover, the information the forward-looking statements are based upon may be limited or incomplete, and may not be based upon all potentially relevant information. We cannot guarantee future events, circumstances, results, performance or achievements. In light of the foregoing, investors are urged not to place undue reliance on any forward-looking statement or third-party data in reaching any conclusion or making any investment decision about any securities of the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise stated or the context otherwise indicates, references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company,&#8221; &#8220;10x&#8221; and similar references refer to 10x Genomics, Inc. and its subsidiaries.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Channels for Disclosure of Information</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors and others should note that we may announce material information to the public through filings with the SEC, our website (https://www.10xGenomics.com), press releases, public conference calls, public webcasts and our social media accounts (https://X.com/10xGenomics, https://www.facebook.com/10xGenomics, https://www.linkedin.com/company/10xgenomics, https://www.youtube.com/@10xGenomics_, https://www.facebook.com/10xGenomics and https://bsky.app/profile/10xgenomics.bsky.social). We use these channels to communicate with our customers and the public about the Company, our products, our services, our financial results, business developments and other matters. We encourage our investors, the media and others to review the information disclosed through such channels as such information could be deemed to be material information. The information on such channels, including on our website and our social media accounts, is not incorporated by reference in this Quarterly Report and shall not be deemed to be incorporated by reference into any other filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing. Please note that this list of disclosure channels may be updated from time to time.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ided02fd2e98d499fb2d5119ce560145c_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10x Genomics, Inc.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="ided02fd2e98d499fb2d5119ce560145c_16"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Financial Statements.</span></div><div id="ided02fd2e98d499fb2d5119ce560145c_19"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10x Genomics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (In thousands)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Note 1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">377,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-32">344,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-33">49,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-34">49,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">52,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">87,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-37">74,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-38">83,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-39">25,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-40">20,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-41">579,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-42">584,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-43">246,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-44">252,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-45">55,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-46">57,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-47">4,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-48">4,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-49">15,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-50">15,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-51">2,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">4,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-53">903,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-54">918,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">10,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">12,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and related benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">21,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">33,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="txg:AccruedExpensesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">45,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="txg:AccruedExpensesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">41,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">20,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">20,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">9,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">9,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">107,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">117,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, noncurrent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">70,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">73,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, noncurrent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">12,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">12,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">5,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-72">5,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-73">196,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-74">208,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 4)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="text-align:right"><span><br/></span></div><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-75"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-76"></ix:nonFraction>Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-79">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-80">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-81">2,208,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-82">2,177,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-83">1,501,405</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-84">1,467,047</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-85">367</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-86">493</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-87">706,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-88">710,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-89">903,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-90">918,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ided02fd2e98d499fb2d5119ce560145c_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10x Genomics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except share and per share data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products and services revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-91">137,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-92">141,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and royalty revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-93">17,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-94">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-95">154,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-96">141,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products and services revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-97">49,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-98">48,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-99">105,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-100">92,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-101">64,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-102">68,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-103">89,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-104">85,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LitigationSettlementGain" format="ixt:num-dot-decimal" scale="3" id="f-105">9,200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:LitigationSettlementGain" format="ixt:fixed-zero" scale="3" id="f-106">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-107">144,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-108">154,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-109">39,328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-110">61,498</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-111">3,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-112">4,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:fixed-zero" scale="3" id="f-113">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:InterestExpenseNonoperating" scale="3" id="f-114">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-115">2,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-116">1,040</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-117">5,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-118">3,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-119">33,506</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-120">57,803</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-121">852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-122">2,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-123">34,358</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-124">59,949</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-125"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-126">0.28</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-127"><ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-128">0.50</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute net loss per share, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-129"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-130">122,606,091</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-131"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-132">119,394,180</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ided02fd2e98d499fb2d5119ce560145c_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10x Genomics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:72.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.508%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.511%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-133">34,358</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-134">59,949</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses) on available-for-sale marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-135">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-136">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-137">146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-138">163</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-139">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-140">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-141">34,232</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-142">59,976</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ided02fd2e98d499fb2d5119ce560145c_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10x Genomics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.652%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.250%"/><td style="width:0.1%"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional&#160;Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other Comprehensive<br/>Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-143">122,291,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-144">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-145">2,177,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-146">1,467,047</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-147">493</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-148">710,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of Class&#160;A common stock related to equity awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-149">841,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-150">422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-151">422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-152">30,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-153">30,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-154">34,358</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-155">34,358</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-156">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-157">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-158">123,133,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-159">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-160">2,208,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-161">1,501,405</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-162">367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-163">706,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.652%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.250%"/><td style="width:0.1%"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional&#160;Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-164">119,095,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-165">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-166">2,025,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-167">1,284,420</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-168">429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-169">741,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of Class&#160;A common stock related to equity awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-170">605,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-171">1,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-172">1,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-173">36,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-174">36,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-175">59,949</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-176">59,949</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-177">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-178">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-179">119,700,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-180">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-181">2,063,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-182">1,344,369</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-183">456</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-184">718,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ided02fd2e98d499fb2d5119ce560145c_31"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10x Genomics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-185">34,358</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-186">59,949</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-187">31,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-188">36,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-189">8,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-190">9,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="f-191">1,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="f-192">2,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease and asset impairment charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseImpairmentLoss" scale="3" id="f-193">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-194">2,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="f-195">575</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="f-196">444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-197">35,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-198">23,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-199">8,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-200">9,937</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-201">5,530</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-202">2,029</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="f-203">2,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-204">216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-205">2,547</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-206">4,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and other related benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-207">11,745</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-208">9,380</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="f-209">347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="f-210">2,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="txg:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-211">4,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="txg:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-212">12,674</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-213">2,631</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-214">2,961</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="f-215">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="f-216">249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-217">34,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-218">15,725</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-219">1,893</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-220">2,910</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities" format="ixt:fixed-zero" scale="3" id="f-221">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities" scale="3" id="f-222">568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:fixed-zero" scale="3" id="f-223">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-224">12,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-225">1,893</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-226">10,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock from exercise of stock options and employee stock purchase plan purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="f-227">422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-228">1,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-229">422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-230">1,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates changes on cash, cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-231">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-232">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-233">32,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-234">3,503</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-235">344,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-236">359,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-237">377,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-238">355,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosures of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for taxes</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-239">462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-240">961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-241">398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-242">1,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ided02fd2e98d499fb2d5119ce560145c_34"></div><hr style="page-break-after:always"/><div style="min-height:65.25pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10x Genomics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:120%">o</span></div><div id="ided02fd2e98d499fb2d5119ce560145c_37"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="f-243" continuedAt="f-243-1" escape="true">Description of Business and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="f-243-1"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization and Description of Business</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10x Genomics, Inc. (the &#8220;Company&#8221;) is a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biological systems at resolution and scale that matches the complexity of biology. The Company&#8217;s integrated solutions include the Company&#8217;s Chromium instruments and the Company's Visium CytAssist and Xenium Analyzer, which the Company refers to as &#8220;Spatial instruments,&#8221; and the Company&#8217;s proprietary microfluidic chips, slides, reagents and other consumables for the Company&#8217;s Chromium, Visium and Xenium solutions, which the Company refers to as &#8220;consumables.&#8221; The Company bundles its software with these products to guide customers through the workflow, from sample preparation through analysis and visualization. The Company was incorporated in the state of Delaware in July 2012 and began commercial and manufacturing operations and selling its instruments and consumables in 2015. The Company is headquartered in Pleasanton, California and has wholly-owned subsidiaries in Asia, Europe, Oceania and North America.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-244" escape="true"><div style="margin-top:18pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements, which include the Company&#8217;s accounts and the accounts of its wholly-owned subsidiaries, are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The condensed consolidated balance sheet at December&#160;31, 2024 has been derived from the audited consolidated financial statements of the Company at that date. Certain information and footnote disclosures typically included in the Company&#8217;s audited consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the Company&#8217;s financial position, results of operations, comprehensive loss and cash flows for the periods presented, but are not necessarily indicative of the results of operations to be anticipated for any future annual or interim period. All intercompany transactions and balances have been eliminated. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and related notes for the year ended December&#160;31, 2024 included in the Company's Annual Report on Form 10-K filed with the SEC on February&#160;12, 2025 (our &#8220;Annual Report&#8221;).</span></div></ix:continuation><div id="ided02fd2e98d499fb2d5119ce560145c_40"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-245" continuedAt="f-245-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-245-1" continuedAt="f-245-2"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as noted below, there were no material changes in the Company&#8217;s significant accounting policies during the three months ended March&#160;31, 2025. See Note 2 &#8211; Summary of Significant Accounting Policies to the consolidated financial statements included in the Company&#8217;s Annual Report for information regarding the Company&#8217;s significant accounting policies.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-246" continuedAt="f-246-1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Revenue Recognition</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Products and Services Revenue</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates revenue from sales of products, which consist of instruments and consumables, and services. Revenue from product sales is recognized when control of the product is transferred, which is generally upon shipment to the customer. Instrument service agreements, which relate to extended warranties, are typically entered into for a <ix:nonNumeric contextRef="c-4" name="us-gaap:ProductWarrantyObligationTerm" format="ixt-sec:durwordsen" id="f-247">one-year</ix:nonNumeric> term, following the expiration of the standard <ix:nonNumeric contextRef="c-4" name="us-gaap:ProductWarrantyObligationTerm" format="ixt-sec:durwordsen" id="f-248">one-year</ix:nonNumeric> warranty period. Revenue for extended warranties is recognized ratably over the term of the extended warranty period as a stand ready performance obligation. Revenue is recorded net of discounts, distributor commissions and sales taxes collected on behalf of governmental authorities. Customers are invoiced generally upon shipment, or upon order for services, and payment is typically due within <ix:nonNumeric contextRef="c-1" name="txg:RevenueFromContractWithCustomerPaymentPeriod" format="ixt-sec:durday" id="f-249">30</ix:nonNumeric> days. Cash received from customers in advance of product shipment or the provision of services is recorded as a contract liability. The Company&#8217;s contracts with its customers generally do not include rights of return or a significant financing component.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly enters into contracts that include various combinations of products and services which are generally distinct and accounted for as separate performance obligations. The transaction price is allocated to each performance obligation in proportion to its standalone selling price. The Company determines standalone selling price using average selling prices with consideration of current market conditions. If the product or service has no history of sales or if the sales volume is not sufficient, the Company relies upon prices set by management, adjusted for applicable discounts.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:65.25pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10x Genomics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div></div><ix:continuation id="f-245-2"><ix:continuation id="f-246-1"><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License and Royalty Revenue</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with third parties that include up-front fees and royalties. Revenue related to the delivery of intellectual property is recognized when the license is delivered to the third parties. Royalty revenue is recognized when the underlying sales occur. If the timing of the reporting of the actual sales from our licensees is after our reporting date, we estimate the royalty revenue receivable at period end and adjust for any changes in estimates in the following period.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-250" escape="true"><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as a single operating segment. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating financial performance. The measures of profitability and significant segment expenses reviewed by the CODM are consistent with the presentation and disclosure in these consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts related to the royalty revenue in the condensed consolidated statements of operations for the three months ended March 31, 2024 have been reclassified to conform to the current presentation.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-251" escape="true"><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Recently Issued Accounting Pronouncement and Disclosure Rules</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standard Update (&#8220;ASU&#8221;) No. 2023-09, Income Taxes (&#8220;ASU No. 2023-09&#8221;), which prescribes standardized categories and disaggregation of information in the reconciliation of provision for income taxes, requires disclosure of disaggregated income taxes paid, and modifies other income tax-related disclosure requirements. The updated standard is effective beginning with the Company&#8217;s fiscal year 2025 annual reporting period. The Company will adopt ASU No. 2023-09 in its fourth quarter of 2025 using a prospective transition method.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses ("ASU 2024-03"), and in January 2025 issued ASU 2025-01, Clarifying the Effective Date ("ASU 2025-01") to provide clarification as to the effective date. ASU 2024-03 requires disaggregated disclosure of income statement expenses. ASU 2024-03 does not change the expense captions currently presented on the income statement; rather it requires disaggregation of certain expense captions into specified categories in disclosures within the footnotes to the financial statements. ASU 2024-03, as amended by ASU 2025-01, is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within fiscal years beginning after December 15, 2027. ASU 2024-03 can be applied on a prospective basis; however, retrospective application is permitted. Early adoption is permitted. As ASU 2024-03 only requires additional disclosure, it will not have a material impact on the Company's financial condition and results of operations.</span></div></ix:nonNumeric></ix:continuation><div id="ided02fd2e98d499fb2d5119ce560145c_43"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="f-253" continuedAt="f-253-1" escape="true">Other Financial Statement Information</ix:nonNumeric></span></div><ix:continuation id="f-253-1" continuedAt="f-253-2"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available-for-sale Securities</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesTextBlock" id="f-254" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consisted of the following (in thousands):<br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.871%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.945%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.089%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.089%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.945%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.089%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.089%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.802%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.113%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:MoneyMarketFundsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-255">352,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:MoneyMarketFundsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-256">352,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:MoneyMarketFundsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-257">322,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:MoneyMarketFundsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-258">322,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="f-259">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-260">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-261">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-262">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="f-263">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-264">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-265">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-266">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-267">49,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-268">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-269">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-270">49,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-271">49,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-272">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-273">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-274">49,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="f-275">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-276">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-277">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-278">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="f-279">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-280">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-281">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-282">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="txg:DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds" format="ixt:num-dot-decimal" scale="3" id="f-283">402,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-284">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-285">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="txg:DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds" format="ixt:num-dot-decimal" scale="3" id="f-286">402,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="txg:DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds" format="ixt:num-dot-decimal" scale="3" id="f-287">371,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-288">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-289">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="txg:DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds" format="ixt:num-dot-decimal" scale="3" id="f-290">371,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:65.25pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10x Genomics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div></div><ix:continuation id="f-253-2" continuedAt="f-253-3"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of marketable securities as of March 31, 2025 were all less than one year.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="f-291"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="f-292">no</ix:nonFraction></ix:nonFraction> material gross realized gains or losses from available-for-sales debt securities during the three months ended March&#160;31, 2025 or March&#160;31, 2024. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The available-for-sale debt securities are subject to a periodic impairment review. For investments in an unrealized loss position, the Company determines whether a credit loss exists by considering information about the collectability of the instrument, current market conditions and reasonable and supportable forecasts of economic conditions. The Company recognizes an allowance for credit losses, up to the amount of the unrealized loss when appropriate, and writes down the amortized cost basis of the investment if it is more likely than not that the Company will be required or will intend to sell the investment before recovery of its amortized cost basis. Allowances for credit losses and write-downs are recognized in &#8220;Other expense, net,&#8221; and unrealized losses not related to credit losses are recognized in &#8220;Accumulated other comprehensive loss.&#8221; There are no allowances for credit losses for the periods presented.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-293" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory was comprised of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-294">36,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-295">38,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-296">23,238</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-297">27,441</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-298">15,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-299">16,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-300">74,710</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-301">83,107</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-302" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.325%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-303">36,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-304">36,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-305">147,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-306">147,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment and machinery </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-307">73,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-308">72,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-309">15,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-310">14,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-311">9,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-312">9,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-313">90,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-314">89,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-315">4,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-316">5,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-317">377,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-318">375,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-319">131,113</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-320">122,967</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-321">246,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-322">252,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2025, the Company recorded impairment charges of $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="6" id="f-323">0.1</ix:nonFraction>&#160;million related to equipment. The impairment charge was triggered by a decision to discontinue an engineering project. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024, the Company recorded impairment charges of $<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="6" id="f-324">2.1</ix:nonFraction>&#160;million related to computer equipment and software of which $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="6" id="f-325">0.3</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="6" id="f-326">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="6" id="f-327">1.1</ix:nonFraction>&#160;million was classified in cost of revenue, research and development, and selling, general and administrative expenses, respectively, in the condensed consolidated statement of operations. The impairment charge was triggered by a decision to discontinue a productivity engineering project.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:65.25pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10x Genomics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div></div><ix:continuation id="f-253-3" continuedAt="f-253-4"><div style="margin-top:18pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation and Related Benefits</span></div><ix:nonNumeric contextRef="c-1" name="txg:ScheduleOfAccruedCompensationandRelatedBenefitsTableTextBlock" id="f-328" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation and related benefits were comprised of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:73.288%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="txg:AccruedPayrollAndRelatedCosts" format="ixt:num-dot-decimal" scale="3" id="f-329">6,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="txg:AccruedPayrollAndRelatedCosts" format="ixt:num-dot-decimal" scale="3" id="f-330">2,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonus</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedBonusesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-331">7,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedBonusesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-332">21,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="txg:AccruedCommissionsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-333">3,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="txg:AccruedCommissionsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-334">5,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherEmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-335">4,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherEmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-336">2,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and related benefits</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-337">21,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-338">33,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><ix:nonNumeric contextRef="c-1" name="txg:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" id="f-339" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities were comprised of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="txg:AccruedLegalAndRelatedExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-340">10,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="txg:AccruedLegalAndRelatedExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-341">6,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties for licensed technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-342">4,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-343">7,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-344">4,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-345">5,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product warranties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" format="ixt:num-dot-decimal" scale="3" id="f-346">9,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" format="ixt:num-dot-decimal" scale="3" id="f-347">8,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-348">4,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-349">4,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-350">12,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-351">9,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="txg:AccruedExpensesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-352">45,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="txg:AccruedExpensesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-353">41,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Warranties</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock" id="f-354" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the reserve for product warranties were as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="3" id="f-355">8,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:ProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="3" id="f-356">8,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts charged to cost of revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProductWarrantyAccrualWarrantiesIssued" format="ixt:num-dot-decimal" scale="3" id="f-357">3,965</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ProductWarrantyAccrualWarrantiesIssued" format="ixt:num-dot-decimal" scale="3" id="f-358">2,355</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repairs and replacements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProductWarrantyAccrualPayments" format="ixt:num-dot-decimal" scale="3" id="f-359">3,127</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ProductWarrantyAccrualPayments" scale="3" id="f-360">764</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of period</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="3" id="f-361">9,453</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:ProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="3" id="f-362">9,707</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue and Deferred Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;March&#160;31, 2025, the aggregate amount of remaining performance obligations related to separately sold extended warranty service agreements or allocated amounts for extended warranty service agreements bundled with sales of instruments was&#160;$<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="f-363">33.5</ix:nonFraction> million, of which approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="f-364">20.9</ix:nonFraction> million&#160;is expected to be recognized to revenue in the next <ix:nonNumeric contextRef="c-69" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="f-365">12</ix:nonNumeric> months, with the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:65.25pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10x Genomics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div></div><ix:continuation id="f-253-4" continuedAt="f-253-5"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">remainder thereafter. The contract liabilities of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-366">33.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-367">24.1</ix:nonFraction> million as of March&#160;31, 2025 and 2024, respectively, consisted of deferred revenue related to extended warranty service agreements.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="f-368" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following revenue recognized for the periods indicated were included in deferred revenue as of December 31, 2024 and 2023, respectively (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.246%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue recognized</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-369">5,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-370">3,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="f-371" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents revenue by source for the periods indicated (in thousands). Spatial products include the Company&#8217;s Visium and Xenium products:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.325%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chromium</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-372">5,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-373">7,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spatial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-374">8,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-375">17,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total instruments revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-376">14,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-377">25,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consumables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chromium</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-378">84,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-379">83,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spatial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-380">31,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-381">26,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consumables revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-382">115,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-383">110,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-384">7,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-385">5,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Products and services revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-386">137,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-387">141,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">License and royalty revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-388">17,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-389">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-390">154,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-391">141,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="f-392" continuedAt="f-392-1" escape="true"><div style="margin-top:18pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.325%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Americas</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-393">86,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-394">75,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Americas (excluding United States)</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-395">3,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-396">3,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Americas</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-397">90,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-398">79,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-399">31,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-400">34,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asia-Pacific</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-401">16,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-402">13,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific (excluding China)</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-403">15,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-404">12,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Asia-Pacific</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-405">32,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-406">26,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenue</span></td><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-407">154,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-408">141,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="f-392-1">(1) Includes license and royalty revenue.</ix:continuation>   </span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:65.25pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10x Genomics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div></div><ix:continuation id="f-253-5"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">License and Royalty Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025, the Company settled its worldwide patent litigation with Vizgen, Inc. As part of that settlement, Vizgen has limited rights to certain intellectual property owned or exclusively licensed by the Company. As one part of the settlement, the Company received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="txg:ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted" format="ixt:num-dot-decimal" scale="6" id="f-409">26.0</ix:nonFraction>&#160;million and will receive royalties on Vizgen&#8217;s sales of products covered by the license. The $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="txg:ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted" format="ixt:num-dot-decimal" scale="6" id="f-410">26.0</ix:nonFraction>&#160;million upfront payment was recorded as a $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:LitigationSettlementGain" format="ixt:num-dot-decimal" scale="6" id="f-411">9.2</ix:nonFraction>&#160;million gain on settlement and $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-412">16.8</ix:nonFraction>&#160;million of license and royalty revenue. The amount attributed to the gain on settlement was determined by applying a royalty rate to the Vizgen historical revenues prior to the settlement.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains or losses from foreign currency remeasurement are included in &#8220;Other income (expense), net&#8221; in the consolidated statements of operations. The Company recognized foreign currency transaction losses of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossRealizedAfterTax" scale="6" id="f-413">1.5</ix:nonFraction> million for the three months ended March&#160;31, 2025, and foreign currency transaction income of $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:ForeignCurrencyTransactionGainLossRealizedAfterTax" scale="6" id="f-414">1.0</ix:nonFraction> million for the three months ended March&#160;31, 2024, respectively.</span></div></ix:continuation><div id="ided02fd2e98d499fb2d5119ce560145c_46"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-415" continuedAt="f-415-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-415-1" continuedAt="f-415-2"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office, laboratory, manufacturing, distribution and server space in various locations worldwide. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-416" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payments due under the Company&#8217;s operating lease liabilities as of March&#160;31, 2025 are as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating&#160;Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 (excluding the three months ended March 31, 2025)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="f-417">10,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-418">15,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-419">15,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-420">15,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-421">14,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="txg:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="f-422">26,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-423">97,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-424">17,407</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-425">80,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-426">9,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, noncurrent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-427">70,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-428">80,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="txg:DisclosureOfAdditionalInformationRelatedToOperatingLeasesTableTextBlock" id="f-429" escape="true"><div style="margin-top:18pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes additional information related to operating leases as of March&#160;31, 2025:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.325%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-430">6.6</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-431">6.8</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-432">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-433">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:18pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation<br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is regularly subject to lawsuits, claims, arbitration proceedings, administrative actions and other legal and regulatory proceedings involving intellectual property disputes, commercial disputes, competition and other matters, and the Company may become subject to additional types of lawsuits, claims, arbitration proceedings, administrative actions, government investigations and legal and regulatory proceedings in the future. As of March&#160;31, 2025, the Company has concluded that a loss is not probable and a contingent liability has not been recorded.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:65.25pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10x Genomics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div></div><ix:continuation id="f-415-2" continuedAt="f-415-3"><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bruker (NanoString)</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 6, 2021, the Company filed suit against NanoString Technologies, Inc. (&#8220;NanoString&#8221;) in the U.S. District Court for the District of Delaware alleging that NanoString&#8217;s GeoMx Digital Spatial Profiler and associated instruments and reagents infringe U.S. Patent Nos. 10,472,669, 10,662,467, 10,961,566, 10,983,113 and 10,996,219 (the &#8220;GeoMx Action&#8221;). On May 19, 2021, the Company filed an amended complaint additionally alleging that the GeoMx products infringe U.S. Patent Nos. 11,001,878 and 11,008,607. On May 4, 2022, the Company filed an amended complaint in the GeoMx Action additionally alleging that the GeoMx products infringe U.S. Patent No. 11,293,917 and withdrawing the Company&#8217;s claims of infringement of U.S. Patent No. 10,662,467. The Company is seeking, among other relief, injunctive relief and unspecified damages (including attorneys&#8217; fees) in relation to NanoString&#8217;s making, using, selling, offering to sell, exporting and/or importing in the United States the GeoMx Digital Spatial Profiler and associated instruments and reagents. NanoString filed its answer to the GeoMx Action on May 18, 2022. A Markman hearing was held on February 17, 2023 and the Court issued its claim construction order on February 28, 2023. On September 7, 2023, the Court issued an order granting the Company&#8217;s motion for summary judgment that the asserted patents are not invalid for indefiniteness and denying NanoString&#8217;s motion for summary judgment that the asserted patents are invalid for indefiniteness and lack of written description. On November 17, 2023, a jury found that NanoString willfully infringed the asserted patents and that the asserted patents are valid. The jury awarded the Company more than $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-6" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="f-434">31</ix:nonFraction>&#160;million in damages, consisting of approximately $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-6" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="f-435">25</ix:nonFraction>&#160;million in lost profits and approximately $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-6" name="us-gaap:PaymentsForRoyalties" format="ixt:num-dot-decimal" scale="6" id="f-436">6</ix:nonFraction>&#160;million in royalties. Post-trial motions, including the Company&#8217;s motions for a permanent injunction, ongoing royalties, enhanced damages, attorneys&#8217; fees and pre- and post-judgment interest, are pending. NanoString filed for bankruptcy protection under Chapter 11 of the United States Bankruptcy Code in the U.S. bankruptcy court in Delaware on February 4, 2024, and the Court&#8217;s consideration of these post-trial motions was stayed due to the bankruptcy filing. In May 2024, Bruker Corporation (&#8220;Bruker&#8221;) acquired certain assets and assumed certain liabilities of NanoString, including the litigation between the Company and NanoString, and the NanoString product lines at issue. On December 23, 2024, the Court denied NanoString&#8217;s motion for judgement as a matter of law on invalidity, non-infringement and damages, and denied its request for a new trial. The Court granted the Company&#8217;s motion for permanent injunction, supplemental damages, and pre-judgment and post-judgment interest. On January 31, 2025, Bruker moved to stay the permanent injunction pending appeal. The Court has not ruled on the motion to stay. Due to the uncertainties in collecting the jury award, the Company has not recorded a receivable from NanoString as of March 31, 2025.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2022, the Company filed a second suit against NanoString in the U.S. District Court for the District of Delaware alleging that NanoString&#8217;s CosMx Spatial Molecular Imager and associated instruments, reagents and services infringe U.S. Patent Nos. 10,227,639 and 11,021,737 (the &#8220;CosMx Action&#8221;). On May 12, 2022, the Company filed an amended complaint in the CosMx Action additionally alleging that the CosMx products additionally infringe U.S. Patent Nos. 11,293,051, 11,293,052 and 11,293,054. NanoString filed its answer to the CosMx Action on May 26, 2022. On March 1, 2023, the Company filed a second amended complaint additionally alleging that the CosMx products infringe U.S. Patent No. 11,542,554. The Company is seeking, among other relief, injunctive relief and unspecified damages (including attorneys&#8217; fees) in relation to NanoString&#8217;s making, using, selling, offering to sell, exporting and/or importing in the United States the CosMx Spatial Molecular Imager and associated instruments, reagents and services. NanoString filed its answer to the second amended complaint on March 22, 2023. Discovery is in progress. A Markman hearing was held on January 10, 2024, and the Court issued its claim construction order on February 1, 2024.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 1, 2023, NanoString filed a motion in the CosMx Action to add antitrust, unfair competition, tort and contract counterclaims. NanoString seeks, among other relief, injunction relief (including that the Company grant NanoString a license to the patents that the Company asserted against NanoString in the CosMx Action) and unspecified damages (including attorneys&#8217; fees). On July 10, 2023, the Court denied NanoString&#8217;s motion for leave to add a contract counterclaim but otherwise granted the motion for leave to amend. On May 24, 2023, NanoString filed a motion to bifurcate its amended counterclaims and a motion for expedited discovery. On June 6, 2023, the Court denied NanoString&#8217;s motion to bifurcate and granted its motion for expedited discovery. The Company believes NanoString&#8217;s claims are meritless and intends to vigorously defend itself. Trial is scheduled for August 2025.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, NanoString filed a counterclaim in the CosMx Action alleging that the Company&#8217;s Visium products infringe U.S. Patent No. 11,377,689 (the &#8220;689 patent&#8221;). The Company filed its answer to NanoString&#8217;s counterclaim in the CosMx Action on August 30, 2022. On November 23, 2022, the Company moved to sever claims relating to NanoString&#8217;s assertion of the 689 patent and consolidate those claims with the patent case NanoString filed against the Company on October 20, 2022 (discussed below). On January 24, 2023, the Court granted the Company&#8217;s motion.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 20, 2022, NanoString filed suit against the Company in the U.S. District Court for the District of Delaware alleging that the Company&#8217;s Visium products infringe U.S. Patent No. 11,473,142 (the &#8220;142 patent&#8221;), a continuation of the 689 patent (the &#8220;NanoString Action&#8221;). NanoString seeks, among other relief, injunctive relief and unspecified damages (including attorneys&#8217; fees) in relation to the Company&#8217;s making, using, selling, offering to sell, exporting and/or importing in the United </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:65.25pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10x Genomics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div></div><ix:continuation id="f-415-3" continuedAt="f-415-4"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">States Visium products and associated instruments, reagents and services. On January 24, 2023, the Court severed NanoString&#8217;s claims with respect to the 689 patent from the CosMx Action and consolidated those claims with this action. NanoString filed an amended complaint on January 27, 2023. The Company filed an answer to the NanoString Action on February 10, 2023. Discovery is in progress. A Markman hearing was held on January 10, 2024, and the Court issued its claim construction order on February 1, 2024. Trial is scheduled for November 2025. The Company believes NanoString&#8217;s claims in the NanoString Action are meritless and intends to vigorously defend itself.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16 and September 25, 2023, the Company filed petitions for inter partes review (&#8220;IPR&#8221;) of the 689 patent and the 142 patent, respectively. On February 1, 2024, IPR was instituted for the 689 patent. Oral argument for the 689 IPR took place on March 12, 2025. On September 5, 2024, trial was instituted for the 142 patent. Oral argument for the 142 IPR is scheduled for May 2025.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 30, 2024, NanoString filed a petition for IPR of U.S. Patent No. 11,542,554, which is asserted by the Company against NanoString in the CosMx Action. On August 23, 2024, IPR was instituted for the 554 patent. Oral argument for the 554 IPR is scheduled for May 2025.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2022, the Company filed suit in the Munich Regional Court in Germany alleging that NanoString&#8217;s CosMx Spatial Molecular Imager and associated instruments, reagents and services infringe EP Patent No. 2794928B1 (the &#8220;EP 928 patent&#8221;) (the &#8220;Germany CosMx Action&#8221;). A hearing on infringement was held on March 23, 2023. On May 17, 2023, the Munich Regional Court found that the CosMx products infringe the EP 928 patent and issued a permanent injunction requiring NanoString to stop selling and supplying CosMx instruments and reagents for RNA detection in Germany. The injunction took effect on June 1, 2023. On May 25, 2023, NanoString filed an appeal of the Germany CosMx Action in the Munich Higher Regional Court. A hearing date has not yet been set for this appeal. On October 30, 2023, NanoString requested that the Higher Regional Court temporarily stay enforcement of the injunction pending the appeal. On December 20, 2023, the Higher Regional Court granted NanoString&#8217;s request conditioned upon NanoString posting a <ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:SecurityDeposit" format="ixt:num-dot-decimal" scale="6" id="f-437">2.3</ix:nonFraction>&#160;million Euro security deposit. The case is currently stayed pending a final legally binding decision on the validity of EP 928.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2022, NanoString filed a nullity action with the German Federal Patent Court challenging the validity of the EP 928 patent. On February 10, 2023, the Federal Patent Court issued a preliminary opinion upholding the validity of certain claims of the EP 928 patent directed to in situ analysis. On May 7, 2024, the German Federal Patent Court revoked the German part of the EP 928 patent. The Company strongly disagrees with this decision.  On September 9, 2024, the Company appealed the decision to the German Federal Court of Justice.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2023, the Company filed requests for preliminary injunctions in the Munich Local Division of the Unified Patent Court (&#8220;UPC&#8221;) alleging that NanoString&#8217;s CosMx Spatial Molecular Imager and associated instruments, reagents and services for RNA detection infringe the EP 928 patent and EP Patent No. 4108782 (the &#8220;EP 782 patent&#8221;). Hearings were held for the EP 782 and EP 928 patents on September 5 and September 19, respectively. On September 19, 2023, the UPC granted the Company&#8217;s request for the EP 782 patent and issued a preliminary injunction requiring NanoString to stop selling and supplying CosMx instruments and reagents for RNA detection in all 17 UPC member states. On October 10, 2023, the UPC denied the Company&#8217;s preliminary injunction request for the EP 928 patent. On October 2, 2023, NanoString filed an appeal of the preliminary injunction for the EP 782 patent in the UPC Court of Appeals. A hearing was held before the UPC Court of Appeals on December 18, 2023. The UPC Court of Appeals overturned the preliminary injunction on February 26, 2024.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 31 and September 18, 2023 we filed main requests in the Munich Local Division of the UPC alleging that NanoString's CosMx Spatial Molecular Imager and associated instruments, reagents and services for RNA detection infringe the EP 782 and EP 928 patents, respectively. A hearing on the main request for EP 782 is scheduled for September 2025. No hearing has yet been set for the main request with regard to EP 928. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 18, 2023, NanoString filed an opposition in the European Patent Office challenging the validity of the EP 782 patent. In March 2025 the European Patent Office held an oral proceeding and upheld the validity of the claims of the EP 782 patent in an amended form.  On July 27, 2023, NanoString filed a revocation action in the Munich Central Division of the UPC challenging the validity of the EP 928 patent. A hearing in the revocation action took place on September 18, 2024. Following the hearing, the UPC revoked EP 928. The Company strongly disagrees with this decision. On December 17, 2024, the Company appealed the decision to the UPC Court of Appeals.</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vizgen  </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vizgen, Inc. (&#8220;Vizgen&#8221;) and the Company were previously engaged in litigation in multiple jurisdictions relating to the Company&#8217;s Xenium products and Vizgen&#8217;s MERSCOPE products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 5, 2025, the Company and Vizgen resolved all outstanding litigation between the two companies. All claims in the litigation have been dismissed with prejudice.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:65.25pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10x Genomics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div></div><ix:continuation id="f-415-4"><div style="margin-bottom:10pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Parse</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 24, 2022, the Company filed suit against Parse Biosciences, Inc. (&#8220;Parse&#8221;) in the U.S. District Court for the District of Delaware alleging that Parse&#8217;s Evercode Whole Transcriptomics products and ATAC-seq products infringe U.S. Patent Nos. 10,155,981 (the &#8220;981 patent&#8221;), 10,697,013 (the &#8220;013 patent&#8221;), 10,240,197 (the &#8220;197 patent&#8221;), 10,150,995 (the &#8220;995 patent&#8221;), 10,619,207 (the &#8220;207 patent&#8221;) and 10,738,357 (the &#8220;357 patent&#8221;). The Company seeks, among other relief, injunction relief and unspecified damages (including attorneys&#8217; fees) in relation to Parse&#8217;s making, using, selling, offering to sell, exporting and/or importing in the United States Parse&#8217;s Evercode Whole Transcriptomics products and ATAC-seq products. On October 17, 2022, Parse filed a motion to dismiss alleging that the asserted claims are directed to patent ineligible subject matter. The Court held a hearing on the motion to dismiss on November 22, 2022, and supplemental briefing was submitted on December 15, 2022. On September 14, 2023, the Court denied the motion. Parse filed its answer on October 6, 2023. Discovery is in progress. A Markman hearing was held on February 21, 2024, and the Court issued its claim construction order on May 3, 2024. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between April 20 and June 21, 2023, Parse filed petitions for IPR of all of the patents asserted. On October 13, 2023, IPR was instituted on the 981 patent. The PTAB denied institution of Parse&#8217;s petitions for IPR on the other five asserted patents. On January 2 and 5, 2024, Parse filed rehearing requests with the PTAB for the 197 and 013 patents, respectively. On February 5, 2024, the PTAB instituted IPRs for the 197 and 013 patents on Parse&#8217;s requests for rehearing. On September 17, 2024, the PTAB found the challenged claims of the 981 patent unpatentable. In February 2025, the PTAB found the challenged claims of the 197 and 013 patents unpatentable. The Company strongly disagrees with these decisions and has appealed.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 25, 2025, the Court entered a consent judgment and permanent injunction enjoining Parse from making, using, selling, or offering for sale in the United States, or inducing others to make, use, sell, or offer to sell in the United States, or importing into the United States, for the remaining term of the 992, 207, and 357 patents, any ATAC-seq Method, Composition, or Product, or any other method, composition or product that is not colorably different from the ATAC-seq Methods, Compositions or Products.  The Court stayed trial with respect to the 197, 031, and 981 patents pending the appeal of the IPR decisions on these patents.</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Curio</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 1, 2023, the Company filed suit against Curio Bioscience, Inc. (&#8220;Curio&#8221;) in the U.S. District Court for the District of Delaware alleging that the Curio Seeker Spatial Mapping Kit and associated products and services infringe U.S. Patent Nos. 10,480,022, 10,662,468, 11,001,879, 11,549,138, and 11,761,030. On February 1, 2024, Curio filed a motion to dismiss alleging that the asserted claims are directed to patent ineligible subject matter. The Court denied that motion on May 9, 2024. On May 31 and June 20, 2024, Curio answered the Complaint and filed antitrust and unfair competition counterclaims. The Company filed a motion to dismiss Curio&#8217;s unfair competition and antitrust counterclaims on July 5, 2024. On February 21, 2025, the Court dismissed all of Curio&#8217;s unfair competition and antitrust counterclaims with the exception of one counterclaim alleging the lawsuit is objectively baseless. The Company believes Curio&#8217;s remaining counterclaim is meritless and intends to vigorously defend itself. Trial is scheduled for May 2026.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 4, 2023, the Company filed a request for a preliminary injunction in the Dusseldorf Local Division of the UPC alleging that the Curio Seeker Spatial Mapping Kit and associated products and services infringe EP Patent No. 2697391 (the &#8220;EP 391 patent&#8221;). A hearing was held on March 26, 2024. On April 30, 2024, the UPC granted the Company&#8217;s request and issued a preliminary injunction requiring Curio to stop offering, marketing, using or possessing these Curio Seeker products and services in Germany, France and Sweden. Curio did not appeal the preliminary injunction. On March 25, 2024, the Company filed a main request in the Dusseldorf Local Division of the UPC alleging that the Curio Seeker Spatial Mapping Kit and associated products and services infringe the EP 391 patent. A hearing in the main action is expected in May 2025.</span></div></ix:continuation><div id="ided02fd2e98d499fb2d5119ce560145c_49"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-438" continuedAt="f-438-1" escape="true">Capital Stock</ix:nonNumeric></span></div><ix:continuation id="f-438-1"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the number of shares of Class&#160;A common stock and Class&#160;B common stock issued and outstanding were <ix:nonFraction unitRef="shares" contextRef="c-102" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-439"><ix:nonFraction unitRef="shares" contextRef="c-102" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-440">109,076,917</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-103" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-441"><ix:nonFraction unitRef="shares" contextRef="c-103" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-442">14,056,833</ix:nonFraction></ix:nonFraction>, respectively.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="ided02fd2e98d499fb2d5119ce560145c_52"></div><hr style="page-break-after:always"/><div style="min-height:65.25pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10x Genomics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-443" continuedAt="f-443-1" escape="true">Equity Incentive Plans</ix:nonNumeric></span></div><ix:continuation id="f-443-1" continuedAt="f-443-2"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="f-444" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the condensed consolidated statement of operations for the periods presented as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-445">2,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-446">2,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-447">14,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-448">16,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-449">14,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-450">17,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-451">31,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-452">36,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="f-453" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units (&#8220;RSUs&#8221;) activity for the three months ended March&#160;31, 2025 is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted&#160;Stock<br/>Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant&#160;Date&#160;Fair&#160;Value<br/>(per share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-454">6,493,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-455">35.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-456">2,016,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-457">12.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-458">564,701</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-459">47.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-460">320,043</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-461">38.48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-462">7,624,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-463">28.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-464" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity for the three months ended March&#160;31, 2025 is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock&#160;Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-465">4,594,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-466">45.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-467">277,212</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-468">1.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled and forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-469">96,812</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-470">52.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-471">4,220,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-472">48.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Stock Awards</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2025, the Company granted <ix:nonFraction unitRef="shares" contextRef="c-110" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-473">561,603</ix:nonFraction> performance stock units (&#8220;PSUs&#8221;) under the 2019 Plan to certain members of management which are subject to the achievement of certain performance conditions established by the Company&#8217;s Compensation Committee of the Board of Directors as described below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.73pt"><ix:nonFraction unitRef="number" contextRef="c-111" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-474">50</ix:nonFraction>% of target PSUs earned will be based on the Company&#8217;s compound annual growth rate (&#8220;CAGR&#8221;) of the Company&#8217;s Revenue over a <ix:nonNumeric contextRef="c-111" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-475">two-year</ix:nonNumeric> performance period from January 1, 2025 to December 31, 2026. Holders may earn from <ix:nonFraction unitRef="number" contextRef="c-112" decimals="2" name="txg:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage" scale="-2" id="f-476">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-113" decimals="2" name="txg:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage" scale="-2" id="f-477">200</ix:nonFraction>% of the target amount of shares and earned PSUs will then be subject to service-based vesting; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:9.96pt"><ix:nonFraction unitRef="number" contextRef="c-114" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-478">50</ix:nonFraction>% of target PSUs earned will be based on the relative Total Shareholder Return (&#8220;TSR&#8221;) of the Company&#8217;s common stock as compared to the TSR of the members of the Russell 3000 Medical Equipment and Services Sector Index over a <ix:nonNumeric contextRef="c-114" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-479">three-year</ix:nonNumeric> performance period from January 1, 2025 to December 31, 2027. Depending on the results relative to the TSR market condition, the holders may earn from <ix:nonFraction unitRef="number" contextRef="c-115" decimals="2" name="txg:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage" scale="-2" id="f-480">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-116" decimals="2" name="txg:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage" scale="-2" id="f-481">200</ix:nonFraction>% of the target amount of shares which will vest at the end of the performance period.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:65.25pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10x Genomics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div></div><ix:continuation id="f-443-2"><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PSUs will be forfeited if the performance conditions are not achieved at the end of the relative performance periods as described above. The vesting of the PSUs can also be triggered upon certain change in control events or in the event of death or disability.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair values of the PSUs relating to CAGR and TSR components were $<ix:nonFraction unitRef="usdPerShare" contextRef="c-117" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-482">10.76</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-118" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-483">13.94</ix:nonFraction> per share, respectively. Stock-based compensation expense recognized for these awards was approximately $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="6" id="f-484">0.1</ix:nonFraction> million for the three months ended March&#160;31, 2025.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-485" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimated the fair values of shares granted under the market-based TSR PSUs using a Monte Carlo simulation model with the following assumptions:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-120" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-486">67</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-120" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-487">4.0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-120" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-488">&#8212;</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the Company granted <ix:nonFraction unitRef="shares" contextRef="c-121" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-489">219,168</ix:nonFraction> PSUs under the 2019 Plan to certain members of management, which are subject to the achievement of certain market-condition and performance-condition goals established by the Company&#8217;s Compensation Committee of the Board of Directors.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the measurement periods for the 2025 and 2024 PSUs were not completed and the market and performance criteria for the stock awards was not met and therefore no shares vested or became exercisable.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A total of <ix:nonFraction unitRef="shares" contextRef="c-122" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-490">4,909,589</ix:nonFraction> shares of Class&#160;A common stock were reserved for issuance under the 2019 Employee Stock Purchase Plan (&#8220;ESPP&#8221;). The price at which Class A common stock is purchased under the ESPP is equal to <ix:nonFraction unitRef="number" contextRef="c-123" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-491">85</ix:nonFraction>% of the fair market value of the common stock on the first day of the offering period or purchase date, whichever is lower.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2025 and 2024, <ix:nonFraction unitRef="shares" contextRef="c-124" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:fixed-zero" scale="0" id="f-492"><ix:nonFraction unitRef="shares" contextRef="c-125" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:fixed-zero" scale="0" id="f-493">no</ix:nonFraction></ix:nonFraction> shares of Class A common stock were issued under the ESPP. As of March&#160;31, 2025, there were <ix:nonFraction unitRef="shares" contextRef="c-126" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-494">3,928,014</ix:nonFraction> shares available for issuance under the ESPP.</span></div></ix:continuation><div id="ided02fd2e98d499fb2d5119ce560145c_55"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-495" continuedAt="f-495-1" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-496" escape="true"><ix:continuation id="f-495-1"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-127" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-497">4,220,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-128" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-498">5,604,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-129" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-499">7,624,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-130" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-500">5,578,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares committed under ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-131" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-501">436,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-132" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-502">116,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-503">12,282,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-504">11,299,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="ided02fd2e98d499fb2d5119ce560145c_1099511628642"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-505" continuedAt="f-505-1" escape="true">Subsequent Event</ix:nonNumeric></span></div><ix:continuation id="f-505-1"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 6, 2025, to decrease its costs and adjust its organizational structure to align with its strategic priorities, the Company committed to a reduction in force that is expected to result in the termination of approximately <ix:nonFraction unitRef="number" contextRef="c-133" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="f-506">8</ix:nonFraction>% of the Company&#8217;s global workforce. In connection with the reduction in force, the Company currently estimates it will incur between $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-507">5.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-508">6.5</ix:nonFraction>&#160;million of costs consisting primarily of cash severance costs which the Company expects to recognize in the second quarter of 2025 and pay by the end of third quarter of 2025. The estimates of costs and expenses that the Company expects to incur in connection with the workforce reduction are subject to a number of assumptions and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the workforce reduction.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="ided02fd2e98d499fb2d5119ce560145c_58"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report and our audited consolidated financial statements and notes thereto and the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2024 filed with the SEC on February&#160;12, 2025 (our "Annual Report"). As discussed in the section titled &#8220;Special Note Regarding Forward-Looking Statements,&#8221; the following discussion and analysis, in addition to historical financial information, contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the section titled &#8220;Risk Factors&#8221; in this Quarterly Report and Part I, Item 1A of our Annual Report.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</span></div><div id="ided02fd2e98d499fb2d5119ce560145c_61"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biology. Our integrated solutions include instruments, consumables and software for analyzing biological systems at resolution and scale that matches the complexity of biology. Our commercial product portfolio includes our Chromium instruments and our Visium CytAssist and our Xenium Analyzer, which we refer to as &#8220;Spatial instruments,&#8221; and our proprietary microfluidic chips, slides, reagents and other consumables for our Chromium, Visium and Xenium solutions, which we refer to as &#8220;consumables.&#8221; We bundle our software with these products to guide customers through the workflow, from sample preparation through analysis and visualization. Customers purchase instruments and consumables from us for use in their experiments. In addition to instrument and consumable sales, we derive revenue from post-warranty service contracts for our instruments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in 2012, we have incurred net losses in each year. Our net losses were $34.4 million and $59.9 million for the three months ended March&#160;31, 2025 and March&#160;31, 2024, respectively. As of March&#160;31, 2025, we had an accumulated deficit of $1.5 billion and cash and cash equivalents and marketable securities totaling $426.9 million. We expect to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term. </span></div><div id="ided02fd2e98d499fb2d5119ce560145c_64"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Three Months Ended March&#160;31, 2025 and 2024</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.239%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.526%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.526%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.526%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.529%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(dollars in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chromium</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,937)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spatial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,701)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total instruments revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,815&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,453&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,638)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consumables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chromium</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spatial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consumables revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,356&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,335&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,021&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Products and services revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,823&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,005&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,182)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">License and royalty revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,883&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,006&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,877&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products and services revenue decreased $3.2 million, or 2%, to $137.8 million for the three months ended March&#160;31, 2025 as compared to the three months ended March&#160;31, 2024. Instruments revenue decreased $10.6 million, or 42%, to $14.8&#160;million </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three months ended March&#160;31, 2025 as compared to the three months ended March&#160;31, 2024. Consumables revenue increased $5.0 million, or 5%, to $115.4&#160;million for the three months ended March&#160;31, 2025 as compared to the three months ended March&#160;31, 2024. Services revenue increased $2.4 million, or 47%, for the three months ended March&#160;31, 2025 as compared to three months ended March&#160;31, 2024, primarily driven by an increase in service plans for instruments coming off warranty.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025, the Company settled its worldwide patent litigation with Vizgen, Inc. As part of that settlement, Vizgen has limited rights to certain intellectual property owned or exclusively licensed by the Company. As one part of the settlement, the Company received an upfront payment of $26.0&#160;million and will receive royalties on Vizgen&#8217;s sales of products covered by the license. The $26.0&#160;million upfront payment was recorded as a $9.2&#160;million gain on settlement and $16.8&#160;million of license and royalty revenue. The amount attributed to the gain on settlement was determined by applying a royalty rate to the Vizgen historical revenues prior to the settlement.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our revenues, excluding the impact of license and royalty revenue, to be approximately flat in the second quarter of 2025.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Products and Services Revenue, Gross Profit and Gross Margin</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.239%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.244%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.670%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.524%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">(dollars in thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products and services revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,438&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,092&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products and services revenue increased $1.3 million, or 3%, to $49.4 million for the three months ended March&#160;31, 2025 as compared to the three months ended March&#160;31, 2024. The increase was primarily driven by higher inventory write-downs of $6.2 million, partially offset by lower manufacturing costs of $2.4 million due to decreased sales and change in product mix, lower royalties of $2.1 million and lower warranty costs of $0.4 million. Gross margin increased to 68% primarily due to license and royalty revenue, reflecting a 3.9% benefit to gross margin, and lower manufacturing costs, partially offset by an increase in inventory reserves. We expect our gross margin to fluctuate through the remainder of 2025 due to the one-time benefit in license and royalty revenue experienced in the first quarter, as well as changes in product mix, changes in product prices and increased costs through the remainder of the year.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.670%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.526%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.526%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.526%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">(dollars in thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,638&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,393)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,200)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,200)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,773&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,412&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,639)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses decreased $4.4 million, or 6%, to $64.2 million for the three months ended March&#160;31, 2025, as compared to the three months ended March&#160;31, 2024. The decrease was primarily driven by a $3.9 million decrease in personnel expenses, including a $2.8 million decrease in stock-based compensation expense, a $1.9 million decrease in allocated costs for facilities and information technology, partially offset by an $0.8 million increase in laboratory materials and supplies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased $4.0 million, or 5%, to $89.7 million for the three months ended March&#160;31, 2025, as compared to the three months ended March&#160;31, 2024. The increase was primarily driven by a $3.6 million increase in outside legal expenses and a $2.0 million increase in personnel expenses, partially offset by a $1.2 million decrease in marketing expenses.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on settlement is a result of the Company settling its worldwide patent litigation with Vizgen and the subsequent allocation of the up-front payment.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our operating expenses to trend lower in 2025 as a result of our actions to reduce operating costs including our May 2025 reduction in force that is expected to result in the termination of approximately 8% of our global workforce and additional planned reductions in non-headcount operating expenses.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.239%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.526%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.526%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.526%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.529%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">(dollars in thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,686&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,050)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,040)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(305)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,822&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,695&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,127&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income decreased by $1.1 million, or 22%, to $3.7 million for the three months ended March&#160;31, 2025 as compared to the three months ended March&#160;31, 2024. The decrease was primarily due to less interest income generated from our investments in marketable securities during the three months ended March&#160;31, 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other income (expense), net increased by $3.2 million to $2.1 million other income, net for the three months ended March&#160;31, 2025 as compared to $1.0 million other expense, net, for the three months ended March&#160;31, 2024. These increase in other income (expense), net was driven by losses from foreign currency rate measurement fluctuations.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s provision for income taxes was $0.9 million and $2.1 million, respectively, for the three months ended March&#160;31, 2025 and 2024. The decrease was primarily due to lower foreign income.</span></div><div id="ided02fd2e98d499fb2d5119ce560145c_67"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, we had approximately $426.9&#160;million in cash and cash equivalents and marketable securities which were primarily held in U.S. banks. We have generated negative cumulative cash flows from operations since inception through March&#160;31, 2025, and we have generated losses from operations since inception as reflected in our accumulated deficit of $1.5 billion.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently anticipate making aggregate capital expenditures of between approximately $10&#160;million and $15&#160;million during the next 12 months, which we expect to include, among other expenditures, equipment to be used for manufacturing and research and development.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors including our revenue growth rate, research and development efforts, investments in or acquisitions of complementary or enhancing technologies or businesses, the timing and extent of additional capital expenditures to invest in existing and new facilities, the expansion of sales and marketing and international activities, legal costs associated with defending and enforcing intellectual property rights and the introduction of new products and new versions of existing products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We take a long-term view in growing and scaling our business and we regularly review acquisition and investment opportunities, and we may in the future enter into arrangements to acquire or invest in businesses, services and technologies, including intellectual property rights, and any such acquisitions or investments could significantly increase our capital needs. We regularly review opportunities that meet our long-term growth objectives.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur operating losses for the foreseeable future. We believe that our existing cash and cash equivalents and cash generated from sales of our products will be sufficient to meet our anticipated cash needs for at least the next 12 months. However, our liquidity assumptions may prove to be incorrect, and we could exhaust our available financial resources sooner than we currently expect. We maintain the majority of our cash and cash equivalents in accounts with major U.S. and multi-national financial institutions, and our deposits at these institutions exceed insured limits. Market conditions can impact the viability of these institutions. In the event of failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely affect our business and financial position.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue to evaluate market conditions and may in the future pursue additional sources of funding, such as mortgage or other financing, to further enhance our financial position and to execute our business strategy. In addition, should prevailing economic, financial, business or other factors adversely affect our ability to meet our operating cash requirements, we could be required to obtain funding though traditional or alternative sources of financing. We cannot be certain that additional funds would be available to us on favorable terms when required, or at all.<br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of liquidity</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating activities</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,351&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,725)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing activities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,893)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing activities</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,638&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates changes on cash, cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,994&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,503)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net cash provided by operating activities of $34.4 million for the three months ended March&#160;31, 2025 was primarily due to a net loss of $34.4&#160;million, net cash inflow from changes in operating assets and liabilities of $28.3 million, primarily offset by stock-based compensation expense of $31.1&#160;million, depreciation and amortization of $8.0 million and amortization of leased right-of-use assets of $1.8 million. The net cash inflow from operating assets and liabilities was primarily due to a decrease in accounts receivable of $35.3 million and a decrease in inventory of $8.1 million. The net cash inflow from operating assets and liabilities was partially offset by a decrease in accrued compensation and other related benefits of $11.7 million related to prior year annual bonus payments, an increase in prepaid expenses and other current assets of $5.5 million, a decrease in operating lease liability of $2.6 million and a decrease in accounts payable of $2.5 million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net cash used in operating activities of $15.7 million for the three months ended March 31, 2024 was primarily due to a net loss of $59.9 million, net cash outflow from changes in operating assets and liabilities of $6.3 million, primarily offset by stock-based compensation expense of $36.1 million, depreciation and amortization of $9.2 million, lease and asset impairment charges of $2.5 million, amortization of leased right-of-use assets of $2.3 million and other non-cash expenses of $0.4 million. The net cash outflow from operating assets and liabilities was primarily due to a decrease in accrued expenses and other current liabilities of $12.7 million primarily driven by a payment of $20.0 million related to purchase consideration, an increase in inventory of $9.9 million, a decrease in accrued compensation and other related benefits of $9.4 million related to prior year annual bonus payments and a decrease in operating lease liability of $3.0 million. The net cash outflow from operating assets and liabilities was partially offset by an increase in accounts receivable of $23.5 million due to timing of collections, an increase in accounts payable of $4.6 million and an increase in deferred revenue of $2.1 million.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net cash used in investing activities of $1.9 million in the three months ended March&#160;31, 2025 was due to purchases of property and equipment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net cash provided by investing activities of $10.6 million in the three months ended March 31, 2024 was due to proceeds from sales and maturities of marketable securities of $0.6 million and $13.0 million, respectively, partially offset by purchases of property and equipment of $2.9 million.</span></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net cash provided by financing activities of $0.4 million in the three months ended March&#160;31, 2025 was primarily from proceeds related to the issuance of common stock from the exercise of stock options.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net cash provided by financing activities of $1.6 million in the three months ended March 31, 2024 was primarily from proceeds related to the issuance of common stock from the exercise of stock options.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="ided02fd2e98d499fb2d5119ce560145c_70"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information and the applicable rules and regulations of the SEC. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes in our critical accounting policies and estimates during the three months ended March&#160;31, 2025 as compared to the critical accounting policies and estimates disclosed in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in our most recent Annual Report on Form 10-K filed with the SEC on February&#160;12, 2025.</span></div><div id="ided02fd2e98d499fb2d5119ce560145c_73"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For financial market risks related to changes in interest rates and foreign currency exchange rates, reference is made to Item 7A &#8220;Quantitative and Qualitative Disclosures about Market Risk&#8221; contained in Part II of our Annual Report. Our exposure to market risk has not changed materially since December&#160;31, 2024.</span></div><div id="ided02fd2e98d499fb2d5119ce560145c_76"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;Controls and Procedures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) as of the end of the period covered by this Quarterly Report.&#160;Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of March&#160;31, 2025.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in our internal control over financial reporting (as such term is defined in Rules&#160;13a-15(f) under the Exchange Act) during the three months ended March&#160;31, 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="ided02fd2e98d499fb2d5119ce560145c_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10x Genomics, Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="ided02fd2e98d499fb2d5119ce560145c_82"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Legal Proceedings.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are regularly subject to lawsuits, claims, arbitration proceedings, administrative actions and other legal and regulatory proceedings involving intellectual property disputes, commercial disputes, competition and other matters, and we may become subject to additional types of lawsuits, claims, arbitration proceedings, administrative actions, government investigations and legal and regulatory proceedings in the future and as our business grows, including proceedings related to product liability or our acquisitions, securities issuances or our business practices, including public disclosures about our business. Our success depends in part on our non-infringement of the patents or proprietary rights of third parties. In the past, third parties have asserted and may in the future assert that we are employing their proprietary technology without authorization. We have been involved in multiple patent litigation matters and other proceedings in the past and we expect that given the litigious history of our industry and the high profile of operating as a public company, third parties may claim that our products infringe their intellectual property rights. We have also initiated litigation to defend our technology including technology developed through our significant investments in research and development. It is our general policy not to out-license our patents but to protect our sole right to own and practice them. There are inherent uncertainties in these legal matters, some of which are beyond management&#8217;s control, making the ultimate outcomes difficult to predict. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 4, Commitments and Contingencies, to the unaudited condensed consolidated financial statements included in Item 1 of Part I of this Quarterly Report on Form 10-Q for information regarding certain legal proceedings in which we are involved.</span></div><div id="ided02fd2e98d499fb2d5119ce560145c_842"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our Class&#160;A common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Quarterly Report and in the Annual Report on Form 10-K that we filed with the SEC on February 12, 2025, including our financial statements and the related notes and the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding whether to invest in our Class&#160;A common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations, cash flows and prospects. In such an event, the market price of our Class&#160;A common stock could decline and you may lose all or part of your investment. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations and the market price of our Class&#160;A common stock. In addition, you should consider the interrelationship and compounding effects of multiple risks occurring simultaneously. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Risk Factors</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to a number of risks, including risks that may prevent us from achieving our business objectives or may adversely affect our business, financial condition, results of operations, cash flows and prospects. These risks are discussed more fully below and include, but are not limited to, risks related to:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks related to our business and industry:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fluctuations in our operating results due to a variety of factors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our dependency on the availability of government funding to and research and development spending by research institutions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to compete effectively;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our pricing strategy;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Trade tariffs, import restrictions, export restrictions, Chinese regulations or other trade barriers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to increase penetration into our existing customer segments and to maintain and increase the effectiveness of our commercial organization;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The size of the market for our solutions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The complexity of data generated by our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to effectively manage product transitions and forecast customer demand, including for both existing and newly introduced products;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to generate sufficient revenue, to attain cash flows from operating activities in excess of our capital investment requirements and to achieve and maintain profitability;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to consistently manufacture our products to necessary specifications in necessary quantities and at acceptable cost and performance level;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to develop new products or new versions of existing products and enhance the capabilities of our existing products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our dependency on revenue generated from the sale of our Chromium solutions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Doing business internationally, including in China and elsewhere in the Asia-Pacific region, and exposure to interest and foreign currency exchange rates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The ability of suppliers to meet our needs and the needs of our customers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The complexity of our operations and manufacturing our products, including in sourcing raw materials and preventing errors and defects in our solutions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our limited operating history, losses since inception, fluctuations in revenue and management of growth; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The success of our products in achieving and sustaining scientific acceptance and generating revenue.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks related to our regulatory environment and taxation:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our products could become subject to more onerous government regulation; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in tax laws or regulations that are applied adversely to us or our customers; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ethical, legal, privacy and social concerns or governmental restrictions surrounding the use of the genomic and multiomic information and gene editing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks related to our intellectual property, information technology and data security:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to obtain, maintain and protect our intellectual property rights; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our dependence on certain intellectual property rights that are licensed to us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks related to litigation and our intellectual property:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our potential involvement in lawsuits in connection with intellectual property rights; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to effectively protect and enforce our intellectual property rights.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks related to ownership of our Class&#160;A common stock:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The multi-class structure of our common stock; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The requirement of our bylaws that the State of Delaware is the exclusive forum for substantially all disputes between us and our shareholders.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General risks:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to meet our publicly announced guidance or other expectations about our business; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The volatility of the market price of our Class A common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The summary risk factors described above should be read together with the text of the full risk factors below in this section titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and the other information set forth in this Quarterly Report on Form 10-Q, including our condensed consolidated financial statements and the related notes, as well as in other documents that we file with the SEC. The risks summarized above or described in full below are not the only risks that we face. Additional risks and uncertainties not precisely known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, results of operations and future prospects.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><br/><br/>Risks related to our business and industry</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results have in the past fluctuated significantly and may continue to fluctuate significantly in the future, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to:</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in, changes in terms of, reductions of or cancellations of U.S. academic and government research funding of life sciences research, generally, or of research projects which utilize or could utilize our solutions, specifically, or other changes that impact budgets, budget cycles, seasonal or other spending patterns or the operations of our customers or the institutions that fund them, including potential freezes of, reductions in or reduced availability of U.S. academic and government research funding, including funding from the National Institutes of Health (NIH) or other sources for our customers; </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effects of competition, including competition with both new and existing companies offering products that compete or intend to compete with our products and may offer performance, price or other advantages as well as researchers developing their own solutions; </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and magnitude of our price changes, including the effects of potentially lowering prices for certain of our products in 2025;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trade tariffs, import restrictions, export restrictions, Chinese regulations or other trade barriers, including retaliatory measures taken by trade partners; </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">modifications to our commercial processes and organization, including changes we made to our commercial processes and organization to increase effectiveness; </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in demand for our products, which may vary significantly, our ability to accurately forecast demand, and our ability to increase penetration with our existing customers and to expand to new customers;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in general market conditions and other factors, including factors unrelated to our operating performance or the performance of our competitors;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effects of inflation on us or our customers, manufacturers and suppliers, including increases in the cost of labor and materials, including as a result of tariffs imposed by the United States which are currently, or in the future, under consideration, proposed or enacted;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">excess capacity expenses and inventory write-downs; </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in volume and product mix, particularly from products with lower gross margins than other products that we sell, or changes in costs related to our instruments and consumables, including products which incur royalty payment obligations at higher rates than other products we sell;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our recently introduced and recently announced products and new versions of existing products, and our ability to generate revenue for such products, and the introduction of new products or product enhancements by us or others in our industry including the timing of such introductions;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions in customers&#8217; on-going experiments or interruptions in the ability of our customers to complete research projects;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">investment decisions we make with respect to the allocation of our resources, including regarding product development or to support our commercial organization;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our business and demand for our products in China and elsewhere in the Asia-Pacific region, including competition or other factors;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differences in purchasing patterns across our customer base or across our two portfolios and variances in consumables spending for each of our portfolios;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">higher than anticipated warranty costs;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and amount of expenditures that we may incur to acquire, develop or commercialize additional products and technologies or for other purposes;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and amount of expenditures (including success fees) related to litigation, as well as the outcomes of and related rulings in the litigation and administrative proceedings which may vary substantially from quarter to quarter;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of any current or future litigation or governmental investigations involving us or other third parties;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability and the ability of our partners to successfully manufacture our instruments and consumables in necessary quantities at necessary quality, including due to the impacts of supply chain disruptions, logistics, shipping and other distribution disruptions and labor shortages;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">shortages, delays, production problems, distribution and quality issues with the materials we purchase for manufacturing, which could impact our ability to manufacture and ship our instruments, consumables and related components;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability or the inability of our customers to source our products or necessary equipment, components and materials used in our products or in conjunction with our products, including shortages of consumables or other components and materials used in gene sequencing (which occurred in 2024), because of issues with suppliers, including supply chain disruptions, logistics, shipping and other distribution disruptions and labor shortages;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our dependence and the dependence of our customers on single source and sole source suppliers for some of the equipment, components and materials used in our products or in conjunction with our products;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in customer payment timing trends including potential increases in the days sales outstanding (DSO);</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses related to our facilities and real estate;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully integrate personnel, technology and other assets that we acquire into our company;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties encountered by our commercial carriers in delivering our instruments or consumables, whether as a result of external factors such as weather, customs or import processes, transportation bottlenecks, port lockdowns or slowdowns or fuel shortages or internal issues such as labor disputes or difficulties hiring and retaining adequate staffing;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reductions in or other difficulties relating to staffing, capacity, shutdowns or slowdowns of laboratories and other institutions, such as reduced or delayed spending on instruments or consumables due to reductions in or other difficulties relating to staffing, capacity, shutdowns or slowdowns of laboratories and other institutions in which our instruments and solutions are used;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation or public perception of us;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impacts of geopolitical issues, infectious disease, epidemics or pandemics on our business operations and on the business operations of our customers, manufacturers and suppliers; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the other factors described in this &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; section.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cumulative effects of the factors discussed above could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors at any time. If our revenue or operating results fall below the expectations of analysts or investors or below any guidance we may provide, or if the guidance we provide is below the expectations of analysts or investors, the price of our Class&#160;A common stock could decline substantially. Such a stock price decline could occur even when we have met or exceeded any previously publicly stated guidance we may provide.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is significantly dependent on researchers and institutions which rely heavily on U.S. academic and government funding, including NIH grants, and any delays, reductions, modification of the terms or cancellations of such funding, or other changes to the budgets, budget cycles, seasonal or other spending patterns or the operations of our customers or the institutions that fund them, could adversely affect our sales and financial performance.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our revenue is derived from sales to academic institutions, research organizations and other entities that rely heavily on U.S. academic and government funding, including grants from the NIH and other government agencies or other funding sources. Government funding is subject to annual appropriations and budgetary constraints, and there is no assurance that such funding will continue at current levels or at all. Changes in U.S. academic and government budgets, priorities, policies or operations could result in delays, reductions or cancellations of funding for our customers' research. If researchers experience delays, reductions or cancellations in U.S. academic and government funding, or modifications of the terms or conditions of funding, they may reduce, delay or cancel entirely their purchases of our products and services, which could have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any changes in U.S. academic and government regulations, policies or operations that affect the terms of research funding could impact our customers&#8217; ability to secure funding and, consequently, the timing and demand for our products and services. For example, in February 2025, the NIH imposed a standard indirect rate of 15% across all NIH grants for indirect costs, defined as &#8220;facilities&#8221; and &#8220;administration,&#8221; in lieu of a separately negotiated rate for indirect costs in every grant. Indirect costs represented $9 billion of the $35 billion in grants awarded by the NIH in 2023, which is more than 25% of total grant dollars awarded by the NIH. Our customers may face increased financial pressure due to this change or any future caps on indirect costs. The imposition of this cap, or other changes to grant terms, conditions or processes including those related to the disbursement of funds, could lead to delayed, reduced or cancelled funding otherwise available for purchasing research supplies and equipment, thereby negatively impacting our sales. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, various private, state, federal and international agencies that provide grants and other funding may be subject to budgetary or other constraints that could result in spending reductions, reduced grant making, reduced allocations or budget cutbacks, budget reprioritizations, delays or funding cancellations, which could jeopardize the ability of researchers to purchase our products. For example, congressional appropriations to the NIH have generally increased year-over-year in recent years, but the NIH also experiences occasional year-over-year decreases in appropriations. There is no guarantee that NIH appropriations will not decrease in the future and in April 2025 the United States Presidential administration proposed cuts to the NIH including a more than 40% cut to the NIH&#8217;s annual budget commencing with the 2026 fiscal year beginning in October 2025. Further, in January 2025 the Executive Office of the President&#8217;s Office of Management and Budget (OMB) issued a memorandum &#8220;temporarily paus[ing] all activities related to obligation or disbursement of all Federal financial assistance...&#8221; which may have the effect of preventing customers or potential customers from accessing grants or funding. Additionally, changes to the operations of our customers or the institutions that fund them including reductions in staffing or reorganizations of U.S. academic and government funding institutions may also cause delays, reductions or cancellations of research spending, negatively impacting our sales. For example, in March 2025, the Department of Health and Human Services, which includes the NIH, announced a reduction in workforce of approximately 20,000 employees, or approximately one quarter of its staff, and the NIH removed the chiefs of four of the NIH&#8217;s twenty-seven institutes and centers. The NIH laid off hundreds of additional employees in May 2025. Fewer staff available to process, review and make decisions regarding funding requests or complete other funding-related activities could delay or prevent our customers from receiving necessary funding to purchase our products. Further, in January 2025 a number of scientific gatherings and panels across federal science agencies, including several meetings of NIH study sections which review applications for fellowships and grants, were canceled pursuant to agency notices. These meetings can be hard to reschedule and can substantially delay grant approvals.  Any cancellations or delays in the ability of NIH or other funding bodies to make and execute decisions to fund research which uses our products could delay or prevent researchers from purchasing our products or reduce their purchases, negatively impacting our financial results. A decrease in the amount of, or delay in the approval of, appropriations to or disbursements from the NIH or other funding organizations, such as the Medical Research Council in the United Kingdom, could result in less funding available for life sciences research or negatively affect the timing of purchases of our products. For example, one potential customer in 2025 was no longer able to purchase our products for an AIDS vaccine-related research project due to a near-total freeze in January 2025 followed by a substantial reduction in March 2025 in funding from the United States Agency for International Development (USAID). Delays, reductions, modification of the terms or cancellations of funding could also result in a decrease in the aggregate amount of grants awarded or funding disbursed for life sciences research or the redirection of existing funding to other projects or priorities, any of which in turn could cause our customers and potential customers to reduce, delay or cancel purchases of our products. For example, in March 2025 the NIH terminated approximately seven hundred research grants totaling more than $2.4 billion that funded scientific research, including studies related to breast cancer, Alzheimer&#8217;s disease and HIV prevention, among other topics. Our operating results may fluctuate substantially due to any such delays, reductions, modification of terms or cancellations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the risks to customer spending posed by recent changes and uncertainty related to U.S academic and government funding including direct government funding of research projects, actions by the federal government of the United States generally targeting federal funding to research institutions who are or could be purchasers of our products pose risks to our operating results. For example, in 2025 the United States government threatened to freeze or cancel billions of dollars of federal funding to multiple institutions, including certain of our customers, if such institutions did not take certain actions to limit activism on campus. These or similar actions, such as revoking the tax exempt status of research universities, could have the effect of delaying, reducing or eliminating institutional funding available for research projects, which could in turn delay, limit or cancel purchases of our products by researchers at targeted institutions and negatively impact our revenue. Some institutions have responded to these risks of losing federal funding by implementing measures that could also have adverse impacts on our revenue, including hiring freezes, rescissions of offers of acceptance to academic programs, caps or additional scrutiny, processes or layers of approval required to authorize expenditures or limitations or reductions on capital expenditures which may, for example, delay or prevent purchases of our instruments. Additionally, in 2025 the United States Department of State revoked the visas or legal statuses of, to date, more than 1,800 international students at more than 280 colleges and universities in the United States on the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">grounds that the &#8220;presence or activities in the United States [of such students]...would have potentially serious adverse foreign policy consequences for the United States.&#8221; These or potential additional future visa or legal status revocations or similar actions could negatively impact our revenue as some affected individuals may be current or potential users or purchasers of our products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is currently significant uncertainty regarding further delays, reductions, modification of the terms or cancellations of U.S. academic and government funding or other changes to the budgets, budget cycles, seasonal or other spending patterns or the operations of our customers or the institutions that fund them. Delays, reductions, cancellations, caps, reprioritizations or other changes to our customers&#8217; budgets, expenditures or operations could materially and adversely affect our business, operating results and financial condition.</span></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business currently depends significantly on research and development spending by research institutions, a reduction in which could limit demand for our products and materially and adversely affect our business and operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A large portion of our revenue comes from sales of Chromium, Visium and Xenium products to research institutions. As a result, the demand for our products will depend upon research priorities and purchasing patterns of these customers, the ability of such customers to adequately staff, access and utilize labs and conduct research, the research and development budgets of these customers and the ability of such customers to receive funding for research, all of which are impacted by factors beyond our control, such as:</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreases or delays in funding of research and development;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in, restrictions upon, availability of, delays or interruptions to funding or other incentives for our customers including administrative or other delays in funding or incentive award processes, changes in the amount of funds or other incentives allocated to different areas of research, changes that have the effect of increasing the length of the funding or incentive award process;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitor product offerings or pricing;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our customers' research priorities;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">macroeconomic conditions including regional, national or global economic downturns, inflation, interest rate or currency fluctuations, trade policies and tariffs, regulatory changes, political instability, labor market conditions, supply chain disruptions and technological changes;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our business in China and elsewhere in the Asia-Pacific region, including macroeconomic conditions, local competition or other factors:</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">scientists&#8217; and customers&#8217; opinions of the utility of our products or services;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability or the inability of our customers to source products or necessary equipment, components and materials used in our products or in conjunction with our products because of issues with suppliers or distribution networks, including supply chain disruptions, logistics, shipping and other distribution disruptions and labor shortages;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">citation of new products, new versions of existing products or services in published research;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the regulatory environment;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differences in budgetary cycles;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in spending while customers or potential customers assess and validate newly introduced products or versions of our products prior to purchasing;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market-driven pressures to consolidate operations and reduce costs; </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reductions in or other difficulties relating to staffing, capacity, slowdowns or shutdowns of laboratories or other institutions in which our solutions are used, including reduced or delayed spending on instruments or consumables due to reductions in or other difficulties relating to staffing, capacity, slowdowns or shutdowns of laboratories or other institutions in which our solutions are used; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market acceptance of relatively new technologies, such as ours.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our industry is highly competitive. If we fail to compete effectively, our business and operating results will suffer.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face significant competition. We currently compete with both established and early-stage companies that have introduced products for, among other things, genomics analysis, single cell analysis, spatial analysis and in situ analysis. We also compete with companies that offer existing tools and technologies for life science research, such as bulk sequencing, flow cytometry, PCR, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunofluorescence, immunohistochemistry and other imaging and cell-based assays, that are replaced by our products. There are additional companies, including both early stage and established, that have indicated that they are designing, manufacturing and marketing products to compete with us or that they intend to do so in the future. Some of these companies may have substantially greater financial and other resources than we do, including larger research and development staff or larger, more established marketing, distribution, service and sales organizations. In addition, they may have greater name recognition than we do. Established companies with multiple product lines may give away or sell products at a significant discount that compete with ours in order to drive adoption and usage of other products they sell. If we are forced to reduce the prices on our products in response, it could negatively impact our revenue and financial results.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other competitors are in the process of developing novel technologies which may lead to products that rival or replace our products. We expect new competitors to continue to emerge and the intensity of competition with both new and existing competitors to continue to increase.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face competition from researchers developing their own solutions. The area in which we compete involves rapid innovation and some of our customers have in the past, and more may in the future, elect to create their own platform or assays rather than rely on a third-party supplier such as ourselves. This is particularly true for the largest research centers and labs which are continually testing and trying new technologies, whether from a third-party vendor or developed internally. We also compete for the resources our customers allocate for purchasing a wide range of products used to analyze biological systems, some of which are additive to or complementary with our own but not directly competitive.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products may not compete favorably or be successful in the face of increasing competition from products and technologies introduced by our existing competitors, companies entering our segments or developed by our customers internally. In addition, our competitors may have or will in the future develop products or technologies that currently or in the future will enable them to produce competitive products with greater capabilities or at lower costs than ours or that are able to run comparable experiments at lower costs. Any failure to compete effectively could materially and adversely affect our business, financial condition and operating results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Price reductions, discounting or future price changes may negatively impact our financial results if we are unable to achieve offsetting benefits.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recently taken a number of steps to lower the cost of single cell experiments through the introduction of new products and new versions of existing products that deliver lower price per cell and per sample and we may in the future choose to implement strategic price reductions or discounting of our products and services. While we believe these actions will drive increased customer adoption, they will also result in lower revenue per unit sold. While we plan to offset these reductions through increased sales volume, operational cost savings and improved operating leverage, our ability to do so will be dependent upon whether our customers increase their usage of our products, and there can be no assurance that these offsetting measures will be successful or will occur in the same time period as the price reductions. We may experience corresponding increases in demand or customers may push out purchases to future periods in anticipation of future product introductions or price reductions or discounting, which would negatively impact our financial results.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to fully offset the impact of lower cost of experiments or lower pricing or discounting through these initiatives, our revenue, gross margins, operating income and overall financial results could be adversely affected. The negative impact could be particularly pronounced if:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the anticipated increase in sales volume fails to materialize or is lower than expected;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our cost reduction and efficiency initiatives do not generate the projected savings;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitive pressures require us to implement price reductions more extensively or rapidly than planned;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we experience delays in implementing operational improvements and cost control measures; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">macroeconomic conditions or other factors negatively impact customer demand or purchasing patterns.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our pricing strategy depends on numerous factors, many of which are outside our control. If we are unable to successfully execute our pricing strategy while maintaining our profitability, our business, financial condition, results of operations and prospects may be materially and adversely affected.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade tariffs, import restrictions, export restrictions, Chinese regulations or other trade barriers may materially harm our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, we have expanded our international operations as part of our growth strategy and have experienced an increasing concentration of sales in certain regions outside the United States, including in the Asia-Pacific region. For the years ended December&#160;31, 2024 and 2023, sales outside of North America constituted a substantial component of our total sales revenue and our largest markets outside of North America were China and Germany. There is currently significant uncertainty about the future relationship between the United States and its trade partners, most significantly China, with respect to trade policies, treaties, government regulations and tariffs and, in 2025, the United States implemented and is considering additional new tariffs or other restrictions on goods from a number of other countries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This has subjected and may in the future subject our business to retaliatory measures taken by trade partners, including China or other countries which have had and may in the future have an adverse impact on our financial results. Such measures have and could in the future include restrictions on our ability to sell or import our products into other countries or increase the prices of our products. For example, in early 2025, the United States Presidential administration implemented significant new tariffs on foreign imports impacting multiple countries, commodities and industries, and these new tariffs and export restrictions also prompted retaliatory tariffs and export restrictions from certain countries. As of April 2025, certain tariffs and retaliatory tariffs have been delayed, but a number of the new tariffs remain in effect, including significant tariffs and trade sanctions between the United States and China. As of the date hereof, substantial uncertainty continues regarding additional tariff-related policy changes of the United States and other countries. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face increased costs due to tariffs imposed by the United States on materials we purchase, which may negatively impact our financial results. These tariffs raise the cost of supplies and components we import, potentially leading to price increases for our products and affecting demand and competitive positioning. Additionally, tariffs could disrupt supply chains and exacerbate economic instability. If we cannot recover higher costs promptly, our margins and profitability may decline. Further tariffs could worsen these risks. Our business has and may in the future be adversely impacted by retaliatory trade measures taken by trade partners, which could materially harm our business, financial condition and results of operations. The nature of the dispute between the United States and its trade partners continues to evolve and our products could become subject to additional tariffs. Further, the continued threats of tariffs, trade restrictions and trade barriers could have a generally disruptive impact on the global economy and customer sentiment outside the United States, including increases in inflation and interest rates, and, therefore, negatively impact our sales. Given the relatively fluid regulatory environment between the United States and its trade partners and uncertainty how each will act with respect to tariffs, international trade agreements and policies, there could be additional tax or other regulatory changes in the future. Any such changes could directly or indirectly adversely impact our financial results and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2025, China&#8217;s Ministry of Commerce (MOFCOM) added Illumina, Inc., the largest sequencer manufacturer, to MOFCOM&#8217;s Unreliable Entity List, potentially in response to tariffs imposed by the United States. In connection with this designation, MOFCOM may impose restrictions or prohibitions on Illumina&#8217;s China-related import or export activities, investments in China, relevant personnel or transportation entering China, work permits, stay or residence status, fines or other penalties. Our Chromium and Visium products are often utilized with Illumina sequencers by researchers conducting single cell or spatial experiments. As a result of Illumina&#8217;s designation by MOFCOM as an &#8220;unreliable entity,&#8221; it may now be difficult or impossible for certain users or potential users of our products in China to access or utilize Illumina&#8217;s products, including in connection with planned or potential Chromium or Visium experiments, and our business in China may suffer as a result. If China were to expand the Unreliable Entity List to include other life sciences companies, including 10x, our business in China, which represented approximately ten percent of our total revenue in 2024, could be materially impacted or eliminated.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, the United States government has a renewed focus on export control matters. For example, the Export Control Reform Act of 2018 and regulatory guidance thereunder have imposed additional controls and may result in the imposition of further additional controls, on the export of certain &#8220;emerging and foundational technologies.&#8221; Our current and future products may be subject to these heightened regulations, which could increase our compliance costs. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade actions, including the imposition of new, or changes in existing, tariffs, trade restrictions, trade barriers, export controls, antitrust investigations or retaliatory measures taken by trade partners in response to U.S. trade practices could adversely impact our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success is dependent upon our ab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ility to increase penetration in our existing customer segments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customer base includes academic, government, biopharmaceutical, biotechnology and other institutions. Our success will depend upon our ability to increase our penetration among these customers, to expand to new customers and to expand our opportunities by developing and marketing new products as well as new versions of and new applications for existing products. We regularly introduce new versions of existing products, and our future success will partially depend on our ability to commercialize these products and gain customer acceptance of these products. We may not be able to further penetrate our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">existing customers or expand to new customers. Any failure to increase penetration with existing customers and expand to new customers could adversely impact our operating results.</span></div><div style="margin-top:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our past or future efforts to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">maintain and increase the effectiveness of our commercial organization may not succeed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in the past needed to, and may in the future need to, identify, adopt and adhere to new or modified commercial processes to maintain and increase the effectiveness of our commercial organization. In 2024, we modified our commercial processes and organization to increase effectiveness. While we believe such changes will serve the long term best interests of the Company, we believe that in the short term these changes negatively impacted our financial results in 2024 and may continue to negatively impact our results in the future. There is no guarantee that the modifications we have made to our commercial processes and organization will result in increased effectiveness. If the modifications to our commercial processes and organization do not result in increased effectiveness, our business, results of operations and growth prospects may be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we may face difficulties identifying, recruiting, training and retaining qualified personnel to staff and manage our commercial organization. Certain of our products, certain customers or certain segments, including biopharmaceutical or translational segments, may require personnel with different skills or experience than those we currently employ in our commercial organization. For example, our restructuring left a number of territories without sales coverage, and we are hiring to fill those positions. We are also in the process of building a team of specialized commercial staff focused on sales of our Xenium products.  If we are unable to quickly fill vacant roles and ramp new personnel, our financial results may be negatively impacted.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The size of the market for our solutions may be smaller than estimated and new opportunities may not develop as quickly as we expect, or at all, limiting our ability to successfully sell our solutions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The demand for genomics products continues to evolve, making it difficult to predict with any accuracy the total potential demand for our solutions. Our estimates of the annual total addressable market and annual serviceable addressable market for our current and future solutions are based on a number of internal and third-party estimates and assumptions. In particular, our market estimates are based on assumptions regarding the size of the global life sciences research tools market, the number of labs and companies participating in such market and currently using single cell, spatial or adjacent research techniques and the anticipated spend levels of such potential customers were they to adopt our solutions. Underlying our market estimates are a number of estimates and assumptions, including the assumption that government or other sources of funding will continue to be available to life sciences researchers at times and in amounts necessary to allow them to purchase our solutions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our growth strategy involves launching new solutions and expanding sales of existing solutions into new areas in which we have limited or no experience. We also expect to pursue additional opportunities that will further expand our opportunity, including new products and new potential applications of our single cell, spatial and in situ technologies in the future. Sales of new or existing solutions into new opportunities may take several years to develop and mature and we cannot be certain that these opportunities will develop as we expect. For example, new life sciences technology is often not adopted until a sufficient amount of research conducted using such technology has been published in peer-reviewed publications. Because there can be a considerable delay between the launch of a new life sciences product, new version or a new application of an existing life science product and publication of research using such product, new life sciences products, versions or applications do not generally contribute a meaningful amount of revenue in the year they are introduced. In certain situations, new life sciences products, versions or applications, even if sufficiently covered in peer-reviewed publications, may not be adopted until the consistency and accuracy of such technology, method or device has been proven. As a result, the sizes of the commercial opportunities available for new products, versions and applications are even more difficult to predict.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe our assumptions and the data underlying our market estimates for our solutions are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates, or those underlying the third-party data we have used, may change at any time, thereby reducing the accuracy of our estimates. As a result, our estimates of the annual total addressable market and annual serviceable addressable market for our solutions may be incorrect.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future growth of our current and future solutions depends on many factors beyond our control including, among other factors, recognition and acceptance of our solutions by the scientific community as best practice and the growth, prevalence and costs of competing products and solutions. Such recognition and acceptance may not occur in the near term, or at all. If demand for our current and future solutions are smaller than estimated or do not develop as we expect, our growth may be limited and our business, financial condition and operational results may be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products generate large-scale complex data which requires advanced analytics to interpret.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products generate highly complex data that can present significant challenges in terms of understanding and interpretation, particularly for customers who may lack bioinformatics expertise or dedicated computational resources. The advanced nature of the data generated by our products requires a certain level of expertise to analyze and interpret effectively. Some of our customers may lack the necessary technical skills or resources to fully understand and utilize the data. As a result, they may experience difficulties in deriving actionable insights, which could delay additional usage of our products or diminish their perceived value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To address the complexity of data, we may need to provide extensive training and support to our customers. Despite these investments, there is no guarantee that customers will achieve the necessary level of proficiency or efficiency in analyzing data. Providing ongoing customer education and technical assistance may increase operational costs, and place additional demands on our customer support teams. If customers struggle to extract meaningful insights from their data, this could reduce the perceived value of our solutions and slow adoption of our solutions. If customers encounter difficulties with data analysis, it could negatively impact their satisfaction with our products, lead to delays in reordering our products or services desire or lead them to decide not to purchase additional products or services, any of which would negatively impact our financial results.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to effectively manage product transitions or accurately forecast customer demand could result in excess or obsolete inventory and resulting charges.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the market for our products is characterized by rapid technological advances, we frequently introduce new products or new versions of existing products designed for improved ease-of-use, improved performance or additional features and functionality. At times, we preannounce products and services, in some cases before such products and services have been fully developed or tested, and risk failing to meet expectations when and if such products and services become available. The risks associated with the introduction of new products or new versions include the difficulties of predicting customer demand and effectively managing inventory levels to ensure adequate supply of the new product or new versions and avoiding excess supply of the legacy product, including legacy versions of our instruments which are supplanted by new versions. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, we recorded charges of $11.3 million and $7.8 million in 2024 and 2023 related to excess and obsolete inventory.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the past supply chain disruptions, logistics, shipping and other distribution disruptions and labor shortages have made it more difficult to predict customer demand and effectively manage inventory levels for our instruments and consumables. At times the risk that we will not be able to source the necessary equipment, components and materials to manufacture our products led us, and may again lead us, to carry higher inventory. Further, differences in purchasing patterns across our customer base could negatively impact our ability to accurately forecast demand.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may strategically enter into non-cancelable commitments with vendors to purchase materials for our products in advance of demand to take advantage of favorable pricing, address concerns about the availability of future supplies or build safety stock to help ensure customer shipments are not dela</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">yed should we experience higher than anticipated demand for materials with long lead times. During periods of decreased demand, which in the past have occurred and which may occur again, these non-cancelable commitments could result in additional inventory-related charges.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These factors may result in excess or obsolete inventory charges adversely impacting our financial results and condition. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to consistently manufacture our instruments and consumables to the necessary specifications or in quantities necessary to meet demand at an acceptable cost or at an acceptable performance level.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are integrated solutions with many different components that work together. As such, a quality defect in a single component can compromise the performance of the entire solution. Certain of our consumables are manufactured at our Pleasanton, California, Singapore, Taiwan and other facilities using complex processes, sophisticated equipment and strict adherence to specifications and quality systems procedures. Our Chromium, Visium CytAssist and Xenium instruments are manufactured by our third-party manufacturers at their facilities. In order to successfully generate revenue from our products, we need to manufacture products that meet our specifications before we allow them to be shipped and to supply our customers with products that meet their expectations for quality and functionality in accordance with established specifications. In order to ensure we are able to meet these expectations, our Pleasanton, California, Singapore and Taiwan manufacturing facilities, as well as the facilities of our third-party manufacturers, have obtained International Organization for Standardization (&#8220;ISO&#8221;) quality management certifications and employ other quality control measures. On occasion, our customers have experienced quality control and manufacturing defects and may again in the future. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, as we continue to evolve and introduce new products and new versions of existing products, and as our products incorporate increasingly sophisticated technology, it will be increasingly difficult to ensure our products are produced in the necessary quantities without sacrificing quality and in the necessary timeframes. There is no assurance that we or our third-party </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturers will be able to continue to manufacture our products so that they consistently achieve the product specifications, quality and volumes that meet our requirements or our customers' expectations. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the raw and other materials we use and certain of our consumables have a shelf life, after which their performance is not ensured. In the past the expiration of raw and other materials have increased, and may in the future increase, our operational costs and cause delays in manufacturing adequate volumes of our products within the timeframes required. Shipments of defective instruments or consumables to customers resulting in recalls and warranty replacements have increased, and may in the future increase, our costs, and depending upon current inventory levels and the availability and lead time for additional inventory, could lead to availability issues. Any design issues, unforeseen manufacturing problems, such as contamination of our third-party manufacturer's facilities, equipment malfunctions, aging components, quality issues with components and materials sourced from third-party suppliers, or failures to strictly follow procedures or meet specifications, may have a material adverse effect on our brand, business, financial condition and operating results and could result in us or our third-party manufacturers losing ISO quality management certifications. If we or our third-party manufacturers fail to manufacture products without defects that meet our specifications or maintain ISO quality management certifications, our customers might choose not to purchase products from us. Furthermore, we or our third-party manufacturers may not be able to increase manufacturing to meet anticipated demand or may experience downtime.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as we increase manufacturing capacity, we have needed, and in the future may need, also to make corresponding improvements to other operational functions, such as our customer service and billing systems, compliance programs and our internal quality assurance programs. We have needed and may in the future need additional equipment, manufacturing and warehouse space and trained personnel to process higher volumes of products. We cannot assure you that such increases in scale, related improvements and quality assurance will be successfully implemented or that equipment, manufacturing and warehouse space and appropriate personnel will be available or that they will realize their intended benefits. As we develop additional products, we may need to bring new equipment online, implement new systems, technology, controls and procedures and hire personnel with different qualifications. Our ability to increase our manufacturing capacity at our Pleasanton, California, Singapore, Taiwan and other locations is complicated by the use of our proprietary equipment that is not readily available from third-party manufacturers.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk of manufacturing defects or quality control issues is generally higher for new products and new versions of existing products, whether produced by us or a third-party manufacturer, products that are transitioned from one manufacturer to another, particularly if manufacturing is transitioned or initiated with a manufacturer we have not worked with in the past, and products that are transferred from one manufacturing facility to another. Our current product roadmap calls for the introduction of new products and new versions of existing products, which may require that we utilize manufacturers with which we have little or no prior manufacturing experience, which could increase the risk of manufacturing defects or quality control issues. The expansion of our manufacturing capabilities has increased and in the future could increase the risk of manufacturing defects or quality control issues in the consumables we manufacture. We and our third-party manufacturers may not be able to launch new products or new versions of existing products on time, transition manufacturing of existing products to new manufacturers, transition our manufacturing capabilities to a new location or transition manufacturing of any additional consumables in-house without manufacturing def</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ects or other issues. </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An inability to manufacture products and components that consistently meet specifications, in necessary quantities and at commercially acceptable costs will have a negative impac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t and may have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our instruments, consumables and related components are specialized, complex and difficult to manufacture. We could experience production problems that impact our ability to manufacture and ship our instruments, consumables and related components, which would materially and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing processes we and our third-party manufacturers use to produce our instruments, consumables and related components are specialized and highly complex and require high-quality components. We may have quality variations, supply issues, backorders, delays, shortages or production difficulties of needed components and may require components that are difficult to obtain or manufacture in necessary quantities and at necessary quality, in a timely manner or in accordance with regulatory requirements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such issues, issues with our manufacturing processes or the manufacturing processes of our third-party manufacturers, shipping issues, inaccurate demand forecasts or other production issues could result in our inability to produce our products in sufficient volumes and at sufficient quality to meet demand, supply our products to our customers and for our research and development needs, backorders, insufficient inventory, excess inventory, shipping delays, product deficiencies or other operational failures. For </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">example, in the past the COVID-19 pandemic disrupted air, sea and other travel in the United States and globally. Similar disruptions in the future could reduce or eliminate our ability to receive components or supply our customers. Many other factors could cause production or shipping delays or interruptions, including difficulties in transporting materials, equipment, raw material or other shortages, raw material failures, spoilage, equipment malfunctions, facility contamination, labor problems, natural disasters, tariffs, trade disputes and other trade restrictions, infectious disease, conflict, war, civil unrest, epidemics or pandem</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, disruption in utility services, terrorist activities or circumstances beyond our control. Additionally, we and our third-party manufacturers may encounter problems in hiring and retaining the experienced specialized personnel needed to develop and operate our manufacturing processes or the manufacturing processes of our third-party manufacturers, which could result in backorders, shortages, delays in our production or difficulties in maintaining compliance with applicable regulatory requirements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These issues, or any other problems with the production or timely manufacture and shipment of our instruments, consumables and related components, could materially harm our business, financial condition and results of operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Undetected errors or defects in our solutions could harm our reputation and decrease market acceptance of our solutions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our instruments and consumables, as well as the software that accompanies them, have in the past and may again in the future contain undetected errors or defects due to design, manufacturing, delivery or other issues. Disruptions or other performance problems with our products or software may adversely impact our customers&#8217; research or business, harm our reputation and result in reduced revenue or increased costs associated with product repairs or replacements. If that occurs, we may also incur significant costs, the attention of our key personnel could be diverted or other significant customer relations problems may arise. We have and may again in the future also be subject to warranty claims related to errors or defects in our solutions, and in the future we may be subject to breach of contract for damages related to such errors or defects.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to develop new products or new versions of existing products, enhance the capabilities of our existing products to keep pace with rapidly changing technology and customer requirements or successfully manage the transition to new product offerings, any of which could have a material adverse effect on our business and operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends on our ability to develop new products. new versions and applications for our technology while improving the performance and cost-effectiveness of our existing products, in each case in ways that address current and anticipated customer requirements. Such success is dependent upon several factors, including feasibility, competition among our products for Company resources and in customer purchasing decisions, functionality, competitive pricing and integration with existing and emerging technologies. The development timelines of certain potential new products or new versions may be delayed or precluded due to prioritization of other new products or versions. New technologies, techniques or products offered by others could emerge that might offer better combinations of price and performance or better address customer requirements as compared to our current or future products or in some cases our own new products or new versions of existing products could erode sales or supplant the demand for other products we sell. In addition, while we have invested, and expect to continue to invest, significantly in research and development and the commercialization of both new products and new versions of existing products, investment decisions we make or have made with respect to the allocation of our substantial but finite resources, including regarding product development or to support our commercial organization, may not be successful or realize their anticipated benefits.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Existing and potential customers for our current and future products, including customers interested in genomics, single cell analysis, spatial analysis or in situ solutions, are accustomed to rapid technological change and innovation. Competitors may be able to respond more quickly and effectively than we can to new or changing opportunities, technologies, standards or customer requirements. Due to the significant lead time involved in bringing a new product or version to market, we are required to make a number of assumptions and estimates regarding the technical or commercial feasibility of a new product or version, including assumptions and estimates regarding our or our partners&#8217; ability to design and manufacture potential solutions, the biological analytes that researchers will want to measure, the appropriate method of measuring such analytes, how researchers intend to use the resulting data and the scope and type of data that will be most useful to researchers. As a result, it is possible that we may fail to introduce certain products which we intended (and in some cases may have publicly announced our intention) to bring to market or we may introduce a new product or a new version of an existing product that fails to meet the performance or price expectations of our customers, uses technologies or methods of analysis that have been displaced by the time of launch, competes with one or more of our other products in a way which harms our business, addresses an opportunity that no longer exists or is smaller than anticipated, targets biological analytes or produces data that provides less utility to researchers than anticipated or otherwise is not competitive at the time of launch. Additionally, even if we are successful in introducing new products or new versions of existing products which are embraced by our customers and the research community, such introductions may result in decreased demand for our existing products which are not offset by increases in demand for our new products or versions, at least temporarily. Our revenues may suffer while customers transition their research to utilize our new products or new versions of existing products, as such transitions can be lengthy and require significant time to reach purchasing levels equivalent to those of our existing products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our Chromium and Visium solutions are used with third-party sequencers to conduct an experiment, we also expect competition from third-party sequencer manufacturers as researchers and labs look to reduce the total cost of any given experiment. For example, if a third-party sequencer manufacturer were successful in providing functionality akin to our products, they potentially could be able to deliver a solution that is capable of running comparable experiments with a total experiment cost that would be less than the cost of running such experiments using our products together with third-party sequencers. The integration of competing products with sequencing products could also create a &#8220;stickiness&#8221; effect advantaging such a third-party sequencer manufacturer, where a potential 10x customer could choose a competing product due to perceived or actual ease of use, simplified workflow or lower overall cost.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conversely, if genome sequencing falls out of favor as a preferred approach for genomic research, whether through the development of alternative solutions or real or perceived problems with sequencing itself or if our Chromium and Visium products are not compatible with third-party sequencers used by our customers or potential customers, the utility of our products which are used in conjunction with third-party sequencers could be significantly impacted. It is critical to our success that we anticipate changes such as these in technology and customer requirements and successfully introduce new, enhanced and competitive technologies to meet our customers&#8217; and prospective customers&#8217; needs on a timely and cost-effective basis. If we do not successfully innovate and introduce new technology into our product lines, our business and operating results will be adversely impacted.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to attract new customers and increase revenue from existing customers depends in large part on our ability to enhance and improve our existing solutions and to introduce compelling new solutions. The success of any enhancement to our solutions depends on several factors, including technical specifications, timely completion and delivery, competitive pricing and features, adequate quality testing, integration with existing technologies and overall market acceptance. Any new solution that we develop may not be introduced in a timely or cost-effective manner, may contain errors, vulnerabilities or bugs, or may not achieve the market acceptance necessary to generate significant revenue. If we are unable to successfully develop new solutions, enhance our existing solutions to meet customer requirements or expectations, or otherwise gain market acceptance, our business, results of operations and financial condition could be harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to attract new customers and increase revenue from existing customers also depends on our ability to deliver any enhanced or new solutions to our customers in a format where they can be easily and consistently deployed by most or all users without significant customer service or training. If our customers believe that deploying our enhanced or new solutions would be overly time-consuming, confusing or technically challenging, or require significant training or retraining, then our ability to grow our business would be substantially harmed. We aim to create and deliver repeatable, user-friendly, prescriptive approaches to deployment that allow users of all kinds to effectively and easily deploy our solutions, and if we fail to do so, our business and results of operations could be harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The typical development cycle of new life sciences products or new versions of existing products can be lengthy and complicated and may require new scientific discoveries or advancements and complex technology and engineering. Such developments may involve external suppliers and service providers, making the management of development projects complex and subject to risks and uncertainties regarding timing, timely delivery of required components or services and satisfactory technical performance of such components or assembled products.&#160;</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are significantly dependent upon revenue generated from the sale of our Chromium solutions, and in particular our Universal Gene Expression solutions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently generate the majority of our revenue from the sale of our instruments and consumables for our Chromium platform. There can be no assurance that we will be able to sustain or increase the success we have historically achieved with our Chromium solutions. For example, revenue from single cell solutions decreased year-over-year in 2024. In addition, we may not be able to design future Chromium products that will meet the needs of our customers or become and remain commercially successful. Our expectations are based on the continued success of our existing solutions and the future success of new products and new versions of existing products that we launch. Revenue from our single cell solutions decreased year-over-year in 2024 which adversely impacted our financial results, and if revenue from our single cell solutions continues to decrease, remains flat or does not increase in line with our expectations, our revenue and financial results could be materially and adversely impacted.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Doing business internationally creates operational and financial risks for our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently serve thousands of researchers in many countries and plan to continue to expand to new international jurisdictions as part of our growth strategy. For the years ended December&#160;31, 2024 and 2023, approximately 43% and 40%, respectively, of our revenue was generated from sales to customers located outside of North America. We believe that a significant portion of our future revenue will come from international sources. We sell directly in North America and certain regions of Asia, Oceania and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Europe and have a significant portion of our sales and customer service personnel in the United States. We sell our products through third-party distributors in certain regions of Asia, Europe, Oceania, Central America, South America, the Middle East and Africa. As a result,&#160;we or our distribution partners may be subject to additional regulations. Conducting operations on an international scale requires close coordination of activities across multiple jurisdictions and time zones.&#160;If we fail to coordinate and manage these activities effectively, our business, financial condition or results of operations could be materially and adversely affected and failure to comply with laws and regulations applicable to business operations in foreign jurisdictions may also subject us to significant liabilities and other penalties.&#160;International operations entail a variety of other risks, including, without limitation:</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variances in demand for our products across regions, including in China and elsewhere in the Asia-Pacific region;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">currency fluctuations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">tariffs or other restrictions imposed by the United States on goods from other countries and tariffs or other restrictions imposed by other countries on United States goods, or increases in existing tariffs;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in diplomatic and trade relationships, including new or enhanced tariffs or duties, trade protection measures, import or export licensing requirements, trade embargoes and other trade barriers;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges in staffing and managing foreign operations, including executing our commercial goals and our dependence on our distributors in certain regions;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potentially longer sales cycles and more time required to engage and educate customers on the benefits of our products outside of the United States;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complexities associated with managing third-party contract manufacturers and suppliers located outside of the United States;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">United States and foreign government trade restrictions, including those which may impose restrictions on the importation, exportation, re-exportation, sale, shipment or other transfer of programming, technology, components and/or services to foreign persons or entities;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced protection for intellectual property rights in some countries and practical difficulties of enforcing intellectual property or other legal rights abroad;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">deterioration of political relations between the United States and China, the United States and Russia or other nations or political organizations, which could have a material adverse effect on our sales and operations in these countries;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in social, political and economic conditions or in laws, regulations and policies governing foreign trade, manufacturing, development and investment both domestically as well as in the other countries and jurisdictions into which we sell our products;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in obtaining export licenses or in overcoming other trade barriers and restrictions resulting in delivery delays or our inability to manufacture or sell our products in certain countries;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">natural disasters, infectious diseases, conflict, geopolitical turmoil, war, civil unrest, epidemics, pandemics or major catastrophic events;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased financial accounting and reporting burdens and complexities;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential need for localized software, documentation and post-sales support; </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">higher levels of credit risk and payment fraud and longer payment cycles associated with, and increased difficulty of payment collections from certain international customers; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant taxes or other burdens of complying with a variety of foreign laws, including laws relating to privacy and data protection such as the European Union General Data Protection Regulation (&#8220;GDPR&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conducting our international operations, we are subject to United States laws relating to our international activities, such as the Foreign Corrupt Practices Act of 1977, as well as foreign laws relating to our activities in other countries, such as the United Kingdom Bribery Act of 2010. Additionally, our business must be conducted in compliance with applicable economic and trade sanctions laws and regulations, such as those administered and enforced by the U.S. Department of Treasury&#8217;s Office of Foreign Assets Control, the U.S. Department of State, the U.S. Department of Commerce, the United Nations Security Council and other relevant sanctions authorities. These laws generally prohibit, unless authorized by the relevant authority or otherwise exempt from the regulations, the conduct of business with persons, countries, regions, and governments that are targeted by &#8220;sanctions,&#8221; including but not limited to persons listed on the United States Department of Commerce&#8217;s List of Denied Persons and the United States Department of Treasury&#8217;s Specially Designated Nationals and Blocked Persons List, and the areas subject to trade </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">embargoes by the United States (currently, Cuba, Iran, Syria, North Korea, and the Crimea, Donetsk and Luhansk regions of Ukraine). Our global operations expose us to the risk of violating, or being accused of violating, these laws and regulations. Failure to comply may subject us to reputational harm, claims or significant financial and/or other penalties in the United States and/or foreign countries that could materially and adversely impact our operations or financial condition, including criminal fines, imprisonment, civil fines, disgorgement of profits, injunctions and debarment from government contracts, as well as other remedial measures. Investigations of alleged violations can be expensive and disruptive.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These risks have become increasingly prevalent as we have expanded our sales into countries that are generally recognized as having a higher risk of corruption and sanctions risks. As a result of the crisis in Ukraine both the United States and the European Union have implemented sanctions against certain Russian individuals and entities. While at this time we no longer do business in Russia, our previous business there could expose us to risks that could adversely affect our business, financial condition, results of operations, cash flows or the market price of our securities, including tariffs, economic sanctions and import-export restrictions. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of complex foreign and United States laws and regulations could result in fines and penalties, criminal sanctions against us, our officers or our employees, prohibitions on the conduct of our business and on our ability to offer our products and services in one or more countries, and could also materially affect our brand, our international growth efforts, our ability to attract and retain employees, our business and our operating results. Even if we implement policies or procedures designed to ensure compliance with these laws and regulations, there can be no assurance that our distribution partners, our employees, contractors or agents will not violate our policies and subject us to potential claims or penalties.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business in China subjects us to unique commercial, operational, competitive and regulatory risks.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weakening economic conditions in China, our dependence on local distributors and other third parties to commercialize our products in China, and local competition and trade tensions between the United States and China (including recent U.S. tariffs imposed or threatened to be imposed on China and any potential retaliatory actions taken by China), among other factors, have in the past resulted, and may again result, in difficulty generating revenue for sales of our products in China. In early 2025, trade and export control tensions between the United States and China substantially increased.  See the risk factor titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade tariffs, import restrictions, export restrictions, Chinese regulations or other trade barriers may materially harm our business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; We purchase certain materials originating in China which are subject to the increased tariffs imposed by the United States and as such, these tariffs have increased and may in the future increase our costs, negatively impacting our financial results. Additionally, tariffs have been implemented in China that cover exports of certain of our products from the United States into China. It is possible that China could raise existing tariff rates on our products or that new or enhanced tariffs may be imposed that could cover imports or the export or sale of our products, which could adversely affect the marketability of our products and our results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to sell our products in China may be negatively impacted by other evolving laws and regulations in the U.S. and China. Certain risks and uncertainties of doing business in China are within the control of the Chinese government, and Chinese law regulates the scope of our investments and business conducted within China. The Chinese government requires compliance with significant technical and other regulatory requirements and may adopt new regulations that may impact entities operating in China, including us, our distributors, suppliers and other third parties, potentially with little advance notice, which may directly or indirectly impact our sales and operations in China. These actions may increase the cost of doing business in China or limit how we may do business in China, which could materially and adversely affect our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we believe that in the past certain of our distributors in China held excess inventory of certain of our products, in part due to fluctuations in customer purchasing patterns in China due to COVID-19, which we believe resulted in lower than anticipated sales of our products to our distributors in China in 2023 as such distributors sold off such excess inventory. Excess inventory held by our distributors, in China or elsewhere, may negatively impact our revenues in the future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have suppliers, employees and manufacturing operations in Taiwan. As a result, our business could be materially and negatively impacted by adverse changes in China-Taiwan relations. Accordingly, further deterioration in military, political and economic relations between China and Taiwan, as well as the ongoing geopolitical and economic uncertainty between the U.S. and China and other geopolitical risks with respect to China and Taiwan, may cause disruptions in our ability to source products or materials from or to China and Taiwan, which may, directly or indirectly, harm our business.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our customers are dependent on single source and sole source suppliers for some of the equipment, components and materials used in our products and in conjunction with our products and the loss of any of these suppliers could harm our business. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have long-term contracts with our suppliers for many of the services, equipment, materials and components we use for the manufacture and delivery of our products. We also rely on single suppliers for certain equipment, materials and components. In many cases we do not have long term contracts with these suppliers, and even in the cases where we do, some such contracts include significant qualifications that would make it extremely difficult for us to force the supplier to provide us with their services, equipment, materials or components should they choose not to do so. We are therefore subject to the risk that these third-party suppliers will not be able or willing to continue to provide us with equipment, materials and components that meet our needs, specifications, quality standards and delivery schedules. Factors that could impact our suppliers&#8217; willingness and ability to continue to provide us with the required equipment, materials and components include shortages, alternative priorities, logistics, tariffs or other trade restrictions impacting our suppliers, shipping or other distribution difficulties, disruption at or affecting our suppliers&#8217; facilities, such as difficulties hiring and retaining adequate staffing, work stoppages or natural disasters, infectious disease, epidemics or pandemics, adverse weather or other conditions that affect their supply, the financial condition of our suppliers, disagreements, disputes or deterioration in our relationships with these suppliers or the decision by such suppliers to introduce products that compete directly with our solutions. If we are not able to obtain equipment, materials and components that meet our needs, specifications, quality standards and delivery schedule on satisfactory terms, our business will be harmed. Any increase in equipment, material and component costs or decrease in availability could reduce our sales, harm our gross margins or prevent us from timely delivering our products to our customers.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, we depend on a limited number of suppliers for enzymes and amplification mixes used in our consumables. In some cases, these manufacturers are the sole source of certain necessary enzymes and reagents. We do not have long-term contracts with many of these sole source suppliers. Lead times for some of these components can be several months or more and in the past have been, and in the future could be, extended due to supply chain disruptions, labor shortages or other factors. In the event that demand increases, a manufacturing &#8216;lot&#8217; does not meet our specifications, we fail to forecast and place purchase orders sufficiently in advance or other issues surface in our supply chain, a material shortage may occur. Some of the components and formulations are proprietary to our vendors, thereby making second sourcing and development of a replacement difficult. Furthermore, such vendors may have intellectual property rights that could prevent us from sourcing such reagents from other vendors. Some vendors could choose to use their enzymes, amplification mixes or other components to create products that directly compete with our consumables and end our current supplier-customer relationship. If enzymes and reagents become unavailable from our current suppliers and we are unable to find acceptable substitutes for these suppliers, we may be required to produce them internally or change our product designs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we make the majority of our equipment in-house, we have not qualified secondary sources for all equipment, materials or components that we source through a single supplier and qualification of a secondary supplier may not prevent future supply issues. Labor shortages, logistics, shipping or other distribution operations difficulties or disruption in the supply of equipment, materials or components could impair our ability to sell our products and meet customer demand, and also could delay the launch of new products or new versions of existing products, any of which could harm our business and results of operations. If we were to have to change suppliers, the new supplier may not be able to provide us equipment, materials or components in a timely manner and in adequate quantities that are consistent with our quality standards and on satisfactory pricing terms. In addition, alternative sources of supply may not be available for equipment or materials.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have taken steps to mitigate potential supply chain and transportation infrastructure system issues, the impact of supply chain disruptions, logistics, shipping and other distribution disruptions, labor shortages or other factors may exacerbate the risks described in this risk factor and could cause certain of our suppliers to reduce their ability to meet our or our customers' needs, be unable to operate temporarily or even go out of business permanently. The realization of any of these risks could prevent us from producing, selling or delivering our products, reduce our sales and harm our gross margins or permanently cause a change in one or more of our products that may not be accepted by our customers or cause us to eliminate that product altogether. In addition, our suppliers or customers may face difficulties in procuring or delivering, or in some cases may be unable to procure or deliver, the equipment, materials or components from their own suppliers necessary to supply us with products, equipment, components or materials or conduct experiments using our solutions. For example:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">tariffs, trade disputes and other trade restrictions could have a material impact on the ability of suppliers to meet our or our customers&#8217; needs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition for shipping and air transport in the past impacted, and in the future may impact, our ability to timely deliver products to our customers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">energy shortages and other issues in the past impacted, and in the future may impact, factory production of upstream components utilized by us or our suppliers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">shortages of non-10x sequencing consumables in the past impacted, and in the future may impact, the workflows of our customers and their ability to complete their experiments;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">plastic component shortages, including of pipette tips utilized by our customers to complete their experiments, in the past impacted, and in the future may impact, the availability of plastic components used by us and our customers in connection with our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">shortages of certain chemicals, oils and beads utilized in our microfluidic chips in the past impacted, and in the future may impact, our ability to carry a buffer of inventory to safeguard against continuous significant shortages of such materials; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">semiconductor chip shortages in the past impacted, and in the future may impact, the availability of semiconductor chips utilized in our instruments and in the manufacture of certain of our products; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the storage and distribution of vaccines in the past impacted, and in the future may impact, the availability of cold storage for components and materials used by us and our customers in connection with our products.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain disruptions in supply of, and changes in the competitive environment for, raw materials integral to the manufacturing of our products may adversely affect our profitability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a broad range of materials and supplies, including metals, chemicals and electronic components, in our products. A significant disruption in the supply of materials could decrease production and shipping levels, materially increase our operating costs and materially adversely affect our profit margins. Shortages of materials or interruptions in production and transportation systems, labor strikes, work stoppages, infectious disease, epidemics or pandemics, geopolitical issues (including tariffs, trade disputes and other trade restrictions), conflict, war, civil unrest, acts of terrorism or other interruptions to or difficulties in the employment of labor or transportation that adversely impact equipment, materials and components we require for the production of our products, may adversely affect our ability to maintain production of our products and generate revenue. In addition, a significant prolonged increase in inflation could negatively impact the cost of materials and components. Even if in some cases we are able to pass some or all such cost increases to customers by increasing the selling prices of our products, higher product prices may also result in a reduction in sales volumes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unforeseen end-of-life or unavailability of certain components, such as enzymes, could force us to purchase materials on the spot market at higher cost or require us to modify our product specifications to accommodate replacement components which could be costly or delay product shipments. If we were to experience a significant disruption in the supply of, or prolonged shortage of, critical components from any of our suppliers and could not procure the components from other sources, we would be unable to manufacture our products and to ship such products to our customers in a timely fashion, which would adversely affect our sales, margins and customer relations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our limited operating history and fluctuations in revenue make it difficult to evaluat</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">e our future prospects and the risks and challenges we may encounter.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We launched our first product in mid-2015 and have historically experienced revenue growth, though our revenue decreased year-over-year in 2024.&#160;In addition, we operate in highly competitive markets characterized by rapid technological advances and our business has, and we expect it to continue, to evolve over time to remain competitive. Our limited operating history, evolving business and fluctuations in revenue make it difficult to evaluate our future prospects and the risks and challenges we may encounter and may increase the risk that we will not continue to grow at or near historical rates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to address the risks and difficulties that we face, including those described elsewhere in this &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; section, our business, financial condition and results of operations could be adversely affected. We have encountered in the past, and will encounter in the future, risks and uncertainties frequently experienced by companies with limited operating histories in rapidly changing industries. If our assumptions regarding these risks and uncertainties, which we use to plan and operate our business, are incorrect or change, or if we do not address these risks successfully, our results of operations could differ materially from our expectations and our business, financial condition and results of operations could be materially and adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our existing and new products or new versions of existing products fail to achieve and sustain sufficient scientific acceptance, we will not generate expected revenue and our prospects may be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The life sciences scientific community is comprised in part of a small number of early adopters and key opinion leaders who significantly influence the rest of the community. The success of life sciences products is due, in large part, to acceptance by the scientific community and their adoption of certain products as best practice in the applicable field of research. The current system of academic and scientific research views publishing in a peer-reviewed journal as a measure of success. In such journal publications, the researchers will describe not only their discoveries but also the methods and typically the products used to fuel such discoveries. We believe mentions in peer-reviewed journal publications is a good barometer for the general acceptance of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our products as best practices. The number of times our products were mentioned in peer-reviewed publications has increased significantly since launching our first product in 2015. During this time, our revenue has also increased significantly. Ensuring that early adopters and key opinion leaders publish research involving the use of our products is important to ensuring our products gain widespread acceptance and market growth. Continuing to maintain good relationships with such key opinion leaders is vital to growing our market. Our products may not continue to be mentioned in peer-reviewed articles with frequency. Any new products or new versions of existing products that we introduce in the future may not be mentioned in peer-reviewed articles. If too few researchers describe the use of our products, too many researchers shift to a competing product and publish research outlining their use of that product or too many researchers negatively describe the use or usability of our products in publications, our existing and potential customers may be driven away from our products, which could harm our operating results.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not sustain or successfully manage our growth and anticipated growth, our business and prospects will be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically experienced rapid organizational growth and we expect that future growth will place significant strains on our management, operational and manufacturing systems and processes, financial systems and internal controls and other aspects of our business. For example, we consummated two acquisitions in each of 2018 and 2020, one in 2021 and another in 2023, and we intend to continue to make investments that meet management&#8217;s criteria to expand or add key technologies that we believe will facilitate the commercialization of new products or new versions of existing products in the future. We intend to launch additional new products and new versions of existing products in the near future. Further development and commercialization of our current and future products are key elements of our strategy. Developing and launching new products and innovating and improving our existing products have required us to hire and retain additional scientific, sales and marketing, software, manufacturing, distribution and quality assurance personnel. As a result, we have experienced rapid headcount growth from 110 employees as of December&#160;31, 2015 to 1,306 employees as of December&#160;31, 2024. As we have grown, our employees have become more geographically dispersed.&#160;We may face challenges integrating, developing and motivating our employee base, including as a result of certain of our employees working remotely. In addition, certain members of our management have not previously worked together for an extended period of time, do not have experience managing a public company or do not have experience managing a global business, which may affect how they manage our business. To effectively manage our business, we must continue to improve our systems and processes</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and continue to effectively expand, train and manage our personnel. As our organization continues to evolve, we may find it increasingly difficult to maintain the benefits of our corporate culture, including our ability to quickly develop and launch new and innovative products or versions.&#160;If we do not successfully manage our anticipated organizational growth, our business, results of operations and growth prospects will be harmed.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since inception, we expect to incur losses in the future and we may not be able to generate sufficient revenue to achieve and maintain cash flows from operating activities in excess of our capital investment requirements or profitability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant losses since we were formed in 2012 and expect to incur losses in the future. We incurred net losses of $182.6 million and $255.1 million for the years ended December&#160;31, 2024 and 2023, respectively. As of March&#160;31, 2025, we had an accumulated deficit of $1.5 billion. We expect that our losses will continue in the near term as we continue to invest significantly in research and development and the commercialization of both new products and improved versions of existing products. We also expect that our operating expenses will continue to increase as we grow our business. To date, we have financed our operations principally from equity offerings, revenue from sales of our products and the incurrence of indebtedness. There can be no assurance that our revenue and gross profit will increase sufficiently such that our net losses decline, or that we attain cash flows from operating activities in excess of our capital investment requirements on a sustained basis or attain profitability, in the future. Further, our limited operating history and fluctuations in revenue over the last several years make it difficult to effectively plan for and model future revenue and operating expenses. Our ability to achieve or sustain profitability is based on numerous factors, many of which are beyond our control, including general economic, industry and market conditions, customer purchasing decisions, the impact of market acceptance of our products, future product development, our market penetration and margins and current and future litigation. Additionally, inflationary pressures could adversely impact our financial results. Our operating costs have increased, and may continue to increase, due to the recent growth in inflation, which may be exacerbated by tariffs imposed by the United States which are currently, or in the future, under consideration, proposed or enacted. We may not fully offset these cost increases by raising prices for our instruments and consumables, which could result in downward pressure on our margins. Further, while we anticipate lowering prices on certain of our products in 2025, our customers may choose to reduce their business with us if in the future we increase our pricing. Additionally, changes in our product mix may negatively affect our gross margins. We may never be able to generate sufficient revenue to achieve or sustain cash flows from operating activities in excess of our capital investment requirements or profitability and our historical growth should not be considered indicative of our future performance. Our failure to achieve, return to or maintain growth, cash flows from operating activities in excess of our capital investment requirements or profitability could negatively impact the value of our Class&#160;A common stock.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations could be materially adversely affected by fluctuations in foreign currency exchange rates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, most of our revenue has been denominated in U.S. dollars, although we have sold our products and services in local currency outside of the United States, principally the euro. For the years ended December&#160;31, 2024 and 2023, approximately 27% and 23%, respectively, of our sales were denominated in currencies other than U.S. dollars. Our expenses are generally denominated in the currencies in which our operations are located. As our operations in countries outside of the United States grow, our results of operations and cash flows will become increasingly subject to fluctuations due to changes in foreign currency exchange rates, which could harm our business in the future. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During periods of economic crises, foreign currencies may be devalued significantly against the U.S. dollar, reducing our margins. In addition, because we conduct business in currencies other than U.S. dollars, but report our results of operations in U.S. dollars, we also face remeasurement exposure to fluctuations in currency exchange rates, which could hinder our ability to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">predict our future results and earnings and could materially impact revenue and our results of operations. We do not currently maintain a program to hedge foreign currency exposures and even if in the future we implement a program to hedge such exposures, we may not be successful in mitigating the effects of fluctuations in foreign currency exchange rates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to our exposure to currencies other than U.S. dollars, an increase in the value of certain currencies against the U.S. dollar could increase our costs by increasing labor and other costs that are denominated in local currency. There can be no assurance that any future hedging activities which are designed to partially offset this impact, will be successful. In addition, our currency hedging activities, if any, in the future, could themselves be subject to risk. These could include risks related to counterparty performance under future hedging contracts and risks related to currency fluctuations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on our key personnel and other highly qualified personnel, and if we are unable to recruit, train, retain and ensure the health and safety of our personnel, we may not achieve our goals.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success depends on our ability to recruit, train, retain and motivate key personnel, including our senior management, research and development, manufacturing and sales, customer service and marketing personnel. In particular, Dr.&#160;Saxonov, our Chief Executive Officer and one of our co-founders, and Dr.&#160;Hindson, our Chief Scientific Officer, President and one of our co-founders, are critical to our vision, strategic direction, culture and products. Competition for qualified personnel is intense, particularly in the San Francisco Bay Area. As we grow, we may continue to make changes to our management team, which could make it difficult to execute on our business plans and strategies. New hires, including executive hires, often require significant training and, in most cases, take significant time before they achieve</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> full productivity. Our failure to successfully integrate our personnel into our business could adversely affect our business. Additionally, some of our employees work remotely and because of the challenges of working remotely, including collaborating with and managing employees, it may take significant time before our teams can achieve full productivity, if at all, and it may take significantly longer for new hires to achieve full productivity, if at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not maintain key person life insurance for an</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y of our employees. Additionally, we have not entered into fixed term contracts with almost any of our employees, including Drs. Saxonov and Hindson, and as a result, almost any of our employees could leave our company with little or no prior notice which could harm our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our scientific personnel in the United States are qualified foreign nationals whose ability to live and work in the United States is contingent upon the continued availability of appropriate visas. W</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e expect to continue to rely on foreign nationals to fill part of our recruiting needs. As a result, changes to United States immigration policies could restrain the flow of technical and professional talent into the United States and may inhibit our ability to hire qualified personnel. Additionally, our current or future employees may be negatively affected by delays, disruptions or changes in United States immigration policies. The current United States administration has made restricting immigration and reforming the work visa process a priority and these efforts may adversely affect our ability to find qualified personnel.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our continued success depends, in part, on attracting, retaining and motivating highly trained sales personnel, including individuals with the necessary </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">scientific background and ability to understand our systems at a technical level to effectively identify and sell to potential new customers. In addition, the continued development of complementary software tools, such as our analysis tools and visualization software, requires us to compete for highly trained software engineers in the San Francisco Bay Area and elsewhere and for highly trained customer service personnel globally. We also compete for computational biologists and qualified scientific personnel with other life sciences companies, academic institutions and research institutions. This competition affects both our ability to retain key employees and hire new ones. In August 2022 we conducted a reduction in force in order to decrease costs and maintain a streamlined organization to support our business and in December 2023, we committed to a restructuring plan related to the closure of one of our research and development facilities. We conducted an additional reduction in force in May 2025 to decrease costs and adjust our organizational structure to align with our strategic priorities. We may not realize the expected benefits of this reduction in force including its anticipated cost savings, and the reduction in force may result </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in negative unintended consequences including, for example, unwanted attrition of valuable employees or organizational strain stemming from the reallocation of some responsibilities across a comparatively smaller employee base. In order to be successful and build our framework for future growth, we must continue to execute and deliver on our initiatives with fewer employees and losses of intellectual capital. We must also attract, retain, train and motivate key employees including highly qualified management, scientific, manufacturing, sales, marketing and other personnel who are critical to our business. Additionally, we compete with both companies that may have greater financial resources than we do and early stage companies that promise short-term growth opportunities. We may not be able to attract, retain, train or motivate qualified employees in the future and our inability to do so could materially harm our operating results and prospects of success.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our facilities or our third-party manufacturers&#8217; facilities become unavailable or inoperable, our research and development programs could be adversely impacted and manufacturing of our instruments and consumables could be interrupted.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing process for our instruments takes place at our third-party manufacturers' facilities.&#160;Many of our consumables are manufactured at our facilities in Pleasanton, California, Singapore, Taiwan or other of our facilities using proprietary equipment. Certain raw materials, such as oligonucleotides and enzymes, are custom manufactured by outside partners. We periodically review the manufacturing capacity of our consumables and we expect to continue to manufacture an increasing amount of consumables in-house. Our Pleasanton facilities also house the majority of our research and development and quality assurance teams. Our Chromium, Visium CytAssist and Xenium instruments are manufactured by our partners at their facilities, while we perform optical and final assembly, instrument integration and testing of our Xenium instrument in-house. The facilities and the equipment we and our third-party manufacturers use to manufacture our instruments and consumables and that we use in our research and development programs would be costly to replace and could require substantial lead times to repair or replace.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our facilities are vulnerable to natural disasters and catastrophic events. For example, our Pleasanton facilities are located near earthquake fault zones and are vulnerable to damage from earthquak</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">es. Our facilities are vulnerable to other types of disasters, including fires, floods, infectious disease, epidemics or pandemics, power loss, conflict, war, civil unrest, communications failures and similar events. If any disaster or catastrophic event were to occur, our ability to operate our business would be seriously, or potentially completely, impaired. If our facilities or any of our third-party manufacturers&#8217; facilities become unavailable or understaffed for any reason, we cannot provide assurances that we will be able to secure alternative manufacturing facilities with the necessary capabilities and equipment on acceptable terms, if at all. Additionally, potential issues with our ability to hire staff or the health and safety of our manufacturing staff could decrease the effectiveness of our manufacturing operations and adversely affect our business and operating results. The inability to manufacture our instruments and/or consumables, combined with potential limited inventory of manufactured instruments and consumables, may result in the loss of customers or harm our reputation, and we may be un</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">able to reestablish relationships with those customers in the future. Because certain of our consumables and the raw materials we use to manufacture consumables are perishable and must be kept in temperature controlled storage, the loss of power to our facilities, mechanical or other issues with our storage facilities or other events that impact our temperature controlled storage could result in the loss of some or all of such consumables and raw materials and we may not be able to replace them without disruption to our customers or at all.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial percentage of our revenue comes from sales to academic institutions, whose research often requires long uninterrupted studies performed on a consistent basis over time; thus interruptions in our ability to supply consumables could be particularly damaging to these studies and our reputation. In addition, the budgetary planning and approval process for academic research programs can be lengthy and begin well in advance of the planned purchase of our instrument and/or consumables. If our products become unavailable during the planning process, researchers may use alternative products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our research and development programs were disrupted by a disaster or catastrophe or for other reasons, the launch of new products or new versions of existing products and the timing of improvements to existing products could be significantly delayed and could adversely impact our ability to compete with other available products and solutions. If our or our third-party manufacturers&#8217; capabilities are impaired, we may not be able to manufacture and ship our products in a timely manner, which would adversely impact our business. Although we possess insurance for damage to our property and the disruption of our business, this insurance may not be sufficient to cover all of our potential losses, may not cover every potential type of loss event (including earthquakes as we do not carry earthquake insurance coverage) and may not continue to be available to us on acceptable terms, or at all.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely exclusively on commercial carriers to transport our products, including perishable consumables, to our customers in a timely and cost-efficient manner and if delivery of our products is disrupted, our business will be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business depends on our ability to quickly and reliably deliver our products and in particular, our consumables, to our customers. The majority of our consumables are perishable and must be kept below certain temperatures. As such, we ship our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">refrigerated consumables on dry ice and only ship such consumables on certain days of the week to reach customers on a timely basis. Disruptions in the delivery of our products, whether due to hiring difficulties or labor disruptions, fuel shortages, dry ice shortages, bad weather, natural disasters, infectious disease, conflict, war, civil unrest, epidemics or pandemics, terrorist acts or threats or for other reasons could result in delivery delays or our customers receiving consumables that are not fit for usage, and if used, could result in inaccurate results or ruined experiments. For example, certain of our customers were negatively impacted by a process breakdown in our logistics cold-chain that resulted in product spoilage which delayed purchases by affected customers, negatively impacting our revenue in 2022. While we work with customers to replace any consumables impacted by delivery disruptions, our reputation and our business may be adversely impacted if customers receive consumables that are not fit for usage. In addition, if we are unable to continue to obtain delivery services on commercially reasonable terms, our operating results may be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the past both shipping and air transport have been negatively impacted in terms of speed and capacity. If we cannot supply our products to our customers in a timely manner, our customers may delay or cancel their orders. Furthermore, even if we have inventory, if we do not have adequate inventory of products in the geographic regions in which they are ordered, we may not be able to deliver products to our customers in a timely manner and customers may delay or cancel their orders. Should we or our commercial carriers encounter difficulties in delivering our instruments or consumables to customers</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, it could adversely impact our ability to recognize revenue for those products and accordingly adversely affect our financial results for that period and such impact could be particularly acute at the end of any financial quarter.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs or other factors related to our facilities and real estate could adversely impact our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may decide to reduce our real estate commitments but be unable to do so. Our real estate leases, which generally obligate us for long periods, subject us to potential financial risk. Our real estate strategy may have committed, and may in the future commit, us to leases or other agreements or arrangements requiring us to incur costs for facilities we later determine are unnecessary for our business. While we have the right to terminate or sublease some of our leases under specified conditions, we may not be able to terminate or sublease certain of our leases if or when we would like to do so or we may incur substantial costs to terminate or sublease such leases. In some cases, we have been unsuccessful, and in the future again may be unsuccessful, in terminating or subleasing certain of our leases even if we have determined the facilities subject to these leases are unnecessary for our business and we have incurred, and may in the future incur, costs for such facilities despite not fully utilizing them. If we decide or are required to permanently vacate facilities we lease, we are typically required to continue to perform obligations under the applicable leases, which generally include, among other obligations, paying rent and certain expenses for the balance of the lease term, and the performance of any of these obligations may be significant. When we assign leases or sublease to third parties, or if we vacate facilities we lease, we can remain liable on the lease obligations for the balance of the term and we could be contingently liable if the assignee does not perform their obligations to us or third parties. Additionally, if we may decide to sublease certain of our facilities to third parties, we may be unable to find suitable sublease arrangements for leased facilities that we do not wish to occupy ourselves.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past we have expanded, and in the future we may expand, our facilities in the locations where we operate or may operate in the future. For example, in 2023 we completed construction of a new facility on land we own located in Pleasanton, California. We believe that maintaining our existing facilities is necessary to maintain our operations and that, in the future, new facilities may be necessary to support our business. Our ability to maintain our existing facilities, build out new or existing facilities and open new operating facilities depends on our ability to identify attractive locations, negotiate leases, subleases, real estate purchase agreements or other agreements on acceptable terms, identify and obtain adequate utility and water sources and comply with environmental regulations, zoning laws and other similar factors. We may not maintain the level of cash flow or access financing opportunities necessary to support our real estate strategy. Our facilities projects may increase demands on our operational, financial, managerial and administrative resources.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs or other factors related to our facilities and real estate ensuing from these and other risks related to our facilities and real estate may adversely impact our business results and financial condition.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to offer high-quality customer service, our business and reputation could suffer.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We differentiate ourselves from our competition in part through our commitment to an exceptional customer experience. Accordingly, high-quality customer service is important for the growth of our business and any failure to maintain such standards of customer service, or a related market perception, could affect our ability to sell products to existing</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and prospective customers. Additionally, we believe our customer service team has a positive influence on recurring consumables revenue. Providing an exceptional customer experience requires significant time and resources from our customer service team, and failure to manage </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our customer service organization adequately or impacts on our ability to provide an exceptional customer experience may adversely impact our business results and financial condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers utilize our service teams and online content for help with a variety of topics, including how</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to use our products efficiently, how to integrate our products into existing workflows, how to determine which of our other products may be needed for a given experiment and how to resolve technical, analysis and operational issues if and when they arise. As we introduce new products</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and new versions of existing products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we expect utilization of our customer service teams to increase. In particular, the introduction of new products or new versions that utilize different workflows or variations on existing workflows may require additional customer service efforts to ensure customers use such products correctly and efficiently. While we have developed significant resources for remote training, including an extensive library of online videos, we may need to rely more on these resources for future customer training or we may experience increased expe</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nses to enhance our online and remote solutions. If our customers do not adopt these resources, we may be required to increase the staffing of our customer service team, which would increase our costs. Also, as our business scales, we may need to engage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> third-party customer service providers, which could increase our costs and negatively impact the quality of the customer experience if such third parties are unable to provide service levels equivalent to ours.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of our customers has grown significantly and such growth, as well as any future growth, will put additional pressure on our customer service organization. We may be unable to hire qualified staff quickly enough or to the extent necessary to accommodate increases in demand.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as we continue to grow our operations and reach a global customer base, we need to be able to provide efficient customer service that meets our customers&#8217; needs globally at scale. In geographies where we sell through distributors, we rely on those distributors to provide customer service. If these third-party distributors do not provide a high-quality customer experience, our business operations and reputation may suffer.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our management uses certain key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions and such metrics may not accurately reflect all of the aspects of our business needed to make such evaluations and decisions, in particular as our business continues to grow.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our consolidated financial results, our management regularly reviews a number of operating and financial metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions, including the key business metrics discussed in our Annual Report. We believe that these metrics are representative of our current business; however, these metrics may not accurately reflect all aspects of our business and we anticipate that these metrics may change or may be substituted for additional or different metrics as our business evolves and as we introduce new products and new versions of existing products. If our management fails to review other relevant information or change or substitute the key business metrics they review as our business evolves and we introduce new products or new versions of existing products, their ability to accurately formulate financial projections and make strategic decisions may be compromised and our business, financial results and future growth prospects may be adversely impacted.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments and acquisitions could disrupt our business, cause dilution to our stockholders and otherwise harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the years, we have acquired technologies and associated intellectual property rights across a broad range of emerging areas within biology and life sciences. We believe we are successfully integrating the technologies we have acquired into our business, but the long-term success of these acquisitions is not guaranteed. We regularly review investment, acquisition and technology licensing opportunities, and we may invest in or acquire additional real estate or additional businesses and legal entities to add specialized employees, products or technologies as well as pursue technology licenses or investments in complementary businesses. Our previous acquisitions and any future transactions could be material to our financial condition and operating results and expose us to many risks, including:</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increases in our expenses and reductions in our cash available for operations and other uses;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties integrating acquired personnel, technologies and operations into our existing business;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to realize anticipated benefits or synergies from such a transaction;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated costs of or legal exposure related to complying with existing and future laws and regulations, including land use, antitrust, environmental or hazardous waste-related laws and regulations;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption in our relationships with customers, distributors, manufacturers, suppliers or other third parties as a result of such a transaction;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated liabilities related to acquired real estate or companies, including liabilities related to acquired intellectual property or litigation relating thereto;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of management time and focus from operating our business;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">possible write-offs or impairment charges relating to acquired businesses; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential higher taxes if our tax positions relating to certain acquisitions were challenged.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign acquisitions, such as our acquisitions of Spatial Transcriptomics Holdings AB, CartaNA AB, Tetramer Shop ApS and Centrillion Technologies Taiwan Co. Ltd., involve unique risks in addition to those mentioned above, including those related to integration of operations across different cultures and languages, currency risks and the particular economic, political and regulatory risks associated with specific countries. Even if we identify a strategic transaction that we wish to pursue, we may be prohibited from consummating such transaction due to the terms of future indebtedness we may incur or due to circumstances outside our control including regulatory approval considerations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future investments, acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial condition. We cannot predict the number, timing or size of future investments, acquisitions or dispositions or the effect that any such transactions might have on our operating results.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Seasonality may cause fluctuations in our revenue and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate on a December&#160;31st year end and believe that there are significant seasonal factors which may cause sales of our products to vary on a quarterly or yearly basis and increase the magnitude of quarterly or annual fluctuations in our operating results. We believe that this seasonality results from a number of factors, including the procurement and budgeting cycles of many of our customers, especially government- or grant-funded customers, whose cycles often coincide with government fiscal year ends. Furthermore, the academic budgetary cycle similarly requires grantees to &#8216;use or lose&#8217; their grant funding, which seems to be tied disproportionately to the end of the calendar year, historically driving sales higher during the fourth quarter. Similarly, our biopharmaceutical customers typically have calendar year fiscal years which also result in a disproportionate amount of their purchasing activity occurring during our fourth quarter. Our international customers also have different purchasing patterns due to procurement or budgeting cycles, holidays or other factors which may result in a disproportionate amount of their purchasing activity occurring in specific periods. These factors have contributed, and may contribute in the future, to substantial fluctuations in our quarterly operating results. Because of these fluctuations, it is possible that in some quarters our operating results will fall below the expectations of securities analysts or investors. If that happens, the market price of our Class&#160;A common stock would likely decrease. These fluctuations, among other factors, also mean that our operating results in any particular period may not be relied upon as an indication of future performance. Seasonal or cyclical variations in our sales have in the past, and may in the future, become more or less pronounced over time, and have in the past materially affected, and may in the future materially affect, our business, financial condition, results of operations and prospects. Other fluctuations, including spikes in customer demand for our products in demand for our products, may make it harder for us to distribute our products in a timely </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manner.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our reliance on distributors for sales of our products in certain geographies outside of the United States could limit or prevent us from selling our products and impact our revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our products through third-party distributors in certain regions of Asia, Europe, Oceania, Central America, South America, the Middle East and Africa. We intend to continue to grow our business internationally and to do so we must attract additional distributors and retain existing distributors to maximize the commercial opportunity for our products. There is no guarantee that we will be successful in attracting or retaining desirable sales and distribution partners, that such partners will agree to our terms and conditions of sale or that we will be able to enter into such arrangements on favorable terms. Additionally, excess inventory held by our distributors may reduce or delay purchases by such distributors. For example, we believe that in the past certain of our distributors in China held excess inventory of certain of our products, in part due to fluctuations in customer purchasing patterns in China due to COVID-19, which we believe resulted in lower than anticipated sales of our products to our distributors in China in 2023 as such distributors sold off such excess inventory. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our distribution relationships are non-exclusive. As such, our distributors may not commit the necessary resources to market our products to the level of our expectations or may choose to favor marketing the products of our competitors. If current or future distributors do not or are unable to perform adequately or if we are unable to enter into effective arrangements with distributors in particular geographic areas, our revenues could be significantly impacted. Additionally, our business, financial condition and results of operations could be materially and adversely affected if we are unsuccessful in selling directly to customers who previously purchased our products from third-party distributors or if our efforts in certain regions to sell directly to certain </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">customers previously served by our distributors negatively impacts our relationships with and the performance of our distributors in such regions or elsewhere.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Uncertain economic or social conditions may adversely impact demand for our products or cause our customers, vendors and suppliers to suffer financial hardship, which could adversely impact our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be negatively impacted by reduced demand for our products related to one or more significant local, regional or global economic or social disruptions. These disruptions have included and may in the future include a slow-down, recession or inflationary pressures in the general economy, reduced market growth rates, tighter credit markets for us, our suppliers, vendors or customers, a significant shift in government policies (including funding for scientific research or changes in laws or policies governing the terms of foreign trade, in particular increased trade restrictions, tariffs or taxes on imports or exports), significant social unrest, or the deterioration of economic relations between countries (such as the U.S. and China) or regions. For example, in early 2025, a number of economists, investment professionals and other analysts have indicated that there is a possibility of a near-term United States economic recession, which, if manifested, could significantly negatively impact our operating results including, for example, by reducing demand for our products. Additionally, adverse economic conditions may cause our suppliers, distributors, contractors or other third-party suppliers or manufacturers to suffer financial or operational difficulties that they cannot overcome, resulting in their inability to provide us with the materials and services we need, in which case our business and results of operations could be adversely affected.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inflationary pressures, and changes in foreign currency exchange rates, interest rates and market value of our investments, including marketable securities, could have a significant effect on results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, our suppliers and our customers are exposed to inflationary pressure and a variety of market risks, including the effects of increases in energy and raw material prices, foreign currency exchange rates and interest rates. Such risks are inherently unpredictable and difficult to mitigate and may be exacerbated by tariffs imposed by the United States which are currently, or in the future, under consideration, proposed or enacted. As a result, significant increases in energy and raw material prices, foreign currency exchange rates or interest rates as well as increased material, freight, logistics, and similar costs could have an adverse effect on our financial condition or results of operations. For example, interest rates have increased significantly as central banks in developed countries attempt to subdue inflation while government deficits and debt remain at high levels in many global markets. Higher government deficits and debt, tighter monetary policy and potentially higher interest rates may drive a higher cost of capital for our business.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AI and machine learning technologies may expose us to significant risks, including development and deployment challenges, regulatory uncertainties, competition for investor research and potential hard-to-predict changes to our business, which could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use artificial intelligence (&#8220;AI&#8221;), machine learning and automated decision-making technologies (collectively, &#8220;AI Technologies&#8221;) in our business and are making targeted investments in this area. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increased investment may be required in the future to continuously improve our use of AI Technologies. As with many technological innovations, there are significant risks involved in developing, maintaining and deploying these technologies and there can be no assurance that the usage of or our investments in such technologies will always enhance our products or services or be beneficial to our business, including our efficiency or profitability. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the regulatory framework for AI Technologies is rapidly evolving as many federal, state and foreign government bodies and agencies have introduced or are currently considering additional laws and regulations. Additionally, existing laws and regulations may be interpreted in ways that could affect the operation of our AI Technologies, or could be rescinded or amended as new administrations take differing approaches to evolving AI Technologies. As a result, implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet completely determine the impact future laws, regulations, standards or market perception of their requirements may have on our business and may not always be able to anticipate how to respond to these laws or regulations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in recent years both public and private investment in AI Technologies has increased substantially, and because investment markets and investor attention are finite, focus of the investment community on opportunities related to AI Technologies may divert investor attention and resources away from us and our industry. Further, in the future AI Technologies may meaningfully change fundamental aspects of our business including, for example, our cost structure, how we sell our products or how customers or potential customers conduct their experiments. The ways in which AI Technologies could affect us </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are uncertain and difficult to predict at present and in the future may significantly impact our business, results of operations and financial condition.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain an effective system of disclosure controls and internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act of 2002, as amended (&#8220;SOX&#8221;), and the rules and regulations of the applicable listing standards of the Nasdaq Global Select Market (&#8220;Nasdaq&#8221;). We expect that the requirements of these rules and regulations will continue to increase our legal, accounting and financial compliance costs, make some activities more difficult, time-consuming and costly, and place significant strain on our personnel, systems and resources.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SOX requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We are continuing to develop and refine our disclosure controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file with the SEC is accurately recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and that information required to be disclosed in reports under the Exchange Act is accumulated and communicated to our principal executive and financial officers. We are also continuing to improve our internal control over financial reporting. In order to maintain and improve the effectiveness of our disclosure controls and procedures and internal control over financial reporting, we have expended, and anticipate that we will continue to expend, significant resources including accounting-related costs and significant management oversight.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current controls and any new controls that we develop may become inadequate because of changes in conditions in our business. Further, weaknesses in our disclosure controls and internal control over financial reporting may be discovered in the future. Any failure to develop or maintain effective controls or any difficulties encountered in their implementation or improvement could harm our results of operations or cause us to fail to meet our reporting obligations and may result in a restatement of our financial statements for prior periods. Any failure to implement and maintain effective internal control over financial reporting also could adversely affect the results of periodic management evaluations and annual independent registered public accounting firm attestation reports regarding the effectiveness of our internal control over financial reporting that we are required to include in our periodic reports. Ineffective disclosure controls and procedures and internal control over financial reporting could also cause investors to lose confidence in our reported financial and other information, which would likely have a negative effect on the trading price of our Class&#160;A common stock. In addition, if we are unable to continue to meet these requirements, we may not be able to remain listed on Nasdaq.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot provide any assurance that significant deficiencies or material weaknesses in our internal controls over financial reporting will not be identified in the future. If we fail to remediate any significant deficiencies or material weaknesses that may be identified in the future or encounter problems or delays in the implementation of internal controls over financial reporting, we may be unable to conclude that our internal controls over financial reporting are effective. Any failure to develop or maintain effective controls or any difficulties encountered in our implementation of our internal controls over financial reporting could result in material misstatements that are not prevented or detected on a timely basis, which could potentially subject us to sanctions or investigations by the SEC or other regulatory authorities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to have an audit of the effectiveness of our internal control over financial reporting. Even if our management concludes that our internal control over financial reporting is effective, our independent registered public accounting firm may issue a report that is adverse in the event it is not satisfied with the level at which our internal control over financial reporting is documented, designed or operating. Any failure to maintain effective disclosure controls and internal control over financial reporting could materially and adversely affect our business, results of operations and financial condition and could cause a decline in the trading price of our Class&#160;A common stock.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The illegal distribution and sale by third parties of stolen, counterfeit or unfit versions of our products could have a negative impact on our reputation and business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties might illegally distribute and sell stolen, counterfeit or unfit versions of our products, which do not meet our rigorous manufacturing, distribution and quality standards. As we expand our business internationally, we expect to encounter counterfeit versions of our products, including our consumables. A researcher who receives and uses counterfeit consumables could obtain erroneous results, experience failed experiments or potentially damage his or her instrument. Our reputation and business could suffer harm as a result of counterfeit products sold under our brand name. Inventory that is stolen from warehouses, plants or while in-transit, and that is subsequently improperly stored and sold through unauthorized channels, could adversely impact our customers&#8217; experiments, our reputation and our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The investment of marketable securities is subject to risks which may cause losses and affect the liquidity of these investments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we have and may invest portions of excess cash and cash equivalents in marketable securities. We have and may invest in liquid, investment-grade marketable securities such as corporate bonds, commercial paper, asset-backed securities, U.S. treasury securities, money market funds, and other cash equivalents. We currently, and expect to continue, to follow an established investment policy and set of guidelines to monitor and help mitigate our exposure to liquidity and credit risks which set forth credit quality standards and limit our exposure to any one issuer as well as our maximum exposure to various asset classes. However, these investments are subject to general credit, liquidity, market and interest rate risks. We may realize losses in the fair value of these investments, which could include a complete loss of these investments, which would have a negative effect on our consolidated financial statements. In addition, should our investments cease paying or reduce the amount of interest paid to us, our interest income would decrease. Interest rate fluctuations can negatively impact the returns on our fixed-income investments.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indebtedness may impair our financial and operating flexibility.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may incur indebtedness in the future. The debt instruments governing such indebtedness could contain restrictive provisions. If we incur debt, a portion of our cash flows would likely be needed to satisfy our debt service obligations. In the event that additional financing is required, we may not be able to raise it on terms acceptable to us or at all. As a result, we would be more vulnerable to general adverse economic, industry and capital markets conditions in addition to the risks associated with indebtedness described in this risk factor.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our regulatory environment and taxation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products could become subject to more onerous regulation by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or other regulatory agencies in the future, which could increase our costs and delay or prevent commercialization of our products, thereby materially and adversely affecting our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make certain of our products available to customers as research-use-only (&#8220;RUO&#8221;) products. RUO products are regulated by the FDA as medical devices, and include in vitro diagnostic products in the laboratory research phase of development that are being shipped or delivered for an investigation that is not subject to the FDA&#8217;s investigational device exemption requirements. Although medical devices are subject to stringent FDA oversight, products that are intended for RUO and are labeled as RUO are exempt from compliance with most FDA requirements, including premarket clearance or approval, manufacturing requirements, and others. A product labeled RUO but which is actually intended for clinical diagnostic use may be viewed by the FDA as adulterated and misbranded under the Federal Food, Drug, and Cosmetic Act (&#8220;FDC Act&#8221;), and subject to FDA enforcement action. In the EU, under Regulation (EU) No 2017/746 (&#8220;EU IVDR&#8221;), RUO products which are intended to be used for research purposes, without any medical objective, are not regarded as devices for performance evaluation used in diagnostic procedures. More importantly, the EU IVDR expressly provides that products intended for RUO are excluded from the scope of the Regulation. A material intended for RUO, without any medical purpose or objective, is therefore not considered as an in vitro diagnostic medical device (&#8220;IVD&#8221;) and is not subject to compliance with IVD requirements. However, depending on the type of RUO products in question, requirements to market some products may be tighter under the EU IVDR such as for laboratory developed tests. Depending on the product in question, other regulations may be applicable to the RUO products. The FDA has indicated that when determining the intended use of a product labeled RUO, the FDA will consider the totality of the circumstances surrounding distribution and use of the product, including how the product is marketed and to whom. The FDA and foreign authorities could disagree with our assessment that our products are properly marketed as RUOs, or could conclude that products labeled as RUO are actually intended for clinical diagnostic use, and could take enforcement action against us, including requiring us to stop distribution of our products until we are in compliance with applicable regulations, which would reduce our revenue, increase our costs and adversely affect our business, prospects, results of operations and financial condition. In the event that the FDA or foreign authorities requires us to obtain marketing authorization or certification of our RUO products in the future, there can be no assurance that these authorities will grant any clearance, approval or certification requested by us in a timely manner, or at all.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also in the future decide to develop products that are intended for clinical or diagnostic uses. In the United States, before we can market a new medical device, or a new use of, new claim for or significant modification to an existing product, we must first receive either clearance under Section 510(k) of the FDC Act, or approval of a premarket approval application from the FDA, unless an exemption applies. In the EU, there is currently no premarket government review of medical devices (including IVDs). However, the EU requires that all IVDs placed on the market in the EU must meet general, safety and performance requirements of the EU IVDR including the requirement that an IVD must be designed and manufactured in such a way that, during normal conditions of use, it is suitable for its intended purpose. IVDs must be safe and effective and must not compromise the clinical condition or safety of patients, or the safety and health of users and &#8211; where applicable &#8211; other persons, provided that any risks </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which may be associated with their use constitute acceptable risks when weighed against the benefits to the patient and are compatible with a high level of protection of health and safety, taking into account the generally acknowledged state of the art. Compliance with general, safety and performance requirements laid down in Annex I to the EU IVDR is a prerequisite for European conformity marking (&#8220;CE mark&#8221;) without which IVDs cannot be marketed or sold in the EU. The EU regulatory landscape concerning IVDs recently evolved. On May 26, 2022, the EU IVDR became applicable, and repealed and replaced the EU IVDD. Unlike the EU IVDD, the EU IVDR is directly applicable in all EU member states without the need for member states to implement into national law. This aims at reducing the risk of discrepancies in interpretation across the different European markets. The EU IVDR may impose increased compliance obligations for us if we decide to market products for clinical or diagnostic uses and impact our development plans. The EU IVDR does not apply in Great Britain (England, Scotland and Wales) since it came into effect after the United Kingdom&#8217;s departure from the EU, and consequently, the regulatory framework for IVDs in Great Britain continues to be largely based on the requirements of the EU IVDD as implemented by national law. However under the terms of the Northern Ireland Protocol the EU IVDR does apply in Northern Ireland. The Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) has confirmed that it will introduce changes to the legislation applicable in Great Britain, and has stated that it expects the core elements of the new regime to apply from July 2025. Until the final legislation and accompanying guidance has been published there will remain uncertainty as to the future IVD regulatory requirements in Great Britain. In addition, the process of obtaining approval or clearance from the FDA or certification from notified bodies in the EU or approved bodies in the United Kingdom for new products, or with respect to enhancements or modifications to existing products, could take a significant period of time, require the expenditure of substantial resources, involve rigorous pre-clinical and clinical testing, require changes to products or result in limitations on the indicated uses of products. There can be no assurance that we will receive the required approvals, clearances or certifications for any new products or for modifications to our existing products on a timely basis or that any approval, clearance or certification will not be subsequently withdrawn or conditioned upon extensive post-market study requirements. Moreover, even if we receive FDA clearance or approval or certification from foreign bodies of new products or modifications to existing products, we will be required to comply with extensive regulations relating to the development, research, clearance, approval, certification, distribution, marketing, advertising and promotion, manufacture, adverse event reporting, recordkeeping, import and export of such products, which may substantially increase our operating costs and have a material impact on our business, profits and results of operations. Failure to comply with applicable regulations could jeopardize our ability to sell our products and result in enforcement actions such as: warning letters, fines, injunctions, civil penalties, termination of distribution, recalls or seizures of products, delays in the introduction of products into the market, total or partial suspension of production, refusal to grant future clearances, approvals or certifications, withdrawals or suspensions of existing clearances, approvals or certifications, resulting in prohibitions on sales of our products, and in the most serious cases, criminal penalties. Occurrence of any of the foregoing could harm our reputation, business, financial condition, results of operations and prospects.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to risks related to taxation in multiple jurisdictions and changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes in both the United States and foreign jurisdictions. Significant judgments based on interpretations of existing tax laws or regulations are required in determining our provision for income taxes. Our effective income tax rate could be adversely affected by various factors, including, but not limited to, changes in the mix of earnings in tax jurisdictions with different statutory tax rates, changes in the valuation of deferred tax assets and liabilities, changes in the level of non-deductible expenses (including share-based compensation), changes in the location of our operations, changes in our future levels of research and development spending, changes in tax benefits from share based compensation, mergers and acquisitions or the result of examinations by various tax authorities. Although we believe our tax estimates are reasonable, if the United States Internal Revenue Service or any other taxing authority disagrees with the positions taken on our tax returns, we could have additional tax liability, including interest and penalties. If material, payment of such additional amounts upon final adjudication of any disputes could have a material impact on our results of operations and financial position.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our domestic and international business operations and our business and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, beginning in 2022, the Tax Cuts and Jobs Act of 2017 (the &#8220;TCJA&#8221;) requires U.S. research and experimental expenditures to be capitalized and amortized ratably over a five-year period. Any such expenditures attributable to research conducted outside the United States must be capitalized and amortized over a 15-year period. In addition, the Inflation Reduction Act of 2022 recently became law and imposes a minimum tax on certain corporations with book income of at least $1 billion, subject to certain adjustments, and a 1% excise tax on certain stock buybacks and similar corporate actions. With the change in the U.S. Executive and Legislative branches in 2025, the likelihood of any proposed changes to the tax law being enacted or implemented is unclear, and we are currently unable to predict whether such changes will occur. If any such changes are </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">implemented, we are currently unable to predict the ultimate impact on our business and therefore there can be no assurance our business will not be adversely affected. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Organization for Economic Co-Operation and Development has released guidance and blueprints covering various topics, including a global minimum effective tax rate of 15% on certain corporate groups known as &#8220;Pillar Two," and rules governing transfer pricing, country-by-country reporting and definitional changes to permanent establishment that could ultimately impact our tax liabilities as those guidance and blueprints are potentially implemented in various jurisdictions. For example, on December 12, 2022, the European Union member states agreed to implement the &#8220;Pillar Two&#8221; global corporate minimum tax rate as of January 1, 2024. In addition, various other countries where we do business have implemented or plan to implement the &#8220;Pillar Two&#8221; global corporate minimum tax rate and are also actively considering changes to their tax laws to adopt certain parts of the OECD&#8217;s proposals. The enactment of this and similar legislation could significantly increase our tax obligations in many countries where we do business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating losses to offset future taxable income may be subject to certain limitations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to utilize our net operating loss carryforwards and research and development credit carryforwards for income tax savings is subject to certain conditions and may be subject to certain limitations in the future due to ownership changes as described below. As such, there can be no assurance that we will be able to utilize such carryforwards. We have experienced a history of losses and a lack of future taxable income would adversely affect our ability to utilize our net operating loss carryforwards and research and development credit carryforwards.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), if a corporation undergoes an &#8220;ownership change,&#8221; the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes, such as research tax credits, to offset its post-change income may be limited. In general, an &#8220;ownership change&#8221; will occur if there is a cumulative change in our ownership by certain significant shareholders that exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under state tax laws. A portion of our net operating loss carryforwards and other tax attributes may be subject to limitation under Section 382 of the Code as a result of previous ownership changes and such limitations may result in expiration of a portion of our net operating loss carryforwards or other tax attributes before utilization. Our ability to use net operating loss carryforwards, research and development credit carryforwards and other tax attributes to reduce future taxable income and liabilities may be further limited as a result of future changes in stock ownership. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards or other pre-change tax attributes to offset United States federal and state taxable income may be subject to limitations, which could potentially result in increased future tax liability to us.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ethical, legal, privacy and social concerns or governmental restrictions surrounding the use of the genomic and multiomic information and gene editing could reduce demand for our products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we do not make gene sequencing or gene editing products, our products are used to better understand genomic information that could further gene editing endeavors. For example, certain of our solutions allow users to examine cells that have been genetically perturbed using clustered regularly interspaced short palindromic repeats (&#8220;CRISPR&#8221;) gene editing technology. Advances in genome editing or gene therapy, such as CRISPR Cas9 technology have been subject to negative publicity and increased regulatory scrutiny, in part due to the underlying ethical, legal, privacy and social concerns regarding the use or potential misuse of such technology. Governmental authorities could, for safety, social or other purposes, call for limits on or regulation of technologies and products used in the genome editing or gene therapy fields. Such concerns or governmental restrictions could limit the use of our products. Because the science and technology of genome editing or gene therapy is incredibly complex, any regulations or restrictions placed on such technology or aimed at curtailing its usage could, intentionally or inadvertently, limit or restrict the usage of our products. Any such restrictions or any reduction in usage of our products as a result of concerns regarding the usage of genome editing technology could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our intellectual property, information technology and data security</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success will depend on our ability to obtain, maintain and protect our intellectual property rights.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success and ability to compete depends in part on our ability to obtain, maintain and enforce issued patents, trademarks and other intellectual property rights and proprietary technology in the United States and elsewhere. If we cannot adequately obtain, maintain and enforce our intellectual property rights and proprietary technology, competitors may be able to use our technologies or the goodwill we have acquired in the marketplace and erode or negate any competitive advantage we may have and our ability to compete, which could harm our business and ability to achieve profitability and/or cause us to incur significant expenses.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a combination of contractual provisions, confidentiality procedures and patent, trademark, copyright, trade secret and other intellectual property laws to protect the proprietary aspects of our products, brands, technologies, trade secrets, know-how and data. These legal measures afford only limited protection, and competitors or others may gain access to or use our intellectual property rights and proprietary information. In addition, patents have a limited lifespan. In the United States, for example, the natural expiration of a utility patent is generally 20 years from the earliest effective non-provisional filing date. Our success will depend, in part, on preserving our trade secrets, maintaining the security of our data and know-how and obtaining, maintaining and enforcing other intellectual property rights. We may not be able to obtain, maintain and/or enforce our intellectual property or other proprietary rights necessary to our business or in a form that provides us with a competitive advantage.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to obtain, maintain and/or enforce intellectual property rights necessary to our business and failure to protect, monitor and control the use of our intellectual property rights could negatively impact our ability to compete and cause us to incur significant expenses. The intellectual property laws and other statutory and contractual arrangements in the United States and other jurisdictions we depend upon may not provide sufficient protection in the future to prevent the infringement, use, violation or misappropriation of our patents, trademarks, data, technology and other intellectual property rights by others, and may not provide an adequate remedy if our intellectual property rights are infringed, misappropriated or otherwise violated by others.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely in part on our portfolio of issued patents and pending patent applications in the United States and other countries to protect our intellectual property and competitive position. However, it is also possible that we may fail to identify patentable aspects of inventions made in the course of the development, manufacture and commercialization activities conducted by or on behalf of us before it is too late to obtain patent protection on such inventions. If we fail to timely file for patent protection in any jurisdiction, we may be precluded from doing so at a later date. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, suppliers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in any of our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. Moreover, should we become a licensee of a third party&#8217;s patents or patent applications, depending on the terms of any future in-licenses to which we may become a party, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain or enforce the patents, covering technology in-licensed from third parties. Therefore, these patents and patent applications may not be prosecuted, maintained and/or enforced in a manner consistent with the best interests of our business. While we generally apply for patents in those countries where we intend to make, have made, use, import, offer for sale or sell our products, we may not accurately predict all of the countries where patent protection will ultimately be desirable. Furthermore, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from importing, manufacturing and/or commercializing our own products or services, or otherwise practicing our own technology. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of companies, including our patent position, may involve complex legal and factual questions that have been the subject of much litigation in recent years, and, therefore, the scope of any patent claims that we have or may obtain cannot be predicted with certainty. Accordingly, we cannot provide any assurances about which of our patent applications will issue, the breadth of any resulting patent, whether any of the issued patents will be found to be infringed, invalid or unenforceable or will be threatened or challenged by third parties, that any of our issued patents have, or that any of our currently pending or future patent applications that mature into issued patents will include, claims with a scope sufficient to protect our products, services or technology. Our pending and future patent applications may not result in the issuance of patents or, if issued, may not issue in a form that will be advantageous to us. The coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. We cannot offer any assurances that the breadth of our issued patents will be sufficient to stop a competitor from developing, manufacturing and commercializing a product or technologies in a non-infringing manner that would be competitive with one or more of our products or technologies, or otherwise provide us with any competitive advantage. Furthermore, any successful challenge to these patents or any other patents owned by or licensed to us after patent issuance could deprive us of rights necessary for our commercial success. Further, there can be no assurance that we will have adequate resources to enforce our patents.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Though an issued patent is presumed valid and enforceable, its issuance is not conclusive as to its validity or its enforceability and it may not provide us with adequate proprietary protection or competitive advantages against competitors with similar products or services. Patents, if issued, may be challenged, deemed unenforceable, invalidated, narrowed or circumvented. Proceedings challenging our patents or patent applications could result in either loss of the patent, or denial of the patent application or loss or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reduction in the scope of one or more of the claims of the patent or patent application. Any successful challenge to our patents and patent applications could deprive us of exclusive rights necessary for our commercial success. In addition, defending such challenges in such proceedings may be costly. Thus, any patents that we may own may not provide the anticipated level of, or any, protection against competitors. Furthermore, an adverse decision may result in a third party receiving a patent right sought by us, which in turn could affect our ability to develop, manufacture or commercialize our products or technologies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our patents and patent applications may in the future be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products, services and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others will not develop, manufacture and/or commercialize similar or alternative products or technologies that do not infringe our patents;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any patents issued to us will provide a basis for an exclusive market for our commercially viable products or technologies, will provide us with any competitive advantages or will not be challenged by third parties;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of our challenged patents will be found to ultimately be valid and enforceable;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of our patents, or any of our pending patent applications, if issued, will include claims having a scope sufficient to protect our products or services;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of our pending patent applications will issue as patents;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we will be able to successfully manufacture and commercialize our products on a substantial scale before relevant patents we may have expire;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we were the first to make the inventions covered by each of our patents and pending patent applications;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we were the first to file patent applications for these inventions;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we will develop additional proprietary technologies or products that are separately patentable; or</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our commercial activities or products will not infringe upon the patents of others.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we cannot successfully enforce our intellectual property rights, the commercial value of our products and technologies will be adversely affected and our competitive position may be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties, including our competitors, may currently, or in the future, infringe, misappropriate or otherwise violate our issued patents or other intellectual property rights, and we may file lawsuits or initiate other proceedings to protect or enforce our patents or other intellectual property rights, which could be expensive, time-consuming and unsuccessful. We regularly monitor for unauthorized use of our intellectual property rights and, from time to time, analyze whether to seek to enforce our rights against potential infringement, misappropriation or violation of our intellectual property rights. However, the steps we have taken, and are taking, to protect our proprietary rights may not be adequate to enforce our rights as against such infringement, misappropriation or violation of our intellectual property rights. In certain circumstances it may not be practicable or cost-effective for us to enforce our intellectual property rights fully, particularly in certain developing countries or where the initiation of a claim might harm our business relationships. We may also be hindered or prevented from enforcing our rights with respect to a government entity or instrumentality because of the doctrine of sovereign immunity. Our ability to enforce our patent or other intellectual property rights depends on our ability to detect infringement. It may be difficult to detect infringers who do not advertise the components or methods that are used in connection with their products or technologies. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s or potential competitor&#8217;s product or technologies. Thus, we may not be able to detect unauthorized use of, or take appropriate steps to enforce, our intellectual property rights. Any inability to meaningfully enforce our intellectual property rights could harm our ability to compete and reduce demand for our products and technologies. We have in the past and may in the future become, involved in lawsuits to protect or enforce our intellectual property rights. An adverse result in any litigation proceeding could harm our business. In any lawsuit we bring to enforce our intellectual property rights, a court may refuse to stop the other party from using the technology at issue on grounds that our intellectual property rights do not cover the technology in question. Any claims we assert against perceived infringers could also provoke these parties to assert counterclaims against us alleging that we infringe, misappropriate or otherwise violate their intellectual property rights. If we initiate legal proceedings against a third party to enforce a patent covering a product or technology, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alleging invalidity or unenforceability are common, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of patentable subject matter, novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from USPTO, or made a misleading statement, during prosecution. Mechanisms for such challenges include re-examination, post-grant review, inter partes review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). In a patent or other intellectual property infringement proceeding, a court may decide that a patent or other intellectual property right of ours is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims or other intellectual property narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents or other intellectual property do not cover the technology in question. Furthermore, even if our patents or other intellectual property rights are found to be valid and infringed, a court may refuse to grant injunctive relief against the infringer and instead grant us monetary damages and/or ongoing royalties. Such monetary compensation may be insufficient to adequately offset the damage to our business caused by the infringer&#8217;s competition in the market. An adverse result in any litigation or administrative proceeding could put one or more of our patents or other intellectual property rights at risk of being invalidated or interpreted narrowly, which could adversely affect our competitive business position, financial condition and results of operations. Moreover, even if we are successful in any litigation, we may incur significant expense in connection with such proceedings, and the amount of any monetary damages may be inadequate to compensate us for damage as a result of the infringement and the proceedings.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property rights.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be subject to claims that our former employees, contractors or collaborators, or other third parties have an ownership interest in our current or future patents, patent applications, or other intellectual property rights, including as an inventor or co-inventor. We may be subject to ownership or inventorship disputes in the future arising, for example, from conflicting obligations of employees, consultants or others who were or are involved in developing our products or services. Although it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property rights to execute agreements assigning such intellectual property rights to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property rights that we regard as our own, and we cannot be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property rights, and other owners may be able to license their rights to other third parties, including our competitors. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we may be subject to claims from third parties challenging ownership interest in or inventorship of intellectual property rights we regard as our own, based on claims that our agreements with employees or consultants obligating them to assign their intellectual property rights to us are ineffective or in conflict with prior or competing contractual obligations to assign inventions and intellectual property rights to another employer, to a former employer, or to another person or entity. Litigation may be necessary to defend against such claims, and it may be necessary or we may desire to obtain a license to such third party&#8217;s intellectual property rights to settle any such claim; however, there can be no assurance that we would be able to obtain such license on commercially reasonable terms, if at all. If our defense to those claims fails, in addition to paying monetary damages or a settlement payment, a court could prohibit us from using technologies, features or other intellectual property rights that are essential to our products or technologies, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of another person or entity, including another or former employers. An inability to incorporate technologies, features or other intellectual property rights that are important or essential to our products or services could have a material adverse effect on our business, financial condition, results of operations, and competitive position, and may prevent us from developing, manufacturing and/or commercializing our products or technologies. In addition, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against these claims, litigation could result in substantial costs and could be a distraction to management and our employees. Any litigation or the threat thereof may adversely affect our ability to hire employees or contract with independent sales representatives. A loss of key personnel or their work product could hamper or prevent our ability to develop, manufacture and/or commercialize our products or services, which could materially and adversely affect our business, financial condition and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on certain intellectual property rights that are licensed to us. We may be unsuccessful in licensing or acquiring intellectual property rights from third parties that may be necessary to develop, manufacture and/or commercialize our current and/or future products or technologies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various proprietary technologies that are used in a substantial majority of our consumables are protected by intellectual property rights that we in-license from third parties. Our rights to use such intellectual property rights in our business are subject to the continuation of and our compliance with the terms of the license agreements between us and each of our licensors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A third party may hold intellectual property rights, including patent rights, that are important or necessary to the development, manufacture and/or commercialization of our current and/or future products or technologies, in which case we would need to acquire or obtain a license to such intellectual property rights from such third party. A third party that perceives us to be a competitor may be unwilling to assign or license its intellectual property rights to us. In addition, the licensing or acquisition of third-party intellectual property rights is a competitive area, and other companies may also pursue similar strategies to license or acquire such third party&#8217;s intellectual property rights. Some of these companies may have a competitive advantage over us due to their size, capital resources and greater development, manufacturing and commercialization capabilities. We also may be unable to license or acquire third party intellectual property rights on commercially reasonable terms that would allow us to make an appropriate return on our investment, or we may be unable to obtain any such license or acquisition at all. If we are unable to successfully license or acquire necessary third-party intellectual property rights, we may not be able to develop, manufacture or commercialize our current and/or future products or technologies, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to execute invention assignment agreements with our employees and contractors involved in the development of intellectual property rights or are unable to protect the confidentiality of our trade secrets, the value of our products and technologies and our business and competitive position could be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patent protection, we also rely on other intellectual property rights, including protection of copyright, trade secrets, know-how and/or other proprietary information that is not patentable or that we elect not to patent.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, trade secrets can be difficult to protect, and some courts are less willing or unwilling to protect trade secrets. To maintain the confidentiality of our trade secrets and proprietary information, we rely heavily on confidentiality provisions that we have in contracts with our employees, consultants, collaborators and other third parties. We generally enter into confidentiality and invention assignment agreements with our employees, consultants and third parties upon their commencement of a relationship with us. However, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes and we may not enter into such agreements with all employees, consultants and third parties who have been involved in the development of our intellectual property rights. Although we generally require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed. In addition, despite the protections we do place on our intellectual property or other proprietary rights, monitoring unauthorized use and disclosure of our intellectual property rights by employees, consultants and other third parties who have access to such intellectual property or other proprietary rights is difficult, and we do not know whether the steps we have taken to protect our intellectual property or other proprietary rights will be adequate. Therefore, we may not be able to prevent the unauthorized disclosure or use of our technical knowledge or other trade secrets by such employees, consultants, advisors or third parties, despite the existence generally of these confidentiality restrictions. These agreements may not provide meaningful protection against the unauthorized use or disclosure of our trade secrets, know-how or other proprietary information in the event the unwanted use is outside the scope of the provisions of the contracts or in the event of any unauthorized use, misappropriation, or disclosure of such trade secrets, know-how or other proprietary information that we fail to detect. There can be no assurances that such employees, consultants, advisors or third parties will not breach their agreements with us, that we will have adequate remedies for any breach, or that our trade secrets will not otherwise become known or independently developed by third parties, including our competitors. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. The exposure of our trade secrets and other proprietary information would impair our competitive advantages and could have a material adverse effect on our business, financial condition and results of operations. In particular, a failure to protect our proprietary rights may allow competitors to copy our technology, which could adversely affect our pricing and market share.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costly and time-consuming litigation could be necessary to enforce and determine the scope of our trade secret rights and related confidentiality and nondisclosure provisions, and outcomes are unpredictable. Further, it is possible that others will independently develop the same or similar technology, products or services or otherwise obtain access to our unpatented technology, and in such </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cases, we could not assert any trade secret rights against such parties. If we fail to obtain or maintain trade secret protection, or if our competitors obtain our trade secrets or independently develop technology or products similar to ours, our competitive market position could be materially and adversely affected. In addition, some courts are less willing or unwilling to protect trade secrets and agreement terms that address non-competition are difficult to enforce in many jurisdictions and might not be enforceable in certain cases.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to contractual measures, we try to protect the confidential nature of our proprietary information by maintaining physical security of our premises and electronic security of our information technology systems. Such security measures may not, for example, in the case of misappropriation of a trade secret by an employee, consultant or other third party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee, consultant or other third party from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our products or services that we consider proprietary. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and time-consuming, and the outcome is unpredictable. Further, we may not be able to obtain adequate remedies for any breach. While we use commonly accepted security measures, trade secret violations are often a matter of state law in the United States, and the criteria for protection of trade secrets can vary among different jurisdictions. If the steps we have taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. In addition, trade secrets may be independently developed by others in a manner that could prevent legal recourse by us. If any of our intellectual property rights or confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, it could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we or our employees have misappropriated the intellectual property rights of a third party, including trade secrets or know-how, or are in breach of non-competition or non-solicitation agreements with our competitors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to claims that our employees or consultants have wrongfully used for our benefit or disclosed to us confidential information, including trade secrets or know-how, of third parties. Many of our employees and consultants were previously employed at or engaged by other medical device companies, including our competitors or potential competitors. Some of these employees and consultants may have executed confidential information non-disclosure and inventions assignment agreements and non-competition agreements in connection with such previous employment or engagements. Although we try to ensure that our employees and consultants do not use the intellectual property rights, proprietary information, know-how or trade secrets of others in their work for us, we may be subject to claims that we or these individuals have, inadvertently or otherwise, misappropriated the intellectual property rights or disclosed the alleged trade secrets or other proprietary information, of these former employers, clients or other third parties. To the extent that our employees or consultants use intellectual property rights or proprietary information owned by others in their work for us, disputes may arise as to the rights in any related or resulting know-how and inventions. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Patent and Trademark Office, or USPTO, and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees, renewal fees, annuity fees and various other government fees on issued patents often must be paid to the USPTO and foreign patent agencies over the lifetime of the patent and/or applications and any patent rights we may obtain in the future. While an unintentional lapse of a patent or patent application can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our patent licensors fail to maintain the patents and patent applications covering our products, services or technology, we may not be able to stop a competitor from marketing products, services or technologies that are the same as or similar to our products, services or technologies which would have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in patent law or the organizational changes to the USPTO could diminish the value of our patents in general, thereby impairing our ability to protect our current and future products, services or technologies, and could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our current or future patents.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to obtain patents and the breadth of any patents obtained is uncertain in part because, to date, some legal principles remain unresolved, and there has not been a consistent policy regarding the breadth or interpretation of claims allowed in patents in the United States and other countries. Changes in either patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property rights or narrow the scope of our patent protection, which in turn could diminish the commercial value of our products, services and technologies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our patents and applications. Furthermore, the U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit have made, and will likely continue to make, changes in how the patent laws of the United States are interpreted. The United States Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the United States Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we own or that we might obtain or license in the future. An inability to obtain, enforce, and defend patents covering our proprietary technologies would materially and adversely affect our business prospects and financial condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, various courts, including the U.S. Supreme Court, have rendered decisions that impact the scope of patentability of certain inventions or discoveries relating to the life sciences. Specifically, these decisions stand for the proposition that patent claims that recite laws of nature (for example, the relationships between gene expression levels and the likelihood of risk of recurrence of cancer) are not themselves patentable unless those patent claims have sufficient additional features that provide practical assurance that the processes are genuine inventive applications of those laws rather than patent drafting efforts designed to monopolize the law of nature itself. What constitutes a &#8220;sufficient&#8221; additional feature is uncertain and has been subject to evolving regulatory guidance which indicates that claims directed to a law of nature, a natural phenomenon or an abstract idea that do not meet the eligibility requirements should be rejected as non-statutory, patent ineligible subject matter; however, method of treatment claims that practically apply natural relationships should be considered patent eligible. We cannot assure you that our patent portfolio will not be negatively impacted by the current uncertain state of the law, new court rulings or changes in guidance or procedures issued by the USPTO. From time to time, the U.S. Supreme Court, other federal courts, the U.S. Congress or the USPTO may change the standards of patentability and validity of patents within the life sciences and any such changes could have a negative impact on our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, foreign courts have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are interpreted. Changes in patent laws and regulations in other countries or jurisdictions, changes in the governmental bodies that enforce them, or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we own or may obtain in the future. Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. In addition, any protection afforded by foreign patents may be more limited than that provided under U.S. patent and intellectual property laws. We may encounter significant problems in enforcing and defending our intellectual property both in the United States and abroad. For example, if the issuance in a given country of a patent covering an invention is not followed by the issuance in other countries of patents covering the same invention, or if any judicial interpretation of the validity, enforceability or scope of the claims or the written description or enablement in a patent issued in one country is not similar to the interpretation given to the corresponding patent issued in other countries, our ability to protect our intellectual property rights in those countries may be limited. Changes in either patent laws or in interpretations of patent laws in the United States and other countries may materially diminish the value of our intellectual property rights or narrow the scope of our patent protection. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by U.S. and foreign legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future. Any of the foregoing could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, the European Unitary Patent system and the European Unified Patent Court (&#8220;UPC&#8221;) were launched. European patent applications now have the option, upon grant of a patent, of becoming a Unitary Patent which is subject to the jurisdiction of the UPC. In addition, conventional European patents, both already granted at the time the new system began and granted </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thereafter, are subject to the jurisdiction of the UPC, unless actively opted out. This was a significant change in European patent practice, and deciding whether to opt-in or opt-out of Unitary Patent practice entail strategic and cost considerations. The UPC provides third parties with a new forum to centrally revoke our European patents and makes it possible for a third party to obtain pan-European injunctions against us. It will be several years before we will understand the scope of patent rights that will be recognized and the strength of patent remedies that will be provided by the UPC. While we have the right to opt our patents out of the UPC over the first seven years of the court&#8217;s existence, doing so may preclude us from realizing the benefits of the UPC. Moreover, the decision whether to opt-in or opt-out of Unitary Patent status will require coordinating with co-applicants, if any, adding complexity to any such decision.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The legal systems in certain countries may also favor state-sponsored or companies headquartered in particular jurisdictions over our first-in-time patents and other intellectual property protection. We are aware of incidents where such entities have stolen the intellectual property of domestic companies in order to create competing products and we believe we may face such circumstances ourselves in the future. For example, through its &#8220;Annual Special 301 Report on Intellectual Property,&#8221; the Office of the United States Trade Representative (&#8220;USTR&#8221;) has been reporting on the adequacy and effectiveness of intellectual property protection in a number of foreign countries that are U.S. trading partners and their protection and enforcement of intellectual property rights. A number of countries in which both we and our distributors operate have been identified in the reports as being on the Priority Watch List. Placement of a country on the Priority Watch List indicates that particular problems exist in that country with respect to intellectual property protection, enforcement, or market access for persons relying on intellectual property rights. Countries placed on the Priority Watch List are the focus of increased bilateral attention concerning the specific problem areas. It is possible that we will not be able to enforce our intellectual property rights against third parties that misappropriate our proprietary technology in those countries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, organizational changes to the USPTO could increase the uncertainties, timing and costs related to the prosecution of our patent applications. For example, in response to the deferred resignation program offered by the United States Office of Personnel Management to all employees of the United States federal civil service on January 28, 2025, a number of USPTO employees have resigned or indicated their intent to resign, including USPTO Commissioner for Patents Vaishali Udupa. Reductions in the staff available to process, review and make decisions regarding patent applications as well as complete other patent-related activities could delay or prevent us from successfully prosecuting our current or future patent applications. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop, manufacture and commercialize products, services or technologies that are similar to or are alternatives or duplicates of any of our products, services or technologies without infringing, misappropriating or otherwise violating our intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that our pending patent applications or those that we may own in the future will not lead to issued patents or even when they issue, the scope of the claims may be narrowed;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop, manufacture and commercialize competitive products, services or technologies for sale in our major commercial markets;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or current or future licensors or collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent application that we license or may own in the future;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or current or future licensors or collaborators, might not have been the first to file patent applications covering certain of our or their inventions;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies that are patentable;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the intellectual property rights of others may harm our business; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may choose not to seek patent protection for some of our proprietary technology to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such trade secrets or know-how.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our competitive position may be harmed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trademarks could be challenged, invalidated, infringed, and circumvented by third parties, and our trademarks could also be diluted, declared generic or found to be infringing on other marks. If any of the foregoing occurs, we could be forced to re-brand our products, services or technologies, resulting in loss of brand recognition and requiring us to devote resources to advertising and marketing new brands, and suffer other competitive harm. Third parties may also adopt trademarks similar to ours, which could harm our brand identity and lead to market confusion. Further, there can be no assurance that competitors will not infringe our trademarks or that we will have adequate resources to enforce our trademarks. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. Certain of our current or future trademarks may become so well known by the public that their use becomes generic and they lose trademark protection. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively. Any of the foregoing could have a material adverse effect on our competitive position, business, financial condition, operating results and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on our trademarks, trade names and brand names, such as our 10X, 10X GENOMICS, CHROMIUM, VISIUM and XENIUM marks, to distinguish our products, services and technologies from the products, services and technologies of our competitors, and have registered or applied to register many of these trademarks in the United States and certain countries outside the United States, however, we have not yet registered all of our trademarks in all of our current and potential markets. There can be no assurance that our trademark applications will be approved for registration. During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in proceedings before the USPTO and comparable agencies in many foreign jurisdictions, third parties may also oppose our trademark applications and may seek to cancel trademark registrations or otherwise challenge our use of the trademarks. Opposition or cancellation proceedings may be filed against our trademark filings in these agencies, and such filings may not survive such proceedings. While we may be able to continue the use of our trademarks in the event registration is not available, particularly in the United States, where trademark rights are acquired based on use and not registration, third parties may be able to enjoin the continued use of our trademarks if such parties are able to successfully claim infringement in court. In addition, opposition or cancellation proceedings may be filed against our trademark applications and registrations and our trademarks may not survive such proceedings. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would. Our trademarks or trade names may be infringed, circumvented, declared generic or determined to be violating or infringing on other marks.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our solutions contain third-party open source software components and failure to comply with the terms of the underlying open source software licenses could restrict our ability to sell our products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our solutions contain software tools licensed by third parties under open source software licenses. Use and distribution of open source software may entail greater risks than use of third-party commercial software, as open source software licensors generally do not provide warranties or other contractual protections regarding infringement claims or the quality of the code. Some open source software licenses contain requirements that the licensee make its source code publicly available if the licensee creates modifications or derivative works using such open source software, depending on the type of open source software the licensee uses and how the licensee uses it. If we combine our proprietary software with open source software in a certain manner, we could, under certain open source software licenses, be required to make available the source code of certain of our proprietary software to the public for free. This could allow our competitors to create similar products with less development effort and time and ultimately could result in a loss of product sales and revenue. In addition, some companies that use third-party open source software have faced claims challenging their use of such open source software and their compliance with the terms of the applicable open source license. We may be subject to suits by third parties claiming ownership of what we believe to be open source software, or claiming non-compliance with the applicable open source licensing terms. Use of open source software may also present additional security risks because the public availability of such software may make it easier for hackers and other third parties to compromise or attempt to compromise our technology platform and systems.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we typically review our use of open source software to avoid subjecting our solutions to conditions we do not intend, the terms of many open source software licenses have not been interpreted by United States courts, and there is a risk that these licenses could be construed in a way that could impose unanticipated conditions or restrictions on our ability to commercialize our solutions. Moreover, our processes for monitoring and controlling our use of open source software in our solutions may not be effective. If we are held to have breached the terms of an open source software license, we could be required to seek licenses from third parties to continue offering our solutions on terms that are not economically feasible, to re-engineer our solutions, to discontinue the sale of our solutions if re-engineering could not be accomplished on a timely basis, to pay statutory or other damages to the license holder or to make generally available, in source code form, our proprietary code, any of which could adversely affect our business, operating results and financial condition.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We collect, process, store, share, disclose and use personal information and other data, which subjects us to governmental regulations and other legal obligations related to privacy and security, and our actual or perceived failure to comply with such obligations could harm our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We collect, process, store, transmit, disclose and use information from our employees, customers and others, including personal information and other data, some of which may be sensitive in nature. There are numerous federal, state and foreign laws and regulations regarding data protection, privacy and security. We strive to comply with applicable laws, our posted policies and legal contractual obligations relating to privacy and data protection. However, the scope of these laws is changing, is subject to differing interpretations, may be costly to comply with and may be inconsistent among countries and jurisdictions or conflict with other rules. Our business, including our ability to operate and expand internationally, could be adversely affected if legislation or regulations are adopted, interpreted or implemented in a manner that is inconsistent with our current business practices and that require changes to these practices.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global data protection landscape is rapidly evolving and new laws and regulations are constantly being enacted such as China's "Personal Information Protection Law" and Singapore's "Personal Data Protection Act." Violations of existing and new laws and regulations may subject companies to significant penalties and fines, government investigations and/or enforcement actions, private litigation and other claims. Our operations abroad may also be subject to increased scrutiny or attention from data protection authorities. For example, in Europe, the GDPR went into effect in May 2018 and imposes stringent requirements for processing personal data of individuals within the European Economic Area ("EEA"). The processing of sensitive personal data, such as physical health conditions, may impose heightened compliance burdens under the GDPR and is a topic of active interest among foreign regulators. In addition, the GDPR provides for breach reporting requirements, more robust regulatory enforcement and greater penalties for noncompliance than previous data protection laws, including fines of up to &#8364;20 million or 4% of a noncompliant company&#8217;s global annual revenue for the preceding financial year, whichever is greater. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries outside the EEA that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EEA and the United States remains uncertain. Case law from, the Court of Justice of the EU (&#8220;CJEU&#8221;) states that reliance on the standard contractual clauses, or SCCs - a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism - alone may not necessarily be sufficient in all circumstances and that transfers must be assessed on a case-by-case basis. On July 10, 2023, the European Commission adopted its Adequacy Decision in relation to the new EU-US Data Privacy Framework (&#8220;DPF&#8221;), rendering the DPF effective as a GDPR transfer mechanism to U.S. entities self-certified under the DPF. We expect the existing legal complexity and uncertainty regarding international personal data transfers to continue. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the SCCs cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the beginning of 2021, we have also been subject to the UK data protection regime, which imposes separate but similar obligations to those under the GDPR and comparable penalties, including fines of up to &#163;17.5 million or 4% of a noncompliant company&#8217;s global annual revenue for the preceding financial year, whichever is greater. On October 12, 2023, the UK Extension to the DPF came into effect (as approved by the UK Government), as a data transfer mechanism from the UK to U.S. entities self-certified under the DPF. Other foreign jurisdictions, such as China and Russia, are increasingly implementing or developing their own privacy regimes with complex and onerous compliance obligations and robust regulatory enforcement powers. As we continue to expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the California Consumer Privacy Act of 2018 (the &#8221;CCPA&#8221;), as amended by the California Privacy Rights Act (collectively,(the "CCPA"), requires covered businesses that process the personal information of California residents to, among other things: (i) provide certain disclosures to California residents regarding the business&#8217;s collection, use and disclosure of their personal information, (ii) receive and respond to requests from California residents to access, delete and correct their personal information, or to opt out of certain disclosures of their  personal information, and (iii) enter into specific contractual provisions with services providers that process California resident personal information on the business&#8217;s behalf.  Additional compliance investment and potential business process changes may also be required. Similar laws have passed in other states and are continuing to be proposed at the state and federal level, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the Federal Trade Commission (&#8220;FTC&#8221;) has authority to initiate enforcement actions against entities that mislead customers about compliance with the Health Insurance Portability and Accountability Act of 1996, as amended (&#8220;HIPAA&#8221;), make deceptive statements about privacy and data sharing in privacy policies, fail to limit third-party use of personal health information, fail to implement policies to protect personal health information or engage in other unfair practices that harm customers or that may violate Section 5(a) of the FTC Act. The FTC and many state Attorneys General also continue to enforce federal and state consumer protection laws against companies for online collection, use, dissemination and security practices that appear to be unfair or deceptive. For example, according to the FTC, failing to take appropriate steps to keep consumers&#8217; personal information secure can constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the FTC Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any failure or perceived failure by us or our vendors or partners to comply with these laws and regulations, our privacy and notice policies, our privacy-related obligations to employees, customers or other third parties or privacy or security-related legal obligations, or any actual or perceived compromise of security that results in the unauthorized access to or disclosure, alteration, theft, loss, transfer or use of personal or other information, including personally identifiable information or other sensitive data, may result in governmental enforcement actions, fines and penalties, litigation or public statements critical of us by consumer advocacy groups or others and could cause our customers, partners or others to lose trust in us, which could have an adverse effect on our business.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our critical third-party providers experience a significant disruption in our information technology systems or breaches of data security, our business could be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We collect and maintain information in digital form that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information, preclinical and clinical trial data, health-related information and personal information of our customers, employees and other related third parties (collectively, &#8220;Confidential Information&#8221;). It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such Confidential Information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on information technology systems to keep financial records, facilitate our research and development initiatives, manage our manufacturing operations, maintain quality control, fulfill customer orders, maintain corporate records, communicate with staff and external parties and operate other critical functions. We operate some of these systems but we also rely on third-party providers for a range of software, products and services that are critical to our operations and business. Both our and our third-party providers&#8217; information technology systems are vulnerable to attack, damage or disruption due to breakdown, malicious intrusion, computer viruses, malware (e.g. ransomware) or other disruptive events, including but not limited to, natural disasters and catastrophes. In addition, malicious code (such as viruses, worms and ransomware), bugs or vulnerabilities in our code, employee theft or misuse, human error, social engineering and phishing scams, denial-of-service attacks and sophisticated nation-state and nation-state supported attacks (including advanced persistent threat intrusions), are all increasingly common threats to companies like us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite significant efforts to create security barriers to such threats, it is impossible for us to entirely mitigate these risks. If our security measures are compromised as a result of third-party action, employee or customer error, malfeasance, stolen or fraudulently obtained log-in credentials or otherwise, our reputation could be damaged, our business may be harmed and we could incur significant liability. If we were to experience a prolonged system disruption in our information technology systems or those of certain of our vendors, it could negatively impact our ability to serve our customers, which could adversely impact our business. If operations at our facilities were disrupted, it may cause a material disruption in our business if we are not capable of restoring functionality on an acceptable timeframe. An attack or security incident that exposes Confidential Information to unauthorized persons could lead to the loss of trade secrets or other intellectual property, or could lead to the exposure of personal data of our employees, customers and others, any of which could have a material adverse effect on our business, reputation, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concerns regarding data privacy and security may cause some of our customers to stop using our platform for Cloud Services or other product solutions. This discontinuance in use could substantially harm our business, operating results and growth prospects. In addition, any access, disclosure, loss or unauthorized use of information or data could result in legal claims or proceedings, regulatory investigations or actions, and other types of liability under laws that protect the privacy and security of personal information, including federal, state and foreign data protection and privacy regulations, violations of which could result in significant penalties and fines. In addition, although we seek to detect and investigate all data security incidents, security breaches </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other incidents of unauthorized access to our information technology systems and data can be difficult to detect and any delay in identifying such breaches or incidents may lead to increased harm and legal exposure of the type described above.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not always been able in the past and may be unable in the future to anticipate or prevent techniques used to obtain unauthorized access or to compromise our systems because the techniques used change frequently and are generally not detected until after an incident has occurred. We may also face increased cybersecurity risks due to our reliance on internet technology when our employees are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Cyberattacks and other malicious internet-based activity continue to increase and cloud-based platform providers of services have been and are expected to continue to be targeted and threat actors are increasingly utilizing tools and techniques designed to evade controls, to avoid detection and even to obfuscate or remove forensic evidence.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced cyberattacks and other security incidents and expect to continue to experience such events. The cost of investigating, mitigating, responding to and remediating potential data security breaches and complying with applicable breach notification obligations to individuals, regulators, partners and others could be significant. Our insurance policies may not be adequate to compensate us for the potential costs and other losses arising from cybersecurity-related disruptions, failures, attacks or breaches. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, defending a suit, regardless of its merit, could be costly, divert management attention and harm our reputation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Threats involving the misuse or access of our network, systems, and information by our current or former employees, contractors, vendors, or partners, whether intentional or unintentional, also pose a risk to the security of our network, systems, information and data. For example, we are subject to the risk that employees may inadvertently share Confidential Information with unintended third parties, or that departing employees may take, or create their own information based on, our Confidential Information upon leaving the company. In addition, any such insiders may be the victims of social engineering attacks that enable third parties to access our network, systems, and information using an authorized person&#8217;s credentials. We and our network, systems, and information are also vulnerable to malicious acts by insiders, including leaking, modifying, or deleting Confidential Information, or performing other acts that could materially interfere with our operations and business. While we provide regular training to our employees regarding cybersecurity threats and best practices, we cannot ensure that such training or other efforts will prevent unauthorized access to or sabotage of our network, systems, and information.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we implement security measures designed to reduce these risks, there is no guarantee these measures will be adequate to safeguard all systems and networks. Any failure to maintain performance, reliability, security and availability of our systems and networks may result in accidental or unlawful destruction, damage, loss, unavailability, alteration, impairment, misuse, unauthorized disclosure of, or unauthorized access to our data, including personal or proprietary information.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on on-premise, co-located and third-party data centers and platforms to host our website and other online services, as well as for research and development purposes and any interruptions of service or failures may impair and harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary software is a crucial component of our solutions, as our software allows our end users to visualize genomic and multiomic information provided by our instruments and reagents. Our software is generally downloadable free of charge from our website for installation and use by end users on their computer systems. Our website is hosted with various third-party service providers located in the United States. We rely on on-premises, co-located and third-party infrastructure in the San Francisco Bay Area and other regions in the United States to perform computationally demanding analysis tasks for our research and development programs and for other business purposes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of any technical problems that may arise in connection with our on-premise, co-located or third-party data centers, we could experience interruptions in our ability to provide products and services to our customers or in our internal functions, including research and development, which rely on such services. Interruptions or failures may be caused by a variety of factors, including infrastructure changes, human or software errors, viruses, worms, ransomware, security attacks, fraud, spikes in customer usage and denial of service issues. Interruptions or failures in our operations or services may reduce our revenue, result in the loss of customers, adversely affect our ability to attract new customers or harm our reputation. Significant interruptions to our research and development programs could cause us to delay the introduction of new products or new versions of existing products, which could adversely impact our business, our results of operations and the competitiveness of our products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current solutions are capable of generating large datasets, the analysis of which can be time consuming without access to a high-performance computing system. The visualization of such data can also be computationally intensive. As we iterate and improve our products and as the related technologies advance, our continued growth may require an ability to provide our customers with direct access to a high-performance computing system and/or alternative means of obtaining our software. As a result, we expect our reliance on internal and third-party data centers to increase in the future.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, as we rely on third-party and public-cloud infrastructure, we will depend in part on third-party security measures to protect against unauthorized access, cyberattacks and the mishandling of customer data. In addition, failures to meet customers&#8217; expectations with respect to security and confidentiality of their data and information could damage our reputation and affect our ability to retain customers, attract new customers and grow our business. In addition, a cybersecurity event could result in significant increases in costs, including costs for remediating the effects of such an event, lost revenue due to a decrease in customer trust and network downtime; increases in insurance coverage costs due to cybersecurity incidents; and damages to our reputation because of any such incident.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to certain manufacturing restrictions related to licensed intellectual property rights that were developed with the financial assistance of United States government grants.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Bayh-Dole Act, the federal government retains a &#8220;nonexclusive, nontransferable, irrevocable, paid-up license&#8221; in inventions produced with its financial assistance (&#8220;Government Funded Inventions&#8221;) for its own benefit. The Bayh-Dole Act provides federal agencies with march-in rights (&#8220;March-In Rights&#8221;), which allows a government agency, in specified circumstances, to require the patent owner or successors in title to the patent directed to such Government Funded Inventions (&#8220;Patent Owner&#8221;) to grant a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a &#8220;responsible applicant or applicants,&#8221; which if exercised, would allow such government agency to require such Patent Owner to grant a non-exclusive, partially exclusive or exclusive license in any field of use to a third-party designated by such agency. The Bayh-Dole Act also provides that the Patent Owner manufacture products embodying the respective Government Funded Inventions domestically in accordance with certain requirements. If this domestic manufacturing requirement is not met, the government agency that funded the relevant grant is entitled to exercise March-In Rights. We are subject to the Bayh-Dole Act with respect to certain licensed technologies that were developed with United States government grants. Such licensed technologies are used, for example, in a substantial majority of our consumables. Further, we cannot be sure that if we acquired intellectual property rights in the future it will be free from government rights or regulations pursuant to the Bayh-Dole Act.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we own, co-own or in-license Government Funded Inventions that are critical to our business, our ability to enforce or otherwise exploit patents covering such technology may be adversely affected. Further, the exercise of March-In Rights, the requirement that we grant additional licenses to third parties, or the termination of our license of the relevant technologies could materially adversely affect our business, operations and financial condition. The restrictions of the Bayh-Dole Act may also limit our ability to manufacture our products in locations where it may be otherwise more favorable for us to do so, which could limit our ability to respond to competitive developments or otherwise adversely affect our results of operations. Any of the foregoing could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to litigation and our intellectual property</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become a party to intellectual property litigation or administrative proceedings that could be expensive, time-consuming, unsuccessful, and could interfere with our ability to develop, manufacture and commercialize our products or technologies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends, in part, on our ability to develop, manufacture or commercialize our products and technologies without infringing, misappropriating or otherwise violating the proprietary rights and intellectual property of third parties. Our industry has been characterized by extensive litigation regarding patents, trademarks, trade secrets, and other intellectual property rights, and companies in the industry have used intellectual property litigation to gain a competitive advantage. While we take steps to ensure that we do not infringe upon, misappropriate or otherwise violate the intellectual property rights of others, there may be other more pertinent rights of which we are presently unaware.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may initiate, and have in the past initiated, legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights. The outcome of such proceedings are uncertain and could have a negative impact on the success of our business. It is possible that U.S. and foreign patents and pending patent applications controlled by third parties may be alleged to cover our products and technologies, or that we may be accused of misappropriating third parties&#8217; trade secrets or infringing third parties&#8217; trademarks. We have in the past, and may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our products or technologies, including interference proceedings, post grant review and inter partes review before the USPTO or equivalent foreign regulatory authority. Furthermore, we may also become involved in other proceedings, such as reexamination, derivation or opposition proceedings before the USPTO or other jurisdictional body relating to our intellectual property rights or the intellectual property rights of others. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. Because patent applications can take many years to issue and because publication schedules for pending applications vary by jurisdiction, there may be applications now pending of which we are unaware and which may result in issued patents, which our current or future products or services infringe. Also, because the claims of published patent </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applications can change between publication and patent grant, there may be published patent applications that may ultimately issue with claims that we infringe. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid and enforceable, and infringed by the use of our products and/or technologies, which could have a negative impact on the commercial success of our current and any future products or technologies. If we were to challenge the validity of any such third-party U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. We will have similar burdens to overcome in foreign courts in order to successfully challenge a third-party claim of patent infringement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our defense of any litigation or interference proceedings may fail and, even if successful, defending such claims brought against us would cause us to incur substantial expenses and distract our management and other employees. If such claims are successfully asserted against us, we could be forced to pay substantial damages. Further, if a patent infringement or other intellectual property rights-related lawsuit were brought against us, we could be forced, including by court order, to cease developing, manufacturing and/or commercializing the infringing product or technologies. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right. Although patent, trademark, trade secret, and other intellectual property disputes have often been settled through licensing or similar arrangements, costs associated with such arrangements may be substantial and could include ongoing royalties. We may not be able to obtain licenses on commercially reasonable terms, or at all, in which event our business would be materially and adversely affected. Even if we were able to obtain a license, the rights may be nonexclusive, which could result in our competitors and other third parties gaining access to the same intellectual property. Ultimately, if we are unable to obtain such licenses or make any necessary changes to our products or services, we could be forced to cease some aspect of our business operations, which could harm our business significantly.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A finding of infringement or an unfavorable interference or derivation proceedings outcome could prevent us from developing, manufacturing and/or commercializing our products or technologies, or force us to cease some or all of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively than we can because of greater financial resources and more mature and developed intellectual property portfolios. We could encounter delays in product introductions while we attempt to develop alternative products or technologies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If third parties assert infringement, misappropriation or other claims against our customers, these claims may require us to initiate or defend protracted and costly litigation on behalf of our customers, regardless of the merits of these claims. If any of these claims succeed or settle, we may be forced to pay damages or settlement payments on behalf of our customers or may be required to obtain licenses for the products they use. If we cannot obtain all necessary licenses on commercially reasonable terms, our customers may be forced to stop using our products or technologies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors, many of which have substantially greater resources and have made substantial investments in patent portfolios, trade secrets, trademarks, and competing technologies, may have applied for or obtained, or may in the future apply for or obtain, patents or trademarks that will prevent, limit or otherwise interfere with our ability to make, use, sell and/or export our products or to use our technologies or product names. As the number of competitors in our market grows and the number of patents issued in this area increases, the possibility of patent infringement claims against us may increase. Moreover, individuals and groups that are non-practicing entities, commonly referred to as &#8220;patent trolls,&#8221; purchase patents and other intellectual property assets for the purpose of making claims of infringement in order to extract settlements. From time to time, we may receive threatening letters, notices or &#8220;invitations to license,&#8221; or may be the subject of claims that our products and business operations infringe, misappropriate or otherwise violate the intellectual property rights of others. These matters can be time-consuming, costly to defend in litigation, divert management&#8217;s attention and resources, damage our reputation and brand and cause us to incur significant expenses or make substantial payments. Additionally, we purchase product components, including hardware and software, from suppliers, and the design of these components may be outside of our direct control. These suppliers may not indemnify us in the event that a third party alleges the use of such components infringes its intellectual property rights.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any lawsuits relating to intellectual property rights could subject us to significant liability for damages and invalidate our intellectual property. Any potential intellectual property litigation also could force us to do one or more of the following:</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">stop developing, making, selling or using products or technologies that allegedly infringe, misappropriate or otherwise violate the asserted intellectual property right;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pay substantial damages or royalties to the party whose intellectual property rights we may be found to be infringing, misappropriating or otherwise violating;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">redesign those products, services or technologies that contain the allegedly infringing intellectual property, which could be costly, disruptive and infeasible; and attempt to obtain a license to the relevant intellectual property rights from third parties, which may not be available on commercially reasonable terms or at all, or from third parties who may attempt to license rights that they do not have;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lose the opportunity to license our intellectual property rights to others or to collect royalty payments based upon successful protection and assertion of our intellectual property rights against others;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur significant legal expenses; or</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pay the attorney&#8217;s fees and costs of litigation to the party whose intellectual property rights we may be found to be infringing, misappropriating or otherwise violating.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, inter partes review and equivalent proceedings in foreign jurisdictions (for example, opposition proceedings). Such proceedings could result in revocation of or amendment to our patents in such a way that they no longer cover our products or technologies. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel, and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity and/or unenforceability, we may lose at least part, and perhaps all, of the patent protection on our products or technologies. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearing, motions, or other interim developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock. Even if we ultimately prevail, a court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may not be an adequate remedy. Furthermore, the monetary cost of such litigation and the diversion of the attention of our management could outweigh any benefit we receive as a result of the proceedings. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our business. Any of the foregoing may cause us to incur substantial costs, and could place a significant strain on our financial resources, divert the attention of management from our core business and harm our reputation.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are involved in lawsuits to protect, enforce or defend our patents and other intellectual property rights, which are expensive, time consuming and could ultimately be unsuccessful.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past we have initiated, and we are currently involved in, litigation to defend our technology including technology developed through our significant investments in research and development. It is our general policy not to out-license our patents but to protect our sole right to own and practice them. There are inherent uncertainties in these legal matters, some of which are beyond management&#8217;s control, making the ultimate outcomes difficult to predict. See Note 4, Commitments and Contingencies, to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for information regarding certain legal proceedings in which we are involved. In addition to the litigation in Note 4, we may in the future be a party to other litigation or legal proceedings to protect, enforce or defend our patents or other intellectual property, which, if resolved adversely to us, could invalidate or render unenforceable our intellectual property or generally preclude us from restraining, enjoining or otherwise seeking to exclude competitors from commercializing products using technology developed or used by us. For example, our patents and any patents which we in-license may be challenged, narrowed, invalidated or circumvented. If patents we own or license are invalidated or otherwise limited, other companies may be better able to develop products that compete with ours, which would adversely affect our competitive position, business prospects, results of operations and financial condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are examples of litigation and other adversarial proceedings or disputes that we could become a party to involving our patents or patents licensed to us:</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have initiated, and in the future may initiate, litigation or other proceedings against third parties to enforce our patent rights;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties have initiated, and in the future may initiate, litigation or other proceedings seeking to invalidate patents owned by or licensed to us or to obtain a declaratory judgment that their product or technology does not infringe our patents or patents licensed to us or that such patents are invalid or unenforceable;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties have initiated, and in the future may initiate, oppositions, IPRs, post grant reviews or reexamination proceedings challenging the validity or scope of our patent rights, requiring us and/or licensors to participate in such proceedings to defend the validity and scope of our patents;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">there are, and in the future may be, more challenges or disputes regarding inventorship or ownership of patents currently identified as being owned by or licensed to us; or</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">at our initiation or at the initiation of a third-party, the USPTO may initiate an interference between patents or patent applications owned by or licensed to us and those of our competitors, requiring us and/or licensors to participate in an interference proceeding to determine the priority of invention, which could jeopardize our patent rights.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, many of our employees were previously employed at universities or other life sciences companies, including our competitors or potential competitors. We or our employees may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers without consent. Although no such claims are currently pending, litigation may be necessary to defend against such claims if they arise in the future. If we fail to successfully defend such claims, in addition to paying monetary damages, we may be subject to injunctive relief and lose valuable intellectual property rights. A loss of key research personnel work product could hamper or prevent our ability to commercialize certain potential products, which could severely harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to ownership of our Class&#160;A common stock</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our Class&#160;A common stock by our existing stockholders could cause the price of our Class&#160;A common stock to decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our Class&#160;A common stock in the public market could occur at any time. We have registered all shares of Class&#160;A common stock that we may issue under our equity compensation and employee stock purchase plans. These shares can be freely sold in the public market upon issuance and, if applicable, vesting, subject to our insider trading policy, where applicable, and applicable securities laws including volume limitations applicable to affiliates under Rule 144 and Rule 701. Sales of Class&#160;A common stock in the public market may make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. These sales also could cause the trading price of our Class&#160;A common stock to fall and make it more difficult for you to sell shares of our Class&#160;A common stock.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The multi-class structure of our common stock has the effect of concentrating voting control with those stockholders who held our capital stock prior to the completion of our IPO, including our co-founders, and may depress the trading price of our Class&#160;A common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Class&#160;A common stock has one vote per share and our Class&#160;B common stock has ten votes per share, except as otherwise required by law. Because of the ten-to-one voting ratio between our Class&#160;B common stock and Class&#160;A common stock, the holders of our Class&#160;B common stock collectively control a majority of the combined voting power of our common stock and therefore are able to control all matters submitted to our stockholders for approval, other than matters that require a supermajority for approval. This concentrated control is expected to limit or preclude Class A stockholders' ability to influence certain corporate matters requiring stockholder approval. In addition, this may prevent or discourage unsolicited acquisition proposals or offers for our capital stock that an investor may feel is in her or his best interest as one of our stockholders.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future transfers by holders of Class&#160;B common stock will generally result in those shares converting to Class&#160;A common stock, subject to limited exceptions, such as certain transfers effected for estate planning purposes where sole dispositive power and exclusive voting control with respect to the shares of Class&#160;B common stock is retained by the transferring holder and transfers between our co-founders. In addition, each outstanding share of Class&#160;B common stock held by a stockholder who is a natural person, or held by the permitted entities of such stockholder (as described in our amended and restated certificate of incorporation), will convert automatically into one share of Class&#160;A common stock upon the death of such natural person. In the event of the death or permanent and total disability of a co-founder, shares of Class&#160;B common stock held by such co-founder or his permitted entities will convert to Class&#160;A common stock, provided that the conversion will be deferred for nine months, or up to 18 months if approved by a majority of our independent directors, following his death or permanent and total disability. Transfers between our co-founders are permitted transfers and will not result in conversion of the shares of Class&#160;B common stock that are transferred. The conversion of Class&#160;B common stock to Class&#160;A common stock has had, and is expected to continue to have, the effect, over time, of increasing the relative voting power of those individual holders of Class&#160;B common stock who retain their shares in the long term. To date, such conversions have had the effect of increasing the relative voting power of our co-founders and certain of our directors and is expected to continue to have such an effect if our co-founders and such directors retain their shares in the long term.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our Class&#160;A common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our status as a Delaware corporation and the anti-takeover provisions of the Delaware General Corporation Law may discourage, delay or prevent a change in control by prohibiting us from engaging in a business combination with an interested stockholder for a period of three years after the person becomes an interested stockholder, even if a change of control would be beneficial to our existing stockholders. In addition, our restated certificate of incorporation and restated bylaws contain provisions that may make the acquisition of our company more difficult, including the following:</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any transaction that would result in a change in control of our company requires the approval of a majority of our outstanding Class&#160;B common stock voting as a separate class;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our multi-class common stock structure provides our holders of Class&#160;B common stock with the ability to significantly influence the outcome of matters requiring stockholder approval, even if they own significantly less than a majority of the shares of our outstanding Class&#160;A common stock and Class&#160;B common stock;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our board of directors is classified into three classes of directors with staggered three-year terms and directors are only able to be removed from office for cause by the affirmative vote of holders of at least two-thirds of the voting power of our then outstanding capital stock;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">certain amendments to our amended and restated certificate of incorporation require the approval of stockholders holding two-thirds of the voting power of our then outstanding capital stock;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any stockholder-proposed amendment to our amended and restated bylaws requires the approval of stockholders holding two-thirds of the voting power of our then outstanding capital stock;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our stockholders are only able to take action at a meeting of stockholders and are not able to take action by written consent for any matter;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our stockholders are able to act by written consent only if the action is first recommended or approved by the board of directors;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">vacancies on our board of directors are able to be filled only by our board of directors and not by stockholders;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">only our chairman of the board of directors, chief executive officer or a majority of the board of directors are authorized to call a special meeting of stockholders;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">certain litigation against us can only be brought in Delaware;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our restated certificate of incorporation authorizes undesignated preferred stock, the terms of which may be established and shares of which may be issued, without the approval of the holders of our capital stock; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance notice procedures apply for stockholders to nominate candidates for election as directors or to bring matters before an annual meeting of stockholders.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These anti-takeover defenses could discourage, delay or prevent a transaction involving a change in control of our company. These provisions could also discourage proxy contests and make it more difficult for stockholders to elect directors of their choosing and to cause us to take other corporate actions they desire, any of which, under certain circumstances, could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our Class&#160;A common stock.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated bylaws designate a state or federal court located within the State of Delaware as the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to choose the judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated bylaws provide that, unless we consent in writing to the selection of an alternative forum, (i)&#160;any derivative action or proceeding brought on our behalf, (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, stockholders or employees to us or our stockholders, (iii)&#160;any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or our amended and restated bylaws or (iv)&#160;any action asserting a claim governed by the internal affairs doctrine of the law of the State of Delaware shall, to the fullest extent permitted by law, be exclusively brought in the Court of Chancery of the State of Delaware or, if such court does not have subject matter jurisdiction thereof, the federal district court of the State of Delaware. Our amended and restated bylaws further provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States are the exclusive forum for the resolution of any claims under the Securities Act or any successor thereto. Nothing in our amended </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and restated bylaws precludes stockholders that assert claims under the Exchange Act, or any successor thereto, from bringing such claims in state or federal court, subject to applicable law. Any person or entity purchasing or otherwise acquiring or holding any interest in any of our securities shall be deemed to have notice of and consented to the foregoing forum selection provisions. These exclusive-forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum of such stockholder&#8217;s choosing for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees and may result in increased costs for investors to bring a claim. If a court were to find the exclusive-forum provisions in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could harm our results of operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General risk factors</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may fail to meet our publicly announced guidance or other expectations about our business, which could cause our stock price to decline. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past we have provided, and in the future we may provide, guidance and other expectations regarding our expected financial and business performance. Our guidance is based on a number of assumptions and does not reflect all possible impacts to our business including, for example, all potential impacts of recently announced changes to government funding of research and the other risks discussed in this section titled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Correctly identifying key factors affecting business conditions and predicting future events is inherently an uncertain process, and our guidance or the other expectations we set may not ultimately be accurate and has in the past been inaccurate in certain respects. For example, we failed to meet our publicly announced guidance regarding full year revenue in both 2022 and 2024 and in May 2025 we withdrew previously provided guidance regarding full year 2025 revenue and implemented quarterly guidance beginning with the second quarter of 2025. Further, in August 2022, we announced our goal to attain cash flows from operating activities in excess of our capital investment requirements by the end of 2023. While we achieved this goal for the quarter ended December 31, 2023, we did not attain cash flows from operating activities in excess of our capital investment requirements for the full year ended December 31, 2024 and we may not be able to maintain cash flows from operating activities in excess of our capital investment requirements in the future on a sustained basis or at all due to a variety of factors, including if we do not generate sufficient revenue or achieve our gross margin targets, if we acquire businesses or technologies (or complete expenditures related to previous acquisitions) or if our spending is higher than anticipated. If our guidance varies from actual results or if we fail to meet other expectations regarding our business, the market value of our Class A common stock could decline significantly. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our Class&#160;A common stock may be volatile, which could result in substantial losses for investors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The&#160;trading price of our Class&#160;A common stock has been and may continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. In addition to the factors discussed in this &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; section and elsewhere in this report, these factors include:</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of our launch of future products and degree to which the launch and commercialization thereof meets the expectations of securities analysts and investors;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure or funding of research at academic and research laboratories and institutions, including changes that would affect their ability to purchase our instruments or consumables;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of existing or new competitive businesses or technologies;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements about new research programs or products of our competitors;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, industry and market conditions;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">volatility and variations in market conditions in the life sciences sector generally, or the genomics sector specifically;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether our financial results meet our publicly announced expectations or the expectations of securities analysts or investors;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated changes in our estimates as to our financial results or development timelines, variations in our financial results or those of companies that are perceived to be similar to us or changes in estimates or recommendations by securities analysts, if any, that cover our Class&#160;A common stock or companies that are perceived to be similar to us;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">investor perceptions of us or our industry;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of expenses related to any of our research and development programs or products;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">litigation and governmental investigations involving us, our industry or both;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcomes of and related rulings in the litigation and administrative proceedings in which we are currently or may in the future become involved;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the recruitment or departure of key personnel;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory or legal developments in the United States and other countries;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the announcement or expectation of additional financing efforts;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">stock-based compensation expense;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure or discontinuation of any of our product development and research programs;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our Class&#160;A common stock or Class&#160;B common stock by us, our insiders or other stockholders;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">natural disasters, infectious diseases, conflict, war, civil unrest, epidemics or pandemics or resurgences or major catastrophic events; and</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the other factors described in this &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; section.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, stock markets in general, and the market for life sciences technology companies in particular (including companies in the genomics, biotechnology, diagnostics and related sectors), have experienced significant price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors may seriously affect the market price of our Class&#160;A common stock, regardless of our actual operating performance. Volatility in our stock price also impacts the value of our equity compensation, which affects our ability to recruit and retain employees. In the past, when the market price of a stock has been volatile, securities litigation has often been brought against that company. Because of the potential volatility of our stock price, we may become the target of securities litigation in the future. Securities litigation could result in substantial costs and divert management&#8217;s attention and resources from our business. We have currently obtained only director and officer liability coverage (commonly referred to as &#8220;Side A&#8221; coverage). This means that while our directors and officers have direct insurance coverage for acts which the company is not legally required or permitted to indemnify them, the company itself does not have coverage for amounts incurred in defending, among other things, stockholder derivative or securities class action lawsuits or in the event of certain investigative actions, for amounts it must pay as a result of such suits or amounts it must pay to indemnify our directors or officers. We are in essence self-insuring for these costs. Any costs incurred in connection with such litigation could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities analysts may not publish favorable research or reports about our business or may publish no information at all, which could cause our stock price or trading volume to decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market of our common stock is influenced to some extent by the research and reports that industry or financial analysts publish about us and our business. We do not control these analysts. The analysts who publish information about our common stock may have had relatively little experience with us or our industry, which could affect their ability to accurately forecast our results and could make it more likely that we fail to meet their estimates. If any of the analysts who cover us provide inaccurate or unfavorable research or issue an adverse opinion regarding our stock price, our stock price could decline. If one or more of these analysts cease coverage of us or fail to publish reports covering us regularly, we could lose visibility in the market, which in turn could cause our stock price or trading volume to decline. If our estimates or judgments relating to our critical accounting policies are based on assumptions that change or prove to be incorrect, our operating results could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our common stock. For example, the market price of our common stock declined after our financial results for the quarters ended June 30, 2022 and September 30, 2024 fell short of the expectations of securities analysts and investors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with generally accepted accounting principles in the United States ("GAAP") requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. If our assumptions change or if actual circumstances differ from our assumptions, our operating results may be adversely affected and could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our common stock.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance initiatives and corporate governance practices, including maintaining an effective system of internal controls over financial reporting. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred and will continue to incur significant legal, accounting and other expenses because the Dodd-Frank Wall Street Reform and Consumer Protection Act, SOX, the listing requirements of Nasdaq and other applicable federal and Delaware rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management and other personnel are required to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have increased our legal and financial compliance costs and have made some activities more time-consuming and costly. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements also could make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. Moreover, these rules and regulations often are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules and regulations applicable to us as a public company and recent trends in the insurance market have made it more expensive for us to obtain director and officer liability insurance. We have currently obtained only director and officer liability coverage (commonly referred to as &#8220;Side A&#8221; coverage). This means that while our directors and officers have direct insurance coverage for acts which the company is not legally required or permitted to indemnify them, the company itself does not have coverage for amounts incurred in defending, among other things, stockholder derivative or securities class action lawsuits or in the event of certain investigative actions, for amounts it must pay as a result of such suits or amounts it must pay to indemnify our directors or officers. We are in essence self-insuring for these costs. Any costs incurred in connection with such litigation could have a material adverse effect on our business, financial condition and results of operations.</span></div><div id="ided02fd2e98d499fb2d5119ce560145c_88"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;&#160;&#160;&#160;Other Information</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of our directors or officers <ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-509"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-510">adopted</ix:nonNumeric></ix:nonNumeric>, modified or <ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-511">terminated</ix:nonNumeric> a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement during the quarter ended March&#160;31, 2025, as such terms are defined under Item 408(a) of Regulation S-K, except as follows:</span></div><ix:nonNumeric contextRef="c-136" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-512" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 12, 2024, <ix:nonNumeric contextRef="c-136" name="ecd:TrdArrIndName" id="f-513">Serge Saxonov</ix:nonNumeric>, <ix:nonNumeric contextRef="c-136" name="ecd:TrdArrIndTitle" id="f-514">Chief Executive Officer</ix:nonNumeric>, <ix:nonNumeric contextRef="c-136" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-true" id="f-515">adopted a Rule 10b5-1 trading arrangement</ix:nonNumeric> that was intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to <ix:nonFraction unitRef="shares" contextRef="c-137" decimals="0" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" id="f-516">35,600</ix:nonFraction> shares of the Company&#8217;s common stock plus up to <ix:nonFraction unitRef="shares" contextRef="c-138" decimals="0" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" id="f-517">136,000</ix:nonFraction> carryover shares from a prior 10b5-1 plan. The expiration date of the trading arrangement was December 31, 2025. On <ix:nonNumeric contextRef="c-136" name="ecd:TrdArrTerminationDate" id="f-518">March 4, 2025</ix:nonNumeric>, the trading arrangement was terminated at the election of Dr. Saxonov.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="ided02fd2e98d499fb2d5119ce560145c_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;Exhibits.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.557%"><tr><td style="width:1.0%"/><td style="width:7.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.503%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.509%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Incorporated by Reference</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit Title</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">File No.</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Filing Date</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed Herewith</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1770787/000119312519245827/d805425dex31.htm">Amended and Restated Certificate of Incorporation of the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">001-39035</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9/16/2019</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1770787/000177078722000057/a20220930-ex32.htm">Amended and Restated Bylaws of the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">001-39035</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11/3/2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1770787/000119312519224368/d737378dex42.htm">Form of Stock Certificate for Class&#160;A common stock of the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-233361</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8/19/2019</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="txg-20250331xex311.htm">Certification of Principal Executive Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="txg-20250331xex312.htm">Certification of Principal Financial and Accounting Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="txg-20250331xex321.htm">Certification of Principal Executive Officer Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.2*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="txg-20250331xex322.htm">Certification of Principal Financial and Accounting Officer Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Instance Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (the Cover Page Interactive Data File does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span><br/></span></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;This certification is deemed not filed for purposes of Section&#160;18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</span></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="ided02fd2e98d499fb2d5119ce560145c_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ided02fd2e98d499fb2d5119ce560145c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.624%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.922%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.154%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10x Genomics, Inc.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 8, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Serge Saxonov</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Serge Saxonov</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer and Director</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 8, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Adam S. Taich</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adam S. Taich<br/>Chief Financial Officer<br/>(Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>txg-20250331xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i979c30cb9cc447d39668fa4cfa2d661f_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PERIODIC REPORT UNDER SECTION 302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Serge Saxonov, certify that&#58;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of 10x Genomics, Inc.&#59;</font></div><div style="text-align:justify;text-indent:22.5pt"><font><br></font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify;text-indent:22.5pt"><font><br></font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify;text-indent:22.5pt"><font><br></font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify;text-indent:22.5pt"><font><br></font></div><div style="padding-left:49.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:49.5pt;text-align:justify"><font><br></font></div><div style="padding-left:49.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:49.5pt;text-align:justify"><font><br></font></div><div style="padding-left:49.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:49.5pt;text-align:justify"><font><br></font></div><div style="padding-left:49.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:49.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:49.5pt;text-align:justify"><font><br></font></div><div style="padding-left:49.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="margin-top:6pt;text-indent:40.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.126%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 8, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Serge Saxonov</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Serge Saxonov</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer and Director</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>txg-20250331xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i68ec14b8ec11489b8522309b119c2be4_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PERIODIC REPORT UNDER SECTION 302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Adam S. Taich, certify that&#58;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of 10x Genomics, Inc.&#59;</font></div><div style="text-align:justify;text-indent:22.5pt"><font><br></font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify;text-indent:22.5pt"><font><br></font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify;text-indent:22.5pt"><font><br></font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify;text-indent:22.5pt"><font><br></font></div><div style="padding-left:49.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:49.5pt;text-align:justify"><font><br></font></div><div style="padding-left:49.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:49.5pt;text-align:justify"><font><br></font></div><div style="padding-left:49.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:49.5pt;text-align:justify"><font><br></font></div><div style="padding-left:49.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:49.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:49.5pt;text-align:justify"><font><br></font></div><div style="padding-left:49.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div style="margin-top:6pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="margin-top:6pt;text-indent:40.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.126%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 8, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Adam S. Taich</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adam S. Taich<br>Chief Financial Officer<br>(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>txg-20250331xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="if41bde61747f440c916c0c388304f4ee_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Serge Saxonov, the Chief Executive Officer of 10x Genomics, Inc. (the &#8220;Company&#8221;), hereby certify, that, to my knowledge&#58;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">The Quarterly Report on Form 10-Q for the period ended March&#160;31, 2025 (the &#8220;Report&#8221;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="margin-top:12pt;text-indent:40.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.126%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 8, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Serge Saxonov</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Serge Saxonov</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer and Director</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>txg-20250331xex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i3849e01d0e114f788aa126b68d845b81_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Adam S. Taich, the Chief Financial Officer of 10x Genomics, Inc. (the &#8220;Company&#8221;), hereby certify, that, to my knowledge&#58;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">The Quarterly Report on Form 10-Q for the period ended March&#160;31, 2025 (the &#8220;Report&#8221;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="margin-top:12pt;text-indent:40.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:0.1%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.930%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 8, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Adam S. Taich</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adam S. Taich<br>Chief Financial Officer<br>(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>txg-20250331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:3ecddcae-0640-4c17-b64e-2ecf664c9fd0,g:adbdc3ab-11fd-421c-ac99-3782b4f382a6-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:txg="http://www.10xgenomics.com/20250331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.10xgenomics.com/20250331">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="txg-20250331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="txg-20250331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="txg-20250331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="txg-20250331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.10xgenomics.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>9952152 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss">
        <link:definition>9952153 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>9952154 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>9952155 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandBasisofPresentation" roleURI="http://www.10xgenomics.com/role/DescriptionofBusinessandBasisofPresentation">
        <link:definition>9952156 - Disclosure - Description of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.10xgenomics.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952157 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialStatementInformation" roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformation">
        <link:definition>9952158 - Disclosure - Other Financial Statement Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.10xgenomics.com/role/CommitmentsandContingencies">
        <link:definition>9952159 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStock" roleURI="http://www.10xgenomics.com/role/CapitalStock">
        <link:definition>9952160 - Disclosure - Capital Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlans" roleURI="http://www.10xgenomics.com/role/EquityIncentivePlans">
        <link:definition>9952161 - Disclosure - Equity Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.10xgenomics.com/role/NetLossPerShare">
        <link:definition>9952162 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvent" roleURI="http://www.10xgenomics.com/role/SubsequentEvent">
        <link:definition>9952163 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.10xgenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialStatementInformationTables" roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationTables">
        <link:definition>9955512 - Disclosure - Other Financial Statement Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.10xgenomics.com/role/CommitmentsandContingenciesTables">
        <link:definition>9955513 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansTables" roleURI="http://www.10xgenomics.com/role/EquityIncentivePlansTables">
        <link:definition>9955514 - Disclosure - Equity Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.10xgenomics.com/role/NetLossPerShareTables">
        <link:definition>9955515 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.10xgenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>9955516 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails" roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails">
        <link:definition>9955517 - Disclosure - Other Financial Statement Information - Available-for-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialStatementInformationAdditionalInformationDetails" roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails">
        <link:definition>9955518 - Disclosure - Other Financial Statement Information - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialStatementInformationAdditionalInformationDetails_1" roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails_1">
        <link:definition>9955518 - Disclosure - Other Financial Statement Information - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialStatementInformationScheduleofInventoryDetails" roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofInventoryDetails">
        <link:definition>9955519 - Disclosure - Other Financial Statement Information - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail" roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail">
        <link:definition>9955520 - Disclosure - Other Financial Statement Information - Schedule Of Property Plant And Equipment (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialStatementInformationScheduleofAccruedCompensationandRelatedBenefitsDetails" roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedCompensationandRelatedBenefitsDetails">
        <link:definition>9955521 - Disclosure - Other Financial Statement Information - Schedule of Accrued Compensation and Related Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialStatementInformationScheduleofAccruedExpenseAndOtherCurrentLiabilitiesDetails" roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedExpenseAndOtherCurrentLiabilitiesDetails">
        <link:definition>9955522 - Disclosure - Other Financial Statement Information - Schedule of Accrued Expense And Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialStatementInformationScheduleofChangesintheReserveforProductWarrantiesDetails" roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofChangesintheReserveforProductWarrantiesDetails">
        <link:definition>9955523 - Disclosure - Other Financial Statement Information - Schedule of Changes in the Reserve for Product Warranties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialStatementInformationScheduleofRevenueofRecognizedinContractLiabilitiesDetails" roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenueofRecognizedinContractLiabilitiesDetails">
        <link:definition>9955524 - Disclosure - Other Financial Statement Information - Schedule of Revenue of Recognized in Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialStatementInformationScheduleofRevenuebySourceDetails" roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebySourceDetails">
        <link:definition>9955525 - Disclosure - Other Financial Statement Information - Schedule of Revenue by Source (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialStatementInformationScheduleofRevenuebyGeographicRegionDetails" roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebyGeographicRegionDetails">
        <link:definition>9955526 - Disclosure - Other Financial Statement Information - Schedule of Revenue by Geographic Region (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail" roleURI="http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail">
        <link:definition>9955527 - Disclosure - Commitments and Contingencies - Schedule of Company's Operating Lease Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail_1" roleURI="http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail_1">
        <link:definition>9955527 - Disclosure - Commitments and Contingencies - Schedule of Company's Operating Lease Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofAdditionalInformationRelatedtoOperatingLeasesDetail" roleURI="http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofAdditionalInformationRelatedtoOperatingLeasesDetail">
        <link:definition>9955528 - Disclosure - Commitments and Contingencies - Schedule of Additional Information Related to Operating Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetail" roleURI="http://www.10xgenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetail">
        <link:definition>9955529 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStockAdditionalInformationDetail" roleURI="http://www.10xgenomics.com/role/CapitalStockAdditionalInformationDetail">
        <link:definition>9955530 - Disclosure - Capital Stock - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansScheduleofRecordedStockBasedCompensationExpenseintheCondensedConsolidatedStatementofOperationsDetails" roleURI="http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRecordedStockBasedCompensationExpenseintheCondensedConsolidatedStatementofOperationsDetails">
        <link:definition>9955531 - Disclosure - Equity Incentive Plans - Schedule of Recorded Stock-Based Compensation Expense in the Condensed Consolidated Statement of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansScheduleofRSUActivityDetail" roleURI="http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRSUActivityDetail">
        <link:definition>9955532 - Disclosure - Equity Incentive Plans - Schedule of RSU Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansScheduleofCompanysStockOptionActivityDetails" roleURI="http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofCompanysStockOptionActivityDetails">
        <link:definition>9955533 - Disclosure - Equity Incentive Plans - Schedule of Company's Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansAdditionalInformationDetails" roleURI="http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails">
        <link:definition>9955534 - Disclosure - Equity Incentive Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansFairValuesofSharesUnderthePerformanceStockUnitsDetails" roleURI="http://www.10xgenomics.com/role/EquityIncentivePlansFairValuesofSharesUnderthePerformanceStockUnitsDetails">
        <link:definition>9955535 - Disclosure - Equity Incentive Plans - Fair Values of Shares Under the Performance Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareSharesofCommonStockEquivalentsWereExcludedFromTheComputationofDilutedNetLossPerShareDetails" roleURI="http://www.10xgenomics.com/role/NetLossPerShareSharesofCommonStockEquivalentsWereExcludedFromTheComputationofDilutedNetLossPerShareDetails">
        <link:definition>9955536 - Disclosure - Net Loss Per Share - Shares of Common Stock Equivalents Were Excluded From The Computation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.10xgenomics.com/role/SubsequentEventsDetails">
        <link:definition>9955537 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="txg_AccruedExpensesAndOtherLiabilitiesCurrent" abstract="false" name="AccruedExpensesAndOtherLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="txg_ProductAndServiceRevenueMember" abstract="true" name="ProductAndServiceRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="txg_LicensingAndRoyaltyRevenueMember" abstract="true" name="LicensingAndRoyaltyRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="txg_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" abstract="false" name="IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="txg_ScheduleOfAccruedCompensationandRelatedBenefitsTableTextBlock" abstract="false" name="ScheduleOfAccruedCompensationandRelatedBenefitsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="txg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" abstract="false" name="ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="txg_DisclosureOfAdditionalInformationRelatedToOperatingLeasesTableTextBlock" abstract="false" name="DisclosureOfAdditionalInformationRelatedToOperatingLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="txg_RevenueFromContractWithCustomerPaymentPeriod" abstract="false" name="RevenueFromContractWithCustomerPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="txg_DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds" abstract="false" name="DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="txg_DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds" abstract="false" name="DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="txg_ProductsAndServicesExcludingGrantRevenueMember" abstract="true" name="ProductsAndServicesExcludingGrantRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="txg_CostOfRevenueMember" abstract="true" name="CostOfRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="txg_VizgenInc.Member" abstract="true" name="VizgenInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="txg_ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted" abstract="false" name="ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="txg_AccruedPayrollAndRelatedCosts" abstract="false" name="AccruedPayrollAndRelatedCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="txg_AccruedCommissionsCurrent" abstract="false" name="AccruedCommissionsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="txg_AccruedLegalAndRelatedExpensesCurrent" abstract="false" name="AccruedLegalAndRelatedExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="txg_InstrumentsMember" abstract="true" name="InstrumentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="txg_ChromiumInstrumentsMember" abstract="true" name="ChromiumInstrumentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="txg_SpatialInstrumentsMember" abstract="true" name="SpatialInstrumentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="txg_ConsumablesMember" abstract="true" name="ConsumablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="txg_ChromiumConsumablesMember" abstract="true" name="ChromiumConsumablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="txg_SpatialConsumablesMember" abstract="true" name="SpatialConsumablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="txg_AmericasExcludingUnitedStatesMember" abstract="true" name="AmericasExcludingUnitedStatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="txg_AsiaPacificExcludingChinaMember" abstract="true" name="AsiaPacificExcludingChinaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="txg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="txg_CompoundAnnualGrowthRateMember" abstract="true" name="CompoundAnnualGrowthRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="txg_TotalShareholderReturnMember" abstract="true" name="TotalShareholderReturnMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="txg_TwoThousandsNineteenPlanMember" abstract="true" name="TwoThousandsNineteenPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="txg_MarketBasedPerformanceAwardsMember" abstract="true" name="MarketBasedPerformanceAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="txg_TwoThousandsNineteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandsNineteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="txg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="txg_SharesUnderEsppPlanMember" abstract="true" name="SharesUnderEsppPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="txg_SergeSaxonovMember" abstract="true" name="SergeSaxonovMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="txg_SergeSaxonovCommonStockPlusMember" abstract="true" name="SergeSaxonovCommonStockPlusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="txg_SergeSaxonovCarryoverSharesFromPrior10b51PlanMember" abstract="true" name="SergeSaxonovCarryoverSharesFromPrior10b51PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>txg-20250331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:3ecddcae-0640-4c17-b64e-2ecf664c9fd0,g:adbdc3ab-11fd-421c-ac99-3782b4f382a6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="txg-20250331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6f8d5bec-713d-4bd8-8510-20d07908b60c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_0f3797bb-c90b-46f6-843f-4d1504fb0f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6f8d5bec-713d-4bd8-8510-20d07908b60c" xlink:to="loc_us-gaap_PreferredStockValue_0f3797bb-c90b-46f6-843f-4d1504fb0f0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b0833981-b5a5-4eb6-85bf-921e6a902623" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6f8d5bec-713d-4bd8-8510-20d07908b60c" xlink:to="loc_us-gaap_CommonStockValue_b0833981-b5a5-4eb6-85bf-921e6a902623" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8be0caad-3560-4ae8-a495-39065932b95c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6f8d5bec-713d-4bd8-8510-20d07908b60c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8be0caad-3560-4ae8-a495-39065932b95c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cbd3c96e-aaba-4a6f-8a27-ff9ce2376663" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6f8d5bec-713d-4bd8-8510-20d07908b60c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cbd3c96e-aaba-4a6f-8a27-ff9ce2376663" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c147559d-0651-465b-9cf2-e78810009e78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6f8d5bec-713d-4bd8-8510-20d07908b60c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c147559d-0651-465b-9cf2-e78810009e78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_65489b69-83c6-4dfb-852e-cbf0f5e117c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_7ff23a1d-02c3-421c-8121-f19557d839e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_65489b69-83c6-4dfb-852e-cbf0f5e117c4" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_7ff23a1d-02c3-421c-8121-f19557d839e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1c7029ce-e682-48c3-959d-8d11e81184a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_65489b69-83c6-4dfb-852e-cbf0f5e117c4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1c7029ce-e682-48c3-959d-8d11e81184a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d50f97df-22c0-4aac-a8ee-f2af914a7121" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_65489b69-83c6-4dfb-852e-cbf0f5e117c4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d50f97df-22c0-4aac-a8ee-f2af914a7121" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_086621a9-d766-460b-9b5d-3af5b4fb34d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_65489b69-83c6-4dfb-852e-cbf0f5e117c4" xlink:to="loc_us-gaap_InventoryNet_086621a9-d766-460b-9b5d-3af5b4fb34d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_693fb8bc-8013-49d1-8a23-7f896b5be910" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_65489b69-83c6-4dfb-852e-cbf0f5e117c4" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_693fb8bc-8013-49d1-8a23-7f896b5be910" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5e39bf33-25a0-47d6-927e-72decb7cc857" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ccbaae4d-f1eb-41c6-a706-2fd11f1b9c59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5e39bf33-25a0-47d6-927e-72decb7cc857" xlink:to="loc_us-gaap_Liabilities_ccbaae4d-f1eb-41c6-a706-2fd11f1b9c59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_dcea09d0-8431-4d99-83fd-ef79c409aef7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5e39bf33-25a0-47d6-927e-72decb7cc857" xlink:to="loc_us-gaap_CommitmentsAndContingencies_dcea09d0-8431-4d99-83fd-ef79c409aef7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_581e43a0-8ffa-4437-b21a-043d4a6b5e45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5e39bf33-25a0-47d6-927e-72decb7cc857" xlink:to="loc_us-gaap_StockholdersEquity_581e43a0-8ffa-4437-b21a-043d4a6b5e45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d7a52188-4b56-48a9-9faf-f6d107356324" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_75f15805-5f41-4b13-a3e6-420d60ad267d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d7a52188-4b56-48a9-9faf-f6d107356324" xlink:to="loc_us-gaap_LiabilitiesCurrent_75f15805-5f41-4b13-a3e6-420d60ad267d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_195b4e49-194d-4d8d-8c83-a6d91ad3b7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d7a52188-4b56-48a9-9faf-f6d107356324" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_195b4e49-194d-4d8d-8c83-a6d91ad3b7fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_467d7de6-e922-411b-b181-6140a458a5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d7a52188-4b56-48a9-9faf-f6d107356324" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_467d7de6-e922-411b-b181-6140a458a5ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a5dc4fd7-f466-49f4-b299-2f9cb51ba337" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d7a52188-4b56-48a9-9faf-f6d107356324" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a5dc4fd7-f466-49f4-b299-2f9cb51ba337" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f2dc7d8a-6bc3-4a7f-bfe7-0f7941052240" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6517e36b-a572-4130-8e12-cceb02642bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f2dc7d8a-6bc3-4a7f-bfe7-0f7941052240" xlink:to="loc_us-gaap_AccountsPayableCurrent_6517e36b-a572-4130-8e12-cceb02642bb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_540d29a4-a915-4e88-ae4b-688b2b419d49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f2dc7d8a-6bc3-4a7f-bfe7-0f7941052240" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_540d29a4-a915-4e88-ae4b-688b2b419d49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_AccruedExpensesAndOtherLiabilitiesCurrent_9f01c0d2-a038-4750-b688-d6b47261e8f4" xlink:href="txg-20250331.xsd#txg_AccruedExpensesAndOtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f2dc7d8a-6bc3-4a7f-bfe7-0f7941052240" xlink:to="loc_txg_AccruedExpensesAndOtherLiabilitiesCurrent_9f01c0d2-a038-4750-b688-d6b47261e8f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_06371704-75c9-43c8-9e28-5bd6f87af422" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f2dc7d8a-6bc3-4a7f-bfe7-0f7941052240" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_06371704-75c9-43c8-9e28-5bd6f87af422" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f4e25ee8-0150-4f7e-bed2-1dc091c7e4fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f2dc7d8a-6bc3-4a7f-bfe7-0f7941052240" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f4e25ee8-0150-4f7e-bed2-1dc091c7e4fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_aa807b4d-f45d-406a-ac24-bc71a1ebd012" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_86bd480f-e048-4c43-88ce-f51fb502c539" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_aa807b4d-f45d-406a-ac24-bc71a1ebd012" xlink:to="loc_us-gaap_AssetsCurrent_86bd480f-e048-4c43-88ce-f51fb502c539" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e9bcb987-06b4-4329-907a-350003cac573" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_aa807b4d-f45d-406a-ac24-bc71a1ebd012" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e9bcb987-06b4-4329-907a-350003cac573" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0771a08b-575b-4784-a603-b4898c3a7d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_aa807b4d-f45d-406a-ac24-bc71a1ebd012" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0771a08b-575b-4784-a603-b4898c3a7d0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e0976a6b-d9b1-41c1-8f5b-cc3af5086e15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_aa807b4d-f45d-406a-ac24-bc71a1ebd012" xlink:to="loc_us-gaap_Goodwill_e0976a6b-d9b1-41c1-8f5b-cc3af5086e15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_30fa24b8-cd77-4057-8d16-0a02f45734ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_aa807b4d-f45d-406a-ac24-bc71a1ebd012" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_30fa24b8-cd77-4057-8d16-0a02f45734ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_07f561a1-2fa4-428a-a684-01a3d51537e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_aa807b4d-f45d-406a-ac24-bc71a1ebd012" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_07f561a1-2fa4-428a-a684-01a3d51537e8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="txg-20250331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_aaa20b0f-302c-42da-b296-d37a7a479b89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_95f8513c-856a-4b07-9624-7cffe21d76a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_aaa20b0f-302c-42da-b296-d37a7a479b89" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_95f8513c-856a-4b07-9624-7cffe21d76a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementGain_343faaad-751f-472f-945b-0b880bab2c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementGain"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_aaa20b0f-302c-42da-b296-d37a7a479b89" xlink:to="loc_us-gaap_LitigationSettlementGain_343faaad-751f-472f-945b-0b880bab2c6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_eaf972ce-60e1-4562-8f51-9f7bcff491dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_aaa20b0f-302c-42da-b296-d37a7a479b89" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_eaf972ce-60e1-4562-8f51-9f7bcff491dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_517d6091-2955-46bc-b8de-e829b4159084" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_4c6bdaf0-687a-44b2-80d7-cad0f9354e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_517d6091-2955-46bc-b8de-e829b4159084" xlink:to="loc_us-gaap_GrossProfit_4c6bdaf0-687a-44b2-80d7-cad0f9354e0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_16c39ae1-4817-4850-a2c6-088e41ef5273" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_517d6091-2955-46bc-b8de-e829b4159084" xlink:to="loc_us-gaap_OperatingExpenses_16c39ae1-4817-4850-a2c6-088e41ef5273" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_b1aa92e3-8622-4a5e-b6d9-60fe52accf43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ed7c08a2-ae8e-493c-8588-56ad373bbee4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_b1aa92e3-8622-4a5e-b6d9-60fe52accf43" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ed7c08a2-ae8e-493c-8588-56ad373bbee4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_ced3b4a6-bb85-4808-acf3-6893ae44b437" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_b1aa92e3-8622-4a5e-b6d9-60fe52accf43" xlink:to="loc_us-gaap_CostOfRevenue_ced3b4a6-bb85-4808-acf3-6893ae44b437" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9685fc9a-1e8d-458f-b877-54cdde9965f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_4d1034c1-7900-4f0d-80f5-8b524ceccefb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9685fc9a-1e8d-458f-b877-54cdde9965f4" xlink:to="loc_us-gaap_InvestmentIncomeInterest_4d1034c1-7900-4f0d-80f5-8b524ceccefb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_fb80a1e1-a0b0-4938-b3cb-d404a662a208" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9685fc9a-1e8d-458f-b877-54cdde9965f4" xlink:to="loc_us-gaap_InterestExpenseNonoperating_fb80a1e1-a0b0-4938-b3cb-d404a662a208" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0d00ef40-afd5-496a-a894-ac39e879e9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9685fc9a-1e8d-458f-b877-54cdde9965f4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0d00ef40-afd5-496a-a894-ac39e879e9e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b071f556-2498-4922-8d3d-76d835eb70b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83d94714-6a5c-445f-82ec-bc671699e9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_b071f556-2498-4922-8d3d-76d835eb70b5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83d94714-6a5c-445f-82ec-bc671699e9aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_56583523-b520-4b25-be4e-a94acab54cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_b071f556-2498-4922-8d3d-76d835eb70b5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_56583523-b520-4b25-be4e-a94acab54cc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2755f248-1edb-45cf-a03d-385e349497b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5d5cd2f6-ab5f-4622-a406-56b74d844aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2755f248-1edb-45cf-a03d-385e349497b9" xlink:to="loc_us-gaap_OperatingIncomeLoss_5d5cd2f6-ab5f-4622-a406-56b74d844aaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_fc388c50-9854-4672-95b8-fbaaf4d456d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2755f248-1edb-45cf-a03d-385e349497b9" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_fc388c50-9854-4672-95b8-fbaaf4d456d2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="txg-20250331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_04bbb6b2-0eff-4839-923a-988a1aefad0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_23fa9b41-6af2-4377-b756-fb409a0f8509" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_04bbb6b2-0eff-4839-923a-988a1aefad0e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_23fa9b41-6af2-4377-b756-fb409a0f8509" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9478f6e7-8f0f-42fc-ab10-7d91ae07eea5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_04bbb6b2-0eff-4839-923a-988a1aefad0e" xlink:to="loc_us-gaap_NetIncomeLoss_9478f6e7-8f0f-42fc-ab10-7d91ae07eea5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b1c2c049-69c3-40d2-be32-b63c73a1baa0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7e47faf2-421e-44ff-a72f-92cfe41af09e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b1c2c049-69c3-40d2-be32-b63c73a1baa0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7e47faf2-421e-44ff-a72f-92cfe41af09e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_37d25a1a-65d5-4773-9ad1-03f1517fe0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b1c2c049-69c3-40d2-be32-b63c73a1baa0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_37d25a1a-65d5-4773-9ad1-03f1517fe0b9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="txg-20250331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c522a15b-0279-43ad-803f-c283b8a1690b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4c5d78a5-99cd-4ca6-a9dd-a7c17c97af0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c522a15b-0279-43ad-803f-c283b8a1690b" xlink:to="loc_us-gaap_NetIncomeLoss_4c5d78a5-99cd-4ca6-a9dd-a7c17c97af0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_257e6eb5-4ee0-4020-90a0-da394f4048a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c522a15b-0279-43ad-803f-c283b8a1690b" xlink:to="loc_us-gaap_ShareBasedCompensation_257e6eb5-4ee0-4020-90a0-da394f4048a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2f879b0e-db5b-4c02-a322-c2383a2427c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c522a15b-0279-43ad-803f-c283b8a1690b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2f879b0e-db5b-4c02-a322-c2383a2427c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_d4120c52-da5c-4bd0-b746-f430645b0384" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c522a15b-0279-43ad-803f-c283b8a1690b" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_d4120c52-da5c-4bd0-b746-f430645b0384" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_ba7e4edc-087c-48b0-aa9b-99994e6f2560" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c522a15b-0279-43ad-803f-c283b8a1690b" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_ba7e4edc-087c-48b0-aa9b-99994e6f2560" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_bbf0cbb0-4cc6-4482-b162-a7d19f774f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c522a15b-0279-43ad-803f-c283b8a1690b" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_bbf0cbb0-4cc6-4482-b162-a7d19f774f4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_bdcd5f8f-c698-4b6e-a3b4-3ae3f3e83598" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c522a15b-0279-43ad-803f-c283b8a1690b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_bdcd5f8f-c698-4b6e-a3b4-3ae3f3e83598" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_a0fcfa39-fddb-4ead-8915-64e6081866ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c522a15b-0279-43ad-803f-c283b8a1690b" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_a0fcfa39-fddb-4ead-8915-64e6081866ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_19565a43-5a71-4654-a994-b9b70c2261cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c522a15b-0279-43ad-803f-c283b8a1690b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_19565a43-5a71-4654-a994-b9b70c2261cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7984a23f-dc5b-47a7-9ed1-1bd555506313" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c522a15b-0279-43ad-803f-c283b8a1690b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7984a23f-dc5b-47a7-9ed1-1bd555506313" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a5b26c3e-8859-4f5f-a705-46dd581dcdef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c522a15b-0279-43ad-803f-c283b8a1690b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a5b26c3e-8859-4f5f-a705-46dd581dcdef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_afdc8ffe-07a0-47f4-9da3-c9e9ee35401d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c522a15b-0279-43ad-803f-c283b8a1690b" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_afdc8ffe-07a0-47f4-9da3-c9e9ee35401d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_91e10ffd-f11a-48e5-94cc-6a78631c2935" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c522a15b-0279-43ad-803f-c283b8a1690b" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_91e10ffd-f11a-48e5-94cc-6a78631c2935" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_89334a3f-fc50-4c05-85dd-48e39a285135" xlink:href="txg-20250331.xsd#txg_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c522a15b-0279-43ad-803f-c283b8a1690b" xlink:to="loc_txg_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_89334a3f-fc50-4c05-85dd-48e39a285135" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_f060b10d-ef91-4c90-af2c-65b25640418b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c522a15b-0279-43ad-803f-c283b8a1690b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_f060b10d-ef91-4c90-af2c-65b25640418b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_65c64d36-dd9a-44ce-8d20-4a3fb2618909" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c522a15b-0279-43ad-803f-c283b8a1690b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_65c64d36-dd9a-44ce-8d20-4a3fb2618909" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_01b79876-379e-4212-8e50-f67ac2d36563" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_81ce1aca-cca5-4fb2-a79e-daea4fc40a24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_01b79876-379e-4212-8e50-f67ac2d36563" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_81ce1aca-cca5-4fb2-a79e-daea4fc40a24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_390d1773-c4f9-4d01-8e2f-0174784fbc2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_01b79876-379e-4212-8e50-f67ac2d36563" xlink:to="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_390d1773-c4f9-4d01-8e2f-0174784fbc2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_910b26fa-1581-468a-8da0-7731e9642f34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_01b79876-379e-4212-8e50-f67ac2d36563" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_910b26fa-1581-468a-8da0-7731e9642f34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0264178e-3476-490a-928d-08ab33d5f6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_d9664a5a-6820-4b11-871b-0cb4605e70db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0264178e-3476-490a-928d-08ab33d5f6b3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_d9664a5a-6820-4b11-871b-0cb4605e70db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_de088372-551e-4ee5-852a-ed1877059810" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_35de5109-7855-493a-bd16-2c7372d71b37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_de088372-551e-4ee5-852a-ed1877059810" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_35de5109-7855-493a-bd16-2c7372d71b37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_340f9f46-08e0-41e2-bf55-ddb7aba17fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_de088372-551e-4ee5-852a-ed1877059810" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_340f9f46-08e0-41e2-bf55-ddb7aba17fb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d9576ede-21f2-4a3b-8f7c-c597fd73883b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_de088372-551e-4ee5-852a-ed1877059810" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d9576ede-21f2-4a3b-8f7c-c597fd73883b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f6aebecf-9f03-46dd-8fa1-5bcc50c52ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_de088372-551e-4ee5-852a-ed1877059810" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f6aebecf-9f03-46dd-8fa1-5bcc50c52ed4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="txg-20250331.xsd#OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e4d4d36c-80a8-447f-bf91-31f95a30c33e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_17f929a3-126f-4cec-a789-97d05c8f0c29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e4d4d36c-80a8-447f-bf91-31f95a30c33e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_17f929a3-126f-4cec-a789-97d05c8f0c29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cb07fd7a-bf9d-4a91-b38e-522cd77cbdaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e4d4d36c-80a8-447f-bf91-31f95a30c33e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cb07fd7a-bf9d-4a91-b38e-522cd77cbdaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b0722620-d65f-438c-a638-1752aeb3c6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e4d4d36c-80a8-447f-bf91-31f95a30c33e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b0722620-d65f-438c-a638-1752aeb3c6d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds_8b5749e3-0d82-41dd-92f1-182334fcea22" xlink:href="txg-20250331.xsd#txg_DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4b445ed6-bb35-4105-a1eb-cd0ffa2e07cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_txg_DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds_8b5749e3-0d82-41dd-92f1-182334fcea22" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4b445ed6-bb35-4105-a1eb-cd0ffa2e07cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_02a5ed3f-c118-4ea7-8532-227766b1e14e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_txg_DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds_8b5749e3-0d82-41dd-92f1-182334fcea22" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_02a5ed3f-c118-4ea7-8532-227766b1e14e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds_495cc03b-5fe6-459f-b982-e0e58c9a9d6a" xlink:href="txg-20250331.xsd#txg_DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_txg_DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds_8b5749e3-0d82-41dd-92f1-182334fcea22" xlink:to="loc_txg_DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds_495cc03b-5fe6-459f-b982-e0e58c9a9d6a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofInventoryDetails" xlink:type="simple" xlink:href="txg-20250331.xsd#OtherFinancialStatementInformationScheduleofInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_db1fb414-d6d9-477d-8ac4-8363077cf81b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_4b5cdd74-d8a7-4b9d-adb1-f060d50619f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_db1fb414-d6d9-477d-8ac4-8363077cf81b" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_4b5cdd74-d8a7-4b9d-adb1-f060d50619f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_56ffc486-4239-45cf-a457-752ac9298ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_db1fb414-d6d9-477d-8ac4-8363077cf81b" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_56ffc486-4239-45cf-a457-752ac9298ba6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7c652387-2e78-425d-a791-fcbc4f966e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_db1fb414-d6d9-477d-8ac4-8363077cf81b" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7c652387-2e78-425d-a791-fcbc4f966e7e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail" xlink:type="simple" xlink:href="txg-20250331.xsd#OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail"/>
  <link:calculationLink xlink:role="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_00f8bee3-bcfb-49b2-8fd2-65d04552585f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_aeda73b0-239e-4422-850c-2d1fa29fd1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_00f8bee3-bcfb-49b2-8fd2-65d04552585f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_aeda73b0-239e-4422-850c-2d1fa29fd1b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b8dca72d-a1b0-46a8-b2b7-220eda6fa753" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_00f8bee3-bcfb-49b2-8fd2-65d04552585f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b8dca72d-a1b0-46a8-b2b7-220eda6fa753" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedCompensationandRelatedBenefitsDetails" xlink:type="simple" xlink:href="txg-20250331.xsd#OtherFinancialStatementInformationScheduleofAccruedCompensationandRelatedBenefitsDetails"/>
  <link:calculationLink xlink:role="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedCompensationandRelatedBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f9c821f9-d925-44bd-bc8c-a85f84d042a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_AccruedPayrollAndRelatedCosts_e5fbc4aa-78b7-428c-bdd8-5e7a42db8f1b" xlink:href="txg-20250331.xsd#txg_AccruedPayrollAndRelatedCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f9c821f9-d925-44bd-bc8c-a85f84d042a6" xlink:to="loc_txg_AccruedPayrollAndRelatedCosts_e5fbc4aa-78b7-428c-bdd8-5e7a42db8f1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_931179cd-dee8-4184-a939-d686f226baa3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f9c821f9-d925-44bd-bc8c-a85f84d042a6" xlink:to="loc_us-gaap_AccruedBonusesCurrent_931179cd-dee8-4184-a939-d686f226baa3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_AccruedCommissionsCurrent_ccab2a3e-de3f-4597-a9b2-b2dc4bfc74b1" xlink:href="txg-20250331.xsd#txg_AccruedCommissionsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f9c821f9-d925-44bd-bc8c-a85f84d042a6" xlink:to="loc_txg_AccruedCommissionsCurrent_ccab2a3e-de3f-4597-a9b2-b2dc4bfc74b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_4b82559a-3944-46ac-846c-5c857c2bc05e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f9c821f9-d925-44bd-bc8c-a85f84d042a6" xlink:to="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_4b82559a-3944-46ac-846c-5c857c2bc05e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedExpenseAndOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="txg-20250331.xsd#OtherFinancialStatementInformationScheduleofAccruedExpenseAndOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedExpenseAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_txg_AccruedExpensesAndOtherLiabilitiesCurrent_24d490fa-d6f7-4efc-9352-1bc703bfae35" xlink:href="txg-20250331.xsd#txg_AccruedExpensesAndOtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_AccruedLegalAndRelatedExpensesCurrent_409e9192-bc32-4079-aff0-6d4b5c644c15" xlink:href="txg-20250331.xsd#txg_AccruedLegalAndRelatedExpensesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_txg_AccruedExpensesAndOtherLiabilitiesCurrent_24d490fa-d6f7-4efc-9352-1bc703bfae35" xlink:to="loc_txg_AccruedLegalAndRelatedExpensesCurrent_409e9192-bc32-4079-aff0-6d4b5c644c15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_960d6074-961a-4861-9145-6f12d7fa65a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_txg_AccruedExpensesAndOtherLiabilitiesCurrent_24d490fa-d6f7-4efc-9352-1bc703bfae35" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_960d6074-961a-4861-9145-6f12d7fa65a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_34125f11-5e60-445c-8356-5f688c16af23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_txg_AccruedExpensesAndOtherLiabilitiesCurrent_24d490fa-d6f7-4efc-9352-1bc703bfae35" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_34125f11-5e60-445c-8356-5f688c16af23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_02cfcdea-d4ad-4072-9e6a-c3eb441f561a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_txg_AccruedExpensesAndOtherLiabilitiesCurrent_24d490fa-d6f7-4efc-9352-1bc703bfae35" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_02cfcdea-d4ad-4072-9e6a-c3eb441f561a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_eb9fb823-9a0f-48ec-9d27-66238bdd0845" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_txg_AccruedExpensesAndOtherLiabilitiesCurrent_24d490fa-d6f7-4efc-9352-1bc703bfae35" xlink:to="loc_us-gaap_TaxesPayableCurrent_eb9fb823-9a0f-48ec-9d27-66238bdd0845" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_7dd105da-af13-4189-84c5-e970e6f63559" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_txg_AccruedExpensesAndOtherLiabilitiesCurrent_24d490fa-d6f7-4efc-9352-1bc703bfae35" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_7dd105da-af13-4189-84c5-e970e6f63559" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail" xlink:type="simple" xlink:href="txg-20250331.xsd#CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_790d40e0-a49f-48cf-b67e-21b178348de6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4d6d8262-6f30-4129-b9f6-1997d75d3a22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_790d40e0-a49f-48cf-b67e-21b178348de6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4d6d8262-6f30-4129-b9f6-1997d75d3a22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0480b218-8247-48a9-94fc-b70a9d9eb400" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_790d40e0-a49f-48cf-b67e-21b178348de6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0480b218-8247-48a9-94fc-b70a9d9eb400" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d7678e7c-1c62-4c55-bf80-d4f8c10dd3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e18337a4-83b8-4090-a45b-ac836624fb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d7678e7c-1c62-4c55-bf80-d4f8c10dd3aa" xlink:to="loc_us-gaap_OperatingLeaseLiability_e18337a4-83b8-4090-a45b-ac836624fb2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_37e69572-08ca-4589-b33b-7aff7d835f42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d7678e7c-1c62-4c55-bf80-d4f8c10dd3aa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_37e69572-08ca-4589-b33b-7aff7d835f42" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail_1" xlink:type="simple" xlink:href="txg-20250331.xsd#CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail_1"/>
  <link:calculationLink xlink:role="http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ae614b58-fe94-451a-959b-e7c34543bbe5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_17b2e26c-5888-44a8-b495-4cf171f59d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ae614b58-fe94-451a-959b-e7c34543bbe5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_17b2e26c-5888-44a8-b495-4cf171f59d0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_447828e7-1ba6-4b3e-b8aa-258bcb476860" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ae614b58-fe94-451a-959b-e7c34543bbe5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_447828e7-1ba6-4b3e-b8aa-258bcb476860" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8cb59cc4-6eb0-45b8-a3c6-c29cd18aad5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ae614b58-fe94-451a-959b-e7c34543bbe5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8cb59cc4-6eb0-45b8-a3c6-c29cd18aad5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d4d3cdff-094c-418c-900c-19974d54750d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ae614b58-fe94-451a-959b-e7c34543bbe5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d4d3cdff-094c-418c-900c-19974d54750d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ac7cf34d-6b21-44bb-a9af-9153bfdc1b28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ae614b58-fe94-451a-959b-e7c34543bbe5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ac7cf34d-6b21-44bb-a9af-9153bfdc1b28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_c7980874-c095-442c-9692-1419135c036d" xlink:href="txg-20250331.xsd#txg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ae614b58-fe94-451a-959b-e7c34543bbe5" xlink:to="loc_txg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_c7980874-c095-442c-9692-1419135c036d" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>txg-20250331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:3ecddcae-0640-4c17-b64e-2ecf664c9fd0,g:adbdc3ab-11fd-421c-ac99-3782b4f382a6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/CoverPage" xlink:type="simple" xlink:href="txg-20250331.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.10xgenomics.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_a673277f-644d-41b9-b777-9e98f6e93ab7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_DocumentInformationTable_a673277f-644d-41b9-b777-9e98f6e93ab7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_820b8e19-3187-45d1-8f40-353bfff33cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_a673277f-644d-41b9-b777-9e98f6e93ab7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_820b8e19-3187-45d1-8f40-353bfff33cb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_820b8e19-3187-45d1-8f40-353bfff33cb0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_820b8e19-3187-45d1-8f40-353bfff33cb0" xlink:to="loc_us-gaap_ClassOfStockDomain_820b8e19-3187-45d1-8f40-353bfff33cb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3692356b-db05-41f5-9ab2-09e1ee0e8d13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_820b8e19-3187-45d1-8f40-353bfff33cb0" xlink:to="loc_us-gaap_ClassOfStockDomain_3692356b-db05-41f5-9ab2-09e1ee0e8d13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_740d6f32-7c56-46f1-88a3-7095dfd8e9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3692356b-db05-41f5-9ab2-09e1ee0e8d13" xlink:to="loc_us-gaap_CommonClassAMember_740d6f32-7c56-46f1-88a3-7095dfd8e9ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_b3113005-602a-4d41-8e82-5b80ff065567" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3692356b-db05-41f5-9ab2-09e1ee0e8d13" xlink:to="loc_us-gaap_CommonClassBMember_b3113005-602a-4d41-8e82-5b80ff065567" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f4e0576d-ed56-4aaf-9268-7e6f92e6ef70" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_DocumentType_f4e0576d-ed56-4aaf-9268-7e6f92e6ef70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_8fbb6123-dac3-4364-82e5-8522140d5619" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_DocumentQuarterlyReport_8fbb6123-dac3-4364-82e5-8522140d5619" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c3dc8421-9d6f-4389-9b36-a4312bc2060e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_DocumentPeriodEndDate_c3dc8421-9d6f-4389-9b36-a4312bc2060e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_3c96c154-d48d-42ca-879b-a7d951c89523" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_DocumentTransitionReport_3c96c154-d48d-42ca-879b-a7d951c89523" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_18a46127-2b5e-4155-8696-f193471a25e3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntityFileNumber_18a46127-2b5e-4155-8696-f193471a25e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_be52ecff-e6c5-4cb1-a3c0-e77146803576" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntityRegistrantName_be52ecff-e6c5-4cb1-a3c0-e77146803576" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_802d964c-c134-4969-b847-e551c36180e0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntityIncorporationStateCountryCode_802d964c-c134-4969-b847-e551c36180e0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_52e3bbce-90c2-451c-9619-0198453b8db5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntityTaxIdentificationNumber_52e3bbce-90c2-451c-9619-0198453b8db5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ac64d23f-470d-41eb-b3bb-2896b06c6d57" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntityAddressAddressLine1_ac64d23f-470d-41eb-b3bb-2896b06c6d57" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_2b15979f-ed7a-4601-a1e9-fb5cdf9aaf41" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntityAddressCityOrTown_2b15979f-ed7a-4601-a1e9-fb5cdf9aaf41" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_37f460e9-eadd-4fb9-a23e-0ffcb6273145" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntityAddressStateOrProvince_37f460e9-eadd-4fb9-a23e-0ffcb6273145" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_efd6de8b-1e6a-4650-8095-2d50d8a1083d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntityAddressPostalZipCode_efd6de8b-1e6a-4650-8095-2d50d8a1083d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3e0a449b-da6c-4712-bade-80d3ebccc3bf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_CityAreaCode_3e0a449b-da6c-4712-bade-80d3ebccc3bf" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_053b2dc1-fa2e-4d31-bb79-cf243af25e19" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_LocalPhoneNumber_053b2dc1-fa2e-4d31-bb79-cf243af25e19" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_326ca273-fd81-4f48-b57f-70ed44364186" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_Security12bTitle_326ca273-fd81-4f48-b57f-70ed44364186" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_cb9892b3-4889-4323-9613-63751bda5965" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_TradingSymbol_cb9892b3-4889-4323-9613-63751bda5965" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_0527cb12-31c2-4c6b-9273-28ec2bcee2a5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_SecurityExchangeName_0527cb12-31c2-4c6b-9273-28ec2bcee2a5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_6afb2984-9bac-4f74-a11f-bbb390e1d6fe" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntityCurrentReportingStatus_6afb2984-9bac-4f74-a11f-bbb390e1d6fe" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_6da11424-59ab-492e-ba13-7f8831c59ca7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntityInteractiveDataCurrent_6da11424-59ab-492e-ba13-7f8831c59ca7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_2b063e37-1a7f-45ac-8217-02e08b7ee139" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntityFilerCategory_2b063e37-1a7f-45ac-8217-02e08b7ee139" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_c28eb434-7965-4d96-9872-045f27e70943" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntitySmallBusiness_c28eb434-7965-4d96-9872-045f27e70943" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_0df78ae8-774d-448e-b681-fb0a60fe365e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntityEmergingGrowthCompany_0df78ae8-774d-448e-b681-fb0a60fe365e" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d26a3869-6fef-41b7-9135-54f0502267ce" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntityShellCompany_d26a3869-6fef-41b7-9135-54f0502267ce" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_a844e496-0288-40c4-89d0-c6db27420809" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_a844e496-0288-40c4-89d0-c6db27420809" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3d0af52b-acc1-4e1e-8edb-ea2e927ac770" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_AmendmentFlag_3d0af52b-acc1-4e1e-8edb-ea2e927ac770" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_55640e2d-5d02-4d6a-b76c-6fc5a955371b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_DocumentFiscalYearFocus_55640e2d-5d02-4d6a-b76c-6fc5a955371b" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_bc6867a7-f11e-43af-95db-5926bf6b0c61" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_DocumentFiscalPeriodFocus_bc6867a7-f11e-43af-95db-5926bf6b0c61" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_ce7bd0ac-58d1-4339-a140-383adb95defe" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_CurrentFiscalYearEndDate_ce7bd0ac-58d1-4339-a140-383adb95defe" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_318e58f5-4c38-4098-8b21-69779a9f7029" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntityCentralIndexKey_318e58f5-4c38-4098-8b21-69779a9f7029" xlink:type="arc" order="28"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="txg-20250331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6046368a-267e-4499-97a0-f75962b7d135" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d1201681-c83f-4d87-8ac4-42a16958b0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6046368a-267e-4499-97a0-f75962b7d135" xlink:to="loc_us-gaap_StatementTable_d1201681-c83f-4d87-8ac4-42a16958b0a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2d13e1aa-6052-4b6a-a66b-c3f53984816c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d1201681-c83f-4d87-8ac4-42a16958b0a8" xlink:to="loc_srt_ProductOrServiceAxis_2d13e1aa-6052-4b6a-a66b-c3f53984816c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2d13e1aa-6052-4b6a-a66b-c3f53984816c_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2d13e1aa-6052-4b6a-a66b-c3f53984816c" xlink:to="loc_srt_ProductsAndServicesDomain_2d13e1aa-6052-4b6a-a66b-c3f53984816c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1c55e22e-8f75-4b01-ba16-53ebb7848d7f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2d13e1aa-6052-4b6a-a66b-c3f53984816c" xlink:to="loc_srt_ProductsAndServicesDomain_1c55e22e-8f75-4b01-ba16-53ebb7848d7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_ProductAndServiceRevenueMember_74c9a3d8-e60f-4468-b7bd-26b7d9967655" xlink:href="txg-20250331.xsd#txg_ProductAndServiceRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1c55e22e-8f75-4b01-ba16-53ebb7848d7f" xlink:to="loc_txg_ProductAndServiceRevenueMember_74c9a3d8-e60f-4468-b7bd-26b7d9967655" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_LicensingAndRoyaltyRevenueMember_3d397950-41c0-410f-8bf6-c0e2ee829092" xlink:href="txg-20250331.xsd#txg_LicensingAndRoyaltyRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1c55e22e-8f75-4b01-ba16-53ebb7848d7f" xlink:to="loc_txg_LicensingAndRoyaltyRevenueMember_3d397950-41c0-410f-8bf6-c0e2ee829092" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9cad0ac6-78b3-4509-8db0-4408cdb8933e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6046368a-267e-4499-97a0-f75962b7d135" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9cad0ac6-78b3-4509-8db0-4408cdb8933e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_c493570e-e63e-4c30-9f37-e877c7e6a9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6046368a-267e-4499-97a0-f75962b7d135" xlink:to="loc_us-gaap_CostOfRevenue_c493570e-e63e-4c30-9f37-e877c7e6a9ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_e0dc7674-2aae-4c40-a607-7ba00580daa6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6046368a-267e-4499-97a0-f75962b7d135" xlink:to="loc_us-gaap_GrossProfit_e0dc7674-2aae-4c40-a607-7ba00580daa6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_8d7240fd-b922-4b08-8d85-da0e70540dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6046368a-267e-4499-97a0-f75962b7d135" xlink:to="loc_us-gaap_OperatingExpensesAbstract_8d7240fd-b922-4b08-8d85-da0e70540dbe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_e009468d-9ac8-43f2-8256-0ca529b72300" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8d7240fd-b922-4b08-8d85-da0e70540dbe" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_e009468d-9ac8-43f2-8256-0ca529b72300" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9ca0d0ee-cb2d-4315-b8eb-3c039862cfdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8d7240fd-b922-4b08-8d85-da0e70540dbe" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9ca0d0ee-cb2d-4315-b8eb-3c039862cfdb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementGain_57d9969f-cc36-40b1-aa62-ba62ab5d6612" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8d7240fd-b922-4b08-8d85-da0e70540dbe" xlink:to="loc_us-gaap_LitigationSettlementGain_57d9969f-cc36-40b1-aa62-ba62ab5d6612" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_98da8389-5817-4d54-8807-3b73f1ddaf41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8d7240fd-b922-4b08-8d85-da0e70540dbe" xlink:to="loc_us-gaap_OperatingExpenses_98da8389-5817-4d54-8807-3b73f1ddaf41" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_12896be9-e320-4a1c-b0ca-7b6c1dc5f991" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6046368a-267e-4499-97a0-f75962b7d135" xlink:to="loc_us-gaap_OperatingIncomeLoss_12896be9-e320-4a1c-b0ca-7b6c1dc5f991" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3e98fcd-1917-44d7-8cfb-c97bd9123c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6046368a-267e-4499-97a0-f75962b7d135" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3e98fcd-1917-44d7-8cfb-c97bd9123c3f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_d8bd1831-c823-4b43-a5d0-eab81e4bc9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3e98fcd-1917-44d7-8cfb-c97bd9123c3f" xlink:to="loc_us-gaap_InvestmentIncomeInterest_d8bd1831-c823-4b43-a5d0-eab81e4bc9c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_75869a69-6326-4f51-a4b6-aca2f14ac1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3e98fcd-1917-44d7-8cfb-c97bd9123c3f" xlink:to="loc_us-gaap_InterestExpenseNonoperating_75869a69-6326-4f51-a4b6-aca2f14ac1e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f4690cde-ceeb-4b45-a009-020f24079b31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3e98fcd-1917-44d7-8cfb-c97bd9123c3f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f4690cde-ceeb-4b45-a009-020f24079b31" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_b2c5833d-543f-4a4c-bd62-1bd9d1271e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3e98fcd-1917-44d7-8cfb-c97bd9123c3f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_b2c5833d-543f-4a4c-bd62-1bd9d1271e6b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d237e111-9a21-4e8a-8b1c-aaab5b653959" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6046368a-267e-4499-97a0-f75962b7d135" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d237e111-9a21-4e8a-8b1c-aaab5b653959" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bb65064c-a2bd-48db-baf8-a31478fd9051" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6046368a-267e-4499-97a0-f75962b7d135" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_bb65064c-a2bd-48db-baf8-a31478fd9051" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_79d8d53c-ba8e-49b9-923d-e6fc50b2533d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6046368a-267e-4499-97a0-f75962b7d135" xlink:to="loc_us-gaap_NetIncomeLoss_79d8d53c-ba8e-49b9-923d-e6fc50b2533d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e9cf37a6-9684-472c-bf7d-32e369e2446f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6046368a-267e-4499-97a0-f75962b7d135" xlink:to="loc_us-gaap_EarningsPerShareBasic_e9cf37a6-9684-472c-bf7d-32e369e2446f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_326f50f8-c847-4e48-9c64-722b9a892f91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6046368a-267e-4499-97a0-f75962b7d135" xlink:to="loc_us-gaap_EarningsPerShareDiluted_326f50f8-c847-4e48-9c64-722b9a892f91" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b93149c4-5af2-4133-ab25-0f9e87c50af2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6046368a-267e-4499-97a0-f75962b7d135" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b93149c4-5af2-4133-ab25-0f9e87c50af2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_61042e48-9470-4d29-9d7d-0169e2524298" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6046368a-267e-4499-97a0-f75962b7d135" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_61042e48-9470-4d29-9d7d-0169e2524298" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="txg-20250331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7c51f4f3-8243-4950-92cf-7fa7a5257587" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8006f53e-2990-4dad-b2ea-7d92185bc7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7c51f4f3-8243-4950-92cf-7fa7a5257587" xlink:to="loc_us-gaap_StatementTable_8006f53e-2990-4dad-b2ea-7d92185bc7fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_68efc688-6d0e-4b89-aee6-ec2eff6f2cad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8006f53e-2990-4dad-b2ea-7d92185bc7fc" xlink:to="loc_us-gaap_StatementClassOfStockAxis_68efc688-6d0e-4b89-aee6-ec2eff6f2cad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_68efc688-6d0e-4b89-aee6-ec2eff6f2cad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_68efc688-6d0e-4b89-aee6-ec2eff6f2cad" xlink:to="loc_us-gaap_ClassOfStockDomain_68efc688-6d0e-4b89-aee6-ec2eff6f2cad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f7063c5c-6688-404b-9eef-bdbe187923db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_68efc688-6d0e-4b89-aee6-ec2eff6f2cad" xlink:to="loc_us-gaap_ClassOfStockDomain_f7063c5c-6688-404b-9eef-bdbe187923db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_e717e405-c9aa-4dff-b2a8-83f290800c35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f7063c5c-6688-404b-9eef-bdbe187923db" xlink:to="loc_us-gaap_CommonClassAMember_e717e405-c9aa-4dff-b2a8-83f290800c35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6403623d-9032-4677-9dd3-f3e24bd02f95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8006f53e-2990-4dad-b2ea-7d92185bc7fc" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6403623d-9032-4677-9dd3-f3e24bd02f95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6403623d-9032-4677-9dd3-f3e24bd02f95_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6403623d-9032-4677-9dd3-f3e24bd02f95" xlink:to="loc_us-gaap_EquityComponentDomain_6403623d-9032-4677-9dd3-f3e24bd02f95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_57f9dd2a-14e8-4ede-a391-dde323eeee2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6403623d-9032-4677-9dd3-f3e24bd02f95" xlink:to="loc_us-gaap_EquityComponentDomain_57f9dd2a-14e8-4ede-a391-dde323eeee2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_638252b4-1d17-4103-888a-16986bee17bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_57f9dd2a-14e8-4ede-a391-dde323eeee2c" xlink:to="loc_us-gaap_CommonStockMember_638252b4-1d17-4103-888a-16986bee17bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_62967932-6fce-45fc-9523-49169161585a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_57f9dd2a-14e8-4ede-a391-dde323eeee2c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_62967932-6fce-45fc-9523-49169161585a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_709d582f-85e4-46bf-a123-479b56b32262" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_57f9dd2a-14e8-4ede-a391-dde323eeee2c" xlink:to="loc_us-gaap_RetainedEarningsMember_709d582f-85e4-46bf-a123-479b56b32262" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_af3ff412-9e4a-4614-8fc1-b41d21d2be83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_57f9dd2a-14e8-4ede-a391-dde323eeee2c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_af3ff412-9e4a-4614-8fc1-b41d21d2be83" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b75aa4cf-e916-4421-bf42-c6d30f208add" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7c51f4f3-8243-4950-92cf-7fa7a5257587" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b75aa4cf-e916-4421-bf42-c6d30f208add" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e41dce6f-d795-48b7-8258-fbfd31e666c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b75aa4cf-e916-4421-bf42-c6d30f208add" xlink:to="loc_us-gaap_SharesOutstanding_e41dce6f-d795-48b7-8258-fbfd31e666c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cfe1b3ae-b64f-4cff-9a3f-aa019b1990e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b75aa4cf-e916-4421-bf42-c6d30f208add" xlink:to="loc_us-gaap_StockholdersEquity_cfe1b3ae-b64f-4cff-9a3f-aa019b1990e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_07960ac8-6ce5-49a3-a807-a24abc152581" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b75aa4cf-e916-4421-bf42-c6d30f208add" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_07960ac8-6ce5-49a3-a807-a24abc152581" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_16d144f8-397b-4b03-8389-9c70ce6c784d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b75aa4cf-e916-4421-bf42-c6d30f208add" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_16d144f8-397b-4b03-8389-9c70ce6c784d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_82c06e98-e0c1-40c0-b8ed-2772eb74b351" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b75aa4cf-e916-4421-bf42-c6d30f208add" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_82c06e98-e0c1-40c0-b8ed-2772eb74b351" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a12b5f55-77f0-427f-b3de-8d6cf1606c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b75aa4cf-e916-4421-bf42-c6d30f208add" xlink:to="loc_us-gaap_NetIncomeLoss_a12b5f55-77f0-427f-b3de-8d6cf1606c6c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b10ad319-1bc3-4c6b-9cb8-3dcf365ad141" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b75aa4cf-e916-4421-bf42-c6d30f208add" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b10ad319-1bc3-4c6b-9cb8-3dcf365ad141" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_60468552-6c31-4a5f-bd26-e0b51cf1337f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_09e129e8-4f2c-4b85-99ac-359f187327af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="txg-20250331.xsd#OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_8b13ed5a-e741-43ec-9cb3-4f975af49f47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_a612ca61-0b34-4f27-811e-7da980c3eeaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8b13ed5a-e741-43ec-9cb3-4f975af49f47" xlink:to="loc_us-gaap_MarketableSecuritiesTable_a612ca61-0b34-4f27-811e-7da980c3eeaf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_664ac004-ddea-4931-8799-67af01318a10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_a612ca61-0b34-4f27-811e-7da980c3eeaf" xlink:to="loc_us-gaap_FinancialInstrumentAxis_664ac004-ddea-4931-8799-67af01318a10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_664ac004-ddea-4931-8799-67af01318a10_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_664ac004-ddea-4931-8799-67af01318a10" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_664ac004-ddea-4931-8799-67af01318a10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0a434c59-fa87-4189-8138-5be39ea6b787" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_664ac004-ddea-4931-8799-67af01318a10" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0a434c59-fa87-4189-8138-5be39ea6b787" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_e345ac35-28e7-4079-b9fb-c8b921cd782a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0a434c59-fa87-4189-8138-5be39ea6b787" xlink:to="loc_us-gaap_MoneyMarketFundsMember_e345ac35-28e7-4079-b9fb-c8b921cd782a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_23ece5ef-dd86-44d2-80f6-1f2b69089075" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0a434c59-fa87-4189-8138-5be39ea6b787" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_23ece5ef-dd86-44d2-80f6-1f2b69089075" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_7c8119a1-d27e-4b99-aed0-7ce5ea31aa82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0a434c59-fa87-4189-8138-5be39ea6b787" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_7c8119a1-d27e-4b99-aed0-7ce5ea31aa82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_d283b6b8-4e40-4efc-bb1e-5cb5a6b57c97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0a434c59-fa87-4189-8138-5be39ea6b787" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_d283b6b8-4e40-4efc-bb1e-5cb5a6b57c97" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4876a824-b9d7-4d76-b5f0-a5aaf947110f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_a612ca61-0b34-4f27-811e-7da980c3eeaf" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4876a824-b9d7-4d76-b5f0-a5aaf947110f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4876a824-b9d7-4d76-b5f0-a5aaf947110f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4876a824-b9d7-4d76-b5f0-a5aaf947110f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4876a824-b9d7-4d76-b5f0-a5aaf947110f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4e7008e-249c-4319-a3d8-1c5cb7d042c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4876a824-b9d7-4d76-b5f0-a5aaf947110f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4e7008e-249c-4319-a3d8-1c5cb7d042c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_e3e24c78-e926-4fc7-b2c6-fda3cd735ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4e7008e-249c-4319-a3d8-1c5cb7d042c6" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_e3e24c78-e926-4fc7-b2c6-fda3cd735ec3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e66f2be4-63ae-4a14-959f-a6f6022f41df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4e7008e-249c-4319-a3d8-1c5cb7d042c6" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e66f2be4-63ae-4a14-959f-a6f6022f41df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_ee03a378-d44e-4b7a-b1ac-3e7aacb9e01d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8b13ed5a-e741-43ec-9cb3-4f975af49f47" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_ee03a378-d44e-4b7a-b1ac-3e7aacb9e01d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_dcbd3e86-6e10-439c-8012-666726957f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8b13ed5a-e741-43ec-9cb3-4f975af49f47" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_dcbd3e86-6e10-439c-8012-666726957f7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ab04296c-88df-4857-9002-bf23335b0306" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8b13ed5a-e741-43ec-9cb3-4f975af49f47" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ab04296c-88df-4857-9002-bf23335b0306" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e77a6889-fbc0-4b5c-8e54-2563238fcb66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8b13ed5a-e741-43ec-9cb3-4f975af49f47" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e77a6889-fbc0-4b5c-8e54-2563238fcb66" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_04fc83d1-6a3d-4c14-ad7d-5bb26329d453" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8b13ed5a-e741-43ec-9cb3-4f975af49f47" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_04fc83d1-6a3d-4c14-ad7d-5bb26329d453" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds_1ff25455-dccb-4358-9fa9-c43814bad933" xlink:href="txg-20250331.xsd#txg_DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8b13ed5a-e741-43ec-9cb3-4f975af49f47" xlink:to="loc_txg_DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds_1ff25455-dccb-4358-9fa9-c43814bad933" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds_c78f1568-5e7c-4132-bc6d-bf32157d50e2" xlink:href="txg-20250331.xsd#txg_DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8b13ed5a-e741-43ec-9cb3-4f975af49f47" xlink:to="loc_txg_DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds_c78f1568-5e7c-4132-bc6d-bf32157d50e2" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails" xlink:type="simple" xlink:href="txg-20250331.xsd#OtherFinancialStatementInformationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_76096b9c-e303-457c-b6ca-b4c422887d72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_us-gaap_ConcentrationRiskTable_76096b9c-e303-457c-b6ca-b4c422887d72" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ad1ec4d8-86c2-40c7-aabb-2f54c9d59486" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_76096b9c-e303-457c-b6ca-b4c422887d72" xlink:to="loc_srt_ProductOrServiceAxis_ad1ec4d8-86c2-40c7-aabb-2f54c9d59486" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ad1ec4d8-86c2-40c7-aabb-2f54c9d59486_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ad1ec4d8-86c2-40c7-aabb-2f54c9d59486" xlink:to="loc_srt_ProductsAndServicesDomain_ad1ec4d8-86c2-40c7-aabb-2f54c9d59486_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ffdc16df-1233-44b8-9f8e-286792073e24" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ad1ec4d8-86c2-40c7-aabb-2f54c9d59486" xlink:to="loc_srt_ProductsAndServicesDomain_ffdc16df-1233-44b8-9f8e-286792073e24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_ProductsAndServicesExcludingGrantRevenueMember_077244b8-68ed-4fe2-b992-7baed56911a0" xlink:href="txg-20250331.xsd#txg_ProductsAndServicesExcludingGrantRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ffdc16df-1233-44b8-9f8e-286792073e24" xlink:to="loc_txg_ProductsAndServicesExcludingGrantRevenueMember_077244b8-68ed-4fe2-b992-7baed56911a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_LicensingAndRoyaltyRevenueMember_cc5fd651-5398-43e9-aae7-610de994a5eb" xlink:href="txg-20250331.xsd#txg_LicensingAndRoyaltyRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ffdc16df-1233-44b8-9f8e-286792073e24" xlink:to="loc_txg_LicensingAndRoyaltyRevenueMember_cc5fd651-5398-43e9-aae7-610de994a5eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_011ccfde-3012-48b4-973a-92a7cac26560" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_76096b9c-e303-457c-b6ca-b4c422887d72" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_011ccfde-3012-48b4-973a-92a7cac26560" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_011ccfde-3012-48b4-973a-92a7cac26560_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_011ccfde-3012-48b4-973a-92a7cac26560" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_011ccfde-3012-48b4-973a-92a7cac26560_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_07fe31f7-6f03-41fd-aef3-d778faa614bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_011ccfde-3012-48b4-973a-92a7cac26560" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_07fe31f7-6f03-41fd-aef3-d778faa614bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_d45ee137-cc9d-47bf-93a7-97873de000e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_07fe31f7-6f03-41fd-aef3-d778faa614bb" xlink:to="loc_us-gaap_ComputerEquipmentMember_d45ee137-cc9d-47bf-93a7-97873de000e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_CostOfRevenueMember_921e97f2-306b-43be-a730-71b03b61d2be" xlink:href="txg-20250331.xsd#txg_CostOfRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComputerEquipmentMember_d45ee137-cc9d-47bf-93a7-97873de000e4" xlink:to="loc_txg_CostOfRevenueMember_921e97f2-306b-43be-a730-71b03b61d2be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_33124716-8e7c-41db-947f-a81967eb541b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComputerEquipmentMember_d45ee137-cc9d-47bf-93a7-97873de000e4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_33124716-8e7c-41db-947f-a81967eb541b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8860e4e7-e936-45af-abb6-0443db67af1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComputerEquipmentMember_d45ee137-cc9d-47bf-93a7-97873de000e4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8860e4e7-e936-45af-abb6-0443db67af1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2be007aa-7963-4a61-bfe7-e7210f65879b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_76096b9c-e303-457c-b6ca-b4c422887d72" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2be007aa-7963-4a61-bfe7-e7210f65879b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9ffa3901-1d3f-47d2-8127-f59d485b1c7d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_76096b9c-e303-457c-b6ca-b4c422887d72" xlink:to="loc_srt_CounterpartyNameAxis_9ffa3901-1d3f-47d2-8127-f59d485b1c7d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9ffa3901-1d3f-47d2-8127-f59d485b1c7d_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_9ffa3901-1d3f-47d2-8127-f59d485b1c7d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9ffa3901-1d3f-47d2-8127-f59d485b1c7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_db89fe7b-f8a7-4bd0-9bd4-c3fe018d31ab" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_9ffa3901-1d3f-47d2-8127-f59d485b1c7d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_db89fe7b-f8a7-4bd0-9bd4-c3fe018d31ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_VizgenInc.Member_5311cd71-7ef2-4f6f-8e42-02d89b70bd32" xlink:href="txg-20250331.xsd#txg_VizgenInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_db89fe7b-f8a7-4bd0-9bd4-c3fe018d31ab" xlink:to="loc_txg_VizgenInc.Member_5311cd71-7ef2-4f6f-8e42-02d89b70bd32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_1f126213-d67c-47d5-8a4b-52571d31dc21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_1f126213-d67c-47d5-8a4b-52571d31dc21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_0199355e-b948-4956-9203-93010e17b809" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_0199355e-b948-4956-9203-93010e17b809" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_acc56c07-0f4c-4322-9c6b-f9d17b585375" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_acc56c07-0f4c-4322-9c6b-f9d17b585375" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c689b7a7-9c09-4f06-837f-4f6fead893be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c689b7a7-9c09-4f06-837f-4f6fead893be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_48a8e736-a2c4-498c-8f3f-6c831f4c0363" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_48a8e736-a2c4-498c-8f3f-6c831f4c0363" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_84fe50d3-8505-4a8b-9451-c90af7e7f6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_us-gaap_ContractWithCustomerLiability_84fe50d3-8505-4a8b-9451-c90af7e7f6e0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted_e5797525-d132-495f-9aad-d4a2927b7ac5" xlink:href="txg-20250331.xsd#txg_ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_txg_ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted_e5797525-d132-495f-9aad-d4a2927b7ac5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementGain_aa3e8772-3793-4084-b441-a2d4b4464988" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_us-gaap_LitigationSettlementGain_aa3e8772-3793-4084-b441-a2d4b4464988" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0d953ec0-5518-44c0-9747-ee84743f4e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0d953ec0-5518-44c0-9747-ee84743f4e6f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossRealizedAfterTax_a8df1652-bff3-47f7-97ac-b002f5c3123a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealizedAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossRealizedAfterTax_a8df1652-bff3-47f7-97ac-b002f5c3123a" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails_1" xlink:type="simple" xlink:href="txg-20250331.xsd#OtherFinancialStatementInformationAdditionalInformationDetails_1"/>
  <link:definitionLink xlink:role="http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_76096b9c-e303-457c-b6ca-b4c422887d72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_us-gaap_ConcentrationRiskTable_76096b9c-e303-457c-b6ca-b4c422887d72" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ad1ec4d8-86c2-40c7-aabb-2f54c9d59486" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_76096b9c-e303-457c-b6ca-b4c422887d72" xlink:to="loc_srt_ProductOrServiceAxis_ad1ec4d8-86c2-40c7-aabb-2f54c9d59486" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ad1ec4d8-86c2-40c7-aabb-2f54c9d59486_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ad1ec4d8-86c2-40c7-aabb-2f54c9d59486" xlink:to="loc_srt_ProductsAndServicesDomain_ad1ec4d8-86c2-40c7-aabb-2f54c9d59486_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ffdc16df-1233-44b8-9f8e-286792073e24" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ad1ec4d8-86c2-40c7-aabb-2f54c9d59486" xlink:to="loc_srt_ProductsAndServicesDomain_ffdc16df-1233-44b8-9f8e-286792073e24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_ProductsAndServicesExcludingGrantRevenueMember_077244b8-68ed-4fe2-b992-7baed56911a0" xlink:href="txg-20250331.xsd#txg_ProductsAndServicesExcludingGrantRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ffdc16df-1233-44b8-9f8e-286792073e24" xlink:to="loc_txg_ProductsAndServicesExcludingGrantRevenueMember_077244b8-68ed-4fe2-b992-7baed56911a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_LicensingAndRoyaltyRevenueMember_cc5fd651-5398-43e9-aae7-610de994a5eb" xlink:href="txg-20250331.xsd#txg_LicensingAndRoyaltyRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ffdc16df-1233-44b8-9f8e-286792073e24" xlink:to="loc_txg_LicensingAndRoyaltyRevenueMember_cc5fd651-5398-43e9-aae7-610de994a5eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_011ccfde-3012-48b4-973a-92a7cac26560" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_76096b9c-e303-457c-b6ca-b4c422887d72" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_011ccfde-3012-48b4-973a-92a7cac26560" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_011ccfde-3012-48b4-973a-92a7cac26560_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_011ccfde-3012-48b4-973a-92a7cac26560" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_011ccfde-3012-48b4-973a-92a7cac26560_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_07fe31f7-6f03-41fd-aef3-d778faa614bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_011ccfde-3012-48b4-973a-92a7cac26560" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_07fe31f7-6f03-41fd-aef3-d778faa614bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_d45ee137-cc9d-47bf-93a7-97873de000e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_07fe31f7-6f03-41fd-aef3-d778faa614bb" xlink:to="loc_us-gaap_ComputerEquipmentMember_d45ee137-cc9d-47bf-93a7-97873de000e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_CostOfRevenueMember_921e97f2-306b-43be-a730-71b03b61d2be" xlink:href="txg-20250331.xsd#txg_CostOfRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComputerEquipmentMember_d45ee137-cc9d-47bf-93a7-97873de000e4" xlink:to="loc_txg_CostOfRevenueMember_921e97f2-306b-43be-a730-71b03b61d2be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_33124716-8e7c-41db-947f-a81967eb541b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComputerEquipmentMember_d45ee137-cc9d-47bf-93a7-97873de000e4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_33124716-8e7c-41db-947f-a81967eb541b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8860e4e7-e936-45af-abb6-0443db67af1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComputerEquipmentMember_d45ee137-cc9d-47bf-93a7-97873de000e4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8860e4e7-e936-45af-abb6-0443db67af1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9ffa3901-1d3f-47d2-8127-f59d485b1c7d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_76096b9c-e303-457c-b6ca-b4c422887d72" xlink:to="loc_srt_CounterpartyNameAxis_9ffa3901-1d3f-47d2-8127-f59d485b1c7d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9ffa3901-1d3f-47d2-8127-f59d485b1c7d_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_9ffa3901-1d3f-47d2-8127-f59d485b1c7d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9ffa3901-1d3f-47d2-8127-f59d485b1c7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_db89fe7b-f8a7-4bd0-9bd4-c3fe018d31ab" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_9ffa3901-1d3f-47d2-8127-f59d485b1c7d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_db89fe7b-f8a7-4bd0-9bd4-c3fe018d31ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_VizgenInc.Member_5311cd71-7ef2-4f6f-8e42-02d89b70bd32" xlink:href="txg-20250331.xsd#txg_VizgenInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_db89fe7b-f8a7-4bd0-9bd4-c3fe018d31ab" xlink:to="loc_txg_VizgenInc.Member_5311cd71-7ef2-4f6f-8e42-02d89b70bd32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_1f126213-d67c-47d5-8a4b-52571d31dc21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_1f126213-d67c-47d5-8a4b-52571d31dc21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_0199355e-b948-4956-9203-93010e17b809" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_0199355e-b948-4956-9203-93010e17b809" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_acc56c07-0f4c-4322-9c6b-f9d17b585375" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_acc56c07-0f4c-4322-9c6b-f9d17b585375" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c689b7a7-9c09-4f06-837f-4f6fead893be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c689b7a7-9c09-4f06-837f-4f6fead893be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_48a8e736-a2c4-498c-8f3f-6c831f4c0363" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_48a8e736-a2c4-498c-8f3f-6c831f4c0363" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_84fe50d3-8505-4a8b-9451-c90af7e7f6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_us-gaap_ContractWithCustomerLiability_84fe50d3-8505-4a8b-9451-c90af7e7f6e0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted_e5797525-d132-495f-9aad-d4a2927b7ac5" xlink:href="txg-20250331.xsd#txg_ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_txg_ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted_e5797525-d132-495f-9aad-d4a2927b7ac5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementGain_aa3e8772-3793-4084-b441-a2d4b4464988" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_us-gaap_LitigationSettlementGain_aa3e8772-3793-4084-b441-a2d4b4464988" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0d953ec0-5518-44c0-9747-ee84743f4e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0d953ec0-5518-44c0-9747-ee84743f4e6f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossRealizedAfterTax_a8df1652-bff3-47f7-97ac-b002f5c3123a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealizedAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossRealizedAfterTax_a8df1652-bff3-47f7-97ac-b002f5c3123a" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail" xlink:type="simple" xlink:href="txg-20250331.xsd#OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail"/>
  <link:definitionLink xlink:role="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d63d71d4-4c8a-4101-9423-d6197f0e693d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dee31d2c-4d3a-44a1-ad4c-de37631d1b79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d63d71d4-4c8a-4101-9423-d6197f0e693d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dee31d2c-4d3a-44a1-ad4c-de37631d1b79" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_169b104f-6b42-4ccd-9d19-91949d5870ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dee31d2c-4d3a-44a1-ad4c-de37631d1b79" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_169b104f-6b42-4ccd-9d19-91949d5870ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_169b104f-6b42-4ccd-9d19-91949d5870ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_169b104f-6b42-4ccd-9d19-91949d5870ab" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_169b104f-6b42-4ccd-9d19-91949d5870ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64fbdb17-361c-465e-b80d-cd991f7d3867" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_169b104f-6b42-4ccd-9d19-91949d5870ab" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64fbdb17-361c-465e-b80d-cd991f7d3867" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_35725f08-7d18-4306-bc57-b1c5d6ec029c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64fbdb17-361c-465e-b80d-cd991f7d3867" xlink:to="loc_us-gaap_LandMember_35725f08-7d18-4306-bc57-b1c5d6ec029c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_868c9a29-9c78-4ef4-81df-3931bde6e367" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64fbdb17-361c-465e-b80d-cd991f7d3867" xlink:to="loc_us-gaap_BuildingMember_868c9a29-9c78-4ef4-81df-3931bde6e367" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_38a211d4-ede6-4544-85a4-d72b408bb475" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64fbdb17-361c-465e-b80d-cd991f7d3867" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_38a211d4-ede6-4544-85a4-d72b408bb475" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_ce512d10-7989-463c-86de-b673f3197d61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64fbdb17-361c-465e-b80d-cd991f7d3867" xlink:to="loc_us-gaap_ComputerEquipmentMember_ce512d10-7989-463c-86de-b673f3197d61" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_104f4450-7e8d-4b5d-8ec1-91472b533d58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64fbdb17-361c-465e-b80d-cd991f7d3867" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_104f4450-7e8d-4b5d-8ec1-91472b533d58" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_d5e4525f-f94c-4419-8f77-e07be0a5519e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64fbdb17-361c-465e-b80d-cd991f7d3867" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_d5e4525f-f94c-4419-8f77-e07be0a5519e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_66e86dd9-4c4d-4f21-89af-bf9cc8b36514" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64fbdb17-361c-465e-b80d-cd991f7d3867" xlink:to="loc_us-gaap_ConstructionInProgressMember_66e86dd9-4c4d-4f21-89af-bf9cc8b36514" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c3e43c55-3a7f-4859-ac23-764cb58526a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d63d71d4-4c8a-4101-9423-d6197f0e693d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c3e43c55-3a7f-4859-ac23-764cb58526a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5b1f12e0-c60d-41be-b9ce-1ccff6b6fab9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d63d71d4-4c8a-4101-9423-d6197f0e693d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5b1f12e0-c60d-41be-b9ce-1ccff6b6fab9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7b6ce8cf-8bf5-4c42-a5cb-fa287e4025b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d63d71d4-4c8a-4101-9423-d6197f0e693d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7b6ce8cf-8bf5-4c42-a5cb-fa287e4025b0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebySourceDetails" xlink:type="simple" xlink:href="txg-20250331.xsd#OtherFinancialStatementInformationScheduleofRevenuebySourceDetails"/>
  <link:definitionLink xlink:role="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebySourceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_55f72c43-9d25-429c-b7bd-41f1c00b2758" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_da2fc763-21db-4985-8119-042306b1290c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_55f72c43-9d25-429c-b7bd-41f1c00b2758" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_da2fc763-21db-4985-8119-042306b1290c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_069c20c4-8587-456a-8062-5c63d770ea68" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_da2fc763-21db-4985-8119-042306b1290c" xlink:to="loc_srt_ProductOrServiceAxis_069c20c4-8587-456a-8062-5c63d770ea68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_069c20c4-8587-456a-8062-5c63d770ea68_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_069c20c4-8587-456a-8062-5c63d770ea68" xlink:to="loc_srt_ProductsAndServicesDomain_069c20c4-8587-456a-8062-5c63d770ea68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8489367e-4c9a-48d3-acb4-b77a9df6db9c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_069c20c4-8587-456a-8062-5c63d770ea68" xlink:to="loc_srt_ProductsAndServicesDomain_8489367e-4c9a-48d3-acb4-b77a9df6db9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_InstrumentsMember_9e9c3da9-29a3-49b3-b036-938cd9177d90" xlink:href="txg-20250331.xsd#txg_InstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8489367e-4c9a-48d3-acb4-b77a9df6db9c" xlink:to="loc_txg_InstrumentsMember_9e9c3da9-29a3-49b3-b036-938cd9177d90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_ChromiumInstrumentsMember_4a2467ec-f98c-40ca-a8a4-d48188736756" xlink:href="txg-20250331.xsd#txg_ChromiumInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txg_InstrumentsMember_9e9c3da9-29a3-49b3-b036-938cd9177d90" xlink:to="loc_txg_ChromiumInstrumentsMember_4a2467ec-f98c-40ca-a8a4-d48188736756" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_SpatialInstrumentsMember_ee1ca9b4-beaf-4a73-9b29-b39b4898e338" xlink:href="txg-20250331.xsd#txg_SpatialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txg_InstrumentsMember_9e9c3da9-29a3-49b3-b036-938cd9177d90" xlink:to="loc_txg_SpatialInstrumentsMember_ee1ca9b4-beaf-4a73-9b29-b39b4898e338" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_ConsumablesMember_688ec4d4-1134-41a9-8517-636d892e6898" xlink:href="txg-20250331.xsd#txg_ConsumablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8489367e-4c9a-48d3-acb4-b77a9df6db9c" xlink:to="loc_txg_ConsumablesMember_688ec4d4-1134-41a9-8517-636d892e6898" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_ChromiumConsumablesMember_1d85b345-92ae-44ad-8f8f-2ad3f0965bf4" xlink:href="txg-20250331.xsd#txg_ChromiumConsumablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txg_ConsumablesMember_688ec4d4-1134-41a9-8517-636d892e6898" xlink:to="loc_txg_ChromiumConsumablesMember_1d85b345-92ae-44ad-8f8f-2ad3f0965bf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_SpatialConsumablesMember_7617ddfb-e057-4c00-b6a5-55c32ac4a5d1" xlink:href="txg-20250331.xsd#txg_SpatialConsumablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txg_ConsumablesMember_688ec4d4-1134-41a9-8517-636d892e6898" xlink:to="loc_txg_SpatialConsumablesMember_7617ddfb-e057-4c00-b6a5-55c32ac4a5d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_463e74e7-e115-4ba5-8f9e-a03979b7b933" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8489367e-4c9a-48d3-acb4-b77a9df6db9c" xlink:to="loc_us-gaap_ServiceMember_463e74e7-e115-4ba5-8f9e-a03979b7b933" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_ProductAndServiceRevenueMember_42014f30-cbd5-4421-9b72-6e2c289c356a" xlink:href="txg-20250331.xsd#txg_ProductAndServiceRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8489367e-4c9a-48d3-acb4-b77a9df6db9c" xlink:to="loc_txg_ProductAndServiceRevenueMember_42014f30-cbd5-4421-9b72-6e2c289c356a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_LicensingAndRoyaltyRevenueMember_cee69345-2e2e-4655-8433-e21834b151a8" xlink:href="txg-20250331.xsd#txg_LicensingAndRoyaltyRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8489367e-4c9a-48d3-acb4-b77a9df6db9c" xlink:to="loc_txg_LicensingAndRoyaltyRevenueMember_cee69345-2e2e-4655-8433-e21834b151a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_08149513-14d7-40b0-9959-779f7bed1878" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_55f72c43-9d25-429c-b7bd-41f1c00b2758" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_08149513-14d7-40b0-9959-779f7bed1878" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebyGeographicRegionDetails" xlink:type="simple" xlink:href="txg-20250331.xsd#OtherFinancialStatementInformationScheduleofRevenuebyGeographicRegionDetails"/>
  <link:definitionLink xlink:role="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebyGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_ead7bd74-83c5-4318-902c-334468f6ca06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_68e54e8f-b92b-476a-aa43-68331693dd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_ead7bd74-83c5-4318-902c-334468f6ca06" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_68e54e8f-b92b-476a-aa43-68331693dd0f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_018e63d8-1121-4d76-a281-d1adba0a9999" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_68e54e8f-b92b-476a-aa43-68331693dd0f" xlink:to="loc_srt_StatementGeographicalAxis_018e63d8-1121-4d76-a281-d1adba0a9999" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_018e63d8-1121-4d76-a281-d1adba0a9999_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_018e63d8-1121-4d76-a281-d1adba0a9999" xlink:to="loc_srt_SegmentGeographicalDomain_018e63d8-1121-4d76-a281-d1adba0a9999_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4737d98a-4eaa-485b-9465-e1d8cf5fecaf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_018e63d8-1121-4d76-a281-d1adba0a9999" xlink:to="loc_srt_SegmentGeographicalDomain_4737d98a-4eaa-485b-9465-e1d8cf5fecaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AmericasMember_e767e1cf-ee06-466e-8e6f-a5df15857f5b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AmericasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4737d98a-4eaa-485b-9465-e1d8cf5fecaf" xlink:to="loc_srt_AmericasMember_e767e1cf-ee06-466e-8e6f-a5df15857f5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f991fc72-350c-4188-969d-8b191dcb6124" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_AmericasMember_e767e1cf-ee06-466e-8e6f-a5df15857f5b" xlink:to="loc_country_US_f991fc72-350c-4188-969d-8b191dcb6124" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_AmericasExcludingUnitedStatesMember_68fb3fad-a17c-4d00-b967-94a37fe8a41c" xlink:href="txg-20250331.xsd#txg_AmericasExcludingUnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_AmericasMember_e767e1cf-ee06-466e-8e6f-a5df15857f5b" xlink:to="loc_txg_AmericasExcludingUnitedStatesMember_68fb3fad-a17c-4d00-b967-94a37fe8a41c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_f9cec866-655b-496a-bc76-cb621cd4fdee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EMEAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4737d98a-4eaa-485b-9465-e1d8cf5fecaf" xlink:to="loc_us-gaap_EMEAMember_f9cec866-655b-496a-bc76-cb621cd4fdee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_9a81cdc5-b1c4-4e3a-a114-0a1a797341d8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AsiaPacificMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4737d98a-4eaa-485b-9465-e1d8cf5fecaf" xlink:to="loc_srt_AsiaPacificMember_9a81cdc5-b1c4-4e3a-a114-0a1a797341d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_1b35cbc7-9494-40f1-b415-52e521b81fef" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_AsiaPacificMember_9a81cdc5-b1c4-4e3a-a114-0a1a797341d8" xlink:to="loc_country_CN_1b35cbc7-9494-40f1-b415-52e521b81fef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_AsiaPacificExcludingChinaMember_5ac84077-6dc7-4ce8-ad2d-b33d82f2085e" xlink:href="txg-20250331.xsd#txg_AsiaPacificExcludingChinaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_AsiaPacificMember_9a81cdc5-b1c4-4e3a-a114-0a1a797341d8" xlink:to="loc_txg_AsiaPacificExcludingChinaMember_5ac84077-6dc7-4ce8-ad2d-b33d82f2085e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0a45cdcc-e550-4690-abcc-ae5983648bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_ead7bd74-83c5-4318-902c-334468f6ca06" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0a45cdcc-e550-4690-abcc-ae5983648bb1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/CapitalStockAdditionalInformationDetail" xlink:type="simple" xlink:href="txg-20250331.xsd#CapitalStockAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.10xgenomics.com/role/CapitalStockAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_3de809db-0423-47e9-a296-03e7a2071496" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d080c260-8be3-4b98-a318-d3fd37fe7058" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_3de809db-0423-47e9-a296-03e7a2071496" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d080c260-8be3-4b98-a318-d3fd37fe7058" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4b17f012-be2e-451b-8d78-962ca66b7ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d080c260-8be3-4b98-a318-d3fd37fe7058" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4b17f012-be2e-451b-8d78-962ca66b7ef9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4b17f012-be2e-451b-8d78-962ca66b7ef9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4b17f012-be2e-451b-8d78-962ca66b7ef9" xlink:to="loc_us-gaap_ClassOfStockDomain_4b17f012-be2e-451b-8d78-962ca66b7ef9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3fc67de0-7d5d-46f6-9aa6-7dcf551a7b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4b17f012-be2e-451b-8d78-962ca66b7ef9" xlink:to="loc_us-gaap_ClassOfStockDomain_3fc67de0-7d5d-46f6-9aa6-7dcf551a7b3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_0a807326-8a82-4e76-8e0f-8834404d682f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3fc67de0-7d5d-46f6-9aa6-7dcf551a7b3c" xlink:to="loc_us-gaap_CommonClassAMember_0a807326-8a82-4e76-8e0f-8834404d682f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_3092883a-0c3b-4344-9339-f156cff4bafa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3fc67de0-7d5d-46f6-9aa6-7dcf551a7b3c" xlink:to="loc_us-gaap_CommonClassBMember_3092883a-0c3b-4344-9339-f156cff4bafa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f72062a7-4e2f-4b4e-a581-c4368cc44ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3de809db-0423-47e9-a296-03e7a2071496" xlink:to="loc_us-gaap_CommonStockSharesIssued_f72062a7-4e2f-4b4e-a581-c4368cc44ce5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1a5f9c44-2f2a-4812-840a-d32964761221" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3de809db-0423-47e9-a296-03e7a2071496" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1a5f9c44-2f2a-4812-840a-d32964761221" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRecordedStockBasedCompensationExpenseintheCondensedConsolidatedStatementofOperationsDetails" xlink:type="simple" xlink:href="txg-20250331.xsd#EquityIncentivePlansScheduleofRecordedStockBasedCompensationExpenseintheCondensedConsolidatedStatementofOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRecordedStockBasedCompensationExpenseintheCondensedConsolidatedStatementofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2f96bfc3-cb8c-4448-a8c3-3fb9f5febbad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bc5b4d47-33cd-4b73-bbe9-18737c66053c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2f96bfc3-cb8c-4448-a8c3-3fb9f5febbad" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bc5b4d47-33cd-4b73-bbe9-18737c66053c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bf1b8900-ebc3-426e-869e-ea6b36cbcb38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bc5b4d47-33cd-4b73-bbe9-18737c66053c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bf1b8900-ebc3-426e-869e-ea6b36cbcb38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bf1b8900-ebc3-426e-869e-ea6b36cbcb38_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bf1b8900-ebc3-426e-869e-ea6b36cbcb38" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bf1b8900-ebc3-426e-869e-ea6b36cbcb38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c3bbd899-612a-424a-a773-35129050ca69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bf1b8900-ebc3-426e-869e-ea6b36cbcb38" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c3bbd899-612a-424a-a773-35129050ca69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_5d1689cd-c313-49e6-88ae-6a8ab8ee69c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c3bbd899-612a-424a-a773-35129050ca69" xlink:to="loc_us-gaap_CostOfSalesMember_5d1689cd-c313-49e6-88ae-6a8ab8ee69c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3e83e236-74f1-4610-94c5-5a37b971aa05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c3bbd899-612a-424a-a773-35129050ca69" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3e83e236-74f1-4610-94c5-5a37b971aa05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_997c2929-3451-4186-b02f-e1bfd862120d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c3bbd899-612a-424a-a773-35129050ca69" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_997c2929-3451-4186-b02f-e1bfd862120d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_529cee79-98ec-4b4b-b5da-224f90abb0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2f96bfc3-cb8c-4448-a8c3-3fb9f5febbad" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_529cee79-98ec-4b4b-b5da-224f90abb0ed" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails" xlink:type="simple" xlink:href="txg-20250331.xsd#EquityIncentivePlansAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40040652-f940-4ef6-8806-94917b6deff1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44d604d6-fcf4-4876-a6c6-ebe03df3688a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40040652-f940-4ef6-8806-94917b6deff1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44d604d6-fcf4-4876-a6c6-ebe03df3688a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ea3adf9e-55d7-41be-bacf-b5cc6b1be50d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44d604d6-fcf4-4876-a6c6-ebe03df3688a" xlink:to="loc_us-gaap_AwardTypeAxis_ea3adf9e-55d7-41be-bacf-b5cc6b1be50d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ea3adf9e-55d7-41be-bacf-b5cc6b1be50d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ea3adf9e-55d7-41be-bacf-b5cc6b1be50d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ea3adf9e-55d7-41be-bacf-b5cc6b1be50d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9f82407-bec0-4660-85a3-f5ec2a064936" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ea3adf9e-55d7-41be-bacf-b5cc6b1be50d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9f82407-bec0-4660-85a3-f5ec2a064936" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_76bd315a-3895-453a-b3e6-f8eb4aa7b2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9f82407-bec0-4660-85a3-f5ec2a064936" xlink:to="loc_us-gaap_PerformanceSharesMember_76bd315a-3895-453a-b3e6-f8eb4aa7b2cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_CompoundAnnualGrowthRateMember_41d3e6ac-9864-47e4-87b7-bd2562805bb2" xlink:href="txg-20250331.xsd#txg_CompoundAnnualGrowthRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9f82407-bec0-4660-85a3-f5ec2a064936" xlink:to="loc_txg_CompoundAnnualGrowthRateMember_41d3e6ac-9864-47e4-87b7-bd2562805bb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_TotalShareholderReturnMember_116bb740-d937-4cf6-8a1c-61ca4fa126fa" xlink:href="txg-20250331.xsd#txg_TotalShareholderReturnMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9f82407-bec0-4660-85a3-f5ec2a064936" xlink:to="loc_txg_TotalShareholderReturnMember_116bb740-d937-4cf6-8a1c-61ca4fa126fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_bbe4e47f-ba3c-4f9c-b0f6-257e8755e3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9f82407-bec0-4660-85a3-f5ec2a064936" xlink:to="loc_us-gaap_EmployeeStockMember_bbe4e47f-ba3c-4f9c-b0f6-257e8755e3cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_bb888aac-4815-44b0-848a-98f23459b2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44d604d6-fcf4-4876-a6c6-ebe03df3688a" xlink:to="loc_us-gaap_PlanNameAxis_bb888aac-4815-44b0-848a-98f23459b2ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_bb888aac-4815-44b0-848a-98f23459b2ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_bb888aac-4815-44b0-848a-98f23459b2ce" xlink:to="loc_us-gaap_PlanNameDomain_bb888aac-4815-44b0-848a-98f23459b2ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f7880d5a-f525-4b03-920e-de0d5ba6fcd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_bb888aac-4815-44b0-848a-98f23459b2ce" xlink:to="loc_us-gaap_PlanNameDomain_f7880d5a-f525-4b03-920e-de0d5ba6fcd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_TwoThousandsNineteenPlanMember_110d52ae-26b8-45ce-8a99-b8e8dc3a32d3" xlink:href="txg-20250331.xsd#txg_TwoThousandsNineteenPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f7880d5a-f525-4b03-920e-de0d5ba6fcd1" xlink:to="loc_txg_TwoThousandsNineteenPlanMember_110d52ae-26b8-45ce-8a99-b8e8dc3a32d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_MarketBasedPerformanceAwardsMember_59f925f9-c3ca-425a-983e-8c6954ec3c6f" xlink:href="txg-20250331.xsd#txg_MarketBasedPerformanceAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f7880d5a-f525-4b03-920e-de0d5ba6fcd1" xlink:to="loc_txg_MarketBasedPerformanceAwardsMember_59f925f9-c3ca-425a-983e-8c6954ec3c6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_TwoThousandsNineteenEmployeeStockPurchasePlanMember_da426847-c6aa-404a-ab4d-045a3192cf15" xlink:href="txg-20250331.xsd#txg_TwoThousandsNineteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f7880d5a-f525-4b03-920e-de0d5ba6fcd1" xlink:to="loc_txg_TwoThousandsNineteenEmployeeStockPurchasePlanMember_da426847-c6aa-404a-ab4d-045a3192cf15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_77676eaf-8230-4a27-abae-8735596ea4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44d604d6-fcf4-4876-a6c6-ebe03df3688a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_77676eaf-8230-4a27-abae-8735596ea4e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_77676eaf-8230-4a27-abae-8735596ea4e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_77676eaf-8230-4a27-abae-8735596ea4e5" xlink:to="loc_us-gaap_ClassOfStockDomain_77676eaf-8230-4a27-abae-8735596ea4e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6194ae26-6671-4939-bac8-095c72cc8c66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_77676eaf-8230-4a27-abae-8735596ea4e5" xlink:to="loc_us-gaap_ClassOfStockDomain_6194ae26-6671-4939-bac8-095c72cc8c66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_eedb656c-ac03-41eb-b8d5-ece6d217fead" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6194ae26-6671-4939-bac8-095c72cc8c66" xlink:to="loc_us-gaap_CommonClassAMember_eedb656c-ac03-41eb-b8d5-ece6d217fead" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_62a855b6-ee32-43ad-aa11-a1c690511bae" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44d604d6-fcf4-4876-a6c6-ebe03df3688a" xlink:to="loc_srt_RangeAxis_62a855b6-ee32-43ad-aa11-a1c690511bae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_62a855b6-ee32-43ad-aa11-a1c690511bae_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_62a855b6-ee32-43ad-aa11-a1c690511bae" xlink:to="loc_srt_RangeMember_62a855b6-ee32-43ad-aa11-a1c690511bae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c96da833-03eb-4e8d-8dfd-b56366dfae86" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_62a855b6-ee32-43ad-aa11-a1c690511bae" xlink:to="loc_srt_RangeMember_c96da833-03eb-4e8d-8dfd-b56366dfae86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_85e6f74d-ab8b-49a9-8b64-88c12b30b935" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c96da833-03eb-4e8d-8dfd-b56366dfae86" xlink:to="loc_srt_MinimumMember_85e6f74d-ab8b-49a9-8b64-88c12b30b935" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cfca9303-7c34-4e98-a85d-978cafa94632" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c96da833-03eb-4e8d-8dfd-b56366dfae86" xlink:to="loc_srt_MaximumMember_cfca9303-7c34-4e98-a85d-978cafa94632" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8826ec8a-ff36-40e6-9d64-56a1ac7e23f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40040652-f940-4ef6-8806-94917b6deff1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8826ec8a-ff36-40e6-9d64-56a1ac7e23f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7419f5c6-5e52-426f-a739-0a0c79f0ac7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40040652-f940-4ef6-8806-94917b6deff1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7419f5c6-5e52-426f-a739-0a0c79f0ac7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b0264e0a-c42d-4beb-86a3-d5fcc14d9528" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40040652-f940-4ef6-8806-94917b6deff1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b0264e0a-c42d-4beb-86a3-d5fcc14d9528" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage_3157a7a2-4eb6-4606-ba81-a5e8cd096b67" xlink:href="txg-20250331.xsd#txg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40040652-f940-4ef6-8806-94917b6deff1" xlink:to="loc_txg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage_3157a7a2-4eb6-4606-ba81-a5e8cd096b67" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8046fd6b-df16-40ab-8a04-8b315a79d1a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40040652-f940-4ef6-8806-94917b6deff1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8046fd6b-df16-40ab-8a04-8b315a79d1a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_60d77a4d-6c8b-42ca-82f8-141c0d233d89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40040652-f940-4ef6-8806-94917b6deff1" xlink:to="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_60d77a4d-6c8b-42ca-82f8-141c0d233d89" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_15751e84-5364-426d-a14d-3b9e644d6575" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40040652-f940-4ef6-8806-94917b6deff1" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_15751e84-5364-426d-a14d-3b9e644d6575" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_63a202f7-ee3d-47ef-8d07-5dc3d910243e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40040652-f940-4ef6-8806-94917b6deff1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_63a202f7-ee3d-47ef-8d07-5dc3d910243e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_97f3a2f2-1478-48d4-88c9-85accc147187" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40040652-f940-4ef6-8806-94917b6deff1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_97f3a2f2-1478-48d4-88c9-85accc147187" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/EquityIncentivePlansFairValuesofSharesUnderthePerformanceStockUnitsDetails" xlink:type="simple" xlink:href="txg-20250331.xsd#EquityIncentivePlansFairValuesofSharesUnderthePerformanceStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.10xgenomics.com/role/EquityIncentivePlansFairValuesofSharesUnderthePerformanceStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05caba7a-a0dd-4a4d-96d5-286fdf28f79c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7c4ce211-ac29-4094-95f9-030dd08afd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05caba7a-a0dd-4a4d-96d5-286fdf28f79c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7c4ce211-ac29-4094-95f9-030dd08afd7d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e3840992-80a7-413c-933a-f54145c69f31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7c4ce211-ac29-4094-95f9-030dd08afd7d" xlink:to="loc_us-gaap_AwardTypeAxis_e3840992-80a7-413c-933a-f54145c69f31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3840992-80a7-413c-933a-f54145c69f31_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e3840992-80a7-413c-933a-f54145c69f31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3840992-80a7-413c-933a-f54145c69f31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3aee3e8-9d2f-48cd-8709-b89104b36655" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e3840992-80a7-413c-933a-f54145c69f31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3aee3e8-9d2f-48cd-8709-b89104b36655" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_789275ce-3775-4058-89ca-cc876342ecee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3aee3e8-9d2f-48cd-8709-b89104b36655" xlink:to="loc_us-gaap_PerformanceSharesMember_789275ce-3775-4058-89ca-cc876342ecee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_371857c5-4250-4bd9-9d5a-99fa42607215" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05caba7a-a0dd-4a4d-96d5-286fdf28f79c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_371857c5-4250-4bd9-9d5a-99fa42607215" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_05342f43-d5ee-486d-b8fe-a88f80cc0169" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05caba7a-a0dd-4a4d-96d5-286fdf28f79c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_05342f43-d5ee-486d-b8fe-a88f80cc0169" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2fe27234-63c0-4bbd-a86b-aed49f7cc218" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05caba7a-a0dd-4a4d-96d5-286fdf28f79c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2fe27234-63c0-4bbd-a86b-aed49f7cc218" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/NetLossPerShareSharesofCommonStockEquivalentsWereExcludedFromTheComputationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="txg-20250331.xsd#NetLossPerShareSharesofCommonStockEquivalentsWereExcludedFromTheComputationofDilutedNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.10xgenomics.com/role/NetLossPerShareSharesofCommonStockEquivalentsWereExcludedFromTheComputationofDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0fbb7c1d-174a-4089-8795-c7516afc3b63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_707237ce-8fee-41b8-a3e0-097f452020f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0fbb7c1d-174a-4089-8795-c7516afc3b63" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_707237ce-8fee-41b8-a3e0-097f452020f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_72e2d02d-a561-4451-a8a1-f317df9cadfc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_707237ce-8fee-41b8-a3e0-097f452020f1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_72e2d02d-a561-4451-a8a1-f317df9cadfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72e2d02d-a561-4451-a8a1-f317df9cadfc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_72e2d02d-a561-4451-a8a1-f317df9cadfc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_72e2d02d-a561-4451-a8a1-f317df9cadfc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0748676e-ce66-4e65-8e36-d44cea58929e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_72e2d02d-a561-4451-a8a1-f317df9cadfc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0748676e-ce66-4e65-8e36-d44cea58929e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f2a6dce3-9602-43d2-8565-dd216cc1c1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0748676e-ce66-4e65-8e36-d44cea58929e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f2a6dce3-9602-43d2-8565-dd216cc1c1b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_54daa5ac-bc28-4cff-aacf-1d7ce05f911e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0748676e-ce66-4e65-8e36-d44cea58929e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_54daa5ac-bc28-4cff-aacf-1d7ce05f911e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_SharesUnderEsppPlanMember_7c54834f-9e85-40db-92c0-7d867be73a87" xlink:href="txg-20250331.xsd#txg_SharesUnderEsppPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0748676e-ce66-4e65-8e36-d44cea58929e" xlink:to="loc_txg_SharesUnderEsppPlanMember_7c54834f-9e85-40db-92c0-7d867be73a87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9a80e567-0980-4669-a180-46432b933f98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0fbb7c1d-174a-4089-8795-c7516afc3b63" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9a80e567-0980-4669-a180-46432b933f98" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="txg-20250331.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.10xgenomics.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_ee2a871e-24c1-4782-8ea4-88c5eb7284e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_750038b3-9ac9-4d43-bc2e-db2fd32f2a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_ee2a871e-24c1-4782-8ea4-88c5eb7284e4" xlink:to="loc_us-gaap_SubsequentEventTable_750038b3-9ac9-4d43-bc2e-db2fd32f2a1f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_22aae27f-0d81-42e5-8bfe-1c6882053a94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_750038b3-9ac9-4d43-bc2e-db2fd32f2a1f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_22aae27f-0d81-42e5-8bfe-1c6882053a94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_22aae27f-0d81-42e5-8bfe-1c6882053a94_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_22aae27f-0d81-42e5-8bfe-1c6882053a94" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_22aae27f-0d81-42e5-8bfe-1c6882053a94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b855f53b-a4c4-430d-b1f9-55a9e94b431d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_22aae27f-0d81-42e5-8bfe-1c6882053a94" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b855f53b-a4c4-430d-b1f9-55a9e94b431d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d42caefb-fccd-4291-b511-20c34efe10d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b855f53b-a4c4-430d-b1f9-55a9e94b431d" xlink:to="loc_us-gaap_SubsequentEventMember_d42caefb-fccd-4291-b511-20c34efe10d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_8ce59a9e-81e0-458a-8f3b-cbf2c15430d2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_750038b3-9ac9-4d43-bc2e-db2fd32f2a1f" xlink:to="loc_srt_StatementScenarioAxis_8ce59a9e-81e0-458a-8f3b-cbf2c15430d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_8ce59a9e-81e0-458a-8f3b-cbf2c15430d2_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_8ce59a9e-81e0-458a-8f3b-cbf2c15430d2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_8ce59a9e-81e0-458a-8f3b-cbf2c15430d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_4565cf35-a75e-4a1f-b9d1-63aaf24d0e44" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_8ce59a9e-81e0-458a-8f3b-cbf2c15430d2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_4565cf35-a75e-4a1f-b9d1-63aaf24d0e44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_7e0b288a-89b0-44f8-bf84-65b9cd4fd800" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_4565cf35-a75e-4a1f-b9d1-63aaf24d0e44" xlink:to="loc_srt_ScenarioForecastMember_7e0b288a-89b0-44f8-bf84-65b9cd4fd800" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_38f01d3a-3308-41c3-8bf3-e57e3392b8cd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_750038b3-9ac9-4d43-bc2e-db2fd32f2a1f" xlink:to="loc_srt_RangeAxis_38f01d3a-3308-41c3-8bf3-e57e3392b8cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_38f01d3a-3308-41c3-8bf3-e57e3392b8cd_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_38f01d3a-3308-41c3-8bf3-e57e3392b8cd" xlink:to="loc_srt_RangeMember_38f01d3a-3308-41c3-8bf3-e57e3392b8cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d2e039d0-2873-465c-91d4-0bca5a7fec02" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_38f01d3a-3308-41c3-8bf3-e57e3392b8cd" xlink:to="loc_srt_RangeMember_d2e039d0-2873-465c-91d4-0bca5a7fec02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_05c33432-e2d9-424d-9cac-e2cc082fc994" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d2e039d0-2873-465c-91d4-0bca5a7fec02" xlink:to="loc_srt_MinimumMember_05c33432-e2d9-424d-9cac-e2cc082fc994" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5be8449e-0194-4b8e-ba7c-fc63f9deee97" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d2e039d0-2873-465c-91d4-0bca5a7fec02" xlink:to="loc_srt_MaximumMember_5be8449e-0194-4b8e-ba7c-fc63f9deee97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1f358f04-fba4-4e2a-a87a-77cc86f86d03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_ee2a871e-24c1-4782-8ea4-88c5eb7284e4" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1f358f04-fba4-4e2a-a87a-77cc86f86d03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_0dcdc0ac-3bb4-413b-a9cc-8cee0605deaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_ee2a871e-24c1-4782-8ea4-88c5eb7284e4" xlink:to="loc_us-gaap_RestructuringCharges_0dcdc0ac-3bb4-413b-a9cc-8cee0605deaf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_SergeSaxonovMember_fbfa0739-8f6b-4329-aae2-33d0f976ae41" xlink:href="txg-20250331.xsd#txg_SergeSaxonovMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_txg_SergeSaxonovMember_fbfa0739-8f6b-4329-aae2-33d0f976ae41" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_SergeSaxonovCommonStockPlusMember_923578cf-ed84-46fa-860b-a55b1df66c72" xlink:href="txg-20250331.xsd#txg_SergeSaxonovCommonStockPlusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_txg_SergeSaxonovCommonStockPlusMember_923578cf-ed84-46fa-860b-a55b1df66c72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_SergeSaxonovCarryoverSharesFromPrior10b51PlanMember_77abdc6a-a00f-495b-94fc-a19b64c99142" xlink:href="txg-20250331.xsd#txg_SergeSaxonovCarryoverSharesFromPrior10b51PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_txg_SergeSaxonovCarryoverSharesFromPrior10b51PlanMember_77abdc6a-a00f-495b-94fc-a19b64c99142" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>txg-20250331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:3ecddcae-0640-4c17-b64e-2ecf664c9fd0,g:adbdc3ab-11fd-421c-ac99-3782b4f382a6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6d71b5f8-dc97-4cca-84a7-b6d16950744a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating&#160;Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d7b199a2-56b2-4f43-9764-46bb99ec15c6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_49702a9a-b107-46fd-b805-a1b2cd1db282_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e8cae5a2-08e1-42e2-9bcc-f870c2038e5c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_16688731-05c4-4e2d-9360-c3dc0f4aa602_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d1179125-6315-42c2-8c28-35f6d2a5c1b7_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_447e5712-0d30-4cc3-992b-bc778284434d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Company's Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_aa7ae822-69f8-4dc0-a207-0183f547518b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_84874085-aa83-4f92-9606-2668704e2c79_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f02e3a79-dca6-4713-8d5b-bbe09dcf79f8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_ProductsAndServicesExcludingGrantRevenueMember_d6ac3729-707a-4716-b6c0-1b0a482375f6_terseLabel_en-US" xlink:label="lab_txg_ProductsAndServicesExcludingGrantRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services, Excluding Grant Revenue</link:label>
    <link:label id="lab_txg_ProductsAndServicesExcludingGrantRevenueMember_label_en-US" xlink:label="lab_txg_ProductsAndServicesExcludingGrantRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products And Services, Excluding Grant Revenue [Member]</link:label>
    <link:label id="lab_txg_ProductsAndServicesExcludingGrantRevenueMember_documentation_en-US" xlink:label="lab_txg_ProductsAndServicesExcludingGrantRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Products And Services, Excluding Grant Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_ProductsAndServicesExcludingGrantRevenueMember" xlink:href="txg-20250331.xsd#txg_ProductsAndServicesExcludingGrantRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_ProductsAndServicesExcludingGrantRevenueMember" xlink:to="lab_txg_ProductsAndServicesExcludingGrantRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_1df17dba-e19e-4054-991b-507c4d453705_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_7e4f1fb1-4de1-4a62-a017-301ea7bd6449_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Class A</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_8e32c793-b482-4eb7-a1cc-0f1df002ccac_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common Class A</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_104dd219-0a9c-4c20-99e2-bd90ddd121eb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Held-to-Maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:to="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_303354b8-fa38-44b9-a529-9d5aaee04a86_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_3be5f600-c5b1-4eeb-bb1f-8ce1cec44134_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_TwoThousandsNineteenPlanMember_05e7ba42-04c8-495a-ab11-47aee8ee002d_terseLabel_en-US" xlink:label="lab_txg_TwoThousandsNineteenPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019 Plan</link:label>
    <link:label id="lab_txg_TwoThousandsNineteenPlanMember_label_en-US" xlink:label="lab_txg_TwoThousandsNineteenPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousands Nineteen Plan [Member]</link:label>
    <link:label id="lab_txg_TwoThousandsNineteenPlanMember_documentation_en-US" xlink:label="lab_txg_TwoThousandsNineteenPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousands Nineteen Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_TwoThousandsNineteenPlanMember" xlink:href="txg-20250331.xsd#txg_TwoThousandsNineteenPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_TwoThousandsNineteenPlanMember" xlink:to="lab_txg_TwoThousandsNineteenPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_6a252fcc-f73b-41dd-a76e-1d0d0c14c966_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_AccruedPayrollAndRelatedCosts_b8cb4e6e-8b74-41c0-bede-6feb002d2d9b_verboseLabel_en-US" xlink:label="lab_txg_AccruedPayrollAndRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued payroll and related costs</link:label>
    <link:label id="lab_txg_AccruedPayrollAndRelatedCosts_label_en-US" xlink:label="lab_txg_AccruedPayrollAndRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Payroll And Related Costs</link:label>
    <link:label id="lab_txg_AccruedPayrollAndRelatedCosts_documentation_en-US" xlink:label="lab_txg_AccruedPayrollAndRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Payroll And Related Costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_AccruedPayrollAndRelatedCosts" xlink:href="txg-20250331.xsd#txg_AccruedPayrollAndRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_AccruedPayrollAndRelatedCosts" xlink:to="lab_txg_AccruedPayrollAndRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_92c32977-3c7c-40e9-b82f-e021b95fa232_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_fc8a74ea-deaf-42cc-8c64-bb4aad093b33_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on available-for-sale marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_29ecf26a-c668-437b-8387-bad5fb56ff38_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_423bab03-1217-419d-bd98-40a5de4c4c13_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_11a9df52-b720-4ed3-bfb9-23de2b377d5f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_12a12a33-b417-43ea-b343-207f2648bc47_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_63e5f7e1-5744-4d82-8cf5-a79495352021_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_d14983e4-4b92-4681-ab31-f85429532c0a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_6fcd0496-e736-4a50-81e8-68cfdee8cb6d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_309de2fb-fbac-457f-a9fb-67d495752056_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_LicensingAndRoyaltyRevenueMember_ed30e339-cf67-47c3-b908-b2515ca403ac_terseLabel_en-US" xlink:label="lab_txg_LicensingAndRoyaltyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License and royalty revenue</link:label>
    <link:label id="lab_txg_LicensingAndRoyaltyRevenueMember_label_en-US" xlink:label="lab_txg_LicensingAndRoyaltyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing And Royalty Revenue [Member]</link:label>
    <link:label id="lab_txg_LicensingAndRoyaltyRevenueMember_documentation_en-US" xlink:label="lab_txg_LicensingAndRoyaltyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Licensing And Royalty Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_LicensingAndRoyaltyRevenueMember" xlink:href="txg-20250331.xsd#txg_LicensingAndRoyaltyRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_LicensingAndRoyaltyRevenueMember" xlink:to="lab_txg_LicensingAndRoyaltyRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_27ab735e-a2c1-481d-85e5-bb0293f68c23_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6910063d-a799-4b78-bfaf-4b2bbe8fa44d_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_8859d17b-d8c9-4534-b721-f7512567e9da_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossRealizedAfterTax_389d9f74-7dfe-45f2-9e82-af4d4efbeb6f_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossRealizedAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognized foreign currency transaction income (loss)</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossRealizedAfterTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossRealizedAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Gain (Loss), Foreign Currency Transaction, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossRealizedAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealizedAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossRealizedAfterTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossRealizedAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_a44375c7-e07d-4441-9491-42293e4b95a3_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_01776a9b-840d-4fff-bf7d-5c804390d9af_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7d3d8ed7-9426-4b87-9c8a-e15fa98d796c_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4b4cc5e-7cc3-417d-898b-eba64069f782_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_24fd7de9-5aba-45b4-93a1-190796d4b87e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_92dace07-3348-46f7-ba27-57f5be2d864d_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_a530a2ff-71ac-43c3-8bf0-675060ea67f8_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_0be46a7c-c312-494b-8fb7-388b8a262924_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_AccruedLegalAndRelatedExpensesCurrent_f2b86aef-267b-4e36-b83d-1d724b23adb4_verboseLabel_en-US" xlink:label="lab_txg_AccruedLegalAndRelatedExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Legal and related costs</link:label>
    <link:label id="lab_txg_AccruedLegalAndRelatedExpensesCurrent_label_en-US" xlink:label="lab_txg_AccruedLegalAndRelatedExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Legal And Related Expenses Current</link:label>
    <link:label id="lab_txg_AccruedLegalAndRelatedExpensesCurrent_documentation_en-US" xlink:label="lab_txg_AccruedLegalAndRelatedExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued legal expenses current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_AccruedLegalAndRelatedExpensesCurrent" xlink:href="txg-20250331.xsd#txg_AccruedLegalAndRelatedExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_AccruedLegalAndRelatedExpensesCurrent" xlink:to="lab_txg_AccruedLegalAndRelatedExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_65246608-84ad-4db7-b5e1-d82ed5f5e66f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cdc3dab1-6cf3-43d8-ad90-aa243c26b0bd_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_dc15e2aa-001c-472d-bef9-3a881c78da52_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_2643bc1b-9ea2-449d-b32c-d289d20dee6e_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_ee612f69-d7ea-4a1f-928c-3081d20ab57d_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_8eaf981a-8eed-45ec-ade1-f5bb4433afff_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_476e1f3a-167d-4d42-8768-81a4f0893677_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c8028815-2bb5-44da-b8ae-3a25aab5425e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EMEAMember_ed8e3675-0bf1-4985-9bbe-c029b5e1757e_terseLabel_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Europe, Middle East and Africa</link:label>
    <link:label id="lab_us-gaap_EMEAMember_label_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">EMEA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EMEAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EMEAMember" xlink:to="lab_us-gaap_EMEAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_41a063b8-4774-4ee3-8a94-448493df420d_terseLabel_en-US" xlink:label="lab_txg_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_txg_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_txg_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Accrued Liabilities And Other Current Liabilities</link:label>
    <link:label id="lab_txg_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_txg_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase decrease in accrued liabilities and other current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" xlink:href="txg-20250331.xsd#txg_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" xlink:to="lab_txg_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0a4176fa-8bd5-4c3c-93f1-759badd46806_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_SpatialInstrumentsMember_b07d11c2-07cb-4229-b00c-a1b6405efb79_terseLabel_en-US" xlink:label="lab_txg_SpatialInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Spatial</link:label>
    <link:label id="lab_txg_SpatialInstrumentsMember_label_en-US" xlink:label="lab_txg_SpatialInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Spatial - Instruments [Member]</link:label>
    <link:label id="lab_txg_SpatialInstrumentsMember_documentation_en-US" xlink:label="lab_txg_SpatialInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Spatial - Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_SpatialInstrumentsMember" xlink:href="txg-20250331.xsd#txg_SpatialInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_SpatialInstrumentsMember" xlink:to="lab_txg_SpatialInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_b40a0e40-f62c-4ba0-8b2e-f9e8b3f1ec6f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued bonus</link:label>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Bonuses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedBonusesCurrent" xlink:to="lab_us-gaap_AccruedBonusesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5a4323db-5d4b-4340-9bdd-6cb90426f7a9_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4e9fbd35-b888-4f57-86d4-e25a05d6d949_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_d812b382-caec-44a5-94d5-10269e49e449_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_d922e77e-4db2-4f91-88f8-c2c092020478_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_21c80192-a3c1-4118-95c2-17c4cbef977a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualPayments_da298db2-8360-473f-9e8c-f9e050e27cc9_negatedLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repairs and replacements</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualPayments_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standard and Extended Product Warranty Accrual, Decrease for Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrualPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualPayments" xlink:to="lab_us-gaap_ProductWarrantyAccrualPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_0ecf3924-0606-4bf6-be39-3a51b0df27bd_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_5c0fcb3e-1151-492b-aa01-36cbb952a3b2_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_8d759605-450c-4406-818f-fe43b6cae51f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_39237d4f-4c87-4277-9dc6-d231ec26af27_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4b0cdc6f-fcf1-4d70-a6bb-a05dd8f21e13_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_791f60cf-50d6-4eab-b815-4ca158fa6c91_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_8475ac97-d7cf-4037-8e33-de6956ceffb5_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_a3b3a4da-b497-45b0-b31a-6ca99e5ca958_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchased materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials and Supplies, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_3450ac40-e768-4a08-bcdb-5b2f049e5736_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_8694f514-b88b-4b59-8f8d-068e7f26a7c1_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_69c8731d-8157-4fdb-aefa-83e653f64a0d_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_660ae165-23a1-478b-b796-12bc12d8a9e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1bff94b9-2bc8-435a-b75d-16245a74eb50_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted&#160;Stock Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_cf3be109-4f3f-4403-9ca3-29d370da556b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in progress</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b731de4d-8a50-437d-b16e-cdf1512050f0_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_96207c13-2298-4a01-830c-c770d86ada94_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_b11019bd-8867-46f4-9d65-065170f0905a_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_SharesUnderEsppPlanMember_944206da-f261-452e-bff4-5946bdbb7215_terseLabel_en-US" xlink:label="lab_txg_SharesUnderEsppPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares committed under ESPP</link:label>
    <link:label id="lab_txg_SharesUnderEsppPlanMember_label_en-US" xlink:label="lab_txg_SharesUnderEsppPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Under ESPP Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_SharesUnderEsppPlanMember" xlink:href="txg-20250331.xsd#txg_SharesUnderEsppPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_SharesUnderEsppPlanMember" xlink:to="lab_txg_SharesUnderEsppPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8729e23b-43ca-4428-be7a-4b4c317835d2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_41f7ccdf-057c-4be8-85bb-68f5af7828e1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_0e1a6d7a-c550-496e-90bc-48f15e803372_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_aba778d8-ed0f-4c11-9e5b-5f6532110aa3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_bb0ead7d-9f80-49c7-98f1-15c4d078285e_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_b42c0d3d-027b-4413-98c7-807cac2f609f_verboseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_89031986-120a-4ee0-ad61-c3cf597e164a_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_SpatialConsumablesMember_e28393b5-9af9-48c2-b07c-49abbed664de_terseLabel_en-US" xlink:label="lab_txg_SpatialConsumablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Spatial</link:label>
    <link:label id="lab_txg_SpatialConsumablesMember_label_en-US" xlink:label="lab_txg_SpatialConsumablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Spatial - Consumables [Member]</link:label>
    <link:label id="lab_txg_SpatialConsumablesMember_documentation_en-US" xlink:label="lab_txg_SpatialConsumablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Spatial - Consumables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_SpatialConsumablesMember" xlink:href="txg-20250331.xsd#txg_SpatialConsumablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_SpatialConsumablesMember" xlink:to="lab_txg_SpatialConsumablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_cefc70a6-46f7-498c-85f5-9f2937836e1c_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_df902c79-6a0d-429b-978b-413a8898b28c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_4beb2783-f6b6-4b31-ab69-7d9582e26a92_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_49e77324-f231-453f-b852-b42e788d354d_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ca519f44-1bfe-40fe-b69c-1223dc42c073_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_fab24d48-6f34-4b9e-aa78-09839a34be18_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8563f577-db78-4cda-8917-efa4a32f2fc2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_ChromiumInstrumentsMember_433221d1-559c-4459-8ba7-cc91a3662c2d_terseLabel_en-US" xlink:label="lab_txg_ChromiumInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chromium</link:label>
    <link:label id="lab_txg_ChromiumInstrumentsMember_label_en-US" xlink:label="lab_txg_ChromiumInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chromium - Instruments [Member]</link:label>
    <link:label id="lab_txg_ChromiumInstrumentsMember_documentation_en-US" xlink:label="lab_txg_ChromiumInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Chromium - Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_ChromiumInstrumentsMember" xlink:href="txg-20250331.xsd#txg_ChromiumInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_ChromiumInstrumentsMember" xlink:to="lab_txg_ChromiumInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_40cd69f3-78db-439e-a2d9-4b0e819b15a5_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_36ed312f-c830-4477-a201-ae146832ca8a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares of common stock used in computing net loss per share, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_391fcf4e-8bc7-44fa-bd10-b44a5c397511_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ccdc6ddf-e7dc-4ed5-b270-2c4849f0271a_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_c1ee2830-3dcb-4b43-a01b-e54adbefcd30_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_ChromiumConsumablesMember_f3fb50a1-31fc-42c0-bfb8-a8b022741f47_terseLabel_en-US" xlink:label="lab_txg_ChromiumConsumablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chromium</link:label>
    <link:label id="lab_txg_ChromiumConsumablesMember_label_en-US" xlink:label="lab_txg_ChromiumConsumablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chromium - Consumables [Member]</link:label>
    <link:label id="lab_txg_ChromiumConsumablesMember_documentation_en-US" xlink:label="lab_txg_ChromiumConsumablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Chromium - Consumables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_ChromiumConsumablesMember" xlink:href="txg-20250331.xsd#txg_ChromiumConsumablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_ChromiumConsumablesMember" xlink:to="lab_txg_ChromiumConsumablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_30a83bcf-41d7-4744-a614-93de23a297dd_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_3d12676f-8e56-45b5-b626-97aaf5ce72a5_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e5e83cbd-7c0f-41d6-8392-299928d0af0b_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9b189cf9-a2ca-4c81-b9eb-cf598a211c19_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_a74cf641-fbb9-497d-a294-ef288fcb44c2_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_d029a363-3c93-4c95-b222-b3ac7cd74e2b_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_dd6db28f-840d-4719-8408-15cb53bab73e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f0c529d2-18e9-446b-9187-debb030d40f0_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_7ea4a689-5153-4436-b6d0-8ee41d27ed4a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_78d8e399-1ec8-46ce-9033-dcad5fff0122_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9e5668f7-37eb-436b-a01c-2993264a2c4c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_6a4fd235-7328-4367-86ec-aa18b6a6fc6a_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_SergeSaxonovCarryoverSharesFromPrior10b51PlanMember_label_en-US" xlink:label="lab_txg_SergeSaxonovCarryoverSharesFromPrior10b51PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Serge Saxonov, Carryover Shares From Prior 10b5-1 Plan [Member]</link:label>
    <link:label id="lab_txg_SergeSaxonovCarryoverSharesFromPrior10b51PlanMember_documentation_en-US" xlink:label="lab_txg_SergeSaxonovCarryoverSharesFromPrior10b51PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Serge Saxonov, Carryover Shares From Prior 10b5-1 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_SergeSaxonovCarryoverSharesFromPrior10b51PlanMember" xlink:href="txg-20250331.xsd#txg_SergeSaxonovCarryoverSharesFromPrior10b51PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_SergeSaxonovCarryoverSharesFromPrior10b51PlanMember" xlink:to="lab_txg_SergeSaxonovCarryoverSharesFromPrior10b51PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ae00f0d3-a01c-4dea-938f-2dc704cc0a54_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ea5f77e0-648f-4a91-a954-60e0dee996e4_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Marketable securities:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_AccruedCommissionsCurrent_f82a29d9-edbc-43ee-b197-544e63c3914b_terseLabel_en-US" xlink:label="lab_txg_AccruedCommissionsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued commissions</link:label>
    <link:label id="lab_txg_AccruedCommissionsCurrent_label_en-US" xlink:label="lab_txg_AccruedCommissionsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Commissions Current</link:label>
    <link:label id="lab_txg_AccruedCommissionsCurrent_documentation_en-US" xlink:label="lab_txg_AccruedCommissionsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued commissions, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_AccruedCommissionsCurrent" xlink:href="txg-20250331.xsd#txg_AccruedCommissionsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_AccruedCommissionsCurrent" xlink:to="lab_txg_AccruedCommissionsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_5011ea94-22d9-44ed-87ac-cf50431da0f7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue of Recognized in Deferred Revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e56825ca-3d3e-46a9-9140-5945a3391b41_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_2d946721-c3cd-42da-95fb-ccf57e7d6b5f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_d3fdc339-154a-4d34-924c-5007064cf626_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_ddab73e4-2892-4525-940b-a82107aebdb3_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_553c72af-4dd3-417f-b104-342818caaa67_verboseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_390003a3-a0f6-459e-9d9c-735d3e011a17_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_e5ee038b-3e08-4d85-b5d9-b7b9c619ca51_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_fede0b93-4aba-466b-937f-f62163ac839d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_f3002947-dcd9-4bac-92a6-7def62ac92d5_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of lost profits</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) from Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_8c3bbaca-a004-47e0-84aa-6631ac3a9cee_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f8dcca9f-1e23-4a9c-ae7d-be1b2e325831_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_16cc12ed-1792-4bda-b4db-29d46cfedf09_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e67a8182-846a-49b7-aace-03aef52199db_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_7897ea47-966d-4508-8444-84865e73c1ed_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e1957609-e55d-416e-bfd7-6dc8b4789a49_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_63a20c42-cfac-481a-8ec8-6a42199ef90d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued in period for previously outstanding awards (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7729bd1-3190-4536-ae03-458e8a29df9c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_8cfb4a3f-64b6-4cb4-a399-f5e4142444b9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Class&#160;A common stock related to equity awards (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_833dd1bb-41ec-45ad-acab-88e30b535ed1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Shares of Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsAtCarryingValue_62fc5c5a-170f-4b3c-80d7-6424d1aa8f80_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted_1fcff54a-804f-4873-bea1-dd8d3872fefb_terseLabel_en-US" xlink:label="lab_txg_ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of litigation settlement and intellectual property license granted</link:label>
    <link:label id="lab_txg_ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted_label_en-US" xlink:label="lab_txg_ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Litigation Settlement And Intellectual Property License Granted</link:label>
    <link:label id="lab_txg_ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted_documentation_en-US" xlink:label="lab_txg_ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Litigation Settlement And Intellectual Property License Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted" xlink:href="txg-20250331.xsd#txg_ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted" xlink:to="lab_txg_ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_5d09b9ea-0931-4e83-a143-bb346686279f_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional&#160;Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_e5b1d35d-ca2e-4bab-a039-1d10e37b18fa_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_fb4b1d36-ed85-4657-8831-8121ae81ab59_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_8fd62b5c-3d9f-4750-aea9-5b46320953a2_terseLabel_en-US" xlink:label="lab_txg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_txg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_label_en-US" xlink:label="lab_txg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due After Year Four</link:label>
    <link:label id="lab_txg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_documentation_en-US" xlink:label="lab_txg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:href="txg-20250331.xsd#txg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="lab_txg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4c311e0a-9e4c-44cd-b9de-5a6d3a7f5ad9_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Issued Accounting Pronouncement and Disclosure Rules</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_89170baf-8624-4577-94df-f98a8a227275_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_40a229c9-fc1c-4ecb-842a-2f974aaa56ed_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_abd1b225-182b-426c-82d0-28bf73a09d3d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_d2948f7d-0ea2-495d-af13-c36829c2e55c_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_87f28252-d990-4ba3-b5ea-bc9c7bad9dd1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_da80abbe-5e9f-47d3-a23c-9aa348dae58d_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0004d88e-f429-46ec-adfa-6f2d0583a6c0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PSA target percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_a87c25fa-be07-434a-b25a-5dba43af58f2_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_d3c2640e-aa82-4a44-9890-64f22b06171e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected workforce reduction percent</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_f62347f1-f9e9-4a45-9679-19598b92967f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_f0f4a941-747f-4c30-bcc4-26d16803a09e_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_bba0004f-b71a-46ad-bf7b-16828f1050b3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_1c7e55cb-8395-4a78-9726-6605db677e8b_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product warranties</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Warranty Accrual, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:to="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_18683051-9441-4dac-98b1-0be3e780ec55_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_9bacf0a1-d3c6-4041-bedd-a739187708ba_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_07cff5a8-4d7f-40af-804e-7435972bf629_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_DisclosureOfAdditionalInformationRelatedToOperatingLeasesTableTextBlock_9af63731-1c35-4055-bd4c-4fdad5d69aa9_terseLabel_en-US" xlink:label="lab_txg_DisclosureOfAdditionalInformationRelatedToOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Additional Information Related to Operating Leases</link:label>
    <link:label id="lab_txg_DisclosureOfAdditionalInformationRelatedToOperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_txg_DisclosureOfAdditionalInformationRelatedToOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Additional Information Related To Operating Leases [Table Text Block]</link:label>
    <link:label id="lab_txg_DisclosureOfAdditionalInformationRelatedToOperatingLeasesTableTextBlock_documentation_en-US" xlink:label="lab_txg_DisclosureOfAdditionalInformationRelatedToOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of additional information related to operating leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_DisclosureOfAdditionalInformationRelatedToOperatingLeasesTableTextBlock" xlink:href="txg-20250331.xsd#txg_DisclosureOfAdditionalInformationRelatedToOperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_DisclosureOfAdditionalInformationRelatedToOperatingLeasesTableTextBlock" xlink:to="lab_txg_DisclosureOfAdditionalInformationRelatedToOperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_cacc760c-8efc-4be2-87cf-cc2ba93ceaee_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_2b4a05a8-7326-4c9c-ba02-a47cfbc411e0_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_76fe29da-6d3e-4df5-a4a3-3f212f529a1b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e45dd98a-e2d2-457f-a16f-04a512f82705_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_8c3bb8aa-0363-4f1d-bcd0-2079a540dc4a_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Services</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_8f0f64ff-1cac-475f-ae79-c45af77b4884_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_dd4755dc-c80b-4b74-855f-7c0d89207ea1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_c6cd7a33-b08b-4457-b469-c3fd26811c6a_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_90f46260-4fd3-40d6-916e-b4fc95f1eb14_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_f12f73a4-9153-4c36-8ef8-8c15e3ad2f28_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_22cef057-6acc-4ef2-a35d-f7866cdd2a7d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_0d20b1c2-a7d3-48be-8821-049f14bdbb20_terseLabel_en-US" xlink:label="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_ea5f98c5-107a-475f-929b-e6015dbc8409_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_73b2b591-b1fb-4ad7-b729-a0c329862f00_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_64b1550c-8c1c-45a4-a470-5a08e56e86ae_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_7bb459b1-a6cb-4b24-a310-6b2ab91c60aa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_bf145234-350c-4f23-9163-5b2442b853fb_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and related benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_24310486-c707-439a-b93f-5f9621febd65_totalLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and related benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_17930810-cdc0-4e92-96d0-02eddf0a382f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_d468f446-771a-4b51-8bc1-8f775051c13e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease and asset impairment charges</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_1c7f7a8d-ecde-491a-b561-24b2e7bd6273_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_259805b7-cca4-4783-b7ac-a18faca7b565_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_478454ae-de2d-4528-9126-c0d997bdc3bd_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_50bca6d8-0cbc-4866-8646-b34e03815b01_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_RevenueFromContractWithCustomerPaymentPeriod_42ec7b08-de38-4876-a718-ecf65ea6e1f3_terseLabel_en-US" xlink:label="lab_txg_RevenueFromContractWithCustomerPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognition, payment due period</link:label>
    <link:label id="lab_txg_RevenueFromContractWithCustomerPaymentPeriod_label_en-US" xlink:label="lab_txg_RevenueFromContractWithCustomerPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Contract With Customer, Payment Period</link:label>
    <link:label id="lab_txg_RevenueFromContractWithCustomerPaymentPeriod_documentation_en-US" xlink:label="lab_txg_RevenueFromContractWithCustomerPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Contract With Customer, Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_RevenueFromContractWithCustomerPaymentPeriod" xlink:href="txg-20250331.xsd#txg_RevenueFromContractWithCustomerPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_RevenueFromContractWithCustomerPaymentPeriod" xlink:to="lab_txg_RevenueFromContractWithCustomerPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_58b3645a-bc73-4699-a6e1-9520e994a351_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9ce06a27-a0f3-44c9-9377-f1fa6a5211e0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancelled and forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_ec185c20-2ffa-40c4-8eae-a95b113e364e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected period of revenue recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_9a118189-4cd1-4c16-91d1-374c6250e6fe_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_f475bd20-fbde-4004-a17f-32771ee6ba2f_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_9d2f781c-a320-4546-813f-af08e1d040c5_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d6bb3a35-2e84-46ee-bbf2-7f6e96305091_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_9f9ffa5c-8ae6-4735-be5e-6e400b838ac6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_cb80eda6-126d-4091-aeb2-481079297882_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_3c98d43c-df75-429b-a2de-558f99fac9d2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_412f03ad-9dd8-4534-ace0-b384a0f315e0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a2c2d786-426e-4d29-8ca1-4ce14346e1e8_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1d0fd921-7bf4-4a74-b1c3-7f4d9bfdce46_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f7b183a1-312a-4cbc-9c76-91dc38cbd2df_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2510854f-990e-48cb-ab48-94cc6ce13132_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation_a4c3e518-d12f-4151-bd33-c8b4f3f11148_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based payment arrangement recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Benefits and Share-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AsiaPacificMember_88e82005-f01b-462e-a26b-12722d664a13_terseLabel_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asia-Pacific</link:label>
    <link:label id="lab_srt_AsiaPacificMember_label_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asia Pacific [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AsiaPacificMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AsiaPacificMember" xlink:to="lab_srt_AsiaPacificMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_20cace26-6eda-4454-bb15-5d96a16c13df_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_0d726d42-8744-42df-be5d-4967ecc16e71_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, noncurrent</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cc80c4aa-90fc-469d-a8be-22673e4840b0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_efe6bba2-277f-4220-acee-8b193f6c0470_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_dc9b131c-7bba-4059-ade2-10a1642837e6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_401c1ecc-368a-4632-b602-72b8f748805d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_5b64c005-5111-4c9c-9a2a-a822ef7029a3_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_977f9933-7b4c-4b2c-8435-940925e0a177_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bf6b2ea4-82ca-4233-a8af-4e4575deeed5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_2481da10-0d7d-4086-ab73-b8e933058e60_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Recorded Stock-based Compensation Expense in the Condensed Consolidated Statement of Operations</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_TotalShareholderReturnMember_330860b9-d7f9-4193-a568-ea972c20ed93_terseLabel_en-US" xlink:label="lab_txg_TotalShareholderReturnMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TSR</link:label>
    <link:label id="lab_txg_TotalShareholderReturnMember_label_en-US" xlink:label="lab_txg_TotalShareholderReturnMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return [Member]</link:label>
    <link:label id="lab_txg_TotalShareholderReturnMember_documentation_en-US" xlink:label="lab_txg_TotalShareholderReturnMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Shareholder Return</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_TotalShareholderReturnMember" xlink:href="txg-20250331.xsd#txg_TotalShareholderReturnMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_TotalShareholderReturnMember" xlink:to="lab_txg_TotalShareholderReturnMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_b094e196-2adc-4e2f-bb46-8d28b3196905_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Financial Statement Information</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_90af521f-0375-4943-b3b9-24e5e77b416a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_ff1502d3-5174-4ea4-a085-f8a580725a3f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and other related benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_2e546801-5f87-4f90-af0c-aa9ff788cbe4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementGain_bbb6a4da-e933-4f36-b42b-e119308dd302_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementGain" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on settlement</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementGain_08d29d63-6a2c-44fc-bbc6-453567840532_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on settlement</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementGain_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementGain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementGain" xlink:to="lab_us-gaap_LitigationSettlementGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_536a06ef-8730-4747-81a5-1633c3cc8567_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5165f3b3-d597-4b69-9424-2d436606265a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b0260e16-c5c5-4cd3-b6ec-315db4f0f0fa_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant date fair value, granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_3d65c70b-dbf9-4688-91a5-cbd8ac8e17e1_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTable" xlink:to="lab_us-gaap_MarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_171be297-5a6f-4381-9038-e53068bc3688_verboseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_d0d38f4c-54bd-4201-922e-9347affda554_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_AccruedExpensesAndOtherLiabilitiesCurrent_2c0228bb-0ffd-46ba-b792-164346160caa_verboseLabel_en-US" xlink:label="lab_txg_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_txg_AccruedExpensesAndOtherLiabilitiesCurrent_500f0bf8-de6d-4114-8ee0-1d18eda33e96_totalLabel_en-US" xlink:label="lab_txg_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_txg_AccruedExpensesAndOtherLiabilitiesCurrent_label_en-US" xlink:label="lab_txg_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Expenses And Other Liabilities Current</link:label>
    <link:label id="lab_txg_AccruedExpensesAndOtherLiabilitiesCurrent_documentation_en-US" xlink:label="lab_txg_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Expenses And Other Liabilities Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:href="txg-20250331.xsd#txg_AccruedExpensesAndOtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="lab_txg_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_27790ed1-1f0a-4346-b976-09a8ef6acfc8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_57572129-2a4f-45bb-8ed9-a004ec05b876_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_AsiaPacificExcludingChinaMember_64adf41c-3cfb-4b55-878d-548a2aa2816b_terseLabel_en-US" xlink:label="lab_txg_AsiaPacificExcludingChinaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asia-Pacific (excluding China)</link:label>
    <link:label id="lab_txg_AsiaPacificExcludingChinaMember_label_en-US" xlink:label="lab_txg_AsiaPacificExcludingChinaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asia-Pacific, Excluding China [Member]</link:label>
    <link:label id="lab_txg_AsiaPacificExcludingChinaMember_documentation_en-US" xlink:label="lab_txg_AsiaPacificExcludingChinaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asia-Pacific, Excluding China</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_AsiaPacificExcludingChinaMember" xlink:href="txg-20250331.xsd#txg_AsiaPacificExcludingChinaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_AsiaPacificExcludingChinaMember" xlink:to="lab_txg_AsiaPacificExcludingChinaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_72f56736-c4e9-44c5-8c3a-29a45d9d5074_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_26ba30e4-ae80-485e-a5a2-2676366c7b24_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_c03689d8-af1e-4156-a932-73e083e6cc3b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock from exercise of stock options and employee stock purchase plan purchases</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds_56b021f8-4665-4f65-8b90-669fec7e9b79_totalLabel_en-US" xlink:label="lab_txg_DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total available-for-sale securities, amortized cost</link:label>
    <link:label id="lab_txg_DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds_label_en-US" xlink:label="lab_txg_DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available For Sale, Amortized Cost Including Money Market Funds</link:label>
    <link:label id="lab_txg_DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds_documentation_en-US" xlink:label="lab_txg_DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available For Sale, Amortized Cost Including Money Market Funds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds" xlink:href="txg-20250331.xsd#txg_DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds" xlink:to="lab_txg_DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_786bcde2-9d60-43a2-a0b7-5defa5f19571_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cb6cfbbc-e183-496c-aa1e-7e0920f762bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_f9f32e05-3308-4f42-a8d9-ff69653e1497_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_323d1896-02d4-41a1-a32a-8083e0d164a2_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_742ba423-8189-4a7c-b83c-22364138cc9e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_af7267bc-2cf7-4a73-9889-b92484b8ee4a_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AmericasMember_31ae8898-8034-4527-b3ea-bc981a99c78c_terseLabel_en-US" xlink:label="lab_srt_AmericasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Americas</link:label>
    <link:label id="lab_srt_AmericasMember_label_en-US" xlink:label="lab_srt_AmericasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Americas [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AmericasMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AmericasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AmericasMember" xlink:to="lab_srt_AmericasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0a5dc58b-2784-4fac-8415-b35408e94ff1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_23b7d186-8e58-41f7-916d-8f66d34f6190_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6e22f06e-13a6-4a29-bd5d-7ba0a7db0960_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c0193585-ed14-48e4-8600-c5b9e2ed726f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_43bbebc0-24b4-41c2-86b2-1599260c120f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement percent</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_16873758-4c4c-44af-8f43-fac08878ba27_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_ba9e922c-1cb1-4114-bdc2-ac09b77f1eca_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_85d7b2cf-5f06-44b6-b7e5-2513d3a70da8_verboseLabel_en-US" xlink:label="lab_txg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expense and Other Current Liabilities</link:label>
    <link:label id="lab_txg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_txg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities And Other Current Liabilities [Table Text Block]</link:label>
    <link:label id="lab_txg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_txg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of accrued liabilities and other current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:href="txg-20250331.xsd#txg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_txg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_189317dd-bfb0-45fc-8624-8a7059b40e9d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_78ba4307-78ab-4fe5-bbdb-58ec58e2b184_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of long lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_2a61c5cc-66c5-4a39-99e3-8c052bfbfd5d_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6c12c172-8271-496e-a83d-e12686e186f8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Class&#160;A common stock related to equity awards</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_07843305-49a5-4c10-bcaf-fb522738c08d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_ConsumablesMember_bd5e189e-6f81-4a50-97bf-6cf92634995c_terseLabel_en-US" xlink:label="lab_txg_ConsumablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consumables</link:label>
    <link:label id="lab_txg_ConsumablesMember_label_en-US" xlink:label="lab_txg_ConsumablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consumables [Member]</link:label>
    <link:label id="lab_txg_ConsumablesMember_documentation_en-US" xlink:label="lab_txg_ConsumablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consumables member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_ConsumablesMember" xlink:href="txg-20250331.xsd#txg_ConsumablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_ConsumablesMember" xlink:to="lab_txg_ConsumablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_6486768b-07ea-402b-9531-9d004275468f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_092e9d62-24f4-47b8-b583-e5a5e63d7da3_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_7b5d52f2-5353-47e4-87b1-9661cfb2725e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingency, damages sought, value</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_b4a8dec7-3fc8-49c9-ae38-1b235f6a4ff8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued_ac96023d-60a9-49d3-918d-92d339bb2952_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts charged to cost of revenue</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standard and Extended Product Warranty Accrual, Increase for Warranties Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrualWarrantiesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:to="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b13317f0-5030-429a-aa86-4df13abd561a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_802d071a-4c87-429d-a09e-77bc166baa33_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_c212d4c9-cdc7-40a2-af50-b2c37f1cd0a1_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_967a3e35-6f9b-4554-804e-55da6c474074_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_76cb8cbb-39bc-4a84-8c08-377f79a6cd60_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_afb7654c-e5e9-40a6-9764-d2f75b84ecc1_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_CostOfRevenueMember_be050276-81e8-42a5-98ed-78fdc4bcd863_terseLabel_en-US" xlink:label="lab_txg_CostOfRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_txg_CostOfRevenueMember_label_en-US" xlink:label="lab_txg_CostOfRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Revenue [Member]</link:label>
    <link:label id="lab_txg_CostOfRevenueMember_documentation_en-US" xlink:label="lab_txg_CostOfRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_CostOfRevenueMember" xlink:href="txg-20250331.xsd#txg_CostOfRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_CostOfRevenueMember" xlink:to="lab_txg_CostOfRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassBMember_ed27a1c1-e11e-4f62-b86e-e76fc351fbfd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Class B</link:label>
    <link:label id="lab_us-gaap_CommonClassBMember_e2dc676a-8960-402e-8797-7e4250077c88_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common Class B</link:label>
    <link:label id="lab_us-gaap_CommonClassBMember_label_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Class B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_InstrumentsMember_20ad2cd9-d541-4549-9373-44ce79a5f6b9_terseLabel_en-US" xlink:label="lab_txg_InstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Instruments</link:label>
    <link:label id="lab_txg_InstrumentsMember_label_en-US" xlink:label="lab_txg_InstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Instruments [Member]</link:label>
    <link:label id="lab_txg_InstrumentsMember_documentation_en-US" xlink:label="lab_txg_InstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Instruments member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_InstrumentsMember" xlink:href="txg-20250331.xsd#txg_InstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_InstrumentsMember" xlink:to="lab_txg_InstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_884e1f24-bfb3-412c-a880-7dcbf96c92d3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_08d6ae2b-e7fd-4208-bbb6-e43189ef38e9_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_4516810f-4e3e-4ead-a04c-c32af5f5425f_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b9b45b8b-5198-41c8-b1c5-9423866aa59f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_e11e1181-c692-464e-bd2b-09ddaf68c15d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_4916db3c-e6f0-4b2c-b57d-c40143b49297_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_2efe4aa0-1a2b-418a-8aa2-177e91068767_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_57157bb6-a553-4d1d-a054-42c3baa12f08_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_184c24cf-8668-4be4-bce0-b9c83624a616_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_SergeSaxonovMember_label_en-US" xlink:label="lab_txg_SergeSaxonovMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Serge Saxonov [Member]</link:label>
    <link:label id="lab_txg_SergeSaxonovMember_documentation_en-US" xlink:label="lab_txg_SergeSaxonovMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Serge Saxonov</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_SergeSaxonovMember" xlink:href="txg-20250331.xsd#txg_SergeSaxonovMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_SergeSaxonovMember" xlink:to="lab_txg_SergeSaxonovMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d74231c8-bdc8-4ee2-b13b-5e1656eab25c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Grant&#160;Date&#160;Fair&#160;Value (per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_e448eba0-bab9-4533-9e0e-b3edc7d0a1e1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_aafdf55b-4a8a-4fa3-bcbd-f080acd14b4c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_ca2be4d2-1dca-451a-bcec-95c35de50c6c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_3a905b6f-cf74-444c-bafa-0f2c6b4490a1_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Source</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_0e5e7707-570b-466a-bdd5-a7ae3c324789_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_9d723398-3c11-4d33-a26e-05e8c04b5ebb_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_AmericasExcludingUnitedStatesMember_17ed47a2-8913-478d-aa3a-376fd4860146_terseLabel_en-US" xlink:label="lab_txg_AmericasExcludingUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Americas (excluding United States)</link:label>
    <link:label id="lab_txg_AmericasExcludingUnitedStatesMember_label_en-US" xlink:label="lab_txg_AmericasExcludingUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Americas, Excluding United States [Member]</link:label>
    <link:label id="lab_txg_AmericasExcludingUnitedStatesMember_documentation_en-US" xlink:label="lab_txg_AmericasExcludingUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Americas, Excluding United States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_AmericasExcludingUnitedStatesMember" xlink:href="txg-20250331.xsd#txg_AmericasExcludingUnitedStatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_AmericasExcludingUnitedStatesMember" xlink:to="lab_txg_AmericasExcludingUnitedStatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_14366525-3a2d-4115-a52b-782fa45897ff_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecurityDeposit_1db5b08b-2777-4a65-b6ce-250460228457_terseLabel_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security deposit</link:label>
    <link:label id="lab_us-gaap_SecurityDeposit_label_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_1e5dc6ab-4be3-4b23-9278-95941fb4d7a3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_78cfd94c-b6cf-48dd-9f9c-4180b0e8e2c1_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f5291287-fef9-4066-a5c3-df69dc65513e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_60b45568-bbeb-460f-a1fa-e021e3f4d7ba_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_b208a970-ff1b-4344-ab92-bf90cf1135c3_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5a78535-c99f-405f-be43-a73b7be504de_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_f262dc50-6140-405e-9e25-53f65eead06b_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Stock Units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_69a63582-bcdd-4e27-a751-fe423ee2c0ea_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_280665a6-051c-44a5-9fde-6d3b7aa71a69_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_23cbc11c-20ff-40e4-bb30-7c1ba0c85636_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_2618a1ca-12b0-455c-8de3-7692a10a5d56_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_15a3d9f3-2343-45ae-b973-6f81b79b44a4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_91278be2-7a73-45ba-aa29-885b19be6aac_verboseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment and machinery</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_11efd3c9-4b9c-495e-9d91-916f6a6cf4b5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in the Reserve for Product Warranties</link:label>
    <link:label id="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Product Warranty Liability [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_e9bfd038-9051-44c4-9fee-38c17be9e817_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_TwoThousandsNineteenEmployeeStockPurchasePlanMember_a1ba7690-b40d-4af9-bfe2-2e027ef0c94a_terseLabel_en-US" xlink:label="lab_txg_TwoThousandsNineteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_txg_TwoThousandsNineteenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_txg_TwoThousandsNineteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousands Nineteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_txg_TwoThousandsNineteenEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_txg_TwoThousandsNineteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2019 Employee Stock Purchase Plan [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_TwoThousandsNineteenEmployeeStockPurchasePlanMember" xlink:href="txg-20250331.xsd#txg_TwoThousandsNineteenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_TwoThousandsNineteenEmployeeStockPurchasePlanMember" xlink:to="lab_txg_TwoThousandsNineteenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_7ce07971-af6f-446b-ad7d-6a777bc7fbb0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0e9dedf4-99d0-4968-81f9-87ffd0e75b76_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_a2e45a84-6eb3-4e0f-970c-5b465c26447a_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrual_0b98cff4-54b4-49cb-ba78-7eb67a8d780c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning of period</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrual_dadec167-7a54-4eb5-910f-fe98a876b371_periodEndLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">End of period</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrual_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standard and Extended Product Warranty Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrual" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrual" xlink:to="lab_us-gaap_ProductWarrantyAccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_b2b5131d-41a4-4d53-b27a-7d4497b18925_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_8811c5c2-a548-4fc7-abe2-9d034d84eddd_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyObligationTerm_af6cb7ec-1fcd-4b5b-804d-c998c8dd2c4c_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyObligationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product warranty term</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyObligationTerm_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyObligationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Warranty Obligation, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyObligationTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyObligationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyObligationTerm" xlink:to="lab_us-gaap_ProductWarrantyObligationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_5aa0e58c-9bb0-4458-b7f8-65783aa7a92b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7c36e2a3-b28b-40cd-b5df-1b18024db1db_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_c56b48b3-ce2e-4260-b8be-16456033ab13_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government debt securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_20c44cc5-3550-482f-96e8-46cf02cb98a9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e9937426-8724-4f1d-824e-180dae22f46f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_806b8384-2299-4be3-8217-b7271f4af728_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_93087d05-4bd8-4823-aae0-6327f92a2020_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_68ee7010-ae56-4d79-a098-7ab58da769ec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock&#160;Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_948d24e4-08ac-448e-8e29-698b1d134770_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_df5a14d7-fd0d-439b-a2ef-be71d01daba8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_6b287036-8769-43fc-9f49-dbd77787a52e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_a446e17c-fad0-4bf0-85dc-350b0eb54ff0_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:to="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_21ca66f3-c169-40ec-9793-2f496d9b6fb9_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_f92ab0c2-75be-4553-9af0-c22261677e29_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_9cda0283-5994-4fa1-a75d-4fb896c510d0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_2ccb495d-9fb1-4c13-81c5-363cca3dd20a_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_38269699-9097-4103-a2a2-ff900b479507_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e348c78d-646e-4ac5-b2de-022df53eb85e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units, granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2a2dc898-e8d5-4353-b5ae-0c0f319324cb_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_accd9b8d-196f-449c-baa7-4602873ca8d9_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_e0d7a33d-55df-455f-9e4e-2eb4289bf5ae_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 4)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_ed9f92ca-0118-4195-b963-848ca0651ced_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties for licensed technologies</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_7b83efb0-f7f2-4f13-9a88-302d0d34f322_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d21eeaef-4026-4588-9c55-2e73206ec436_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_878e9fb9-5617-41e8-9942-cc1e1ffa5059_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Incentive Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_7f1de6bb-cdfe-4683-86d7-9b7407878b59_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Geographic Location</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_31805455-4a30-4f63-922f-8dd901c205a4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e84e20f5-fd83-4bf1-8449-3cd150b1ceee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of the Company's Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_8f3e9165-c899-4709-a867-e352ba1de5ef_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_d5fe13e2-6d58-4c1d-9d47-76a33c530ea9_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_c26f8693-3fe4-456d-bc78-b6e1f2a0885b_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_9640f4c2-4490-49e3-bba5-a927c05794f8_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f53a7537-3d6e-4038-94d5-f3743e67641e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds_4f687214-d0e6-4448-9685-a6921c1abbbb_terseLabel_en-US" xlink:label="lab_txg_DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total available-for-sale securities, fair value</link:label>
    <link:label id="lab_txg_DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds_label_en-US" xlink:label="lab_txg_DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available For Sale, Including Money Market Funds</link:label>
    <link:label id="lab_txg_DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds_documentation_en-US" xlink:label="lab_txg_DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available For Sale, Including Money Market Funds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds" xlink:href="txg-20250331.xsd#txg_DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds" xlink:to="lab_txg_DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_ff5387dd-326e-45b4-a4f4-b9d42c96b1b8_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_cb5d7863-335c-4a49-b8ae-0c7b351d1a0a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_68c1eded-bc9e-40bf-a01d-00ff1f51893a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Revenue from External Customer, Product and Service [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_f08297d8-327c-4825-b8ba-4d5585b25dee_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_cf2705e8-4cd5-4920-96b3-cfe50dc60589_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_05e267e2-4b1b-4965-bc74-278e64e04c82_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2b8edfa5-2cf7-4ffa-95a1-93fbcf1ba505_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rates changes on cash, cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_bc910c9c-e5f4-49ed-a6fe-31cbeed979ab_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025 (excluding the three months ended March 31, 2025)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1121a8cb-13aa-4d64-8785-62fa806e8af3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_d650f687-47c1-414f-a8ca-4964a16bf69d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_a6d21001-e4a7-41d2-b732-fb8a5a68989b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fa8fa242-3965-4e6b-8798-5c9182184404_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d4f73ef8-c54b-4977-9100-9a55f3d330cf_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d2c1734b-fbcc-4773-b736-ee27a38c51a3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_939a3c4d-b75d-4267-967d-6f90a8e1122e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_CompoundAnnualGrowthRateMember_26db8877-b8e0-4553-8a8e-683734c086eb_terseLabel_en-US" xlink:label="lab_txg_CompoundAnnualGrowthRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CAGR</link:label>
    <link:label id="lab_txg_CompoundAnnualGrowthRateMember_label_en-US" xlink:label="lab_txg_CompoundAnnualGrowthRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compound Annual Growth Rate [Member]</link:label>
    <link:label id="lab_txg_CompoundAnnualGrowthRateMember_documentation_en-US" xlink:label="lab_txg_CompoundAnnualGrowthRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Compound Annual Growth Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_CompoundAnnualGrowthRateMember" xlink:href="txg-20250331.xsd#txg_CompoundAnnualGrowthRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_CompoundAnnualGrowthRateMember" xlink:to="lab_txg_CompoundAnnualGrowthRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_9dc5caed-0389-4c45-b6e2-934eafd163fe_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for royalties</link:label>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_label_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties" xlink:to="lab_us-gaap_PaymentsForRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage_28524dc6-45da-44ed-a559-748f2bf75466_terseLabel_en-US" xlink:label="lab_txg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PSA target amount of shares percentage</link:label>
    <link:label id="lab_txg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage_label_en-US" xlink:label="lab_txg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Multiplier, Percentage</link:label>
    <link:label id="lab_txg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage_documentation_en-US" xlink:label="lab_txg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Multiplier, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage" xlink:href="txg-20250331.xsd#txg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage" xlink:to="lab_txg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_590885e2-f1df-4281-b499-0b4358b06fba_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_ScheduleOfAccruedCompensationandRelatedBenefitsTableTextBlock_ff7f993d-569e-4113-8a0c-c134a834b6cb_terseLabel_en-US" xlink:label="lab_txg_ScheduleOfAccruedCompensationandRelatedBenefitsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Compensation and Related Benefits</link:label>
    <link:label id="lab_txg_ScheduleOfAccruedCompensationandRelatedBenefitsTableTextBlock_label_en-US" xlink:label="lab_txg_ScheduleOfAccruedCompensationandRelatedBenefitsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued CompensationAnd Related Benefits [Table Text Block]</link:label>
    <link:label id="lab_txg_ScheduleOfAccruedCompensationandRelatedBenefitsTableTextBlock_documentation_en-US" xlink:label="lab_txg_ScheduleOfAccruedCompensationandRelatedBenefitsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of accrued compensation and related benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_ScheduleOfAccruedCompensationandRelatedBenefitsTableTextBlock" xlink:href="txg-20250331.xsd#txg_ScheduleOfAccruedCompensationandRelatedBenefitsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_ScheduleOfAccruedCompensationandRelatedBenefitsTableTextBlock" xlink:to="lab_txg_ScheduleOfAccruedCompensationandRelatedBenefitsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_116b822f-4082-4c0d-b462-a6c2f5bcea77_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_af060f68-b60a-4212-abca-886d2fd42e5f_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of products and services revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_d1d44a45-7dd8-4f0e-981a-54a342a77ee7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_88a8313e-cc1f-4e69-89ca-9af6b332fc4f_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_SergeSaxonovCommonStockPlusMember_label_en-US" xlink:label="lab_txg_SergeSaxonovCommonStockPlusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Serge Saxonov, Common Stock Plus [Member]</link:label>
    <link:label id="lab_txg_SergeSaxonovCommonStockPlusMember_documentation_en-US" xlink:label="lab_txg_SergeSaxonovCommonStockPlusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Serge Saxonov, Common Stock Plus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_SergeSaxonovCommonStockPlusMember" xlink:href="txg-20250331.xsd#txg_SergeSaxonovCommonStockPlusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_SergeSaxonovCommonStockPlusMember" xlink:to="lab_txg_SergeSaxonovCommonStockPlusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_d6e20997-cc06-48df-a265-99d0cc6c53e2_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_fb29fb7f-1772-416c-975e-0c03ccb7e669_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_eb859de5-ac6c-41d0-bcbe-187a2991a69b_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_7b98e3fa-00e5-4658-a038-e8e02a5ace23_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_19271084-1203-47de-9dcd-f23fc44769f6_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_MarketBasedPerformanceAwardsMember_cc5f6227-109c-426d-ac7a-5861607a242d_terseLabel_en-US" xlink:label="lab_txg_MarketBasedPerformanceAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market-based Performance Awards</link:label>
    <link:label id="lab_txg_MarketBasedPerformanceAwardsMember_label_en-US" xlink:label="lab_txg_MarketBasedPerformanceAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market-based Performance Awards [Member]</link:label>
    <link:label id="lab_txg_MarketBasedPerformanceAwardsMember_documentation_en-US" xlink:label="lab_txg_MarketBasedPerformanceAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market-based Performance Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_MarketBasedPerformanceAwardsMember" xlink:href="txg-20250331.xsd#txg_MarketBasedPerformanceAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_MarketBasedPerformanceAwardsMember" xlink:to="lab_txg_MarketBasedPerformanceAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_eed9f2f3-f091-4836-a24c-618db74ed664_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares of common stock used in computing net loss per share, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_VizgenInc.Member_9edec5ad-01f0-426f-8b38-a92d0fcd5b9f_terseLabel_en-US" xlink:label="lab_txg_VizgenInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vizgen, Inc.</link:label>
    <link:label id="lab_txg_VizgenInc.Member_label_en-US" xlink:label="lab_txg_VizgenInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vizgen, Inc. [Member]</link:label>
    <link:label id="lab_txg_VizgenInc.Member_documentation_en-US" xlink:label="lab_txg_VizgenInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vizgen, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_VizgenInc.Member" xlink:href="txg-20250331.xsd#txg_VizgenInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_VizgenInc.Member" xlink:to="lab_txg_VizgenInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesLineItems_faa0ce9c-7c32-49c3-a841-21cddcbeba65_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems" xlink:to="lab_us-gaap_MarketableSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_807fdf32-87d9-46c0-8bdd-968dd6c4ef19_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_1e2c4377-7eaf-4568-9cf6-fb47fb80144b_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_6db1cee9-dd91-4b59-b233-27b1c64ae6fa_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_c51c32fc-354f-4088-a115-049f7f294d96_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities, available-for-sale, realized gain (loss)</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_txg_ProductAndServiceRevenueMember_f653754e-d96d-448d-a296-8e1d44e27d07_terseLabel_en-US" xlink:label="lab_txg_ProductAndServiceRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and services revenue</link:label>
    <link:label id="lab_txg_ProductAndServiceRevenueMember_label_en-US" xlink:label="lab_txg_ProductAndServiceRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product And Service Revenue [Member]</link:label>
    <link:label id="lab_txg_ProductAndServiceRevenueMember_documentation_en-US" xlink:label="lab_txg_ProductAndServiceRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product And Service Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_txg_ProductAndServiceRevenueMember" xlink:href="txg-20250331.xsd#txg_ProductAndServiceRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_txg_ProductAndServiceRevenueMember" xlink:to="lab_txg_ProductAndServiceRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_54d67477-8fac-4662-9e7b-052684ebf38b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_066d8341-6354-41c9-ab38-47a7f66df4ec_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional services</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_edb720ac-d9cc-449a-ba7c-4322dcb9190f_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8e256c0d-3469-4a4b-8401-dc5e468a58d0_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cancelled and forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_f1951c1f-9148-41c5-9f10-5e08be46faf3_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_4350a0da-e03d-42d5-8637-d742a374955c_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Transaction price allocated to remaining performance obligations</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_9354a492-7f24-43ff-a709-6ed745ad0a4f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>txg-20250331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:3ecddcae-0640-4c17-b64e-2ecf664c9fd0,g:adbdc3ab-11fd-421c-ac99-3782b4f382a6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.10xgenomics.com/role/CoverPage" xlink:type="simple" xlink:href="txg-20250331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_794f6f92-2ea0-42a5-bbd6-b7a951995ddd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_a673277f-644d-41b9-b777-9e98f6e93ab7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_794f6f92-2ea0-42a5-bbd6-b7a951995ddd" xlink:to="loc_dei_DocumentInformationTable_a673277f-644d-41b9-b777-9e98f6e93ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_820b8e19-3187-45d1-8f40-353bfff33cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_a673277f-644d-41b9-b777-9e98f6e93ab7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_820b8e19-3187-45d1-8f40-353bfff33cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3692356b-db05-41f5-9ab2-09e1ee0e8d13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_820b8e19-3187-45d1-8f40-353bfff33cb0" xlink:to="loc_us-gaap_ClassOfStockDomain_3692356b-db05-41f5-9ab2-09e1ee0e8d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_740d6f32-7c56-46f1-88a3-7095dfd8e9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3692356b-db05-41f5-9ab2-09e1ee0e8d13" xlink:to="loc_us-gaap_CommonClassAMember_740d6f32-7c56-46f1-88a3-7095dfd8e9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_b3113005-602a-4d41-8e82-5b80ff065567" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3692356b-db05-41f5-9ab2-09e1ee0e8d13" xlink:to="loc_us-gaap_CommonClassBMember_b3113005-602a-4d41-8e82-5b80ff065567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_a673277f-644d-41b9-b777-9e98f6e93ab7" xlink:to="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f4e0576d-ed56-4aaf-9268-7e6f92e6ef70" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_DocumentType_f4e0576d-ed56-4aaf-9268-7e6f92e6ef70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_8fbb6123-dac3-4364-82e5-8522140d5619" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_DocumentQuarterlyReport_8fbb6123-dac3-4364-82e5-8522140d5619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c3dc8421-9d6f-4389-9b36-a4312bc2060e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_DocumentPeriodEndDate_c3dc8421-9d6f-4389-9b36-a4312bc2060e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_3c96c154-d48d-42ca-879b-a7d951c89523" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_DocumentTransitionReport_3c96c154-d48d-42ca-879b-a7d951c89523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_18a46127-2b5e-4155-8696-f193471a25e3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntityFileNumber_18a46127-2b5e-4155-8696-f193471a25e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_be52ecff-e6c5-4cb1-a3c0-e77146803576" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntityRegistrantName_be52ecff-e6c5-4cb1-a3c0-e77146803576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_802d964c-c134-4969-b847-e551c36180e0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntityIncorporationStateCountryCode_802d964c-c134-4969-b847-e551c36180e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_52e3bbce-90c2-451c-9619-0198453b8db5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntityTaxIdentificationNumber_52e3bbce-90c2-451c-9619-0198453b8db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ac64d23f-470d-41eb-b3bb-2896b06c6d57" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntityAddressAddressLine1_ac64d23f-470d-41eb-b3bb-2896b06c6d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_2b15979f-ed7a-4601-a1e9-fb5cdf9aaf41" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntityAddressCityOrTown_2b15979f-ed7a-4601-a1e9-fb5cdf9aaf41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_37f460e9-eadd-4fb9-a23e-0ffcb6273145" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntityAddressStateOrProvince_37f460e9-eadd-4fb9-a23e-0ffcb6273145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_efd6de8b-1e6a-4650-8095-2d50d8a1083d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntityAddressPostalZipCode_efd6de8b-1e6a-4650-8095-2d50d8a1083d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3e0a449b-da6c-4712-bade-80d3ebccc3bf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_CityAreaCode_3e0a449b-da6c-4712-bade-80d3ebccc3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_053b2dc1-fa2e-4d31-bb79-cf243af25e19" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_LocalPhoneNumber_053b2dc1-fa2e-4d31-bb79-cf243af25e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_326ca273-fd81-4f48-b57f-70ed44364186" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_Security12bTitle_326ca273-fd81-4f48-b57f-70ed44364186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_cb9892b3-4889-4323-9613-63751bda5965" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_TradingSymbol_cb9892b3-4889-4323-9613-63751bda5965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_0527cb12-31c2-4c6b-9273-28ec2bcee2a5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_SecurityExchangeName_0527cb12-31c2-4c6b-9273-28ec2bcee2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_6afb2984-9bac-4f74-a11f-bbb390e1d6fe" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntityCurrentReportingStatus_6afb2984-9bac-4f74-a11f-bbb390e1d6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_6da11424-59ab-492e-ba13-7f8831c59ca7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntityInteractiveDataCurrent_6da11424-59ab-492e-ba13-7f8831c59ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_2b063e37-1a7f-45ac-8217-02e08b7ee139" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntityFilerCategory_2b063e37-1a7f-45ac-8217-02e08b7ee139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_c28eb434-7965-4d96-9872-045f27e70943" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntitySmallBusiness_c28eb434-7965-4d96-9872-045f27e70943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_0df78ae8-774d-448e-b681-fb0a60fe365e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntityEmergingGrowthCompany_0df78ae8-774d-448e-b681-fb0a60fe365e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d26a3869-6fef-41b7-9135-54f0502267ce" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntityShellCompany_d26a3869-6fef-41b7-9135-54f0502267ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_a844e496-0288-40c4-89d0-c6db27420809" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_a844e496-0288-40c4-89d0-c6db27420809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3d0af52b-acc1-4e1e-8edb-ea2e927ac770" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_AmendmentFlag_3d0af52b-acc1-4e1e-8edb-ea2e927ac770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_55640e2d-5d02-4d6a-b76c-6fc5a955371b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_DocumentFiscalYearFocus_55640e2d-5d02-4d6a-b76c-6fc5a955371b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_bc6867a7-f11e-43af-95db-5926bf6b0c61" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_DocumentFiscalPeriodFocus_bc6867a7-f11e-43af-95db-5926bf6b0c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_ce7bd0ac-58d1-4339-a140-383adb95defe" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_CurrentFiscalYearEndDate_ce7bd0ac-58d1-4339-a140-383adb95defe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_318e58f5-4c38-4098-8b21-69779a9f7029" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cc4013d6-a644-4f45-8e1f-ada494330beb" xlink:to="loc_dei_EntityCentralIndexKey_318e58f5-4c38-4098-8b21-69779a9f7029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="txg-20250331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_80f63b3d-3612-48e3-b25c-951f79d62d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_69822737-f72e-4b1e-9ffa-04a5af365a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_80f63b3d-3612-48e3-b25c-951f79d62d8d" xlink:to="loc_us-gaap_AssetsAbstract_69822737-f72e-4b1e-9ffa-04a5af365a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_7a205833-26c5-439b-b551-7ccd76793f71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_69822737-f72e-4b1e-9ffa-04a5af365a0b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_7a205833-26c5-439b-b551-7ccd76793f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_11b23614-899f-4ced-93c3-c3ea4f400676" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7a205833-26c5-439b-b551-7ccd76793f71" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_11b23614-899f-4ced-93c3-c3ea4f400676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_655f5234-e6a8-4c6f-9b50-9e280063db1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7a205833-26c5-439b-b551-7ccd76793f71" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_655f5234-e6a8-4c6f-9b50-9e280063db1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a6b204e2-5d9f-482b-b488-a543845967be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7a205833-26c5-439b-b551-7ccd76793f71" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a6b204e2-5d9f-482b-b488-a543845967be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_8cdb8cce-c50f-43ab-97b6-7d9d06dbd9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7a205833-26c5-439b-b551-7ccd76793f71" xlink:to="loc_us-gaap_InventoryNet_8cdb8cce-c50f-43ab-97b6-7d9d06dbd9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d839acc8-64c6-4404-ae9f-047dfb334c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7a205833-26c5-439b-b551-7ccd76793f71" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d839acc8-64c6-4404-ae9f-047dfb334c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c1d6187c-83dc-41c0-befc-469fbb21cff7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7a205833-26c5-439b-b551-7ccd76793f71" xlink:to="loc_us-gaap_AssetsCurrent_c1d6187c-83dc-41c0-befc-469fbb21cff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_814b6284-7233-4063-9401-3b3cbf2dd0c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_69822737-f72e-4b1e-9ffa-04a5af365a0b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_814b6284-7233-4063-9401-3b3cbf2dd0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_fa04c093-0960-4f09-87eb-7f5b084ecd49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_69822737-f72e-4b1e-9ffa-04a5af365a0b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_fa04c093-0960-4f09-87eb-7f5b084ecd49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7bf25869-6a0a-4655-86bc-b06c2bc1c92b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_69822737-f72e-4b1e-9ffa-04a5af365a0b" xlink:to="loc_us-gaap_Goodwill_7bf25869-6a0a-4655-86bc-b06c2bc1c92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5f3bd57b-578f-4a2c-b360-ff493f947d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_69822737-f72e-4b1e-9ffa-04a5af365a0b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5f3bd57b-578f-4a2c-b360-ff493f947d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_24da0e5b-3078-4974-981d-7fbaa8310150" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_69822737-f72e-4b1e-9ffa-04a5af365a0b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_24da0e5b-3078-4974-981d-7fbaa8310150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a0f121f6-3df9-4e77-a652-63589f541ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_69822737-f72e-4b1e-9ffa-04a5af365a0b" xlink:to="loc_us-gaap_Assets_a0f121f6-3df9-4e77-a652-63589f541ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8b22650-60d6-4c63-bd12-b1fb2c0ac8af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_80f63b3d-3612-48e3-b25c-951f79d62d8d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8b22650-60d6-4c63-bd12-b1fb2c0ac8af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_c527d803-5193-43e5-9563-2ed13cf8a5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8b22650-60d6-4c63-bd12-b1fb2c0ac8af" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_c527d803-5193-43e5-9563-2ed13cf8a5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_64a7ea32-abe8-4a54-a485-11df9fdb29c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c527d803-5193-43e5-9563-2ed13cf8a5bb" xlink:to="loc_us-gaap_AccountsPayableCurrent_64a7ea32-abe8-4a54-a485-11df9fdb29c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5407dbfd-efc8-4450-93a0-822721b1194e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c527d803-5193-43e5-9563-2ed13cf8a5bb" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5407dbfd-efc8-4450-93a0-822721b1194e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_AccruedExpensesAndOtherLiabilitiesCurrent_1ffb4f74-37f2-483b-bfa7-ac9c877fc244" xlink:href="txg-20250331.xsd#txg_AccruedExpensesAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c527d803-5193-43e5-9563-2ed13cf8a5bb" xlink:to="loc_txg_AccruedExpensesAndOtherLiabilitiesCurrent_1ffb4f74-37f2-483b-bfa7-ac9c877fc244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_fcda312b-d795-4860-96a9-0e3daeecf280" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c527d803-5193-43e5-9563-2ed13cf8a5bb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_fcda312b-d795-4860-96a9-0e3daeecf280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_eff6f2be-c387-45d0-bbeb-e46bf23892ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c527d803-5193-43e5-9563-2ed13cf8a5bb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_eff6f2be-c387-45d0-bbeb-e46bf23892ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3e12aa71-344e-4771-a1b0-31bc5c9e96c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c527d803-5193-43e5-9563-2ed13cf8a5bb" xlink:to="loc_us-gaap_LiabilitiesCurrent_3e12aa71-344e-4771-a1b0-31bc5c9e96c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_aa4d6425-2dc6-43d5-8ac7-bfce7c46e1af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8b22650-60d6-4c63-bd12-b1fb2c0ac8af" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_aa4d6425-2dc6-43d5-8ac7-bfce7c46e1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_974db026-12e2-438d-bab0-2b88886214ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8b22650-60d6-4c63-bd12-b1fb2c0ac8af" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_974db026-12e2-438d-bab0-2b88886214ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_4334d8a0-c4c2-4220-b994-1131881c6b23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8b22650-60d6-4c63-bd12-b1fb2c0ac8af" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_4334d8a0-c4c2-4220-b994-1131881c6b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_cded9e84-ff28-4f1e-a456-350158901626" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8b22650-60d6-4c63-bd12-b1fb2c0ac8af" xlink:to="loc_us-gaap_Liabilities_cded9e84-ff28-4f1e-a456-350158901626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_0e3d616e-1d87-46d0-9825-07884c8df6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8b22650-60d6-4c63-bd12-b1fb2c0ac8af" xlink:to="loc_us-gaap_CommitmentsAndContingencies_0e3d616e-1d87-46d0-9825-07884c8df6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_8a958e51-2cbb-4dd8-9d3d-be94df5e1822" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8b22650-60d6-4c63-bd12-b1fb2c0ac8af" xlink:to="loc_us-gaap_StockholdersEquityAbstract_8a958e51-2cbb-4dd8-9d3d-be94df5e1822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_bcf3d0af-ac7c-49d7-82b3-56c11a9a1283" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8a958e51-2cbb-4dd8-9d3d-be94df5e1822" xlink:to="loc_us-gaap_PreferredStockValue_bcf3d0af-ac7c-49d7-82b3-56c11a9a1283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_75297e67-948c-4c93-9671-1b7ef09225e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8a958e51-2cbb-4dd8-9d3d-be94df5e1822" xlink:to="loc_us-gaap_CommonStockValue_75297e67-948c-4c93-9671-1b7ef09225e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_741e51e6-dec4-4505-a71d-614afbe90e96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8a958e51-2cbb-4dd8-9d3d-be94df5e1822" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_741e51e6-dec4-4505-a71d-614afbe90e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5f1d735a-82f8-4650-9093-a989972a8101" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8a958e51-2cbb-4dd8-9d3d-be94df5e1822" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5f1d735a-82f8-4650-9093-a989972a8101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_93b33ce9-8050-4022-b33a-e3dde65127a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8a958e51-2cbb-4dd8-9d3d-be94df5e1822" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_93b33ce9-8050-4022-b33a-e3dde65127a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_683650f3-36c4-4e28-b28a-fefe17bca930" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8a958e51-2cbb-4dd8-9d3d-be94df5e1822" xlink:to="loc_us-gaap_StockholdersEquity_683650f3-36c4-4e28-b28a-fefe17bca930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c6965a2b-147b-43f0-940e-8bb43d499d00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8b22650-60d6-4c63-bd12-b1fb2c0ac8af" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_c6965a2b-147b-43f0-940e-8bb43d499d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="txg-20250331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_c2c775cd-b4f1-4dc5-908c-d5fe6fc16c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d1201681-c83f-4d87-8ac4-42a16958b0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c2c775cd-b4f1-4dc5-908c-d5fe6fc16c5b" xlink:to="loc_us-gaap_StatementTable_d1201681-c83f-4d87-8ac4-42a16958b0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2d13e1aa-6052-4b6a-a66b-c3f53984816c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d1201681-c83f-4d87-8ac4-42a16958b0a8" xlink:to="loc_srt_ProductOrServiceAxis_2d13e1aa-6052-4b6a-a66b-c3f53984816c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1c55e22e-8f75-4b01-ba16-53ebb7848d7f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2d13e1aa-6052-4b6a-a66b-c3f53984816c" xlink:to="loc_srt_ProductsAndServicesDomain_1c55e22e-8f75-4b01-ba16-53ebb7848d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_ProductAndServiceRevenueMember_74c9a3d8-e60f-4468-b7bd-26b7d9967655" xlink:href="txg-20250331.xsd#txg_ProductAndServiceRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1c55e22e-8f75-4b01-ba16-53ebb7848d7f" xlink:to="loc_txg_ProductAndServiceRevenueMember_74c9a3d8-e60f-4468-b7bd-26b7d9967655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_LicensingAndRoyaltyRevenueMember_3d397950-41c0-410f-8bf6-c0e2ee829092" xlink:href="txg-20250331.xsd#txg_LicensingAndRoyaltyRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1c55e22e-8f75-4b01-ba16-53ebb7848d7f" xlink:to="loc_txg_LicensingAndRoyaltyRevenueMember_3d397950-41c0-410f-8bf6-c0e2ee829092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6046368a-267e-4499-97a0-f75962b7d135" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d1201681-c83f-4d87-8ac4-42a16958b0a8" xlink:to="loc_us-gaap_StatementLineItems_6046368a-267e-4499-97a0-f75962b7d135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9cad0ac6-78b3-4509-8db0-4408cdb8933e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6046368a-267e-4499-97a0-f75962b7d135" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9cad0ac6-78b3-4509-8db0-4408cdb8933e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_c493570e-e63e-4c30-9f37-e877c7e6a9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6046368a-267e-4499-97a0-f75962b7d135" xlink:to="loc_us-gaap_CostOfRevenue_c493570e-e63e-4c30-9f37-e877c7e6a9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_e0dc7674-2aae-4c40-a607-7ba00580daa6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6046368a-267e-4499-97a0-f75962b7d135" xlink:to="loc_us-gaap_GrossProfit_e0dc7674-2aae-4c40-a607-7ba00580daa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_8d7240fd-b922-4b08-8d85-da0e70540dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6046368a-267e-4499-97a0-f75962b7d135" xlink:to="loc_us-gaap_OperatingExpensesAbstract_8d7240fd-b922-4b08-8d85-da0e70540dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_e009468d-9ac8-43f2-8256-0ca529b72300" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8d7240fd-b922-4b08-8d85-da0e70540dbe" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_e009468d-9ac8-43f2-8256-0ca529b72300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9ca0d0ee-cb2d-4315-b8eb-3c039862cfdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8d7240fd-b922-4b08-8d85-da0e70540dbe" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9ca0d0ee-cb2d-4315-b8eb-3c039862cfdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementGain_57d9969f-cc36-40b1-aa62-ba62ab5d6612" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementGain"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8d7240fd-b922-4b08-8d85-da0e70540dbe" xlink:to="loc_us-gaap_LitigationSettlementGain_57d9969f-cc36-40b1-aa62-ba62ab5d6612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_98da8389-5817-4d54-8807-3b73f1ddaf41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8d7240fd-b922-4b08-8d85-da0e70540dbe" xlink:to="loc_us-gaap_OperatingExpenses_98da8389-5817-4d54-8807-3b73f1ddaf41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_12896be9-e320-4a1c-b0ca-7b6c1dc5f991" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6046368a-267e-4499-97a0-f75962b7d135" xlink:to="loc_us-gaap_OperatingIncomeLoss_12896be9-e320-4a1c-b0ca-7b6c1dc5f991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3e98fcd-1917-44d7-8cfb-c97bd9123c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6046368a-267e-4499-97a0-f75962b7d135" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3e98fcd-1917-44d7-8cfb-c97bd9123c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_d8bd1831-c823-4b43-a5d0-eab81e4bc9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3e98fcd-1917-44d7-8cfb-c97bd9123c3f" xlink:to="loc_us-gaap_InvestmentIncomeInterest_d8bd1831-c823-4b43-a5d0-eab81e4bc9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_75869a69-6326-4f51-a4b6-aca2f14ac1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3e98fcd-1917-44d7-8cfb-c97bd9123c3f" xlink:to="loc_us-gaap_InterestExpenseNonoperating_75869a69-6326-4f51-a4b6-aca2f14ac1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f4690cde-ceeb-4b45-a009-020f24079b31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3e98fcd-1917-44d7-8cfb-c97bd9123c3f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f4690cde-ceeb-4b45-a009-020f24079b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_b2c5833d-543f-4a4c-bd62-1bd9d1271e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3e98fcd-1917-44d7-8cfb-c97bd9123c3f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_b2c5833d-543f-4a4c-bd62-1bd9d1271e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d237e111-9a21-4e8a-8b1c-aaab5b653959" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6046368a-267e-4499-97a0-f75962b7d135" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d237e111-9a21-4e8a-8b1c-aaab5b653959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bb65064c-a2bd-48db-baf8-a31478fd9051" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6046368a-267e-4499-97a0-f75962b7d135" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_bb65064c-a2bd-48db-baf8-a31478fd9051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_79d8d53c-ba8e-49b9-923d-e6fc50b2533d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6046368a-267e-4499-97a0-f75962b7d135" xlink:to="loc_us-gaap_NetIncomeLoss_79d8d53c-ba8e-49b9-923d-e6fc50b2533d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e9cf37a6-9684-472c-bf7d-32e369e2446f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6046368a-267e-4499-97a0-f75962b7d135" xlink:to="loc_us-gaap_EarningsPerShareBasic_e9cf37a6-9684-472c-bf7d-32e369e2446f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_326f50f8-c847-4e48-9c64-722b9a892f91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6046368a-267e-4499-97a0-f75962b7d135" xlink:to="loc_us-gaap_EarningsPerShareDiluted_326f50f8-c847-4e48-9c64-722b9a892f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b93149c4-5af2-4133-ab25-0f9e87c50af2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6046368a-267e-4499-97a0-f75962b7d135" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b93149c4-5af2-4133-ab25-0f9e87c50af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_61042e48-9470-4d29-9d7d-0169e2524298" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6046368a-267e-4499-97a0-f75962b7d135" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_61042e48-9470-4d29-9d7d-0169e2524298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="txg-20250331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2d2a6e85-649d-4b32-9624-5b00eb457ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7fd5cb63-4e72-407a-935b-122ebef8b743" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2d2a6e85-649d-4b32-9624-5b00eb457ec8" xlink:to="loc_us-gaap_NetIncomeLoss_7fd5cb63-4e72-407a-935b-122ebef8b743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_33f24527-c692-40a9-be01-6955c1b7fbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2d2a6e85-649d-4b32-9624-5b00eb457ec8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_33f24527-c692-40a9-be01-6955c1b7fbbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a6a06256-c100-4635-90b9-341c7d402ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_33f24527-c692-40a9-be01-6955c1b7fbbe" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a6a06256-c100-4635-90b9-341c7d402ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_a7844c4d-7f4e-49f1-83d2-ca601245524d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_33f24527-c692-40a9-be01-6955c1b7fbbe" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_a7844c4d-7f4e-49f1-83d2-ca601245524d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e3a1eac7-8948-4974-b0c8-0b9ee16c58be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_33f24527-c692-40a9-be01-6955c1b7fbbe" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e3a1eac7-8948-4974-b0c8-0b9ee16c58be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_128a46fb-e356-43b8-83ad-061536a0ed9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2d2a6e85-649d-4b32-9624-5b00eb457ec8" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_128a46fb-e356-43b8-83ad-061536a0ed9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="txg-20250331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_77eb4ba0-8de1-482e-9f9f-e86cf2aa89be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8006f53e-2990-4dad-b2ea-7d92185bc7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_77eb4ba0-8de1-482e-9f9f-e86cf2aa89be" xlink:to="loc_us-gaap_StatementTable_8006f53e-2990-4dad-b2ea-7d92185bc7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_68efc688-6d0e-4b89-aee6-ec2eff6f2cad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8006f53e-2990-4dad-b2ea-7d92185bc7fc" xlink:to="loc_us-gaap_StatementClassOfStockAxis_68efc688-6d0e-4b89-aee6-ec2eff6f2cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f7063c5c-6688-404b-9eef-bdbe187923db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_68efc688-6d0e-4b89-aee6-ec2eff6f2cad" xlink:to="loc_us-gaap_ClassOfStockDomain_f7063c5c-6688-404b-9eef-bdbe187923db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_e717e405-c9aa-4dff-b2a8-83f290800c35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f7063c5c-6688-404b-9eef-bdbe187923db" xlink:to="loc_us-gaap_CommonClassAMember_e717e405-c9aa-4dff-b2a8-83f290800c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6403623d-9032-4677-9dd3-f3e24bd02f95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8006f53e-2990-4dad-b2ea-7d92185bc7fc" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6403623d-9032-4677-9dd3-f3e24bd02f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_57f9dd2a-14e8-4ede-a391-dde323eeee2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6403623d-9032-4677-9dd3-f3e24bd02f95" xlink:to="loc_us-gaap_EquityComponentDomain_57f9dd2a-14e8-4ede-a391-dde323eeee2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_638252b4-1d17-4103-888a-16986bee17bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_57f9dd2a-14e8-4ede-a391-dde323eeee2c" xlink:to="loc_us-gaap_CommonStockMember_638252b4-1d17-4103-888a-16986bee17bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_62967932-6fce-45fc-9523-49169161585a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_57f9dd2a-14e8-4ede-a391-dde323eeee2c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_62967932-6fce-45fc-9523-49169161585a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_709d582f-85e4-46bf-a123-479b56b32262" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_57f9dd2a-14e8-4ede-a391-dde323eeee2c" xlink:to="loc_us-gaap_RetainedEarningsMember_709d582f-85e4-46bf-a123-479b56b32262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_af3ff412-9e4a-4614-8fc1-b41d21d2be83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_57f9dd2a-14e8-4ede-a391-dde323eeee2c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_af3ff412-9e4a-4614-8fc1-b41d21d2be83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7c51f4f3-8243-4950-92cf-7fa7a5257587" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8006f53e-2990-4dad-b2ea-7d92185bc7fc" xlink:to="loc_us-gaap_StatementLineItems_7c51f4f3-8243-4950-92cf-7fa7a5257587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b75aa4cf-e916-4421-bf42-c6d30f208add" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7c51f4f3-8243-4950-92cf-7fa7a5257587" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b75aa4cf-e916-4421-bf42-c6d30f208add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e41dce6f-d795-48b7-8258-fbfd31e666c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b75aa4cf-e916-4421-bf42-c6d30f208add" xlink:to="loc_us-gaap_SharesOutstanding_e41dce6f-d795-48b7-8258-fbfd31e666c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cfe1b3ae-b64f-4cff-9a3f-aa019b1990e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b75aa4cf-e916-4421-bf42-c6d30f208add" xlink:to="loc_us-gaap_StockholdersEquity_cfe1b3ae-b64f-4cff-9a3f-aa019b1990e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_07960ac8-6ce5-49a3-a807-a24abc152581" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b75aa4cf-e916-4421-bf42-c6d30f208add" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_07960ac8-6ce5-49a3-a807-a24abc152581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_16d144f8-397b-4b03-8389-9c70ce6c784d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b75aa4cf-e916-4421-bf42-c6d30f208add" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_16d144f8-397b-4b03-8389-9c70ce6c784d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_82c06e98-e0c1-40c0-b8ed-2772eb74b351" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b75aa4cf-e916-4421-bf42-c6d30f208add" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_82c06e98-e0c1-40c0-b8ed-2772eb74b351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a12b5f55-77f0-427f-b3de-8d6cf1606c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b75aa4cf-e916-4421-bf42-c6d30f208add" xlink:to="loc_us-gaap_NetIncomeLoss_a12b5f55-77f0-427f-b3de-8d6cf1606c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b10ad319-1bc3-4c6b-9cb8-3dcf365ad141" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b75aa4cf-e916-4421-bf42-c6d30f208add" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b10ad319-1bc3-4c6b-9cb8-3dcf365ad141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_60468552-6c31-4a5f-bd26-e0b51cf1337f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b75aa4cf-e916-4421-bf42-c6d30f208add" xlink:to="loc_us-gaap_SharesOutstanding_60468552-6c31-4a5f-bd26-e0b51cf1337f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_09e129e8-4f2c-4b85-99ac-359f187327af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b75aa4cf-e916-4421-bf42-c6d30f208add" xlink:to="loc_us-gaap_StockholdersEquity_09e129e8-4f2c-4b85-99ac-359f187327af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="txg-20250331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_77828572-d5a0-4d69-9a26-1a97a1cc7d75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_70b87f5b-e650-455c-a3d8-c6aedb4a7eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_77828572-d5a0-4d69-9a26-1a97a1cc7d75" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_70b87f5b-e650-455c-a3d8-c6aedb4a7eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_84e3944d-d1c6-4eb0-a819-8ca16d5a47da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_70b87f5b-e650-455c-a3d8-c6aedb4a7eb0" xlink:to="loc_us-gaap_NetIncomeLoss_84e3944d-d1c6-4eb0-a819-8ca16d5a47da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9be75b79-985e-48cf-a555-fb0ab31b903d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_70b87f5b-e650-455c-a3d8-c6aedb4a7eb0" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9be75b79-985e-48cf-a555-fb0ab31b903d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5ec0973f-f58c-48eb-a0ed-2347940285a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9be75b79-985e-48cf-a555-fb0ab31b903d" xlink:to="loc_us-gaap_ShareBasedCompensation_5ec0973f-f58c-48eb-a0ed-2347940285a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ab0f2052-3d86-4616-8491-127545d0627d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9be75b79-985e-48cf-a555-fb0ab31b903d" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ab0f2052-3d86-4616-8491-127545d0627d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_50c57b43-ba36-4a1f-9a3b-7466ffcccbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9be75b79-985e-48cf-a555-fb0ab31b903d" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_50c57b43-ba36-4a1f-9a3b-7466ffcccbb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_0c765a11-2834-43fe-a057-a12dc505a878" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9be75b79-985e-48cf-a555-fb0ab31b903d" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_0c765a11-2834-43fe-a057-a12dc505a878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_d2849787-f843-4103-b268-bcb3e6da4f29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9be75b79-985e-48cf-a555-fb0ab31b903d" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_d2849787-f843-4103-b268-bcb3e6da4f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_594a5ea8-79d4-4f95-90ea-c48f3f7eb8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9be75b79-985e-48cf-a555-fb0ab31b903d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_594a5ea8-79d4-4f95-90ea-c48f3f7eb8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_bc8e2268-c00f-441a-b809-87345ca369c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_594a5ea8-79d4-4f95-90ea-c48f3f7eb8a0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_bc8e2268-c00f-441a-b809-87345ca369c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_46bb99de-4a5b-4e9a-a199-d36ce7e87626" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_594a5ea8-79d4-4f95-90ea-c48f3f7eb8a0" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_46bb99de-4a5b-4e9a-a199-d36ce7e87626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_44f74494-ec74-40aa-ac4b-f67987538d21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_594a5ea8-79d4-4f95-90ea-c48f3f7eb8a0" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_44f74494-ec74-40aa-ac4b-f67987538d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_af67ed22-7c15-42ff-b751-6eb58a634b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_594a5ea8-79d4-4f95-90ea-c48f3f7eb8a0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_af67ed22-7c15-42ff-b751-6eb58a634b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1b7ba8fc-cc7f-41e3-935b-0809a51b7c01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_594a5ea8-79d4-4f95-90ea-c48f3f7eb8a0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1b7ba8fc-cc7f-41e3-935b-0809a51b7c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_13ff12bf-cbee-4c01-a771-e5a54d70483b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_594a5ea8-79d4-4f95-90ea-c48f3f7eb8a0" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_13ff12bf-cbee-4c01-a771-e5a54d70483b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_3627b515-3df4-4c9d-8a9d-2a6d2fe4b26d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_594a5ea8-79d4-4f95-90ea-c48f3f7eb8a0" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_3627b515-3df4-4c9d-8a9d-2a6d2fe4b26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_87491be1-886c-4844-819e-76366f068b80" xlink:href="txg-20250331.xsd#txg_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_594a5ea8-79d4-4f95-90ea-c48f3f7eb8a0" xlink:to="loc_txg_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_87491be1-886c-4844-819e-76366f068b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_5a520b66-a841-4103-9ffe-a358f31cc90c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_594a5ea8-79d4-4f95-90ea-c48f3f7eb8a0" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_5a520b66-a841-4103-9ffe-a358f31cc90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_96d1f453-659e-40f6-beb2-612a0e624afe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_594a5ea8-79d4-4f95-90ea-c48f3f7eb8a0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_96d1f453-659e-40f6-beb2-612a0e624afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_96eccbd2-9c53-45fc-963e-99206bb946e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_70b87f5b-e650-455c-a3d8-c6aedb4a7eb0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_96eccbd2-9c53-45fc-963e-99206bb946e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0f16cc71-0b50-4d90-b894-2fef183fa561" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_77828572-d5a0-4d69-9a26-1a97a1cc7d75" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0f16cc71-0b50-4d90-b894-2fef183fa561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f93d6590-2985-47bb-b314-2c828da13198" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0f16cc71-0b50-4d90-b894-2fef183fa561" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f93d6590-2985-47bb-b314-2c828da13198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_434bd9ba-d03e-4eb1-8a3f-7170e67b1baa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0f16cc71-0b50-4d90-b894-2fef183fa561" xlink:to="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_434bd9ba-d03e-4eb1-8a3f-7170e67b1baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_0eff3a1c-8a11-452d-8e7e-286d781b1531" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0f16cc71-0b50-4d90-b894-2fef183fa561" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_0eff3a1c-8a11-452d-8e7e-286d781b1531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6bc93770-3207-43ec-a999-f2bbe89c655d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0f16cc71-0b50-4d90-b894-2fef183fa561" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6bc93770-3207-43ec-a999-f2bbe89c655d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d3741dfa-ca8c-4209-8d33-e1b0c16d521f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_77828572-d5a0-4d69-9a26-1a97a1cc7d75" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d3741dfa-ca8c-4209-8d33-e1b0c16d521f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_5fe15602-6aa3-4ef2-a5f9-bebc69064c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d3741dfa-ca8c-4209-8d33-e1b0c16d521f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_5fe15602-6aa3-4ef2-a5f9-bebc69064c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_50940e2a-b4b5-4407-8127-4d94edb71bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d3741dfa-ca8c-4209-8d33-e1b0c16d521f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_50940e2a-b4b5-4407-8127-4d94edb71bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d2d48e01-a9d6-4e98-a011-7cda709527a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_77828572-d5a0-4d69-9a26-1a97a1cc7d75" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d2d48e01-a9d6-4e98-a011-7cda709527a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_211af553-49c9-48df-8f8b-dfc0f6af706f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_77828572-d5a0-4d69-9a26-1a97a1cc7d75" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_211af553-49c9-48df-8f8b-dfc0f6af706f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_93b1fc69-000f-4611-b61d-5443a5f1e449" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_77828572-d5a0-4d69-9a26-1a97a1cc7d75" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_93b1fc69-000f-4611-b61d-5443a5f1e449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_feada85e-b1d8-436a-afac-d774680f6921" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_77828572-d5a0-4d69-9a26-1a97a1cc7d75" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_feada85e-b1d8-436a-afac-d774680f6921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_ac250626-389b-4f70-8495-563d3fb42f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_77828572-d5a0-4d69-9a26-1a97a1cc7d75" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_ac250626-389b-4f70-8495-563d3fb42f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_3dee488f-b065-49a3-b9a5-a854bef42dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ac250626-389b-4f70-8495-563d3fb42f4e" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_3dee488f-b065-49a3-b9a5-a854bef42dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_43f6923b-9c31-4912-91c2-b856e266a7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_77828572-d5a0-4d69-9a26-1a97a1cc7d75" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_43f6923b-9c31-4912-91c2-b856e266a7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_e2395a04-a14e-466c-98a5-2a017a995308" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_43f6923b-9c31-4912-91c2-b856e266a7fe" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_e2395a04-a14e-466c-98a5-2a017a995308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/DescriptionofBusinessandBasisofPresentation" xlink:type="simple" xlink:href="txg-20250331.xsd#DescriptionofBusinessandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/DescriptionofBusinessandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad693e53-5057-4fc3-ad86-8493b72fd539" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_04ee9d62-4713-419d-8604-742d72386332" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad693e53-5057-4fc3-ad86-8493b72fd539" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_04ee9d62-4713-419d-8604-742d72386332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="txg-20250331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1fc0d555-5a9e-4799-ae8c-aed276fbe494" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_38c592ac-17f3-433a-9080-cfc9722bd613" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1fc0d555-5a9e-4799-ae8c-aed276fbe494" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_38c592ac-17f3-433a-9080-cfc9722bd613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformation" xlink:type="simple" xlink:href="txg-20250331.xsd#OtherFinancialStatementInformation"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/OtherFinancialStatementInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7609f00f-3f7f-4a19-9c1c-1ff95126cbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_66b042e4-08e8-4fe7-ae52-e42d81d5e1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7609f00f-3f7f-4a19-9c1c-1ff95126cbb1" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_66b042e4-08e8-4fe7-ae52-e42d81d5e1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="txg-20250331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_60d3b949-7c07-4c30-8334-72fce4aabc66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_bcfb21b3-a43a-46cb-87ce-84cba3809916" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_60d3b949-7c07-4c30-8334-72fce4aabc66" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_bcfb21b3-a43a-46cb-87ce-84cba3809916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/CapitalStock" xlink:type="simple" xlink:href="txg-20250331.xsd#CapitalStock"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/CapitalStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2651fc95-4e29-4765-b711-044f336efe45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7b39e377-6ac8-4a3a-a7e9-6ed5edd766c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2651fc95-4e29-4765-b711-044f336efe45" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7b39e377-6ac8-4a3a-a7e9-6ed5edd766c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/EquityIncentivePlans" xlink:type="simple" xlink:href="txg-20250331.xsd#EquityIncentivePlans"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/EquityIncentivePlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_edebf354-4dc6-473a-807a-3828092447b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_fb06ee9d-e0f2-469c-a20c-be6ba186868c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_edebf354-4dc6-473a-807a-3828092447b1" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_fb06ee9d-e0f2-469c-a20c-be6ba186868c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/NetLossPerShare" xlink:type="simple" xlink:href="txg-20250331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_64a4c59d-06cb-47b0-93b8-c1ffd2da0f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_24abc46f-a61e-490d-9ed4-d15617926864" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_64a4c59d-06cb-47b0-93b8-c1ffd2da0f8a" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_24abc46f-a61e-490d-9ed4-d15617926864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/SubsequentEvent" xlink:type="simple" xlink:href="txg-20250331.xsd#SubsequentEvent"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/SubsequentEvent" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_9b149d5b-f7f9-422e-92c5-aa6615711b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_a14809a4-e641-4039-a1dd-b3c1becf9b17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_9b149d5b-f7f9-422e-92c5-aa6615711b3b" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_a14809a4-e641-4039-a1dd-b3c1becf9b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="txg-20250331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_aeecb166-042f-49a7-af7a-7328d96bd040" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a270e42e-5f82-4aff-890d-7e6ce0293dee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aeecb166-042f-49a7-af7a-7328d96bd040" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a270e42e-5f82-4aff-890d-7e6ce0293dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_93bb7503-68ed-4b5c-88eb-bfdc05dfd757" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aeecb166-042f-49a7-af7a-7328d96bd040" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_93bb7503-68ed-4b5c-88eb-bfdc05dfd757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_60dcf206-1419-42e7-9ff0-66963018788f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aeecb166-042f-49a7-af7a-7328d96bd040" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_60dcf206-1419-42e7-9ff0-66963018788f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_61e4c8da-4924-4b8b-92fb-8bc082ac9402" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aeecb166-042f-49a7-af7a-7328d96bd040" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_61e4c8da-4924-4b8b-92fb-8bc082ac9402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationTables" xlink:type="simple" xlink:href="txg-20250331.xsd#OtherFinancialStatementInformationTables"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/OtherFinancialStatementInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_98009b0d-ace5-4d03-80c8-48c6b3f67136" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_f14226d8-e115-4ea6-82d8-980bd3b4e9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_98009b0d-ace5-4d03-80c8-48c6b3f67136" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_f14226d8-e115-4ea6-82d8-980bd3b4e9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4d2fb4d9-ea79-4ac5-aec4-a3482e512028" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_98009b0d-ace5-4d03-80c8-48c6b3f67136" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4d2fb4d9-ea79-4ac5-aec4-a3482e512028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_927019d6-6734-43a6-bca3-0456782071f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_98009b0d-ace5-4d03-80c8-48c6b3f67136" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_927019d6-6734-43a6-bca3-0456782071f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_ScheduleOfAccruedCompensationandRelatedBenefitsTableTextBlock_7820b57c-b5bb-450a-8980-b86e4a6293ba" xlink:href="txg-20250331.xsd#txg_ScheduleOfAccruedCompensationandRelatedBenefitsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_98009b0d-ace5-4d03-80c8-48c6b3f67136" xlink:to="loc_txg_ScheduleOfAccruedCompensationandRelatedBenefitsTableTextBlock_7820b57c-b5bb-450a-8980-b86e4a6293ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_ba71fd41-f9d0-4630-966e-3d7cdfc28599" xlink:href="txg-20250331.xsd#txg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_98009b0d-ace5-4d03-80c8-48c6b3f67136" xlink:to="loc_txg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_ba71fd41-f9d0-4630-966e-3d7cdfc28599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_a047fd90-1474-49e9-a5d9-0fad1b79951e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_98009b0d-ace5-4d03-80c8-48c6b3f67136" xlink:to="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_a047fd90-1474-49e9-a5d9-0fad1b79951e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_f657557a-ce77-40d9-af75-d2684e91fca0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_98009b0d-ace5-4d03-80c8-48c6b3f67136" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_f657557a-ce77-40d9-af75-d2684e91fca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_8fb8399f-ef5c-41f9-9d55-3071ec16256b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_98009b0d-ace5-4d03-80c8-48c6b3f67136" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_8fb8399f-ef5c-41f9-9d55-3071ec16256b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_7266bb9e-f12e-40e9-a1cc-2dae7f32202c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_98009b0d-ace5-4d03-80c8-48c6b3f67136" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_7266bb9e-f12e-40e9-a1cc-2dae7f32202c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="txg-20250331.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b07a6247-c940-4ffd-8aa5-8b63370491a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1560a561-98aa-4d32-bbec-871b294d7167" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b07a6247-c940-4ffd-8aa5-8b63370491a4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1560a561-98aa-4d32-bbec-871b294d7167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_DisclosureOfAdditionalInformationRelatedToOperatingLeasesTableTextBlock_2e67ba82-8778-4b13-a2f3-1fc1b9cac3e6" xlink:href="txg-20250331.xsd#txg_DisclosureOfAdditionalInformationRelatedToOperatingLeasesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b07a6247-c940-4ffd-8aa5-8b63370491a4" xlink:to="loc_txg_DisclosureOfAdditionalInformationRelatedToOperatingLeasesTableTextBlock_2e67ba82-8778-4b13-a2f3-1fc1b9cac3e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/EquityIncentivePlansTables" xlink:type="simple" xlink:href="txg-20250331.xsd#EquityIncentivePlansTables"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/EquityIncentivePlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4d1c0f5c-2003-41ce-8551-e6f895ab7118" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_72a78c77-0fc5-4754-a71d-d0c242cc2826" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4d1c0f5c-2003-41ce-8551-e6f895ab7118" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_72a78c77-0fc5-4754-a71d-d0c242cc2826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_c6ecfa7a-3548-4c3c-bf84-6a13cbad0986" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4d1c0f5c-2003-41ce-8551-e6f895ab7118" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_c6ecfa7a-3548-4c3c-bf84-6a13cbad0986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4da8494c-ab10-4da6-8e5f-b3df77d27848" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4d1c0f5c-2003-41ce-8551-e6f895ab7118" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4da8494c-ab10-4da6-8e5f-b3df77d27848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8859ede9-1939-4d43-a7f2-afbc21347043" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4d1c0f5c-2003-41ce-8551-e6f895ab7118" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8859ede9-1939-4d43-a7f2-afbc21347043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="txg-20250331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_393345f6-62f3-4736-ab1c-f82c7b5e519e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4d658afe-571c-428b-9290-1e99f4f4d261" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_393345f6-62f3-4736-ab1c-f82c7b5e519e" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4d658afe-571c-428b-9290-1e99f4f4d261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="txg-20250331.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_178d6e84-5626-4008-b911-09757e2b5b21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyObligationTerm_1f7bb25b-5090-4540-8d16-012945701160" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyObligationTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_178d6e84-5626-4008-b911-09757e2b5b21" xlink:to="loc_us-gaap_ProductWarrantyObligationTerm_1f7bb25b-5090-4540-8d16-012945701160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_RevenueFromContractWithCustomerPaymentPeriod_41cb87d5-68f9-4561-95d0-d0ebefc310ae" xlink:href="txg-20250331.xsd#txg_RevenueFromContractWithCustomerPaymentPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_178d6e84-5626-4008-b911-09757e2b5b21" xlink:to="loc_txg_RevenueFromContractWithCustomerPaymentPeriod_41cb87d5-68f9-4561-95d0-d0ebefc310ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_28bc1274-367d-461c-9b09-53bcdab8ea7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_178d6e84-5626-4008-b911-09757e2b5b21" xlink:to="loc_us-gaap_NumberOfOperatingSegments_28bc1274-367d-461c-9b09-53bcdab8ea7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="txg-20250331.xsd#OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_856b9193-c062-4164-9def-4778383ec77d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_a612ca61-0b34-4f27-811e-7da980c3eeaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_856b9193-c062-4164-9def-4778383ec77d" xlink:to="loc_us-gaap_MarketableSecuritiesTable_a612ca61-0b34-4f27-811e-7da980c3eeaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_664ac004-ddea-4931-8799-67af01318a10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_a612ca61-0b34-4f27-811e-7da980c3eeaf" xlink:to="loc_us-gaap_FinancialInstrumentAxis_664ac004-ddea-4931-8799-67af01318a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0a434c59-fa87-4189-8138-5be39ea6b787" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_664ac004-ddea-4931-8799-67af01318a10" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0a434c59-fa87-4189-8138-5be39ea6b787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_e345ac35-28e7-4079-b9fb-c8b921cd782a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0a434c59-fa87-4189-8138-5be39ea6b787" xlink:to="loc_us-gaap_MoneyMarketFundsMember_e345ac35-28e7-4079-b9fb-c8b921cd782a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_23ece5ef-dd86-44d2-80f6-1f2b69089075" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0a434c59-fa87-4189-8138-5be39ea6b787" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_23ece5ef-dd86-44d2-80f6-1f2b69089075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_7c8119a1-d27e-4b99-aed0-7ce5ea31aa82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0a434c59-fa87-4189-8138-5be39ea6b787" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_7c8119a1-d27e-4b99-aed0-7ce5ea31aa82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_d283b6b8-4e40-4efc-bb1e-5cb5a6b57c97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0a434c59-fa87-4189-8138-5be39ea6b787" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_d283b6b8-4e40-4efc-bb1e-5cb5a6b57c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4876a824-b9d7-4d76-b5f0-a5aaf947110f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_a612ca61-0b34-4f27-811e-7da980c3eeaf" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4876a824-b9d7-4d76-b5f0-a5aaf947110f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4e7008e-249c-4319-a3d8-1c5cb7d042c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4876a824-b9d7-4d76-b5f0-a5aaf947110f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4e7008e-249c-4319-a3d8-1c5cb7d042c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_e3e24c78-e926-4fc7-b2c6-fda3cd735ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4e7008e-249c-4319-a3d8-1c5cb7d042c6" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_e3e24c78-e926-4fc7-b2c6-fda3cd735ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e66f2be4-63ae-4a14-959f-a6f6022f41df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b4e7008e-249c-4319-a3d8-1c5cb7d042c6" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e66f2be4-63ae-4a14-959f-a6f6022f41df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesLineItems_8b13ed5a-e741-43ec-9cb3-4f975af49f47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_a612ca61-0b34-4f27-811e-7da980c3eeaf" xlink:to="loc_us-gaap_MarketableSecuritiesLineItems_8b13ed5a-e741-43ec-9cb3-4f975af49f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_ee03a378-d44e-4b7a-b1ac-3e7aacb9e01d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8b13ed5a-e741-43ec-9cb3-4f975af49f47" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_ee03a378-d44e-4b7a-b1ac-3e7aacb9e01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_dcbd3e86-6e10-439c-8012-666726957f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8b13ed5a-e741-43ec-9cb3-4f975af49f47" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_dcbd3e86-6e10-439c-8012-666726957f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ab04296c-88df-4857-9002-bf23335b0306" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8b13ed5a-e741-43ec-9cb3-4f975af49f47" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ab04296c-88df-4857-9002-bf23335b0306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e77a6889-fbc0-4b5c-8e54-2563238fcb66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8b13ed5a-e741-43ec-9cb3-4f975af49f47" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e77a6889-fbc0-4b5c-8e54-2563238fcb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_04fc83d1-6a3d-4c14-ad7d-5bb26329d453" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8b13ed5a-e741-43ec-9cb3-4f975af49f47" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_04fc83d1-6a3d-4c14-ad7d-5bb26329d453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds_1ff25455-dccb-4358-9fa9-c43814bad933" xlink:href="txg-20250331.xsd#txg_DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8b13ed5a-e741-43ec-9cb3-4f975af49f47" xlink:to="loc_txg_DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds_1ff25455-dccb-4358-9fa9-c43814bad933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds_c78f1568-5e7c-4132-bc6d-bf32157d50e2" xlink:href="txg-20250331.xsd#txg_DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesLineItems_8b13ed5a-e741-43ec-9cb3-4f975af49f47" xlink:to="loc_txg_DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds_c78f1568-5e7c-4132-bc6d-bf32157d50e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails" xlink:type="simple" xlink:href="txg-20250331.xsd#OtherFinancialStatementInformationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5e52cf76-10bf-44a9-8d3c-d5877cb4919d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_76096b9c-e303-457c-b6ca-b4c422887d72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5e52cf76-10bf-44a9-8d3c-d5877cb4919d" xlink:to="loc_us-gaap_ConcentrationRiskTable_76096b9c-e303-457c-b6ca-b4c422887d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ad1ec4d8-86c2-40c7-aabb-2f54c9d59486" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_76096b9c-e303-457c-b6ca-b4c422887d72" xlink:to="loc_srt_ProductOrServiceAxis_ad1ec4d8-86c2-40c7-aabb-2f54c9d59486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ffdc16df-1233-44b8-9f8e-286792073e24" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ad1ec4d8-86c2-40c7-aabb-2f54c9d59486" xlink:to="loc_srt_ProductsAndServicesDomain_ffdc16df-1233-44b8-9f8e-286792073e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_ProductsAndServicesExcludingGrantRevenueMember_077244b8-68ed-4fe2-b992-7baed56911a0" xlink:href="txg-20250331.xsd#txg_ProductsAndServicesExcludingGrantRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ffdc16df-1233-44b8-9f8e-286792073e24" xlink:to="loc_txg_ProductsAndServicesExcludingGrantRevenueMember_077244b8-68ed-4fe2-b992-7baed56911a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_LicensingAndRoyaltyRevenueMember_cc5fd651-5398-43e9-aae7-610de994a5eb" xlink:href="txg-20250331.xsd#txg_LicensingAndRoyaltyRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ffdc16df-1233-44b8-9f8e-286792073e24" xlink:to="loc_txg_LicensingAndRoyaltyRevenueMember_cc5fd651-5398-43e9-aae7-610de994a5eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_011ccfde-3012-48b4-973a-92a7cac26560" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_76096b9c-e303-457c-b6ca-b4c422887d72" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_011ccfde-3012-48b4-973a-92a7cac26560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_07fe31f7-6f03-41fd-aef3-d778faa614bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_011ccfde-3012-48b4-973a-92a7cac26560" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_07fe31f7-6f03-41fd-aef3-d778faa614bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_d45ee137-cc9d-47bf-93a7-97873de000e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_07fe31f7-6f03-41fd-aef3-d778faa614bb" xlink:to="loc_us-gaap_ComputerEquipmentMember_d45ee137-cc9d-47bf-93a7-97873de000e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_CostOfRevenueMember_921e97f2-306b-43be-a730-71b03b61d2be" xlink:href="txg-20250331.xsd#txg_CostOfRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComputerEquipmentMember_d45ee137-cc9d-47bf-93a7-97873de000e4" xlink:to="loc_txg_CostOfRevenueMember_921e97f2-306b-43be-a730-71b03b61d2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_33124716-8e7c-41db-947f-a81967eb541b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComputerEquipmentMember_d45ee137-cc9d-47bf-93a7-97873de000e4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_33124716-8e7c-41db-947f-a81967eb541b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8860e4e7-e936-45af-abb6-0443db67af1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComputerEquipmentMember_d45ee137-cc9d-47bf-93a7-97873de000e4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8860e4e7-e936-45af-abb6-0443db67af1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2be007aa-7963-4a61-bfe7-e7210f65879b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_76096b9c-e303-457c-b6ca-b4c422887d72" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2be007aa-7963-4a61-bfe7-e7210f65879b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9ffa3901-1d3f-47d2-8127-f59d485b1c7d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_76096b9c-e303-457c-b6ca-b4c422887d72" xlink:to="loc_srt_CounterpartyNameAxis_9ffa3901-1d3f-47d2-8127-f59d485b1c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_db89fe7b-f8a7-4bd0-9bd4-c3fe018d31ab" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_9ffa3901-1d3f-47d2-8127-f59d485b1c7d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_db89fe7b-f8a7-4bd0-9bd4-c3fe018d31ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_VizgenInc.Member_5311cd71-7ef2-4f6f-8e42-02d89b70bd32" xlink:href="txg-20250331.xsd#txg_VizgenInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_db89fe7b-f8a7-4bd0-9bd4-c3fe018d31ab" xlink:to="loc_txg_VizgenInc.Member_5311cd71-7ef2-4f6f-8e42-02d89b70bd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_76096b9c-e303-457c-b6ca-b4c422887d72" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_1f126213-d67c-47d5-8a4b-52571d31dc21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_1f126213-d67c-47d5-8a4b-52571d31dc21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_0199355e-b948-4956-9203-93010e17b809" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_0199355e-b948-4956-9203-93010e17b809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_acc56c07-0f4c-4322-9c6b-f9d17b585375" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_acc56c07-0f4c-4322-9c6b-f9d17b585375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c689b7a7-9c09-4f06-837f-4f6fead893be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c689b7a7-9c09-4f06-837f-4f6fead893be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_48a8e736-a2c4-498c-8f3f-6c831f4c0363" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_48a8e736-a2c4-498c-8f3f-6c831f4c0363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_84fe50d3-8505-4a8b-9451-c90af7e7f6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_us-gaap_ContractWithCustomerLiability_84fe50d3-8505-4a8b-9451-c90af7e7f6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted_e5797525-d132-495f-9aad-d4a2927b7ac5" xlink:href="txg-20250331.xsd#txg_ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_txg_ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted_e5797525-d132-495f-9aad-d4a2927b7ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementGain_aa3e8772-3793-4084-b441-a2d4b4464988" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementGain"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_us-gaap_LitigationSettlementGain_aa3e8772-3793-4084-b441-a2d4b4464988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0d953ec0-5518-44c0-9747-ee84743f4e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0d953ec0-5518-44c0-9747-ee84743f4e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossRealizedAfterTax_a8df1652-bff3-47f7-97ac-b002f5c3123a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealizedAfterTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e1e8df00-1b44-4b95-9548-660519918bdd" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossRealizedAfterTax_a8df1652-bff3-47f7-97ac-b002f5c3123a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofInventoryDetails" xlink:type="simple" xlink:href="txg-20250331.xsd#OtherFinancialStatementInformationScheduleofInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7662e8e5-3151-4baf-97d5-44fa64bd4d60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_cc0e326c-6cc2-432d-bcc2-a307debe8baa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7662e8e5-3151-4baf-97d5-44fa64bd4d60" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_cc0e326c-6cc2-432d-bcc2-a307debe8baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f6b7cc51-4df9-47c2-95b6-23514045c24e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7662e8e5-3151-4baf-97d5-44fa64bd4d60" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f6b7cc51-4df9-47c2-95b6-23514045c24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_528415d2-fce6-4289-be98-d316f85fca47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7662e8e5-3151-4baf-97d5-44fa64bd4d60" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_528415d2-fce6-4289-be98-d316f85fca47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e4a82562-335b-4ff3-802d-e4112cbc56fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7662e8e5-3151-4baf-97d5-44fa64bd4d60" xlink:to="loc_us-gaap_InventoryNet_e4a82562-335b-4ff3-802d-e4112cbc56fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail" xlink:type="simple" xlink:href="txg-20250331.xsd#OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e6fe8ab4-7ae7-4879-a7a5-f41af2407fed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dee31d2c-4d3a-44a1-ad4c-de37631d1b79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e6fe8ab4-7ae7-4879-a7a5-f41af2407fed" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dee31d2c-4d3a-44a1-ad4c-de37631d1b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_169b104f-6b42-4ccd-9d19-91949d5870ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dee31d2c-4d3a-44a1-ad4c-de37631d1b79" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_169b104f-6b42-4ccd-9d19-91949d5870ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64fbdb17-361c-465e-b80d-cd991f7d3867" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_169b104f-6b42-4ccd-9d19-91949d5870ab" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64fbdb17-361c-465e-b80d-cd991f7d3867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_35725f08-7d18-4306-bc57-b1c5d6ec029c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64fbdb17-361c-465e-b80d-cd991f7d3867" xlink:to="loc_us-gaap_LandMember_35725f08-7d18-4306-bc57-b1c5d6ec029c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_868c9a29-9c78-4ef4-81df-3931bde6e367" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64fbdb17-361c-465e-b80d-cd991f7d3867" xlink:to="loc_us-gaap_BuildingMember_868c9a29-9c78-4ef4-81df-3931bde6e367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_38a211d4-ede6-4544-85a4-d72b408bb475" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64fbdb17-361c-465e-b80d-cd991f7d3867" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_38a211d4-ede6-4544-85a4-d72b408bb475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_ce512d10-7989-463c-86de-b673f3197d61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64fbdb17-361c-465e-b80d-cd991f7d3867" xlink:to="loc_us-gaap_ComputerEquipmentMember_ce512d10-7989-463c-86de-b673f3197d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_104f4450-7e8d-4b5d-8ec1-91472b533d58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64fbdb17-361c-465e-b80d-cd991f7d3867" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_104f4450-7e8d-4b5d-8ec1-91472b533d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_d5e4525f-f94c-4419-8f77-e07be0a5519e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64fbdb17-361c-465e-b80d-cd991f7d3867" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_d5e4525f-f94c-4419-8f77-e07be0a5519e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_66e86dd9-4c4d-4f21-89af-bf9cc8b36514" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_64fbdb17-361c-465e-b80d-cd991f7d3867" xlink:to="loc_us-gaap_ConstructionInProgressMember_66e86dd9-4c4d-4f21-89af-bf9cc8b36514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d63d71d4-4c8a-4101-9423-d6197f0e693d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dee31d2c-4d3a-44a1-ad4c-de37631d1b79" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d63d71d4-4c8a-4101-9423-d6197f0e693d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c3e43c55-3a7f-4859-ac23-764cb58526a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d63d71d4-4c8a-4101-9423-d6197f0e693d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c3e43c55-3a7f-4859-ac23-764cb58526a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5b1f12e0-c60d-41be-b9ce-1ccff6b6fab9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d63d71d4-4c8a-4101-9423-d6197f0e693d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5b1f12e0-c60d-41be-b9ce-1ccff6b6fab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7b6ce8cf-8bf5-4c42-a5cb-fa287e4025b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d63d71d4-4c8a-4101-9423-d6197f0e693d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7b6ce8cf-8bf5-4c42-a5cb-fa287e4025b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedCompensationandRelatedBenefitsDetails" xlink:type="simple" xlink:href="txg-20250331.xsd#OtherFinancialStatementInformationScheduleofAccruedCompensationandRelatedBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedCompensationandRelatedBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8991542-7340-4978-9fe8-06cfb9cbd11a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_AccruedPayrollAndRelatedCosts_c66bfe20-8f85-4a77-82f1-2abe38ef34c1" xlink:href="txg-20250331.xsd#txg_AccruedPayrollAndRelatedCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8991542-7340-4978-9fe8-06cfb9cbd11a" xlink:to="loc_txg_AccruedPayrollAndRelatedCosts_c66bfe20-8f85-4a77-82f1-2abe38ef34c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_2e05841d-99c6-4747-81ff-fea289c68eab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8991542-7340-4978-9fe8-06cfb9cbd11a" xlink:to="loc_us-gaap_AccruedBonusesCurrent_2e05841d-99c6-4747-81ff-fea289c68eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_AccruedCommissionsCurrent_334ea720-4ee7-42a7-b64b-922e3878cd66" xlink:href="txg-20250331.xsd#txg_AccruedCommissionsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8991542-7340-4978-9fe8-06cfb9cbd11a" xlink:to="loc_txg_AccruedCommissionsCurrent_334ea720-4ee7-42a7-b64b-922e3878cd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_f52c9381-0840-4c4b-8b58-03e161834e09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8991542-7340-4978-9fe8-06cfb9cbd11a" xlink:to="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_f52c9381-0840-4c4b-8b58-03e161834e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2edc0540-12d5-43e9-83d0-b886e74a6065" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8991542-7340-4978-9fe8-06cfb9cbd11a" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2edc0540-12d5-43e9-83d0-b886e74a6065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedExpenseAndOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="txg-20250331.xsd#OtherFinancialStatementInformationScheduleofAccruedExpenseAndOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedExpenseAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fd0b1b4b-27a8-430a-be88-0e553edc0d56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_AccruedLegalAndRelatedExpensesCurrent_a0334394-fc8e-4441-8966-95bbe47d002e" xlink:href="txg-20250331.xsd#txg_AccruedLegalAndRelatedExpensesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fd0b1b4b-27a8-430a-be88-0e553edc0d56" xlink:to="loc_txg_AccruedLegalAndRelatedExpensesCurrent_a0334394-fc8e-4441-8966-95bbe47d002e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_f6f68769-6ce0-4ea1-b6b9-a5a04192f452" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fd0b1b4b-27a8-430a-be88-0e553edc0d56" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_f6f68769-6ce0-4ea1-b6b9-a5a04192f452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_6a413312-4918-4275-8bf2-dc5ad299e225" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fd0b1b4b-27a8-430a-be88-0e553edc0d56" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_6a413312-4918-4275-8bf2-dc5ad299e225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_fb03267c-7519-4eb7-b61f-af5737d0fcd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fd0b1b4b-27a8-430a-be88-0e553edc0d56" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_fb03267c-7519-4eb7-b61f-af5737d0fcd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_a71fa505-88a8-4353-87d4-5e61170409a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fd0b1b4b-27a8-430a-be88-0e553edc0d56" xlink:to="loc_us-gaap_TaxesPayableCurrent_a71fa505-88a8-4353-87d4-5e61170409a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_1fdf0138-970a-49e5-b16c-ca0f0171f391" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fd0b1b4b-27a8-430a-be88-0e553edc0d56" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_1fdf0138-970a-49e5-b16c-ca0f0171f391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_AccruedExpensesAndOtherLiabilitiesCurrent_ac651f0b-f4d1-499d-97b0-92375645c4be" xlink:href="txg-20250331.xsd#txg_AccruedExpensesAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fd0b1b4b-27a8-430a-be88-0e553edc0d56" xlink:to="loc_txg_AccruedExpensesAndOtherLiabilitiesCurrent_ac651f0b-f4d1-499d-97b0-92375645c4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofChangesintheReserveforProductWarrantiesDetails" xlink:type="simple" xlink:href="txg-20250331.xsd#OtherFinancialStatementInformationScheduleofChangesintheReserveforProductWarrantiesDetails"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofChangesintheReserveforProductWarrantiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_95b2d9f9-550b-4bd8-8f21-a8d93de172a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_4af79ed4-d8d3-487e-83d0-8c9c94a961fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_95b2d9f9-550b-4bd8-8f21-a8d93de172a1" xlink:to="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_4af79ed4-d8d3-487e-83d0-8c9c94a961fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrual_a53d9b6a-4605-459f-ad03-7b228db6a4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrual"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_4af79ed4-d8d3-487e-83d0-8c9c94a961fe" xlink:to="loc_us-gaap_ProductWarrantyAccrual_a53d9b6a-4605-459f-ad03-7b228db6a4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualWarrantiesIssued_0d19c2b3-04c9-43b9-9db3-34bf5e9651ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrualWarrantiesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_4af79ed4-d8d3-487e-83d0-8c9c94a961fe" xlink:to="loc_us-gaap_ProductWarrantyAccrualWarrantiesIssued_0d19c2b3-04c9-43b9-9db3-34bf5e9651ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualPayments_33a56c26-5ead-4341-bb24-b18d94b27860" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrualPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_4af79ed4-d8d3-487e-83d0-8c9c94a961fe" xlink:to="loc_us-gaap_ProductWarrantyAccrualPayments_33a56c26-5ead-4341-bb24-b18d94b27860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrual_63867387-b248-414c-841e-54328c0f867d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrual"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_4af79ed4-d8d3-487e-83d0-8c9c94a961fe" xlink:to="loc_us-gaap_ProductWarrantyAccrual_63867387-b248-414c-841e-54328c0f867d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenueofRecognizedinContractLiabilitiesDetails" xlink:type="simple" xlink:href="txg-20250331.xsd#OtherFinancialStatementInformationScheduleofRevenueofRecognizedinContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenueofRecognizedinContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_19113473-32d4-4a23-9bec-d0e9c38b975c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8510dbc4-9067-4e54-ad36-97279d18fb29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_19113473-32d4-4a23-9bec-d0e9c38b975c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8510dbc4-9067-4e54-ad36-97279d18fb29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebySourceDetails" xlink:type="simple" xlink:href="txg-20250331.xsd#OtherFinancialStatementInformationScheduleofRevenuebySourceDetails"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebySourceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bba79820-1f3f-40ad-90a9-47aa41e8b4db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_da2fc763-21db-4985-8119-042306b1290c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bba79820-1f3f-40ad-90a9-47aa41e8b4db" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_da2fc763-21db-4985-8119-042306b1290c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_069c20c4-8587-456a-8062-5c63d770ea68" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_da2fc763-21db-4985-8119-042306b1290c" xlink:to="loc_srt_ProductOrServiceAxis_069c20c4-8587-456a-8062-5c63d770ea68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8489367e-4c9a-48d3-acb4-b77a9df6db9c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_069c20c4-8587-456a-8062-5c63d770ea68" xlink:to="loc_srt_ProductsAndServicesDomain_8489367e-4c9a-48d3-acb4-b77a9df6db9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_InstrumentsMember_9e9c3da9-29a3-49b3-b036-938cd9177d90" xlink:href="txg-20250331.xsd#txg_InstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8489367e-4c9a-48d3-acb4-b77a9df6db9c" xlink:to="loc_txg_InstrumentsMember_9e9c3da9-29a3-49b3-b036-938cd9177d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_ChromiumInstrumentsMember_4a2467ec-f98c-40ca-a8a4-d48188736756" xlink:href="txg-20250331.xsd#txg_ChromiumInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txg_InstrumentsMember_9e9c3da9-29a3-49b3-b036-938cd9177d90" xlink:to="loc_txg_ChromiumInstrumentsMember_4a2467ec-f98c-40ca-a8a4-d48188736756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_SpatialInstrumentsMember_ee1ca9b4-beaf-4a73-9b29-b39b4898e338" xlink:href="txg-20250331.xsd#txg_SpatialInstrumentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txg_InstrumentsMember_9e9c3da9-29a3-49b3-b036-938cd9177d90" xlink:to="loc_txg_SpatialInstrumentsMember_ee1ca9b4-beaf-4a73-9b29-b39b4898e338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_ConsumablesMember_688ec4d4-1134-41a9-8517-636d892e6898" xlink:href="txg-20250331.xsd#txg_ConsumablesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8489367e-4c9a-48d3-acb4-b77a9df6db9c" xlink:to="loc_txg_ConsumablesMember_688ec4d4-1134-41a9-8517-636d892e6898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_ChromiumConsumablesMember_1d85b345-92ae-44ad-8f8f-2ad3f0965bf4" xlink:href="txg-20250331.xsd#txg_ChromiumConsumablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txg_ConsumablesMember_688ec4d4-1134-41a9-8517-636d892e6898" xlink:to="loc_txg_ChromiumConsumablesMember_1d85b345-92ae-44ad-8f8f-2ad3f0965bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_SpatialConsumablesMember_7617ddfb-e057-4c00-b6a5-55c32ac4a5d1" xlink:href="txg-20250331.xsd#txg_SpatialConsumablesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txg_ConsumablesMember_688ec4d4-1134-41a9-8517-636d892e6898" xlink:to="loc_txg_SpatialConsumablesMember_7617ddfb-e057-4c00-b6a5-55c32ac4a5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_463e74e7-e115-4ba5-8f9e-a03979b7b933" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8489367e-4c9a-48d3-acb4-b77a9df6db9c" xlink:to="loc_us-gaap_ServiceMember_463e74e7-e115-4ba5-8f9e-a03979b7b933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_ProductAndServiceRevenueMember_42014f30-cbd5-4421-9b72-6e2c289c356a" xlink:href="txg-20250331.xsd#txg_ProductAndServiceRevenueMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8489367e-4c9a-48d3-acb4-b77a9df6db9c" xlink:to="loc_txg_ProductAndServiceRevenueMember_42014f30-cbd5-4421-9b72-6e2c289c356a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_LicensingAndRoyaltyRevenueMember_cee69345-2e2e-4655-8433-e21834b151a8" xlink:href="txg-20250331.xsd#txg_LicensingAndRoyaltyRevenueMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8489367e-4c9a-48d3-acb4-b77a9df6db9c" xlink:to="loc_txg_LicensingAndRoyaltyRevenueMember_cee69345-2e2e-4655-8433-e21834b151a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_55f72c43-9d25-429c-b7bd-41f1c00b2758" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_da2fc763-21db-4985-8119-042306b1290c" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_55f72c43-9d25-429c-b7bd-41f1c00b2758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_08149513-14d7-40b0-9959-779f7bed1878" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_55f72c43-9d25-429c-b7bd-41f1c00b2758" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_08149513-14d7-40b0-9959-779f7bed1878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebyGeographicRegionDetails" xlink:type="simple" xlink:href="txg-20250331.xsd#OtherFinancialStatementInformationScheduleofRevenuebyGeographicRegionDetails"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebyGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ec9d1f96-5e5f-4ee0-a6bd-974e61cab4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_68e54e8f-b92b-476a-aa43-68331693dd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ec9d1f96-5e5f-4ee0-a6bd-974e61cab4a0" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_68e54e8f-b92b-476a-aa43-68331693dd0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_018e63d8-1121-4d76-a281-d1adba0a9999" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_68e54e8f-b92b-476a-aa43-68331693dd0f" xlink:to="loc_srt_StatementGeographicalAxis_018e63d8-1121-4d76-a281-d1adba0a9999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4737d98a-4eaa-485b-9465-e1d8cf5fecaf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_018e63d8-1121-4d76-a281-d1adba0a9999" xlink:to="loc_srt_SegmentGeographicalDomain_4737d98a-4eaa-485b-9465-e1d8cf5fecaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AmericasMember_e767e1cf-ee06-466e-8e6f-a5df15857f5b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AmericasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4737d98a-4eaa-485b-9465-e1d8cf5fecaf" xlink:to="loc_srt_AmericasMember_e767e1cf-ee06-466e-8e6f-a5df15857f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f991fc72-350c-4188-969d-8b191dcb6124" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_AmericasMember_e767e1cf-ee06-466e-8e6f-a5df15857f5b" xlink:to="loc_country_US_f991fc72-350c-4188-969d-8b191dcb6124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_AmericasExcludingUnitedStatesMember_68fb3fad-a17c-4d00-b967-94a37fe8a41c" xlink:href="txg-20250331.xsd#txg_AmericasExcludingUnitedStatesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_AmericasMember_e767e1cf-ee06-466e-8e6f-a5df15857f5b" xlink:to="loc_txg_AmericasExcludingUnitedStatesMember_68fb3fad-a17c-4d00-b967-94a37fe8a41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_f9cec866-655b-496a-bc76-cb621cd4fdee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EMEAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4737d98a-4eaa-485b-9465-e1d8cf5fecaf" xlink:to="loc_us-gaap_EMEAMember_f9cec866-655b-496a-bc76-cb621cd4fdee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_9a81cdc5-b1c4-4e3a-a114-0a1a797341d8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AsiaPacificMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4737d98a-4eaa-485b-9465-e1d8cf5fecaf" xlink:to="loc_srt_AsiaPacificMember_9a81cdc5-b1c4-4e3a-a114-0a1a797341d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_1b35cbc7-9494-40f1-b415-52e521b81fef" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_AsiaPacificMember_9a81cdc5-b1c4-4e3a-a114-0a1a797341d8" xlink:to="loc_country_CN_1b35cbc7-9494-40f1-b415-52e521b81fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_AsiaPacificExcludingChinaMember_5ac84077-6dc7-4ce8-ad2d-b33d82f2085e" xlink:href="txg-20250331.xsd#txg_AsiaPacificExcludingChinaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_AsiaPacificMember_9a81cdc5-b1c4-4e3a-a114-0a1a797341d8" xlink:to="loc_txg_AsiaPacificExcludingChinaMember_5ac84077-6dc7-4ce8-ad2d-b33d82f2085e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_ead7bd74-83c5-4318-902c-334468f6ca06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_68e54e8f-b92b-476a-aa43-68331693dd0f" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_ead7bd74-83c5-4318-902c-334468f6ca06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0a45cdcc-e550-4690-abcc-ae5983648bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_ead7bd74-83c5-4318-902c-334468f6ca06" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0a45cdcc-e550-4690-abcc-ae5983648bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail" xlink:type="simple" xlink:href="txg-20250331.xsd#CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a3e3023b-820a-47ec-aaec-f8c21e303681" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_52c747e8-19d7-4f60-8363-b31350fe4356" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a3e3023b-820a-47ec-aaec-f8c21e303681" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_52c747e8-19d7-4f60-8363-b31350fe4356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_58079f4e-5134-41d2-9667-062543ad08ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_52c747e8-19d7-4f60-8363-b31350fe4356" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_58079f4e-5134-41d2-9667-062543ad08ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_37fccb38-a5de-4673-8dc9-f74dcb7c4531" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_52c747e8-19d7-4f60-8363-b31350fe4356" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_37fccb38-a5de-4673-8dc9-f74dcb7c4531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a86c76dc-849c-4e89-a89d-e9f2e082848b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_52c747e8-19d7-4f60-8363-b31350fe4356" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a86c76dc-849c-4e89-a89d-e9f2e082848b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bd46f4a1-9d1f-406a-98fa-653ee1824e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_52c747e8-19d7-4f60-8363-b31350fe4356" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bd46f4a1-9d1f-406a-98fa-653ee1824e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_91b4e83d-e507-40f1-bb29-94057b373b68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_52c747e8-19d7-4f60-8363-b31350fe4356" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_91b4e83d-e507-40f1-bb29-94057b373b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_d215de33-65ab-402e-8124-2f44cfb2101f" xlink:href="txg-20250331.xsd#txg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_52c747e8-19d7-4f60-8363-b31350fe4356" xlink:to="loc_txg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_d215de33-65ab-402e-8124-2f44cfb2101f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c57597dc-7462-4ba1-a10c-1a0125c9b291" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_52c747e8-19d7-4f60-8363-b31350fe4356" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c57597dc-7462-4ba1-a10c-1a0125c9b291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4c1687e7-189c-40fc-8f69-0305c055db91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_52c747e8-19d7-4f60-8363-b31350fe4356" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4c1687e7-189c-40fc-8f69-0305c055db91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_61905315-c93f-4bbe-b4f4-2cbc5a141de2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_52c747e8-19d7-4f60-8363-b31350fe4356" xlink:to="loc_us-gaap_OperatingLeaseLiability_61905315-c93f-4bbe-b4f4-2cbc5a141de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e1919f5c-1495-4d88-b784-afd745c49395" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_52c747e8-19d7-4f60-8363-b31350fe4356" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e1919f5c-1495-4d88-b784-afd745c49395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5f602484-da81-4191-aea1-6f718812c627" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_52c747e8-19d7-4f60-8363-b31350fe4356" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5f602484-da81-4191-aea1-6f718812c627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b02a401e-7cb0-4760-bbeb-9e78bb91e264" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_52c747e8-19d7-4f60-8363-b31350fe4356" xlink:to="loc_us-gaap_OperatingLeaseLiability_b02a401e-7cb0-4760-bbeb-9e78bb91e264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofAdditionalInformationRelatedtoOperatingLeasesDetail" xlink:type="simple" xlink:href="txg-20250331.xsd#CommitmentsandContingenciesScheduleofAdditionalInformationRelatedtoOperatingLeasesDetail"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofAdditionalInformationRelatedtoOperatingLeasesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_07fadb42-6566-41ae-b77a-254676e3e7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f14b0489-2e5b-4b97-885b-217a3e4d8b19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_07fadb42-6566-41ae-b77a-254676e3e7a6" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f14b0489-2e5b-4b97-885b-217a3e4d8b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_139989aa-8310-4687-b470-04743d10ecee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_07fadb42-6566-41ae-b77a-254676e3e7a6" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_139989aa-8310-4687-b470-04743d10ecee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="txg-20250331.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bd969814-d0c5-4081-aa32-5da1aafe6190" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_b9b1db1d-edeb-47fa-8c13-7ef87813e109" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bd969814-d0c5-4081-aa32-5da1aafe6190" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_b9b1db1d-edeb-47fa-8c13-7ef87813e109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_fbdbedc4-192c-4be3-a0bf-77f863579fae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bd969814-d0c5-4081-aa32-5da1aafe6190" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_fbdbedc4-192c-4be3-a0bf-77f863579fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_6e205ac4-0d60-42fc-834d-f3b355e744ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bd969814-d0c5-4081-aa32-5da1aafe6190" xlink:to="loc_us-gaap_PaymentsForRoyalties_6e205ac4-0d60-42fc-834d-f3b355e744ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_c75ad424-7d1e-4951-8668-bf4911b27aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bd969814-d0c5-4081-aa32-5da1aafe6190" xlink:to="loc_us-gaap_SecurityDeposit_c75ad424-7d1e-4951-8668-bf4911b27aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/CapitalStockAdditionalInformationDetail" xlink:type="simple" xlink:href="txg-20250331.xsd#CapitalStockAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/CapitalStockAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ff122391-6a94-4c5d-ad97-493106bc381e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d080c260-8be3-4b98-a318-d3fd37fe7058" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ff122391-6a94-4c5d-ad97-493106bc381e" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d080c260-8be3-4b98-a318-d3fd37fe7058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4b17f012-be2e-451b-8d78-962ca66b7ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d080c260-8be3-4b98-a318-d3fd37fe7058" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4b17f012-be2e-451b-8d78-962ca66b7ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3fc67de0-7d5d-46f6-9aa6-7dcf551a7b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4b17f012-be2e-451b-8d78-962ca66b7ef9" xlink:to="loc_us-gaap_ClassOfStockDomain_3fc67de0-7d5d-46f6-9aa6-7dcf551a7b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_0a807326-8a82-4e76-8e0f-8834404d682f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3fc67de0-7d5d-46f6-9aa6-7dcf551a7b3c" xlink:to="loc_us-gaap_CommonClassAMember_0a807326-8a82-4e76-8e0f-8834404d682f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_3092883a-0c3b-4344-9339-f156cff4bafa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3fc67de0-7d5d-46f6-9aa6-7dcf551a7b3c" xlink:to="loc_us-gaap_CommonClassBMember_3092883a-0c3b-4344-9339-f156cff4bafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_3de809db-0423-47e9-a296-03e7a2071496" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d080c260-8be3-4b98-a318-d3fd37fe7058" xlink:to="loc_us-gaap_ClassOfStockLineItems_3de809db-0423-47e9-a296-03e7a2071496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f72062a7-4e2f-4b4e-a581-c4368cc44ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3de809db-0423-47e9-a296-03e7a2071496" xlink:to="loc_us-gaap_CommonStockSharesIssued_f72062a7-4e2f-4b4e-a581-c4368cc44ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1a5f9c44-2f2a-4812-840a-d32964761221" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3de809db-0423-47e9-a296-03e7a2071496" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1a5f9c44-2f2a-4812-840a-d32964761221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRecordedStockBasedCompensationExpenseintheCondensedConsolidatedStatementofOperationsDetails" xlink:type="simple" xlink:href="txg-20250331.xsd#EquityIncentivePlansScheduleofRecordedStockBasedCompensationExpenseintheCondensedConsolidatedStatementofOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRecordedStockBasedCompensationExpenseintheCondensedConsolidatedStatementofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_406e21e5-f890-42c6-847c-8f9085c71ead" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bc5b4d47-33cd-4b73-bbe9-18737c66053c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_406e21e5-f890-42c6-847c-8f9085c71ead" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bc5b4d47-33cd-4b73-bbe9-18737c66053c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bf1b8900-ebc3-426e-869e-ea6b36cbcb38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bc5b4d47-33cd-4b73-bbe9-18737c66053c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bf1b8900-ebc3-426e-869e-ea6b36cbcb38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c3bbd899-612a-424a-a773-35129050ca69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bf1b8900-ebc3-426e-869e-ea6b36cbcb38" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c3bbd899-612a-424a-a773-35129050ca69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_5d1689cd-c313-49e6-88ae-6a8ab8ee69c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c3bbd899-612a-424a-a773-35129050ca69" xlink:to="loc_us-gaap_CostOfSalesMember_5d1689cd-c313-49e6-88ae-6a8ab8ee69c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3e83e236-74f1-4610-94c5-5a37b971aa05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c3bbd899-612a-424a-a773-35129050ca69" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3e83e236-74f1-4610-94c5-5a37b971aa05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_997c2929-3451-4186-b02f-e1bfd862120d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c3bbd899-612a-424a-a773-35129050ca69" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_997c2929-3451-4186-b02f-e1bfd862120d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2f96bfc3-cb8c-4448-a8c3-3fb9f5febbad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bc5b4d47-33cd-4b73-bbe9-18737c66053c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2f96bfc3-cb8c-4448-a8c3-3fb9f5febbad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_529cee79-98ec-4b4b-b5da-224f90abb0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2f96bfc3-cb8c-4448-a8c3-3fb9f5febbad" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_529cee79-98ec-4b4b-b5da-224f90abb0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRSUActivityDetail" xlink:type="simple" xlink:href="txg-20250331.xsd#EquityIncentivePlansScheduleofRSUActivityDetail"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRSUActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a3239399-c099-4799-bb2f-cbdf6a29715f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_423dda51-643c-445a-a91e-86ab1022ffe2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a3239399-c099-4799-bb2f-cbdf6a29715f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_423dda51-643c-445a-a91e-86ab1022ffe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f68b1972-1f1d-4557-be56-6c9ca7d5dd6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_423dda51-643c-445a-a91e-86ab1022ffe2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f68b1972-1f1d-4557-be56-6c9ca7d5dd6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2f3d3a12-bb26-48d3-81ea-5c4cb18ba47e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_423dda51-643c-445a-a91e-86ab1022ffe2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2f3d3a12-bb26-48d3-81ea-5c4cb18ba47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ba7b0347-00a6-4b74-8c21-ef1a0e9d1a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_423dda51-643c-445a-a91e-86ab1022ffe2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ba7b0347-00a6-4b74-8c21-ef1a0e9d1a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_15f6cd85-84ed-4718-861f-a6758f937a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_423dda51-643c-445a-a91e-86ab1022ffe2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_15f6cd85-84ed-4718-861f-a6758f937a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_360f9cb8-db89-4a32-9188-621635fe8bde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_423dda51-643c-445a-a91e-86ab1022ffe2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_360f9cb8-db89-4a32-9188-621635fe8bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a9a0e1ba-fb96-4eb6-80c5-956bdcfdddef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a3239399-c099-4799-bb2f-cbdf6a29715f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a9a0e1ba-fb96-4eb6-80c5-956bdcfdddef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_75599ee4-4695-45b9-acbe-9ee266fe7c74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a9a0e1ba-fb96-4eb6-80c5-956bdcfdddef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_75599ee4-4695-45b9-acbe-9ee266fe7c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ea149c7c-25c5-4e70-9c74-a41943ba17b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a9a0e1ba-fb96-4eb6-80c5-956bdcfdddef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ea149c7c-25c5-4e70-9c74-a41943ba17b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_102c4ef5-d240-4203-951a-abec51e9a5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a9a0e1ba-fb96-4eb6-80c5-956bdcfdddef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_102c4ef5-d240-4203-951a-abec51e9a5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f942271a-849f-4767-a417-988e88851052" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a9a0e1ba-fb96-4eb6-80c5-956bdcfdddef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f942271a-849f-4767-a417-988e88851052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_be72c160-b0b8-4bb4-a04b-f1c39d214195" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a9a0e1ba-fb96-4eb6-80c5-956bdcfdddef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_be72c160-b0b8-4bb4-a04b-f1c39d214195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofCompanysStockOptionActivityDetails" xlink:type="simple" xlink:href="txg-20250331.xsd#EquityIncentivePlansScheduleofCompanysStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofCompanysStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6a77fcd0-0db5-4094-85ce-e9b3abdf7593" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_216ea200-97d0-4b9b-9189-334a6db6230a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6a77fcd0-0db5-4094-85ce-e9b3abdf7593" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_216ea200-97d0-4b9b-9189-334a6db6230a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f1345c5e-dab7-40d3-9ea9-cf546e2c5b12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_216ea200-97d0-4b9b-9189-334a6db6230a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f1345c5e-dab7-40d3-9ea9-cf546e2c5b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_cac4e316-0de0-4948-b870-d1b9197597fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_216ea200-97d0-4b9b-9189-334a6db6230a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_cac4e316-0de0-4948-b870-d1b9197597fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f91ce791-7124-4bae-823f-07add068ad5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_216ea200-97d0-4b9b-9189-334a6db6230a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f91ce791-7124-4bae-823f-07add068ad5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3a95325a-ffbd-471f-83eb-5f7ac559339e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_216ea200-97d0-4b9b-9189-334a6db6230a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3a95325a-ffbd-471f-83eb-5f7ac559339e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6254ac1e-bc14-4c8e-bbd2-6ade94efd4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6a77fcd0-0db5-4094-85ce-e9b3abdf7593" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6254ac1e-bc14-4c8e-bbd2-6ade94efd4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cd270c64-81a5-4267-9f30-e296a94c6191" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6254ac1e-bc14-4c8e-bbd2-6ade94efd4a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cd270c64-81a5-4267-9f30-e296a94c6191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5ff44544-8f2a-40c1-a2cc-a9bb6ef6021d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6254ac1e-bc14-4c8e-bbd2-6ade94efd4a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5ff44544-8f2a-40c1-a2cc-a9bb6ef6021d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_292a6cc0-c17b-4882-8623-3282940ed19e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6254ac1e-bc14-4c8e-bbd2-6ade94efd4a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_292a6cc0-c17b-4882-8623-3282940ed19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a346bb34-37eb-4c66-82b5-a53bb449f039" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6254ac1e-bc14-4c8e-bbd2-6ade94efd4a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a346bb34-37eb-4c66-82b5-a53bb449f039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails" xlink:type="simple" xlink:href="txg-20250331.xsd#EquityIncentivePlansAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8de45058-be2c-4900-bd37-eb238b7e7724" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44d604d6-fcf4-4876-a6c6-ebe03df3688a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8de45058-be2c-4900-bd37-eb238b7e7724" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44d604d6-fcf4-4876-a6c6-ebe03df3688a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ea3adf9e-55d7-41be-bacf-b5cc6b1be50d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44d604d6-fcf4-4876-a6c6-ebe03df3688a" xlink:to="loc_us-gaap_AwardTypeAxis_ea3adf9e-55d7-41be-bacf-b5cc6b1be50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9f82407-bec0-4660-85a3-f5ec2a064936" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ea3adf9e-55d7-41be-bacf-b5cc6b1be50d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9f82407-bec0-4660-85a3-f5ec2a064936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_76bd315a-3895-453a-b3e6-f8eb4aa7b2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9f82407-bec0-4660-85a3-f5ec2a064936" xlink:to="loc_us-gaap_PerformanceSharesMember_76bd315a-3895-453a-b3e6-f8eb4aa7b2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_CompoundAnnualGrowthRateMember_41d3e6ac-9864-47e4-87b7-bd2562805bb2" xlink:href="txg-20250331.xsd#txg_CompoundAnnualGrowthRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9f82407-bec0-4660-85a3-f5ec2a064936" xlink:to="loc_txg_CompoundAnnualGrowthRateMember_41d3e6ac-9864-47e4-87b7-bd2562805bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_TotalShareholderReturnMember_116bb740-d937-4cf6-8a1c-61ca4fa126fa" xlink:href="txg-20250331.xsd#txg_TotalShareholderReturnMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9f82407-bec0-4660-85a3-f5ec2a064936" xlink:to="loc_txg_TotalShareholderReturnMember_116bb740-d937-4cf6-8a1c-61ca4fa126fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_bbe4e47f-ba3c-4f9c-b0f6-257e8755e3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9f82407-bec0-4660-85a3-f5ec2a064936" xlink:to="loc_us-gaap_EmployeeStockMember_bbe4e47f-ba3c-4f9c-b0f6-257e8755e3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_bb888aac-4815-44b0-848a-98f23459b2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44d604d6-fcf4-4876-a6c6-ebe03df3688a" xlink:to="loc_us-gaap_PlanNameAxis_bb888aac-4815-44b0-848a-98f23459b2ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f7880d5a-f525-4b03-920e-de0d5ba6fcd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_bb888aac-4815-44b0-848a-98f23459b2ce" xlink:to="loc_us-gaap_PlanNameDomain_f7880d5a-f525-4b03-920e-de0d5ba6fcd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_TwoThousandsNineteenPlanMember_110d52ae-26b8-45ce-8a99-b8e8dc3a32d3" xlink:href="txg-20250331.xsd#txg_TwoThousandsNineteenPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f7880d5a-f525-4b03-920e-de0d5ba6fcd1" xlink:to="loc_txg_TwoThousandsNineteenPlanMember_110d52ae-26b8-45ce-8a99-b8e8dc3a32d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_MarketBasedPerformanceAwardsMember_59f925f9-c3ca-425a-983e-8c6954ec3c6f" xlink:href="txg-20250331.xsd#txg_MarketBasedPerformanceAwardsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f7880d5a-f525-4b03-920e-de0d5ba6fcd1" xlink:to="loc_txg_MarketBasedPerformanceAwardsMember_59f925f9-c3ca-425a-983e-8c6954ec3c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_TwoThousandsNineteenEmployeeStockPurchasePlanMember_da426847-c6aa-404a-ab4d-045a3192cf15" xlink:href="txg-20250331.xsd#txg_TwoThousandsNineteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f7880d5a-f525-4b03-920e-de0d5ba6fcd1" xlink:to="loc_txg_TwoThousandsNineteenEmployeeStockPurchasePlanMember_da426847-c6aa-404a-ab4d-045a3192cf15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_77676eaf-8230-4a27-abae-8735596ea4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44d604d6-fcf4-4876-a6c6-ebe03df3688a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_77676eaf-8230-4a27-abae-8735596ea4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6194ae26-6671-4939-bac8-095c72cc8c66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_77676eaf-8230-4a27-abae-8735596ea4e5" xlink:to="loc_us-gaap_ClassOfStockDomain_6194ae26-6671-4939-bac8-095c72cc8c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_eedb656c-ac03-41eb-b8d5-ece6d217fead" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6194ae26-6671-4939-bac8-095c72cc8c66" xlink:to="loc_us-gaap_CommonClassAMember_eedb656c-ac03-41eb-b8d5-ece6d217fead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_62a855b6-ee32-43ad-aa11-a1c690511bae" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44d604d6-fcf4-4876-a6c6-ebe03df3688a" xlink:to="loc_srt_RangeAxis_62a855b6-ee32-43ad-aa11-a1c690511bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c96da833-03eb-4e8d-8dfd-b56366dfae86" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_62a855b6-ee32-43ad-aa11-a1c690511bae" xlink:to="loc_srt_RangeMember_c96da833-03eb-4e8d-8dfd-b56366dfae86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_85e6f74d-ab8b-49a9-8b64-88c12b30b935" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c96da833-03eb-4e8d-8dfd-b56366dfae86" xlink:to="loc_srt_MinimumMember_85e6f74d-ab8b-49a9-8b64-88c12b30b935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cfca9303-7c34-4e98-a85d-978cafa94632" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c96da833-03eb-4e8d-8dfd-b56366dfae86" xlink:to="loc_srt_MaximumMember_cfca9303-7c34-4e98-a85d-978cafa94632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40040652-f940-4ef6-8806-94917b6deff1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_44d604d6-fcf4-4876-a6c6-ebe03df3688a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40040652-f940-4ef6-8806-94917b6deff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8826ec8a-ff36-40e6-9d64-56a1ac7e23f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40040652-f940-4ef6-8806-94917b6deff1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8826ec8a-ff36-40e6-9d64-56a1ac7e23f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7419f5c6-5e52-426f-a739-0a0c79f0ac7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40040652-f940-4ef6-8806-94917b6deff1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7419f5c6-5e52-426f-a739-0a0c79f0ac7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b0264e0a-c42d-4beb-86a3-d5fcc14d9528" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40040652-f940-4ef6-8806-94917b6deff1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b0264e0a-c42d-4beb-86a3-d5fcc14d9528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage_3157a7a2-4eb6-4606-ba81-a5e8cd096b67" xlink:href="txg-20250331.xsd#txg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40040652-f940-4ef6-8806-94917b6deff1" xlink:to="loc_txg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage_3157a7a2-4eb6-4606-ba81-a5e8cd096b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8046fd6b-df16-40ab-8a04-8b315a79d1a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40040652-f940-4ef6-8806-94917b6deff1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8046fd6b-df16-40ab-8a04-8b315a79d1a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_60d77a4d-6c8b-42ca-82f8-141c0d233d89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40040652-f940-4ef6-8806-94917b6deff1" xlink:to="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_60d77a4d-6c8b-42ca-82f8-141c0d233d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_15751e84-5364-426d-a14d-3b9e644d6575" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40040652-f940-4ef6-8806-94917b6deff1" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_15751e84-5364-426d-a14d-3b9e644d6575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_63a202f7-ee3d-47ef-8d07-5dc3d910243e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40040652-f940-4ef6-8806-94917b6deff1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_63a202f7-ee3d-47ef-8d07-5dc3d910243e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_97f3a2f2-1478-48d4-88c9-85accc147187" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_40040652-f940-4ef6-8806-94917b6deff1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_97f3a2f2-1478-48d4-88c9-85accc147187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/EquityIncentivePlansFairValuesofSharesUnderthePerformanceStockUnitsDetails" xlink:type="simple" xlink:href="txg-20250331.xsd#EquityIncentivePlansFairValuesofSharesUnderthePerformanceStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/EquityIncentivePlansFairValuesofSharesUnderthePerformanceStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5013cdb5-3cc6-469f-9bde-a438ebbc8c29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7c4ce211-ac29-4094-95f9-030dd08afd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5013cdb5-3cc6-469f-9bde-a438ebbc8c29" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7c4ce211-ac29-4094-95f9-030dd08afd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e3840992-80a7-413c-933a-f54145c69f31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7c4ce211-ac29-4094-95f9-030dd08afd7d" xlink:to="loc_us-gaap_AwardTypeAxis_e3840992-80a7-413c-933a-f54145c69f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3aee3e8-9d2f-48cd-8709-b89104b36655" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e3840992-80a7-413c-933a-f54145c69f31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3aee3e8-9d2f-48cd-8709-b89104b36655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_789275ce-3775-4058-89ca-cc876342ecee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3aee3e8-9d2f-48cd-8709-b89104b36655" xlink:to="loc_us-gaap_PerformanceSharesMember_789275ce-3775-4058-89ca-cc876342ecee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05caba7a-a0dd-4a4d-96d5-286fdf28f79c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7c4ce211-ac29-4094-95f9-030dd08afd7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05caba7a-a0dd-4a4d-96d5-286fdf28f79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_371857c5-4250-4bd9-9d5a-99fa42607215" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05caba7a-a0dd-4a4d-96d5-286fdf28f79c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_371857c5-4250-4bd9-9d5a-99fa42607215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_05342f43-d5ee-486d-b8fe-a88f80cc0169" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05caba7a-a0dd-4a4d-96d5-286fdf28f79c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_05342f43-d5ee-486d-b8fe-a88f80cc0169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2fe27234-63c0-4bbd-a86b-aed49f7cc218" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05caba7a-a0dd-4a4d-96d5-286fdf28f79c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2fe27234-63c0-4bbd-a86b-aed49f7cc218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/NetLossPerShareSharesofCommonStockEquivalentsWereExcludedFromTheComputationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="txg-20250331.xsd#NetLossPerShareSharesofCommonStockEquivalentsWereExcludedFromTheComputationofDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/NetLossPerShareSharesofCommonStockEquivalentsWereExcludedFromTheComputationofDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_beafa618-917f-4926-a436-8adb001c58df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_707237ce-8fee-41b8-a3e0-097f452020f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_beafa618-917f-4926-a436-8adb001c58df" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_707237ce-8fee-41b8-a3e0-097f452020f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_72e2d02d-a561-4451-a8a1-f317df9cadfc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_707237ce-8fee-41b8-a3e0-097f452020f1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_72e2d02d-a561-4451-a8a1-f317df9cadfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0748676e-ce66-4e65-8e36-d44cea58929e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_72e2d02d-a561-4451-a8a1-f317df9cadfc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0748676e-ce66-4e65-8e36-d44cea58929e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f2a6dce3-9602-43d2-8565-dd216cc1c1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0748676e-ce66-4e65-8e36-d44cea58929e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f2a6dce3-9602-43d2-8565-dd216cc1c1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_54daa5ac-bc28-4cff-aacf-1d7ce05f911e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0748676e-ce66-4e65-8e36-d44cea58929e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_54daa5ac-bc28-4cff-aacf-1d7ce05f911e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_SharesUnderEsppPlanMember_7c54834f-9e85-40db-92c0-7d867be73a87" xlink:href="txg-20250331.xsd#txg_SharesUnderEsppPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0748676e-ce66-4e65-8e36-d44cea58929e" xlink:to="loc_txg_SharesUnderEsppPlanMember_7c54834f-9e85-40db-92c0-7d867be73a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0fbb7c1d-174a-4089-8795-c7516afc3b63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_707237ce-8fee-41b8-a3e0-097f452020f1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0fbb7c1d-174a-4089-8795-c7516afc3b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9a80e567-0980-4669-a180-46432b933f98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0fbb7c1d-174a-4089-8795-c7516afc3b63" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9a80e567-0980-4669-a180-46432b933f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.10xgenomics.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="txg-20250331.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.10xgenomics.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_bc6d2bd1-8d48-4107-867d-e96d0ac37eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_750038b3-9ac9-4d43-bc2e-db2fd32f2a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_bc6d2bd1-8d48-4107-867d-e96d0ac37eeb" xlink:to="loc_us-gaap_SubsequentEventTable_750038b3-9ac9-4d43-bc2e-db2fd32f2a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_22aae27f-0d81-42e5-8bfe-1c6882053a94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_750038b3-9ac9-4d43-bc2e-db2fd32f2a1f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_22aae27f-0d81-42e5-8bfe-1c6882053a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b855f53b-a4c4-430d-b1f9-55a9e94b431d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_22aae27f-0d81-42e5-8bfe-1c6882053a94" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b855f53b-a4c4-430d-b1f9-55a9e94b431d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d42caefb-fccd-4291-b511-20c34efe10d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b855f53b-a4c4-430d-b1f9-55a9e94b431d" xlink:to="loc_us-gaap_SubsequentEventMember_d42caefb-fccd-4291-b511-20c34efe10d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_8ce59a9e-81e0-458a-8f3b-cbf2c15430d2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_750038b3-9ac9-4d43-bc2e-db2fd32f2a1f" xlink:to="loc_srt_StatementScenarioAxis_8ce59a9e-81e0-458a-8f3b-cbf2c15430d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_4565cf35-a75e-4a1f-b9d1-63aaf24d0e44" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_8ce59a9e-81e0-458a-8f3b-cbf2c15430d2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_4565cf35-a75e-4a1f-b9d1-63aaf24d0e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_7e0b288a-89b0-44f8-bf84-65b9cd4fd800" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_4565cf35-a75e-4a1f-b9d1-63aaf24d0e44" xlink:to="loc_srt_ScenarioForecastMember_7e0b288a-89b0-44f8-bf84-65b9cd4fd800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_38f01d3a-3308-41c3-8bf3-e57e3392b8cd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_750038b3-9ac9-4d43-bc2e-db2fd32f2a1f" xlink:to="loc_srt_RangeAxis_38f01d3a-3308-41c3-8bf3-e57e3392b8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d2e039d0-2873-465c-91d4-0bca5a7fec02" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_38f01d3a-3308-41c3-8bf3-e57e3392b8cd" xlink:to="loc_srt_RangeMember_d2e039d0-2873-465c-91d4-0bca5a7fec02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_05c33432-e2d9-424d-9cac-e2cc082fc994" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d2e039d0-2873-465c-91d4-0bca5a7fec02" xlink:to="loc_srt_MinimumMember_05c33432-e2d9-424d-9cac-e2cc082fc994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5be8449e-0194-4b8e-ba7c-fc63f9deee97" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d2e039d0-2873-465c-91d4-0bca5a7fec02" xlink:to="loc_srt_MaximumMember_5be8449e-0194-4b8e-ba7c-fc63f9deee97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_ee2a871e-24c1-4782-8ea4-88c5eb7284e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_750038b3-9ac9-4d43-bc2e-db2fd32f2a1f" xlink:to="loc_us-gaap_SubsequentEventLineItems_ee2a871e-24c1-4782-8ea4-88c5eb7284e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1f358f04-fba4-4e2a-a87a-77cc86f86d03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_ee2a871e-24c1-4782-8ea4-88c5eb7284e4" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1f358f04-fba4-4e2a-a87a-77cc86f86d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_0dcdc0ac-3bb4-413b-a9cc-8cee0605deaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_ee2a871e-24c1-4782-8ea4-88c5eb7284e4" xlink:to="loc_us-gaap_RestructuringCharges_0dcdc0ac-3bb4-413b-a9cc-8cee0605deaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_SergeSaxonovCommonStockPlusMember" xlink:href="txg-20250331.xsd#txg_SergeSaxonovCommonStockPlusMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_txg_SergeSaxonovCommonStockPlusMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_SergeSaxonovCarryoverSharesFromPrior10b51PlanMember" xlink:href="txg-20250331.xsd#txg_SergeSaxonovCarryoverSharesFromPrior10b51PlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_txg_SergeSaxonovCarryoverSharesFromPrior10b51PlanMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_txg_SergeSaxonovMember" xlink:href="txg-20250331.xsd#txg_SergeSaxonovMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_txg_SergeSaxonovMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>txg-20250331_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 txg-20250331_g1.jpg
M_]C_X  02D9)1@ ! @$ D "0  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     !  D     $  0"0     0 !_^&.%FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI
M2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN
M<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@-2XV+6,Q-#4@-SDN
M,38S-#DY+" R,#$X+S X+S$S+3$V.C0P.C(R(" @(" @(" B/@H@(" \<F1F
M.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M
M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G
M+V1C+V5L96UE;G1S+S$N,2\B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z
M>&UP1TEM9STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(*
M(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @
M(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SII
M;&QU<W1R871O<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O<B\Q
M+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS
M(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+V<O(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N
M<RYA9&]B92YC;VTO<&1F+S$N,R\B"B @(" @(" @(" @('AM;&YS.G!D9G@]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F>"\Q+C,O(CX*(" @(" @(" @/&1C
M.F9O<FUA=#YI;6%G92]J<&5G/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT
M:71L93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^5V5B/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @
M(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!);&QU<W1R871O<B!#0R R,RXP
M("A-86-I;G1O<V@I/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z
M0W)E871E1&%T93XR,#$Y+3 X+3(S5#$S.C(T.C(R+3 W.C P/"]X;7 Z0W)E
M871E1&%T93X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,3DM,#@M,C-4
M,C Z,C0Z,C):/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A
M9&%T841A=&4^,C Q-BTP."TR.50R,CHT.#HR,RTP-SHP,#PO>&UP.DUE=&%D
M871A1&%T93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @
M(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I
M9'1H/C(U-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM
M<$=);6<Z:&5I9VAT/C(U-CPO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @
M(" @(" @(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*
M(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*
M4F=!0D%G14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!
M*S!!04%!04%"04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB
M,DIL04=404%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G
M9TQ$06]+0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X
M=V)'>'-C2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X
M9B8C>$$[2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9DAX.&9(>#AF+SA!04519T)!045!07=%4B8C>$$[04%)
M4D%135)!9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(
M0T%K2T-W14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)
M0U%O3$5!04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%
M,D5I8UE%54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K
M<4MY63-00TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T
M3E9+0G)Y-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V
M63-2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM
M6B8C>$$[<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%5
M14)1645#04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(
M=T9-2%(T4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15
M:W=G2D-H9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515
M-5!2;&195U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q
M*V8S3T5H66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/
M:W!A86YQ2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y531Q-T9867$W
M1EA9<3=&6%EQ-R8C>$$[1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1B8C>$$[6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6"8C>$$[67$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98628C>$$[<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<28C>$$[-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-R8C>$$[1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1B8C>$$[6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6"8C>$$[67$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98628C>$$[<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<28C>$$[-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-R8C>$$[1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1B8C>$$[6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6"8C>$$[67$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98628C>$$[<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<28C>$$[-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-R8C>$$[1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1B8C>$$[6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6"8C>$$[67$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98628C>$$[<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<28C>$$[-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-R8C>$$[1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1B8C>$$[6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6"8C>$$[67$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98628C>$$[<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<28C>$$[-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-R8C>$$[1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1B8C>$$[6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6"8C>$$[67$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98628C>$$[<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<28C>$$[-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-R8C>$$[1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1B8C>$$[6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6"8C>$$[67$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98628C>$$[<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6"\O,E$]/3PO>&UP1TEM9SII;6%G93X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L
M=#X*(" @(" @(" @/"]X;7 Z5&AU;6)N86EL<SX*(" @(" @(" @/'AM<$U-
M.E)E;F1I=&EO;D-L87-S/G!R;V]F.G!D9CPO>&UP34TZ4F5N9&ET:6]N0VQA
M<W,^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^=75I9#HV
M-44V,SDP-C@V0T8Q,41"039%,D0X.#=#14%#0C0P-SPO>&UP34TZ3W)I9VEN
M86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N
M9&ED.F%A83,P96(R+6$U-&4M-# Q-2UA8C<U+3 R,#0S9&4R-68Q83PO>&UP
M34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^=75I
M9#HU83$P,S=E-RTY,S@P+3!F-#@M8F(R."TU930P,#-A,34X.6$\+WAM<$U-
M.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T
M86YC94E$/G5U:60Z9C<V9C,V-30M,#-B82UF-#0Q+3@Q,F,M9C X8C@R,S5F
M,39F/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C
M=6UE;G1)1#YX;7 N9&ED.C<Q,F,X93 V+6%A,S0M-#8S82TX-C<W+30T,C,Q
M,&4P8C=E.#PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F
M.F]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C8U138S.3 V.#9#1C$Q1$)!-D4R
M1#@X-T-%04-"-# W/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @
M(" @(" @(#QS=%)E9CIR96YD:71I;VY#;&%S<SYP<F]O9CIP9&8\+W-T4F5F
M.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M
M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI3
M97$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z140W1C$Q-S0P-S(P-C@Q,3DQ,#E$,C!#.3!#13<Y
M-#0\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,#DM,3(M,C!4,C(Z-#<Z-#0M,#@Z,# \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M($EL;'5S=')A=&]R($-3-3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z86%A,S!E8C(M
M834T92TT,#$U+6%B-S4M,#(P-#-D93(U9C%A/"]S=$5V=#II;G-T86YC94E$
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#$V+3 X+3(Y5#(R
M.C0X.C(R+3 W.C P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#0R R,#$W
M("A-86-I;G1O<V@I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@
M(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QI;&QU<W1R871O
M<CI3=&%R='5P4')O9FEL93Y796(\+VEL;'5S=')A=&]R.E-T87)T=7!0<F]F
M:6QE/@H@(" @(" @(" \:6QL=7-T<F%T;W(Z5'EP93Y$;V-U;65N=#PO:6QL
M=7-T<F%T;W(Z5'EP93X*(" @(" @(" @/'AM<%109SI.4&%G97,^,3PO>&UP
M5%!G.DY086=E<SX*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE5')A;G-P
M87)E;F-Y/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3X*
M(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/D9A;'-E/"]X
M;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#X*(" @(" @(" @/'AM<%109SI-
M87A086=E4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(#QS=$1I;3IW/CDV,"XP,# P,# \+W-T1&EM.G<^"B @(" @(" @(" @
M(#QS=$1I;3IH/C4V,"XP,# P,# \+W-T1&EM.F@^"B @(" @(" @(" @(#QS
M=$1I;3IU;FET/E!I>&5L<SPO<W1$:6TZ=6YI=#X*(" @(" @(" @/"]X;7!4
M4&<Z36%X4&%G95-I>F4^"B @(" @(" @(#QX;7!44&<Z4W=A=&-H1W)O=7!S
M/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W871C:"!'<F]U<#PO>&UP1SIG
M<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P5'EP93XP
M/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z0V]L
M;W)A;G1S/@H@(" @(" @(" @(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @
M(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C
M:$YA;64^5VAI=&4\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6]D93Y21T(\+WAM<$<Z;6]D93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'
M.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G)E9#XR
M-34\+WAM<$<Z<F5D/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIG<F5E;CXR-34\+WAM<$<Z9W)E96X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F)L=64^,C4U/"]X;7!'.F)L=64^"B @(" @(" @(" @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y";&%C:SPO>&UP
M1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM;V1E/E)'0CPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z<F5D/C \+WAM<$<Z<F5D/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIG<F5E;CXP/"]X;7!'.F=R
M965N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;'5E/C \
M+WAM<$<Z8FQU93X*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIS=V%T8VA.86UE/E)'0B!2960\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y21T(\+WAM<$<Z;6]D
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#
M15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G)E9#XR-34\+WAM<$<Z<F5D/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIG<F5E;CXP/"]X;7!'.F=R965N/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIB;'5E/C \+WAM<$<Z8FQU93X*(" @(" @
M(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/E)'0B!9
M96QL;W<\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6]D93Y21T(\+WAM<$<Z;6]D93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G)E9#XR-34\+WAM
M<$<Z<F5D/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIG<F5E
M;CXR-34\+WAM<$<Z9W)E96X^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F)L=64^,#PO>&UP1SIB;'5E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^4D="($=R965N/"]X;7!'.G-W
M871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO
M9&4^4D="/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIR960^,#PO>&UP1SIR960^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F=R965N/C(U-3PO>&UP1SIG<F5E
M;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQU93XP/"]X
M;7!'.F)L=64^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M<W=A=&-H3F%M93Y21T(@0WEA;CPO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/E)'0CPO>&UP1SIM;V1E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%
M4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z<F5D/C \+WAM<$<Z<F5D/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIG<F5E;CXR-34\+WAM<$<Z9W)E96X^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F)L=64^,C4U/"]X;7!'.F)L=64^"B @(" @
M(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y21T(@
M0FQU93PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM;V1E/E)'0CPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<F5D/C \+WAM<$<Z
M<F5D/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIG<F5E;CXP
M/"]X;7!'.F=R965N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIB;'5E/C(U-3PO>&UP1SIB;'5E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G-W871C:$YA;64^4D="($UA9V5N=&$\+WAM<$<Z<W=A
M=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D
M93Y21T(\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G)E9#XR-34\+WAM<$<Z<F5D/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIG<F5E;CXP/"]X;7!'.F=R965N
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;'5E/C(U-3PO
M>&UP1SIB;'5E/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G-W871C:$YA;64^4CTQ.3,@1STS.2!"/30U/"]X;7!'.G-W871C:$YA;64^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^4D="/"]X
M;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y
M<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIR960^,3DS/"]X;7!'.G)E9#X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z9W)E96X^,SD\+WAM<$<Z9W)E96X^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L=64^-#4\+WAM<$<Z8FQU
M93X*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.
M86UE/E(],C,W($<],C@@0CTS-CPO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/E)'0CPO>&UP1SIM;V1E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%
M4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z<F5D/C(S-SPO>&UP1SIR960^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.F=R965N/C(X/"]X;7!'.F=R965N/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIB;'5E/C,V/"]X;7!'.F)L=64^"B @(" @
M(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y2/3(T
M,2!'/3DP($(],S8\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6]D93Y21T(\+WAM<$<Z;6]D93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'
M.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G)E9#XR
M-#$\+WAM<$<Z<F5D/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIG<F5E;CXY,#PO>&UP1SIG<F5E;CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8FQU93XS-CPO>&UP1SIB;'5E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^4CTR-#<@1STQ-#<@
M0CTS,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM;V1E/E)'0CPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<F5D/C(T-SPO>&UP
M1SIR960^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F=R965N
M/C$T-SPO>&UP1SIG<F5E;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQU93XS,#PO>&UP1SIB;'5E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^4CTR-3$@1STQ-S8@0CTU.3PO
M>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM;V1E/E)'0CPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<F5D/C(U,3PO>&UP1SIR960^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F=R965N/C$W-CPO
M>&UP1SIG<F5E;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8FQU93XU.3PO>&UP1SIB;'5E/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G-W871C:$YA;64^4CTR-3(@1STR,S@@0CTS,SPO>&UP1SIS
M=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M;V1E/E)'0CPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z<F5D/C(U,CPO>&UP1SIR960^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F=R965N/C(S.#PO>&UP1SIG
M<F5E;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQU93XS
M,SPO>&UP1SIB;'5E/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G-W871C:$YA;64^4CTR,3<@1STR,C0@0CTS,SPO>&UP1SIS=V%T8VA.
M86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/E)'
M0CPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z<F5D/C(Q-SPO>&UP1SIR960^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F=R965N/C(R-#PO>&UP1SIG<F5E;CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQU93XS,SPO>&UP
M1SIB;'5E/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^4CTQ-# @1STQ.3@@0CTV,SPO>&UP1SIS=V%T8VA.86UE/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/E)'0CPO>&UP
M1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E
M/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z<F5D/C$T,#PO>&UP1SIR960^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F=R965N/C$Y.#PO>&UP1SIG<F5E;CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQU93XV,SPO>&UP1SIB;'5E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA
M;64^4CTU-R!'/3$X,2!"/3<T/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^4D="/"]X;7!'.FUO9&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T53
M4SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIR960^-3<\+WAM<$<Z<F5D/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIG<F5E;CXQ.#$\+WAM<$<Z9W)E96X^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F)L=64^-S0\+WAM<$<Z8FQU93X*(" @(" @
M(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/E(],"!'
M/3$T-B!"/38Y/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUO9&4^4D="/"]X;7!'.FUO9&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT
M>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIR960^,#PO
M>&UP1SIR960^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F=R
M965N/C$T-CPO>&UP1SIG<F5E;CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8FQU93XV.3PO>&UP1SIB;'5E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^4CTP($<],3 T($(]-34\
M+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6]D93Y21T(\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G)E9#XP/"]X;7!'.G)E9#X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)E96X^,3 T/"]X
M;7!'.F=R965N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB
M;'5E/C4U/"]X;7!'.F)L=64^"B @(" @(" @(" @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z<W=A=&-H3F%M93Y2/3,T($<],3@Q($(],3$U/"]X;7!'.G-W
M871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO
M9&4^4D="/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIR960^,S0\+WAM<$<Z<F5D/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIG<F5E;CXQ.#$\+WAM<$<Z9W)E
M96X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L=64^,3$U
M/"]X;7!'.F)L=64^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z<W=A=&-H3F%M93Y2/3 @1STQ-CD@0CTQ-3<\+WAM<$<Z<W=A=&-H3F%M
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y21T(\
M+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G)E9#XP/"]X;7!'.G)E9#X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z9W)E96X^,38Y/"]X;7!'.F=R965N/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;'5E/C$U-SPO>&UP1SIB
M;'5E/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C
M:$YA;64^4CTT,2!'/3$W,2!"/3(R-CPO>&UP1SIS=V%T8VA.86UE/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/E)'0CPO>&UP1SIM
M;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!2
M3T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z<F5D/C0Q/"]X;7!'.G)E9#X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z9W)E96X^,3<Q/"]X;7!'.F=R965N/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIB;'5E/C(R-CPO>&UP1SIB;'5E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^
M4CTP($<],3$S($(],3@X/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^4D="/"]X;7!'.FUO9&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIR
M960^,#PO>&UP1SIR960^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F=R965N/C$Q,SPO>&UP1SIG<F5E;CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8FQU93XQ.#@\+WAM<$<Z8FQU93X*(" @(" @(" @
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/E(]-#8@1STT
M.2!"/3$T-CPO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM;V1E/E)'0CPO>&UP1SIM;V1E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<F5D/C0V/"]X
M;7!'.G)E9#X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)E
M96X^-#D\+WAM<$<Z9W)E96X^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F)L=64^,30V/"]X;7!'.F)L=64^"B @(" @(" @(" @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y2/3(W($<],C @0CTQ,# \
M+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6]D93Y21T(\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G)E9#XR-SPO>&UP1SIR960^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F=R965N/C(P/"]X
M;7!'.F=R965N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB
M;'5E/C$P,#PO>&UP1SIB;'5E/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G-W871C:$YA;64^4CTQ,#(@1STT-2!"/3$T-3PO>&UP1SIS
M=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M;V1E/E)'0CPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z<F5D/C$P,CPO>&UP1SIR960^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F=R965N/C0U/"]X;7!'.F=R
M965N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;'5E/C$T
M-3PO>&UP1SIB;'5E/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G-W871C:$YA;64^4CTQ-#<@1STS.2!"/3$T,SPO>&UP1SIS=V%T8VA.
M86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/E)'
M0CPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z<F5D/C$T-SPO>&UP1SIR960^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F=R965N/C,Y/"]X;7!'.F=R965N/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;'5E/C$T,SPO>&UP
M1SIB;'5E/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^4CTQ-3@@1STP($(].3,\+WAM<$<Z<W=A=&-H3F%M93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y21T(\+WAM<$<Z
M;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y0
M4D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G)E9#XQ-3@\+WAM<$<Z<F5D/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIG<F5E;CXP/"]X;7!'.F=R965N/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIB;'5E/CDS/"]X;7!'.F)L=64^"B @
M(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y2
M/3(Q,B!'/3(P($(].3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y21T(\+WAM<$<Z;6]D93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X
M;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G)E
M9#XR,3(\+WAM<$<Z<F5D/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIG<F5E;CXR,#PO>&UP1SIG<F5E;CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8FQU93XY,#PO>&UP1SIB;'5E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^4CTR,S<@1STS
M,"!"/3$R,3PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM;V1E/E)'0CPO>&UP1SIM;V1E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<F5D/C(S-SPO
M>&UP1SIR960^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F=R
M965N/C,P/"]X;7!'.F=R965N/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIB;'5E/C$R,3PO>&UP1SIB;'5E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^4CTQ.3D@1STQ-S@@0CTQ
M-3,\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6]D93Y21T(\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G)E9#XQ.3D\+WAM<$<Z
M<F5D/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIG<F5E;CXQ
M-S@\+WAM<$<Z9W)E96X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F)L=64^,34S/"]X;7!'.F)L=64^"B @(" @(" @(" @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y2/3$U,R!'/3$S-"!"/3$Q-SPO
M>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM;V1E/E)'0CPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<F5D/C$U,SPO>&UP1SIR960^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F=R965N/C$S-#PO
M>&UP1SIG<F5E;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8FQU93XQ,3<\+WAM<$<Z8FQU93X*(" @(" @(" @(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIS=V%T8VA.86UE/E(],3$U($<].3D@0CTX-SPO>&UP1SIS
M=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M;V1E/E)'0CPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z<F5D/C$Q-3PO>&UP1SIR960^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F=R965N/CDY/"]X;7!'.F=R
M965N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;'5E/C@W
M/"]X;7!'.F)L=64^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z<W=A=&-H3F%M93Y2/3@S($<]-S$@0CTV-3PO>&UP1SIS=V%T8VA.86UE
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/E)'0CPO
M>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT
M>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z<F5D/C@S/"]X;7!'.G)E9#X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z9W)E96X^-S$\+WAM<$<Z9W)E96X^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L=64^-C4\+WAM<$<Z8FQU
M93X*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.
M86UE/E(],3DX($<],34V($(],3 Y/"]X;7!'.G-W871C:$YA;64^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^4D="/"]X;7!'.FUO
M9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/
M0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIR960^,3DX/"]X;7!'.G)E9#X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z9W)E96X^,34V/"]X;7!'.F=R965N/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIB;'5E/C$P.3PO>&UP1SIB;'5E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^
M4CTQ-C8@1STQ,C0@0CTX,CPO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/E)'0CPO>&UP1SIM;V1E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\
M+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M<F5D/C$V-CPO>&UP1SIR960^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F=R965N/C$R-#PO>&UP1SIG<F5E;CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8FQU93XX,CPO>&UP1SIB;'5E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^4CTQ-# @
M1STY."!"/34W/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUO9&4^4D="/"]X;7!'.FUO9&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT
M>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIR960^,30P
M/"]X;7!'.G)E9#X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M9W)E96X^.3@\+WAM<$<Z9W)E96X^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.F)L=64^-3<\+WAM<$<Z8FQU93X*(" @(" @(" @(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/E(],3$W($<]-S8@0CTS
M-CPO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIM;V1E/E)'0CPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<F5D/C$Q-SPO>&UP1SIR
M960^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F=R965N/C<V
M/"]X;7!'.F=R965N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIB;'5E/C,V/"]X;7!'.F)L=64^"B @(" @(" @(" @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y2/3DV($<]-38@0CTQ.3PO>&UP1SIS
M=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M;V1E/E)'0CPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z<F5D/CDV/"]X;7!'.G)E9#X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)E96X^-38\+WAM<$<Z9W)E
M96X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L=64^,3D\
M+WAM<$<Z8FQU93X*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIS=V%T8VA.86UE/E(]-C8@1STS,R!"/3$Q/"]X;7!'.G-W871C:$YA;64^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^4D="/"]X
M;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y
M<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIR960^-C8\+WAM<$<Z<F5D/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIG<F5E;CXS,SPO>&UP1SIG<F5E;CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQU93XQ,3PO>&UP1SIB;'5E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" \+WAM
M<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y'<F%Y<SPO>&UP1SIG
M<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P5'EP93XQ
M/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z0V]L
M;W)A;G1S/@H@(" @(" @(" @(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @
M(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C
M:$YA;64^4CTP($<],"!"/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y21T(\+WAM<$<Z;6]D93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3
M/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G)E9#XP/"]X;7!'.G)E9#X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z9W)E96X^,#PO>&UP1SIG<F5E;CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8FQU93XP/"]X;7!'.F)L=64^"B @(" @(" @(" @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y2/3(V($<],C8@
M0CTR-CPO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM;V1E/E)'0CPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<F5D/C(V/"]X;7!'
M.G)E9#X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)E96X^
M,C8\+WAM<$<Z9W)E96X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F)L=64^,C8\+WAM<$<Z8FQU93X*(" @(" @(" @(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIS=V%T8VA.86UE/E(]-3$@1STU,2!"/34Q/"]X;7!'
M.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUO9&4^4D="/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIR960^-3$\+WAM<$<Z<F5D/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIG<F5E;CXU,3PO>&UP1SIG
M<F5E;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQU93XU
M,3PO>&UP1SIB;'5E/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G-W871C:$YA;64^4CTW-R!'/3<W($(]-S<\+WAM<$<Z<W=A=&-H3F%M
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y21T(\
M+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G)E9#XW-SPO>&UP1SIR960^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F=R965N/C<W/"]X;7!'.F=R965N/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;'5E/C<W/"]X;7!'.F)L
M=64^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H
M3F%M93Y2/3$P,B!'/3$P,B!"/3$P,CPO>&UP1SIS=V%T8VA.86UE/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/E)'0CPO>&UP1SIM
M;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!2
M3T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z<F5D/C$P,CPO>&UP1SIR960^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F=R965N/C$P,CPO>&UP1SIG<F5E;CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQU93XQ,#(\+WAM<$<Z8FQU93X*
M(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE
M/E(],3(X($<],3(X($(],3(X/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^4D="/"]X;7!'.FUO9&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T53
M4SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIR960^,3(X/"]X;7!'.G)E9#X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z9W)E96X^,3(X/"]X;7!'.F=R965N/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIB;'5E/C$R.#PO>&UP1SIB;'5E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^4CTQ
M-3,@1STQ-3,@0CTQ-3,\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y21T(\+WAM<$<Z;6]D93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X
M;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G)E
M9#XQ-3,\+WAM<$<Z<F5D/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIG<F5E;CXQ-3,\+WAM<$<Z9W)E96X^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F)L=64^,34S/"]X;7!'.F)L=64^"B @(" @(" @
M(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y2/3$W.2!'
M/3$W.2!"/3$W.3PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM;V1E/E)'0CPO>&UP1SIM;V1E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z
M='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<F5D/C$W
M.3PO>&UP1SIR960^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F=R965N/C$W.3PO>&UP1SIG<F5E;CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8FQU93XQ-SD\+WAM<$<Z8FQU93X*(" @(" @(" @(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/E(],C T($<],C T
M($(],C T/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUO9&4^4D="/"]X;7!'.FUO9&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIR960^,C T/"]X
M;7!'.G)E9#X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)E
M96X^,C T/"]X;7!'.F=R965N/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIB;'5E/C(P-#PO>&UP1SIB;'5E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^4CTR,S @1STR,S @0CTR
M,S \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6]D93Y21T(\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G)E9#XR,S \+WAM<$<Z
M<F5D/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIG<F5E;CXR
M,S \+WAM<$<Z9W)E96X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F)L=64^,C,P/"]X;7!'.F)L=64^"B @(" @(" @(" @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y2/3(T,B!'/3(T,B!"/3(T,CPO
M>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM;V1E/E)'0CPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<F5D/C(T,CPO>&UP1SIR960^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F=R965N/C(T,CPO
M>&UP1SIG<F5E;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8FQU93XR-#(\+WAM<$<Z8FQU93X*(" @(" @(" @(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(#PO<F1F.E-E<3X*(" @
M(" @(" @(" @(" @(" @/"]X;7!'.D-O;&]R86YT<SX*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U
M<$YA;64^5V5B($-O;&]R($=R;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @(" @
M(" @(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C$\+WAM<$<Z9W)O=7!4>7!E
M/@H@(" @(" @(" @(" @(" @(" \>&UP1SI#;VQO<F%N=',^"B @(" @(" @
M(" @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y2/38S($<],38Y
M($(],C0U/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUO9&4^4D="/"]X;7!'.FUO9&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIR960^-C,\+WAM
M<$<Z<F5D/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIG<F5E
M;CXQ-CD\+WAM<$<Z9W)E96X^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F)L=64^,C0U/"]X;7!'.F)L=64^"B @(" @(" @(" @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y2/3$R,B!'/3(P,2!"/38W
M/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUO9&4^4D="/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIR960^,3(R/"]X;7!'.G)E
M9#X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)E96X^,C Q
M/"]X;7!'.F=R965N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIB;'5E/C8W/"]X;7!'.F)L=64^"B @(" @(" @(" @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y2/3(U-2!'/3$T-R!"/3,P/"]X;7!'
M.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUO9&4^4D="/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIR960^,C4U/"]X;7!'.G)E9#X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)E96X^,30W/"]X;7!'
M.F=R965N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;'5E
M/C,P/"]X;7!'.F)L=64^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z<W=A=&-H3F%M93Y2/3(U-2!'/3(Y($(],S<\+WAM<$<Z<W=A=&-H
M3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y2
M1T(\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G)E9#XR-34\+WAM<$<Z<F5D/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIG<F5E;CXR.3PO>&UP1SIG<F5E;CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQU93XS-SPO>&UP
M1SIB;'5E/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^4CTR-34@1STQ,C,@0CTQ-S(\+WAM<$<Z<W=A=&-H3F%M93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y21T(\+WAM
M<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP
M93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G)E9#XR-34\+WAM<$<Z<F5D/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIG<F5E;CXQ,C,\+WAM<$<Z9W)E96X^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L=64^,3<R/"]X;7!'.F)L
M=64^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H
M3F%M93Y2/3$X.2!'/3(P-"!"/3(Q,CPO>&UP1SIS=V%T8VA.86UE/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/E)'0CPO>&UP1SIM
M;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!2
M3T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z<F5D/C$X.3PO>&UP1SIR960^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F=R965N/C(P-#PO>&UP1SIG<F5E;CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQU93XR,3(\+WAM<$<Z8FQU93X*
M(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @(" @(" @(" @/"]X;7!'
M.D-O;&]R86YT<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4W=A=&-H1W)O=7!S
M/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#$U
M+C P/"]P9&8Z4')O9'5C97(^"B @(" @(" @(#QP9&9X.D-R96%T;W)697)S
M:6]N/C(Q+C N,#PO<&1F>#I#<F5A=&]R5F5R<VEO;CX*(" @(" @/"]R9&8Z
M1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_B#%A)0T-?
M4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 & #$
M &%C<W!-4T94     $E%0R!S4D="                  #VU@ !     -,M
M2% @(
M        $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P    %&)K
M<'0   ($    %')865H   (8    %&=865H   (L    %&)865H   )
M%&1M;F0   )4    <&1M9&0   +$    B'9U960   -,    AG9I97<   /4
M    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P    #')44D,
M  0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P>7)I
M9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C
M     !)S4D="($E%0S8Q.38V+3(N,0              $G-21T(@245#-C$Y
M-C8M,BXQ
M              !865H@        \U$  0    $6S%A96B
M        6%E:(        &^B   X]0   Y!865H@        8ID  +>%   8
MVEA96B         DH   #X0  +;/9&5S8P         6245#(&AT=' Z+R]W
M=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                                         &1E
M<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P
M86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@1&5F875L="!2
M1T(@8V]L;W5R('-P86-E("T@<U)'0@                            !D
M97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#
M-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET
M:6]N(&EN($E%0S8Q.38V+3(N,0
M=FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(
M3 E6 %    !7'^=M96%S          $                        "CP
M  )S:6<@     $-25"!C=7)V        !      %  H #P 4 !D '@ C "@
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M P,# P,# P,# P,# P,# P,# __  !$( [8%> ,!$0 "$0$#$0'_Q #P  $
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MX?$FA-5&&>)DI/_:  P# 0 "$0,1 #\ O\
M
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MJT9NG6C*%1;TTT^P]IEX3A4CSZ;4H/A3Q791]\<9]
M
M
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ML[F-Y:T[J*<8U(*23WK%'>8Z1V0
M                  /%_)GS$>$W#UB7^D1R1UGK^ZB,E(5A/SR>3;(?:47X
MMR+K7$6;[.I##JNB2=37^"1G\I9%U,9C+L@SG-FOH^WJ5(/V6&$/?RPCZIC[
MS-LNL%_%UH0EQ8XR]ZL9>H5^>1OJQN/6*.V-/Q@X[[#W!-84Y'C9ALRZK=58
MBXX7:;=C74U='S3+;F!T,R\*6U2/FHO^:70SG>7]%U_52GF5Q3I+VL$YRZC;
MYL4^ISD1:[UQ:0QC94IU'QR?-78VM]? @LW[ZD;S/]U*F0\6V)@W'K'I25L*
MJ-*8'7Q9ZXW51-&YEVP7\^R^)/)'0W'Z^;7DI9&:4-I/L*:V/1YIJSP=6G.X
MJ+AJ2>'O8\V.'(TR-76KLYN-D)QI0XH1]>7.?8:(>=N<C.0&_K)5OO'=VV=O
MV)O^\(D[*V%E>:G'<+O)M,)O(;6P9@,,(6:&FF4MMM-_(0E*2(A+;7+["QCS
M+*C2I1]Q",>TEB8"O=W5T^=<U*E1^ZDWVV=,CMG7
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MW,NQ+!OK8DAPP!E0
M
M
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MKAJ6XZXM1J4I1F9F?4Q+$DE@MQ@&VWB]Y_D
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M8
M
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M5*O&KNJ?M'>_.9^,R\,C]#VWR,>T2$# F5
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MK:B=T*]&YI*M;RC.D]S3Q7^7)P'8@ZYR@
M
M
M            $.7FA><[QP\M['IF+O2(FW.2UG6^\8MH_';=EM^H*4SWP,@V
MC<L(F%A..J)27&F5MKL[%)E[LP;1N269;IK2&8:AJ*JL:67)]U4:W\:@O9/U
M%PO'8\!G.H;3*(<SXR\:V03W<LGP+U7P+A,[#F7SCY'\\MK3-M<BL\F9-9)5
M)CXKBD$WJ[ ]>TLATG2Q_!L8*0]$IH!$A!.O*-V;-6@G)3[[O58O[*,ER_([
M56N7P48^RD]LIOCE+A?J+<DD5/F&97>9U_+W<L7P+V,5Q17!VWPMGD894Z(
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MY"K\SSF_S6ISKJ?P>.R"V176X7RO%\I'X,Z8L
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MO'P-]S)^Y;X?<O;Q-E@H0,E(
M
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M9F8N.G3IT::I4HJ-**P22P22W));$BNYSG4FZE1N4V\6WM;?&V?#'V?(
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M.*<==<4I;BU&I1F9F8M:,8PBHQ244L$EN2XD0-MR;E)XR9^0?I^
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M_7>GN:VK86;0KT;FE&O0DITI+%-;4_\ +AXGL9V . Y0
M
M
M             #SIRBY7Z#X::GN=T<B=A5&O\)JNL:(J8LY-[E%VMEU^'C&&
MX]&\2UR?)+!+*C;BQ6UJ0VA;SIML-NNHR&697?9O=*SR^FZE9]B*XY/<DN-]
M1;6D=2]OK7+Z#N+N:A379;XDM[?(NT9Z'FJ>>IR \P>?=ZPUZJXT9Q0*2Y'C
M:V@3VD9=LJ(P\2HEKN"]KG5HFD[V$ZB@A/'3Q%&DG53WF6Y8OK3&BK#(8QN;
MC"OFF'?M=S#DII^,^Z?!S4VBJL[U+=9JW1I8TK'VO#+EF_S5L7+O()!-B-
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MRJDSS45SF\W2AC3L4]D>%\LN-\2W+E>TA($R(Z
M                                           2B^67YKG(?RT=C?..
M"SGLYTCD]HQ*VAH>^LY#6+9*1MM1'\AQM\T2OH9G\>"RA#5I&:44A++34UJ4
MPVVVB-:CTO8:BM^;77,O8KN*J7=+D?MHX^Q>[:TTWB9G)\\N\GJXTGSK:3[J
M#W/E7%+E[.*-*#AIS5X_\\-+TN[^/>7-7U!.2U$R/&;%4*)G.NLD\(G)>(;
MQZ+-G+H;^)_G)Z..Q9C!HDQ'I$5QIY>O&;Y/?Y)>2LK^'-J+<UWLU[:+P6*]
M5/8TFFBWLOS&US.W5S:RQB]ZX8OBDN!^H]ZQ1ZP&+.\
M
M
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MCUWB]I3N<YU<YQ<<^IC&WB^XACL2XWQR?"^LMA&$)(88
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M>:6V;6RN+=[=THO?%\3]9[FNNE[@&%,D
M
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M\''O>_!4WGF=5LXN>>\8VL,>9'B7&_=/AXMRY8JQ)C"
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MGBG@TT7/E]_;YE:QNK9XP>]<,7PI\J]7>MC/4XQAW0
M
M
M\Z<HN5^@^&FI[G='(G851K_":KK&B*F+.3>Y1=K9=?AXQAN/1O$M<GR2P2RH
MVXL5M:D-H6\Z;;#;KJ,AEF5WV;W2L\OINI6?8BN.3W)+C?46UI'4O;ZUR^@[
MB[FH4UV6^)+>WR+M&>;YK'GH;]\PR?<:PP#YXT=Q/;F*1$UI L$(RS94>*]W
M0;?<-W6NK;L"6I!/MT$-U5/#<[/$.>^PU,*^M,:*L<@BKFOA6S3#OVNYAQJF
MGNXN<^Z?!S4VBJL[U+=9JW1I8T[''O>&7+-_FK8N5K$@G$V(T
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M@EBHXNI-39\\TN/-[=OS"F]GNW[9\GM5Q;=[P5?D3LBP
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M>]-;_P#]=SWHN6C6I7%*->BU*E-)IKA3.=#@.4
M
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MREPOU%N22V%49AF-WF==W%W+G2X%[&*XHK@7JOA;9Y.&4.B
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MO7A+U#!W.4YE:;;BA4C%</-;7OEBO5/&@RYCP
M "TUZ<?S7GN.VS:[@WO3(E)T5N3)B3J"_MY*U1M5;?R"2VPU0$\Z9^X81M"P
M<2TXCK[O!OEMR22VB;8/BL^D'2ZS"V>=64?XVC'X1+V=-</+*"Z[CLVX11--
M)9X[2LLMN7_#5)=PW[&3X.I+U);>%LO]BBRT0
M
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MS,7%3ITZ4%2I14:<5@DDDDEN22V)+B17DYSJ2<YMRFWBVWBV^-OA/C#Z/D
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MV6&&D$1)0A))21="(1ER<FY2;<GPF:226"V(_4/P_0
M     \)<CO+(X$<L6Y[N\N+FJ<EOK'Q%2<XI:$L#V*XZM/1#SNPL"=QK,9?@
MK(E);?FNL=W7J@R4HCS>7ZDSS*\%97-6,%[%OG0][+&/81C+O)LLOL?.:,)2
M?"ES9>^C@_5*Z_*?TFV!VK5E?<->15YB-D:7'H>N=^06LEQU]]9K446'L?#:
MVMOJ& S[$MIDT=T^9?Y[QF74Y_EG2C7BU#-[>,X^WI;'[R3:;ZDHKD(I>Z'I
M2QEE]5Q?M9[5[Y;5V'U2KSS \L/F_P &)4E[D)HK**7#6Y7NT3:N,(1FNJ+
MW'_ A'].<<.=54DJS5[8\&V.NLEIZ]8Y=#(K*RG4F39TL+"O&5;#O'W,UQ]R
M\&\.%QQ7*0N_R;,LM?\ %4I*G[9;8^^6Q=1X/D/ HSAC
M    #^DJ4A25H4I"T*)25),TJ2I)]4J2HNADHC+V& -);R O,\/G5QK_ #2;
M4OE3N3?'.JJ:++Y=C)2Y9[+UWT*MQ#9Q*<,I,ZV:)E-9?N?C5?.+;4MU9'8M
MMIUYUUIOZ$S'SJUCAEMPVXX;H3WRAR+ACR8I=Z6[I?.?I.S\A7>-Y223XY1X
M)=7@ER[>$G]$%)0
M
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MNPZC^J5>-7=4_:.]^<S\9EX9'Z'MOD8]HD(&!,J
M       'SK>WJZ"IL[Z\L85/24E=-M[BVLI+,*NJZNMC.S+"QL)DA;<>)"A1
M&5NNNK4E#;:34HR(C,?4(2J24()N;>"2VMM[DN5GY*48Q<I-**6+?$C+2\X;
MS$;CS%^7N4; J9T]O1NNE3M?Z Q^24J,VQA,*:9S<SF5CZR3%R/8UDS\XRC-
MM#[40H<-PU^YH4>R^D\@AI_*8T))>>U,)57[KVN/%!;%P8XOA*6S_-I9M?RJ
MQ;\VAW,%R<?5EO?)@N BH$G,(                  '??'+B]O[EOL>OU/Q
MTU;E.T\WG)2^]7X]"(Z^CKC<2RN[RK()BXM!B5 RZM*%SK*3%BDXM+?>;BT)
M5T<PS*QRJW=UF%6-*BN%[V^**WR?(DV=FTLKJ_K*A:0E.H^+@Y6]R7*\$71^
M 7I<=.:Y9IM@\\LK3NS.&U1Y[>F<#L[:BU#2NDAMY$7)\D::J,SSZ9&D)(U(
MCKIZWJ2FG6IK2NXZ@SWI+N[ANAD<?(T=WE)).H_!6V,>OSGPIQ98>5Z+MZ.%
M7,Y>4J>TBVHKJO8Y>HNJ6HL UW@.J,1I< UAA6*:[P;'(I0J##\)Q^JQ?&J:
M*1FKP*VDI8L*NAH4M1J5V-EW*,U'U,S,5E7N*]U5=>YG*I6D]LI-R;ZK>TFM
M*E2H4U2HQC"FMR222ZR.8CA.0                               #\LZ
M#"LX4RMLH<6PKK"+(@SX$Z.U+A3H4MI;$J',BOH<8DQ9+#BD.-K2I"T*,C(R
M,?L92C)2BVI)XIK>F?C2:P>U,KK\^O3<<.>435UF_'9F/Q*W++4]-+Z&5*9F
ME<DFJ[G%,WFL&GX<?%52#2EM$C''JZ/'[E.N09CA]#G^1=(>;Y:U1S#^*LUL
M[I_")<D_9=2>+>[G(BF::1R^]QJ6GP%QR+N'U8\'XN'491[YL^79RQ\OW-48
MCR.UM*I*NRE.Q\2V7CKCN0ZLSI+?CK)>+9BS&CL*FJ8CJ=56SFH-Q'9Z+?B-
M)4DSN?)L_P KSVCY7+ZBE)+NH/9./A1]=8Q? V5OF.4WV5U/)W<,(O=);8RZ
MC]9X/C1X@&9,<                  'K_@CS$V#P1Y1:PY(Z]<?D/8?;HB9
MCC"9"H\3.]=6[C47-,*L#ZFSX=S4DHXSKB7$P[%J-*2DW&$#%9WE-#.\MJ9=
M<;%-=R_:S7>R74>_C6*X3OY9F%7++V%W2]B]J]M%[UUUNXG@^ UBM,[>P+?V
MI]=[KU?<HR#7VT<1I,UQ*V2CP79%/?06IL=J;%-2G(%I"-PV)<5SH[%E-N-.
M$2T*(M7;RTKV-U4L[E<VO2FXR7*GALXT]Z?"MI>%O7I75"%Q1>-*<4T^1^OQ
MG9@ZQS
M
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M7C5W5/VCO?G,_&9>&1^A[;Y&/:)"!@3*@
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M^]XO:6G96%IEU%4+2"A#AXV^-O>WU>ML/2PQQW
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M.B\UP<LIK/9ME3[<HKQE^,76!3I8@
M
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M)))+<DEL27$BO)SG4DYS;E-O%MO%M\;?"?&'T?(
M                  !K&^4[\,_@M]V'4?U2KQJ[JG[1WOSF?C,O#(_0]M\C
M'M$A P)E0                          .N]N;4PC1NKM@[CV5<M8_@.L,
M/R#.,NMW2\0X=#C=;(M)YQHY&3DV>\S&-N-';ZNR9"T--DI:TD?8M;6M>W-.
MTMUSJ]2:C%<K>"ZW&^!;3BKUZ=M1G<5GA2A%MOD6TR5.:W*C-.:G*'<7)7.5
MR&K'966S+"EI'I!R6\2PN 2*O",.B+Z^&<?&<7AQ8AK022?=;6\HN]Q9GM-D
M^64<GRVCEU#O:<,&_;2>V4NO+%\FXHS,;VIF-[4O*N^<MBXEN2ZRP1Y9&2.D
M                !;3\D7R!I>\4XCR[YP8L_ TD^Q"R34.C+8I4&WVR1N)D
MUF8[#AFEB36:O=;0EZ!7*4E_(D+2Z\3=9V)LJMUEKI67/RK)98WFU5*BVJ''
M&''/C>Z&Y=UWLYTYI=W/-O\ ,HX6^^,'OERR]SQ+V74WWLZJJK**LKJ2DKH%
M/34\"'55%150X]?65597QVXD"NKH$1MF)!@08C*&F66D);:;224D1$1"DY2E
M.3G-MS;Q;>UMO>V^%LLN,8QBHQ244L$EN2/WCY/T
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MN/C:4VL>-;XR7)*.#7(R]+&[IW]I3NZ7>3CCU'PKJIXI]0]##H';
M
M                                                    ,\WU OF3
M<Y<[Y!;+X69UC=OQMT9A-HA,775':JE2=Y8TZLY.+;'S'-(*([65XID49!2X
M5/#-%97OD;$U$BR@J<9OK0FG<EH6%/.*$E<7LUW[7Q;]E",7WLEN<GM:VK",
ML'56J<WS*K=3RZJG1MHOO4^_7!)OA3WI+8MSQ:*S@L8AX
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M-*4H2E"$I0A"22A"2)*4I271*4I+H24I(NA$7X!19:!_0
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M4ZN'$^\D^H\8M^ZBN G^B<RYLYY75>R7=PZJ[Y+JKNNLV7=!318P
M
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M^6*:>QI[4]C*;N;>M:5Y6UQ%QK0>#7^7!PI\*.JQV3A
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M*M5DY592;;>UMO:VWPMLN6$(4X*G32C3BDDEN26Y(^\/@^@
M                                   _E24K2I"TI6A:32M"B)25)471
M25)/J2DJ(^AD?X0!G8>H2\J&/POW"QR9T9CBH7&3>M_(18T=;&4FLT_MN:B7
M9V.*,-MDIN%A^81XSUC2IZI;C.HEP4H;9CQ?%O[06J'G%I]'7LL<RH1V-[ZE
M/<I<LH[%+CV2VMO"J-59&LON//+986=5[ENA+BZCWKKK@16[%A$1
M       .\.-6^\UXM[^U%R&UX[V9=J'.Z#-:R,N2_%BW+-5,0JVQJS>C?CRI
M<JI5R*V<E/M<ARW4_P#.'3S&QHYG8U;"X^*JP<7R8[FN6+P:Y4CL6=U4LKJG
M=TOC*<DURX;T^1K8^1FNYIS:V'[UU-K;=&OI_P Y81M7!\8S_%IBC:\9=)E=
M/$N8#4QMEUY$:QBLS":DL]QJ8D(6VKY23(:IW=K6LKJI9UUA6I3<9=6+P?6X
MN-%[V]>G<T(7%)XTYQ4EU&L3LD=<Y@
M
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M+&A:QYWX\L5#L=U+JQ1$M8YAYKEOFL'A5KO#\58.79V1ZC9G3B_BIP
M        #L#5.KLZW;LO!-0ZQQ^9E.P=DY338;B%!!(O&LKR]FM0(32W5FEF
M)$;<>\21(=4AB,PA;KJDMH4HN"ZN:%E;3N[F2C0IQ<I-\"2Q?_X6]O8CEH4:
MMS6C0HKG59R22Y6:N7EU\'\!\OGBKKWCOAA0K&XJXIY!L_-8\1$:3L+9]VTR
M[E6425>"S)7"0ZTW!JVWNYV+40XK"E*4V:E:P:@SJOGV9U,PK8J#>$(^T@N]
MCU>&7')M\)=V4Y;2RJRA:4\');9/VTGO?K+B22/<8PID@
M                                    .D>2/'W6W*K1>SN/>W*E-Q@&
MT\6G8S=-)1'.=6NN]DFGR.E=DLR&8>1XK=QHUE6R#0OW>=%:<Z'V]#[N77]Q
MEE[3O[5X5Z4DUQ/C3Y)+%-<*;.M=VM&]MIVM=8TIQP?K-<J>U<J,G3F1Q6V)
MPJY)[4XV;.84>0ZWR-^!!NFXST:NS#%9B4S\2S:E2\:C.IRG'Y+$MM/<I;"W
M%,.='FG$IVBRC,[?.,NI9C;?%U(XM<,9;I1?+%XKEW[F4?F%E5RZ\G9UN_@]
M_&N!KD:V^H>8QD3I@              %_P ]+)S"5M7BGL+B7E%EXV5\9LH*
M^PE$F0UX\O4>T9UI;MPXC2U*ES/HGL"/:E(=ZFW'C6\!@B21)(Z+Z3,I\US2
MGFM-?!7,<)>'!)?E1YN'&XR9:&BK_P O8SL9ONZ,L5X,L7ZDL>RD6F169-0
M
M
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MLTS:PR:U=YF%10I+=PN3]K%;VWR;M[P6+.Y8V%UF-=6]I!RJ/?Q)<;>Y+_\
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M^$ZV'9A!^.UX'*6%HO*L>=FU9<<:?:E+\U?C%U,4\6&
M                                      5<_4X>7VSO7CE5<T=?T_B[
M3XRURJ_8*(4=3LW*M$6=IX\UU_L4I2UZMO[!RU;,DI2W63K-QQ1^&T2;+Z.,
M^=EF#R>N_P"&N7C'BC52_/2YO545QD+UCE7G-HLPI+X>BNZY8-_FO;U'(S]A
M>I5P              !+7Y(/+-7$'S'=$9=9V2J[ =HVQZ%V:I3QL1"Q7:4R
MOJZRRLG5/LLMUN+YY'IKB0M9+)+%>LR3W=#*+:SROZ6T]7I16->DO*P\*&+:
M7*X\Z*Y69S3E]YAF]*HWA2F^9+J2V+L2P?6-2H:T%T@
M
M                                             !4T\_OR2BWM6Y-S
M=XC8?W;NIH3EIN_4F+UB/&W)51>YR;L'%JZ)V*?VE41.J["(TA;F116^]HCL
MF^RQM+0NLO,I1R;-9_P3>%.I)_%O@A)^T? _8/?W/>P;5&G/.4\QL(_Q*6,X
MI=^O;+W2X5[)<N^ANI*D*4A:5(6A1I4E1&E25)/HI*DGT,E$9>TA=Q69_(
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M5;ZY>->K-R?7X%R+<EP))%[6MM2M+>%K16%*$4EUN%\KWOE.W!U#G
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M<<)>%'9+LM8]1GO<8,R@
M
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M*4DDB(4Y.<ZLW4J-RJ2;;;>+;>]MO:V^%EB1C&$5""2@E@DMB2XDCZH^3Z
M   ,T/U(OQ:=Z_D7H_[(L1&Q?1[]EJ'AU/VDBG]7>G:O@P\5$$PFI&@
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M=Q#PGMD^JE@OQF7DA2Y9
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MZO-[)<G%1E@
M
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M8K+LLI6K6%11QEX4MLNPWAU$>^Q@C*
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M/K&ID-9RZ0
M
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MV]5X+KFJ"-92Z@
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MPCZXZJ_O"[_M)?A'Z57)+^?#9G\;;;_2 _J5T@?WSF/]O/\ "/KCJK^\+O\
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M,Y/;5ACMQXYPX>%QP>W"3),!L,6P
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MK_\ [G,?^Y'U&T3_ '/E7_24/W8_.OM+^<K/_P"..1?PB'^(/I[_ /-]7_\
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MM]V'4?U2KQJ[JG[1WOSF?C,O#(_0]M\C'M$A P)E0
M  *[/J<]^+U-Y;,S6U=.]WN^1VV<&UNY'962)AXEC;DS:&2S4*/HI,(IF%5T
M"1V'W+19$@R-"U])_P!&]CYUJ%7$EW%O2E/\9]PEV)-KJ$4UE=>0RAT4^ZK5
M(QZR[I]I+KF<@-@2I0              "ZYZ2;CHEJIY5<M+.(DW9L_'./&%
MS?"(EM,U[$#8^RV/&4DU+:ENS\4-)(,B)4=7<2C[>VG>E/,,96N51>Q)U9=?
M&$.U/LEB:%M.YKWTN%JFO&E^:7.14)8(
M                                 %6SU5_'5&P.&>I>1-;"<?O./&V4
MTMQ);:,T1->[EAQ:*VD274=3+LSS',:9:)9=I'*7T,E*Z*LOHQS#R&;U<OD^
MXN*6*\.GM7Y+GV"%ZVM/*Y?3NTNZI5,'X,]C_*4>R9_HO4JX
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MG;[)ON:D.&%1=]'J<,7PQ:>Q[%W8)@9\
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M[:-!['MX)U=L8\*ASI;&X-R>#W9-,
M ,T/U(OQ:=Z_D7H_[(L1&Q?1[]EJ'AU/VDBG]7>G:O@P\5$$PFI&@
M       #6-\IWX9_!;[L.H_JE7C5W5/VCO?G,_&9>&1^A[;Y&/:)"!@3*@
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MA%C.@
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MV--/%-;&C;"G4A5IQJTFI4Y)--/%-/:FGPIK:F?J'(?8
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MQ4(+_P"B1J55J3K595JCQJ3DVWQMO%^J7]"$:<%3@L(122ZBV(^\/@^@
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M7U36^?M6LFLAM'*%".[G>WK-<=1I<U/O8**P4N=CWX-NBK@
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MQG=%/O8-S?XJ>'Y6!I_C6TN4
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M,_XFK%.ZDGWM-K&-''CJ+"4_<81VJ;2D1'LR:F
M             &:'ZD7XM.]?R+T?]D6(C8OH]^RU#PZG[213^KO3M7P8>*B"
M834C0              !K&^4[\,_@M]V'4?U2KQJ[JG[1WOSF?C,O#(_0]M\
MC'M$A P)E0                   "+'SL]L'IORL>9F3M2DQI=_JL]5PTDZ
MEM^2O<V0T>J);,5)J2MUUNKS&0\LD=5)9:6O_-29E)M&VOG>IK.FULC5Y_\
M9IS[<48745?S?);B?"X<WW[4>TS*X&S12@              !;4])/JQ%UR7
MY6;G<80Z6NM)8GKIEU9&HXTK;F;_ $@2XRDT*;0^N+IUY'B=R5DVI:2ZI6L5
M;TIW/,RZUL_UE:4_>1P_WB)SH6ASKRO<>TIJ/OGC^87P12)9@
M                                                     !33]7-J
MM+^+\,-VQ8Z4+JK_ &SJN\EDR1JD)OZ[$LMQ6.Y()!&E,,\:N5(0I1]?'4:2
M+HKK;O15=85;RR?#&$UUG*,NW'L%?Z[H8PM[E<#E%]?!KM,I+"XRN@
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MFDS;JUNK>]MJ=Y:R4[:K!2C);FFL4_\ +:MS/M#MG8
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MC%);<6][;;;//F\O+K,+NI?7LY5;RM-SG.3Q<I2>+;ZK/W#*G6
M                         ,T/U(OQ:=Z_D7H_[(L1&Q?1[]EJ'AU/VDBG
M]7>G:O@P\5$$PFI&@              #6-\IWX9_!;[L.H_JE7C5W5/VCO?G
M,_&9>&1^A[;Y&/:)"!@3*@                   %9'U5>SU8GY?NM]<Q)"
MVYVV>1V)QIS!$WX<G%\)Q#-<GL26I1FZ2VLF13*224]#+NZJ+H25V/T8VWE<
M]J7#[VE;RP\*4HI>ISB':VK>3RN%%;ZE9=A)OMX&>P+Y*K
M +]OI-M;-T?#/D-M1UM3<W87(Q6)MF9MF3]+K;7F)S(,A))(UI2=OG]BUT4K
MKU:,R21&1JHWI1N.?F]O:^QIV_.Z\YR3]2*+/T/1YN7U:_#.MAUHQ7KR9:H%
M8DV
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M$\+6K+&@W[&H]]/D4]\?=XK:Y[)QQN0;!@
M      !U[M#8E3K##[+*+/M><93[M4UWB$VY:V[Z%^YP6U=#-*%&@UNK(C-M
ME"U=#,B(Z<Z=^F73_03T;WNO<]PJ5Z:\E:6_.YLKN[FGY&A%[6HMISJS2;IT
M85*BC)Q47*]%Z3OM:9_1R2RQC"3YU6IABJ5*+7/F^7;A%;.=-QCBL<5#)D>0
M6N5WEID5Y*7,M;>6Y,F/J,^AN.="0TTDS5X4>.TE+;2"/M;;0E)>PB'\R^M-
M8:@Z0-5W^M-4UY7.H,RN)5JU1X]]+=&*;?-ITXJ-.E!/FTZ<(0CA&*1Z'Y1E
M5CD>64,HRV"IV-O34(17$M[?'*3QE)[Y2;;VL^*(P9$                #
M]M96S[FPA5-7%>G65C*8A08<=/>])E2'$M,LMI]A=RUJ(O;T(OPG[!E,CR3-
MM2YS:Z>R&WJ7>=7M>%&A1IK&=2K4DHPA%<<I-+;@EO;239UKR\M<OM*E]>SC
M2LZ,'.<Y;%&,5BV^HB8_3&K8&J<-B4C9,OW4SLG9)9-IZG-LUHZ>"VX9$LX-
M>@_"82?0NA&OH2EJZ_TK?=EZ!<I^[]T:6^EZ*IU=47.%?,KF*VUKEKO(R:4O
M(6Z?DJ$7@L%*JXJI5J8^?/2)K:ZUSJ&>8SYT<NIXPMZ;]A33WM;N?-]U-[=N
M$<7&,3ML;$$#                                     S0_4B_%IWK^
M1>C_ +(L1&Q?1[]EJ'AU/VDBG]7>G:O@P\5$$PFI&@              #6-\
MIWX9_!;[L.H_JE7C5W5/VCO?G,_&9>&1^A[;Y&/:)"!@3*@
M      %(OU=.QBE9MPHU(Q)2DZ/%=R;&M8:7&C4\656V"XSC\EYKO4^VF-]#
M;-+2C2E"_%<(C4:3[+EZ*K?"C>737?2IP7XJDWXR*YUW5QJ6U!<$9R?7<4NT
MRF\+;(                :=/IY]?'@'E,<9ER(RXMGG3^U-@V2%H6CQ2O\
M;&9QZ&2@G&F7#1)Q&LKEDHR,E=>J5*0:3/7#7M?R^J;G!XQAS(KK0CC^4V7'
MI6EY+(Z..^7.EV9/#U,":P0XD0
M                              !'%YO>OBV=Y8W-_&/=SE+A\?<WSEEA
M/<:UR=71&]FQ3;2AYA3CJ).((4E)&9K41)[%]>Q4ATI<>;:DLJF[&O&/O^X_
M.,1GU+RV37,/]$W[WNO6,H<;/E(@              %OGTCNRSKMU<Q=.KD*
M,LQU=K?9<:(I]/:@];99=8M.D,QE(4LE.?G6CI=6A22/M;)9*^0:*IZ5+;G6
M=I=^TJSA[^*DO$9/-"UL+BXM_;0C+WK:_.+S@I4LD
M X%L[7&,;;P3(]?9A#*71Y' 7$>-))*3!E),GJ^U@.*(R9L:J:VV^RHR-/B-
MD2B4DU)/":CR#+M49+<9%FL.?9W$.:^.+WQG%\$H22E%\:VIK%&-S?*K3.LN
MJY9?1YUO5C@^-/>I+BE%X-<JV["K'N34V4:2V)D.NLL9(K"ED]8D]IM:(5Y4
M2.KE9>5QKZFJ'8QNBNG4U-.$MI?1QM9%YLZLTQF.C\^KY#F:^'HR[F27<U(/
M;"I'W,EMXT\8ONHM&G^>Y+=Y!FE7*[U?"TWL?!.+[V<>22[#Q3VIG5XCAB
M               /]8\A^(^S*BO.QI,9UN1'D1W%LOQWV5I<9>9>;4EQIUIQ
M)*2I)D:3(C(^H^H3G2FJE-N-2+333P::VIIK:FGM31^QE*$E.#:FGBFMC36Y
MI\990X2<F6>0.MD0<@EL_G-PAF)698P:T(?NXOADU79>PR1)(T6I-FB42"[6
MIB%_)0VXR1^@O0_TAPUSI]4;Z2^L5FHPKKAJ+#"%=+W>&$\-D:B>Q1E%&U>@
M-61U+E2IW,E]+6Z4:BX9KV-1+W7LL-TD]R<3VH+=)Z
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MZ[T3E,_X:E).ZDGWU1;8T<>*F\)3]WA'8X23]SCU:-9P
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MU*/5C4-?SG/KRMCBG<U,.HIM+U$O6+TRBEY'*K>GPJC#'JN*;]4]K##&1
M
M  .N-QX2C9>HMJ:X=:2^WL#7&<82XRHVTI>1E>,VE$MI2G5(:)+B9_0S4HD^
MWVF1#L6E;S:[I7"WTZD9>]:?K'#<4_+4)T?;P:[*:,;$;<%
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M<XZ]5XY+,I4MMI[,93"B)3$-U*7HM"3B3[DN3$&EZ21=/Q)H1U,G'$EY._\
ML1^\J\MM)= 6B[C"_N(1GG%6F]M.C)*=*P4D\5*LN;6N4L/@72I-RC6K06S?
M0/T?><55K?-Z?P%-M6D9>RFMDJ^'%!XQI^[YTL$X19'J/&\VP
M       #OOC[J%[:F7H.P:<3B./K8FY"^1F@I1FI2H=*RLNBO%L5M'XAIZ&V
MPE9D9*-'7;G[GGW<KCI^Z1HRS>G./1WD\J=;,*BV>5Q;=&R@]_.N7!^4<<'3
MH1J24HU'24JMZ5=?4]$9 U:R3SZZ4H4([^;P3K-<5--<U/OIN*P<>=A+PTTU
M'::88:;989;0TRRTA+;333:20VTTV@DH;;;0DB2DB(B(NA#^C.WM[>TMX6EI
M"%*UI0C"$(1480A%)1C&*248Q22C%)))))8&A-2I.K.56K)RJ2;;;>+;>UMM
M[6V]K;WG^@YCX                                      #-#]2+\6G
M>OY%Z/\ LBQ$;%]'OV6H>'4_:2*?U=Z=J^##Q403":D:               -
M8WRG?AG\%ONPZC^J5>-7=4_:.]^<S\9EX9'Z'MOD8]HD(&!,J
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M$V!IP5.G&FMT4EV%@<D'&?8
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M)SG.3XY2;;X.))'H+:6EM8VM.RLX1IVM*"A",=BC&*P27(DC\8QIV
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MM99_6SN^Q2F^;3ACBJ5)8\RFMV[%N327.FY2PVG/A;Q%@
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M'0S6KY#*[FONYEO4EV(-G:L*?E;ZC2]M5@NS)(V#1J<7V
M                                                     &4!YN>*
MHPWS-^<M0AM+13.2&R<J-*4/H(UYW=.YPXYTD&IPU/+R$UF9?(4:NJ.B#20V
MATK5\MIRRGQ6\(^]7-]8I#/8>3SFYC_II/WSQ]<CI&?,2             '=
MW&?-%ZWY'\?MB-.*:<P+=VJ<T;=3XA*;7BV=T-XAQ)M28;I*0J#U+M>:5_R+
M2?RBZ>8T?.,OKV[W5*,X^^BUZYV+.IY&[I5?:U(OL23-B<:EE^@
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M                  "3OBMILL/H2SO((G;DV2Q$_-C#Z.CM+0/=KK9=BO\
MHIUMT2XYU^4ADD(^29NI/W9^X%]VE=&^DETLZPM^;KK.[=>;0FNZLLOGA**P
M?>U[ON:E3'NH452I=Q*5>,M+^F_I!>?YI]6,JJ8Y-9S^$E%[*U=;'MX84ML8
M\#GSI;4H->O!Z,E"                                          9H
M?J1?BT[U_(O1_P!D6(C8OH]^RU#PZG[213^KO3M7P8>*B"834C0
M     !K&^4[\,_@M]V'4?U2KQJ[JG[1WOSF?C,O#(_0]M\C'M$A P)E0
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MU>+P
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M.VWZ">CWS&V6M,WI_P 96BU:Q:VPIO%2JX/=*HMD/]'BTVJFSP^/+ V4
M              #U%QCTY^<+)?I->Q?$P_%Y+2W6W4F;-U=()#\6KZ'\EV-&
M(TO2B]I&@T-F71TS+?/[BOW:OZQZX^O&K+?G]'&0UXRE&2[B]O4E4I6NW9*E
M23C6NEM3@Z5&47&NW&E.F;I!^JF3?0V63PS^]@TFGMHT7C&53DE+;"F]F#YT
MT\8;951[_FCX                                           9H?J1
M?BT[U_(O1_V18B-B^CW[+4/#J?M)%/ZN].U?!AXJ()A-2-
M &L;Y3OPS^"WW8=1_5*O&KNJ?M'>_.9^,R\,C]#VWR,>T2$# F5
M         #HKE'DCF'<9N167M*D(=Q716W,D:7$["EH<H\ R"S0J*;II;]X2
MJ*1H[C)/=TZ^P=[+*?ELRMZ3W2KTUV9)'6O9^3LZM3VM*3[$6S'?&V108
M           !,/Y U+\_>;KPY@^*AGP+[:MUWN->,D_HWH7:F1>$2.Y/1;_S
M7V)5U^0I1*Z'TZ'$]=3YFE+N7N8+LU8+US/Z7CSL^MURR?8A)^L:APUK+F
M
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MI=B%7#W$\/C)%%=*ND?_ .I\OAQ*XBNQ&KAV(S_%EAWS(;!J:46
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MIWX9_!;[L.H_JE7C5W5/VCO?G,_&9>&1^A[;Y&/:)"!@3*@
M    !X8\SN[^CWEQ\[K(DO*6?$?D'6,JCN>$\S(O=6Y/1QI2'.I&GW218I=/
MH9*Z(/I[>@S6FX>4U!8Q_P#]JD^Q-/UC&YS+F93<O_0379BT9*(VF*,
M          )Z/37TSMIYL.GIS:(ZD8YKS=ER^I__ *1MI_6M[CQ+B?(7^Z#?
MOD)/VI_%*7[?\APCI$FHZ7K1?LJE-?EI^L2;2$>=GE-\4)O\EKUS2M&NQ;X
M
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M/95J;I5N5/O:>..$,9+!SDCTD-VBGP
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M:,BGG.+X*,GZJ7KFC(-?BV0
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M*+P?53WIK9)---IIFH5Y9W.7W=2RO(.%S2FXRB^!KMKA3W-8-;&<?'1.L
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M'I'*:F&9W4/AY1WTZ$O88\$ZJV-;U3Q>SGQ9)6/;\T[
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MSJOMHF.B$GFU1O@MY>/ T)Q0Q:@
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M_HI0RC;R[*(SB?&9427:6C6:F9-AW$?<W+FFE3$8RZ&GHXX1I4VGNT"^_?\
M>4_I%HG^GVDKAPZ1<^H27/@\)65BVX5;C'?&M7:E0MFL''"M64HSHP4[OZ%N
MC[ZT9Q].9I!/(;*:V-;*U9;8PPW.,-DZG ^Y@TU)X18CP*-W
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MJ7M>HYSD^&3>.Q<"6Y);$DDMB/K"0'1
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M=3\)--#17TE5EPJ@UV9Q_ 7^Q11:(
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MKG4,KBDY1R6WQA;P?M<>ZJ->WJM)OBBH0V\W%]W#:0K<
M                                ,T/U(OQ:=Z_D7H_[(L1&Q?1[]EJ'
MAU/VDBG]7>G:O@P\5$$PFI&@              #6-\IWX9_!;[L.H_JE7C5W
M5/VCO?G,_&9>&1^A[;Y&/:)"!@3*@                 !!+ZD7X2V]/RUT
M?]KF)";='GVIH>!4\21&=7>@ZOA0\9&:(-BBH               "U9Z2_\
M7/Y'_=@?^U;78K+I2]#V_P Y_,F3;0WI"M\C^=$OTBC"SP
M                                                      I8>KZ8
M92]Y>\E++29#K7*UAV03:">=9CKXW.1V7'2+Q%M,.2G%(29F23<49=.X^MP]
M%#>%^N#X#_?%>:\2QM7P_"_[LI<BWRO0              #0J]*18S)OER[4
MC27O%8J.8VR*ZN1X;2/=X;NGM!6RV>YM"%N]UA:/N=RS4HN_MZ]J4D5#=)\4
MM04FM[M(-_VE5=I(M31#;RF:>Y7$O$@_7+-8K@F(
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M='ZT9D?G=_##4-Y%2JX[Z4-\:*?N=]3#?-X;5"+/.8TN+<
M    #WQQ(TWWJ1M7(XOR4*>8PZ'(0?REEW,2L@4A7L-*#[V8O4C^42W"(NC2
MAZZ?^NW[M/E)QZ?]:6_P<7.GDU&I'>UC"KF#3V8+NZ-KBGW7E:R2<:%1ZN=/
M'2%S4]#Y1/:\)7<HO@[Z-#'EV3J8<'-ACMG$]_CU^-5P
M                                 #-#]2+\6G>OY%Z/^R+$1L7T>_9:
MAX=3]I(I_5WIVKX,/%1!,)J1H               UC?*=^&?P6^[#J/ZI5XU
M=U3]H[WYS/QF7AD?H>V^1CVB0@8$RH                  02^I%^$MO3\M
M='_:YB0FW1Y]J:'@5/$D1G5WH.KX4/&1FB#8HJ                M6>DO_
M %S^1_W8'_M6UV*RZ4O0]O\ .?S)DVT-Z0K?(_G1+](HPL\
M                                                       *6GJ^
M_P#X\_\ S9_^F<7!T4?\_P#ZC_?%>:\_Y3_6_P"[*6HN KT
M  T'?2??#LW/]]/8OV&\<Q0_2CZ?H_,X?M*I:>A_1-3YQ+Q*99X%;DR
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MGT%:.AG^HY9Y?1YV79;S9)-;)5Y8^36W>J:3J/#:I*GCL9%N/!,W8
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M4Y5+FK-RG*3Q<I2>,I-\+;>+9^D=XX0
M                    #-#]2+\6G>OY%Z/^R+$1L7T>_9:AX=3]I(I_5WIV
MKX,/%1!,)J1H               UC?*=^&?P6^[#J/ZI5XU=U3]H[WYS/QF7
MAD?H>V^1CVB0@8$RH                  02^I%^$MO3\M='_:YB0FW1Y]J
M:'@5/$D1G5WH.KX4/&1FB#8HJ                M6>DO\ US^1_P!V!_[5
MM=BLNE+T/;_.?S)DVT-Z0K?(_G1+](HPL\
M                                          *6GJ^__CS_ /-G_P"F
M<7!T4?\ /_ZC_?%>:\_Y3_6_[LI:BX"O0              #0=])]\.S<_WT
M]B_8;QS%#]*/I^C\SA^TJEIZ']$U/G$O$IEG@5N3(
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MQJ2J3EYZ:\UC>:WU#5S>XQC:KN*%/@ITDWS5X4N^F^&3>'<J*79PO4A@
M                                               &:'ZD7XM.]?R+
MT?\ 9%B(V+Z/?LM0\.I^TD4_J[T[5\&'BH@F$U(T               :QOE.
M_#/X+?=AU']4J\:NZI^T=[\YGXS+PR/T/;?(Q[1(0,"94
M   ()?4B_"6WI^6NC_M<Q(3;H\^U-#P*GB2(SJ[T'5\*'C(S1!L45
M         6K/27_KG\C_ +L#_P!JVNQ672EZ'M_G/YDR;:&](5OD?SHE^D48
M6>
M          %)CU>EPI[)>!- ;"4HK:/DE<)D^(9J>5>3]'0EL&UVD2$QRQY*
MB5W'W>*9="[?;<?13#"G?5..5%=A5/PE=:\EC.UAQ*H^SS/P%-$6Z5^
M          :'/I4ZA-;Y;NP)J7U/'D'+?9ENMLVR0453.L=)T),)42U>*E2*
M0G>XR3T-PT]/9U.A.DZ?.U#37M;2"_+J/URU=$QPRB3XZ\G^3!>L67!71,
M                                X?G^"XWLS#,BP/+8*;#'\FK7ZVP8
M/M)QLG.BX\R(XI*O=Y]?*0A^.Z1=S3S:5%[2&*SS)<OU%E-?)<TAY2QN*;A)
M<*QW2B^"47A*+X))/@.CF676N;6%7+KV/.MJL'&2[37$XO!I\#295FWMIK)=
M#[+R#7F2-K<.O>]ZH[?PE-1LAQR6MQ53=Q.O<CMDLH-#R$J63$IMUDU&ILQY
MM:TTGF&BM0U\AS!-^3>-.>&"JTI8\RI'JK9))OFS4H8XQ9I_J+(KO3F;5<LN
MMO->,)8;)P?>S756QK@DG'>CI\14P@                $Z?E13I+FKMH5B
MEF<2)GT*<PWU5T1)L<=A1Y2R2:C01N-5;)=2(C/M]IGT+IN=]V6M4EIO,;=O
MX*-]&27+*E%/LJ$>P;#=#523R>[I-]Q&Y375E!)^*B58;+%Q@    $$>3S%V
M.2Y#8.]QN3KRVF.&HR-1KE3Y#Z^XR))&KN7[?80_DWUUF57.=;YSG%?'R]WF
MMW6EB\7SJMQ4F\6DDWC+:\%U$>G&2V\;3)[2UAWE*VI074C"*7:/B"*F3
M              DBXFZ<^8:M.R\AB]MS=1E-XU%?:Z.5E*^DTN6?19=R)=R@
M^C9D1&F)[2,R>42?;3_UZ?=J^J60QZ<=94,-39I0<<LI5(]U;64UA*Z[I8QJ
MWD=E-I)QM-JE)7,XQU Z=>D'Z4O7HW*9_P#Q]M-.XE%[*E9;J>S?&D^^QWU>
M!.FF_:H]/C7,
M     ,T/U(OQ:=Z_D7H_[(L1&Q?1[]EJ'AU/VDBG]7>G:O@P\5$$PFI&@
M           #6-\IWX9_!;[L.H_JE7C5W5/VCO?G,_&9>&1^A[;Y&/:)"!@3
M*@                 !"MZAYIMSR?.7*EMH6IE>@765+0E2FG#Y.Z79-QHS
M(S;6;+JT=2Z'VJ,OP&8F&@7_ /NRT_UO[&H1W5?H"O\ B?M(&8F-D"G
M          "T%Z3N;*;\P?=U<A]:84KAMG,V1&(R\-V5 W;H!B&^LNG4UQV;
M)]*?_HZH5MTHI?0-&7"KN/JTZOX$3+0[?TK47!YO+QX&@F*(+3
M                                                          "C
MYZNQUL]D\'V2<0;S>#[Q=6T2TFXAMV^UJEIQ:.O<E#JF5DDS+HHT*Z?@,7/T
M5+^&O7P<^GVIE<:[^.MO!GVXE.T6R0$               T7O2XUTR%Y9$R3
M*9\)BXY([7L:Y?B-+]XAM46 5*WNUM:UL]MA5OM]KA)6?A]W3M4DSH#I+DI:
MC26]6\$^S)]IHMC1::R;%[G6EVHKUBQN*^):
M           >,>:W&>/R#UH[(HHC);,PMJ3:8?*(D-NVS/9XEEB4EY71)Q[=
M#9*CFLR)F:AL^Y+:GNZI>E[H\IZZT\YV45]8;-.="6YS6^=!OBGAW./>U%%X
MJ+EC!-?:3CJ;*7*WBOI:W3E2?#)>RIM\4O8\4DMJ3EC6JDQI$.0_$EL/19<5
MYV-*BR6EL2(TAA:FGF'V74I<9>9<2:5)41*2HC(RZCSXJ4ZE*I*E5BXU8MII
MIIIIX--/:FGL:>U,U3G"5.3A-.,XO!I[&FMZ:X&C_$?!\@
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M1248I)))+!));$DMB2V)&B,I2G)RDVY-XMO>WQL_H?9^
M                                     !FA^I%^+3O7\B]'_9%B(V+Z
M/?LM0\.I^TD4_J[T[5\&'BH@F$U(T               :QOE._#/X+?=AU']
M4J\:NZI^T=[\YGXS+PR/T/;?(Q[1(0,"94                  (E//7K7K
M7RFN9T5B)[ZMK!,2LE,]B'.QFFVK@5O(E]J_87N$>"I_N_"GP^I>TB$JT3)1
MU39MO#NY+LPDO5QP,%J5<[([A+;W*]2469:HV6*7               +*_I6
M+:37>9+G,-A#"VK_ (F[.J9BG4N*<;C,['TU>I7&-#B$H?.72M),U$M/AJ67
M3N,E)KOI.@I:=@WOC=0?Y%1>N2_1,FLWDEPT)+\J#]8T/A09:P
M                                                          41
M/5N28R^2?$N&F0PJ6QH_+Y+\5+K9R68TO/7&HLAU@E&ZVQ)=A/);69$E:FED
M1F:5=+MZ*T_HZZ?!Y:/BE::Z:\[H+A\F_&*DHM,@H              !I->F
M@J9-=Y5&N9CZV%M7^UMSVT-+2G%.-QF<Q?HE(DDMM"4/G+I75$236GPU(/KW
M&:4Z\](LU+4]1+?&E37Y./KENZ/BUDD'QSF_5P]8G[$%)0
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M-0I1PA3BEYW:KU+F&KL]KYYF+^%JR[F*[VG36R%./)%>^DW)[9,YH+.(Z
M                                                    9H?J1?BT
M[U_(O1_V18B-B^CW[+4/#J?M)%/ZN].U?!AXJ()A-2-               &L
M;Y3OPS^"WW8=1_5*O&KNJ?M'>_.9^,R\,C]#VWR,>T2$# F5
M      ".#S?JAN[\L/G'#=>6PEGCQGEN2VTI4I3F/P$WS+)DKV=DAZM2VH_P
MDE1F7M$ATG/F:DLFOYB*[+P]<Q&?1YV37*_T4GV-IE$C9\I$
M   L)^F-M'*_S2L:B(FIBIO-([@JW6#=0V=DVS6U-T4)*5GW/*;=J$R.U/RB
M)@U?@28@?2/'G:9D\,>;6IOJ;6O7PZY*M&RPSI+'?3FNT_6-((:]EM@
M
M  !0"]65;1GN=/'^C2A\I==Q-H;9]Q26RC*C76X-OPXJ&EDX;JGVW:%XW"-"
M4DE2.AJ,U$F]>BV+625Y\#NFNQ3I_A*NUS)?25*/"J"?9G+\!5G%ED+
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M\[2/IIZ0?K1F_P!!97/'(;*;6*>RM66R4^6,-L*? ^ZFFU)8>JAO\4@
M                                                   !FA^I%^+3
MO7\B]'_9%B(V+Z/?LM0\.I^TD4_J[T[5\&'BH@F$U(T               :Q
MOE._#/X+?=AU']4J\:NZI^T=[\YGXS+PR/T/;?(Q[1(0,"94
M      /)7/NC<R?@ES5QIEQ;+V0\2N1U&T\U'5+<:<MM.YE 0XW$2XTJ4M"I
M!&39*2:S+IU+KU&5R*?D\[LZCW1NJ3[%2+.CFD>?EEQ#CH5%V8,R'QM640
M             3?^G/N/FSS=^,T+W?Q_I#2[WI_$\;P_=/ T!LV_]X[/"<]X
M[OF/PNSJCIXO=W?)[50SI ASM*7+]JZ3_P!K!>N2/2<N;GU%<:FOR)/UC36&
MN1<0
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M)1>Z4)+;&2V-&IN9Y9>Y/>SR_,(.G=4W@T^'B:>YQ:VIK8T<+&(.@
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M$4Y+;!-;JLUOX:<'CLE*+C)4/;XT\
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M5E(VC.H")4HHA$K*\(RS%T+\4T.=ZD+N"4373\>9>'U3W=2C.LZ?E-,7D?\
M18^]E&7K=8S>G)<S.[=^[P[*:]<U01K*74
M                                          &:1ZDG(BN_-FW=6%(:
M>^A^#:0QTVVVE-KB')U1B^6^[OK4DB?=464>*2D]2)#J4]>J3(MBNCRGS-+4
M9>WG4?Y<H_FE0:NGSL\J+VL8+\E/UR"$38C(              !K>^6OC*L/
M\O/@YCSK3K$N#Q,X^N6+#S[,A;%M8:LQ>RMV"?C&IAQIFSF.I0:%*3V$712O
M\X]6-15/*Y_>U.!W57#J*<DO4+TRB'D\JMH<*H0[/-6/JGM@88R(
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MMJ,+>A%0H4XJ,8K<HQ6"2Y$E@C<ZG3A1IQHTDHTH1226Y)+!)=1'ZQRGV
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MHQC%*,8QBL(QC%8))))))8);$:O3G.I-U*C<IR;;;>+;>]M\+?"S^QR'R
M                                                       &:'ZD
M7XM.]?R+T?\ 9%B(V+Z/?LM0\.I^TD4_J[T[5\&'BH@F$U(T
M   :QOE._#/X+?=AU']4J\:NZI^T=[\YGXS+PR/T/;?(Q[1(0,"94
M             QPM]XE] =Y[HP0V?=CPK;&Q<2./X;#/@?1S,+BG\'PHIG%:
M\+W/M[6S-M/3HGV=!MM8U?+V5&O[>E"79BF4#=4_)7-2E[6I)=AM'4X[1P
M           ![6\MO)TX=YA/![(W5H;BU_++C\FP<6RY(\*JG;3Q>NMG$,LF
M3BWVZV6ZIOMZGXA%[#_ >'U#3\MD-[36]VM7#J\R37JF1RB?D\UMI\"KP['.
M6/J&M^-5R]
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M[:C;0;6Q-QHP@FUQM-D6S#-LUS:KY;-;FXN:RW2JU)U&NHYMM'V!)#'@
M                                                         9H?
MJ1?BT[U_(O1_V18B-B^CW[+4/#J?M)%/ZN].U?!AXJ()A-2-
M   &L;Y3OPS^"WW8=1_5*O&KNJ?M'>_.9^,R\,C]#VWR,>T2$# F5
M             ,FKS6<-3@7F4<Y,>;9]W9<Y-[;R6-'+P2;8B9OEMCFL1EA$
M=B.TS%;C9 DFFR3^+:)*3-1D:CVCTQ6\OIVRJ</FU->]BH^L4=G=/R6;W,/]
M-)]EX^N1_C.F+             #L'4F7'K_:VLL\)_W4\)V#AF7%)_=7[G/&
M\CK;DG_W#^[OQ)PN[\3^-]GR/E=!P75+R]K4H;^?3E'LIKAV'+0J>2KPJ^UF
MGV'B;*@U&-@
M                    R.?,<RHLW\P+FYE+:N^+;<K]_N5RC;0TLZF/M+*(
M51XJ&UN()XJN,R3ADI1*7U/J?4;4Z?I>1R*RI/>K6ECU>9''U2BLWGY3-+F?
M Z\^QSGAZAXP&7,>             ';&A,.+8F]-+Z_..B66=;8USAQQ7$17
M&Y)9-F%/2''<;G*3!6A[W[M,GC)HR/HL^WJ.K?5O-[*M7W<RE.78BWP;> Y[
M6GY6YITO;5(KLM(V/1J27\
M
M                                           !FA^I%^+3O7\B]'_9
M%B(V+Z/?LM0\.I^TD4_J[T[5\&'BH@F$U(T               :QOE._#/X+
M?=AU']4J\:NZI^T=[\YGXS+PR/T/;?(Q[1(0,"94
MS,/48X)]"_-GY"3VVO!A[!Q_3N=PFR]J?W3J?$,:LW4J-YU:O>;[%Y;I]W9T
M4LR2DD$DSV-Z/Z_EM+6\>&G*I%^_DUZC13VK*7D\\JO@FH2_)2?JID'(F9&P
M              #8HXT9L6R^./'_ &.E[WA.P-):IS9+_<A7CEE>"4-Z3W<W
M)FMJ\0I_=U2\ZD^OL6HOE'J9F-'S;,*]O^KK3C[V37)Q%^V=3RUI2K>WIQ?9
MBF=VCI'8
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M7[U\[UC6!&KQ>
M
M                                   &:'ZD7XM.]?R+T?\ 9%B(V+Z/
M?LM0\.I^TD4_J[T[5\&'BH@F$U(T               :QOE._#/X+?=AU']4
MJ\:NZI^T=[\YGXS+PR/T/;?(Q[1(0,"94                    H%^K'U\
M=+S5X_[*994U&SSC9%QQY71WLD6^ ;'S:1+?[UD;7BE59I ;4E"ODI;29I(U
M=RKTZ+J_/R>O;O?"XQZTH1]>+*OUQ2YN8TJW!*CAUXR?K-%5X680H
M        U7O)DV G9?E:\(\B3*3+*MTC2Z_-U+I/$A6I[*UU8N+WD_(Z*A+P
MTV31W%X9M]O:CIV)UCU?0\VU->T\,,:SE[]*?YQ=FGZOELEMI\5-1][C'UB3
M<1LS(
M         !Y8YRY^6JN%O+79!/JC/X1QLW;DL%Q"E)=.TJM;Y'*J66%(=844
MB39MM-M]'&_EK+Y2?PED\EH>=9Q:V^]3N*:?4<UCZATLRJ^0R^O6X8T9OKJ+
MP]4R$1M:4.               3S^FRU^6:^:YJ*[7'1(9U=K[<FP'DNDA3;9
MO8!:Z]BR#;<]BUQ[#/F5M]"-2'"2LNAI(RA'2'7\CI>K#AJU*<?RE/M1)-I"
MEY3/*<O:0G+\EQ_.-*X:[%O@
M
M                                             9H?J1?BT[U_(O1_
MV18B-B^CW[+4/#J?M)%/ZN].U?!AXJ()A-2-               &L;Y3OPS^
M"WW8=1_5*O&KNJ?M'>_.9^,R\,C]#VWR,>T2$# F5
M *@'JY-:+L=.\-MQ-QNC>'[+V?K2;,0T1=R]D8MCN45D:0\1DI78G54M;*5=
M23W.FGIU5W6QT57/-N[NT;VSIPG[R3B_'7J$"UW1QM[>X]K.4??)/\UE&D70
M5N               :._IA=D*SCRO*?%ER%.GIS>NW-=MLJ<D*]V9MGZ';1-
MH0^1-MM./;/<61,]6C6I1]?$\0BU]Z2+?R.I75_74*<^QC#\PMK1M;RF2J'Z
MNK*/9PE^<6'A 25@
M                    $.7G[[(3K7RG.5TMN2EBRS"GP/6]6R;I,KFJSG9N
M'4=W&;4;3Q*4WB;]B^I/0N]#*DDI)GW%+="V_G&J;5-=S!RF^3FPDU^5@C :
MHK>1R.N^&2C%?C22?J8F7N-DRF0              "VSZ2/7+EGR5Y9[;)A2
MFL(T;B6N5R?QG:TYM+/F<F;8/H7A=TA.GE*+N^5^*/M]G<*LZ5+CFY=:VG#.
MO*?O(X?[PG.A:/.O*]?VM-1]]+'\PO>"DBS
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M_P!OGH9_O/4__46/_P#+CCQ^=%R_,S,JO3:2,S,DEA=]T21G^ N[,E*Z%_\
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M.KK-\M4*U2E=5;:I"5LI85Y15&TH24J4'Y9R<^:J=.HN:VUA/J+;/-@
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MH5I75VF-<9+2U%I&^MLQR2MWM:A-3CBDFXRPVPG'%<^G-1G![)13V'-AB"1
M                                                           &
M:'ZD7XM.]?R+T?\ 9%B(V+Z/?LM0\.I^TD4_J[T[5\&'BH@F$U(T
M       :QOE._#/X+?=AU']4J\:NZI^T=[\YGXS+PR/T/;?(Q[1(0,"94
M                 @1]2EJW\XGE5;/R!MGWB5IK9.HMI1&TM>*Z7B9:SK&P
M>9(DJ4CW6FV7)=<473M90OJ?3J1SGH[N?-]3TZ?!6IU(?D\]>K!$8U?1\KDD
MY\-.<9>KS>U(S6!L.5"               7;?2,;0*1B7-+2TJ2E!U&1:CVA
M21#<4:I!9'6YEBF4R6V3^0A,/Z+4Z5J+VJ\=)'_FD*;Z5;;"K9WB6^-2#ZSC
M*/C2[!8NA*V-.XMWP.,EU\4^TBY0*C+
M                                     *MGJO=H_1KA!I'5<65X$_:/
M(JNN);*97AJFXSKG!LMDV,940NBI+",CRBG>-9F:&EM(ZI-2TFFR^B^V\IG-
M:Z:[FE;M=><HX>I&1"];UN9EM.@M\ZN/6C%^NT9_HO4JX
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MP]1"N2Y@
M      S0_4B_%IWK^1>C_LBQ$;%]'OV6H>'4_:2*?U=Z=J^##Q403":D:
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M7R^GE72VT:\)-\DL8/U91);HNOY+-W2;V5*4EUUA+M)FBH* +8
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MEGMU'IBUC04\IMJKCEE&:QC5KP;4[N46L'"A).%#''&NIU.Y=&#G6W%*GJP
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M4@]L*D91>U'8(P9*0
M             ,T/U(OQ:=Z_D7H_[(L1&Q?1[]EJ'AU/VDBG]7>G:O@P\5$$
MPFI&@              #6-\IWX9_!;[L.H_JE7C5W5/VCO?G,_&9>&1^A[;Y
M&/:)"!@3*@                     8_/,/4"N/_*_DGI'W=,:-JO>.T,&J
MT(2:&7:+'LRN*_'YD9*DH442PI&8[[/5*5>$XGJ1'["VPRF[\_RNWO>&K1A)
M]5Q3?8>**%O[?S6^K6W!"I**ZB;P]0\X#('4             #W=Y8.ZBX]>
M83P_VP](3#JZ'>N$4V23%+4@HF'9W8E@&:R_D>U:HV)91-62#Z$X:>TS(C,Q
MA-26?G^0W=JEC*5"37A17.C^5%&3R:X\TS6WKOO552?4EW+]1LUIQJT7D
M
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M5JSG[Z3EZY?MK15M;4[=;J<(Q]ZDO6.VQU3G
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M#TU/#@             )B_*8YK?F0V$6AMA6B6=5;3N8Y4-A-=[(V$[$F^!
MARE/K43<6ARM*&HDPU_BV)*([_5I!25+U6^\UT1_7#(OKID5/'4N6TGY2,5M
MN+6.,I+#>ZE';.GAME%SAA)^32WY^XY]X?\ ISJK^F>JJRCHG.KB/D9S>$;.
M^GA"$L7LC1N<(TJN/<PJ*E4QA'RSE:N'FN>V8
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MJUM76>*/2PQQW
M               .([ S:BUI@>;;'RF1[GC&O\1R3-LCE]4E[K18I33;VWD=
M5J2@O KX#BO:9%[/:8Y:%&=S7A;TEC4J345U9/!>JSCJU(T:4JT^\A%M]1+%
MF.CM#8%WMC9>Q-IY,I*\DV7G.6[ R!:5&M*[O,K^PR*U4E2B2I253[)PR,R(
MS&VMM0A:VU.UI_%TX1BNI%)+U$4%6JRKUIUY]_.3D^JWBS@PYCC
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MH Z&LLZ%- T-/4>95U!<85K^X2VU;AK;&+W^1H)^3HK9L4JCBIU)X^0A'2\
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MYZMZ<JFG;>:EEFGK.E:1P>,77J)7%S+PDZD*$ULP=OAABFW%*-E320
M         MJ>59S6/D3K%6J-@6WO&Y-55D5A<N;(4[.SK!6/!@UF3K=?6I^7
M<U+JD0[11]REK4Q(4HUR5I;\R/O)=$?U$U#]9LCI<W2F95&^;%81M[AXRG1P
M6R-.:QJ45L22G322IIR]RON4_>(?2OHYZ(U37YVO\DHQ3E.6,[RS6$*=PVWC
M*K2;5*Y>UMNE5<G*M)1EE&LIO$
M                     9H?J1?BT[U_(O1_V18B-B^CW[+4/#J?M)%/ZN].
MU?!AXJ()A-2-               &L;Y3OPS^"WW8=1_5*O&KNJ?M'>_.9^,R
M\,C]#VWR,>T2$# F5                      IX^K;T6JRUIQ,Y)UU<?=B
M.9YMIC*K%ELUJ<BYQ3P\SPQJ8HDJ-N/7RL'N2;49I3XDXTGU-21;/19>\VYN
MLND^_A&I%>"^;+L\Z/8(#KJVQHT+Q+O9.#_&6*\5]DH\"YRN
M   #13]+WR"+:?EVS=06$U+U[QKVWEV(1HBE*<DMX/GSJ=EXW.><49F;3V1Y
M#>Q&4]?D-0"271))(4#TE6'FN?J[BNXN*49?C1[AKL*+ZY:^C+KR^4NW;[JC
M4:ZTNZ7JN2ZQ9"%>DN
M                    A>]0#R 3H'RM^02HLU,/(=TM4/'_ !M)O$R<U6RI
MJV\RA)_Y[JG-7U-\OL3U[B0?7Y/<93#0EAY_J6ABL:='&J_Q.]_+<2/:INO-
M<EJX=_4P@OQM_P"2I&86-D"FP              "U!Z431*LTYB[PWW-B&_4
MZ.TNUC5<_P!IDF)FNX;]$2KD$Y[2,_H?A-^R:/PGXY'U+IT.L^E"]\CE-&QB
M^[KUL7X--;?RI1[!-=$6WE,PJ73[VG3PZ\WL]12+^HHLM
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MQ\5>J>2'_L+RVUH=(N1YK3CA=W&32IS?&J-Q4<&^7X62;WX**W)$VPL\\_0
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M.=O7CLK6]3##NZ4]F."4X\VI'N)Q;[L$1+$
M                            #-#]2+\6G>OY%Z/^R+$1L7T>_9:AX=3]
MI(I_5WIVKX,/%1!,)J1H               UC?*=^&?P6^[#J/ZI5XU=U3]H
M[WYS/QF7AD?H>V^1CVB0@8$RH                     $47G><?W.1GEA<
MJL4KX/ON1X3@Z-TXN2&U/2V['3=C$S^U9KF$)6X_86^(TMG7--H2IQPYG8@N
MY1"4:,OUE^I+6K)X4YS\G+J5%S5CR*33ZQ@]1VOG>35X)=W&//7XG=/LI-=<
MRQQLP4L               69/2U\DV]4\[\PT-<3_=J#D]JVQJZR,9I0W)V5
MJDYN<XLM]Q:TH2A&%+REE">AK<D26DI]I]#KKI+R[SK)(7T%C4MJJ;\"?<R_
M*YG63)AHN\\AF<K63[FM#!>%'NEZG.-#$4(6J
M                                      !1Y]6AR33;[%XR<2Z:R[H^
M&8W?[SSN P^XMA=UF$MW#=?MS6T]([5C3TV/7;J4JZNE'MTJZ)0XDUW/T6Y=
MS+>YS6:VSDJ<7R1[J6'(VX]>)7&N;SG5:-C%[(ISEU7LCV$GV2G@+9("
M           :)/I<]!*UCY>5QN"QAI:N.1^X<LRB!+-!MO.X-KTF=;4$1TE)
M)2B8RNBR"0VKKVJ;ED9%_E.@NDJ^\YS]6D7W%O1C%^%+NW^2XKK%K:+M?(Y4
M[A]]6J-_BQ[E>JI=DLF"O"7@
M1\>8IS&B<3].N-X[*9<W!L1N=2:[@]&WE4Z&VVT7.;SF7.YOW/'6I*"CH4E1
M2)[S*#0II+ZFX?K+4D=/Y;A1:^D:V,::XN.;Y(X[..37!CALW]USH*K=-&NE
M+-(26ALK<*M[/:O*MMNE:0:V\ZNXOGM-<RC&I+G*;IJ5.J7+EV$N5/GRI$V=
M-D/2YLV6\Y)ERY<EQ3TB5*D/*6](D2'EFM:UF:EJ,S,S,QKC*4IR<YMN;>+;
MVMM[VV>Z-"A1MJ,+:VA&G;TXJ,(12C&,8K",8Q6"C&*222222P1^<?)R@
M             6F?)1PF30\8<OS"8P;2\]VM</5KG57251XW1T5*R\77HDC3
M>ILFSZ=?^C_#_D*^>C&U=+(JES);:MP\.6,8QCXW.1X[??\ M04LRZ7;'(Z$
MN='+<FI*HO:UJ]6M5:_L?(2Z^[A<Q8L<T7     *('*3"9&N>2.]<*D,K9*@
MVKG$:$3C?A*=J'LAG3*263?:DDHFT\EAY/0NG:X73V=![.]'&;PS[0.39O!I
MNOEMNY8/'":I1C4CC[F:E%\J/YG^FC3M72?2YJ73M6+BK7.[R,,5AC2=><Z,
ML.*=*4)K@P:PV'0HFA68                $F?EE\TG.+6VBQ7-+-;6D]H3
MH-=E_CK4N+B%]_\ B4V>,(4LDQV(GBDQ:FCVNUY^(:7'(K"!KW]X3HDCTCZ8
M^DLIIIZNRZ$I4,-]>GWU2V?&Y8<ZCCNJ]SC&-2;-PON>?>%GT+ZY^A=0UFNC
MO.:D*=USGC&UK=[2O8K'N8QQYESAME0[IJ<J-.)<#;<;>;;>9<0ZTZA#C3K:
MTK;<;6DE(<;6DS2M"TF1D9&9&1CRSE&4).$TU)/!I[&FN!GO1"<*D%4IM2A)
M)IIXII[FGPI\#/['X?0
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M\TJL*U*-:F\:<XJ2?&FL5ZARX<1R
M                          !_#KK;+;CSSB&F6D+====6EMMIMM)J6XXM
M1DE"$)(S,S,B(B!+'8MX,EKS,^4!\QN=G)3?T2>NPQ?*MBV5/KQXW5K9_-GA
M#4?"=>O,,J)*(GSEBE!%F/-(+M]ZDNJ,U*4I:MI=.9;]$9);V#6%6--.?AR[
MJ?8DVER)%&9Q>_2&9UKI/&$IX1\%;(^HD^J>$AFS&@            !^^KJ[
M&[LZZEJ(4BQMK>?$JZNOB-*>ES[&?(;B0H45E!&MV1*DNI0A)>U2E$1#\E*,
M(N<WA!+%OB2WG[&+E)1BL9-X(U^N(6B8/&+BWQ^X^P?"5^:+4F#X18R6>SLL
ML@IZ&&SD]R?A?BO%O,C.5,7V_)-;Y]/8-4,VO99EF=>_E_G:LI+D3>Q=98+K
M%\V%LK.RI6J_S=-+KI;7UWBST8,>=L
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MOQ:=Z_D7H_[(L1&Q?1[]EJ'AU/VDBG]7>G:O@P\5$$PFI&@
M #6-\IWX9_!;[L.H_JE7C5W5/VCO?G,_&9>&1^A[;Y&/:)"!@3*@
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MXEH
M 0\^>MR];X@^7+N>XJ;4J_8^Z8A: UDEMYQF<5QL>#/B93<0G6$./PY&,:ZB
M7$^/(Z)2W.8C([T+=08ENB<I^EM04836-O1?E9\6$,.:NO/FIKBQXC :EO\
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MUJ"A.VSJQN)T:U*6^%2G)QDN)K%8QDFXRBU*+<6F^,#(&'
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M3)NG#H\M=99;S*69?%7MLI8NVNH)>4AOQ\G/%5*,GME2G''":DEZB%<ES
M                                               &:'ZD7XM.]?R+
MT?\ 9%B(V+Z/?LM0\.I^TD4_J[T[5\&'BH@F$U(T               :QOE.
M_#/X+?=AU']4J\:NZI^T=[\YGXS+PR/T/;?(Q[1(0,"94
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MEAMXL34!&MI<H
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MY/5BW&4<87=VL)4[?;LE3IK"K<+;BG3I..%9RC4V&OQ[2
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MGFEC1S/+JL*^7W%*%6E4@U*%2G4BIPG"2V2C.+4HM;&FFCZ(X#M@
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M4W;QTROQW+?4.Q<DPU,Y]KP57=- G+<QG)6VB)))BY1C3\2Q9]A=6923Z%^
M;797?T\TRZCF%+O*M-2PXFUM7XKQ3ZA0]]:SL;RI:3[ZG-KJK@?76#//@[QU
M0              #3]\C#GY^GCP@Q.;EMK[]O'1'S9J'<?O4KWBTO9E14L?1
M#8\OOZ/+_.!CK!.R'C(DN7$2P2@NQLAK=K7(OH3.9*DL+*OC4I\2Q?=0_%>[
MW+B7+IK-/I/+8NH\;FEA&?&\%LE^,O53)F!$"0
M                                 '@WS+.:>.<!>'.VN0UJ_ 7E-;5*
MQ74E#/-*DY5MW*(TN+A-,F,9I5,B0Y++MI8(0?>FIKI;A>U SFG<GJ9[F]*P
MCCY)OG3:]C3CWSZ_>KW31C,XS&&5Y?4NY8<]+"*XY/<O7?(F9.V29'>YCD5_
MEV4VLV^R;*;JUR/(KRR>5)L;F]NYS]G;VMA(7\N1-L;"4X\ZL_:MQ9F?X1M#
M3IPI4XTJ24:<4DDMR26"2Y$BCYSE4FZDVW.3;;XV][/BC[/D
M /H5%39WUK645+ E6ES=6$*IJ:R"RN1-L;.QDMPX$"'';)3C\J7*>0VVA)&:
MEJ(B]IC\G*,(N<VE!+%M\"6]G[&,I248K&3>"7*:YW [C-6\.N'O'OC; ;CI
ME:PUQ35V4R(AM*C66P+CQLEV1<1UM(0E4>XSRYL9+77N433J2-2S+N/57/,Q
MEF^;7&8RW5:C<>2*V076BDB]<LLUE]A2LUOA!8^$]LGUY-GK<8H[X
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MDK+1NFJ7D\IL:*A''OJDGW52K4?#4JS<JDWL7.D\$HI)=7CHDO
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MV+DWX5:V3_TM)2^(IEAP:+GJL
M             &:'ZD7XM.]?R+T?]D6(C8OH]^RU#PZG[213^KO3M7P8>*B"
M834C0              !K&^4[\,_@M]V'4?U2KQJ[JG[1WOSF?C,O#(_0]M\
MC'M$A P)E0                        "B7ZK3B!]#-V:<YIXS7>'2;FI4
MZDV;(8:Z--;'P&O5+PRUGO=A=\W*=>I<A-))1]&<8/V)Z]579T89MY:SK9/4
M?=T9<^'@2?=)<D9;?QRM-;V'D[BGF,%W-1<V7A1W/KQV?BE1X6H04
M        E>\F[S")GEX<R,2V!?SIA:0V.F+K;?-6S[P^TWA=M/95"S9F"PA]
M<FVUU;FBR;)MI<AZ&F7$:[3E&8B^KLA6?Y1.A!+SVGW=)^Z2[W'BFMG%C@WN
M,WI_-7E.81JR?\-/N9KD?#U8O;U,5PFI156E;>5E==4T^':T]Q AVE5:5\AJ
M7 LJVPCMRX,^#+84MF3#F17D.-.(4:5H41D9D8UIE&4).$TU-/!I[TUO3+IC
M)2BI1>,6L4S]X^3]
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M(0V<VC=*,IPV<V$U5HIR\DY/W&*=-D
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MM]V'4?U2KQJ[JG[1WOSF?C,O#(_0]M\C'M$A P)E0
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MYRY'ZCV<3<PHB9GP
M    \)^8?S[T_P"77QVR+>&T9;5C=O)?H]5ZXBRVF<@V=GST9;E=C]8A7<N+
M4PRZ2;:P4E35? 0M?1Q]3##V;R#(KO4&81LK980WSGP0CPM\O!%<+XEBUC,U
MS2WRFT=S6VRW1CPREQ=3C? N7!&67R6Y&[6Y:;OV%R!W5D+N1["V->/6]I(Z
MNHKJJ&E*8U-C./0WGGSK,9QFI99@U\8EJ\&*P@C4I7<M6S&79?:Y594["SCS
M;>G'!<;XV^-M[6^-E+7EW7OKF=U</&K-XODXDN1+8N0Z*'=.L
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M^M/:?RC2F1VFF\@H0M\FLJ$*-&G%;(P@L%RN3[Z<GC*<FY2;DVWQ4=<S(
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MO>U&L;?;LC2NWWF&R-SAL^'G*-G4>>!['@
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M=7!\!EOJ2I"E(6E2%H4:5)41I4E23Z*2I)]#)1&7M(;+%+G\@
M    #OWC'R:W)Q W5AF_=#Y6_B>PL)FF]$?-!RJB\JI)$S<8ME%4;C;-WC&0
M0NK$R*LTFI)DMM;;S;3J.CF66VF;6<[&^CS[>:ZZ?!*+X&MZ?K8H[5G>7%A<
M1NK:7-JQ?6:X4UPI\*]<TW?*_P#-#TIYE^F6LNP]V'A^Y,1APHVY=+3+%N1=
MX;;NI)HKNE4X34C(-?WDA*E5UDALNA]8\A+4EM;8UQU+IJ\TY>>2JXSLYM^3
MJ8;)+B?%)<*ZZQ1<639U;YQ;^4I]S<1[^'"GQKCB^!]9[23L1LS(
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M*GEM>-.>K[Y0K9A6CMQJX/F4(2VXTK92E"#6R<W4JI1\IS5X@$7-A
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MIW2D^[NJ."C2O4O9.?>7&'>UUSFHQK4TY,!KX;@@
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M=[P2Y8O\U[5RK:3OB$$F
M  B_\R3S8.,WEL8,Y,V+;HS?<]Y5O2]=Z%Q>QCEF.3.&3C42TR"3X4QG!L*]
M[0:7;6:THUDAQ,-B8\@V1)-/:7S+45;"W7,LXONZLEW*Y%[:7N5UVEM,-F^>
M6>44L:KYUPUW,%O?*_:KE?63,W3G#SOY#>8)N6=N3D!E";"4TF3 PK!Z4I4'
M =:8X^\EXL<PFBD2IAPHZS:;5*E/./S[!UM+DI]U24FG87)<DL,AM%:6$<%O
ME)[93?')\/(MB7 D5'F69W>:W#N+J6+X$N]BN)+MO>^%GC49<QX
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MD1)(NA>P;%I**48K"*/#NI4J5JDJU:4I592;E)MMMMXMMO:VWM;>UL_U'Z?
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MKD^84%4CNYU.7>U*-1+%*K1J*5*HL6E.+P;6#?9XCI,@
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M59<$EOY4]TERIM<I8MK>6M[25:TG&=-\*[36]/D:3.[QTCL@
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M%;]"WH6M&-O;0C3H16"C%))+D2*]JU:M>HZM:3E5D\6V\6^N<.'*<8
M            :5OI_O+C5P=XC1-A[%I/<.0_)>+29YGC,Z(VW:X1A)1G9&N]
M;J4M)2HDJ%5V"K.V963;C=K/7&=2KW)I0UWUWJ#Z:S5V]O+&PMFXQPW2E[.?
M96$?<K%=\RWM+93]&V'E:JPNZV$I<:7L8^N^5X<!/0(.2<
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M&17]51S.G!;*%W-I0NDDME.Z?<U7NC<X2;<KA*,$XW+/-4
M    ):?*JYK?H\[-/4>?VB8^G-K6L9HYDQWPXN#9X^EF!5Y&;JU$S&IKIM#4
M*S-71+9)CR36A$=PG-9/O)]$?UZT]]9\DI\[5>6TF^;%8NXMEC*=+#>ZE-MU
M*.&UXSII-U(N.\GW)_O#_P!*M8_475%91T!G=>*Y\WA&SO980IU\7LC2K)1H
MW&."BE2K.48TIJ=M >9)[D
M    9H?J1?BT[U_(O1_V18B-B^CW[+4/#J?M)%/ZN].U?!AXJ()A-2-
M          &L;Y3OPS^"WW8=1_5*O&KNJ?M'>_.9^,R\,C]#VWR,>T2$# F5
M                              *2/J>O+/.FMX7F,:=Q\RJKUVEP_DY4
M545*6*Z\_$4V#[=<;;,^UJ_1X%%;K(D(3+:KWNU;LJ4Z+DZ-]1\^#T_=R[J.
M,J+?"M\J?6VRCR<Y;DD5UK+)^;)9M;KN7@JB7'NC+K]Z^7#C938%N%?@
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MRAOS^WJ0@O98<Z#_ !XXQZV./(36RS;+LP7\)5A*7M<<)>]>#Z^&![:&&,B
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M-:PN9+!7%K)OFXM=SY6D\:5:*PPG'GJ*A.#?DT684>
M%K+RFN:Q[QUV6BMB6WC[7U;4,II+"=(4Y-SG7L0V8<.<Z\\M3DN^Q53C4.89
M_+>C*COF;CBI"T^:WWFNB/ZG9[]<LBI8::S*J_*1BL(V]S+&4HI+9&G6P<Z?
M!&2J07-BJ:?MK]QW[P_]2-*?TUU77YVM\EH+R,YRQG>6,<(0FVWC*M;8QI57
MOG3=*HW*;JR4PXU7-]P                                       #-
M#]2+\6G>OY%Z/^R+$1L7T>_9:AX=3]I(I_5WIVKX,/%1!,)J1H
M     UC?*=^&?P6^[#J/ZI5XU=U3]H[WYS/QF7AD?H>V^1CVB0@8$RH
M                        !P[8>OL-VQ@>8ZRV)C]?E>"9_C=SB.78W:LD
M_7W>/7\!^MM:Z4CJ2B1(B2%))232M"NBDF2B(RYK>O6M:\+FWDX5Z<E*+6]-
M/%,XZM*G7I2HU4I4I)II\*>\RQ/-4\O#-/+?Y49-J.R*?<:LR<YF9:)SN2V:
MD95KJ9.=1%K["6AMN.K,,,=45=<-)2V9OMHE(;1'EQS5LSIC/Z.H<LC=QP5S
M'N:L?:SPWKW,M\>39O3*5SO*:F47KH/%T);82XX_A6Y]G<T1K"0F(
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M94<NM(6E!=Q!;^%OA;Y6_P &X],#''<
M   K'^;ES3+966N<:-<6YN8'@-MXNR+.ODD<7+,[@+[6\?[V3_=%/A$@E)=0
MI1MNVW<9HZPV'#H[I#U-Y[<?0EE+^$HR^$:>R=1>QY5#AXY\'<IGKA]R7H#>
ME,E72SJJAAJ/,J.%C3G'NK:TFMM;!][5NXX.+2QC;8)2PKU(J$L5@>@(
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M%R4IVUS#!5J$]S[B6V$FH^4I2IU5%*:1W^(06@
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M);B5)922",C]B2(OP#(4J%&BL*,(P7N4EVCISJU:KQJ2E)\K;[9Q,<I\
M                        !^VMK;&YL8%/3P)MK;6LV+6U=76Q7YUC96,Y
M]N+"@0(45MV3,FS)+J6VFFTJ<<<424D9F1#\E*,(N<VE!+%M[$DM[;/U)R:C
M%-R;V(TI?(K\J.'Y>^B%;&VM2PU\L-VU,&9G[[A,2G]8X>LV9]-J6JF-FZVF
M3&>2B7?.L*\.59DADE.LPH[BM=]:ZH>?7WF]JW]%T6^;[N6YS?:CCN6W8Y-%
MO::R-95;>5KI>?5%W7N5P17;EQOJ(GC$(),
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M3?:PU'5\KG-_7=2H]O-CCLA3@FVXTZ4%&G3CB^;",8X[#L,=PBX
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MAG\%ONPZC^J5>-7=4_:.]^<S\9EX9'Z'MOD8]HD(&!,J
M                 %=;SX?)VC\[]=JY"Z#HXK'+?5M"<=-3$1$B%O7!:[Q7
M_H18R'GHD=O-:(G%NT,YU1DZGOKG_P 6[&>A3_1&K7DEQYA?2?T55EO_ %4G
M[)>Y?LE^,MS3B>IL@69TO.[5?Q\%N]O'BZJ]B^L^##.=G09M9-F5ME#E5]C7
MRI$&? G1W8DV#-B.K8E0YD5]#;\:5&?;4AQM:4K0M)D9$9#8",E)*46G%K%-
M<)4S33P>QH_*/T
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M(>BO15EHG3L7YE:4^ZJ-)3KUI;:M>IA[.I/%X8X0CS81PA"*73 QA/0
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M]V'4?U2KQJ[JG[1WOSF?C,O#(_0]M\C'M$A P)E0
M              "IMY]WD>)WU%S+F_Q'QQ*-VU=;)R#=VH:2$1%N*LJ89NSL
MYPJOAM=ZMKPH,<U38#:3/)6T=[)?.I&BRM'0^M/,7#)LUE_!-X4ZC_S;>Z,G
M[3'<_8</<][!]3Z;\Z4LRL%_$I8SBO9X>R7NN->R\+?0U4E2%*0M*D+0HTJ2
MHC2I*DGT4E23Z&2B,O:0N\K(_D
M                                     6UO(7\C2;N:RPSFWS#Q+W?2
M]<_&R/2.FLEKDJ<W#,:_'56?9O4SFC)&K(CW:_6P7D=<C=2EYQ/S424V=6:X
MUK&SC/)LIG_&/94J)_%\<8M>SX&_8;EW7>SG3&FW<..8YA'^'6V$'[+BDU[7
MB7LO!WWO4I2A*4(2E"$))*$)(DI2E)=$I2DNA)2DBZ$1?@%)%F']
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M-8QM<5MC4N5A.JL4U;M1:<;C990%UGE$
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M^+3O7\B]'_9%B(V+Z/?LM0\.I^TD4_J[T[5\&'BH@F$U(T
M :QOE._#/X+?=AU']4J\:NZI^T=[\YGXS+PR/T/;?(Q[1(0,"94
M                           "J'YXOD+,\BG,KY@<,,=@5F]DQYU_MW3%
M8PB'!W8MA"I,S+<(CLH3&@[:=2E2ID/HAC)%?C4FBS[SL;0T7KAY?S<ISB3=
MCL5.H]]/W,N.'$]\-W>]["-2:85WSK_+TE<[Y07L^5>ZXU[+J[Z&UO46N/VM
MG0WU984EY26$VHN::WA2:VUJ+6MDNP[&LLZZ8TS,@6$"8RMIYEU"'&G$*2I)
M*(R%WPG&I%3@U*$EBFMJ:>YI\*964HRA)QDFI)X-/>GQ,^>/T_
M                                                         +=_
MDB^0#8[1?PWE_P Y\4D56L&'8&2ZCX\Y'7*9L-H(-IF?39OLZ%)6AVMUWW*0
M["I'FO'OR(G91-UO:U9U5K/74;93RG)98W.U5*J>R' XP?#/CENCN7=;8SO3
MFEW6<;_,HX4=\8/V7$Y>YXE[+AV;[T+##,5EF-&9:CQX[3;$>.PVAIEAEI!-
MM,LM-DEMIIIM))2E)$22+H0I5MMXO>64DDL%N/\ 4?@
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MQ=9_G=:=QF]Y7G6K5)=].I4DY2D\,$L6]B222P2222.1#F,6
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M95=T(5J-6#QA4I5(J<)Q?%*+375VGV1U#(
M       !FA^I%^+3O7\B]'_9%B(V+Z/?LM0\.I^TD4_J[T[5\&'BH@F$U(T
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MJN;6XLZSM[F#A6CO3[:XT^!K8^ ZA':.
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M5:X:52KO:[BESI1I19[*$E*(
M    /Y6A#B%MN(2MM:5(6A:24A:%$:5(6E1&E25)/H9'[#(?J;BU*+PDC\E&
M,XN,DG%K!I[FN)E0SS/^%B^,FV%9WA%8;6E=J64R=CS<9CLAX5E3I.SKC!E&
MV1,L0>U+DNI+HCK"[V$DHXBW%^HOW=NEM=(>F?H;.*F.KLMIQC5;?=7%%81A
M<;=KENA6W_"83;7E5%>$/WRON\RZ'=;O4NG*/-Z/,[K2G048X0M+EXSJV;PV
M*'?5;;=\#SJ:3="4Y1=C8LTR                  "?SR>.:Q4M@SQ,V7<$
MBIN)4N;I:UGNF2*^ZE..S;;7ZY#B_":BW;RG)E8E1)_=RGV"4M<F.VG27[U/
M1'YW0?2;I^EC=4HQC?PBN^II*,+G!;6Z:PA6>WX-0G@E3J2?J#]P?[Q'T==1
MZ#M7W&%C<3E/*:DWLA6DW.K8N3>"C6?.JVZ>'PSJ4DY2K4H*QZ-"#UK
M                            #-#]2+\6G>OY%Z/^R+$1L7T>_9:AX=3]
MI(I_5WIVKX,/%1!,)J1H               UC?*=^&?P6^[#J/ZI5XU=U3]H
M[WYS/QF7AD?H>V^1CVB0@8$RH
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M@@
M]^\#?+2Y6>8EG1XOH3!UIQ*IFQHV<;@RLI=-J[ V7C;4HK?(4Q9"[.Z-A9.-
M5-<U,LWD?+)DF4K=1@\\U%E>04/*WT_A6NYIQVSEU%P+W3P7+CL,IEF3WV;5
M>9:Q^#3VS>R,>J^%\BQ9H7>6?Y.W&'RV<<9ML6KT;1Y!6E=[IEV_<OJ82,B[
M)#'A3Z+7M7WS6==XC(-2B<CQGGILU)D4V7)2VREJA-1ZMS+453FU7Y*P3[FE
M%[.1S?LY<K6"]BEMQM3)\@LLHASH+GW36V;6WJ17L5ZKX6]A+4(L9T
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MJ=EBMCC2?-JU\,?A53IMJ5*K$GS%MGFR
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M*[C%884[E1;:22A6C5II<Q0<O?XI$VA
M   S0_4B_%IWK^1>C_LBQ$;%]'OV6H>'4_:2*?U=Z=J^##Q403":D:
M         -8WRG?AG\%ONPZC^J5>-7=4_:.]^<S\9EX9'Z'MOD8]HD(&!,J
M                                        !\ZWJ*F_J[&COJRNNZ2X
MA2:VVI[>%&LJNTKIK*X\ROL:^8T]$FPI<=Q2'6G4*;<0HTJ(R,R'U"<J<E.#
M:FGBFMC37"GP,_)1C*+C))Q:VI[F56_,:],9IO<[M]M3@K<4V@-CRE2K*=IF
M^*6O2&33%]7EM8M)ALS;G5,R2ZI9I99:L*0C\-EB)7M$IP6;I_I(N[-1M<[3
MKVZV*HOC%X7!/JO"7"W)D)S;1MO<8U\M:I5O:/O'U.&/JKB2*5/);B7R.X?9
M])UKR1U'EVJLI:7(]Q3?P4N4.1QHRTMNV>'Y97.3<7S&H2M9).563)3"5GV*
M42R-)7%EV:Y?FU!7.7585:7#@]JY)1?=1?(TF5Y>6-W85?(W=.4)\NY]1[FN
M5-GG4=\Z@
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M_P#C;6I*.64Y)-5:\6XU+MI^QH-.%!\-;G37-=&#E7 %+GJF
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MI2;<FVVVVWM/V#Z.
M  BK\TGA47)+5GYR<"J/>=U:KKI,FL8B-I][S;"VU.3;G$5$A/BR[."9N3:E
M/RC.1XT=">LON1LG]W'I<^H&I/H#.JO-TEF51*;D^YMZ[PC3K\482V4ZSV=S
MS:C>%+!Z4??1^[Q_5W17UNTQ0Y_2'DE*4J<8KNKNT3<ZMJ\-LJD.ZJVRVOG^
M4I16-?G1J-F1I,TJ(TJ29DI)D9&1D?0R,C]I&1CT^336*W'A4TT\'O/^
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M=AU']4J\:NZI^T=[\YGXS+PR/T/;?(Q[1(0,"94
M                        ZHW3HK3G(S +?5N]=:X?M77]VE/O^+YI2Q+B
MO]X;)7NUC!4^@Y-3<P5*[XTZ(XQ,BN=%LNH61*+M6=[=Y?75S95)TJ\=THO!
M]1\:?"GBGPHX+BVM[NDZ-S",Z3X&L?\ ]'Q-;450.;_I4L.O?G/-.!&U%X18
M*][F'I/=5C8W>*.F?BOM5^';,A0I^44J&T(2PQ'NHUNIYQ?<]8LI(S%H9-TG
M5H84<\I<^/ZRFDI=64-D7QMQ<>2+(1F6B:<L:F5SYK]I/:NM+>NOCU2I=RCX
M.<L>%^1_1KDMHW.-8N/2G(E5D5C7)L\%R-ULE*46+[ HG;/#,B632>];<2<Z
M\TDR\1"#/H+3RS.LKSBGY3+JT*FS:D\)+PHO"2ZZ(+>Y;?9?/F7E*4.)^Q?4
MDMCZS/*(R9T@                                            #N?1
MO'3>_)C,6, T!J3/=NY<ZICQ:C!L<L;PZUB2M:&I][.C,G6X[5=S2N^9/>C1
M6R2HU.)(C,NI>YA99=1\O?584J7')I8\BX6^18L[%M:7-Y4\E:TY5*G%%8]G
MB7*]A:<X.^E5V+DKM5FG/?9T?7%&:69:M)Z:M*O(\]D&9=RH&6[(?B6>$XVI
MEU':ZU3,Y 4AE?XN;&<+J599UTG6]-.CD=/RD_UE1-1ZL8;)/\;FX/@9-<MT
M35GA4S2?,C[2#3EUY;EUN=U46].+/#/C+PLP0M><:=1XQK*B?\!RZFUK+]AE
M65S([?AMV.7YC;O3\FR>:DNO8J9*=0P2C0REM'1!53F>;YEG%?SC,:LJD^!/
M9&/)&*P2ZRV\).[++[/+J7DK.G&$>'C?5;VOKL]/#&G=
M                     \@<V>5E!Q*TM;9Q(5"G9Q=>-0ZTQF0OJJ[R=YGJ
M4R3'0M#RJ+'65E+G+(TD:"0R2TNOM=8YJ?/Z.GLLE=/!W4NYI1?LI<;]S'?+
MK+>T7A]W_H:S/IKU]0T]252GIZWPK7]Q%?%6Z?>Q;37EJ[7DZ*VO%RJ.+A3G
MA2WR?)K_ #3([S+LJMIE[DN2VLZ[O;FP=\:;9VME(<E39DESH1&X^^ZI70B)
M*?P$1$1$-9Z]>M<UIW%Q)SKSDY2D][;VML]\,HRC+<@RNWR3)J-.VRFTHPI4
M:4%A"G3IQ481BN)));<6][;9\(<1D0                .;ZVUWENVL\Q76
MV"U;MSEF8W$:EI8#1+[52)!FIV5*<0ASW6MKHK;DF4^HNR/&:<=7T2@S':LK
M.XS"[IV5K'G7%22C%>N^));6^!)LC^J]49+HK3EYJO45:-#);"A*K5F\-T=T
M8IM<Z<Y-0IP6V=2481VR1=AXK<<<3XM:9QG56,$U+EPVBL\PR(F29D99F4YE
MGY[O7TGU<0PMQI+$1I1J5'A,LM&I1H-:MG<@R6WR'+(6%#!R6V<O;S??2]9+
M@BDN \ .F3I4SKIAUY=ZRS?G0HU)>3MJ&.,;:U@WY*BN!M)N=2224ZLYS22D
MDO1@S)5H                                                58_-
MNX4GI[/'.0VNJDVM9;,N%EE]= 8(HF$["G$N0^\EMOVQJ/,UH=DM'T\*//)Y
MGJA+L5H>D'W8NESZU9*M"Y]5QU#E]+X"<GW5Q;1V)8O?4H;(/AE3YDL&XU)'
MBQ]^?[N_U!U,^E72=##1V<7#\ZIPCW-I?3QDW@N]HW;4JD=G-A7\I3QC&=&!
M#$-L3SZ                  ":'RC^:OYH<[1QVV+;&UK79EP@\,L9KIG&P
M_8E@IB)'B&XLS]UH\R4E##G_ /&Q8$T[T0EZ2X-3/O/]$?UIR5Z[R&ECJ#+Z
M3\O&*VU[6.,G+#AJ4-LEPRI<Z.UQIQ/0C[BWWA_J'J5=%&K*_-TAG%PO-*DW
MW-K?3YL8QQ?>T;O!0E[&%?F3PBJE:9:8'G">T@
M       !FA^I%^+3O7\B]'_9%B(V+Z/?LM0\.I^TD4_J[T[5\&'BH@F$U(T
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M-/4E3J:AN,*U_<17QMPUWL6TGY&@GY.BMBP4JCBIU)X^01'2\
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MC.\9TZ;\I;5^:XQN;6;?DJT>#%I.%6*;5.M"I3Q?-Q?G03PJ<
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M.B?\/'Y/7[(/_'_E#_;8.[]?M6?S?^RH_NSK?53(/Y?\NI^F/\/'Y/7[(/\
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M<RYUQ4DY2>"6+>UO!))=9)&<H4*5M1C;T%S:,(I)8MX);MKQ?99V$.N<H
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M/NKZ]OI^4O:M2K4XYR<NQBWAUB0T+6VM8\RVIPIPXHI+M';(ZIS@
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M1$70B(B]A$1"<&IC;;Q>UL_Z!^
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MB("6X
M                                                        !U_G
M6IM5[0CE$V7K/7^Q(A-)8*+G6&8YEL<F4J>4EDF;^ML&R:2J0X9)Z="-:O\
ME/KST+JZMGC;5*E-^YDX]IHXJM"A66%:$)KW23[9XOSCRE/+-V$4CZ0\'>.$
M9<M+A/O8AK6CUW)6;S3K+CI2M?,8Q(;D*2\I7BI43GB='.[O2E19BCJK4=OA
MY.]N'A[:;GXW.,?4R+)ZO?VU'K14?%P/*67>G5\I'*5/.Q.-MOATI]$PG).(
M[HW3&23LEMMMJ0S77>>WM-%7 4@ULH:C(9-2C\1#A="+*4M?ZJI;'<*:]U3I
M]M13V]7J'1J:3R*>ZBXODG/UY-'GC)/2S^6A>>/\UWW)[#?&\#P_HWM/$97N
MOA=GB>!]+]897W>]=I]_B^)T[C[.SV=._3Z3-1P[Z-M/JPE^;.)U)Z*R>7>N
MM'J27KQ9T]<>DQX3/O3%4'(KE-61UM=(#5Q8:EO'HSWNZ4^),?A:QQY$YKWH
MC7V(;CGX9DCNZEXA]N'2EG*2\I;VS?#@IK\]X>J=>6ALN?>5:Z7+S7^:CK]W
MTD''HVW"9Y>;F;>-"R:6[@>$.MH<-)]BW&DRV5.H2KH9I):#47L[B_".PNE2
M_P =MI1P\*1Q_46TX*]3'J(X=_A$M=_MQYI_431_VH#F_JM7_DH?VK_0./ZB
M4?YF7O%^D/\ "):[_;CS3^HFC_M0#^JU?^2A_:O] ?42C_,R]XOTCD55Z1S1
MS,4T7?,C:]A,\59D_5:RQ"FBDP9)[&SB2\@O73=2HE&:_'(E$9%VETZGQ2Z5
M+UON+2DERSD_67:/J.A;;#NKBHWR12]=G-:KTE7$EF,:+OD]R,L)GBK,GZJ!
MK.GC$R9)[&SB2\6O73=2HE&:_'(E$9%VETZGPRZ4\U;[BVMTN5S?YR[1R1T-
M8X=U6K-\G-7K,[AIO2I>6]5N.KG;#Y<Y&ESPNQFYV9J]AMCPU*-?A'CVD:%X
M_')1$KO6OH1%V]I]3/J3Z3M0R[VG:1ZD)^O49V(Z)RB.^==]64?6@CO_ !?T
MVWE,X^ONMM)9UG!>*\YX>4;OVM$0:'&4-(8ZX5E&(.>%'6DW$'W=YK49*4I'
M1!=&KTAZIJ=Y6A#P:</SE([4-(Y''OJ<I=6<O6:/4F%>3!Y6> JCJHN$FE)Y
MQE$ILLUJK;925&DV#+WA&Q;C*D2T_N9/4G261]5=?\]?=C*VK]35^_O*RQ]J
MU#Q%$[M/3V2TN]MJ;ZJ<O&;/:&O.-7'/42F%ZHT#I36"XR4)C+UYJO!<+5'2
MT;!MI85C=#6FTELXK1I)/3IX:>G^:73#W&8YA=_\57K5<?;SE+MMF1I6=I0^
M(I4X>#&*[2.ZQTSL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M=6MQ""X7"7-]]AAZID:&:9;<O"A7I2D^!26/8QQ]0]<C%'?
M
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M]=#%'?
M                                         /Q65E74\"7:6]A"JJR
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ME5X,=S7'&2V27*FT3NSOK2_I>6M*D9T^3>N1K>GR-(]#CH';
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M+%Q>#QX(\XE>DLYKQOW97=24Z=9=RY2;PDMJWOV2Q7*\"^R*.+.
M      *U/J5/,$R#BSQFPSCYI_-[7#MW<C+PIDR]Q2YFTN68=J'")D6??6U=
M;U$B-9T,_+<G]QJXSR5MG)@HLT(5W-J--B='>0T\SS&=_=P4[*WCL4EC&526
MQ)I[&HQQD^)\TB&K\UG96<;6WDXW-9[T\&HK>\5M6+P74YQ1>_3;YG?M<\GO
MZ_-J_P"]8NOZ&RC^4MO[*'Z)6OTCF'Z^M[^7X1^FWS._:YY/?U^;5_WK#Z&R
MC^4MO[*'Z(^D<P_7UO?R_"/TV^9W[7/)[^OS:O\ O6'T-E'\I;?V4/T1](YA
M^OK>_E^$Y?K[FIS(DY]@\:3RTY,R(\C+\:8?8?WQM-UE]EVZA-NLO-.94I#C
M3B%&E25$9&1]#'#7R?*%0FU:VV/,?^:AQ>"<E+,<P=6*=>MASE[.7'U37(&J
MQ>H           'A#S0<BR#$?+LYIY/BE[<XQDM#QPVG:4>0X]9S:6\I;.'B
MT]Z)8U-M6OQI]=/BNI)3;S+B'$*(C29&,WIJG3JZ@LZ56*E3E<0332::YRV-
M/8T8S.ISIY3<3@W&:HR::>#3PX&9>_Z;?,[]KGD]_7YM7_>L;*?0V4?REM_9
M0_1*9^D<P_7UO?R_"/TV^9W[7/)[^OS:O^]8?0V4?REM_90_1'TCF'Z^M[^7
MX1^FWS._:YY/?U^;5_WK#Z&RC^4MO[*'Z(^D<P_7UO?R_"7*_2L;GW#N' >9
MTG;FU]E;2D4.7Z48HW]C9UE&;O4S,^EV0Y.9JG<FM+-=<U-7%:4\EDT$X;:#
M5U[2Z5%TG6=I:5[-6M*G24H5,>9&,<<'##'!+' L#1-Q<7%*X=><YM2AASI-
MX;);L6RV8*M)R               >'^:/F+\1> F*-Y%R0VM5X[<645R3BVM
M:)*<DVGF9-^*DE8YA,!WYP.N4^R;2K*:<.H8>-*'I;2EI(\UD^G\USVKY/+Z
M3E!/NIO9"/5D]F/(L9/@3,;F.;6&5PY]W-*3W16V3ZB]=X+C93TYB^J@Y/;+
MD6F-<.]>8YQSP]2G8\//<PC56R]NS64O+\*P8@V<-W6^)'*BF27(:H%ZXRLC
M4W._!TMG*>C++;9*IFU25Q5]K'&%-<FSNY=7&/+$@68:UO*S<,O@J-/VSPE+
MU>Y74PEU2NGO#E7R6Y+6KMSO_?&U]O2UR%R66,\SG(+^HK5K<6[X5)039RZ*
M@AMN.*-$>#&CL-]Q]B"ZB?V65Y=ET>98T*5)>YBDWU7AB^JVV1.YO;R\ESKJ
MK.H_=-M=9;EUCH$=XZH    !]_&,KRG";N#DV&9+?XCDE6Z3]9D&,7%C07=<
M^DR4EZ#:U4F)/B.I,B,E-N),C(?%2E2K0=.M&,Z;WII-/JI[#ZA.=.2G3;C-
M;FG@^RB:CBIZACS*.-$BIK<@VI'Y)8# 5'9D8AOZ&YEEN["07A2/<]G0WZW9
M:+)4?IX+LZSLHS3J$K5&<+Q$.0[,]!:=S%.5.EYO7?LJ7<KWFV&'42?*2*QU
M5F]FTIS\M27!/:_?=]V6^H6X^ ?J%>$_,Y^CP//[%?%O>-IX$1G"MHW,%>"9
M):NFE!0\%VQX-90V+[[SB&V(ENQ26,I]?A1H\@R[CJO/=!9SDZE7H+SFR7LH
M)\Y+W4-K7*XN22VMHG65ZJR[,&J55^1N7P2?<M^YEL76>#XDR>L0<DX
M           '0_(SD[H7B5K6SVYR)V=C.KL$K%> 5G?RE'-N+%2%.,TF,4,)
MN5>Y5?R6T*4W!KHTF4IM"U]G8A:D][+\MOLUN5:9?3E5KO@6Y+C;>R*Y6TCK
M7=Y:V-%U[N<84EPOAY$M[?(MI3LYO^JLV!D$FWPO@7JZ)@-"29$-K=>Y:V#D
M&;RU=>Q%EBFMH\N;B&.$TMLULN7#]Y[PTX7BPHRTF@6UDW1C0II5L\JNI/\
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MQ]RS77VY<C!?'1=Z K?/)_LZ15FN/2U/YO'QZA6'%D$-
M    +/'I/OB)[G^Y9L7[<N.8K?I1] 4?GD/V=4F6A_2U3YO+QZ9H.BARTP
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M6VI);N-07L5R]\^%X;%4V<ZAO,VDX8^3L\=D$]_+)^R?J+@7"0W"6F
M        #T;Q=Y:<@^&>T:W;_'+95]KG,8/AL3RKGBD4&55"7DO/8YFF-2R>
MI,KQZ2M)*5%FLNI;=)+S1MOMMNHQ^99589O;.TS"G&I1>['?%\<7OB^5=1[-
MAV[*^NLOK*XM)N%1=AKB:W-=7MFB!Y1_G9:>\Q^A8UQFK%-J+EC0U7O-]K94
MY:,=V)$@L(.RRS4DNQ?<ES8C9DIZ72/NO6=8UU5WRXS:Y8H/56C;O3T_.*.-
M7*Y/9/#;#'=&>'J26Q\CV%K9%J*WS>/D:F%.^2VQX)<L?76]<JVDY A9)
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M'/,Q>9YE4N4_@L>;#P5N[.V3Y61QB0&)   #FFM_Y1,"_+3%OW\@CBN/B)^
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M<3Y:<GL?XLGV)-O<3C169>1N99;4?P=7NH\DTMJ_&BOR5QE\T4@6:
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MC',9+.<SCC8PE\'!K94DM\GQPB]F&Z4L4]B:<(U5J"5G%Y=92PNI+NY+V"?
MO=-</ MVU[*#RE*6I2UJ4M:U&I2E&:E*4H^JE*4?4S49G[3%XE8G\@
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M8Z*<;<9<<9>;6TZTM3;K3B5(<;<0HTK;<0HB4A:%$9&1D1D9#NIX[5N.L?P
M     )S_ ".?-:O/+TW[%P+8]U*D<3=V7U96;0K)*WI,76^125,UE3N2BC)[
MUQG*9!MLWS3"3584R3/PWI,.$E$*UII>&?V+KV\5]*48MP?MUO=-]7V..Z7"
MDY$DTWG<LJNO)5G_  -1X27M7P374]EQKC:1I?QI,:;&CS(<AB7$EL-28LJ,
MZV_&DQGVTNL2([[2EM/,/-+)2%I,TJ29&1]!KJTT\'L:+@336*W'^X_#]
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MPXAUE]EU!.-/,NMFIMUIUM1*2I)F2B/J0UA::>#WEW)IK%;C_4?@
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M%WH"M\\G^SI%6:X]+4_F\?'J%8<600T   -I4:?FPH
M        %5+U:'ZF/&_[SS/V5;#%G=%OI>X^;?GQ(3KGT?1^6_-D4%Q>16
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MZ3IQQ4OUL5O?AKV2X>^7"E56IM/K+)^>6B_@IRVKVC?!X+X.+<^#&MN+"(B
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M,*=3P6^XEUI-Q?"^='@1/M$YES:D\KJ/9+&<.JEW2ZZ6/6?&7@13!8X
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M>@*WSR?[.D59KCTM3^;Q\>H5AQ9!#0   VE1I^;"@
M       54O5H?J8\;_O/,_95L,6=T6^E[CYM^?$A.N?1]'Y;\V107%Y%8
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M>T])#^KMRZ_IIP?ZC/"D^E3_ (^T^1EXQ9>A?^$K_*+Q2W"*K)T
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MH07_ -$C4>K4G6JRK5'C4G)MOC;>+]4O^$(TX*G!80BDEU%L1]X?!]
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MX>/SA?V0?^/_ !>_ML#Z_:3_ )O_ &5;]V/JIG_\O^73_3-/ :WER
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MI;UIV]985H2<9+8\'%X-8K%/!K@>!GJ=2%:G&K3>-.44T^--8K?MW'*!Q'V
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M5Y=VE[&IOQZD]_A)\:1:&C\X\ZM_HVN_XBDNYQ]E#BZL=W4PXF6G169-0
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MGV68N\M:L8+?)+GQ]]#G1[+)+:YUE5[@K>O3<GP-\V7O98/U#WN,&9,
M           #-#]2+\6G>OY%Z/\ LBQ$;%]'OV6H>'4_:2*?U=Z=J^##Q403
M":D:  ]/<)/USN(WWGM!_:KB@QV<^B+OYM5\21W,N](4/EH>,C7W&J!?(
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M!?(   4Z?5V_R=\'/RTWM^\>KQ;?13\?>^!2[<R Z[^)MO"GVHE( 7*5P
M        !=*]()_\AG_E,_\ 4P*?Z5_^0_U_^Y+"T'_S?^J_WA=+%/EA@
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M$1( #NGC;^L3H3^FG5GUYHAU,P_X"O\ (S\5G8L_^+I?*1\9&Q8-2B_0
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M11X   7?_2)?R=\X_P M-$_O'M 4UTK?'V7@5>W L?0GQ-SX4.U(N+"I"?
M      !XL\R3X=G/C[EG*7[#<Z&8T]Z?L?GE']I$QV;^B;KYO4\21D>C:@HL
M   +I7I!/_D,_P#*9_ZF!3_2O_R'^O\ ]R6%H/\ YO\ U7^\+I8I\L,
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MHM*WN;>[I*O:SA4HRW2BU)/KK%$&JT:U"HZ5>,H5%O4DT^PS@XYCC
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MJ[?Y.^#GY:;V_>/5XMOHI^/O? I=N9 ==_$VWA3[42D +E*X
MNE>D$_\ D,_\IG_J8%/]*_\ R'^O_P!R6%H/_F_]5_O"Z6*?+#
M,^+U8/Q$],?<LUU]N7(P7QT7>@*WSR?[.D59KCTM3^;Q\>H5AQ9!#0
M            U]N$?ZF'$7[L&@OLIQ,:HYSZ8N_G-7QY%\Y=Z/H?(P\5'I\8
MT[@         !52]6A^ICQO^\\S]E6PQ9W1;Z7N/FWY\2$ZY]'T?EOS9%!<7
MD5@   &Q7QM_5UT'_0KJSZC40U+S'TA7^6GXS+]M/^$I?)Q[2.ZATSL'^3[#
M,IEZ-)9:D1Y#3C$B.^VAUE]EU!MNLO-.$IMUIUM1I4E1&2B/H8_4VGBMX:36
M#W&93YZGEIN^7YRNFW.OJ-V+QHW[(NLWU [%CDFKPNT]\2_F6H26E1FTG"Y<
M]EVL)9%WTDR*CO>>8E*3L;HK42S[*U"O+',:&$:G')>QJ?C8;?=)[DT4[J7)
M_HN^<J2_@ZN+AQ)\,>MP<C7"F0BB9$<   #2&]/AYF?Z;/&9.DMI7_OO)/C7
M45-#?R;&;XUMLG5J"168;L8U2GW)]C;UQ-HJ;]X_%/WU$:6ZX2[)#:->]>:<
M^ALQ\]MHX9=<-M8;H3WRAQ)/OH\F*7>XEMZ5SCZ1L_-JS_C**2?'*/!+J\$N
M7!\)8/$#)49\7JP?B)Z8^Y9KK[<N1@OCHN] 5OGD_P!G2*LUQZ6I_-X^/4*P
MXL@AH 'M/RV_B)\!_OI\6OMRP48?4/H"^^9UOV<C(91Z6M?G%/QXFN$-5R]0
M         #-#]2+\6G>OY%Z/^R+$1L7T>_9:AX=3]I(I_5WIVKX,/%1!,)J1
MH #T]PD_7.XC?>>T']JN*#'9SZ(N_FU7Q)'<R[TA0^6AXR-?<:H%\@
M      !G6^J8^)A1?=AU9];=G"_NC/[.2^<S\6!4^M/3"^1CVY%;P6$1( #N
MGC;^L3H3^FG5GUYHAU,P_P" K_(S\5G8L_\ BZ7RD?&1L6#4HOT
M S>/4W?%,RS^A;3O[SV V$Z./LS#Y:IVT5)K'TU+Y.':97Q$\(J !(/Y3WQ+
M^"WWG]1?6ZN&"U1]G+WYM4\5F5R/TQ;?+1[9K'#5PO \L\V.+.'\TN+6YN-.
M:)CM0-FX?-KJ6X?:\4\6S2O4W<8-ES!)0MWQ<9RR!#F*2CVO--+:/JAQ1'D\
MFS.KD^9T<QH]]3GBU[:+V2CUXMKDWG2S&RIYC95+.ING'8^)[T^L\&9(.P\
MR[5.?9KK#/Z65CF<Z\RO(,)S"@FD12Z;)<7M95+=UK_::D*<AV,)QON29I5V
M]4F9&1C:BWKTKJA"YH-2HU(J46N%26*?8**JTJE"K*C56%2$FFN)IX,X<.4^
M  /=?EL<RKO@9S)TYR+@*F/XU07A8]M"DA]5N9'JG*NRISBK1'ZI3)GQ:QWY
MPKT*/L3:08RS]B!A=0Y1#/,HK9?+#RDHXP?%..V+ZF.Q^Y;,EE&82RS,*=VN
M\3PDN.+V->NN5(LI^J4Y]TN18[H_A3J?*ZV\I,GK:/D1MFTH9K,^%845C&<+
M2U$B?$6Y'>AVL9^9D#S)GU4T53(3\AQ)JKOHTR*=.I6SBZBXSBW2@GL::^,>
M')LC[]$OUIFD9PIY=0DG&25237%[!=?;+WK*8(MXKX   -&#TU?!M/&KA5^D
M%F5&J#MCEM(KLU2Y-9)$^GTQ3HE,ZMJFB6E2H[62MSIF1+6VI)2HMI"2ZGNC
M)Z4!TB9U](YQYA1EC:VN,=FYU'W[ZV"AR.+XRV-(9;YGEWG5185Z^WJ07>KK
M[9==<18U%?$M*"WJT/US^.'W8&/M6V(+SZ+?0]Q\Y_,@5AKGTA1^1_.D54Q9
MI"0 .::W_E$P+\M,6_?R".*X^(GX#[3.2C\='PEVS9A&HAL"           !
M'OYL7PS^=/W8=N?5*P&>TM]H[+YS#QD8K//0]S\C+M&3D-HBCP   N_^D2_D
M[YQ_EIHG]X]H"FNE;X^R\"KVX%CZ$^)N?"AVI%Q85(3X        /%GF2?#L
MY\?<LY2_8;G0S&GO3]C\\H_M(F.S?T3=?-ZGB2,CT;4%%@  !=*]()_\AG_E
M,_\ 4P*?Z5_^0_U_^Y+"T'_S?^J_WA=+%/EA@
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MJ!?(   4Z?5V_P G?!S\M-[?O'J\6WT4_'WO@4NW,@.N_B;;PI]J)2 %RE<
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M@ >T_+;^(GP'^^GQ:^W+!1A]0^@+[YG6_9R,AE'I:U^<4_'B:X0U7+U
M     ,T/U(OQ:=Z_D7H_[(L1&Q?1[]EJ'AU/VDBG]7>G:O@P\5$$PFI&@ /3
MW"3]<[B-]Y[0?VJXH,=G/HB[^;5?$D=S+O2%#Y:'C(U]QJ@7R
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M]%84[A<V>'ZR*V-^%'Q&^$L[168NM:SR^H\9TGC'P);U^++QDN M>"KR;@
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M:97Q$\(J !(/Y3WQ+^"WWG]1?6ZN&"U1]G+WYM4\5F5R/TQ;?+1[9K'#5PO
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M')?YFGV7^ ?WT'E9_MMZ6_VG<?P,'U/U-_)UNPOPCZPY+_,T^R_P$G@C9F0
M                      _!:559>5L^FNJZ!<4]K#D5]I56D./85ME EM*8
MEP9\&6V]%F0Y+*U(<:<0I"TF9&1D8^HRE"2G!M33Q36QI\:9^2C&2<9).+WI
ME/;SHO3U8-+P[->5_ ?#VL2RC&8=AE6S>-N-QG/HSE-)%1)L+S(]/4[).?1[
M)JQ@C=7C<1**Z=&;--<U'E(1&FVQH_7M=5H97GD^?2DU&%9[XO<E4?"G[=[4
M^^;6V,!U#I6FZ<K[*X\V:VRIK<UPN"X'[E;'P8/8Z00N8KD   )I?3[[PE:2
M\U#CPGWSW6AV_P#2S1^3M=Y-^_1<[Q^6[B\/N,C+V;'I:-[IT^7X7:70S(RA
M^N[)7NF;C9C.ES:BY.:^Z_(<B0Z6N7;9W2]K4Q@_QEL_*2-/ :WER
M9IGJ2XDJ-YLNZGGV'66I^!Z1EPG'$&E$J*C5N-05OL*,NCC29D)YHS+V=[:B
M_"1C8KH\:>EJ*6]3J8^_;]<J#5Z:SRICPQAXJ('1-B,@ =[<6\I@X-R:XZ9M
M9]GS;A^]M1938>*ZIAOW'']@8];2_$?0S)6RCP(BNJR;<-)>TDJ_ ?2S.E*O
MEUQ1CWTZ$XKJN+1V;*:IWE*I+=&K%]B29L/C4POP             ,6H;@&O
M0   72O2"?\ R&?^4S_U,"G^E?\ Y#_7_P"Y+"T'_P W_JO]X72Q3Y88
M     !GQ>K!^(GIC[EFNOMRY&"^.B[T!6^>3_9TBK-<>EJ?S>/CU"L.+((:
M  &TJ-/S84                          "JEZM#]3'C?]YYG[*MABSNBW
MTO<?-OSXD)USZ/H_+?FR*"XO(K    -BOC;^KKH/^A75GU&HAJ7F/I"O\M/Q
MF7[:?\)2^3CVD=U#IG8   #X.4XOCN;XQD>%Y?35V1XGE]#;XOE&/6\9N;4W
MV.W]?(J;NFLX;I*:EUUI6RW6'FE$:7&W%)/V&/NE5J4:D:U)N-6$E*+6]-/%
M-<J>T^9PA4@Z=1)TY)II[FGL:?5,L+S:O+VR'RYN767ZH;9GS=09>J3GNA<I
ME)>=*WUS:SGB8H)TYQ3A2<FP*9W55B:E)=?-EJ8;;;4QE(V:TMGU/4&50NG@
MKN'<U8\4TMZ7%+OEQ8M;TRE<]RJ>4W\J&WS>7=0?'%\'5CN?9X2,42,PP 'Z
MZ^PGU,^%:U4V766E9+C6%;95\EZ'/KY\-Y$F'-A3(RVY$27$D-I<:=;4E;:T
MDI)D9$8_)1C.+C))Q:P:>YKB9^IN+4HO"2)!_,9YW7OF"Y5QGVKG$5UO:>NN
M)^%Z-VU9FA"(F59UA&T-Q7!YI")M+3:59?B^65EA-;0VTS'LWY3+*29;;,\#
MI_)(9#2N;6B_X:I=2J07M8RA37-?@RBTN-)-[3*9MF<LUG1KU/CX4%"3XY*4
MWCUTTWRXD=HSYB@ /:?EM_$3X#_?3XM?;E@HP^H?0%]\SK?LY&0RCTM:_.*?
MCQ-<(:KEZ@         &:'ZD7XM.]?R+T?\ 9%B(V+Z/?LM0\.I^TD4_J[T[
M5\&'BH@F$U(T !Z XFY%7XARGXT99;+\.JQ?D!IK(K-SO;;[*^EV+CEE-7WO
M+;:1VQHRCZJ4E)?Y3(AT<TIRJY9<TH=]*A42ZK@T=JQFJ=[1G+O55@WUI(V%
M1J:7V             &;EZFG,XV4>:AFM(P\RZ[KG3NG,,F(:\/OCR9V/2-A
M)9D]C[JO&5$SQIPNY+2O#6CY)IZ+7L+T<T72TS";W5*U278?,_-*CUC44\[E
M%>PIP7J<[\XK[B=D6  ],\*\97FG,CB7AS;3K[F6<F=#XRAAA]B,\\N^VGBM
M6EIF3),HT=UPY71*W#)"#/JKV$8QV<5/(Y1=5O:6U5]B$F=S+H>4S"A3]M6@
MNS)(U_!J@7R          9O'J;OBF99_0MIW]Y[ ;"=''V9A\M4[:*DUCZ:E
M\G#M,KXB>$5  D'\I[XE_!;[S^HOK=7#!:H^SE[\VJ>*S*Y'Z8MOEH]LUCAJ
MX7@   &?!ZG7@LG0W*RAY9X36)C:YY5-2EY:W%;),:CW?BT.(UD:EH01(8:S
MW'U1;5LSZKD6+5FX?0B(7ST;YWY]E<LKK/\ B+7O>6G+=[UXQY%S2J]999YK
M?*^IKX&OOY)K?[Y;>KB5B18Y#@    #V9Y??$?).<?+W2O&ZA:FHK\WRN+(S
MRY@_(<Q?6-!_WUL'(_>%LOQHTJ#C,-]$+QB\-^Q=CL?YSJ2/$9]FM/)<IK9C
M/#G0CW*?LIO9!==X8\2Q? 9#*K">97].TCCA*7=/BBMLGV-W+@C6HQ'$\;P+
M%,8P;#J:%CN(89CU+B>*X_6M^#746-X[6QJ>CIJ]DS4;4*LK(;3#2>I]K:"(
M:M5:M2O5E7K-RJSDY2;WMMXMOJO:7E3A"E"-*FDJ<4DEQ);$NLCD(XS[  H+
M>K0_7/XX?=@8^U;8@O/HM]#W'SG\R!6&N?2%'Y'\Z153%FD)  YIK?\ E$P+
M\M,6_?R".*X^(GX#[3.2C\='PEVS9A&HAL"           !'OYL7PS^=/W8=
MN?5*P&>TM]H[+YS#QD8K//0]S\C+M&3D-HBCP   N_\ I$OY.^<?Y::)_>/:
M IKI6^/LO J]N!8^A/B;GPH=J1<6%2$^        #Q9YDGP[.?'W+.4OV&YT
M,QI[T_8_/*/[2)CLW]$W7S>IXDC(]&U!18   7,/2%W]=&R/GOBSKO2WN:7C
M7?P6>]@O$KL:G;SKK1WPU/)DJ\*3E<,NY#:FT]_1:DF:"7472M3DZ=C57>*5
M9/JM4VO%98&@Y)3NH>R:IOL<_'MHNRBG"Q0           *<OJ[G6RU_P99-
MQ!/.9COIU#1K23BVVJ752'7$(Z]RD-*>02C(NB36GK^$A;?13\?>O@YE+MS(
M!KOXJV7NI]J)2$%RE<@  !M*C3\V%          .H]S;]TAQUQ-W.M\;9U[J
M'$F_&2B]V%EE+BT.;(90EQ4&J^=I<9ZYM%DM)-Q(B7I+JE)2AM2E$1]NSL;W
M,*OD+&E4JU>*$7+KO#<N5[#@N+JVM*?E;FI"G3XY-+L8[WR(YSA^78UG^)8M
MGF&7$/(</S;'*3+L4OZ]2UP+S&LDK(MS17$%;B&UKAV=7-:?:-24F:%EU(AP
M5:52A5E0K)QJPDXR3WIIX-/J,Y*=2%6G&K3>-.233XT]J?71R,<9]@
M     9:_GB<7J/B=YE&_\'PZI8I, SF;3[GP2KB13A0*^HV=7HO+NLJXB3-B
M+44N=%;P8;3)^"U&C-H0E!)\-&R^B\RGFFG:%:L^=7@G3D^%N#P3?*X\UOE9
M2^I+*-CF]6G36%*34XKDEM:7(I8I<A$D)28( #TUPIRIW!>9/$S-F5/(=Q#D
MOHG)D*C-LO/]:+:.+69DTQ(6U'?6HHW0D.*2VOKVJ,DF8QV<4E7RBZHO=.VJ
M+LPDCN9=/R684*B]C6@^Q)&OV-4"^0      ,];U5>NGL8\P?7&>-1U)K-F\
M:<-D+EFE:4O9#B.:Y_CMI%(U.+2M46C14K,TD@OQY%V]2-2KZZ,;A5,AJ4'W
MU.YEV)1BUZO.*KUM2<,UA5]C.BNRG)/U,"LF+&(<   &M;Y:/*"#S%X,<;M]
MMV#5AD&3:XJ*;8/8M'C1=GX4E6'[$9D1R,W8B9&64DJ3'0X1*7"D,NEU0XE2
MM6M19;+*,ZN+%K"G&HW#P)=U#\EI/E31>>3WJO\ +:-UCC*4$I>$MDO53ZQ[
MH&$,D          >8>:VZH''3B)R4WA/F>Y?FTTML/)JQPG"9=D9)&QJP9Q2
MMC.&XT29MOD[\2(Q\I/XYY/M+\(R63V<LPS6WLHK'RE:"?4Q7.?42Q;Y#I9C
M<*TL*UR]G,IR?7PV=EX(R"!M<4.   %XGTBN-.1=7<V\P.&A#-[GVE<:18%W
M>))<Q/'=A6CL-74NWL@IS-"T]/;UD'U_R"F.E6HG<V5+';&%1X>$X+U>;ZA8
M^A(84;FIQR@NPI/URX8*F)\          9\7JP?B)Z8^Y9KK[<N1@OCHN] 5
MOGD_V=(JS7'I:G\WCX]0K#BR"&@  !M*C3\V%
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MMJLDR_Z*RFWR_9SJ5**EANYV^3Z\FV43F=WY]F%:[]C.;:\'='U$CR<,H=$
M"7_R&M1R=P>:MQ2KTQG7JO \FR';EY);(^RNC:TQ"]R:FDOFDR,FI.7Q*R(7
M^3ODIZ^SJ(IK>[5IIBZECW4XJFN7GR2?Y.+ZQGM,T'<9W07L8MR?XJ;7JX(U
M%AK47.          9O'J;OBF99_0MIW]Y[ ;"=''V9A\M4[:*DUCZ:E\G#M,
MKXB>$5  D'\I[XE_!;[S^HOK=7#!:H^SE[\VJ>*S*Y'Z8MOEH]LUCAJX7@
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M<,C)M!O.EU5_D+VCI9G)0RVXG+O50J/L19V;%.5[1BM[JP\9&PX-3"_
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MZ8^Y9KK[<N1@OCHN] 5OGD_V=(JS7'I:G\WCX]0K#BR"&@  !M*C3\V%
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M]3'C?]YYG[*MABSNBWTO<?-OSXD)USZ/H_+?FR*"XO(K    -BOC;^KKH/\
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MIBE4EW*]K!;(KK12QXWB^$O+*[&&6V%.SA[".U\<GMD^N\<.3!'L,8D[X
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MLTA( '--;_RB8%^6F+?OY!'%<?$3\!]IG)1^.CX2[9LPC40V!
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M)Z8^Y9KK[<N1@OCHN] 5OGD_V=(JS7'I:G\WCX]0K#BR"&@
M      $[/INOBTZ*_(O>'V19<(5TA?9:OX=/]I$DND?3M+P9^*S2\&NA<
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MK,&AW1$B1F4R9<K%ZUE%=D)]75%5M1)?:VS"FO*MOHZU/&BUI^^EA"3QHR?
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MYAXR,5GGH>Y^1EVC)R&T11X   7?_2)?R=\X_P M-$_O'M 4UTK?'V7@5>W
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M^REQR?#P+<N%NX,DR6ADUOS(]U<SPY\N/D7%%<''O?$I4Q&#-@
M  !7D\RKT\7&/FI.R+;.D94#C+R)MW9-I:6]#3)DZIV+<OK]XDR\YP>"N)\S
MWEJ_W&_<TZF7EO/.29D6P>/VS[3NOLRR=1M;W&YR];$F^[@O<R>]+@C+J)Q1
M%,XTI9YBW7ML*-V]K:7<R?NEP-\:ZK3*0_,GRO.;G!*SEHW]I._AX8U(>:K]
MN88A>:ZEN&42#C1Y+>:4K3L:@=L%%W,0;MNKM%-GW*BI(7+E&I<FSN*\QK1=
M;AA+N9K\5[\.%QYT>4KG,,ES'+'_ !5-^3]LML7UUNZCP?(1^C.F+
M   /1O&_B)R7Y>9>C!^-NEL[VU>)>CLV+V,TSJL=QQ,I7:Q+R_,)QP\3PZN<
M5["DVDV(P:C))*-1D1X_,,UR[*J7ELQK0I0X,7M?@Q7=2?)%-G;M+"\OZGD[
M.G*I+D6Q=5[EUVBY_P"6GZ9+6VFY^.;BYYVU!NO8$!42VJ-$8^;\K3F-3TDS
M+CGG=G+8ASMGV5>^1)<@$U&H/$0MMY-HPM*A4&HND>XNXRM,C4J-!['5?QC7
MN5N@GQ[9<7-9863Z.HV[5QF;52JMJ@N\7A>VZG>^$BU_!@PJR%#K:V'%KZZO
MBQX,"!!CM1(4&%$:0Q%APXK"&V(T6,PVE#;:$I0A"2(B(B%7RE*4G*3;DWBV
M][9-TDE@MB1^H?A^@            !GQ>K!^(GIC[EFNOMRY&"^.B[T!6^>3
M_9TBK-<>EJ?S>/CU"L.+((:                    3L^FZ^+3HK\B]X?9%
MEPA72%]EJ_AT_P!I$DND?3M+P9^*S2\&NA<         54O5H?J8\;_O/,_9
M5L,6=T6^E[CYM^?$A.N?1]'Y;\V107%Y%8   !L5\;?U==!_T*ZL^HU$-2\Q
M](5_EI^,R_;3_A*7R<>TCNH=,[          !YNY=<7=;<S>.NT.-^UHGBXI
MLG'GJU%HRPT_9XID,5Q$_%\SHR>-*$76*7\:/-8(U$ATVC:<[FG'$JR.59E<
M91F%+,;5_"TY8X<$ENE%\DEBGV5M.I?V5',+2=I7[R:[#X&N5/:9.W*'CCLK
MB/OW9_'7;E6JKSK5V32:&P4A"TP;JN6VU88[E5*MSHM^@R['ID6R@.*(EJB2
MF^]*5]R2VARW,+;-;&EF%H\:%6.*XT]SB^6+Q3Y44=>VE:PNIVE=8582PZO$
MUR-8-<C.A!WCK  >T_+;^(GP'^^GQ:^W+!1A]0^@+[YG6_9R,AE'I:U^<4_'
MB:X0U7+U               *]WF5>GHXO\V)>0;7TS(A\9^1=FJ996%[CM.B
M3JS8MN\A;ZGL^P:&J)\UW-C,(O&NZ=3$@U/.ORXMDZ:"3/-.Z]S+)E&UO,;G
M+UL2;[N"]S+A2]K+%;DG%$5SC2MEF+=>W^!NWPI=S)^ZCP/E75:92-YE>53S
MEX)SK%[>FE+Q6!PI#C47<> H?SC4EBPE;;3,Q>6548EXP4UQSHQ&OHU1/<Z'
MTC]"%RY1J?)<[BE95H^7:^+EW,U^*]^'"XN2Y2N<PR3,LL;\YIOR7MX[8]E;
MOQL'R$=HSYB@         "0_AAY5_-WGA95RM%:8O/H#+EICS]RYPV]ANI*E
ME+ILRY)9;:,$62NP%ET>AT;%I8HZD?N_3J98#.-39-DD7Y[6CY=+93CW4W^*
MMV/'+FKE,KE^29CF;7FU-^2]N]D5UWOZBQ?(7D/+.]/]Q?X*2:/:FSG(?)+D
MG7*:G5^:Y-2HBX!KNP2HGD+UM@<M^PCHN8+I)\.]LURK%*VDNPT5W>XTJE]1
MZ[S+.U*UML;?+GL<4^ZFO=RV;'[58+@?.WED9/I>RRQJO6^&O%PM=S'P8\?*
M\7Q8$^P@Q*               #-X]3=\4S+/Z%M._O/8#83HX^S,/EJG;14F
ML?34ODX=IE?$3PBH $@_E/?$OX+?>?U%];JX8+5'V<O?FU3Q697(_3%M\M'M
MFL<-7"\                   H+>K0_7/XX?=@8^U;8@O/HM]#W'SG\R!6&
MN?2%'Y'\Z153%FD)  YIK?\ E$P+\M,6_?R".*X^(GX#[3.2C\='PEVS9A&H
MAL"           !'OYL7PS^=/W8=N?5*P&>TM]H[+YS#QD8K//0]S\C+M&3D
M-HBCP   N_\ I$OY.^<?Y::)_>/: IKI6^/LO J]N!8^A/B;GPH=J1<6%2$^
M             #I[?''_ $UR=UCD.G-]:\QW9NN,G:2FTQO)(AO-(DM)<*';
M5,YA;%G0W]8IU2XEA!>CS8CA]S+J%>T=NQO[S+;F-W8U)4[B.YKM-;FGPIXI
M\*.O=6MO>47;W4%.C+>GVUQ/B:VHI2^8/Z7;;NOIE[L?@-D?YXL%-<NR7H[.
M+6NI=K8XP:E/G!Q'*)IU^*[!KH;1+\-N8[56I-I;:0FQ?4IP[BR'I*M*ZC;Y
MY'R-?=Y2*;@^64=LH/J<Z/#W**[S71E>DW6RM^4I>T;PDNH]TNO@^JRK%LK5
MFS--9=98!MS7^9ZRS>H5TL\2SW&KC$\AAI-QUI#KU3>0X4TH[RV5^&[V&VX2
M3-*C+VBS;>YMKNDJ]K4A4HO=*+4EV5BB%5J%:WJ.E7A*%1<$DT^PS@0YCC
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M2QQYRYO>SD^^PW(RN2TM+1S"#RNI.5YA+!-5,,,'CWT4MV/"6JA6)-@
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MJ:NG5=S4==85^?+G>%B\=VS?Q%C4>8J,%2VTN:L.IAL]0YV. Y0
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MN>E#R<N?;T>9S7CMH;L-O^=/N%'1'/7,JU.=BL-E7?[PO+BEBR
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M##R27NO)-P]^\29Y.M+*266.BZ^.QRQY^/)Y3"7O=A8)$$)2
M        1H>8;_=5?1-?]XS^C#[O\UR/FC\ZOS#^=;YO[#]X_-Y\S?\ _8?&
M[/\ P_\ C_P=/\@D>0?6?RO_ .W_ #G'';S,>9C[O'X/WVPP^:_0GD__ );R
M.&&SG8<[\7#N_>E2C=O'[TNVP')=AJ+G?O/0-BZOK$JJG57)#8N$1&U*-2T*
MJL^X_P!CFDE:2Z$A1Y&DDEU[DK,R,K3LK_I*H)1N[&A7CQN=&$NS&JH_D$%N
M;71E7;0N:M)\2C4DNQ*&/Y1&GG_#3RT(+CZM6^<=KW)VC\5<9C/^$W,7!7&^
MJB-B._*QW MB)=[4F9+>2RCN-/4FB[NU,BH9OJ*7_$Y14B_<W%O+MRA_EPF(
MJY?DZ^)S"$O"HU8]J,CSE9<6]"QUS5UOF2<.;*,QXZX27->^81 L)S;9*4R@
MXR^##\&+*D$1%VJE*:2H_:YT^4,A',[YX<[+KM/P[5I?_P#3ZQU'96JQPO+=
MKP:_[GUSYU7QETG/C-2)OF(\/:1:UJ2Y!L,'Y_R)K*$N&GQ%'4<&[.O7XB"[
MDDF09]#(E=I]2+ZEF5Y%X++[N7*I6N'JW*?J'S&SMFL7=VZZU?UJ)Z%PCAQY
M>,]]M.R/."U)BD<U+\5W".''-+8+Z$DM)-FW'OM7:R;<4I!F9D;J.TR(NI]>
MI="MF^?Q7\/E-6;]U<6\.U.9VZ>7Y4W\-?TXKDI5I=N,22K2?'#TQ^#/Q;'<
MGF&;SWK-8\/QZ?\ ,OR&UCA<WH?5WQZW%M!3,R;[S+HGPLA;[4F?X3Z**.WF
M8=(]=.-I84*$>/RE*<EUY5>;^09>WM-'4GC<7=6J^+F5(KU(8_E%LKRW?[HC
MYB=_NW?T:/?_ '(_GCZ"^[?GN^:^U/;],OIS_P#]Q^:_P^'\[?B.[O[/E=XJ
MW4/UKY__ .X?.>;CLYWQ>/N>;\'CX.TG.4?0/,_^(\CCAMYO?X<O.[OLDJXC
(!FP    #_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">10x Genomics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-5614458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6230 Stoneridge Mall Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Pleasanton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">401-7300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class&#160;A common stock, par value $0.00001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TXG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001770787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,092,774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,040,976<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 377,061<span></span>
</td>
<td class="nump">$ 344,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">49,844<span></span>
</td>
<td class="nump">49,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">52,549<span></span>
</td>
<td class="nump">87,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">74,710<span></span>
</td>
<td class="nump">83,107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">25,566<span></span>
</td>
<td class="nump">20,016<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">579,730<span></span>
</td>
<td class="nump">584,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">246,087<span></span>
</td>
<td class="nump">252,648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">55,577<span></span>
</td>
<td class="nump">57,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">4,511<span></span>
</td>
<td class="nump">4,511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">15,192<span></span>
</td>
<td class="nump">15,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">2,296<span></span>
</td>
<td class="nump">4,129<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">903,393<span></span>
</td>
<td class="nump">918,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">10,068<span></span>
</td>
<td class="nump">12,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and related benefits</a></td>
<td class="nump">21,957<span></span>
</td>
<td class="nump">33,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txg_AccruedExpensesAndOtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">45,483<span></span>
</td>
<td class="nump">41,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">20,949<span></span>
</td>
<td class="nump">20,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">9,443<span></span>
</td>
<td class="nump">9,286<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">107,900<span></span>
</td>
<td class="nump">117,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, noncurrent</a></td>
<td class="nump">70,631<span></span>
</td>
<td class="nump">73,327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="nump">12,569<span></span>
</td>
<td class="nump">12,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">5,398<span></span>
</td>
<td class="nump">5,029<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">196,498<span></span>
</td>
<td class="nump">208,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 4)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">2,208,665<span></span>
</td>
<td class="nump">2,177,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,501,405)<span></span>
</td>
<td class="num">(1,467,047)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(367)<span></span>
</td>
<td class="num">(493)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">706,895<span></span>
</td>
<td class="nump">710,134<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 903,393<span></span>
</td>
<td class="nump">$ 918,636<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txg_AccruedExpensesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Expenses And Other Liabilities Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txg_AccruedExpensesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 154,883<span></span>
</td>
<td class="nump">$ 141,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of products and services revenue</a></td>
<td class="nump">49,438<span></span>
</td>
<td class="nump">48,092<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">105,445<span></span>
</td>
<td class="nump">92,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">64,245<span></span>
</td>
<td class="nump">68,638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">89,728<span></span>
</td>
<td class="nump">85,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementGain', window );">Gain on settlement</a></td>
<td class="num">(9,200)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">144,773<span></span>
</td>
<td class="nump">154,412<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(39,328)<span></span>
</td>
<td class="num">(61,498)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">3,686<span></span>
</td>
<td class="nump">4,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">2,136<span></span>
</td>
<td class="num">(1,040)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">5,822<span></span>
</td>
<td class="nump">3,695<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(33,506)<span></span>
</td>
<td class="num">(57,803)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">852<span></span>
</td>
<td class="nump">2,146<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (34,358)<span></span>
</td>
<td class="num">$ (59,949)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares of common stock used in computing net loss per share, basic (in shares)</a></td>
<td class="nump">122,606,091<span></span>
</td>
<td class="nump">119,394,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares of common stock used in computing net loss per share, diluted (in shares)</a></td>
<td class="nump">122,606,091<span></span>
</td>
<td class="nump">119,394,180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txg_ProductAndServiceRevenueMember', window );">Products and services revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 137,823<span></span>
</td>
<td class="nump">$ 141,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txg_LicensingAndRoyaltyRevenueMember', window );">License and royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 17,060<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain from litigation settlement for amount awarded from other party. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483049/450-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txg_ProductAndServiceRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txg_ProductAndServiceRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txg_LicensingAndRoyaltyRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txg_LicensingAndRoyaltyRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (34,358)<span></span>
</td>
<td class="num">$ (59,949)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains (losses) on available-for-sale marketable securities</a></td>
<td class="num">(20)<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">146<span></span>
</td>
<td class="num">(163)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">126<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (34,232)<span></span>
</td>
<td class="num">$ (59,976)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional&#160;Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Common Class A</div></th>
<th class="th">
<div>Common Class A </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>Common Class A </div>
<div>Additional&#160;Paid-in Capital</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,095,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 741,043<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2,025,890<span></span>
</td>
<td class="num">$ (1,284,420)<span></span>
</td>
<td class="num">$ (429)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of Class&#160;A common stock related to equity awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">605,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of Class&#160;A common stock related to equity awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">36,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(59,949)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59,949)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,700,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">718,834<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">2,063,657<span></span>
</td>
<td class="num">(1,344,369)<span></span>
</td>
<td class="num">(456)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,291,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">710,134<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">2,177,672<span></span>
</td>
<td class="num">(1,467,047)<span></span>
</td>
<td class="num">(493)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of Class&#160;A common stock related to equity awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">841,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of Class&#160;A common stock related to equity awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">30,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(34,358)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,358)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,133,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="nump">$ 706,895<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2,208,665<span></span>
</td>
<td class="num">$ (1,501,405)<span></span>
</td>
<td class="num">$ (367)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (34,358)<span></span>
</td>
<td class="num">$ (59,949)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">31,076<span></span>
</td>
<td class="nump">36,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">8,022<span></span>
</td>
<td class="nump">9,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">1,792<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Lease and asset impairment charges</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">2,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="num">(575)<span></span>
</td>
<td class="nump">444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">35,325<span></span>
</td>
<td class="nump">23,516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">8,058<span></span>
</td>
<td class="num">(9,937)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(5,530)<span></span>
</td>
<td class="num">(2,029)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other noncurrent assets</a></td>
<td class="nump">2,314<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(2,547)<span></span>
</td>
<td class="nump">4,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and other related benefits</a></td>
<td class="num">(11,745)<span></span>
</td>
<td class="num">(9,380)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">347<span></span>
</td>
<td class="nump">2,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txg_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">4,329<span></span>
</td>
<td class="num">(12,674)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(2,631)<span></span>
</td>
<td class="num">(2,961)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other noncurrent liabilities</a></td>
<td class="nump">360<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">34,351<span></span>
</td>
<td class="num">(15,725)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,893)<span></span>
</td>
<td class="num">(2,910)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities', window );">Proceeds from sales of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,974<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(1,893)<span></span>
</td>
<td class="nump">10,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Issuance of common stock from exercise of stock options and employee stock purchase plan purchases</a></td>
<td class="nump">422<span></span>
</td>
<td class="nump">1,638<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">422<span></span>
</td>
<td class="nump">1,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rates changes on cash, cash equivalents</a></td>
<td class="nump">114<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">32,994<span></span>
</td>
<td class="num">(3,503)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">344,067<span></span>
</td>
<td class="nump">359,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">377,061<span></span>
</td>
<td class="nump">355,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="nump">462<span></span>
</td>
<td class="nump">961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities</a></td>
<td class="nump">$ 398<span></span>
</td>
<td class="nump">$ 1,899<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txg_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued liabilities and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txg_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of securities that had been designated as held-to-maturity. Excludes proceeds from maturities, prepayments and calls by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business and Basis of Presentation</a></td>
<td class="text">Description of Business and Basis of Presentation<div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization and Description of Business</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10x Genomics, Inc. (the &#8220;Company&#8221;) is a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biological systems at resolution and scale that matches the complexity of biology. The Company&#8217;s integrated solutions include the Company&#8217;s Chromium instruments and the Company's Visium CytAssist and Xenium Analyzer, which the Company refers to as &#8220;Spatial instruments,&#8221; and the Company&#8217;s proprietary microfluidic chips, slides, reagents and other consumables for the Company&#8217;s Chromium, Visium and Xenium solutions, which the Company refers to as &#8220;consumables.&#8221; The Company bundles its software with these products to guide customers through the workflow, from sample preparation through analysis and visualization. The Company was incorporated in the state of Delaware in July 2012 and began commercial and manufacturing operations and selling its instruments and consumables in 2015. The Company is headquartered in Pleasanton, California and has wholly-owned subsidiaries in Asia, Europe, Oceania and North America.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements, which include the Company&#8217;s accounts and the accounts of its wholly-owned subsidiaries, are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The condensed consolidated balance sheet at December&#160;31, 2024 has been derived from the audited consolidated financial statements of the Company at that date. Certain information and footnote disclosures typically included in the Company&#8217;s audited consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the Company&#8217;s financial position, results of operations, comprehensive loss and cash flows for the periods presented, but are not necessarily indicative of the results of operations to be anticipated for any future annual or interim period. All intercompany transactions and balances have been eliminated. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and related notes for the year ended December&#160;31, 2024 included in the Company's Annual Report on Form 10-K filed with the SEC on February&#160;12, 2025 (our &#8220;Annual Report&#8221;).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as noted below, there were no material changes in the Company&#8217;s significant accounting policies during the three months ended March&#160;31, 2025. See Note 2 &#8211; Summary of Significant Accounting Policies to the consolidated financial statements included in the Company&#8217;s Annual Report for information regarding the Company&#8217;s significant accounting policies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Revenue Recognition</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Products and Services Revenue</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates revenue from sales of products, which consist of instruments and consumables, and services. Revenue from product sales is recognized when control of the product is transferred, which is generally upon shipment to the customer. Instrument service agreements, which relate to extended warranties, are typically entered into for a one-year term, following the expiration of the standard one-year warranty period. Revenue for extended warranties is recognized ratably over the term of the extended warranty period as a stand ready performance obligation. Revenue is recorded net of discounts, distributor commissions and sales taxes collected on behalf of governmental authorities. Customers are invoiced generally upon shipment, or upon order for services, and payment is typically due within 30 days. Cash received from customers in advance of product shipment or the provision of services is recorded as a contract liability. The Company&#8217;s contracts with its customers generally do not include rights of return or a significant financing component.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly enters into contracts that include various combinations of products and services which are generally distinct and accounted for as separate performance obligations. The transaction price is allocated to each performance obligation in proportion to its standalone selling price. The Company determines standalone selling price using average selling prices with consideration of current market conditions. If the product or service has no history of sales or if the sales volume is not sufficient, the Company relies upon prices set by management, adjusted for applicable discounts.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License and Royalty Revenue</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with third parties that include up-front fees and royalties. Revenue related to the delivery of intellectual property is recognized when the license is delivered to the third parties. Royalty revenue is recognized when the underlying sales occur. If the timing of the reporting of the actual sales from our licensees is after our reporting date, we estimate the royalty revenue receivable at period end and adjust for any changes in estimates in the following period.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as a single operating segment. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating financial performance. The measures of profitability and significant segment expenses reviewed by the CODM are consistent with the presentation and disclosure in these consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts related to the royalty revenue in the condensed consolidated statements of operations for the three months ended March 31, 2024 have been reclassified to conform to the current presentation.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Recently Issued Accounting Pronouncement and Disclosure Rules</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standard Update (&#8220;ASU&#8221;) No. 2023-09, Income Taxes (&#8220;ASU No. 2023-09&#8221;), which prescribes standardized categories and disaggregation of information in the reconciliation of provision for income taxes, requires disclosure of disaggregated income taxes paid, and modifies other income tax-related disclosure requirements. The updated standard is effective beginning with the Company&#8217;s fiscal year 2025 annual reporting period. The Company will adopt ASU No. 2023-09 in its fourth quarter of 2025 using a prospective transition method.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses ("ASU 2024-03"), and in January 2025 issued ASU 2025-01, Clarifying the Effective Date ("ASU 2025-01") to provide clarification as to the effective date. ASU 2024-03 requires disaggregated disclosure of income statement expenses. ASU 2024-03 does not change the expense captions currently presented on the income statement; rather it requires disaggregation of certain expense captions into specified categories in disclosures within the footnotes to the financial statements. ASU 2024-03, as amended by ASU 2025-01, is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within fiscal years beginning after December 15, 2027. ASU 2024-03 can be applied on a prospective basis; however, retrospective application is permitted. Early adoption is permitted. As ASU 2024-03 only requires additional disclosure, it will not have a material impact on the Company's financial condition and results of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Statement Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Financial Statement Information</a></td>
<td class="text">Other Financial Statement Information<div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available-for-sale Securities</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consisted of the following (in thousands):<br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.871%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.945%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.089%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.089%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.802%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.945%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.089%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.089%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.802%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,324&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,322&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371,329&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371,347&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of marketable securities as of March 31, 2025 were all less than one year.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred no material gross realized gains or losses from available-for-sales debt securities during the three months ended March&#160;31, 2025 or March&#160;31, 2024. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The available-for-sale debt securities are subject to a periodic impairment review. For investments in an unrealized loss position, the Company determines whether a credit loss exists by considering information about the collectability of the instrument, current market conditions and reasonable and supportable forecasts of economic conditions. The Company recognizes an allowance for credit losses, up to the amount of the unrealized loss when appropriate, and writes down the amortized cost basis of the investment if it is more likely than not that the Company will be required or will intend to sell the investment before recovery of its amortized cost basis. Allowances for credit losses and write-downs are recognized in &#8220;Other expense, net,&#8221; and unrealized losses not related to credit losses are recognized in &#8220;Accumulated other comprehensive loss.&#8221; There are no allowances for credit losses for the periods presented.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory was comprised of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,930&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,238&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,441&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,710&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,107&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,765&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,765&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment and machinery </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377,200&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375,615&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131,113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122,967)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,087&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,648&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2025, the Company recorded impairment charges of $0.1&#160;million related to equipment. The impairment charge was triggered by a decision to discontinue an engineering project. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2024, the Company recorded impairment charges of $2.1&#160;million related to computer equipment and software of which $0.3&#160;million, $0.7&#160;million and $1.1&#160;million was classified in cost of revenue, research and development, and selling, general and administrative expenses, respectively, in the condensed consolidated statement of operations. The impairment charge was triggered by a decision to discontinue a productivity engineering project.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation and Related Benefits</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation and related benefits were comprised of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:73.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonus</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and related benefits</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,957&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,615&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities were comprised of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,563&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties for licensed technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product warranties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,483&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,165&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Warranties</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the reserve for product warranties were as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,116&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts charged to cost of revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,965&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,355&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repairs and replacements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(764)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of period</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,453&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,707&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue and Deferred Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;March&#160;31, 2025, the aggregate amount of remaining performance obligations related to separately sold extended warranty service agreements or allocated amounts for extended warranty service agreements bundled with sales of instruments was&#160;$33.5 million, of which approximately&#160;$20.9 million&#160;is expected to be recognized to revenue in the next 12 months, with the </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">remainder thereafter. The contract liabilities of $33.5 million and $24.1 million as of March&#160;31, 2025 and 2024, respectively, consisted of deferred revenue related to extended warranty service agreements.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following revenue recognized for the periods indicated were included in deferred revenue as of December 31, 2024 and 2023, respectively (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.336%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.246%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue recognized</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,857&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents revenue by source for the periods indicated (in thousands). Spatial products include the Company&#8217;s Visium and Xenium products:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chromium</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spatial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total instruments revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,815&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,453&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consumables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chromium</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spatial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consumables revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,356&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,335&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Products and services revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,823&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,005&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">License and royalty revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,883&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,006&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:18pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.325%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Americas</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Americas (excluding United States)</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Americas</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,570&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,630&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asia-Pacific</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific (excluding China)</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Asia-Pacific</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,655&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenue</span></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,883&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,006&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Includes license and royalty revenue.   </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">License and Royalty Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025, the Company settled its worldwide patent litigation with Vizgen, Inc. As part of that settlement, Vizgen has limited rights to certain intellectual property owned or exclusively licensed by the Company. As one part of the settlement, the Company received an upfront payment of $26.0&#160;million and will receive royalties on Vizgen&#8217;s sales of products covered by the license. The $26.0&#160;million upfront payment was recorded as a $9.2&#160;million gain on settlement and $16.8&#160;million of license and royalty revenue. The amount attributed to the gain on settlement was determined by applying a royalty rate to the Vizgen historical revenues prior to the settlement.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains or losses from foreign currency remeasurement are included in &#8220;Other income (expense), net&#8221; in the consolidated statements of operations. The Company recognized foreign currency transaction losses of $1.5 million for the three months ended March&#160;31, 2025, and foreign currency transaction income of $1.0 million for the three months ended March&#160;31, 2024, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office, laboratory, manufacturing, distribution and server space in various locations worldwide. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payments due under the Company&#8217;s operating lease liabilities as of March&#160;31, 2025 are as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating&#160;Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 (excluding the three months ended March 31, 2025)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,481&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,407)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,443&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, noncurrent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,074&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes additional information related to operating leases as of March&#160;31, 2025:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:18pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation<br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is regularly subject to lawsuits, claims, arbitration proceedings, administrative actions and other legal and regulatory proceedings involving intellectual property disputes, commercial disputes, competition and other matters, and the Company may become subject to additional types of lawsuits, claims, arbitration proceedings, administrative actions, government investigations and legal and regulatory proceedings in the future. As of March&#160;31, 2025, the Company has concluded that a loss is not probable and a contingent liability has not been recorded.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bruker (NanoString)</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 6, 2021, the Company filed suit against NanoString Technologies, Inc. (&#8220;NanoString&#8221;) in the U.S. District Court for the District of Delaware alleging that NanoString&#8217;s GeoMx Digital Spatial Profiler and associated instruments and reagents infringe U.S. Patent Nos. 10,472,669, 10,662,467, 10,961,566, 10,983,113 and 10,996,219 (the &#8220;GeoMx Action&#8221;). On May 19, 2021, the Company filed an amended complaint additionally alleging that the GeoMx products infringe U.S. Patent Nos. 11,001,878 and 11,008,607. On May 4, 2022, the Company filed an amended complaint in the GeoMx Action additionally alleging that the GeoMx products infringe U.S. Patent No. 11,293,917 and withdrawing the Company&#8217;s claims of infringement of U.S. Patent No. 10,662,467. The Company is seeking, among other relief, injunctive relief and unspecified damages (including attorneys&#8217; fees) in relation to NanoString&#8217;s making, using, selling, offering to sell, exporting and/or importing in the United States the GeoMx Digital Spatial Profiler and associated instruments and reagents. NanoString filed its answer to the GeoMx Action on May 18, 2022. A Markman hearing was held on February 17, 2023 and the Court issued its claim construction order on February 28, 2023. On September 7, 2023, the Court issued an order granting the Company&#8217;s motion for summary judgment that the asserted patents are not invalid for indefiniteness and denying NanoString&#8217;s motion for summary judgment that the asserted patents are invalid for indefiniteness and lack of written description. On November 17, 2023, a jury found that NanoString willfully infringed the asserted patents and that the asserted patents are valid. The jury awarded the Company more than $31&#160;million in damages, consisting of approximately $25&#160;million in lost profits and approximately $6&#160;million in royalties. Post-trial motions, including the Company&#8217;s motions for a permanent injunction, ongoing royalties, enhanced damages, attorneys&#8217; fees and pre- and post-judgment interest, are pending. NanoString filed for bankruptcy protection under Chapter 11 of the United States Bankruptcy Code in the U.S. bankruptcy court in Delaware on February 4, 2024, and the Court&#8217;s consideration of these post-trial motions was stayed due to the bankruptcy filing. In May 2024, Bruker Corporation (&#8220;Bruker&#8221;) acquired certain assets and assumed certain liabilities of NanoString, including the litigation between the Company and NanoString, and the NanoString product lines at issue. On December 23, 2024, the Court denied NanoString&#8217;s motion for judgement as a matter of law on invalidity, non-infringement and damages, and denied its request for a new trial. The Court granted the Company&#8217;s motion for permanent injunction, supplemental damages, and pre-judgment and post-judgment interest. On January 31, 2025, Bruker moved to stay the permanent injunction pending appeal. The Court has not ruled on the motion to stay. Due to the uncertainties in collecting the jury award, the Company has not recorded a receivable from NanoString as of March 31, 2025.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2022, the Company filed a second suit against NanoString in the U.S. District Court for the District of Delaware alleging that NanoString&#8217;s CosMx Spatial Molecular Imager and associated instruments, reagents and services infringe U.S. Patent Nos. 10,227,639 and 11,021,737 (the &#8220;CosMx Action&#8221;). On May 12, 2022, the Company filed an amended complaint in the CosMx Action additionally alleging that the CosMx products additionally infringe U.S. Patent Nos. 11,293,051, 11,293,052 and 11,293,054. NanoString filed its answer to the CosMx Action on May 26, 2022. On March 1, 2023, the Company filed a second amended complaint additionally alleging that the CosMx products infringe U.S. Patent No. 11,542,554. The Company is seeking, among other relief, injunctive relief and unspecified damages (including attorneys&#8217; fees) in relation to NanoString&#8217;s making, using, selling, offering to sell, exporting and/or importing in the United States the CosMx Spatial Molecular Imager and associated instruments, reagents and services. NanoString filed its answer to the second amended complaint on March 22, 2023. Discovery is in progress. A Markman hearing was held on January 10, 2024, and the Court issued its claim construction order on February 1, 2024.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 1, 2023, NanoString filed a motion in the CosMx Action to add antitrust, unfair competition, tort and contract counterclaims. NanoString seeks, among other relief, injunction relief (including that the Company grant NanoString a license to the patents that the Company asserted against NanoString in the CosMx Action) and unspecified damages (including attorneys&#8217; fees). On July 10, 2023, the Court denied NanoString&#8217;s motion for leave to add a contract counterclaim but otherwise granted the motion for leave to amend. On May 24, 2023, NanoString filed a motion to bifurcate its amended counterclaims and a motion for expedited discovery. On June 6, 2023, the Court denied NanoString&#8217;s motion to bifurcate and granted its motion for expedited discovery. The Company believes NanoString&#8217;s claims are meritless and intends to vigorously defend itself. Trial is scheduled for August 2025.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, NanoString filed a counterclaim in the CosMx Action alleging that the Company&#8217;s Visium products infringe U.S. Patent No. 11,377,689 (the &#8220;689 patent&#8221;). The Company filed its answer to NanoString&#8217;s counterclaim in the CosMx Action on August 30, 2022. On November 23, 2022, the Company moved to sever claims relating to NanoString&#8217;s assertion of the 689 patent and consolidate those claims with the patent case NanoString filed against the Company on October 20, 2022 (discussed below). On January 24, 2023, the Court granted the Company&#8217;s motion.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 20, 2022, NanoString filed suit against the Company in the U.S. District Court for the District of Delaware alleging that the Company&#8217;s Visium products infringe U.S. Patent No. 11,473,142 (the &#8220;142 patent&#8221;), a continuation of the 689 patent (the &#8220;NanoString Action&#8221;). NanoString seeks, among other relief, injunctive relief and unspecified damages (including attorneys&#8217; fees) in relation to the Company&#8217;s making, using, selling, offering to sell, exporting and/or importing in the United </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">States Visium products and associated instruments, reagents and services. On January 24, 2023, the Court severed NanoString&#8217;s claims with respect to the 689 patent from the CosMx Action and consolidated those claims with this action. NanoString filed an amended complaint on January 27, 2023. The Company filed an answer to the NanoString Action on February 10, 2023. Discovery is in progress. A Markman hearing was held on January 10, 2024, and the Court issued its claim construction order on February 1, 2024. Trial is scheduled for November 2025. The Company believes NanoString&#8217;s claims in the NanoString Action are meritless and intends to vigorously defend itself.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16 and September 25, 2023, the Company filed petitions for inter partes review (&#8220;IPR&#8221;) of the 689 patent and the 142 patent, respectively. On February 1, 2024, IPR was instituted for the 689 patent. Oral argument for the 689 IPR took place on March 12, 2025. On September 5, 2024, trial was instituted for the 142 patent. Oral argument for the 142 IPR is scheduled for May 2025.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 30, 2024, NanoString filed a petition for IPR of U.S. Patent No. 11,542,554, which is asserted by the Company against NanoString in the CosMx Action. On August 23, 2024, IPR was instituted for the 554 patent. Oral argument for the 554 IPR is scheduled for May 2025.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2022, the Company filed suit in the Munich Regional Court in Germany alleging that NanoString&#8217;s CosMx Spatial Molecular Imager and associated instruments, reagents and services infringe EP Patent No. 2794928B1 (the &#8220;EP 928 patent&#8221;) (the &#8220;Germany CosMx Action&#8221;). A hearing on infringement was held on March 23, 2023. On May 17, 2023, the Munich Regional Court found that the CosMx products infringe the EP 928 patent and issued a permanent injunction requiring NanoString to stop selling and supplying CosMx instruments and reagents for RNA detection in Germany. The injunction took effect on June 1, 2023. On May 25, 2023, NanoString filed an appeal of the Germany CosMx Action in the Munich Higher Regional Court. A hearing date has not yet been set for this appeal. On October 30, 2023, NanoString requested that the Higher Regional Court temporarily stay enforcement of the injunction pending the appeal. On December 20, 2023, the Higher Regional Court granted NanoString&#8217;s request conditioned upon NanoString posting a 2.3&#160;million Euro security deposit. The case is currently stayed pending a final legally binding decision on the validity of EP 928.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2022, NanoString filed a nullity action with the German Federal Patent Court challenging the validity of the EP 928 patent. On February 10, 2023, the Federal Patent Court issued a preliminary opinion upholding the validity of certain claims of the EP 928 patent directed to in situ analysis. On May 7, 2024, the German Federal Patent Court revoked the German part of the EP 928 patent. The Company strongly disagrees with this decision.  On September 9, 2024, the Company appealed the decision to the German Federal Court of Justice.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2023, the Company filed requests for preliminary injunctions in the Munich Local Division of the Unified Patent Court (&#8220;UPC&#8221;) alleging that NanoString&#8217;s CosMx Spatial Molecular Imager and associated instruments, reagents and services for RNA detection infringe the EP 928 patent and EP Patent No. 4108782 (the &#8220;EP 782 patent&#8221;). Hearings were held for the EP 782 and EP 928 patents on September 5 and September 19, respectively. On September 19, 2023, the UPC granted the Company&#8217;s request for the EP 782 patent and issued a preliminary injunction requiring NanoString to stop selling and supplying CosMx instruments and reagents for RNA detection in all 17 UPC member states. On October 10, 2023, the UPC denied the Company&#8217;s preliminary injunction request for the EP 928 patent. On October 2, 2023, NanoString filed an appeal of the preliminary injunction for the EP 782 patent in the UPC Court of Appeals. A hearing was held before the UPC Court of Appeals on December 18, 2023. The UPC Court of Appeals overturned the preliminary injunction on February 26, 2024.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 31 and September 18, 2023 we filed main requests in the Munich Local Division of the UPC alleging that NanoString's CosMx Spatial Molecular Imager and associated instruments, reagents and services for RNA detection infringe the EP 782 and EP 928 patents, respectively. A hearing on the main request for EP 782 is scheduled for September 2025. No hearing has yet been set for the main request with regard to EP 928. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 18, 2023, NanoString filed an opposition in the European Patent Office challenging the validity of the EP 782 patent. In March 2025 the European Patent Office held an oral proceeding and upheld the validity of the claims of the EP 782 patent in an amended form.  On July 27, 2023, NanoString filed a revocation action in the Munich Central Division of the UPC challenging the validity of the EP 928 patent. A hearing in the revocation action took place on September 18, 2024. Following the hearing, the UPC revoked EP 928. The Company strongly disagrees with this decision. On December 17, 2024, the Company appealed the decision to the UPC Court of Appeals.</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vizgen  </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vizgen, Inc. (&#8220;Vizgen&#8221;) and the Company were previously engaged in litigation in multiple jurisdictions relating to the Company&#8217;s Xenium products and Vizgen&#8217;s MERSCOPE products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 5, 2025, the Company and Vizgen resolved all outstanding litigation between the two companies. All claims in the litigation have been dismissed with prejudice.</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Parse</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 24, 2022, the Company filed suit against Parse Biosciences, Inc. (&#8220;Parse&#8221;) in the U.S. District Court for the District of Delaware alleging that Parse&#8217;s Evercode Whole Transcriptomics products and ATAC-seq products infringe U.S. Patent Nos. 10,155,981 (the &#8220;981 patent&#8221;), 10,697,013 (the &#8220;013 patent&#8221;), 10,240,197 (the &#8220;197 patent&#8221;), 10,150,995 (the &#8220;995 patent&#8221;), 10,619,207 (the &#8220;207 patent&#8221;) and 10,738,357 (the &#8220;357 patent&#8221;). The Company seeks, among other relief, injunction relief and unspecified damages (including attorneys&#8217; fees) in relation to Parse&#8217;s making, using, selling, offering to sell, exporting and/or importing in the United States Parse&#8217;s Evercode Whole Transcriptomics products and ATAC-seq products. On October 17, 2022, Parse filed a motion to dismiss alleging that the asserted claims are directed to patent ineligible subject matter. The Court held a hearing on the motion to dismiss on November 22, 2022, and supplemental briefing was submitted on December 15, 2022. On September 14, 2023, the Court denied the motion. Parse filed its answer on October 6, 2023. Discovery is in progress. A Markman hearing was held on February 21, 2024, and the Court issued its claim construction order on May 3, 2024. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between April 20 and June 21, 2023, Parse filed petitions for IPR of all of the patents asserted. On October 13, 2023, IPR was instituted on the 981 patent. The PTAB denied institution of Parse&#8217;s petitions for IPR on the other five asserted patents. On January 2 and 5, 2024, Parse filed rehearing requests with the PTAB for the 197 and 013 patents, respectively. On February 5, 2024, the PTAB instituted IPRs for the 197 and 013 patents on Parse&#8217;s requests for rehearing. On September 17, 2024, the PTAB found the challenged claims of the 981 patent unpatentable. In February 2025, the PTAB found the challenged claims of the 197 and 013 patents unpatentable. The Company strongly disagrees with these decisions and has appealed.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 25, 2025, the Court entered a consent judgment and permanent injunction enjoining Parse from making, using, selling, or offering for sale in the United States, or inducing others to make, use, sell, or offer to sell in the United States, or importing into the United States, for the remaining term of the 992, 207, and 357 patents, any ATAC-seq Method, Composition, or Product, or any other method, composition or product that is not colorably different from the ATAC-seq Methods, Compositions or Products.  The Court stayed trial with respect to the 197, 031, and 981 patents pending the appeal of the IPR decisions on these patents.</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Curio</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 1, 2023, the Company filed suit against Curio Bioscience, Inc. (&#8220;Curio&#8221;) in the U.S. District Court for the District of Delaware alleging that the Curio Seeker Spatial Mapping Kit and associated products and services infringe U.S. Patent Nos. 10,480,022, 10,662,468, 11,001,879, 11,549,138, and 11,761,030. On February 1, 2024, Curio filed a motion to dismiss alleging that the asserted claims are directed to patent ineligible subject matter. The Court denied that motion on May 9, 2024. On May 31 and June 20, 2024, Curio answered the Complaint and filed antitrust and unfair competition counterclaims. The Company filed a motion to dismiss Curio&#8217;s unfair competition and antitrust counterclaims on July 5, 2024. On February 21, 2025, the Court dismissed all of Curio&#8217;s unfair competition and antitrust counterclaims with the exception of one counterclaim alleging the lawsuit is objectively baseless. The Company believes Curio&#8217;s remaining counterclaim is meritless and intends to vigorously defend itself. Trial is scheduled for May 2026.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 4, 2023, the Company filed a request for a preliminary injunction in the Dusseldorf Local Division of the UPC alleging that the Curio Seeker Spatial Mapping Kit and associated products and services infringe EP Patent No. 2697391 (the &#8220;EP 391 patent&#8221;). A hearing was held on March 26, 2024. On April 30, 2024, the UPC granted the Company&#8217;s request and issued a preliminary injunction requiring Curio to stop offering, marketing, using or possessing these Curio Seeker products and services in Germany, France and Sweden. Curio did not appeal the preliminary injunction. On March 25, 2024, the Company filed a main request in the Dusseldorf Local Division of the UPC alleging that the Curio Seeker Spatial Mapping Kit and associated products and services infringe the EP 391 patent. A hearing in the main action is expected in May 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Capital Stock</a></td>
<td class="text">Capital Stock<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the number of shares of Class&#160;A common stock and Class&#160;B common stock issued and outstanding were 109,076,917 and 14,056,833, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Plans</a></td>
<td class="text">Equity Incentive Plans<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the condensed consolidated statement of operations for the periods presented as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,481&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,076&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,129&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units (&#8220;RSUs&#8221;) activity for the three months ended March&#160;31, 2025 is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted&#160;Stock<br/>Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant&#160;Date&#160;Fair&#160;Value<br/>(per share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,493,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,016,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(564,701)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320,043)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,624,647&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity for the three months ended March&#160;31, 2025 is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock&#160;Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,594,582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277,212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled and forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,812)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,220,558&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Stock Awards</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2025, the Company granted 561,603 performance stock units (&#8220;PSUs&#8221;) under the 2019 Plan to certain members of management which are subject to the achievement of certain performance conditions established by the Company&#8217;s Compensation Committee of the Board of Directors as described below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.73pt">50% of target PSUs earned will be based on the Company&#8217;s compound annual growth rate (&#8220;CAGR&#8221;) of the Company&#8217;s Revenue over a two-year performance period from January 1, 2025 to December 31, 2026. Holders may earn from 0% to 200% of the target amount of shares and earned PSUs will then be subject to service-based vesting; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:9.96pt">50% of target PSUs earned will be based on the relative Total Shareholder Return (&#8220;TSR&#8221;) of the Company&#8217;s common stock as compared to the TSR of the members of the Russell 3000 Medical Equipment and Services Sector Index over a three-year performance period from January 1, 2025 to December 31, 2027. Depending on the results relative to the TSR market condition, the holders may earn from 0% to 200% of the target amount of shares which will vest at the end of the performance period.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PSUs will be forfeited if the performance conditions are not achieved at the end of the relative performance periods as described above. The vesting of the PSUs can also be triggered upon certain change in control events or in the event of death or disability.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair values of the PSUs relating to CAGR and TSR components were $10.76 and $13.94 per share, respectively. Stock-based compensation expense recognized for these awards was approximately $0.1 million for the three months ended March&#160;31, 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimated the fair values of shares granted under the market-based TSR PSUs using a Monte Carlo simulation model with the following assumptions:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the Company granted 219,168 PSUs under the 2019 Plan to certain members of management, which are subject to the achievement of certain market-condition and performance-condition goals established by the Company&#8217;s Compensation Committee of the Board of Directors.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the measurement periods for the 2025 and 2024 PSUs were not completed and the market and performance criteria for the stock awards was not met and therefore no shares vested or became exercisable.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A total of 4,909,589 shares of Class&#160;A common stock were reserved for issuance under the 2019 Employee Stock Purchase Plan (&#8220;ESPP&#8221;). The price at which Class A common stock is purchased under the ESPP is equal to 85% of the fair market value of the common stock on the first day of the offering period or purchase date, whichever is lower.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2025 and 2024, no shares of Class A common stock were issued under the ESPP. As of March&#160;31, 2025, there were 3,928,014 shares available for issuance under the ESPP.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,220,558&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,604,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,624,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,578,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares committed under ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436,873&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,282,078&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,299,861&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text">Subsequent Event<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 6, 2025, to decrease its costs and adjust its organizational structure to align with its strategic priorities, the Company committed to a reduction in force that is expected to result in the termination of approximately 8% of the Company&#8217;s global workforce. In connection with the reduction in force, the Company currently estimates it will incur between $5.5&#160;million and $6.5&#160;million of costs consisting primarily of cash severance costs which the Company expects to recognize in the second quarter of 2025 and pay by the end of third quarter of 2025. The estimates of costs and expenses that the Company expects to incur in connection with the workforce reduction are subject to a number of assumptions and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the workforce reduction.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (34,358)<span></span>
</td>
<td class="num">$ (59,949)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=txg_SergeSaxonovMember', window );">Serge Saxonov [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 12, 2024, Serge Saxonov, Chief Executive Officer, adopted a Rule 10b5-1 trading arrangement that was intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 35,600 shares of the Company&#8217;s common stock plus up to 136,000 carryover shares from a prior 10b5-1 plan. The expiration date of the trading arrangement was December 31, 2025. On March 4, 2025, the trading arrangement was terminated at the election of Dr. Saxonov.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Serge Saxonov<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Executive Officer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrTerminationDate', window );">Termination Date</a></td>
<td class="text">March 4, 2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=txg_SergeSaxonovCommonStockPlusMember', window );">Serge Saxonov, Common Stock Plus [Member] | Serge Saxonov [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">35,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=txg_SergeSaxonovCarryoverSharesFromPrior10b51PlanMember', window );">Serge Saxonov, Carryover Shares From Prior 10b5-1 Plan [Member] | Serge Saxonov [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">136,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=txg_SergeSaxonovMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=txg_SergeSaxonovMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=txg_SergeSaxonovCommonStockPlusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=txg_SergeSaxonovCommonStockPlusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=txg_SergeSaxonovCarryoverSharesFromPrior10b51PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=txg_SergeSaxonovCarryoverSharesFromPrior10b51PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements, which include the Company&#8217;s accounts and the accounts of its wholly-owned subsidiaries, are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The condensed consolidated balance sheet at December&#160;31, 2024 has been derived from the audited consolidated financial statements of the Company at that date. Certain information and footnote disclosures typically included in the Company&#8217;s audited consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the Company&#8217;s financial position, results of operations, comprehensive loss and cash flows for the periods presented, but are not necessarily indicative of the results of operations to be anticipated for any future annual or interim period. All intercompany transactions and balances have been eliminated. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Revenue Recognition</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Products and Services Revenue</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates revenue from sales of products, which consist of instruments and consumables, and services. Revenue from product sales is recognized when control of the product is transferred, which is generally upon shipment to the customer. Instrument service agreements, which relate to extended warranties, are typically entered into for a one-year term, following the expiration of the standard one-year warranty period. Revenue for extended warranties is recognized ratably over the term of the extended warranty period as a stand ready performance obligation. Revenue is recorded net of discounts, distributor commissions and sales taxes collected on behalf of governmental authorities. Customers are invoiced generally upon shipment, or upon order for services, and payment is typically due within 30 days. Cash received from customers in advance of product shipment or the provision of services is recorded as a contract liability. The Company&#8217;s contracts with its customers generally do not include rights of return or a significant financing component.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly enters into contracts that include various combinations of products and services which are generally distinct and accounted for as separate performance obligations. The transaction price is allocated to each performance obligation in proportion to its standalone selling price. The Company determines standalone selling price using average selling prices with consideration of current market conditions. If the product or service has no history of sales or if the sales volume is not sufficient, the Company relies upon prices set by management, adjusted for applicable discounts.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License and Royalty Revenue</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with third parties that include up-front fees and royalties. Revenue related to the delivery of intellectual property is recognized when the license is delivered to the third parties. Royalty revenue is recognized when the underlying sales occur. If the timing of the reporting of the actual sales from our licensees is after our reporting date, we estimate the royalty revenue receivable at period end and adjust for any changes in estimates in the following period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting, Policy</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as a single operating segment. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating financial performance. The measures of profitability and significant segment expenses reviewed by the CODM are consistent with the presentation and disclosure in these consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncement and Disclosure Rules</a></td>
<td class="text"><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Recently Issued Accounting Pronouncement and Disclosure Rules</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standard Update (&#8220;ASU&#8221;) No. 2023-09, Income Taxes (&#8220;ASU No. 2023-09&#8221;), which prescribes standardized categories and disaggregation of information in the reconciliation of provision for income taxes, requires disclosure of disaggregated income taxes paid, and modifies other income tax-related disclosure requirements. The updated standard is effective beginning with the Company&#8217;s fiscal year 2025 annual reporting period. The Company will adopt ASU No. 2023-09 in its fourth quarter of 2025 using a prospective transition method.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses ("ASU 2024-03"), and in January 2025 issued ASU 2025-01, Clarifying the Effective Date ("ASU 2025-01") to provide clarification as to the effective date. ASU 2024-03 requires disaggregated disclosure of income statement expenses. ASU 2024-03 does not change the expense captions currently presented on the income statement; rather it requires disaggregation of certain expense captions into specified categories in disclosures within the footnotes to the financial statements. ASU 2024-03, as amended by ASU 2025-01, is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within fiscal years beginning after December 15, 2027. ASU 2024-03 can be applied on a prospective basis; however, retrospective application is permitted. Early adoption is permitted. As ASU 2024-03 only requires additional disclosure, it will not have a material impact on the Company's financial condition and results of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Statement Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consisted of the following (in thousands):<br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.871%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.945%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.089%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.089%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.802%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.945%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.089%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.089%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.802%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents: </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,324&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,322&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371,329&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371,347&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory was comprised of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,930&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,238&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,441&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,710&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,107&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,765&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,765&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment and machinery </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377,200&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375,615&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131,113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122,967)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,087&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,648&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txg_ScheduleOfAccruedCompensationandRelatedBenefitsTableTextBlock', window );">Schedule of Accrued Compensation and Related Benefits</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation and related benefits were comprised of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:73.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonus</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and related benefits</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,957&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,615&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Accrued Expense and Other Current Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities were comprised of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,563&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties for licensed technologies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product warranties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,483&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,165&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock', window );">Schedule of Changes in the Reserve for Product Warranties</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the reserve for product warranties were as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,116&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts charged to cost of revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,965&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,355&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repairs and replacements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(764)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of period</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,453&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,707&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Revenue of Recognized in Deferred Revenue</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following revenue recognized for the periods indicated were included in deferred revenue as of December 31, 2024 and 2023, respectively (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.336%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.246%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue recognized</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,857&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of Revenue by Source</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents revenue by source for the periods indicated (in thousands). Spatial products include the Company&#8217;s Visium and Xenium products:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chromium</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spatial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total instruments revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,815&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,453&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consumables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chromium</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spatial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consumables revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,356&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,335&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Products and services revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,823&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,005&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">License and royalty revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,883&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,006&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenue by Geographic Location</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.325%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Americas</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Americas (excluding United States)</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Americas</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,570&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,630&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asia-Pacific</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific (excluding China)</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Asia-Pacific</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,655&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenue</span></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,883&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,006&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>(1) Includes license and royalty revenue.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txg_ScheduleOfAccruedCompensationandRelatedBenefitsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of accrued compensation and related benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txg_ScheduleOfAccruedCompensationandRelatedBenefitsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of accrued liabilities and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Company's Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payments due under the Company&#8217;s operating lease liabilities as of March&#160;31, 2025 are as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating&#160;Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 (excluding the three months ended March 31, 2025)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,101&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,481&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,407)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,443&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, noncurrent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,074&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txg_DisclosureOfAdditionalInformationRelatedToOperatingLeasesTableTextBlock', window );">Schedule of Additional Information Related to Operating Leases</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes additional information related to operating leases as of March&#160;31, 2025:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txg_DisclosureOfAdditionalInformationRelatedToOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of additional information related to operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txg_DisclosureOfAdditionalInformationRelatedToOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Recorded Stock-based Compensation Expense in the Condensed Consolidated Statement of Operations</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the condensed consolidated statement of operations for the periods presented as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,481&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,076&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,129&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of RSU Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units (&#8220;RSUs&#8221;) activity for the three months ended March&#160;31, 2025 is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted&#160;Stock<br/>Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant&#160;Date&#160;Fair&#160;Value<br/>(per share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,493,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,016,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(564,701)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320,043)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,624,647&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of the Company's Stock Option Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity for the three months ended March&#160;31, 2025 is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock&#160;Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,594,582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277,212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled and forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,812)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,220,558&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimated the fair values of shares granted under the market-based TSR PSUs using a Monte Carlo simulation model with the following assumptions:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Shares of Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,220,558&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,604,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,624,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,578,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares committed under ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436,873&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,282,078&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,299,861&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyObligationTerm', window );">Product warranty term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txg_RevenueFromContractWithCustomerPaymentPeriod', window );">Revenue recognition, payment due period</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txg_RevenueFromContractWithCustomerPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer, Payment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txg_RevenueFromContractWithCustomerPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyObligationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of warranty or group of similar warranties, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyObligationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Statement Information - Available-for-Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txg_DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds', window );">Total available-for-sale securities, amortized cost</a></td>
<td class="nump">402,324<span></span>
</td>
<td class="nump">371,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txg_DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds', window );">Total available-for-sale securities, fair value</a></td>
<td class="nump">402,322<span></span>
</td>
<td class="nump">371,347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="nump">352,478<span></span>
</td>
<td class="nump">322,012<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">Government debt securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities:</a></td>
<td class="nump">49,846<span></span>
</td>
<td class="nump">49,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, fair value</a></td>
<td class="nump">49,844<span></span>
</td>
<td class="nump">49,335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txg_DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available For Sale, Amortized Cost Including Money Market Funds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txg_DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txg_DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available For Sale, Including Money Market Funds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txg_DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Statement Information - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Debt securities, available-for-sale, realized gain (loss)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price allocated to remaining performance obligations</a></td>
<td class="nump">33,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">20,949,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,658,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liability</a></td>
<td class="nump">33,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementGain', window );">Gain on settlement</a></td>
<td class="nump">9,200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">154,883,000<span></span>
</td>
<td class="nump">141,006,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossRealizedAfterTax', window );">Recognized foreign currency transaction income (loss)</a></td>
<td class="num">(1,500,000)<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=txg_VizgenInc.Member', window );">Vizgen, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txg_ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted', window );">Amount of litigation settlement and intellectual property license granted</a></td>
<td class="nump">26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementGain', window );">Gain on settlement</a></td>
<td class="nump">$ 9,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-04-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Expected period of revenue recognition</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long lived assets</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=txg_CostOfRevenueMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txg_ProductsAndServicesExcludingGrantRevenueMember', window );">Products and Services, Excluding Grant Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">20,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txg_LicensingAndRoyaltyRevenueMember', window );">License and royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">17,060,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txg_LicensingAndRoyaltyRevenueMember', window );">License and royalty revenue | Vizgen, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 16,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txg_ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Litigation Settlement And Intellectual Property License Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txg_ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossRealizedAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of realized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477346/946-830-45-38<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossRealizedAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain from litigation settlement for amount awarded from other party. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483049/450-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=txg_VizgenInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=txg_VizgenInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-04-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-04-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=txg_CostOfRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=txg_CostOfRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txg_ProductsAndServicesExcludingGrantRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txg_ProductsAndServicesExcludingGrantRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txg_LicensingAndRoyaltyRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txg_LicensingAndRoyaltyRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Statement Information - Schedule of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves', window );">Purchased materials</a></td>
<td class="nump">$ 36,180<span></span>
</td>
<td class="nump">$ 38,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">23,238<span></span>
</td>
<td class="nump">27,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">15,292<span></span>
</td>
<td class="nump">16,736<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">$ 74,710<span></span>
</td>
<td class="nump">$ 83,107<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Statement Information - Schedule Of Property Plant And Equipment (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 377,200<span></span>
</td>
<td class="nump">$ 375,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(131,113)<span></span>
</td>
<td class="num">(122,967)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">246,087<span></span>
</td>
<td class="nump">252,648<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">36,765<span></span>
</td>
<td class="nump">36,765<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">147,235<span></span>
</td>
<td class="nump">147,094<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Laboratory equipment and machinery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">73,792<span></span>
</td>
<td class="nump">72,498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">15,008<span></span>
</td>
<td class="nump">14,953<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">9,745<span></span>
</td>
<td class="nump">9,586<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">90,180<span></span>
</td>
<td class="nump">89,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 4,475<span></span>
</td>
<td class="nump">$ 5,152<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Statement Information - Schedule of Accrued Compensation and Related Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txg_AccruedPayrollAndRelatedCosts', window );">Accrued payroll and related costs</a></td>
<td class="nump">$ 6,303<span></span>
</td>
<td class="nump">$ 2,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonus</a></td>
<td class="nump">7,648<span></span>
</td>
<td class="nump">21,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txg_AccruedCommissionsCurrent', window );">Accrued commissions</a></td>
<td class="nump">3,281<span></span>
</td>
<td class="nump">5,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">4,725<span></span>
</td>
<td class="nump">2,848<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and related benefits</a></td>
<td class="nump">$ 21,957<span></span>
</td>
<td class="nump">$ 33,615<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txg_AccruedCommissionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued commissions, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txg_AccruedCommissionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txg_AccruedPayrollAndRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Payroll And Related Costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txg_AccruedPayrollAndRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred for employer-related costs classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherEmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Statement Information - Schedule of Accrued Expense And Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txg_AccruedLegalAndRelatedExpensesCurrent', window );">Legal and related costs</a></td>
<td class="nump">$ 10,563<span></span>
</td>
<td class="nump">$ 6,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties for licensed technologies</a></td>
<td class="nump">4,191<span></span>
</td>
<td class="nump">7,042<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional services</a></td>
<td class="nump">4,201<span></span>
</td>
<td class="nump">5,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent', window );">Product warranties</a></td>
<td class="nump">9,453<span></span>
</td>
<td class="nump">8,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">4,775<span></span>
</td>
<td class="nump">4,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">12,300<span></span>
</td>
<td class="nump">9,157<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txg_AccruedExpensesAndOtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 45,483<span></span>
</td>
<td class="nump">$ 41,165<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txg_AccruedExpensesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Expenses And Other Liabilities Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txg_AccruedExpensesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txg_AccruedLegalAndRelatedExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued legal expenses current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txg_AccruedLegalAndRelatedExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Statement Information - Schedule of Changes in the Reserve for Product Warranties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward', window );"><strong>Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrual', window );">Beginning of period</a></td>
<td class="nump">$ 8,615<span></span>
</td>
<td class="nump">$ 8,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualWarrantiesIssued', window );">Amounts charged to cost of revenue</a></td>
<td class="nump">3,965<span></span>
</td>
<td class="nump">2,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualPayments', window );">Repairs and replacements</a></td>
<td class="num">(3,127)<span></span>
</td>
<td class="num">(764)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrual', window );">End of period</a></td>
<td class="nump">$ 9,453<span></span>
</td>
<td class="nump">$ 9,707<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualWarrantiesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the standard and extended product warranty accrual from warranties issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualWarrantiesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Statement Information - Schedule of Revenue of Recognized in Contract Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Deferred revenue recognized</a></td>
<td class="nump">$ 5,857<span></span>
</td>
<td class="nump">$ 3,595<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Statement Information - Schedule of Revenue by Source (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 154,883<span></span>
</td>
<td class="nump">$ 141,006<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txg_InstrumentsMember', window );">Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">14,815<span></span>
</td>
<td class="nump">25,453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txg_ChromiumInstrumentsMember', window );">Chromium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">5,913<span></span>
</td>
<td class="nump">7,850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txg_SpatialInstrumentsMember', window );">Spatial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">8,902<span></span>
</td>
<td class="nump">17,603<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txg_ConsumablesMember', window );">Consumables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">115,356<span></span>
</td>
<td class="nump">110,335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txg_ChromiumConsumablesMember', window );">Chromium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">84,109<span></span>
</td>
<td class="nump">83,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txg_SpatialConsumablesMember', window );">Spatial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">31,247<span></span>
</td>
<td class="nump">26,408<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">7,652<span></span>
</td>
<td class="nump">5,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txg_ProductAndServiceRevenueMember', window );">Products and services revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">137,823<span></span>
</td>
<td class="nump">141,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txg_LicensingAndRoyaltyRevenueMember', window );">License and royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 17,060<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txg_InstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txg_InstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txg_ChromiumInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txg_ChromiumInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txg_SpatialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txg_SpatialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txg_ConsumablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txg_ConsumablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txg_ChromiumConsumablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txg_ChromiumConsumablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txg_SpatialConsumablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txg_SpatialConsumablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txg_ProductAndServiceRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txg_ProductAndServiceRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txg_LicensingAndRoyaltyRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txg_LicensingAndRoyaltyRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Statement Information - Schedule of Revenue by Geographic Region (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 154,883<span></span>
</td>
<td class="nump">$ 141,006<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AmericasMember', window );">Americas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">90,570<span></span>
</td>
<td class="nump">79,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">86,818<span></span>
</td>
<td class="nump">75,637<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=txg_AmericasExcludingUnitedStatesMember', window );">Americas (excluding United States)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">3,752<span></span>
</td>
<td class="nump">3,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember', window );">Europe, Middle East and Africa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">31,895<span></span>
</td>
<td class="nump">34,721<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember', window );">Asia-Pacific</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">32,418<span></span>
</td>
<td class="nump">26,655<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">16,883<span></span>
</td>
<td class="nump">13,924<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=txg_AsiaPacificExcludingChinaMember', window );">Asia-Pacific (excluding China)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 15,535<span></span>
</td>
<td class="nump">$ 12,731<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AmericasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AmericasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=txg_AmericasExcludingUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=txg_AmericasExcludingUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EMEAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaPacificMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=txg_AsiaPacificExcludingChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=txg_AsiaPacificExcludingChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Company's Operating Lease Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating&#160;Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2025 (excluding the three months ended March 31, 2025)</a></td>
<td class="nump">$ 10,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">15,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">15,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">15,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">14,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">26,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">97,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(17,407)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">80,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">9,443<span></span>
</td>
<td class="nump">$ 9,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, noncurrent</a></td>
<td class="nump">70,631<span></span>
</td>
<td class="nump">$ 73,327<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 80,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Due After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Additional Information Related to Operating Leases (Detail)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">5.80%<span></span>
</td>
<td class="nump">5.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Nov. 17, 2023</div></th>
<th class="th"><div>Dec. 20, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Contingency, damages sought, value</a></td>
<td class="nump">$ 31.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Amount of lost profits</a></td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Payments for royalties</a></td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Stock - Additional Information (Detail)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued (in shares)</a></td>
<td class="nump">109,076,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding (in shares)</a></td>
<td class="nump">109,076,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued (in shares)</a></td>
<td class="nump">14,056,833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding (in shares)</a></td>
<td class="nump">14,056,833<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Schedule of Recorded Stock-Based Compensation Expense in the Condensed Consolidated Statement of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 31,076<span></span>
</td>
<td class="nump">$ 36,129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">2,481<span></span>
</td>
<td class="nump">2,033<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">14,106<span></span>
</td>
<td class="nump">16,888<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 14,489<span></span>
</td>
<td class="nump">$ 17,208<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Schedule of RSU Activity (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted&#160;Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">6,493,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">2,016,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(564,701)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled (in shares) | shares</a></td>
<td class="num">(320,043)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">7,624,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant&#160;Date&#160;Fair&#160;Value (per share)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 35.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">12.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">47.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">38.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 28.35<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Schedule of Company's Stock Option Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock&#160;Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">4,594,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(277,212)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled and forfeited (in shares) | shares</a></td>
<td class="num">(96,812)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">4,220,558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 45.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">1.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled and forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">52.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 48.09<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units, granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,016,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txg_MarketBasedPerformanceAwardsMember', window );">Market-based Performance Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share based payment arrangement recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units | 2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units, granted (in shares)</a></td>
<td class="nump">561,603<span></span>
</td>
<td class="nump">219,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=txg_CompoundAnnualGrowthRateMember', window );">CAGR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">PSA target percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Performance period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=txg_CompoundAnnualGrowthRateMember', window );">CAGR | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage', window );">PSA target amount of shares percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=txg_CompoundAnnualGrowthRateMember', window );">CAGR | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage', window );">PSA target amount of shares percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=txg_CompoundAnnualGrowthRateMember', window );">CAGR | Market-based Performance Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=txg_TotalShareholderReturnMember', window );">TSR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">PSA target percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Performance period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=txg_TotalShareholderReturnMember', window );">TSR | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage', window );">PSA target amount of shares percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=txg_TotalShareholderReturnMember', window );">TSR | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_txg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage', window );">PSA target amount of shares percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=txg_TotalShareholderReturnMember', window );">TSR | Market-based Performance Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock | 2019 Plan | Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share-based compensation arrangement percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock | 2019 Employee Stock Purchase Plan | Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="nump">3,928,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,928,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,909,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued in period for previously outstanding awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Multiplier, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txg_MarketBasedPerformanceAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txg_MarketBasedPerformanceAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txg_TwoThousandsNineteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txg_TwoThousandsNineteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=txg_CompoundAnnualGrowthRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=txg_CompoundAnnualGrowthRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=txg_TotalShareholderReturnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=txg_TotalShareholderReturnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txg_TwoThousandsNineteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txg_TwoThousandsNineteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Fair Values of Shares Under the Performance Stock Units (Details) - Performance Stock Units<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">67.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Shares of Common Stock Equivalents Were Excluded From The Computation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">12,282,078<span></span>
</td>
<td class="nump">11,299,861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">4,220,558<span></span>
</td>
<td class="nump">5,604,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">7,624,647<span></span>
</td>
<td class="nump">5,578,818<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=txg_SharesUnderEsppPlanMember', window );">Shares committed under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">436,873<span></span>
</td>
<td class="nump">116,883<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=txg_SharesUnderEsppPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=txg_SharesUnderEsppPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event - Forecast<br> $ in Millions</strong></div></th>
<th class="th">
<div>May 06, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Expected workforce reduction percent</a></td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Estimated restructuring charges</a></td>
<td class="nump">$ 5.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Estimated restructuring charges</a></td>
<td class="nump">$ 6.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>56
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( '&,J%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( '&,J%JL+B>_\0   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DMM*Q# 0AE]%<M].#U0D='NC>*4@N*!X%Y+9
MW6!S(!EI]^U-XVY7T0<0<I.9/]]\ ^FEY](%? K.8R"-\6HVHXU<^@T[$'D.
M$.4!C8AE2MC4W+E@!*5KV(,7\EWL$9JJN@:#))0@ 0NP\"N1#;V27 84Y,()
MK^2*]Q]AS# E 4<T:"E"7=; AF6B/\YC#Q?  B,,)GX54*W$7/T3FSO 3LDY
MZC4U35,YM3F7=JCA]?'A.:];:!M)6(GI5=2<CAXW[#SYI;V]V]ZSH:F:KJC2
MN=DV-6\[WK9OB^L/OXNP<4KO]#\S[KX9GP6''G[]B^$34$L#!!0    ( '&,
MJ%J97)PC$ 8  )PG   3    >&PO=&AE;64O=&AE;64Q+GAM;.U:6W/:.!1^
M[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?A1%8C6QY9)&$?[]'-A#+E@WMDDVZ
MFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@V2_;UKNW+][@5S(D$4$P&:>O\, *
MI4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<X%L:+R/6ZK3;W5:$:6RA&$=D8'U>
M+&A T%116F]?(+3E'S/X%<M4C66C 1-702:YB+3R^6S%_-K>/F7/Z3H=,H%N
M,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1TDB @LE]E 6Z2?:CTQ4(,@T[.IU8
MSG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP' 3@4;N>PIWT;+^D00FTHVG09-CV
MVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=TXZ)QJW0> V^\4^'PZZ)QJO0=.MI
M)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP=M;,T@.67BGZ=90:V1V[W4%<\%CN
M.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,4'RO0;:*X,*2TER0UL\IM5 :")K(
M@?5'@B'%W*_]]9>[R:0S>IU].LYKE']IJP&G[;N;SY/\<^CDGZ>3UTU"SG"\
M+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E,L_O^0KK3CQG'U:6L%W/S^2>C'(C
MN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZY!$XM4D-,A,_")V&F&I0' *D"3&6
MH8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A6$G:A/@01AKBG'/F<]%L^P>E1M'V
M5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\'1,2S90+!D&&ER0F$JDY?DU($_XK
MI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:P4:O&W6':-(\>OX%^9PU"AR1&QT"
M9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:<K46@;9QJ81@6A+&T7A.TK01_%FL
M-9,^8,CLS9%USM:1#A&27C="/F+.BY 1OQZ&.$J:[:)Q6 3]GE[#2<'H@LMF
M_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >CFED)O816:I^JAS0^J!XR"@7QN1X^
MY7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_+GW/I>^Y]#VATK<W(WUGP=.+6]Y&
M;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?P.S]:#Z>\>WZV22$KYI9+2,6D$N!
MLT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T
M/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KTL<QP3A[+##MG/)(=MG>@'37[]EUV
MY".E,%.70[@:0KX#;;J=W#HXGIB1N0K34I!OP_GIQ7@:XCG9!+E]F%=MY]C1
MT?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'>7M?F&>5QE T%&ULK"0L1K=@N-?Q
M+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW
M&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^:CVT%4[/_EFMR)\,$4X6"Q)(8Y07
MIDJB\QE3ON<K2<15.+]%,[82EQB\X^;'<4Y3N!)VM@\",KF[.:EZ93%GIO+?
M+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!8/+]<,E'#^4[YU_T74.N?O;=X_IN
MDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0!A,!S93)1/ "@F2F'("8^@N]\@RY
M*17.K3XY?T4L@X9.7M(E$A2*L P%(1=RX^_ODVIWC-?Z+(%MA%0R9-47RD.)
MP3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+PWING2TG_]M>U#VT%SU&\Z.9X!ZS
MAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83+$.D?L%]BHJ $:MBOKJO3_DEG#NT
M>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'?!^2!F.,6_0T7X\48JVFL:W&VC$,
M>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 Y3_;U UH]@TT')$%7C&9MC:CY$X*
M/-S^[PVPPL2.X>V+OP%02P,$%     @ <8RH6N_.E<U*!@  LR,  !@   !X
M;"]W;W)K<VAE971S+W-H965T,2YX;6RUFFM3XS84AO^*)NUTVAD@EIP+;"$S
M(<"6Z;*;)?0^_2!L)?&L;:62S.7?]\A.;&#ED]2-^4!\.Z_UZDCR(UNGCU)]
MT4LA#'E*XE2?=9;&K-YUNSI8BH3K([D2*9R92Y5P [MJT=4K)7B8!R5QEWG>
MH)OP*.V,3O-C4S4ZE9F)HU1,%=%9DG#U?"YB^7C6H9W-@=MHL33V0'=TNN(+
M,1/FE]54P5ZW5 FC1*0ZDBE18G[6&=-W$W]H _(K?HW$HWZQ3:R5>RF_V)WK
M\*SCV1*)6 3&2G#X>1 3$<=6"<KQSUJT4][3!K[<WJA?Y>;!S#W78B+CWZ+0
M+,\ZQQT2BCG/8G,K'W\2:T-]JQ?(6.?_R6-Q;:_7(4&FC4S6P5"")$J+7_ZT
MKH@7 7U:$\#6 >Q- *V[@[\.\'.C1<ER6Q?<\-&IDH]$V:M!S6[D=9-'@YLH
MM6F<&05G(X@SHXE\$(I,(6/DD.@E5T*?=@T(V]/=8"UR7HBP&A&?W,C4+#6Y
M3$,1OH[O0H'*4K%-J<X9*GC#U1'QZ0%A'NL[RC/!P\<K&^ZYPE\5QR\KR<_U
M_!J]R]1$YIE<IT6WL<WOKP]P#;DV(M%_NRJL$.RY!6W??*=7/!!G'>A\6J@'
MT1E]]PT=>#^ZW.Y)[)7W7NF]AZF/+F200;<UY.YY)5Q.\7#J'7YV64*C&EKJ
MEY;ZNUGZG'%EA(J?R:U8265<]G IHS)7I4S0J(;V!J6]P6[VID)%,K2=DL#8
MX$P>KE1VP]I^B,8W]#DL?0YW;)F*PV,E[Y;U><2UYCS6SD2B80T-'I<&C]%"
MK8>=JR@6Y&.6W OE,H9K>!X]]$\\WYD]-+2AN9/2W,DNYF[%(M(&$FC(1YXX
MVRBN0[TG\EZD,HD"?0!#='#D<HIJ-'1*O>H9Z^WB%0HG%;3/_ ER0&8&.B61
MBDQDEAKU#+^ALP*VJ%]<NASC04TMO\ *NHOE._Y$KD/HI-$\"HHG9WU+WB+9
MZQ_V![37ZQ\[_:+!3?VRRB_;Q>\X#$$=&N)Z@^28\"EUYQ67'##?@T8B4QC&
M0^"S&Q['Y%;RT&D?U6IJOP(DBC+(5_8G=@^:]IU\3)W6<;EI++B&,4&Z@B=X
M<%.O%1!1'&G>>BW[\53)AR@-W+G&-2=CI]$V*(E6F$1QN'EK="JUX3'Y,UK5
M#U6XX@ET7G?O;0.8:$5,% >=O+F.81I<;PP7.''C$1[5U%8%2!2GF@\R@'Q-
MES"$8,,N+M(#@ACZGN?TUP8>T8J/* XW=Y$!-))S0MGW]S^0F0@R!9ETFL25
M)C'7NBC9F 0R2>!!!7/OX,L!67%%'GB<"?*M=^3!'R4KF#+G<V5GG;1!5;3"
M*HKS$,!P&*4+,GM.[F7LK(HM K^_=]IJ Z%8A5 ,AYQ-;LGE4[#D*3P.ZW!Q
MB]#'\>QB[)R2XH%-'5;$Q'8BIDFFE)W4%#.9/)/P?,F<;V6V*/[A?)<SP:.:
M^JQ(B>U$2M<IS+R+EWAV=LHWQIT^<<4ZGVT@$:N0B.V$1';V!H@/B+"0RCDT
M;='YP!6T]G$0"! "F;"0=#IN XQ8!49L)S":)194SS,-I[6[W>(ZM9-Q/*ZI
MOXJ'V$X\=)D(M; =\STHF"4@0[+BJ3NUN&"]T39PB%4XQ'":V21R*2"1F#U<
MIMY>&UC$*BQB.-&,$Y&&^9NCJY@OG,8:OBW"XYH:JWB(X113OA&[BK0EOS\$
ML,L5''3W0ERL]M5[&WS#*KYA.)Z\];A^R5GO$I?[3)T>VX =OX(='V>4#0.\
M3"/V%G>+W.$A98>^TR@>V=1HQ3S^;LP#9A48O4Y#\41^%L[!9HN4!?/AT!L>
M#YT^VV >OV(>'R>423&CR&<9Q#75/\<%_O,'HS;0QW_QN6S_W\OV^\&L#1#R
M*Q#R=P*A==9GQ3QREG]<)9\RHPU/[1S-60][0IQU/11J_5S-?M%_&%%*O1,V
M'/9.NP\NDQ4-^3B\O&K3YTXO>Z*8M9<VF,BOF,@?[+U-[PESUO[;@":_@B8?
M9Y[_TZ;W1$7K>AA^W::9U_-.AH,W3;K[8EF$9?9\M8@F@?W<4JR0*(^6*U+&
M^3J,;G5YL9SEAEODUR06<PCUCH9P>U6L$"EVC%SEBRSNI3$RR3>7@H="V0O@
M_%Q*L]FQ-RC7Z8S^!5!+ P04    " !QC*A:]D]]Y2,&  "S&@  &    'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;*V9VV[;.!"&7X5PBZ(%FEH\Z)0F!MH$
MN]N+;H.FW;UF)#H6(HFN1"?-V^]0<B59/#C!]B:Q[.'HGQ$YWY Z>Y#-7;L1
M0J&?55FWYXN-4MO3Y;+--J+B[3NY%37\LI9-Q15<-K?+=ML(GG>#JG))@B!:
M5KRH%ZNS[KNK9G4F=ZHL:G'5H'975;QY_"A*^7"^P(M?7WPM;C=*?[%<G6WY
MK;@6ZOOVJH&KY> E+RI1MX6L42/6YXL/^/2",CV@L_BG$ _MY#/2H=Q(>:<O
M/N7GBT K$J7(E';!X=^]N!!EJ3V!CA][IXOAGGK@]/,O[W]TP4,P-[P5%[+\
MM\C5YGR1+% NUGQ7JJ_RX2^Q#RC4_C)9MMU?]-#;1G2!LEVK9+4?# JJHN[_
M\Y_[1$P&8.880/8#R%,'T/T V@7:*^O"NN2*K\X:^8 :;0W>](<N-]UHB*:H
M]6.\5@W\6L XM;J0=0X/1>0(/K6R+'*NX.(C+WF="72M';?H!'V_OD2O7[Y!
M+U%1HV\;N6MYG;=G2P4:M*=EMK_?Q_Y^Q'&_S[QYARA^BTA 0LOP"__P2Y$-
MP]GA\"5$/H1/AO!)YX^ZPM\UC:@5XFT+<9[:XND=,+L#O<I.VRW/Q/D"EE$K
MFGNQ6+UZ@:/@O2VZW^3L(%8ZQ$I]WE<7O-T@>&HHTQ_$CUUQSTL(WOH4>U=1
MYTJ7@OL5C>,@PF?+^VD\%C/&@B@>S Z4LD$I\RJ%27(G%+\I!6I%MFL*50BK
MRMY-.+D]2Q/&9B)M5I2&=HWAH#'T:OR097('R8-:E@G()(A]BVJA;#)#0T!(
M0I;.9)I629Q$Q"XS&F1&7IF?ZGMXQ+)YM.F*C#O&+,;!3)=IE5 <.!YQ/.B*
MO;JN&K'E18[$SZTN/VTW,:7:B :JWG1-VG3'AB(2AE$TTVVQ"@(<V74G@^[$
MJ_N;5+Q\@L3$?.1Q&M-Y;BUF":.)([GI(#(]DES ?*,>NZ3JA;X%\"KG]$S-
M1+$HF(CHM5K,0A*QQ*X5!R.! J_:+Z"5JZ*^1:4 (*-&D_=$KD]V<.'.\-[K
M0>[",)ZKMIG%) T<JB?<Q%[5?TJ9/Q1E:96&S8H3XGGM/&9U*&PD&O9"!%:\
MXO5MH8MGGSSG<]\[F@K (4[)7*?-+(I=0D<<83^/OG2KO9;U\=6T]W0P]T@Z
M7_ 6*X9)ZM YP@C[:=0O>8\XDR]I0&E*Y_(L=CB)J*,BX9%$.'Q2$U,6_*8H
M.UA:.QGL)=IS6YG?Y>TPZ)%KV ^V@;];_JCA:PW81!>&[4TR?S 6,Z@0KHDS
M(@[[&0<2FQTTTYFL-.1XOV^!DMR(LNNR;T0MUH5C5EGPA=/0*&^F&:41=C0W
M>,0<]G/NEW8/GR?3S1J R386LL18%18SC"-7 ","L9^!EV(M0*=.-G1 ._O\
ML" M2(W&S&H6A0[PD1%\Y'G@.Y)08I(L96R>3YL521PUAHRX(W[<'?8]QY2:
M9(.&,0WFW8_-#L<1I0ZUDUV=GX&>S+Z=$,>JW:0=['OH'-XV,TJ)HW$C(Q2)
M'XKS:7M4KLD\3,)H/H7M9MB5Z)&-Q,]&@^''9H;)P)"F\X)LLPI<("<C)XE_
MR];/X6,*S6T83B-F:C3M2)" 3(?*$6S$#[8+656%T@U[7W0S6>N9+.H,%*/7
M?TLE$'MCE>YU;"<RLIY2_']'A\&/R"2QMY6Y5C*[V\@R%TW[ZD5"</R^V\"H
M1_O9C!? SSZ<^4W>#F,?D4O\R(4M\7[MMSH+UGA-6!HUU6=RJ&QD*?&S5$])
M:%W<LBR G,ORF1P>9XW\I'Y^?LCS0O=4L*CU6<))4:.,;PM8Y-83+1.,!%9L
M-&DU]F=:%D,<QU'L$CQ"E/HA"DW5KMKUO5\.G5]66&LZ-;%X@L, L\"0:K-D
M41PP!XCHB%#J1^A4Z[[O@S:V$1M]A'\/2)6M_>#0!.,)C>9MJ\V*I0X<T<D)
MIY^>?85OG47$*MA$(P _28U<6^QP@"ESB!X92I^ROYQ@J2O[SPR"&0>QUCVH
MS<ZV!UU.WBCHUSF?>7-;U"VT4VL8&+R+(0U-_X:DOU!RV[UDN)%*R:K[N!$<
MQ&L#^'TM@5O["_W>8GA/M?H/4$L#!!0    ( '&,J%JKN"J)704  &P6   8
M    >&PO=V]R:W-H965T<R]S:&5E=#,N>&ULK5C;;MLX$/T5PELL6B".1.J>
M=0PT[EX*M+M!TVZ?&8NVA4JBEZ2=].]W*,N2+5)L _@ED>29X3DSY!R2LR<N
MOLD-8PH]5V4M;R<;I;8WGB>7&U91><VWK(9?5EQ45,&K6'MR*QC-&Z>J](CO
MQUY%BWHRGS7?[L5\QG>J+&IV+Y#<5145W^]8R9]N)WAR_/"I6&^4_N#-9UNZ
M9@],?=G>"WCSNBAY4;%:%KQ&@JUN)V_QS8(DVJ&Q^+=@3_+D&6DJCYQ_TR_O
M\]N)KQ&QDBV5#D'AWYXM6%GJ2(#COS;HI!M3.YX^'Z/_T9 ',H]4L@4OOQ:Y
MVMQ.T@G*V8KN2O6)/_W%6D*1CK?DI6S^HJ?6UI^@Y4XJ7K7.@* JZL-_^MPF
MXL0!XM@=2.M A@[AB$/0.@0-T0.RAM8[JNA\)O@3$MH:HNF')C>--[ I:EW&
M!R7@UP+\U'S!ZQR*PG($3Y*714X5O#PH^ ?54A+Q%?IGRP3569=HBKX\O$.O
M7[U!KU!1H\\;OI.TSN7,4X!&Q_26[<AWAY')R,@!^LAKM9'H=T"0G_M[P**C
M0HY4[H@SX$<JKE& KQ#Q263!L_AY]] !)^@R&S3QPI%XG]B>U3MF2\S!,6X<
M]3K;SW$4IFDP\_:G>"UF(8;EV9F=X0H[7*$3UX)+I8NZ%3S?+:' 4#XDF=@7
M2R9A98ZB/H2-3N"$61BD ] 6J]3/B!USU&&.G)C_%%Q*C7A5*!NTR!@4^U$8
M1@-LIEE&,AS:L<4=MKAQ"T:PM8NC7B/VO-5+2=[8(,8N@KI9W\@M7;+;"71C
M70TVF?_Z"X[]WVPS^4+!SO@F'=_D!_-:,BJ6FV;>Y#!=2K[5G<)&.C$2'H?$
M*(O%*HU/)M89S+2#F3IA/H R0%&NT)K54*"R@4MS:*&%5+I@>^LD3PTL:9:0
MX22W6$5),C*1L@YQYI[D(+H(E$TRI4HVEM+,&'J:@68/ )I6OAT<]GNA\)WP
M/G,%6>3&;+=V?M]<D&&8),,.9[.#=8M'V@4^437L!/M!]XN5X-41,&B7%2@V
MTQED@5%PFUV,PVQDDF+2 R7N[J$V3("2+GG%T.LVIV^L':2-=*$6<JEHY[Q[
M<<1N=7Q?*P9Q54O=RC<P<AY 8QA6QK0*DV!$(W$ODMBMDAV^MB16@*;6#=>A
MQ62*1[#U8HC=:FB?,U>H9M:.@4W9(S@P\FA:3;$?CK6-7AVQ4XR.;>,$LA5C
M;(P>I80,,9I609Q%(Q![0<-N16N:Q2.#,Q'3>XQ]T9Q1X/688T6?1_J<*5W3
M((A\([D6NRA)_6 $>B]RV*UR]R^#:],M(\FF$<'AV(+JQ0V[U>UO.)*6D&@K
MKLS8Z4Z#,(B,+FRQB[(LS.S@2*]MQ*UM1W (Q +)#17L2A\.BR5Z#9J<\[*D
MXN3'-S82[1#)*3C_VE 2N]G('":]X!&WX-D8Y$6YTX>Y%W# /\?!:C;&H=="
MXM2<^=?FS,WR*=V#9J_9 6AS H5Y7>FMD>++;VBGCZO "3YN=\U>I';6[Q#&
M3IB8&Q!"8C_V,SPD;3'%69"%.!UIDJ170^)6P\LR/ZV[B[NIG*/<+:8_X-XK
M+7$K[?U+SZ'N>"_=!UTJVCG[7LN)6\L=MP2MY]GY/TA2,MQ$V^ST/<'8>NRE
MF[BE^P-4 G8636$$_TY+]=U9EXL><2\5[9Q[OR<@/SKECO-,S'PGL&J&9;&8
M#2KBG=S;54RLF^M,":M[5ZO#O5?W]7!E>H=O%LW-XN#[6WSSMKE ]/HPAWO8
MCU2LBUJBDJT@I'^=P&01AZO-PXOBV^9V\)$KQ:OF<<-HSH0V@-]7G*OCBQZ@
MNV">_P]02P,$%     @ <8RH6G_99[H\ P  K D  !@   !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6RM5FUOTS 0_BM6F- FK4N;I*^TD=8"8A*#:67P ?'!
M3:Z-F6,7VVTW?CUGIPU]22N0]B7QR]WCY^[LN^NOI'K4&8 A3SD7>N!EQLQ[
MOJ^3#'*JK^0<!.Y,I<JIP:F:^7JN@*9.*>=^4*^W_)PRX<5]MW:GXKY<&,X$
MW"FB%WE.U?,0N%P-O(:W6;AGL\S8!3_NS^D,QF >YG<*9WZ)DK(<A&92$ 73
M@7?=Z(VZ5MX)?&6PTEMC8BV92/EH)S?IP*M;0L A,1:!XF\)(^#< B&-7VM,
MKSS2*FZ/-^COG>UHRX1J&$G^C:4F&W@=CZ0PI0MN[N7J ZSM:5J\1'+MOF2U
MEJU[)%EH(_.U,C+(F2C^]&GMART%Q*E6"-8*P;Y"=$0A7"N$SM""F3/K+34T
M[BNY(LI*(YH=.-\X;;2&"1O%L5&XRU#/Q",I4HP)I 1'6G*64H.3L<$?!LMH
M(J>XE>,5R6SLED ^2JU)C3R,WY+SLPMR1I@@7S*YT%2DNN\;9&6Q_63-8%@P
M"(XP",FM%";3Y!TR27?U?;2F-"G8F#0,3@+>4G5%PL8E">I!LX+/Z-_5HQ-T
MPM+#H<,+C^"5KCSTY(U(9 [D^_5$&X47^D>5]PKTJ!K=/O*>GM,$!AX":U!+
M\.+7KQJM^ILJTU\(;,<14>F(Z!1Z_ ES$L>[4V5DH=ERFC;Q+.-:&(7-3M]?
M;M.O$&MVNU&W%-LAUBR)-4]&Z+/)0)%D)S2L",VY)7QQ202X\!GZU*NBWWS)
M&+T0V(XK6J4K6B=C]""P%'#V&U/ #$N +AP ^H+8E+NDC-,)AQI6CYJF'# 3
MJ4<P=HUH2!:*&0:5 2Z.;6Y'+JCO1?=0IA&VJD/;+NUIG[0'4STF<H&95"D0
MR3/!=R8TIT4)27]B@K5/LXIQ^Y!-U-IC?"A3:[3":LJ=DG+G).7_NHU5Q#N'
MQ(-]XH<RM:!=S;M;\NZ>Y+V;VHX]]&[50P_"8(]?A1@^]/;^;?"W"E\.:N;Z
M 8W.6PA3%(QRM6@YAMARN-*\MXZMR+6KP/Y?F**/P7(PLP^!PQ0AZU=M=)HJ
M>H-B8N3<E=>)-%BLW3##=@J4%<#]J91F,[$'E U:_ =02P,$%     @ <8RH
M6M#\<BFJ!@  .3D  !@   !X;"]W;W)K<VAE971S+W-H965T-2YX;6S%FVMS
MFS@4AO\*XW:ZFYEUC<2]33R3V-QF]I)IVMT/._N!@A(S!>0B'+?_?@4FMA$R
M,=O3[I<8G'.>(Z'70M9K+K>T_,16A%3*ESPKV-5D557K-[,9BU<DC]AKNB8%
M_\\]+?.HXJ?EPXRM2Q(E35*>S;"JFK,\2HO)_+)Y[[:<7])-E:4%N2T5MLGS
MJ/QZ0S*ZO9J@R=,;[]*'556_,9M?KJ,'<D>J#^O;DI_-]I0DS4G!4EHH);F_
MFERC-R%N$IJ(/U.R94?'2MV5CY1^JD_"Y&JBUBTB&8FK&A'QET>R(%E6DW@[
M/K?0R;YFG7A\_$3WFL[SSGR,&%G0[*\TJ597$WNB).0^VF35.[H-2-LAH^;%
M-&/-7V7;QJH3)=ZPBN9M,F]!GA:[U^A+>R&.$I!V(@&W"?C<!*U-T(0$;)U(
MT-L$74PXU0>C33"$!-T\D6"V":;8!^-$@M4F6&*3[!,)=IM@BTW")Q*<-L%I
MY+ ;OV;PEU$5S2]+NE7*.IK3ZH-&04TV'_.TJ,5^5Y7\ORG/J^8+6B1<NB11
M^!&C69I$%3^YJ_@+UW3%%'K/SVC\:46SA)3LU0L;(^NMXG[>I-579:I\N%LJ
M/[^\4%XJ::&\7]$-BXJ$7<XJWKJZQBQN6W*S:PD^T9+WM(HR2=IB.&U!\YQ_
M:)HF2K*7P]G729+6'[HH>_4"F>K;VRA-IKP?BVB=RIOC/@.,XTV^R9J+N"3W
M:9Q6$HAW/N2/:D5*/C@YG\M6]23S2)2PB&E.E)]_I8Q=2/#^69=LD46,*=>2
M_&!,OO+,"(2C8*,&9,;%OE<\WBL>-P7U$P5OR$-:%&GQP"?)+"IB?ATYGZVB
MDK +):KXL,6O%0W]HF 5:S(=#_+KN],;MHYB<C7A0\9(^4@F\UUG9.K>P8P&
M5M^9'N<(.:IC:":^G#T>*QFRK L)\R!A/B0L@(2%0+".:K6]:K61JCU'J3NF
M>20N2T>JKG65M>B'B=J31*C8L!VU&^?VXZ8(V[J.A4!/$JACIQOD#UZ2L5*
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MT]N=5'3=/,3UD585S9O#%8D24M8!_/_WE%9/)_5S8?NG)>?_ E!+ P04
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M2B+[<%Y <KA1P4+.[3>V!URKC:RZ\&(83T=4%N)1*^DZVT]UA?:QNP0&'C6
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M^507NW3L>M='^9XA/1LMGKV@>F7(8&K(>&.B'-E_!!CR1#F<CUV:0&H$HBG
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M+V?A=)MNO&GY._?*>)R*^;)4$F,U+<![PFFZ(07]/SZN?P-02P,$%     @
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M0?T(Y6\:+'.BT!4K"Y,S+YC[]##W%I'/?L-80 9 _*TU%< P\L)HSL+$B^.
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MK*$^D"(H*ZB$H$VC"X:N@AM+JQ+VUB'?>4R6+=##9*6Q$-(-G=2I]I,4I*&
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M\[0%VS.T+2$ [2R9Q><DR8BG\P!])NAM/K:$B<@KL1)V*.P6KX[,F*[H\S4
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M?I8VX/U*J;K[0@SZ7Z1<_@]02P,$%     @ <8RH6O02 2>@%   RTP  !D
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M(LH&]Z;,[+6_W&]#+1$[F ^3>7]*Q.Y$O<ZK=&?=;M?W:[5'@;(CDB;#_=[
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MP/J$<K!\<1O"]7NA=%]B7 +QR'[ Y'<P!5O<S12]/_/#21)RMH;BMTV)J_T
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MIJ8%+ /L>P/Z!8+\XX=D&G^Z(G \"!Q?8__W#_@/.%D9HO8$[["HADL,B:V
MR$;L0+NHJ2A6X:P-I\:0%2F4$#@@QE-06?:!]=L ,Z:!TL=QN(U%@\D#:4$#
M2>*;,)Y-PYMDYA.2<1A/IN$\RT*<7%.#GSU^'%VZL.BL>P7H@Y]1@X<WTG:-
M/.P.S\"JZ_Z_Z=T;@I4?F#2$PQZA\6@V"8CNYK)SK*K]+.R4Q<GR9H5/&6B7
M@/&]4O;DN .&QS'_ U!+ P04    " !QC*A:]T7P]!@(  #+%   &0   'AL
M+W=O<FMS:&5E=',O<VAE970Q,BYX;6RU6&MOV[@2_2N$MUVT@&)+LOS*"TBR
MN;N]0+%!TNY^6-P/M$3;O)5$EZ3B^/[Z>V8H.<ZCZ;;%?D@L49SAS)DS#^EX
M8^PGMU+*B[NJK-U);^7]^G P</E*5=+US5K5>+(PMI(>MW8Y<&NK9,%"53E(
MXW@\J*2N>Z?'O'9E3X]-XTM=JRLK7%-5TF[/56DV)[VDURU<Z^7*T\+@]'@M
ME^I&^8_K*XN[P4Y+H2M5.VUJ8=7BI'>6')YGM)\W_*'5QNU="_)D;LPGNGE7
MG/1B,DB5*O>D0>+G5EVHLB1%,.-SJ[.W.Y($]Z\[[?]BW^'+7#IU8<H_=>%7
M)[UI3Q1J(9O27YO-;ZKU9T3Z<E,Z_B\V86\V[(F\<=Y4K3 LJ'0=?N5=B\.>
MP#3^@D#:"J1L=SB(K?Q%>GEZ;,U&6-H-;73!KK(TC-,U!>7&6SS5D/.GEY\;
M[;?B79VKFO 15Z6LW?' 0S?M&.2MGO.@)_V"GJ%X;VJ_<N*R+E3Q4'X FW:&
MI9UAY^F+"M]+VQ?#)!)IG(Y>T#?<.3ID?<,OZ+M92:L.SA' 0ES)+7CEQ9FU
MLEXJOO[K;.Z\!4G^\YSS07?VO&Y*G$.WEKDZZ2$SG+*WJG?Z\T_).#YZP?)L
M9WGVDO9O"-'WZ!$WWN2?#N8,S(6ID.U.<L)\6"E>D/46Z9<;B\ *M[<[W]^M
M[NA:"5T+#\'<@ =UV%4[4^I">A;'#^-M%@*5Q;*P$Z@N+(85;0HG&,::)"0]
M+%$[G'C#NDWC9%VXMX<PT"KU@'=,%OJ7P7+'AUAUJ^I&B5<BC;)IPK_Q<"BN
M<8"T^4I &=+X%N5IS88E693$8Y&,H^ET*FY0+W2]C,12U;"VY.VR0"9JH@OC
M"(EL.A/))$KCJ?A@/+9]%:=71.YX,J:+<92D,[+(6YV3TQP3\;'6WNTOLU+1
M\/*;GW^:IFE\='WST?%E<O0VU#@*<H>G9XBJ )%BB-ZSUUUF">WV(#Y\:L2?
M7-=4<7!V"_^72OS>>$2Q+H *20+B7U2NJKFRG=),C*-L-HR&TPEY-^J/1N)7
M9!HI!?A -HXSD:3])!%_X#PLOQF-LV@2)V]%-NEGJ;B08&E9TI-A&D=Q-GPK
MAM-^-GWF^$<.3:)QFD7CC,Y.I_WAJ'7D]W6@6K@SZ_NF\$. /53^76AET6B&
MOVD*B[-1?S@1EW?*YIJX\R:=@%9)^E8D_=$^+L1#&+U0FO&;@:ZT:Y22QU\%
M*8O G6@TFM*1TWX\$U?*<HN'_M:GLXVT2,5W=2M,@A&#U%6%91O4T3B)QO&0
MLG>GXSFN7NUSM0&X ?,T3F9<C(0W(E?68Y80%8/$MD.A;*OT9J4I92WT-_/_
MHK.3".F0^4HCB;O2TFG9MXA*D@YA NGDO-1HFX68;_=](O.2R9%[6 IQ4VGO
MP0SHIMWG!MAP-#5*HS>625$HEUL])Z4T[1P*W1>C^#4+2;O$B$4("-2=&GLV
MNBRQ480B8>IGS:#:81JJ.77=H*XLT3S\2J#RJ!VL%V>_7N]@;0U\K.>Z+8,&
MO!12^(TYV,*.!P"%XBL6UE3BWQ+'V:WH" .8'Q-WW!>_F;*@(%5RRUX%67B,
M[1@+7W?6M-[+"JYP?!QU8\<D;M%@9!@2"-2$RUZ$J:7J7+7U]!;A [./6%Q_
M.\96E:%PAU+-D\&*/0%,OH$;';(?;KX*+ *$:M'278: 05_1$1,J.M$]2M/M
M=>,PG99B&,>Q>*\*G<,8:M*A#Y%S-\%O%"TF&7*Q4'>[&%*I^N$H3OI8 M.Y
M5NP <AAJW3U0>[Y@=/\$D'?)%"K"Z@>)$/*:HT71%=+S=IC523YUL<\3RCUO
M$.;[@JB?2NWE/Q60VOBN:A3/G+?S_>G!CW)=SA&08$S+S$X'VY:CKLG2&;(/
MK76Y5,2.9@VLNRJ5KV@,I=$)-GJ+EP#*5@0 (6_G*5X@O862R'\\*+23<UVB
M>86S-UWKD6WKX>HL:.X2"ZFMN)5EH]P#VX*3,!AAHBK"I*,H<]FIV88-[!6O
MDKB/684>OTJ&_5E&4(3@1427M>*WJQ*VW'QM\J%9<EGK_ZFBZ[I8E*'9;("L
M7*^MN=-XXX(^\2KN)WCQP10&%7^[2_<?3*\4E8KG3Q)^!$;+P*Z7W;>EP/36
M$P*%(6L<-U4>.W&"M"7*DZZ:,CA9F4+1.QQBQ&?QF!#:,-Y[PY1PB/Y.@%$I
M,R1'013CR6MQK=VG@P7YIJ'=4B9PI<_Z2*&=4(&1I2"J;K4J"\&E*#UZ_:!3
M9\]WZC291<EXVKKR'1TX^N86W,*XRSXFT5Y2[3U9&B3*/]&<^^+LF2DH:JNR
M=(T-9G?YW?&,BR;9RW-:*#6JK1W$[5+Y=A2[)\QC_P3*!&*IY4YKVRON&4_J
MJE82&ZS"3CJDX^9M&)(A/E>YK% -PGP(F%!X.'B7,,9L53>[735P%,0-03U#
MB*C3 8$LFL4SS)JS3C?6+DJ0$YL>M#+VLWV9#8FJP6!VZ!%O7CRZZZ27-U=7
M72L-R;G&:X:BPAL(]:P1F+77K;K]S"1E]$Q]II$(])N.=AV&L[N-!"=Y]^"!
MXK;1+;1U5"*WW2:S6"!42->VB\+MS@"NI"W]%75@&(#<5A8-M&&9O_?^T-$I
MV@OPBT$@W)^X_P*CK0IRPVB63O&ZE>VFK5NI2^+,E\+)BI_[8C'8^\!4*;1P
M^HQ&LPZZ>/C6M%O=?:D["Q^H[K>'SWPP>*G1@DNU@"BZRJ@G;/AT%FZ\6?/G
MJKGQWE1\N5(2)M(&/%\8X[L;.F#W_?+T_U!+ P04    " !QC*A:A'(G;?4"
M  !9!@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6R-5=MNVS ,_17"
M _;DU=<D;I8$:+L.&[ .0=-M#\,>%)N.A<J2*\E-]_>CY#1+L338BW4A>7@H
MZ="SK=+WID&T\-0*:>9!8VTWC2)3-M@R<Z8ZE&2IE6Z9I:7>1*;3R"H?U(HH
MC>-QU#(N@\7,[RWU8J9Z*[C$I0;3MRW3OR]1J.T\2(+GC5N^::S;B!:SCFUP
MA?9;M]2TBO8H%6]1&JXD:*SGP44RO<R=OW?XSG%K#N;@*EDK=>\6GZMY$#M"
M*+"T#H'1\(A7*(0#(AH/.\Q@G](%'LZ?T3_ZVJF6-3-XI<0/7MEF'A0!5%BS
M7MA;M?V$NWI&#J]4PO@O; ??+ Z@[(U5[2Z8&+1<#B-[VIW#04#Q6D"Z"T@]
M[R&19_F!6;:8:;4%[;P)S4U\J3Z:R''I+F5E-5DYQ=G%5[KW+\H86**&5<,T
MSB)+N,X:E3N,RP$C?04C@QLE;6/@6E98O8R/B,^>5/I,ZC(]"7C#]!ED20AI
MG(Y.X&7[(C./E[V"=\VTY')S4"3\O%@;J^E-_#I6[P"7'X=S.IF:CI4X#T@(
M!O4C!HNW;Y)Q_/X$V7Q/-C^%_I\W<A+C.,-_@>&N0:B5(&72\0!IUE@F*S<W
MSFY U5"JMB7YT$LL[P$?>O[(!$IK8(N$@$^EZ.G6H=:J!4MXY-_UEGG-47C%
M16_)+BF[<-D[RN[1*;/V$;3#54461U4ZYS66K#<(7#ITQX?\6A)X+RIHV"/2
MIP)&HI:6O_,I2-N =4UBGU)9&O'%H_0OR7UR6/E"5.<(&K *NEZ7#0G[9:5Y
MF*9Q.!H5, K'<1[2[<(MTIOAI6,X./62TT%,PG&:A^-\0JZC21$623&<K_&0
MW+J GFAHN%XMEY!GX["89) D-!89W"G+!"1IF!9I&$\*,H3I^7E8C!,X]J"B
M [FWJ#>^J;E<O;2#\O>[^[YY,;2+O^Y#TR6E;3@=@\":0N.SR2@ /32R86%5
MYYO'6EEJ17[:4.]'[1S(7BMEGQ<NP?YOLO@#4$L#!!0    ( '&,J%KLR0#G
MH0,  #P(   9    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;)5637/;-A#]
M*Q@FS<DC2I3EN(ZD&=M-ISEXZHG[<>CT )(K$@D(T !H6?GU?0M(K-+8GO1"
M$>#NV[</NPLMM]9]]BU1$(^=-GZ5M2'T%WGNJY8ZZ2>V)X,O&^LZ&;!T3>Y[
M1[*.3IW.B^GT+.^D,MEZ&?=NW7IIAZ"5H5LG_-!UTNVN2-OM*IMEAXV/JFD#
M;^3K92\;NJ/P>W_KL,I'E%IU9+RR1CC:K+++V<75*=M'@S\4;?W1N^!,2FL_
M\^)#O<JF3(@T58$1)'X>Z)JT9B#0N-]C9F-(=CQ^/Z#_''-'+J7T=&WUGZH.
M[2H[ST1-&SGH\-%N?Z%]/@O&JZSV\2FVR;;X,1/5X(/M]LY@T"F3?N7C7H<C
MA_/I,P[%WJ&(O%.@R/(G&>1ZZ>Q6.+8&&K_$5*,WR"G#AW(7'+XJ^(7UW5!Z
MNA_(!/'^ <]E'H#*W_)JCW"5$(IG$.;BQIK0>O'>U%1_[9^#S4BI.%"Z*EX$
MO)%N(N:S$U%,B\4+>/,QQ7G$FW]GBE[\=5GZX% 0?S^5;D([?1J-F^3"][*B
M588N\.0>*%N_>34[F[Y[@>OIR/7T)?3O.H[_AR!^->)&[L19TO-$!(NJK=#
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MGSTL@3%+9&3\ZCB]OJ0%'J\/[+?.N_&R(0J6@OVDN2X2[\I#.6Q)S?2]:+Y
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M_\E^_+"1U"Y+M6CLQ )3O1)S 5Q5_8Z#@_PHG\-._+@7Q+VA])8WN9/<ZRQ
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;)U6;6_;-A#^*P<UZQ)
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MV0WT?BZEV=Y8!_V$/_X'4$L#!!0    ( '&,J%KX<C8/& ,  *,&   9
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;(U5VV[;.!#]E8$6*'8!-;I8MM74
M-I"D6;3 MC#B;/M0](&61A81BE1)*D[_?H>4K-I8U^B+>)LY/(<<'BWV2C^9
M&M'"2R.D60:UM>UU%)FBQH:9*]6BI)5*Z899&NI=9%J-K/1)C8C2.)Y%#>,R
M6"W\W%JO%JJS@DM<:S!=TS#]XQ:%VB^#)#A,//!=;=U$M%JT;(<;M/^V:TVC
M:$0I>8/2<"5!8[4,;I+KV\S%^X#/'/?FJ ].R5:I)S?X4"Z#V!%"@85U"(R:
M9[Q#(1P0T?@^8 ;CEB[QN'] _]MK)RU;9O!.B2^\M/4RR ,HL6*=L ]J_QX'
M/5.'5RAA_!?V0VP<0-$9JYHAF1@T7/8M>QG.X7<2TB$A];S[C3S+=\RRU4*K
M/6@736BNXZ7Z;"+'I;N4C=6TRBG/KC[1O?^CC($U:MC43"/\^<BV LU?B\C2
M!BXL*@:PVQXL_078!#XJ:6L#][+$\C0_(F(CN_3 [C:]"/B1Z2N8)"&D<3J]
M@#<9U4X\WN07>/=,2RYWQVJ_WFR-U50<W\[I[>&R\W#NP5R;EA6X#.A%&-3/
M&*Q>_9',XK<7R&8CV>P2^FI##[#L!(*J>J[&]>Y4TU U;ZPJGN#^>\>?F4!I
MZ<Q?"M'1L4.E5>/"VLXR7_F4]8Z+SM+:_Z_[G.J+O,ZK?JP1*B7HC=/Y KU^
M8YDL7=^,U(N>NO'4\8CZ'NDB\(2_);SB5$,Y:)"D03@-+6GPZ+2S]ADTPU5)
M*XZ7=,%;+%AG$+ATZ(X/Q35D%9THH6;/2)\2&-F#M/RUWX)< K"JR#:NX;'6
MB"=5[4O1?;+A#E3K"!JP"MI.%S59Q*G2+$S3.)Q.<YB&LS@+J3S@ :GH>.$8
M]D&=Y'00\W"69N$LFU/H=)Z'>9(?KMY!<NL2.J*AX7ZS7D,VF87Y? ))0FT^
M@4=EF8 D#=,\#>-Y3@MA^N9-F,\2.%>1T9%Q-*AWWA[=7IVTO8>,LZ,#W_3&
M\S.\MV]ZJCM.QR"PHM3X:CX-0/>6V ^L:KT-;94E4_/=FOXBJ%T K5=*V</
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M/#^?T+_XV"F6'3-XK\1/GMO](O@80(X%:X3=J/8K]O','%ZFA/%?:#O=V]L
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MG9$#$K+"12J_LMTG4A<4:KPE2T7Y"79UK.> 92$DR^IDQ2"C>?6-7^I&'"3
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MF<+""(9-6(=LT) ->LD^$"%NU)JQ++(B50I/U*VN>J(D7RTFBCS.&)?TG_*
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M2E=7VZST]P\(8Z#GMYRKIXXIL<,75?X34$L#!!0    ( '&,J%H!2![%'@,
M !\(   9    >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;*U646_3,!#^*Z>
M$)-@:9,V@=%&6CL0>YB86L8>$ ]><FTL'#O83CO^/6>G"UV753SPLMC.?5^^
MN\^]VV2K]$]3(EJXKX0TTZ"TMCX+0Y.76#%SJFJ4]&:E=,4L;?4Z-+5&5GA0
M)<)H,$C"BG$99!-_=JVSB6JLX!*O-9BFJIC^/4.AMM-@&#P<+/BZM.X@S"8U
M6^,2[4U]K6D7=BP%KU :KB1H7$V#\^'9/'7Q/N ;QZW96X/+Y$ZIGVYS64R#
M@1.$ G/K&!@]-CA'(1P1R?BUXPRZ3SK@_OJ!_9//G7*Y8P;G2MSRPI;3X%T
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MAMV'U3Z8Q&VL2>RN[5+FWZ_S03Y:DZ$:K_I"D_3>DWO//3*'RV3+Q3>9$*+
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MZ?HNFUMZ8,&X"32^UAJ?.NX.;Y[L^"=02P,$%     @ <8RH6AR-:ZUI @
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M]Z=VTA--3EERD^=BA3LOM6MZ^#JNF#2$PQ)=H_,1:NBVD;03JQK_>-\IBZW
M#VOLO:"= >XOE;)/$]</^FY>_ )02P,$%     @ <8RH6MN4<6^A P  B X
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M+[Y]Z+O.:#BU]_7<6JR&KC>IK!I!#ZJ@!YU!+[@TGX. /;!=:W2= *\]H)[
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M8QRE,"T#  #J$@  #0   'AL+W-T>6QE<RYX;6S=6&UOVC 0_BN1NTZM-#5
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M>V<J2FT&465%&:CJ#33:?ZAKU$I;U7R%Y@.4U]+4<R_289=9K(Y3M+_JC/D
M9=_L%R>;_7>__3?+=[\ 4$L#!!0    ( '&,J%KN2=W_G@$   @:   :
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M^W?J'=/U%.*CY[[&^[^3ZM1=&QZWORWOFR^/R@UG!S]^%K]02P,$%     @
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M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
M<8RH6JPN)[_Q    *P(  !$              ( !PP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ <8RH6IE<G",0!@  G"<  !,
M ( !XP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !QC*A:[\Z5
MS4H&  "S(P  &               @($D"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ <8RH6O9/?>4C!@  LQH  !@
M ("!I X  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( '&,
MJ%JKN"J)704  &P6   8              " @?T4  !X;"]W;W)K<VAE971S
M+W-H965T,RYX;6Q02P$"% ,4    " !QC*A:?]EGNCP#  "L"0  &
M        @(&0&@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%
M  @ <8RH6M#\<BFJ!@  .3D  !@              ("! AX  'AL+W=O<FMS
M:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( '&,J%J@L5NZ30<  $0@   8
M              " @>(D  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"
M% ,4    " !QC*A:5)SZ\K\&   0$0  &               @(%E+   >&PO
M=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ <8RH6EK$=B:2"0
M!!D  !@              ("!6C,  'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;%!+ 0(4 Q0    ( '&,J%HG 9#0N@P  )TB   8              " @2(]
M  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !QC*A:]!(!
M)Z 4  #+3   &0              @($22@  >&PO=V]R:W-H965T<R]S:&5E
M=#$P+GAM;%!+ 0(4 Q0    ( '&,J%K2-  ?3P(  "@%   9
M  " @>E>  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @
M<8RH6O=%\/08"   RQ0  !D              ("!;V$  'AL+W=O<FMS:&5E
M=',O<VAE970Q,BYX;6Q02P$"% ,4    " !QC*A:A'(G;?4"  !9!@  &0
M            @(&^:0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4
M Q0    ( '&,J%KLR0#GH0,  #P(   9              " @>IL  !X;"]W
M;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ <8RH6N8P*'-% @
MF@4  !D              ("!PG   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
M;6Q02P$"% ,4    " !QC*A:RJ<#54$$   X$   &0              @($^
M<P  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( '&,J%J+
M(39S!PL  "(>   9              " @;9W  !X;"]W;W)K<VAE971S+W-H
M965T,3<N>&UL4$L! A0#%     @ <8RH6OO$!!6I"   )1D  !D
M     ("!]((  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '&,J%J.8P8S=@0  ,<7   9              "
M@9Z:  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ <8RH
M6G3-BV8+!P  !#   !D              ("!2Y\  'AL+W=O<FMS:&5E=',O
M<VAE970R-"YX;6Q02P$"% ,4    " !QC*A:@^FVO+X"   O!P  &0
M        @(&-I@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0
M   ( '&,J%HH>9B>F@0  'X9   9              " @8*I  !X;"]W;W)K
M<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ <8RH6JP6A'?I @  # @
M !D              ("!4ZX  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q0
M2P$"% ,4    " !QC*A:$.GZX$\#  !="0  &0              @(%SL0
M>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( '&,J%H!2![%
M'@,  !\(   9              " @?FT  !X;"]W;W)K<VAE971S+W-H965T
M,CDN>&UL4$L! A0#%     @ <8RH6B2(DEBA @  *08  !D
M ("!3K@  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " !Q
MC*A:*\TVJ,L$   P'0  &0              @($FNP  >&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( '&,J%JHGF!YA 0  /08   9
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M970S-BYX;6Q02P$"% ,4    " !QC*A:VY1Q;Z$#  "(#@  &0
M    @('HT   >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (
M '&,J%K-*$QS1P,  ,\*   9              " @<#4  !X;"]W;W)K<VAE
M971S+W-H965T,S@N>&UL4$L! A0#%     @ <8RH6@G8"EH6 P  M@D  !D
M             ("!/M@  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"
M% ,4    " !QC*A:WB@XQ3T(  #G50  &0              @(&+VP  >&PO
M=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( '&,J%K^+)T.F0(
M !0&   9              " @?_C  !X;"]W;W)K<VAE971S+W-H965T-#$N
M>&UL4$L! A0#%     @ <8RH6J/<G=^O P  UP\  !D              ("!
MS^8  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " !QC*A:
MY?SF+X$"  #9!P  &0              @(&UZ@  >&PO=V]R:W-H965T<R]S
M:&5E=#0S+GAM;%!+ 0(4 Q0    ( '&,J%IC'*4P+0,  .H2   -
M      "  6WM  !X;"]S='EL97,N>&UL4$L! A0#%     @ <8RH6I>*NQS
M    $P(   L              ( !Q?   %]R96QS+RYR96QS4$L! A0#%
M  @ <8RH6F>,X"#% P  -QT   \              ( !KO$  'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( '&,J%KN2=W_G@$   @:   :
M  "  :#U  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M '&,J%JHRH?9JP$  $$:   3              "  7;W  !;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     S #, W T  %+Y      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>138</ContextCount>
  <ElementCount>231</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>61</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - Condensed Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - Description of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/DescriptionofBusinessandBasisofPresentation</Role>
      <ShortName>Description of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Other Financial Statement Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/OtherFinancialStatementInformation</Role>
      <ShortName>Other Financial Statement Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Capital Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/CapitalStock</Role>
      <ShortName>Capital Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Equity Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/EquityIncentivePlans</Role>
      <ShortName>Equity Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.10xgenomics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Other Financial Statement Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/OtherFinancialStatementInformationTables</Role>
      <ShortName>Other Financial Statement Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.10xgenomics.com/role/OtherFinancialStatementInformation</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.10xgenomics.com/role/CommitmentsandContingencies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Equity Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/EquityIncentivePlansTables</Role>
      <ShortName>Equity Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.10xgenomics.com/role/EquityIncentivePlans</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.10xgenomics.com/role/NetLossPerShare</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Other Financial Statement Information - Available-for-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails</Role>
      <ShortName>Other Financial Statement Information - Available-for-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Other Financial Statement Information - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails</Role>
      <ShortName>Other Financial Statement Information - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Other Financial Statement Information - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofInventoryDetails</Role>
      <ShortName>Other Financial Statement Information - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Other Financial Statement Information - Schedule Of Property Plant And Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail</Role>
      <ShortName>Other Financial Statement Information - Schedule Of Property Plant And Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Other Financial Statement Information - Schedule of Accrued Compensation and Related Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedCompensationandRelatedBenefitsDetails</Role>
      <ShortName>Other Financial Statement Information - Schedule of Accrued Compensation and Related Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Other Financial Statement Information - Schedule of Accrued Expense And Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedExpenseAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Other Financial Statement Information - Schedule of Accrued Expense And Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Other Financial Statement Information - Schedule of Changes in the Reserve for Product Warranties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofChangesintheReserveforProductWarrantiesDetails</Role>
      <ShortName>Other Financial Statement Information - Schedule of Changes in the Reserve for Product Warranties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Other Financial Statement Information - Schedule of Revenue of Recognized in Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenueofRecognizedinContractLiabilitiesDetails</Role>
      <ShortName>Other Financial Statement Information - Schedule of Revenue of Recognized in Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Other Financial Statement Information - Schedule of Revenue by Source (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebySourceDetails</Role>
      <ShortName>Other Financial Statement Information - Schedule of Revenue by Source (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Other Financial Statement Information - Schedule of Revenue by Geographic Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebyGeographicRegionDetails</Role>
      <ShortName>Other Financial Statement Information - Schedule of Revenue by Geographic Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Commitments and Contingencies - Schedule of Company's Operating Lease Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail</Role>
      <ShortName>Commitments and Contingencies - Schedule of Company's Operating Lease Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Commitments and Contingencies - Schedule of Additional Information Related to Operating Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofAdditionalInformationRelatedtoOperatingLeasesDetail</Role>
      <ShortName>Commitments and Contingencies - Schedule of Additional Information Related to Operating Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Capital Stock - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/CapitalStockAdditionalInformationDetail</Role>
      <ShortName>Capital Stock - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Equity Incentive Plans - Schedule of Recorded Stock-Based Compensation Expense in the Condensed Consolidated Statement of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRecordedStockBasedCompensationExpenseintheCondensedConsolidatedStatementofOperationsDetails</Role>
      <ShortName>Equity Incentive Plans - Schedule of Recorded Stock-Based Compensation Expense in the Condensed Consolidated Statement of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Equity Incentive Plans - Schedule of RSU Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRSUActivityDetail</Role>
      <ShortName>Equity Incentive Plans - Schedule of RSU Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Equity Incentive Plans - Schedule of Company's Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofCompanysStockOptionActivityDetails</Role>
      <ShortName>Equity Incentive Plans - Schedule of Company's Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Equity Incentive Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails</Role>
      <ShortName>Equity Incentive Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Equity Incentive Plans - Fair Values of Shares Under the Performance Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/EquityIncentivePlansFairValuesofSharesUnderthePerformanceStockUnitsDetails</Role>
      <ShortName>Equity Incentive Plans - Fair Values of Shares Under the Performance Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Net Loss Per Share - Shares of Common Stock Equivalents Were Excluded From The Computation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/NetLossPerShareSharesofCommonStockEquivalentsWereExcludedFromTheComputationofDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Shares of Common Stock Equivalents Were Excluded From The Computation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="txg-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.10xgenomics.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.10xgenomics.com/role/SubsequentEvent</ParentRole>
      <Position>43</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="txg-20250331.htm">txg-20250331.htm</File>
    <File>txg-20250331.xsd</File>
    <File>txg-20250331_cal.xml</File>
    <File>txg-20250331_def.xml</File>
    <File>txg-20250331_lab.xml</File>
    <File>txg-20250331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>txg-20250331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="451">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="10">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>63
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "txg-20250331.htm": {
   "nsprefix": "txg",
   "nsuri": "http://www.10xgenomics.com/20250331",
   "dts": {
    "inline": {
     "local": [
      "txg-20250331.htm"
     ]
    },
    "schema": {
     "local": [
      "txg-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "txg-20250331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "txg-20250331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "txg-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "txg-20250331_pre.xml"
     ]
    }
   },
   "keyStandard": 217,
   "keyCustom": 14,
   "axisStandard": 18,
   "axisCustom": 0,
   "memberStandard": 37,
   "memberCustom": 22,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/dei/2024": 5,
    "http://fasb.org/us-gaap/2024": 1
   },
   "contextCount": 138,
   "entityCount": 1,
   "segmentCount": 61,
   "elementCount": 475,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 451,
    "http://xbrl.sec.gov/dei/2024": 30,
    "http://xbrl.sec.gov/ecd/2024": 10
   },
   "report": {
    "R1": {
     "role": "http://www.10xgenomics.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations",
     "longName": "9952152 - Statement - Condensed Consolidated Statements of Operations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
     "longName": "9952153 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "longName": "9952154 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-25",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-25",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows",
     "longName": "9952155 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.10xgenomics.com/role/DescriptionofBusinessandBasisofPresentation",
     "longName": "9952156 - Disclosure - Description of Business and Basis of Presentation",
     "shortName": "Description of Business and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.10xgenomics.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952157 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.10xgenomics.com/role/OtherFinancialStatementInformation",
     "longName": "9952158 - Disclosure - Other Financial Statement Information",
     "shortName": "Other Financial Statement Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.10xgenomics.com/role/CommitmentsandContingencies",
     "longName": "9952159 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.10xgenomics.com/role/CapitalStock",
     "longName": "9952160 - Disclosure - Capital Stock",
     "shortName": "Capital Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.10xgenomics.com/role/EquityIncentivePlans",
     "longName": "9952161 - Disclosure - Equity Incentive Plans",
     "shortName": "Equity Incentive Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.10xgenomics.com/role/NetLossPerShare",
     "longName": "9952162 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.10xgenomics.com/role/SubsequentEvent",
     "longName": "9952163 - Disclosure - Subsequent Event",
     "shortName": "Subsequent Event",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R16": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.10xgenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationTables",
     "longName": "9955512 - Disclosure - Other Financial Statement Information (Tables)",
     "shortName": "Other Financial Statement Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.10xgenomics.com/role/CommitmentsandContingenciesTables",
     "longName": "9955513 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.10xgenomics.com/role/EquityIncentivePlansTables",
     "longName": "9955514 - Disclosure - Equity Incentive Plans (Tables)",
     "shortName": "Equity Incentive Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.10xgenomics.com/role/NetLossPerShareTables",
     "longName": "9955515 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.10xgenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
     "longName": "9955516 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ProductWarrantyObligationTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ProductWarrantyObligationTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails",
     "longName": "9955517 - Disclosure - Other Financial Statement Information - Available-for-Sale Securities (Details)",
     "shortName": "Other Financial Statement Information - Available-for-Sale Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails",
     "longName": "9955518 - Disclosure - Other Financial Statement Information - Additional Information (Details)",
     "shortName": "Other Financial Statement Information - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofInventoryDetails",
     "longName": "9955519 - Disclosure - Other Financial Statement Information - Schedule of Inventory (Details)",
     "shortName": "Other Financial Statement Information - Schedule of Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail",
     "longName": "9955520 - Disclosure - Other Financial Statement Information - Schedule Of Property Plant And Equipment (Detail)",
     "shortName": "Other Financial Statement Information - Schedule Of Property Plant And Equipment (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedCompensationandRelatedBenefitsDetails",
     "longName": "9955521 - Disclosure - Other Financial Statement Information - Schedule of Accrued Compensation and Related Benefits (Details)",
     "shortName": "Other Financial Statement Information - Schedule of Accrued Compensation and Related Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "txg:AccruedPayrollAndRelatedCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "txg:ScheduleOfAccruedCompensationandRelatedBenefitsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "txg:AccruedPayrollAndRelatedCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "txg:ScheduleOfAccruedCompensationandRelatedBenefitsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedExpenseAndOtherCurrentLiabilitiesDetails",
     "longName": "9955522 - Disclosure - Other Financial Statement Information - Schedule of Accrued Expense And Other Current Liabilities (Details)",
     "shortName": "Other Financial Statement Information - Schedule of Accrued Expense And Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "txg:AccruedLegalAndRelatedExpensesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "txg:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "txg:AccruedLegalAndRelatedExpensesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "txg:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofChangesintheReserveforProductWarrantiesDetails",
     "longName": "9955523 - Disclosure - Other Financial Statement Information - Schedule of Changes in the Reserve for Product Warranties (Details)",
     "shortName": "Other Financial Statement Information - Schedule of Changes in the Reserve for Product Warranties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ProductWarrantyAccrual",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ProductWarrantyAccrual",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenueofRecognizedinContractLiabilitiesDetails",
     "longName": "9955524 - Disclosure - Other Financial Statement Information - Schedule of Revenue of Recognized in Contract Liabilities (Details)",
     "shortName": "Other Financial Statement Information - Schedule of Revenue of Recognized in Contract Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebySourceDetails",
     "longName": "9955525 - Disclosure - Other Financial Statement Information - Schedule of Revenue by Source (Details)",
     "shortName": "Other Financial Statement Information - Schedule of Revenue by Source (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-74",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebyGeographicRegionDetails",
     "longName": "9955526 - Disclosure - Other Financial Statement Information - Schedule of Revenue by Geographic Region (Details)",
     "shortName": "Other Financial Statement Information - Schedule of Revenue by Geographic Region (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-88",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail",
     "longName": "9955527 - Disclosure - Commitments and Contingencies - Schedule of Company's Operating Lease Liabilities (Detail)",
     "shortName": "Commitments and Contingencies - Schedule of Company's Operating Lease Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofAdditionalInformationRelatedtoOperatingLeasesDetail",
     "longName": "9955528 - Disclosure - Commitments and Contingencies - Schedule of Additional Information Related to Operating Leases (Detail)",
     "shortName": "Commitments and Contingencies - Schedule of Additional Information Related to Operating Leases (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "txg:DisclosureOfAdditionalInformationRelatedToOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "txg:DisclosureOfAdditionalInformationRelatedToOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.10xgenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
     "longName": "9955529 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-100",
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-100",
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.10xgenomics.com/role/CapitalStockAdditionalInformationDetail",
     "longName": "9955530 - Disclosure - Capital Stock - Additional Information (Detail)",
     "shortName": "Capital Stock - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-102",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-102",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRecordedStockBasedCompensationExpenseintheCondensedConsolidatedStatementofOperationsDetails",
     "longName": "9955531 - Disclosure - Equity Incentive Plans - Schedule of Recorded Stock-Based Compensation Expense in the Condensed Consolidated Statement of Operations (Details)",
     "shortName": "Equity Incentive Plans - Schedule of Recorded Stock-Based Compensation Expense in the Condensed Consolidated Statement of Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRSUActivityDetail",
     "longName": "9955532 - Disclosure - Equity Incentive Plans - Schedule of RSU Activity (Detail)",
     "shortName": "Equity Incentive Plans - Schedule of RSU Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofCompanysStockOptionActivityDetails",
     "longName": "9955533 - Disclosure - Equity Incentive Plans - Schedule of Company's Stock Option Activity (Details)",
     "shortName": "Equity Incentive Plans - Schedule of Company's Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails",
     "longName": "9955534 - Disclosure - Equity Incentive Plans - Additional Information (Details)",
     "shortName": "Equity Incentive Plans - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-119",
      "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.10xgenomics.com/role/EquityIncentivePlansFairValuesofSharesUnderthePerformanceStockUnitsDetails",
     "longName": "9955535 - Disclosure - Equity Incentive Plans - Fair Values of Shares Under the Performance Stock Units (Details)",
     "shortName": "Equity Incentive Plans - Fair Values of Shares Under the Performance Stock Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-120",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-120",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.10xgenomics.com/role/NetLossPerShareSharesofCommonStockEquivalentsWereExcludedFromTheComputationofDilutedNetLossPerShareDetails",
     "longName": "9955536 - Disclosure - Net Loss Per Share - Shares of Common Stock Equivalents Were Excluded From The Computation of Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Shares of Common Stock Equivalents Were Excluded From The Computation of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.10xgenomics.com/role/SubsequentEventsDetails",
     "longName": "9955537 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-133",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-133",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "txg-20250331.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r684"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_AccruedBonusesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedBonusesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedCompensationandRelatedBenefitsDetails": {
       "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedCompensationandRelatedBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued bonus",
        "label": "Accrued Bonuses, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "txg_AccruedCommissionsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "AccruedCommissionsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedCompensationandRelatedBenefitsDetails": {
       "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedCompensationandRelatedBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued commissions",
        "label": "Accrued Commissions Current",
        "documentation": "Accrued commissions, Current"
       }
      }
     },
     "auth_ref": []
    },
    "txg_AccruedExpensesAndOtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "AccruedExpensesAndOtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedExpenseAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedExpenseAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Accrued expenses and other current liabilities",
        "label": "Accrued Expenses And Other Liabilities Current",
        "documentation": "Accrued Expenses And Other Liabilities Current"
       }
      }
     },
     "auth_ref": []
    },
    "txg_AccruedLegalAndRelatedExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "AccruedLegalAndRelatedExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedExpenseAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "txg_AccruedExpensesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedExpenseAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Legal and related costs",
        "label": "Accrued Legal And Related Expenses Current",
        "documentation": "Accrued legal expenses current."
       }
      }
     },
     "auth_ref": []
    },
    "txg_AccruedPayrollAndRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "AccruedPayrollAndRelatedCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedCompensationandRelatedBenefitsDetails": {
       "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedCompensationandRelatedBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued payroll and related costs",
        "label": "Accrued Payroll And Related Costs",
        "documentation": "Accrued Payroll And Related Costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedExpenseAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "txg_AccruedExpensesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedExpenseAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional services",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedRoyaltiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedExpenseAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "txg_AccruedExpensesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedExpenseAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties for licensed technologies",
        "label": "Accrued Royalties, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r643"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r115",
      "r502"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r65",
      "r122",
      "r499",
      "r527",
      "r528"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r9",
      "r17",
      "r376",
      "r379",
      "r418",
      "r523",
      "r524",
      "r812",
      "r813",
      "r814",
      "r820",
      "r821",
      "r822",
      "r824"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Financial Statement Information",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additional\u00a0Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r820",
      "r821",
      "r822",
      "r824",
      "r893",
      "r947"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r322"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r719",
      "r729",
      "r739",
      "r771"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r732",
      "r742",
      "r774"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r733",
      "r743",
      "r767",
      "r775",
      "r779",
      "r787"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRecordedStockBasedCompensationExpenseintheCondensedConsolidatedStatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r355"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "txg_AmericasExcludingUnitedStatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "AmericasExcludingUnitedStatesMember",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Americas (excluding United States)",
        "label": "Americas, Excluding United States [Member]",
        "documentation": "Americas, Excluding United States"
       }
      }
     },
     "auth_ref": []
    },
    "srt_AmericasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "AmericasMember",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Americas",
        "label": "Americas [Member]"
       }
      }
     },
     "auth_ref": [
      "r949",
      "r950",
      "r951",
      "r952"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.10xgenomics.com/role/NetLossPerShareSharesofCommonStockEquivalentsWereExcludedFromTheComputationofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.10xgenomics.com/role/NetLossPerShareSharesofCommonStockEquivalentsWereExcludedFromTheComputationofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.10xgenomics.com/role/NetLossPerShareSharesofCommonStockEquivalentsWereExcludedFromTheComputationofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.10xgenomics.com/role/NetLossPerShareSharesofCommonStockEquivalentsWereExcludedFromTheComputationofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "txg_AsiaPacificExcludingChinaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "AsiaPacificExcludingChinaMember",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asia-Pacific (excluding China)",
        "label": "Asia-Pacific, Excluding China [Member]",
        "documentation": "Asia-Pacific, Excluding China"
       }
      }
     },
     "auth_ref": []
    },
    "srt_AsiaPacificMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "AsiaPacificMember",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asia-Pacific",
        "label": "Asia Pacific [Member]"
       }
      }
     },
     "auth_ref": [
      "r949",
      "r950",
      "r951",
      "r952"
     ]
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetBackedSecuritiesMember",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset-backed securities",
        "label": "Asset-Backed Securities [Member]",
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans."
       }
      }
     },
     "auth_ref": [
      "r665",
      "r685",
      "r835",
      "r836",
      "r837"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r103",
      "r118",
      "r144",
      "r175",
      "r179",
      "r194",
      "r195",
      "r235",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r371",
      "r373",
      "r399",
      "r495",
      "r574",
      "r654",
      "r655",
      "r684",
      "r710",
      "r859",
      "r860",
      "r903"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r124",
      "r144",
      "r235",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r371",
      "r373",
      "r399",
      "r684",
      "r859",
      "r860",
      "r903"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails": {
       "parentTag": "txg_DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails": {
       "parentTag": "txg_DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Marketable securities:",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r243",
      "r494"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Marketable securities, fair value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r243",
      "r387",
      "r488",
      "r671",
      "r676",
      "r833",
      "r895",
      "r896",
      "r897"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Debt Securities, Available-for-Sale, Current",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r243"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.10xgenomics.com/role/EquityIncentivePlansFairValuesofSharesUnderthePerformanceStockUnitsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.10xgenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BuildingMember",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Building",
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.10xgenomics.com/role/DescriptionofBusinessandBasisofPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business and Basis of Presentation",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r77",
      "r78"
     ]
    },
    "country_CN": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "CN",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "China",
        "label": "CHINA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r74",
      "r141"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r74"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r808",
      "r912"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "txg_ChromiumConsumablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "ChromiumConsumablesMember",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebySourceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chromium",
        "label": "Chromium - Consumables [Member]",
        "documentation": "Chromium - Consumables"
       }
      }
     },
     "auth_ref": []
    },
    "txg_ChromiumInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "ChromiumInstrumentsMember",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebySourceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chromium",
        "label": "Chromium - Instruments [Member]",
        "documentation": "Chromium - Instruments"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.10xgenomics.com/role/CapitalStockAdditionalInformationDetail",
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.10xgenomics.com/role/CoverPage",
      "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r119",
      "r120",
      "r121",
      "r144",
      "r165",
      "r166",
      "r168",
      "r170",
      "r177",
      "r178",
      "r235",
      "r268",
      "r270",
      "r271",
      "r272",
      "r275",
      "r276",
      "r281",
      "r282",
      "r285",
      "r288",
      "r295",
      "r399",
      "r531",
      "r532",
      "r533",
      "r534",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r562",
      "r583",
      "r601",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r797",
      "r818",
      "r825"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.10xgenomics.com/role/CapitalStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r177",
      "r281",
      "r282",
      "r283",
      "r285",
      "r288",
      "r293",
      "r295",
      "r531",
      "r532",
      "r533",
      "r534",
      "r662",
      "r797",
      "r818"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 4)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r96",
      "r496",
      "r561"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.10xgenomics.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r255",
      "r256",
      "r625",
      "r847",
      "r850"
     ]
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://www.10xgenomics.com/role/CapitalStockAdditionalInformationDetail",
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.10xgenomics.com/role/CoverPage",
      "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Class A",
        "verboseLabel": "Common Class A",
        "label": "Common Class A [Member]",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://www.10xgenomics.com/role/CapitalStockAdditionalInformationDetail",
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Class B",
        "verboseLabel": "Common Class B",
        "label": "Common Class B [Member]",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock reserved for issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r701",
      "r702",
      "r703",
      "r705",
      "r706",
      "r707",
      "r708",
      "r820",
      "r821",
      "r824",
      "r893",
      "r944",
      "r947"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.10xgenomics.com/role/CapitalStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.10xgenomics.com/role/CapitalStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock shares outstanding (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r56",
      "r562",
      "r580",
      "r947",
      "r948"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r498",
      "r684"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "txg_CompoundAnnualGrowthRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "CompoundAnnualGrowthRateMember",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CAGR",
        "label": "Compound Annual Growth Rate [Member]",
        "documentation": "Compound Annual Growth Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r129",
      "r131",
      "r135",
      "r489",
      "r508",
      "r509"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails",
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Computer equipment and software",
        "terseLabel": "Computer equipment and software",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Line Items]",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Table]",
        "label": "Concentration Risk [Table]",
        "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r29",
      "r45",
      "r93",
      "r624"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "txg_ConsumablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "ConsumablesMember",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebySourceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consumables",
        "label": "Consumables [Member]",
        "documentation": "Consumables member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue of Recognized in Deferred Revenue",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liability",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r298",
      "r309"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred revenue",
        "terseLabel": "Deferred revenue",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r298",
      "r309"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, noncurrent",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r298",
      "r309"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenueofRecognizedinContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue recognized",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r665",
      "r667",
      "r671",
      "r685",
      "r699",
      "r941"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of products and services revenue",
        "label": "Cost of Revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r144",
      "r235",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r399",
      "r654",
      "r859"
     ]
    },
    "txg_CostOfRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "CostOfRevenueMember",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of revenue",
        "label": "Cost of Revenue [Member]",
        "documentation": "Cost of Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRecordedStockBasedCompensationExpenseintheCondensedConsolidatedStatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cost of revenue",
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r277",
      "r283",
      "r419",
      "r439",
      "r493",
      "r646",
      "r648"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "txg_DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total available-for-sale securities, amortized cost",
        "label": "Debt Securities, Available For Sale, Amortized Cost Including Money Market Funds",
        "documentation": "Debt Securities, Available For Sale, Amortized Cost Including Money Market Funds"
       }
      }
     },
     "auth_ref": []
    },
    "txg_DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails": {
       "parentTag": "txg_DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total available-for-sale securities, fair value",
        "label": "Debt Securities, Available For Sale, Including Money Market Funds",
        "documentation": "Debt Securities, Available For Sale, Including Money Market Funds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities, available-for-sale, realized gain (loss)",
        "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)",
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r175",
      "r184",
      "r195",
      "r654",
      "r655"
     ]
    },
    "txg_DisclosureOfAdditionalInformationRelatedToOperatingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "DisclosureOfAdditionalInformationRelatedToOperatingLeasesTableTextBlock",
     "presentation": [
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Additional Information Related to Operating Leases",
        "label": "Disclosure of Additional Information Related To Operating Leases [Table Text Block]",
        "documentation": "Disclosure of additional information related to operating leases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Incentive Plans",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r324",
      "r352",
      "r353",
      "r354",
      "r669"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Recorded Stock-based Compensation Expense in the Condensed Consolidated Statement of Operations",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r40"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "us-gaap_EMEAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EMEAMember",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Europe, Middle East and Africa",
        "label": "EMEA [Member]",
        "documentation": "Regions of Europe, Middle East and Africa."
       }
      }
     },
     "auth_ref": [
      "r949",
      "r950",
      "r951",
      "r952"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r163",
      "r165",
      "r168",
      "r169",
      "r170",
      "r174",
      "r367",
      "r370",
      "r384",
      "r385",
      "r490",
      "r510",
      "r649"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r165",
      "r168",
      "r169",
      "r170",
      "r174",
      "r367",
      "r370",
      "r384",
      "r385",
      "r490",
      "r510",
      "r649"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.10xgenomics.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r171",
      "r172",
      "r173"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rates changes on cash, cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based payment arrangement recognized",
        "label": "Employee Benefits and Share-Based Compensation",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedCompensationandRelatedBenefitsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedCompensationandRelatedBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued compensation and related benefits",
        "totalLabel": "Accrued compensation and related benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRecordedStockBasedCompensationExpenseintheCondensedConsolidatedStatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.10xgenomics.com/role/NetLossPerShareSharesofCommonStockEquivalentsWereExcludedFromTheComputationofDilutedNetLossPerShareDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options to purchase common stock",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Information [Line Items]",
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebySourceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from External Customer [Line Items]",
        "label": "Revenue from External Customer [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r110",
      "r132",
      "r133",
      "r134",
      "r147",
      "r148",
      "r149",
      "r151",
      "r156",
      "r158",
      "r160",
      "r176",
      "r236",
      "r237",
      "r249",
      "r296",
      "r361",
      "r362",
      "r364",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r383",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r408",
      "r409",
      "r418",
      "r506",
      "r523",
      "r524",
      "r525",
      "r537",
      "r601"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r719",
      "r729",
      "r739",
      "r771"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r716",
      "r726",
      "r736",
      "r768"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r386",
      "r388",
      "r389",
      "r390",
      "r391",
      "r394",
      "r395",
      "r397",
      "r426",
      "r427",
      "r428",
      "r660",
      "r661",
      "r665",
      "r666",
      "r667",
      "r671",
      "r676"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r312",
      "r317",
      "r388",
      "r395",
      "r426",
      "r665",
      "r666",
      "r667",
      "r671"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r312",
      "r317",
      "r388",
      "r389",
      "r395",
      "r427",
      "r660",
      "r661",
      "r665",
      "r666",
      "r667",
      "r671"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r386",
      "r388",
      "r389",
      "r390",
      "r391",
      "r394",
      "r395",
      "r397",
      "r426",
      "r427",
      "r428",
      "r660",
      "r661",
      "r665",
      "r666",
      "r667",
      "r671",
      "r676"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amortization of right-of-use assets",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r413",
      "r683"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r245",
      "r246",
      "r279",
      "r293",
      "r381",
      "r398",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r507",
      "r658",
      "r671",
      "r674",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r685",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r838",
      "r839",
      "r840",
      "r841",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossRealizedAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossRealizedAfterTax",
     "crdr": "credit",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognized foreign currency transaction income (loss)",
        "label": "Realized Gain (Loss), Foreign Currency Transaction, after Tax",
        "documentation": "Amount, after tax, of realized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r621",
      "r622",
      "r945",
      "r946"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r733",
      "r743",
      "r775"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r733",
      "r743",
      "r775"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r733",
      "r743",
      "r775"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r733",
      "r743",
      "r775"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r733",
      "r743",
      "r775"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossRelatedToLitigationSettlement",
     "crdr": "credit",
     "presentation": [
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of lost profits",
        "label": "Gain (Loss) from Litigation Settlement",
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process."
       }
      }
     },
     "auth_ref": [
      "r654",
      "r851"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r247",
      "r487",
      "r655",
      "r659",
      "r673",
      "r684",
      "r843",
      "r844"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r68",
      "r102",
      "r144",
      "r235",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r399",
      "r651",
      "r654",
      "r826",
      "r828",
      "r829",
      "r830",
      "r831",
      "r859"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long lived assets",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r32",
      "r83",
      "r672"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before provision for income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r98",
      "r102",
      "r491",
      "r504",
      "r651",
      "r654",
      "r826",
      "r828",
      "r829",
      "r830",
      "r831"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRecordedStockBasedCompensationExpenseintheCondensedConsolidatedStatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r392",
      "r393",
      "r396",
      "r520",
      "r522",
      "r586",
      "r637",
      "r675",
      "r914"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRecordedStockBasedCompensationExpenseintheCondensedConsolidatedStatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252",
      "r392",
      "r393",
      "r396",
      "r520",
      "r522",
      "r586",
      "r637",
      "r675",
      "r914"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r107",
      "r159",
      "r160",
      "r175",
      "r185",
      "r195",
      "r357",
      "r358",
      "r363",
      "r511",
      "r670"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for taxes",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r140",
      "r359",
      "r360"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "txg_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase Decrease In Accrued Liabilities And Other Current Liabilities",
        "documentation": "Increase decrease in accrued liabilities and other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Deferred Revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and other related benefits",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liability",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r800",
      "r817"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other noncurrent liabilities",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other noncurrent assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r733",
      "r743",
      "r767",
      "r775",
      "r779",
      "r787"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r715",
      "r791"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r715",
      "r791"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r715",
      "r791"
     ]
    },
    "txg_InstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "InstrumentsMember",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebySourceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Instruments",
        "label": "Instruments [Member]",
        "documentation": "Instruments member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r845",
      "r846"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r816"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r644"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventory",
        "totalLabel": "Inventory",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r642",
      "r684"
     ]
    },
    "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchased materials",
        "label": "Inventory, Raw Materials and Supplies, Net of Reserves",
        "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r810"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work in progress",
        "label": "Inventory, Work in Process, Net of Reserves",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r645"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r182",
      "r195",
      "r654",
      "r815"
     ]
    },
    "us-gaap_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LandMember",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land",
        "label": "Land [Member]",
        "documentation": "Part of earth's surface not covered by water."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r417"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Company's Operating Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "txg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, Payments, Due After Year Four",
        "documentation": "Lessee, Operating Lease, Liability, Payments, Due After Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 (excluding the three months ended March 31, 2025)",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r53",
      "r54",
      "r144",
      "r235",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r372",
      "r373",
      "r374",
      "r399",
      "r560",
      "r650",
      "r710",
      "r859",
      "r903",
      "r904"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r97",
      "r501",
      "r684",
      "r819",
      "r842",
      "r900"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r113",
      "r144",
      "r235",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r372",
      "r373",
      "r374",
      "r399",
      "r684",
      "r859",
      "r903",
      "r904"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "txg_LicensingAndRoyaltyRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "LicensingAndRoyaltyRevenueMember",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails",
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebySourceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License and royalty revenue",
        "label": "Licensing And Royalty Revenue [Member]",
        "documentation": "Licensing And Royalty Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LitigationSettlementGain",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gain on settlement",
        "terseLabel": "Gain on settlement",
        "label": "Litigation Settlement, Gain",
        "documentation": "Amount of gain from litigation settlement for amount awarded from other party. Excludes claims within an insurance entity's normal claims settlement process."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyDamagesSoughtValue",
     "crdr": "debit",
     "presentation": [
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingency, damages sought, value",
        "label": "Loss Contingency, Damages Sought, Value",
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r851",
      "r852",
      "r853"
     ]
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Laboratory equipment and machinery",
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "txg_MarketBasedPerformanceAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "MarketBasedPerformanceAwardsMember",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market-based Performance Awards",
        "label": "Market-based Performance Awards [Member]",
        "documentation": "Market-based Performance Awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesLineItems",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities [Line Items]",
        "label": "Marketable Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesTable",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities [Table]",
        "label": "Marketable Securities [Table]",
        "documentation": "Disclosure of information about investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Marketable Securities",
        "label": "Marketable Securities [Table Text Block]",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.10xgenomics.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r318",
      "r356",
      "r391",
      "r455",
      "r519",
      "r521",
      "r529",
      "r552",
      "r553",
      "r606",
      "r608",
      "r610",
      "r611",
      "r613",
      "r635",
      "r636",
      "r657",
      "r662",
      "r668",
      "r676",
      "r677",
      "r681",
      "r682",
      "r695",
      "r861",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.10xgenomics.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r318",
      "r356",
      "r391",
      "r455",
      "r519",
      "r521",
      "r529",
      "r552",
      "r553",
      "r606",
      "r608",
      "r610",
      "r611",
      "r613",
      "r635",
      "r636",
      "r657",
      "r662",
      "r668",
      "r676",
      "r677",
      "r681",
      "r695",
      "r861",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds, at Carrying Value",
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofChangesintheReserveforProductWarrantiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]",
        "label": "Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r76",
      "r99",
      "r111",
      "r127",
      "r130",
      "r134",
      "r144",
      "r150",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r159",
      "r160",
      "r167",
      "r235",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r367",
      "r370",
      "r385",
      "r399",
      "r505",
      "r582",
      "r599",
      "r600",
      "r709",
      "r859"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.10xgenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Pronouncement and Disclosure Rules",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r733",
      "r743",
      "r767",
      "r775"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncash investing and financing activities:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.10xgenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r655",
      "r827"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r651",
      "r826",
      "r828",
      "r829",
      "r830",
      "r831"
     ]
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseImpairmentLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease and asset impairment charges",
        "label": "Operating Lease, Impairment Loss",
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating\u00a0Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of operating lease liabilities",
        "totalLabel": "Total operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail",
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liabilities",
        "terseLabel": "Operating lease liabilities, current",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail",
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liabilities, noncurrent",
        "terseLabel": "Operating lease liabilities, noncurrent",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofAdditionalInformationRelatedtoOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r683"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofAdditionalInformationRelatedtoOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r683"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other noncurrent assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r9",
      "r92"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss), net of tax:",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive income (loss), net of tax",
        "terseLabel": "Other comprehensive income (loss)",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r9",
      "r92",
      "r128",
      "r131",
      "r156"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gains (losses) on available-for-sale marketable securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r234"
     ]
    },
    "us-gaap_OtherEmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherEmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedCompensationandRelatedBenefitsDetails": {
       "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedCompensationandRelatedBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Employee-related Liabilities, Current",
        "documentation": "Amount of obligations incurred for employer-related costs classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedExpenseAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "txg_AccruedExpensesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedExpenseAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r684"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other noncurrent liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense), net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Operating Activities, Cash Flow Statement",
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r721",
      "r731",
      "r741",
      "r773"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r724",
      "r734",
      "r744",
      "r776"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r724",
      "r734",
      "r744",
      "r776"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "us-gaap_PaymentsForRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for royalties",
        "label": "Payments for Royalties",
        "documentation": "The amount of cash paid for royalties during the current period."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.10xgenomics.com/role/EquityIncentivePlansFairValuesofSharesUnderthePerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Stock Units",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r497",
      "r684"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock from exercise of stock options and employee stock purchase plan purchases",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r13"
     ]
    },
    "txg_ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted",
     "crdr": "debit",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of litigation settlement and intellectual property license granted",
        "label": "Proceeds From Litigation Settlement And Intellectual Property License Granted",
        "documentation": "Proceeds From Litigation Settlement And Intellectual Property License Granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturities of marketable securities",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r834"
     ]
    },
    "us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfHeldToMaturitySecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales of marketable securities",
        "label": "Proceeds from Sale of Held-to-Maturity Securities",
        "documentation": "The cash inflow associated with the sale of securities that had been designated as held-to-maturity. Excludes proceeds from maturities, prepayments and calls by the issuer."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r202"
     ]
    },
    "txg_ProductAndServiceRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "ProductAndServiceRevenueMember",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebySourceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Products and services revenue",
        "label": "Product And Service Revenue [Member]",
        "documentation": "Product And Service Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails",
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebySourceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r197",
      "r456",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r640",
      "r663",
      "r694",
      "r695",
      "r696",
      "r698",
      "r700",
      "r854",
      "r855",
      "r863",
      "r913",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r942",
      "r943"
     ]
    },
    "us-gaap_ProductWarrantyAccrual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductWarrantyAccrual",
     "crdr": "credit",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofChangesintheReserveforProductWarrantiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning of period",
        "periodEndLabel": "End of period",
        "label": "Standard and Extended Product Warranty Accrual",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r262",
      "r264",
      "r267"
     ]
    },
    "us-gaap_ProductWarrantyAccrualClassifiedCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductWarrantyAccrualClassifiedCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedExpenseAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "txg_AccruedExpensesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedExpenseAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product warranties",
        "label": "Product Warranty Accrual, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r857",
      "r858"
     ]
    },
    "us-gaap_ProductWarrantyAccrualPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductWarrantyAccrualPayments",
     "crdr": "debit",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofChangesintheReserveforProductWarrantiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repairs and replacements",
        "label": "Standard and Extended Product Warranty Accrual, Decrease for Payments",
        "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "us-gaap_ProductWarrantyAccrualWarrantiesIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductWarrantyAccrualWarrantiesIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofChangesintheReserveforProductWarrantiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts charged to cost of revenue",
        "label": "Standard and Extended Product Warranty Accrual, Increase for Warranties Issued",
        "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued."
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "us-gaap_ProductWarrantyObligationTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductWarrantyObligationTerm",
     "presentation": [
      "http://www.10xgenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product warranty term",
        "label": "Product Warranty Obligation, Term",
        "documentation": "Term of warranty or group of similar warranties, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails",
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebySourceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r197",
      "r456",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r640",
      "r663",
      "r694",
      "r695",
      "r696",
      "r698",
      "r700",
      "r854",
      "r855",
      "r863",
      "r913",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r942",
      "r943"
     ]
    },
    "txg_ProductsAndServicesExcludingGrantRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "ProductsAndServicesExcludingGrantRevenueMember",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Products and Services, Excluding Grant Revenue",
        "label": "Products And Services, Excluding Grant Revenue [Member]",
        "documentation": "Products And Services, Excluding Grant Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails",
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r417"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total property and equipment",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r114",
      "r503"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r417",
      "r492",
      "r503",
      "r684"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails",
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r417"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.10xgenomics.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r311",
      "r318",
      "r347",
      "r348",
      "r349",
      "r356",
      "r391",
      "r429",
      "r438",
      "r455",
      "r519",
      "r521",
      "r529",
      "r552",
      "r553",
      "r606",
      "r608",
      "r610",
      "r611",
      "r613",
      "r635",
      "r636",
      "r657",
      "r662",
      "r668",
      "r676",
      "r677",
      "r681",
      "r682",
      "r695",
      "r703",
      "r848",
      "r861",
      "r896",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.10xgenomics.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r311",
      "r318",
      "r347",
      "r348",
      "r349",
      "r356",
      "r391",
      "r429",
      "r438",
      "r455",
      "r519",
      "r521",
      "r529",
      "r552",
      "r553",
      "r606",
      "r608",
      "r610",
      "r611",
      "r613",
      "r635",
      "r636",
      "r657",
      "r662",
      "r668",
      "r676",
      "r677",
      "r681",
      "r682",
      "r695",
      "r703",
      "r848",
      "r861",
      "r896",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r716",
      "r726",
      "r736",
      "r768"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r277",
      "r283",
      "r419",
      "r439",
      "r493",
      "r647",
      "r648"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRecordedStockBasedCompensationExpenseintheCondensedConsolidatedStatementofOperationsDetails",
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development",
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r717",
      "r727",
      "r737",
      "r769"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r718",
      "r728",
      "r738",
      "r770"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r725",
      "r735",
      "r745",
      "r777"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.10xgenomics.com/role/NetLossPerShareSharesofCommonStockEquivalentsWereExcludedFromTheComputationofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://www.10xgenomics.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected workforce reduction percent",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.10xgenomics.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated restructuring charges",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r253",
      "r254",
      "r849"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r89",
      "r500",
      "r526",
      "r528",
      "r535",
      "r563",
      "r684"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r147",
      "r148",
      "r149",
      "r151",
      "r156",
      "r158",
      "r160",
      "r236",
      "r237",
      "r249",
      "r361",
      "r362",
      "r364",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r375",
      "r377",
      "r378",
      "r380",
      "r383",
      "r408",
      "r409",
      "r523",
      "r525",
      "r537",
      "r947"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails",
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebyGeographicRegionDetails",
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebySourceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "verboseLabel": "Total revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101",
      "r175",
      "r180",
      "r181",
      "r193",
      "r195",
      "r197",
      "r198",
      "r200",
      "r307",
      "r308",
      "r456"
     ]
    },
    "txg_RevenueFromContractWithCustomerPaymentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "RevenueFromContractWithCustomerPaymentPeriod",
     "presentation": [
      "http://www.10xgenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognition, payment due period",
        "label": "Revenue From Contract With Customer, Payment Period",
        "documentation": "Revenue From Contract With Customer, Payment Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.10xgenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r639"
     ]
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Revenue by Geographic Location",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Transaction price allocated to remaining performance obligations",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected period of revenue recognition",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.10xgenomics.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r319",
      "r823"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.10xgenomics.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Domain]",
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r161",
      "r319",
      "r798",
      "r823"
     ]
    },
    "txg_ScheduleOfAccruedCompensationandRelatedBenefitsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "ScheduleOfAccruedCompensationandRelatedBenefitsTableTextBlock",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Compensation and Related Benefits",
        "label": "Schedule of Accrued CompensationAnd Related Benefits [Table Text Block]",
        "documentation": "Schedule of accrued compensation and related benefits"
       }
      }
     },
     "auth_ref": []
    },
    "txg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Accrued Expense and Other Current Liabilities",
        "label": "Schedule of Accrued Liabilities And Other Current Liabilities [Table Text Block]",
        "documentation": "Schedule of accrued liabilities and other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.10xgenomics.com/role/NetLossPerShareSharesofCommonStockEquivalentsWereExcludedFromTheComputationofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.10xgenomics.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Shares of Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRecordedStockBasedCompensationExpenseintheCondensedConsolidatedStatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebySourceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from External Customers by Products and Services [Table]",
        "label": "Segment Reporting, Revenue from External Customer, Product and Service [Table]",
        "documentation": "Disclosure of information about revenue from external customer by product and service when not provided as part of reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Revenue by Source",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r62",
      "r63",
      "r64"
     ]
    },
    "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in the Reserve for Product Warranties",
        "label": "Schedule of Product Warranty Liability [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r417"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r66"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.10xgenomics.com/role/EquityIncentivePlansFairValuesofSharesUnderthePerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r323",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of RSU Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the Company's Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r90"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.10xgenomics.com/role/CapitalStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock, Class of Stock [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r85",
      "r87",
      "r88",
      "r89",
      "r119",
      "r120",
      "r121",
      "r177",
      "r281",
      "r282",
      "r283",
      "r285",
      "r288",
      "r293",
      "r295",
      "r531",
      "r532",
      "r533",
      "r534",
      "r662",
      "r797",
      "r818"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://www.10xgenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security deposit",
        "label": "Security Deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r549",
      "r550",
      "r551",
      "r607",
      "r609",
      "r612",
      "r614",
      "r623",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r641",
      "r664",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r697",
      "r703",
      "r863",
      "r913",
      "r915",
      "r916",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r942",
      "r943"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.10xgenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting, Policy",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r196",
      "r198",
      "r652",
      "r653",
      "r656"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRecordedStockBasedCompensationExpenseintheCondensedConsolidatedStatementofOperationsDetails",
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Selling, general and administrative",
        "terseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "txg_SergeSaxonovCarryoverSharesFromPrior10b51PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "SergeSaxonovCarryoverSharesFromPrior10b51PlanMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Serge Saxonov, Carryover Shares From Prior 10b5-1 Plan [Member]",
        "documentation": "Serge Saxonov, Carryover Shares From Prior 10b5-1 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "txg_SergeSaxonovCommonStockPlusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "SergeSaxonovCommonStockPlusMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Serge Saxonov, Common Stock Plus [Member]",
        "documentation": "Serge Saxonov, Common Stock Plus"
       }
      }
     },
     "auth_ref": []
    },
    "txg_SergeSaxonovMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "SergeSaxonovMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Serge Saxonov [Member]",
        "documentation": "Serge Saxonov"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ServiceMember",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebySourceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Services",
        "label": "Service [Member]",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service."
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "txg_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PSA target amount of shares percentage",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Multiplier, Percentage",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Multiplier, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRSUActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cancelled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRSUActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancelled (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRSUActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Restricted stock units, granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRSUActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "verboseLabel": "Weighted-average grant date fair value, granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRSUActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRSUActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted\u00a0Stock Units",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRSUActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRSUActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Grant\u00a0Date\u00a0Fair\u00a0Value (per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRSUActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRSUActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansFairValuesofSharesUnderthePerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansFairValuesofSharesUnderthePerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansFairValuesofSharesUnderthePerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.10xgenomics.com/role/EquityIncentivePlansFairValuesofSharesUnderthePerformanceStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r323",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofCompanysStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cancelled and forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofCompanysStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r329"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofCompanysStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock\u00a0Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofCompanysStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r329"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofCompanysStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued in period for previously outstanding awards (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails",
      "http://www.10xgenomics.com/role/EquityIncentivePlansFairValuesofSharesUnderthePerformanceStockUnitsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofCompanysStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofCompanysStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancelled and forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PSA target percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation arrangement percent",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "txg_SharesUnderEsppPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "SharesUnderEsppPlanMember",
     "presentation": [
      "http://www.10xgenomics.com/role/NetLossPerShareSharesofCommonStockEquivalentsWereExcludedFromTheComputationofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares committed under ESPP",
        "label": "Shares Under ESPP Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.10xgenomics.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r142"
     ]
    },
    "txg_SpatialConsumablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "SpatialConsumablesMember",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebySourceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Spatial",
        "label": "Spatial - Consumables [Member]",
        "documentation": "Spatial - Consumables"
       }
      }
     },
     "auth_ref": []
    },
    "txg_SpatialInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "SpatialInstrumentsMember",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebySourceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Spatial",
        "label": "Spatial - Instruments [Member]",
        "documentation": "Spatial - Instruments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.10xgenomics.com/role/CapitalStockAdditionalInformationDetail",
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.10xgenomics.com/role/CoverPage",
      "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r119",
      "r120",
      "r121",
      "r144",
      "r165",
      "r166",
      "r168",
      "r170",
      "r177",
      "r178",
      "r235",
      "r268",
      "r270",
      "r271",
      "r272",
      "r275",
      "r276",
      "r281",
      "r282",
      "r285",
      "r288",
      "r295",
      "r399",
      "r531",
      "r532",
      "r533",
      "r534",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r562",
      "r583",
      "r601",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r797",
      "r818",
      "r825"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r56",
      "r59",
      "r60",
      "r110",
      "r132",
      "r133",
      "r134",
      "r147",
      "r148",
      "r149",
      "r151",
      "r156",
      "r158",
      "r160",
      "r176",
      "r236",
      "r237",
      "r249",
      "r296",
      "r361",
      "r362",
      "r364",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r383",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r408",
      "r409",
      "r418",
      "r506",
      "r523",
      "r524",
      "r525",
      "r537",
      "r601"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r549",
      "r550",
      "r551",
      "r607",
      "r609",
      "r612",
      "r614",
      "r623",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r641",
      "r664",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r697",
      "r703",
      "r863",
      "r913",
      "r915",
      "r916",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r942",
      "r943"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r176",
      "r409",
      "r456",
      "r530",
      "r548",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r562",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r581",
      "r584",
      "r585",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r601",
      "r704"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.10xgenomics.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r161",
      "r319",
      "r798",
      "r799",
      "r823"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r176",
      "r201",
      "r409",
      "r456",
      "r530",
      "r548",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r562",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r581",
      "r584",
      "r585",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r601",
      "r704"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r720",
      "r730",
      "r740",
      "r772"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Class\u00a0A common stock related to equity awards (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r55",
      "r56",
      "r89"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofCompanysStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r55",
      "r56",
      "r89",
      "r333"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Class\u00a0A common stock related to equity awards",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r55",
      "r56",
      "r89"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r59",
      "r60",
      "r80",
      "r564",
      "r580",
      "r602",
      "r603",
      "r684",
      "r710",
      "r819",
      "r842",
      "r900",
      "r947"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.10xgenomics.com/role/CapitalStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital Stock",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r143",
      "r280",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r294",
      "r296",
      "r382",
      "r604",
      "r605",
      "r620"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.10xgenomics.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r421"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.10xgenomics.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r421"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.10xgenomics.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r421"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.10xgenomics.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r421"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.10xgenomics.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r421"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.10xgenomics.com/role/SubsequentEvent"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r422"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosures of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedExpenseAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "txg_AccruedExpensesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedExpenseAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes payable",
        "label": "Taxes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49"
     ]
    },
    "txg_TotalShareholderReturnMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "TotalShareholderReturnMember",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TSR",
        "label": "Total Shareholder Return [Member]",
        "documentation": "Total Shareholder Return"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.10xgenomics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r279",
      "r293",
      "r381",
      "r398",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r507",
      "r671",
      "r674",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r685",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r838",
      "r839",
      "r840",
      "r841",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "txg_TwoThousandsNineteenEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "TwoThousandsNineteenEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Employee Stock Purchase Plan",
        "label": "Two Thousands Nineteen Employee Stock Purchase Plan [Member]",
        "documentation": "2019 Employee Stock Purchase Plan [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "txg_TwoThousandsNineteenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "TwoThousandsNineteenPlanMember",
     "presentation": [
      "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Plan",
        "label": "Two Thousands Nineteen Plan [Member]",
        "documentation": "Two Thousands Nineteen Plan"
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentDebtSecuritiesMember",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government debt securities",
        "label": "US Government Debt Securities [Member]",
        "documentation": "Debt securities issued by the United States government."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "txg_VizgenInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.10xgenomics.com/20250331",
     "localname": "VizgenInc.Member",
     "presentation": [
      "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vizgen, Inc.",
        "label": "Vizgen, Inc. [Member]",
        "documentation": "Vizgen, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares of common stock used in computing net loss per share, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r170"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares of common stock used in computing net loss per share, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r170"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477346/946-830-45-38"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483049/450-30-50-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-6"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>64
<FILENAME>0001770787-25-000032-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001770787-25-000032-xbrl.zip
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M9PDTT9.OCDMUXJT;+@>6A_^W-F3Y9-/=R*&P<=!CD,-6:7."T#8BM,*&-XM
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M+,]H?[DPG(E.[VIA/B"6%TOS1BC-&R<MS9\?KW\\W3&9+<1YJCCW8\*)Y/G
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MW(?3Q#Y<:80E(NT[L<F0R<"X0/ 7T],#?JD59L=>V\2:>B8S=V:B$V4K/RF
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MW0H,FGSDTB$T9O?&+NFD^& &)[=PS;,OG,"5D.:0FQACPBS@]Z%#+%P"(GO
MUL*OMY&P"+Q/AR8V<F<'-YSXX(:<N- AL@%EX*;! &@8X#!ES6%4G4Q,G^ M
MWA[\J=/D*$[@X]*AKP"]#;RE-P1IV$"/3I#@>'S#2"*# <X_6A1U60P5((\S
MA0X"MC#7@<^YNI(94&P/GSON$ 3VGX1/-QX'A6,H95Q@*D\.X8CW5O"IF38
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M0J/TI^U2F,:?U)"&Q+0]3FS4^X@7[Y$78EH8_:F"P*MZ(-:D,7%_T3",1/7
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MZ28IG)YBD<100[R1]-5R7KTBK">C]/[P,Y+$'\LX^SL;%(H30*^&MWH!"8X
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M<R,$S.,Y7,XQ/?>;4YG82T@$[KS'@E]M,HNF%1$03P!>[B!<1$)LK.^T/8]
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M)OGZS?16N])K=.5.H[6KC'F'=/<A8S;9$A'DM2-YY6^6=W+3:8+>#D1O'XI
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M"^;E/@5;Y^#)_'#Q80[>/+B2QZ![UCSW>:\E7D]:\V!'T*]$>7GQ_[OO&*
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M9[*K(>C!,-U=90,@JOL&G)'XPSR@F9_&>.5G\%Q(QP_;IS->_4HMS#C0>/$
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MQ+-;'%V8OH7VY,?N1)M;CPS^@[$0_%_DW,I-UABX!W9T=8"]G98Q+(>F6R_
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M?L$T!?Y"YV#XA>?"$HD9CN:R$ M"LFOBF!-8>#L-_ 55TCK>(SR U?MABH[
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M9DI9IP*0&JV6 ASTV+7KV@SMN2<\>4KPFEDI6?8@B JVRZ_1LGBWV"4@T^=
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MV/ Y7P@P(3:-J,J)=+YM^P)1W6] <JVK8^O!A1.E*?T/,FO YLV+^$UF[%G
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M&C)-B=@;#_I]C_$K&\MF+>T^#0^*1L1?+]%OH)9*WSRTYZ*E0I P>-IS:<+
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M>\0%QAW Z;R9[\QII%5P^<CB2,91/2GW>[%4N35,J84]X<#8(&B8EPR#W;#
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M*2ADY1"7;'SRQUF:NL,!)#1Y;<KH,ES3BH,J*F80<N"BR-G@]LI$/8[B"ZD
M%*LC;4U>M8D 4\=0/$G8B:OZV-,PEWE7T)DK)&M&NN=K E/8\\G/UXX0/EU;
M%,4F:Z"H"P"E1JDK=IH**)CIF*078^XH*PP8C.PND1&&21Y;Z*?$"?TF\/L_
M6_*=L?WRFXQ.!\D0>_86*+83OZOQ&DI;@HBSK"5+[&_!H*>)%\EUH?C>VQU+
M]*2%=-<OL1'U1$C;CU@;XW F,<?*ON2O.'<GK(@EF3K3AB7$A]_L^ZO\M89
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M9(G9^5M;7P\<,"U7"8ZQ8,:P,F'81?]42,823%!$F6JA_TS0 E&-68%%W?'
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M';K[VQT.2!\,K&Y7'#>#!*+9B$8ZI=K?$9HP39AZ6J"RH16[(*FQKYMQ13M
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M:-]A54ZIGG B&Q@]]4X))BFXXW.+2>KL33P7$)L11UMJ#D9J;_LY,.^\]FO
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M@]]0.2QU<Q@W$^"*B:DI)>N.@9[30 OWAU)C9&R%JC)R;-40N(;*29#Y$^+
M(M$AP^-MQ1UT($^<[BP_5FX*GB[O"1:G1MEAR4-\%9 #8J'HCE" /;.R'CES
M*F4$57D33TRP.*+[O*M)9MBM#/WQJ]?_^N+S9R_^4"4$L[Z.^K' 8D,*9:)N
M-^^E2E5]_G69!/$3$T'+OC7V+>7<-ZIVDP]*#.C+8<+@B6Y'OAW]$C8:#A'
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M1D7\_@XN'28TNN_1+5ZJ<B)7G-;0OUT&<2R;,4/Q)1@WUYR*JG,6F$K\Q'Z
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M?M[0..?HV'<#PF;M99(*^VB&L^L=TN<?>YV+&44+X.6HVA;?O1^:<>NP6=F
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M+EJ?\S]U[1_O>/G@JS+%+A:QI).#6TV;3EU'+N=^R*CN=K)HRY7M!?:"<0A
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M_1SJI$+@F#PKE4^-?LFP?L9E9D>6GJ26W4\$OF6\^9S\:SJ,Y;(U:J4C;IW
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M5N>!W*:G01;WRHITG,D3/7)G7D>%L5"B><6+D4F]0KL3/M+%=4WMVYS+ZG=
M:CA^C/[F0S;]</9()?OD1 ])0+5B@?>^)#!.M52/Q2;$ M1L[&<I#2]B.P*3
M9B(/O8J%Z6&M/7F+2VHH<S 0)@/CJ]+IUU)>07GGJL3PYKK'L,JE<P=Z!&M.
MH4MUMZ&69Z;=;J@=!Y48CU5_O.[,G0CZ#[FFO*PX;QSCU#GJIVA=!['TA&(>
MJJLR17JIDTT%2#CIIC6G/ZU/:-+71/K*(]C-K&%I[./6\?^?O6]M;N.ZMOPK
MJ,S<&;NJR5A*;"?6U%0ILIPH$T<J2X[OUP;0(-H"NI%N@#3RZ^?LM1]GG]/=
M(.@X,FGSBRV20#_.8Y_]6'LMQZHV>'[EV*2=P*H'L;I_T/J*:U/HB&5>@+=N
MJ^5U*&G-R&3 G>.';G4BZS:B=6]88.R)AQYYHWK>E8)[8V-%!T+K:E,51]6
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M20D<"PW+-5%1HI&R T9#L6R$"N[3E6@WG$R+&EAF-%=4^&?9@\[/*\>AK$9
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MN@AWH7,(#YA6]8;%J6O:4&5XU"L,:85R?7(&X*@^D>NT WMD@]!APZJVD0C
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M/=K#67:HQG6_M3\/RY6!/[=8<L0]*W05R?91_U4.Z-I\V,F5Z'K,1A21TB/
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M9-*2 POPC1/JQ'L.!MJ/)3[A7]*_'$E GGZMT;="Z88*1C7)QX%=04Z0)/)
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M1Q_ <<^Z'*Y/2*>]L.,#-]Z[!\"## KA<J_:*/1YUP["_T#7X(<.64X&*-\
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M48C8Q+J+NY7/;J"XA:S3FA-KG"B!VHA5X0*!ZMWXIA$_WE2H;KG3!%@U.'Z
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M6?D,@I42FPDG*=FT:V= E82':@],N<OB0I$IPWS(NB3,[NF=X4+>(/:[[O(
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MS.ZMV,D.,KA-<&>@BH!?'_@[B_:(VOEQPV243J$%/@I_,4D&.42LLE37TRU
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MT''\Z?5WW7%L/XX_)8-TTIW$[B1NYR2^__!#=Q+;3^)[4EJ=59VG^O@?^_/
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M*W.J?SUQN-/5::JC03Y:NG]<5]/)M_\?4$L#!!0    ( '&,J%KR5#Z(P@P
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M[<%33TM'J?@$'#L5-$KX:W4CWC PB@0Y,;'>W+ S4NS!4-I'W]H_#0[?VGM
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M)Q,RRY$<;V-E=;P%"\5%XJH.(C?O[K(1LC[%LVUYTH%DVN<\+DY'#XQPV?)
M[E<PAFD;$XL^(T,O0]3"!.Y;5XJN@;%S]#ZE#R$578;S@4XV9BB<6>]J\6VD
MJ>79L029EZ",1MXZIKOT^%Y:S"WE?2V@WW*6VQ/X?*D*FU2 NH2\H*C1&\Z
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MQUQ;,EO2F-P+;RVT;P)U"Z!-N.._>^YL*Z$.2;.\#_$%%IQ.<?V]B/5R%&M
M*V; +:X9KPV^@V8Q1,>3E%:DUEUPMT.Z"<W"=T^SYC+MD']7[/49-A>\!DGC
MSVG1+1$<"Y@%$S$;^H=;)5HG"39#ME'>D7_W!-M9:'OPIY8W6 S 1&F30N:]
MH9$74_<T>6T9D+/Q@DPWEKTY4TM0&]'H.\M?MY54AP2Z^9:+ 92<?"G(N%M<
MJ5@T"QD42_5L%RJCN>C>#MZ,;R-:?6<)\,[DUR'#5H9Y=>P^"!2\E'H/KP"F
M/1H6*"AE%IPGK9ED4*V+XNX$M1&7OK.,>%M)-;G?9JW6K!>P?'O]ZUFUPUGW
MT<N$]T$I#33\4@O==2)MZDW.%;D*(&O'ORO,6GOIS6XH-J+2=Y(-W[/,NG3,
MU]_&,2C<\BAXO0$Z4-R00CWO+&D)D/4V5G,M?/M^%1N"VXAIWUGNO!O)=1WQ
M731+ODQ]:Y+565F6<Z@-V!+Y@KD>TZ3E0+ZA\*'YL8/[X-N(7M]9/KTS^;4\
M8+!N(LY:O7P[$5Q$BE*=9<H%K$6NDI$)YZQ8!TD2<&-;YQ4V1[?S53!PNJB(
M^SA9=OB]\8*2@1<)!21@*0'%5R0;BK1H1C(@Z)(TA^97J6^.[IZU70^28MF5
M7-?NDNE&=BVO&4J(>7&V\P.,\&WY)X[RQ\EO,*]EY:<7Y>4#%7@6M0 VZ4+*
M)G-!TR +X\+5:T]*I+EHS:V-T3V""K'FU.I&=)U0:XF)L"Q2V&=K@MC_'$:C
MV=OR[ 2&HYHJ>C69UJ%<@AX$)P-3@ GC:S;; UD>BO%I- *#U;*HYAJM!?!'
M4'?6)2'W(_"N78VSTJ<K,R2M%LXC4]K5"\$YL"!]9MQ#5"J;8IM?5KTYNI9K
M]O5L=EP+O]Z612WJ[(\QD9:\1I+D\*1N.JTO4:V&;49O.VLU^F$^27^]_;SH
M$S#(P5H-!ICUBQ8M@M20$^2]IJ@M-^AX;AUA=CJ@1U"LOBN#;UOC#TN0=LUH
M:=KJ?]43.R%=M"@!F<VGPS0GX/0+&LFW+UQZY]DYN^NQU')T+[^F0QA_PO<P
MQY>E8)H/,G+OE9/,F'H4#[%F@20PS,([QTWPHG51XGY'V)$N7A?_*I/1"!Z8
M\[57>%# 8KV&2R9',YR).LT[!V][,.>!&Q?TE^-KCL-T(?Z'R$HHS4LHNG:;
MKX<U!$H6"R'-.3J((%R)S=L<;YF5>."&"8^>GKN*_R$\V1R,LYB125%/AH.*
MS!>76#+!E>P4S=&>CC7>Z<D^;/ST^.FYJ_B;T?-LB&_+Y6&_'>\TP8-B 2.F
MPD+A:E%40@,!P4Q,R=03*9A;J]D.AM&GDT6/B/ /3:BN#_TO-F66RQ=&YX<<
M7H_+9'HFR_-<2KF:2WF!<_K5-MT 6CRU49N YA/0J'_ U136"XSS2\U8SD[&
MU<AW-J<0>#@;H,YU"RTQS\$SK5TA=R (ID0)!A1/2K6NW+\OQEVU^QW/2^GX
MZ'A1N[6XY>2BJTUM9W/61;(VJR''*,@ B@EI"ZN7-#!P/K#@,C?)%YYDZ\WB
M)L![M;_5*3VO*N']R[V90[(M]'J"\0)ZBKSZ3%"G+),O1?,6E4=FI*PWA*>8
MFW<B;@*\3T'@HV#L]F+OC+&7S=WE0=0NZU):R5FVM<&R\K2>K/),.'*N,*ID
M<^N=BDVQ]2FZ>U#>-1%>DX+4*\.^@O.;:3CWY7^;C/'T-YC^A?-7Q^,\&_AH
MG ZH&,^>8DI!GG.013#AI5*Z) 0I[W ]6V'IAR^CH]8&<[UX31F:$&X8"(PL
M95X*2.0NM3ZD\OWX,@]"RVY\F_OPH&>^#9= R&M5H1"^GF=U%)TKR:1TSMHH
M4#3O@_#=^#:/FL';TV /!NGFJ=+!I,159*:@9=H$,L^!)@TY&I\"A&QA9QNT
MH=EY&,_F05FW+]$]?.+M0SK$?#S"25D=_S_M,N-VR^/VEFK;=,B-<FSG#_D=
MYX,<18E::/*(<ZBM6#/SD#3SRBI.P5;QHHO[5%?/;W%/[.*SWL.7WVAFIS3%
MM2+NP_'GSR-:)8MNM.]QAM,3<O]U-"EG1X/UI&AUI/ 2: )8/>J1#;<BE-95
M(O<"V*?BAJU9LNX2V6Y$U/#4S1+BGY/I7[4AQ"3A[ HP8TM)VI,"E2HL;]71
MQK$:.:8@@X]@N^+.S;#ZX(YUQYA&XFC/$U+GPQDI[7],)OD*,)>LD<H[)M&1
M1R=-[3(;B, IUCIQ:]&U;R5T)ZP^.%#=\:21./KC_+PM-YYH.?,,.O6%[G[Z
MWEVC>TY((T_IQF=6YG)>?$1RXV,JD>D0)?,ER]K3GFMCI/&F=1+J-CP-BM37
M?_8B?AT 9G J<D;JMMYU42\7-3PQF44!&4H6L;7K=#NB/OE*S7BRIC"\E5#:
MY;\N4AN;]$2^^6A>]#F!DZ2016TK:<&S*"-I:LEI7+: ,\UW4AIA[]4MP)VQ
M[T$DW1\C/"G+1A27SUE +7%:3,GRBN1.ZX&VA/( F8OMIZJ1K;ZYC]&R:<B@
MA.2E*('E( UIRYAI4=0=0%H"7M-RD,TCN#M![9+*74[Y.SBM-\ ^.Y_MFGV<
M#= 4\G !F/.TTK2D@<:</3/H0,L<?;F:V%F;L+WU(7VRP6WE?SGOVFZ>6]K@
M"NG7R?AX=C' H(1P]8*3C$BQCO"U1R5%Q]EZ6Z2T$: #@WH=2)^2$MW0HIT<
MFFSJ7"C?H^%L5@_]K:"D!%&"0H*B2LW].X)"/D"4.>E8DM-1;*X%KC^@3WF%
MSC7 CO/;MMO^W:/5T4MC C 5=+VQ&Q+SVB9FDC<NR9BXZ:35_CV-WL,6Y7>K
M'SJ05 _]XRL=DZ\W:=NKB[PQFH?SDK>;L!T=Y4N*;/G\\[9Z:R@I==:!%R"C
M5<BMP9)84$8R$9/C*A; C5HA;OS !N;O#7Z"2^[9ZIGGBXP'#"*0;DY*,LU=
M8% *9S;7/2>K=1+W&-'M#^N#8]R=O->8QH9SW]I)?C\YA='EH0;+L^5.LV 7
M74FM8$%HPVP1,KL"UD#K\^TW0.F#H]P]35K*HS4YWDTG!1<N'8Q>X04FI84T
M10@*XRPGHV_((BMCF2G6^R0L%-E1*'4#HCXXVGNG2@OIM.R\E8_3_$^83F$\
M/UU A-'S$1# ,J3H8 F.RU121AJWAEQUG60!+;"D,&HMBB&6M]\IV01:'_SN
M_7&H"WDU(]-'^(JK3OXK(!A#H4"@WH7-2^U?3(/-TC%KI?(Q9^YUZ[[F:V#T
MX3Z]_9%D5SFTC>G7#,[E++C)0/Z24#67%"@T3(9A<!QML8KBQBZ"^.VB]JZ[
M^>Z/&"WDT?W5]4='P_FB"2",ZX7OM54*4AB*LXN0L^[(P/ATMK[-]7FLN45L
MWO3QC8+Q[J:DT3;53=W&7>!9<^0,=*A*)Q46K:MM1*)P7FF?L?7FU$9=X9N-
M\#P4S#9[:26Y]ZKV[Y&!D;ZU3(3@LC-973O,UM5 >Q2KMV3'[;?%[B2/CBX8
M/L=TT29]P+7G40K/O-2DNST$%C0I\.@XA!S(->/=WC*\!E0?PO4'8,J64FE&
MEC<4 B+> &[5"OS%,0ZRL\ZC2TPDXC-99<-B\9P<^T)1(<_$Y=:1UZ;8.EHP
M Q1>*0>U7C9Z"E[J)17:1 ;)*_)7:[_SUNW#=[E,9$^+HQ/&;+A:[B62_:R1
M/\9Y.%M<'E?=YEI+_^RH_C10#FTP%/!RGX!I0\YL5"HR!Z6X[)4INK4MW@IH
MGQ3O7KC5O3@?4VPR$ \<G1" 'L8G5Z>E482R,<$!K=#1>%8P:**; !9,B(PX
MK[31*D9LG:_:E[G=Z#GO\0B&M3OWV_**%B2,_@=A.A N2I1U\][[VL>DUKKJ
M8$@!%.%$,2'S!W%"UJ)]E$;[/KR[EV)M)]B]^[Z_T^+_^ 5')_@;Z93#V4!K
MYR69'R8B6*:C0A8] )/&QQ2UL]ZVCI^VQ?HHK7OG)-Q5J'NG8%TD'[],!CY%
M$U+2S&(M]C?D!(-*EB494A8$-S<_%W5/B'W82^TEX;81X</PC(A#'K;.*N52
M& \ZU5Q\8H'SM$A=Z6RT,[QU\'MOD'W8<^TOU^XMQ@=AVZO)\70 R:6B=&8V
M2E'+0"FB#U!8$$;%DI.(TC\@V2K&/FS=]I9K]Q9BD\K\31$^*W.<GL-,+GCN
MG6:)5P=32UH1-D@FM A"F<25O:+8UI8J;O7P/FSS[H5$^Q'/AGF6Y>OU2R0,
MO_SP_U!+ P04    " !QC*A:>J:K9?,X  #BA0( %    '1X9RTR,#(U,#,S
M,5]D968N>&UL[7U9<UNYDN9[_XJ:ZM=!&?MRHY>0MVK'N,H>VW5OS[PPL"0D
M3E&D^Y!T6?WK)\%%HB12XH)#4K0J'"Z)D@\^Y)<'R$QD)O[EW[]?]G[Z!LVP
M.^C_Z\_L%_KS3]"/@]3MG__KSW]\>4OLS__^;__T3__R/PCYSY>?WO_T>A#'
ME] ?_?2J 3^"]--?W='%3Z,+^.D?@^;/[C?_T\>>'^5!<TG(OTW^V:O!UZNF
M>WXQ^HE3KN:_-O]I\S<!,:7H@5 M*9&1&1*T!,(A9JUE=#G1_WG^-Y]"BL('
MPEA.1'(6B8_.$6$L#S(+R[V>/+37[?_YM_)7\$/X":?7'TZ^_=>?+T:CKW][
M\>*OO_[ZY7MH>K\,FO,7G%+Q8O[;/\]^_?N]W_]+3'Z;.>=>3'YZ_:O#[K)?
MQ,>R%__YV_O/\0(N/>GVAR/?CS<#X/!I=/T/%]&H%],?XJ\.NW\;3O[]^T'T
MHPE!CT[AIY6_4;XC\U\CY2/".!'LE^_#]/.__=-//TTEYYO8#'KP"?)/LR__
M^/3N/M)N?_0B=2]?S'[GA>_U$/'D":.KK_"O/P^[EU][,/_LHH&\$OU\R@64
M*G#^N3SMQ<Z8+A!($\<!"'X*_:+B%3$N>_KNF*^?11)D/^Z-*B*^_^RJ> >7
MOEM3P/<>70'MY$'D$BX#-#6AWGKN LXYR+L(RR,9_7X._<%E-PY_B8/+%Q.$
MKP:X&'_TY_ XNM'W<U*65"JF+_$_W_S;!01(=;??+:O'>_QV]H RU-98X/L(
M^@FFB\9\F-X@WOJE7EFR!M<R[OD O<FGG03=SIO^J#NZ>M<O^X2?88-W([@<
M=F*4E(FDB==2$IFE(A98)CYYZ:00-$"XS])PSOH0XB_G@V\O<!2DBLOR19&2
MG/+TX-A3L6TWH_F^N/#<+S[TH..U$=R83' ZN&^QX$@PQA 'SF8-#K<TL]-\
M5HU\>S8W:G#6S.<U>RLV6MQS,[BLSN-H4%F04\80_L\_#9H$#5HV^*/)2_NW
MV!L,(>'KTXSAYL-!?X1Z_:8'96Q\W^"\?+&M1HR'Y-S[KYW/([21RH->]?QP
M^"%_'@WBGV??N\..Y32@/-!^8=80J1(C-J/](Y0(.6<A8J /J$7VPS"A:C;2
M5#>@-QK./[E1DD?!5-24![;<VYI3A^9!&^)>ICP[ZL$BGM>3O6(M1)T[-D E
M1;B/IJ(&K#1@;OBO3->@%5GO1PN$=EPH'4@*5*&V9T6<#YQ0!PR @DU,/%'V
M;YF#!R1_$Q&W0?K@\G+0G^ Z^VUB'W:,I$EGP8F)2A.I,T[0>D$,=2KE9 'Q
MU2;]'HJ:I"^SJN\SOBLW=ZG>3;#WJ:85J7XY0Q0$8P*]!*(I]T0FB8C <J*"
MI3E3K91^R/K;D>J7IT?U-H*M^%8OFBY?\'<[60)51B<"J:B<]YDXKBTQH+/C
MH"&;A^RX]<W[,MK^B&S9N-]8=!7?UD4<_WOLFQ$TO:M/\'70C#HVAZ 9%R3Y
M*(@46A++ 2>G.&>XN"C-7!4V[PQ\,L3N(M"67M./T'0'Z4T_O4:#HQ-%BE9R
M1ASN% C(.N*"P/E*P7B(G&JZ) BT!<.WACT9?K<7YGUV>95%N/%H;Y9)SC1.
M1*<C4Y(D:<LY0?3$&A>(-\DI%JU3_"&+>H,%^<[()\/Q3B*]3[/8A>;I--]V
M>_#[>++O,^LE+BB&\*  S0B%D]-.D\R<D(9YKF W>N^.^.1IW4F$]^F4N]/Y
M"<Z[PQ%JV>AW?PF= *J<]64".J)E& ,C7D1*P!@FM:4"C80*E-X>]41HW4&4
M]ZE5NU/[KA\'#2X:DTE.7/Q7@W%_U%R]&B3H6,J3TS*2R 3.U6E'@I6&@,)E
M1&AF*>QF+*\!XD2(KR?H^WJ@=]>#+_[[NX1[23=WIT?7L[4'U5.$$($X&CF1
MB(8X- $)9<Y*)8)-0570@!7#GPCW-81[GW6S.^MG*34P',[^5Z;+.CYJF;A
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M_&[?-U<3@PMG5Y+A4-R]R?SFFR,7!AACQ'E>"F70(+.A7!KJT3<.6@FGZN]
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MZ/D)?%,L99QHK0W73IEL:M^MNRG&4U*?5OEI8;%Y!.]-<>?D(ND_^@WX7IE
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M20XSTRXP*C/10:+;$6,B+C%'''/2)64-7>_L_32J2]I1ARWJ33:AY4#% NM
M?*XWV9':+:H&MN'E0"JD90XI,$.$9O@JZ7*F:&DB,:'%FDT25IM349T*]29M
M:\XF=+2@,>]]/\V3H97A*E-+3"H>JZ":A*@,"2RJI-&5Y2[6#CI=CWZ<524;
MD7,WWK2=9%M(]'@Y[O9*>&*>LZQM=)ZC"D>#:"!+8EG*1#C!0@(-HOH"<!O!
MZ7&]@X1;>*=_\_$"#?7F:G&F<U6TGK-BMP/B(%))A*:\),GP(*D-059/T7@
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M4,LXBTGF!+5K4F]&?\J+[(ZRK+UE#KO^HX_=W(WS1 EO<4ST/@,K#>!!H!O
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M07<I.5'*G8O/Y%DDFD4OLV=<W\W#7JH:#XWQ@RM&-?&WT:-E'L$L28 S2"&
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M2#E4O^)V<J<1@#SSC+DF/H_[C4#U1Z[4H>0/%QQV@TY!SX ;[49T_YQ'GI8
M6@ ]8 ]@/X 5P G@!1P%  %@@#A $G "H 10!V@## "F@%, -, 6@ <0 1X
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M,R^S C.:^2?F-.8ZYK']V_<+[E?;;[<_<'_^_O;]<P>8#D /&!WP/!!_H/K
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M>0O(0;N[N=32TG78^;(-6YOF#]VT&R"?I63"/P%T! \1@CG:YB5"?_2Y5#X
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MAL;@83WB%]S/PZ,QXL=U(^M.<OQ/NU[]/5O_.WXI]\K/'_7O^KF[-NC;9]?
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M0RJ;9#/JMVXHBR+CZN6X)NH&!K"/G=;7HEW5R_U0I:5B8K@S3_,>6^K!JX>
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MY5T?BW-#'BJ4NUZPS-[(1&-K"23*TX%5WV&O#+ZB.CIB2PJEJQ.#*T0LZV7
M5!/3T+Z>.\$_[9W.E37/8VA>ECCSSF4]J]XWW'U(I]$Z<0P5WM)+ !J\Z4ML
M?5XJ<:NTKC$S4HN4[YYVPD2A\><"D:+3(SN=)Z41(3X* !QQ<ZQ!F*D;="?9
M2R<)ARW)^<[E'"A- G [J&H.R#9I?<_F[YCU[T%:!28;.#I9-.@O$^OOAI"@
MN374@;264.=X.. )*3L"(KM7S6!]898+/J63]J-Z523$Q[Z#QNXY1P> +;-@
MUR3SH99:'P,$^]BC>4V8*L78/:=U,_Q@,RJSU#.:I^OVNA@V:P0;E2D5UP%]
MWUH&W-00=UJB\"6MZYYY?6NU_HMR6=]3H_=J%ZKB"-5.N'0&DAG6CAJ:1%34
M4;1E,CFT(^VKH@9F)'L+;<5GJ+4E:]MHG1,L^,WYDH.6M$Y#$TT;]KP\&T_D
M+B"ORY119^$IG8JK/RA^\YI(CC^C57]D+JMUSEP+/ \.L,7>.[^KF$KBLW?(
M-)CIX#PI&2T 2A99R?H4ZZC-N ;MBG;YZ0U[''M,Y*H(S[XI+@NB'D#9]RHY
M_$;RHDIZ.'U4JKU]\361D+4,+68KJM+\?F507N5&GK&-OLWP/V?Q/P6^U\OE
M"\U& PSB;; FSYQPL]ZH>[%7^SEEL3\3,X1V%$TXW)^O(V=T8U/?4 MJ#E%G
MC"R6][/D,.$J#EHZH"=67+]K4YMDE@)L*G(;GQ;J >Z4OYH)J&?V0,TAR(<;
M_*02)7SM*UHBIL[:ZYD;3,E*3IX,S.'*!F(&.F%;#8%R_;*GB5Z'5!\6#"9&
M)L:ZW=C/UFG(";:ZM#M@8506>)BC,P.(4%165KB,@DL6?D;>JE2'JLOU RBP
MN5H)-O/LP_&?D<TB.V1#.W]3Z:"%PB>D&P#9C"@5ZY+S=\A<'+J0$H>EL89&
M6=:8"],F)MB>\L/4;<5B%<3\S0.#V+:.*FGK%NJ'!*VKU?!MG+7>J:%*]U2]
MB>./*DT( >EU353\6X;C9K9B(\UY#$5R%T#7.K30-9%2Y+A]]*+EPONN<L&T
MM+YK(A;G.@^W+%/29'JWZ;JKE=9D@1!G3R8X/$V#28;H0ZWP9G&AC.^*V+&@
M#"F#Z$OC=*.9M;L-%+OP)*ZJNYO)CPI&C]OZMPWX#)-00*2 <$I1=2MBB][F
M6/!%&6G9<3?JT2N6O"@BD>=_(,N._R!+GLO_PV1I*[]V8['U5&])OO97'6/_
MJ\;Y(OKY+=(P4PX%-W-*<4@CW4A-C1WM,7*CF%CY(0]G==S/#)H)]@IW99AS
MA,OAHH<\ZI:NKCM5%\Z[GA_AU:]1.FGYUT1?JGT+FARTMZA-,$'GC$W !PF<
M[!X_2!4,7;7?.WR^#<98R0B'@M3 9NM,8KG^ZNG*I^<=RL,3K[3STC'\'L?S
M3YA![^6CZJ'V8H]4U9_A; /?A#V#"IQHH!A3GIUL^C @0G/W2GPG:L%==(&%
MJOL&\]0Z%+N6?T?/OX^;II<:3!9.V^92>NXJ%D,GC9I1M=CR<>Y01HU^;(U2
M)C)6;.R< B'@A[KZW*O?!TNH,Y+N[Z((HE=,%X)'G4[8DG&571.%H7VZ(L2T
M+P[0S7J4G0J',7K+XI%/\C!,$5OH7V>6FIM5V.0M_1)_3*)5+6!D_"/MS$^G
M'B8;3? V_H07[\KQ<DS8K7Q0:880QI1587M& +T"HW.G"WZ0]\1&_+ .O[[X
MJ:]8@9*]%D3-H9^6X5A>4XDLMQ7>M$QVI4S?3G3Q.,7VH$@BE =CTP ;;R3_
M?!@-"JNA_K_:O8!2=/]\#R2P:1+O[OUN/-AK*__M8O[V<$JSE2RT1X\:W=-X
MFZKL_3CR*%%1H[CB'8YJ28D2<_1N(WVCLJ9&L&J?1X6SW^[BD8].(=>NRQOR
MH,$=^5^/C^4VZ'4=ODAI/JV(W>6QED3,E#LUXV;->]RV<QI@>3POC'5#<Y03
M.10=M'7C5_(*N;[V*((W6;PI4R]^^[=Q_6PO6QJ0*$6]],S[%S'89+-,!WZ=
M0R1NJWBMSH"-ZYB6UZJ-<5C7+7!F-7H6@!L/<DN8DK/ZNARS#S-1I)ZC2S=<
M//,CC6A%V8QB';:ZW LN(V95,?Y/#+U!SV&KA*9I$/Q$AOVH?V=/Z17&K+>X
M<B6GW9S6E1#BE]6HL=MK,3:;0F"Z4;P>?A=]FN3K-P0@1BO[QY<F+2\D5]WI
M@R%EK-OM>]Y%=46%32C]DK9T&N;IL;5_+\93DFJEP]^PR\V\^/M^3]6\3:BF
MUY[/_P5W6^A.SV[/#F9T\8T<Z&GX]U"Z__7R10M5YOHI-?RJN_)A92#395+.
M[/!E7D2P@9]7>0@9Y0,USKP?__;E3_95\]GN(XZO\(&V"2JZ 13?;1A# EU=
MV.X[Z]C[OC]GO9CHJ$58]]4/K;K)Q?AZFPY-F;AR6ZH:PQR 42BEI%Z)_LV]
MP^GA O3D![/A&6.>P[X@!Y^J"TPI83OG=OC;(Y6]-&&IBFSIT0""JI0;UX21
M:CR@U:,NF=5T8HC)]+W;(F"UL&L!&-@A -%*2T#09M=T#G<^C=*UJH@PY.C6
M@J(E>*!.%R$'%W\;L$QC=!JU^"+5Q7"&WYCK\)%EG7L1OV#I?,Q&P:& L2K0
MQ,:+ORH/O2\NI#89R8-E$R)E,# 8;E31?(J!)XV/M-2?%+UT"ZAW5DW2O($V
MEJ'RJA5R+L3C3K PH)MU\R$Y_O1AF7D(SH>+_@!5_A6/;5SJ>Z0SJVNH+,5H
M,],L3PI[Y)I94^V9)Y[J;>#6TU.=1TN>U_=AO6@-D1JMCVDJ3YG6PZ!]QHHE
MN,:^F4:ZF=YE-Q]%#9<*S$*4+$$/@9[U%GS3IQJ3C,\S_NDH! BJQFC92BY>
ML26,*& ZA=-,3-W9X%5@84B9??GC%B,7/4O&8%9%/KI3#>$ULG'4Z/>$.'"H
M4%J,33_>M9"6,VTZS2<?K0.PNS,<@A3-8$^#1,M%TXKYQNULS;R1[9LR=4W1
ML;%.P2@8&./6'!FWNVN=#;%"%1 16 T+>LAJJ$^-^#;=&AYJ"7**+;95JO'S
M%P_S3M#J8PM/2'B5-I?A!73C]RIW&^+>F!%*,DK1K?'99]V-G(\D,.M8+ZKM
M=/?3_.WUU2]GH(10#GOM#S7<"8GL_?_6\;F!ECNJ.8QHU+WWEX3N)8M?3F8P
MB^K'D\6//[%8-])"?*;B3_L_90??_6+3 \(EPR_V82];?FVE'C%??8KP%N#E
MHBSVB^<_8Y.IKU2]IU48)7O76VN#,WY1K<D-,I,GC)70;'%M-:?P4JT:E5/V
MG_RU[[_&P?]!4'P\O.G+06FU3QK@2DRFX#BV;43&(;HD8'B6$<HQEM?7,#7N
M:2-/657FD;'K9L\OBK>F,["'Z4 R\IWE;I>@)_MBQ;,]&Z*!<A>Z"R>7</_S
M&4BT=Y''MD1FFJ$*>D;[KI=MBU20!*U:G'/B_]XR_72VOKY,T S5T[MGEHG(
MJ!\YK*W=S4H%M 9TQ=$Q<+^<9^DA7^S],&?BD(]#U->2:RO;*LIS<+<*:CLH
M\9OXP^;MUC34E?EHA>>NM*_2Z1G"5[ZP!'04YN.TLAO,9B\,=,H_85"@1G:%
M[,9E)=]4GP-6(/E55*>V7;TCR,D\<K;%_%"UR.]Y-, S+-M19XJ7@)O7'2,^
M=K&KU;1).&?#D9H2FB8L&=>RB7=.FA@O?*!*8P4%]KN.H"@(;7Y1U].^(!2E
M&*F\DMGWU!F6A1)YM5Y4Q%L\$?LS"H5AXW8(HX62B.*!/$#V=Z%24@,EO[>6
MS$N'UD5"MZ'-I1@JP[@H2\H[[!^3[OY>#QU;!-#\?7K_GS&H+O5(7,^B-3XY
M)D,17J'CC@+H0!JJ3W9GQ*>5^5Y7;(F]'=.T:;F(F SG:JE(@LE;V7QEL7C[
MSOB2&HS17IL72]MRZ-")#16H@B0J<0S'_3)&G8&E<&(]&M!P6U.QVD#-S"78
M4 --?I!X\],E#X,8A'.<D)WAZREM438:1XWP."AT\JZ*6N<IBW6HJKIW3('7
M[4^2>ZL:8AB:XPB:MW'[D'?(GJI[R;6TE=G,D!2_523/H_,YLO7NGI35687B
ML2)XS=/15H^JV_O!3M8$H,A0J!.\$"IH]*]X/B7GH<&K"=K.F!$&?">?=DGD
M"WS'B(R"#K=39ESQ/B%4B*0R8R]=@I+^T81(##T) GS2E]E!IXG4Q0?2+%TI
M'Y6IZUTP@K^$AU-.<<P^L[KXF;BTZIJ(!WJ_D[@Q_[1JQ^;(BZ-Z-X(ELJ;T
M!ZD_;T[#IM7\CX1ZIA]/&96Z<?.OG/Y2OI[IWF'0;P#]_ GE\GI.:H:.TC./
M =R.>IMN>QG9"Q@IZ?>8 1EYBY>BH#>K@+CX14,LHU?&60^58%A3)V4)^U$^
MD@F^!5[;]^?HZ5 V_%?,\"\CF!>DG\CB /I:DZ8?^I"'%Q29"\O+UM;65?G:
M?4UTY^?704'F0&0GG_\T>/<YQ>9\EHI]^%%99=='D*>T"%N-9YL[1UXD8UU:
M>,$VLB!N]DJ@Z.YVKHS-RZR829.AYQ#FO!P&N&CR]^2&<E*])4KU]>ZPZ@Q'
MS,%N\:%RYKZ4;&NG?*O$E)+_K1,#=##LR!ERKX+X2>AW7EDQ?[IK$NC^"**]
M&B,+Z<T,S3#E$6QJO\$I!Y#13C9Q-%=)ML#JZ$D.2!%-"5&9UIDXC>:A8H[U
M"9 56Z/,&!W';:$U7@\#IJ.3W#K42;+]IM&$F2WE[QG8&J#5%+JEFIA&??KR
ME&HE6\A>]]S FA?NM=>\ M2-?BW>E-DN%H)+8TTU*"CB-^2:Q8(H\IE:$M[B
M09!F_OQ'9#*TNH(%HW7H?2_4R2!V=]MU"]FK5?9%S)LO/ ,'+HY;+78JY#U\
M51@8'OB9Z47YP/0I5:N/XN/XOQK\EGU0GD6DQN%%Y. UD8WANW%,;%#ORYVU
M()R2?'&SC,'G\(AWG(^T17^8HS]Y]2"\O[^X$+=GTK?]8?25;9$M'[+DV^XV
MF1"CL''L;9V$M)*"W*89Y632H/[D0+&R+_&S6"''V*)8L*BRV8%7>EU4$B6$
M2]_,:#/6BF%DE"=3W7<YM=^(:U(GH..DD7G1/=LTW)+_AVNTVT<$9]EYIRK\
ME.<( I4&Y36)D:PE?TFP!](EU19TOWL7U=='WP:9) %?E)]\["*6Y.F*OG?I
M]Q@\7"_+GVU'_?;%AZVA@6@C9Y]A9( *M= 2A&#'QU8/9Y-\903DN MZF6DZ
MC(8/B#1&+NSF+?>'OV9:DDNH#"A-CE&WJMJH2BPVU-7J-*= ]59,,RKZ;_P:
M]?%?"(/;RFXNBE87V?.C2_/3-B\TY.H.1[7>8%/R00JKBU,C+4QPUG>X*%@Q
M@^/RU 8;[351.JLPV45(8]*,7J_+RLS@"5:/3;",S'%-+"(@:MW<1.%H%%&J
ML9?'X)=2&EMR!'_<_#K$!M\FVU^;#S%N<.HU!T]PDB0-2^>58DO2R='ISP*-
MYX9&>$WIC8^-180LTY3'7I9K++T5M&^R'WZ38$$'ZP T@$GT$U9&$NDB[WV(
MCS15EV4N<GV(#?B;#N1="R$]9(.Q?5^B)DS/A=(KU4,2RU66.N<NN%VT-D>#
MWHTTVJP6WK5M2!9+U;%=CQ!^#KZ-MF"/4CK,LCA(RD C**.-7??BUH:VLAC*
M9!?'1-+<MOOV(T1<[FB8=@TG=8S[ "H+/XRZK?XK_/*OX[1.=$2*4:Y,+MCH
MY[6((Y2GV(A8B3+7J(DN7LF+,A$<1<OM)CK^:!:#RG)H+R05KP:]Z^X+'^:2
M=M?CJ:/MR$\;'S+1T7P-W].*FIMESS#^C$0C/]D)+2<N]+M\<EK3O_PZ?"0^
M*3=NT!U+)6R6"@7G5A%T=-ZUN@%=.":$++VJ_(=B\8#Y2"%P0!>IMG6+_*\>
MYN5AOL_[7-*,:B4/*5^4VS3CCK3,R2<BHE4+12^J&K(\'=,KTM?VZ;\%Q(YC
MJ@DAG@N/<+QJ78ECL"_LLEW;D/V;RNG(^K:?/ZO;I+>Q%+DJ?4C@X8N59QX>
M=C-XZ-N\"VB+DA/@55*RCB[)P[B13TK,22<;@K_GB4E8=+P)#[+Q??\Y95MX
MP D5O6X(Q]"8;U.B>LU&/$&\[J]98NA\Y4IX&X!DM^UU6CY3_GS9W4=T9=K6
M+[!5/0L=,;X59? ::.:5>WR&%WCRBXAQ?Y*V^K.WH>FNAI;E'[CY9Z3[1'J1
MGBGJ6/-./IM?Z^%,-]<P5!,0\"DTW^AYM['*S=;+A&SZ #G$I[CUG B9;_\V
M4;;A:THG-=L6W<W,1TKOHB-7CC=JR4B1F^PZ9XU#M0$T/@5O+,78_O*WF?US
M[?5(WRV2;A;-NS!(Y%^B=ZB)-=<REG_-YP^E,ZG*CIJOWBAR@#F<*E].5=]7
MM(^\6&8&!B=X5Q&D;*5"B6F\1QP[Y13QZH=)TY6CS>CH3(1)H3/RKFH%2K!Q
MW'K3W]<E?MIT 7WS;21D(VRT<V\+9]S3XZ5_-,24#;;DL5%4C1.V":VO7C'3
MA=-;WE'(H)2&W%%B3R8W(><&_GX;,2WL0G5JM!<^>/*W\8*0,"2-#O::2-A<
MXM<DST7+,$LCS67DKZC]F[SW*LU ">!2 ^,GY;!%9\V$]I)\C]@) GCSZ,Y
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M+",-C6 4XUXOYPS'L+'2-TY*U$/$V?J[(X49\C]<.&CEB2)$+WSOUR?F.(B
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MDO36DTV+V/OC='@MF48@V_@*(P!Q9S0YH:%^:3_'P>%64VW[*(\W3X%.9$(
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MO)Z= [4*MI8%=/Q@9--I3G']S*R$N"O-:/(+>G51;8+1Q[S3M]R"9KN/%]\
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MW;.9NOVV7SW88SGC7*-7B6;KJ0 YV^:4/O*,\QA:=]=(5TQL=>4FHB*8:=L
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M Z(O-M/@<UW[,,%VR'F?_':"\_U?3TH_=/!(6-- 5NVX>W^BXS%5;3FAZXY
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M38[YQ$Y'E\W]:Q@Q?( [R-K\[C%_X2@.B4$ZE&<7&PMFQMU\@<GO"0@!WNJ
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M!Q%F-4 GV[2"LU,IA;959:ZE$KN$MPY13SWH"LQ&U-Y(/KK^0,4@8J<D@V,
MGR<?>/VGH'Z7]:)V^JB<FVS/5=KEN^.T")CB_KMA-3]G%KNLV9(<H[R0 :"7
M!#<]&:1>,4*;X[P;G5D#J"O]<I*7FMM):Q#)VQOUVV*U[;-07<% &PJB\57U
MI%M_[O_.G0N=<I% L1E4 #.W :F"^D4 6P01Q]4="@#3:0H>W*,*PP#Z<[@K
MS#,A@&IP^>]'=PZOP$CDFO)YA(4X5XLHQQ;8P2'T'K!]O;$P!9/B\SR0YVYK
MBJ>P.#.$8]W2=6M^LLJ?947]X$")]0#WEMT%DJQ/M1B\B3]$I:G5_52;I$9R
MR#1$92WK[\(U/A9.DNI1HV'X8($)Z9+W:%3 JG9HW<0]%]]R2Z5%MZVF%Y,*
MD"+)97EOZYP--V*3]^0C+98^\4@0\ \*HZ#R=F15/<0_TF4-WWF1$]^4WO[L
M#!?G3%UZE=FX"4)5%U^G?*$!;&19&@@N2CM9/RT_!K?EG",<MAR=<V(U\$SK
M9K>J_=4M;W_,M WS&<84H!S3-586U9F8G36_'#\_J&5WXZJ_>R+$/S\J$?_:
MV31JM/GP:/]HZ&_S@/X+__]S=@:>]9<41[N7%#UI%PDMG_N5SBXI3J)_=V6R
M\[*D2XJ/ !O0]W7?_(/RN@_GU-V>OL/!D0;36F<:68A,6N:NF.\ 'K'D]YQX
MW%P+L4B]:J_RRW_3(VM?VMG+LYVO:<E2<K7)HP8G/P2'AJPSS,WKQ<KP5N\]
M#QJP;R\M-(CC_H[.$:^XRQ:KN2RD(2WFXKQ?QG[BQATD\;:5\BN63'P@@)%.
M,IPFN!Q-2=PT$QJR&-").7$#G:BUBBT0^AU^(!"S2^P92Z-]J%JCCGEYFH6>
MD_Y4#EAI6].]^PL\CJ%;=?$V0_*.X_@D@ZKE>(%!_X&&R#/"6V%QCH0Y4?&W
MH* <,]2=4YT,\4L*Q<36HI APG&^P])Q [OCX^N*2.=41E!28Y;[^.OQ44 _
M^:VG@S3.)WP7+&.AW::F^NJDQ%W5J8VR!XLQ/3 O[8[O$V:1"DKR"1YQO%MZ
M"GJ?C%@PLB,&,SC>8H6$=$=$XZF4I\6TWN)5\9HHU=]\D#0^FR!$6D">6="W
M0(!B%6&VSH;6EQ0:>[Z_"]A#'NL%')>]:463]PYI9#FY2[O(H(];BM]S>J9?
MI1A(G604-OG<_)!.H3RGQDMS;7?QDL(T14QW:39CQ>C)'&V*M'J>% [0"<3W
M=RWGYN,Y4OG=[KXF1(N;2L"J%^I=I>/2GAE(T%]D8CU\'K\QPNZ:Q\+9C?6.
MA2L]LV-SM\A9^-F2&'NI^Z(O_R#9*S5"EKF8BEVN_8UTTG9>K&439Z(_C/)'
M<!-'_HA+>(:5 ?#:F.]D[C-@(^O6R>->'^+%9G7PY.VL3G%I=V)02-<X2%!B
MNU7LQ:*;R-Y"I6X-VDC"RS& UJ #VB%6LYK5XRPOCUB>^-RR2+L=6/MXW"J(
MC#(>2/1>?BW:$]3[AMLT72[4Z"[0^\;Z<_]KDOS,+:8_C-W+5$+R?F@"YF2\
M&%/]"87B^_1<-BNBC+=KQY PQ=EI/5C9N6[=&,F@-9/Y>P$-N10Q!;L(4YI,
MFDHVCTL*9T?CG1DW-TT,-+',*3GK]P(: K'>P,IPJV6FV8#_D:7],WM-Z(K"
M$=1!O<OHR4%UZ,U*I30;:W=:*?"]%*,EB7H:*7/+$!&N;X^^OA]*15U2#,O&
M7%*\N7XQ5#%24 /;DV[H]1,P'Y/WE*MLOW"![H4]+?OT/^+X!WR/32UNN)"Z
MI-BU^C^\O7=84UFW/XYC144$%:2+$" @(+W#2$_HH8<V= D$"!!Z8$8!%0A(
M:%("4D(OTCLHO2,06N@=0N_2?\[[OO>.]WN?M\Q]?L]\_CCYY^2LO=K>:Y^S
MUMJ7)!D(9S>M2Q*9B[3S'5/[OF.-@X;-3FC(KX4__V V+Z9!1TTEKN?[A[RC
M3O0MY /AF2MGO4RE.5!OIGXA:00O99SM;T:13_XIQ88D\\1?SH9M;,L_$7;M
MS9:'U;&EROD8R[GCQ$):XP\==M= %CGG'"[RC@/K=@O5(_*L<>!2CTS',+_\
MI6DH?[RGE<<0DS30(0WQS&J8_GYNN>8,9%G)8HD]'\6VRI2R=1%?%$8#[YX6
MX\83:XV,(Y+&E'Z3=G/G<>0K%MK/^?5_#.;9T!>UX(NV>>FKG*ZMYP5L^-I[
M/4V0F#0]GCE+G?CA-*'\Q?FP1NT@&QM[K>1CI52&.\N#?2>21;F&\ZXP'%QD
ME_<6\BPR8YJ';<S-(UY%<,!],&LG7T&<_Y)$OUC*SU: 47MD#L\V\YT4Q<T.
MWVPO]>F.MU@1YOD"H9 O2HBL.,Y7D&>:9@LL$K&L<?M/SZ3("7+'K:<[^[_I
MFZ'F]X9HP[P<5407W:A$L[Q2$97&H)HQXXI7!A:1+7EJQRM.+&&@C\^*PJBI
M[29Z=HY-2J</P?'B]V%\=C_R>&5_U2ZOF Y&%/<,4R\MBVE^S$?[=,M;/A!S
M/VF>7^ZEAFDN-!03$)&M**]H*98A..R5AR2+B1[4VZON*[GS5C,%3+<,28^R
M*/+D:'%*7,";/UP63J,:4>'K?K:;0#L68ZX%*4Y1ZW7Q^7Z+;_XV:Q%\!@-/
M5RU/&XZ.+R%['=:T/?W)\.'XFF!FZGK^E"Q8+MU&/C6$'J/V_/4EB5 Z1;)N
M?)3_(/GD^,?U\(\\:&Y!4Z/NW$2-VT='P%\VG=@?+;*6LV5K@R IY)9@"I?6
M]!QU4V_['DNO_ ,RXZGYQX2"N4#IVVZ1OD.S*O4)LY&>'IQ =^<ZY5_^,P?X
M:Q*.;P&^ARR BLS%@O!3X^: \;2^,D')VTFL;WL+]AG,;C/R"\C3/=3Y46FP
M/I#_6G+[][7]ZB4)C+"N9P+T9IQ>EHGCAZ?4,1LM^(L#3A0>&\[\9US^#WL
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MK-3&A2F])$GN'T.Z3+](EM768&VO9M)U<II<9LF.7E'Z,&R@TU"--=@Y%@6
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MEQ.F!XI1OU1'@"R'/"V.U37YE7Y_"_F39%7N&SHJSP(/FK3MS#8/VE($JWQ
M5Y!C7P[DDJ0STUK!'>Q]27+8]I11V'_C:IH=U+;:'Y? Z=\TV1]CB 2\ I=1
M2X0H?EO6B]JT#+\&3ZU$%YU6$:_K=9ZJZL4V0N(K,RJ]2AH?.2^$1HL,9?7=
M#N<@B_]#?&)LS,'&-L< =6[9MG!;)R#?V.8FFV6YO",H#F@'CII0UOJ:::)%
M$<=\\VOH"45/M=C*)0G$+3._^/QZ^JJ7PQY?0783O5?47&0T> BJUAI-"].%
M=;#AGVQ#8DAG]\[V> >]%'RW!&.%>Z?HE]O8JY\'CX5FLJ4]*K$W*"V/E"G\
M!$.YOANRB,HZ[[N2IA.G M9^VOEE,R3!DJ/K;#F]YMN=[$@X1C,9$Q7AKS9)
M[J:=<4*U<M*4ML'+-+,!G-?+!>E452811H2@T^*1$T4PK-!MK<:'<[%80B%D
MB;9&JC#)AG<6UE45O&4W:,2L+AEA>J+6L1$I]K'D[?\NF/YG^$LZ28>1BQ"#
M-L\^';>1C<0T&LZW?M^/PX&0J"69*R+=Q5:%ME9O<B&$\&V,CHUI/_. ZQ),
MA:WA0_!ZK90K1;(2-M*X<!^"0F=HL=AV_MB?Z1G[*KK4I:&'B_;MN^S@A!Z6
M2L[)7R;E;*W&A<I$%$B!AD>2&9-9JF'XLU0V,K/?V)Z@6-JP&5;;;0G0!"+<
M?J2I %SJ\*D7TX82*Q@\0#\)JHOYOY33:]X9BH;3;+KM7* Y?'$C".&@L:.'
M,9W\:2:.9 WW.&D-11VS#R=3/"=89"$@B#AM*!Y4Y\T=8@CPVI;(J'FX>D%9
M,,)O!H*$W_Z8;.-R=MVP)4;V\Q^/OZJNH;[(A634K-7W_1#!J+;>LXP4XB>U
M$Z%W?5\#J:9;+Y^#O Q_FE'.WS^8HZ<TI6B54D![X>A=L.JLH*URRB$];MV&
M8^EI?RE-W>>_ 5A[8,'<_$^^I_T-Y.'O-;47=?2^#<N9,0Z'G51;JY6YI7NT
M)9A)!;9&,^!/R<M:$_F)BF#0J7)[>RC2*0\NP,59A=IGT>NM$Y-UCEE55+F1
MK"OSV=EX7+.V HOKUMD@*K1J^<3;WPBN<WD3/B*)) A[!B1[QH6.>L8^EEIK
MCCP>9T M F+210F:T[U#]Y!H;M8H).(:$:(F/I:<B&)9L:_[_<1K7;'!KAQ+
M">_PL0$G"[C#\I>C!P;<N8F8T+2P5.*&D)G*TEY1$G]I+!+L-/:BG@G)>&A4
MGN?\):W7XB>%_Y8HJTB7D1Y*;-I?-:.5/5O(1&*D2QO]H&@(8PPX"764P*+0
MM01='E?.PWB35R8RBUSCF\<9]7'#TRIZ8<)><'9M6(L7]$,CQE?- _GTVVIJ
MSTHF^XF<UO&Y KH.*R*M[EL42HT6ZOJIZ;4/.O%O!,7#O6;]U0_\M,%=IMPA
M]\/F4E@5'1FP2H9YQ?T47#N14#BB:^P;H\R7;XHUJ#5O_HN\??)DNQ"8G[88
M#K;U;,"@JS?O@O9^4-ND7JBM4PW2ML8[R<TVJS[/7N59:WI5.29[(6?'2[RN
MR0E#EGT!O/OZ.$:*_ ]] D1":9U6J,3VBR]XW\0L["08\I_<2DI/-XSLGW&3
MSG$TWGSG_8))@3V5CA_ ;(+:/WV+(OBG>W.=!.;F'V.?VI8^Q;/3LUM:$;#B
MCZ6*\LVJ\IV3*,,>9G7R10/W2L,SDM[[E=I<DKRP=FUC+DXPR"PNLR[67@P5
M;DR^NIF1 #'PSG+:4?Y_C>R?XTH\4S;UW&"=_]-]_S&JI\*\:=/%>$GQY-((
M#>*6^M"V^5PJ:0 >_<,_;A35:S?<O;B#&D4R#7'NY%9G;C!L]=K.\V^WGY/#
M=_DV*.\_9]/Y'T2N=AB?IKFRS\0*(3*,C7BM),$+2#H-(0;(A%T77"+N9SET
MLPJ:$_(U^YK5&)"MA >K4J@5W9ZYL%<C'N[FF"W=HER2%J^4'&,L%Q:H,/::
MGXE.3^M''D0N$D_#$R0GO_7<F3SS3Q>LF4INWJF5<=L6O-'3<!361]KGN7D<
MWKA.#$OB]?#HV- 12+_E6HKK.BR(O"2QO[Z&D6+G<40I(+(+VR,/T$)!5=3W
M2?X\;*V)B0T2R?P3CI6+0D^*U'E@A)^L2P%<OT)<I;*C3G.)8(BC>$F'VJZ
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MG_I^VW=]7IFY[<N1@8!NU_55E)4(#PZFHK WQ@V&=@]U[$^]-6-M@%%D0S(
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M)TQI*L8)8=AWPU)F<CUE0AN2SUM+8AO _HDF\7Z%,1WPS!8UI:EY)H-(!)W
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M]S?]\B](L6$75$PWFND<O;\(QF1*5JC@,8>0LCH(RM3&\O&N0_!ZLOO-)'T
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MLJ:/.:YS6*,J_R[U_\?;>X<UG77MPCHS%E!44'I3>FA*[SB"E 0)$CHA(-T
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MV/GH#^CW,T]N+R>EC,T$7+TNJ]4&)$QIHYU6DUK,.:]4YR[U"1\JE%<C=/N
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M=7F=PVJ9BN-?58Y-!)-;+))'RVXL=-&_><)2EM([J_)',[V>+WK6L-V0.#!
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M&]WWG<)/#)T1)O25X&8*A@8U]/)H(IK9-&HE3@7-^WGNTSA]Q>6<K:XGZ?Z
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M/(I,QK.G"A%:](KJ6JM"!WG.MV+_J9_SA>M#U4EVUK/C(N&X";V"3AGQ^(Q
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M#\!ELX[>'N)4<$871)I4\2X\NM1/K&T O"X&@FKIITH<-S<4=,-B&O+(G[T
MIQS4I[Y*J!66D$#1:N6$*($2[]JNVA[8]E[IU+)L5,9.!H3KI:-?W;*1%<,N
M\/VW6]_%J0"-!4'I)I)Q#6CH1:'VXPBMH7?@1.Y/EUV?_]\VWZO#M4]O&,YK
MUW0B:(1!H4:-GO6L(DX0;L-$M:=K?W!'@;!8;4VMKSH4/?T,AECG%:B(]:<
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MQ)8O?TT0F&5,7YBTN/SC/V>H^C<V4?\![K3!N_T]UN<?X(E<I!G.!K"[*_T
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MVGZJZ?6HI*ERK;(Y7T6X2,AOTN3R8.8VQR1[?(^KPJGWPRF9ID//^N@91%M
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M*:Y>0JPK"<HK"4W+\X@);(\5' A)D,>QIJ[$&J!3<<4# P,7Z?%^L/K8A:
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MW!?@W V%4A<CI9=9VK-#RB4E2#G;"8%H31CVG,J@$ B.#YE"9VQE[#^K2U6
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MTO@GK ^O$ -YYQ4@^JMXWB\XM%M#HH2,0H=2T;)\MM*;Y>E3IO<3VOD$"8O
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M9X'W^ZD/=LA6PTC_S OB+.XIMPB:!+T5%/O^-YIT1:.A)MNIM,!^N0WU>$"
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MPY&8M;JZT7R;+W0SN-+HA%@/]Y1@\]%XNCVL/R*7W]A%[Z$]J_7HB(>WFLX
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MPW^GJW?"_!9.]==(=K30T?'7E(?'SP[,FH_-T%QC^Q?N9*GG43ERC=W@R@[
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MA5Q[<MKLS3U1G4UM=DV!TTY0'IY;OZHYR%X<L0YBLSJ+4MI7_NV#W\K\AF/
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M),%6;>>C$HUE0[_ZK-TH-]A,UZI*<R,]\<5%H&O0>?&22>L7$XHEQ/TSO=?
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M31E:H-+5S-YBAZE:P=8GQ?"# A&G.\?#Q62U@/Q*T=0NFP?%[3[NTY)5 G%
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M,&6C>*PLF> 3NX1:*^(1ML=#.:8ZSW.*WL8M$07IF4:=N*0M/K/50\%P>L'
MC2%G#1:A!>Q )VFX:"1+%Z^.:845)/8G<X.VM(T^M89%/Z.3]?I[DOYMLPL
M3*G#SDN^_6^K]^]_$'$G YST /')?1&;DN&"7YFN-*>XWROU?M*N5II$OJ!\
M"]CWF"(AQ6I<&9'LT6$6RG)/(BR3D560,)JJ'$:T4K#.R9U[\P4#7X<J/JE=
MJL\4<Y6%KO6G,3U=Y';<G^Z7*4XUO06 5H[RAK3G5+.2O8=7BYR]W0ZV%LU=
M\7[*'EH8A,2/7#V6,!L$ 6=$9:5),1+&5?A=:#PX  "8/+L?].48QD5PL$<
M*[T;!7=)41_TYQ^-F['A"\PWULRQ5Y$%-HM8)Q4CM<50^H4BRY@R)/_4BX,$
M?FE@:HK.C>95\"U@A669S<M^6@K%7^6935KW_ V2+R#6D)OE%O %]<6BNYV[
M?7'%/N"NRME_YSZVCNJ*I1G3DB@NZ1'M0E3:-Q^:GVM@T8YK/@O:B$";UUXZ
MKKQO%.$ZNF>?"CYQ#BZ'>NBF]2\O8]CQ.3Z1 ZA'#J;/@O9H=I'MQ=4<+XR.
M";YQ-UKHG3CRDLEE%_HX@#N#BIZ-.A[_O91W^24AW.U(CQN9]5M &8>TC:%<
MDUFN&UP21I<V.I>2O]#:+DWT"$4.( !_B#X>6!*<\WQSG;?TF2KY@FYW==0+
M1-57-_Q"0I>:%WA*_LWPU;\P<A_>B(H(\B.=#=#TMIULN5D?W%II=)(DN0<N
M%'_=*"N.)JXG(7P.P-]8MM\D2I?,2=$Y7@V$\Q&<X=T"Z"6)4T(DSVH-66G(
M*$B>*G#_(V[^S=N2/#H_Z7XF62'@.9O,Y'-N+)"SVYZ1TC=5"*ZLY@PN:.RN
M%88L"DV'<:)+(ODZS*2S$O7?@G/;UUSA-KPA(5.2% HQ.;6EVB<"5%ME<Z0Z
M?A16::20C!"<>(#> 9_4FM?[N3J]B#HN4K3Y5!RPMM7NDL*AIHI&H$LRJ3A?
M#,),E=UM!35N>9QC&![ FGUS#W_ T%N*MRS;UV8_4Q-/,9IJXP 9[(5*%G09
MM2FRL-8S4W"$W5!GZFG1BVB[#-0 /$B#*2,&W$*Z9M]T/W7&1<?@; :J&<T?
M-=8,'> Y[K\R>QD;TI^M0H?D[F#J*T# N XB.,U3@]?-?O3S7I 5&6IQUYSE
ME5A3,S?R0DO=@#WAHV&SBH]K79WKSA2I\Q;U94O!>=;1R),JT@:@9NW,U.IH
M?CVIY6+\#CQ8I\)L3(9+68M\[+EIA:Q5B 2?HQ<K!W=FZ0JMK1!(]X5,WKA+
M94%1GLX,EZV'FD,4%HS?2;2HIS@VUR":^*PF8S];",65J9T2+K+V&@ @V[Q(
M03>NGF#[:8@_;,9VC25K%CE**%/SQL1K7G9RAE&;J]&.T@[B>;R>L5Z]0(A)
MN[:FYDLS7.IKZ6UF>L7U.:+,X7'[@F +1J'3!A6G#FA^4IN&1R_O8=*QF?+5
MTWO5"'M?H_=H&J&"KZ6!'P" Y[0#<\3*BW9$+3TSJ"#5*I?3977;Z])O"H+O
M:A^AJ^"Q<NT\AG#7RG?9[]Y7PG-3AZ,49?*CHLQA#(3O'966A-NMNR'-T^_0
M!^^\O"8Z4[CJDUIG%LR<Q-!8S#;F1J20V@O-$]T,ST"(U43.\76P (1SJF]4
M7W/W*NF='CQ<JCD+.B.H&%"0I*)YY-(?+YM!\<N_#![UC8WADQOGZPF7M5'V
M.ZG#\Y9;C4X$9"\+#G^<2M)S#45_G:*+^*G)=F\BN5=VDWT1B<RG$99XUMGV
M$65[;"<+VA=$2W9>+"Y94&WU+V=_-2JFLPK:VUKKG"F/:3)"_^B#[8(GK@XB
MMNE,RGVE9[WFD$'T]$.5]TA^\O5PPZNT*W]?+-\M0.V7M W#&ZEKW\NHEA^^
MA[ZXICE2Q1?G1K__\U\UZS!FW[GT#EN?+!6"7U0*KD%:]4POC3OY(XYV=19N
M ;RMW7DE0I@(MSIZWM:)TM/Q#5-D%5V:F@^-UJ-?L\@+5"(.9_(9"N$<P\51
M8?+-<NCDTN9>Z@/>UB>:5P_]"WIVRT6<Z4W J8NL)K,R1L'A5(=0Z#UMR=;.
MM<>7KVX!G3?<OK:?^BZNLVX!2;< ,[U34W9<CN]5$W;DFN>&6E+(</+!C>2^
MYZ4-0?$4^+SI1*/)12+/XA;0>Z,O.4*SN'SH=_W5=_D60-I4]?T_M&+R3R-\
MX#N%V+\O]26#G/=9!B6['0*QJR^VX.5:4;;6WG5APA-9[9[4LP\M+*7-?\%\
M<2N%96&YM<CB#,;3.>^;P_C$DX=)>VX!*KJ:^D<P-OM\<,WTZ.KR.*OX&YMM
MON"CZY"D*!RX]IBGM4#V5=3+]P  QP:6$$?:YP:/6(;:85,,I"K/UI1W1H4$
MG.2S!B<OK#(S'9:'/9//59?7='%94;)M]/ 0D=S5)6,T*V)9JQIJU7!/3@#%
MT<GND!TO7A8RB1<18>$IV'*"$M\0,U5RI-* M!!6-*JXA!A'[7ZK:<!HD1PW
MA[<9F(1=52Z[<NU5E=\([H@QVRS[8UR9O<DKP8,UEU$0*W,2O:!!:0[DLS)=
MB+EJP6*;U\@V [E2Z(9-*UN?8]Z<%$^FB(80CQ[-9\:9;L><(=,I0UW#D8.J
M6'HA1_'\O.JB6KD,6;'M?R'G'^:W],DR#%$YO@H9N@68:@=.-$;X]+[;P_D,
MRTCF-XAJ-0<$!S(10?@!U*F+S)LI;?;U)Y\O-=KOBPH?R<SWYYU%B2:X9K%X
M58B96N\ ?VO\[;\0('_:@G\_L@@FV,=W%_<9G]^[&R,Y$3]V"\@5*3\'GU3X
MND'3= \(5B7ID.O_N8[WF]&T'M_*S,OFX^)7-R8';#Z_WP*>K46/;WO? @#"
M4M=! 1@JG2ODI:YD/<W_=4T\O_QB[C;6T;+_U,]?Q^LP8"V^X;Y%L-YE\L5N
MBD-!1A[C+'%<_TGI^ZDWISATO^A"MU'"4U>7FB\<88PO"F6S&V#38]J:7Y)-
MJ\0H#9X:EX+OUU#?]TB1UT225\SQ8U^,+"L;5V_/.'YL\_X;/'<TN#4#<"8=
MMX#Z0TDSO2<ZLR07!LNK\VG/B8J\:>2P30(R]]I7-'_6M-'JF!\=?W,+>%M;
MC@,^P]1W#A/?Z/KP<4^#SQ0,F:F'661P @<#UT3NS\+5<,&_MBZ?,NZN*=1\
MUB?+/?98=N^R,VL$A963?:'-=79?$2HVT&2(R#!EZA%Y-D*8&;5+'5%),XR@
MD=57I+BT+*"8%_&,QG6:&C(#MVUC_0N[KSIV!RTY.*W%ZU533VJCYFHW'65L
M9/RE?X*TJ3,GK:^O>C7!]_.E+^W^Z?V/Z58&6655B CO0><O9M5/$Q^NKLGT
MUF(B.'/]4W=.659:!7XT.2$V5+WI-@9YZB^LAB5;M.)<XDI13=19IV>@_2Q=
M<DFAPWS?3.NF)5:N-1HS?*X"5_CK)3.DC+GRSQX'0T8_[Q.-T#CVPT^P7<U>
MSOKK>/-B:5L;Q.8U1Y6229V=N9J4.K_R \21V.I]H@7)>7"(H9TV2RN.YC=#
MKX'JK153W@A%W:NEM @B*&T>]I_+XO_'-O"336\U&B(\[CK\@HOI<K_KH;3)
M;J]5'PZ\-%T/(Z]03T=V-PXZ!@#52,?\&/-;7V61\LW^9SASFCWB&UD?=E$2
MWWWG1H@$KP '>8SA/W[)OQDJ_>K+NAOD>Z_Q\")D$_ZAV2JB/*Y) +54SAYY
M83R-S9SFT,?E+927VE9&Q-]_#,F6JK J5MC]TFJ"DJL(G$&+% NG+-+:L0H
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MG 3#ZZ3"+G690X)MDMUQ&%W>5O#D4L(3+4))TK[U[F4%0GBP84<$\!/P.95
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M'B%JB3WJ2&8*=W89*^I^:7#'?*4ML=:56MX41F\9NC,76F9/"U,3*6A\7NT
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M?,5J'LL6J+5 ]DUB(EZ6&LR>:BV&!< TNK_E74J$Y&CEMQMN&!*1.3'KI)Z
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M%;U ?9HU/IZ9%Y36^\#Q'HVKWWKZZIFDI(2PQ!<X0!84RL(N2Z8L2R:?! <
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MC9_>RVL_>G;Q/[M0_D%/% _;/F3"UK%F,8S0)F.)!?U(7PEA'BO!D5+Z7G*
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M9-(? "5EYB\D^B#.$.KCRF\1S(&YYW^.."7ZWQT>3$1>N]ET7K=1V8=:.56
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M)98V'Z$BI;3MK!G&'XO>.9EVEX#6 L%[(ORMQELO^GS=N2TI-LH7/=Q GV7
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M.^;;+IN8TE?)T9M7?9CP)=>@"!Z)YIV$BE?$3G^$M]NY_P%02P,$%     @
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MWO&4"T@R-T*CK:86YYB+DMCG@FDD\2 *8Q=BXKLPC0/D"=9YU,%Z78/L\LU
MQ2[ -54_U2XO=/W5%CKX0X '/?P]D\OZP#L=BJTYL H@%W9DU9EPZ-!JO&O8
MM$=\2S[B!_ZND&5XJS"ES$%)"'GDAQ#AP(&QRV,8"@7*.(\I";6&[.XO/[.H
M-_4;$AKXVL+3+ I^P0LUL3:G4$^ -8C3[X5SE 9;_6[V%U^VI\U1P@[ZUAQ_
M2D^@FI*S\GGUZY>5[R2,>RF!*<$4HB!*(4[$KV'$A/T1"?LC4"KRWRTY>\I$
M)O/JOM2X5DU]&) [+B=F1.C)QJ\?KV^OWH$OMY>W5U_.%XM#E$>N1;J'6TGH
M?MD)P6"I1;[XAZCW7_8C?]'/2?Z047E#GM_)A,'B&:_KY_V^XISY#O?]!-(T
M%$YZ1(6[GC@Q)%[@!A0CQ\=4M1QR"MC,0M&"YVTV<@M>SX948MBX\-AF@YY8
M;2&WV;<=#\Q[U$\R0ST[V293S!*41YEC)S=9E<B1].3))1;+4%8E9IBDK/S.
M&9F8EU7%ZVH0-O<B3"(_X!![U(4H=AF, QY 0APO\5-A"7NZ%SG'X,Q_>=,D
M$^RN%P!N,##(;#Q@D>+-PKED:]XF-/2V\&:Z/Q@CR&8*WP&,Y?/O3I%Y-'GN
MY,-Z<BFG75_EM?!M;_&W:R86RM*,-FKYXZ8Y(,+$=9S0ET7+20(1B81ED<ID
M9^(1PN,4(Z3DGDY"FMFV:&'+'%6P#QVTX-5'O8_S:UQ0K7)!3UB-&: U'%Z)
M.*-A\>,K+S8\7HG X3!YM1?,CM-+L2#+UILZ>^*[!-E!0"6.@X2Y$8$LID)Z
M Q_)&WX7IE'@>D$8\81I19>G ,XLQ$/P>WGL9X2@)GFH=O3:Y(R>8)_)%.TS
M69522\?S)+A%3VI5XE\>VLKOF2F"]T7)L[N\#5#3Y]L2YU7;LJW/H/_<)=9?
MRE(-6>CBQPE+T@C!B*5<J(;4@PF//8A3Q!!/"2>A5LJ//@HS*XO/G!9W>5/'
MDK:X =HA!^H==B!KQ[ T-4N:N90&;%?3)O,R4T^_])#VJX Z#$&/(AC@.$M!
MD#E++"DB P0654WF#'JIK,Y8R4Q]_5+D_/F7IBKP_29G_<A[X5OX44 CR)V(
M0820"Q.4N!!Y7N)S1)( :Y57'@<SLQIJ@'8ECR"58/5TS G>J.F1\RG6TQ4M
ML2U T$"<H11ZG"A+TGX"R*(2/4[H2ZF=>-HT47"]EG5X/.<EEDT++ME#EF=5
M+=,3G[AL%IM7O/]2.FX4A3@A,$:.$-@T32%)A>@&-':0GS@LP:E>($\+_NP!
MO@Z;"W#7XM/<5. ]C'33"'78&S&?Q9Q%0@MZ(40D%C_16([Y"U*<Q"Q*0J6K
MGMF9:Y27^:JL55.GLS%,3\MN>?7S@%?[J( >EQGTKQ$7K&5PZL!>.)/3@"V'
M&9TFBYCI]H^\EH,V;\KB*6.<O7G^M>)LT-[N4IA\3^U\*V%L(4H##B-*?8A<
MH=/C)":0$QPB)Q1^9.RM:CD-0DWSJ(/64CM;!)1%22 ":#-MM$,%D&?PPT9@
M(_S"'T&QK9? 6XSTU) &D]5TT#RLTU- DFO-C-:;(==^[;FVJS*YG.::MOK1
M9X EW:,!>%'%H\^0EUK'8(6Y5<XEJ9I$S)6'4A8QGL  $PQ10!!,?.Q"-W&$
MO<.D%:0T?]P<A9DMGT]'=,Q?YU(R6[;:5C8FS)I=Z8"O/5H6S1]SGBRNA[8(
M?*?ZZ"6#S/72P4IF^JF;$/TL6R+UM0:)QS#E3@1]'\40A:GL*>!%,(C2@'"/
MQ:':#?@(C)DU3#MA_+$%J:=9CC%$376<2::>;NAGJ#?09JBK&"'&DE ?@["H
MU(Z0^%(LQQX]KR:B&>V% ]_!7IK"R)7)W+[P.&*2.C", B=T. ZC-#:IB%A@
MWMJ@9,!@1-H>%]2DS)0V/?%2)LNX#F*&>6![2[]*#<38+*ZCSQC&:&41@4RG
MO?KG1E8I%0^/12Y^K9KOD4,X"G%$(?5=#Z($$1BG1)QF<4QB[(5>XB&MH.$8
MM+F3N!J08 ?32,S&^:48";3%!3U!U&: ?G!/A3!;P;Q16,L&[U3(/@C6*;UD
MW(?^ [_#@S[1?>RO-\-2C\0AYBGTPHA Q/T0DMAGT&61AXCG8T:0=C_Z<9BS
M7[ TX"UTHY]@W;B,S\(./3GO>[&W_!AV8M_&]:=L7$/6:+>KM\>B\]K6KQM6
M\9X]75ZTW9[U:K1.]ZZ?6&?I'O9J9!WI9:_XHIE9<_7PN"Z>.?_"RZ>,\J:_
MV!M<R8;Y#Q).\S6Y7#<;)W[ZE.X2OMJNL$UC_0_;7JYAX*$P=&(8(\P@8L(&
M(@%W(8L]SH(TX*%>PIME_.:^7Y7H02+QDWYR.Z%F-ZWFHE<L3*V3["([IF:*
MO>(^Z"GU=@O>*&R!/ #?XL>L;K.L^EZDEIO\SLQ 2T:B;>P6-2MG8NU+0W0N
M,.9MM'_A]7W!=IVP%-L=GWA]9MVXUU2[!:W>Y/@4Q>/*RQ*QFE;E(9W@J]7F
M7@IDG=4Y_.6:B_<./T'4L>[AIQ[5%ZK;$LN&JN*L>/-\G;/;9KJWHD0=>W?N
MZX86Y/!LJR[D99V GSUE;(/7ZN)UE/9IV3J7;,WKAVF*A:!)'"S)V!AY1@)V
M=,'%I&N,G*%HC3YG6$+73T!Y7Y1R_LFN.$<.2]G]MJ*,^@P3%X8T]2'R60PQ
M2QR(L8=\ZH7$(4POMU45].Q1EU^.S>.Y "G.2O"$U[H=W)19JF;?S\$F/?%6
M&)MCL;Q.DUQ;97:J8)<MM]-DQD'9G>[[IN7SHUWU&74#[F$,'<>E$$4>@X2G
M"?1Q'+LTBAD.E$;RJ8&;^PZFK2,_UHU?J1F_"0/'%85]MFA>RIS)$8,">\,!
M!:I5]J\_E$"/U,-Z^QD&$T@#Y#JO,O%D9X<TC7:%]K@I"ZV940JKS/=M[8"#
MWF;MP3=!)XD#9S,-E-(@V\B&55E_,9-6@]BAA:OSFD%TAOWCMI Q(8T)5,-W
MYH[#;$<*@KH P]B5_NRI/5(58C&&5&H&8$X2:'7:U#%BS,(NPX66B[4<07\O
MP'+L[X;>'V.99#]>W^",7>==T'UP>JR\$/F$N@0F''L0(3EEQO<H9%Z<,,]A
MG(=<T^^;!#J[Q[=# 3P*'&"6 ]IBH>GJ3?-/T<FSRA-=J=PR0P('@AD=^(L]
MH\ZBCZ=,K2WO;AK@LGZ=,@,./#KU-PT&->Z,1'E#(D3K6?.T/+W"S&>GSF&B
M0_?TT6F'9#V1'< $/=#YSM-I"LV&.)Y>=KE9CI.D[8UTG'[:P"B]NZO?W@MC
M-Z_RW_#Z.O^R>7AH%Z[J_):LWQ?EY>.:K/^G[(JU52U7W87G-F_O[DI^AVL.
MWM[+:P)YT-R(YZ4Y^)L,LX(B!9>4;AXV;:[7&Y[S-*ME^R)PN1:GDVS-*K[;
M,G>XZN;U--5/0%*&7XK K7JYA]D^*)C5<VZ!YBG_&MRW6'U_%CO-K']M:,NY
M"*:,V/,CC!<QC1)_><#K]9M-)5SYJEH)S\'UTC"!+.(8(NRF,/%B"GTG=H5G
M@4D0:;96W5M_F3AP Q+T,'6COOL,40WS&I-I%-=5I- @BGN4CC/"MOOK+1RG
M/4K,86#V^&/Z5L/;X@M?<RHTL/Y0]6/O+F">XUQ\F3K _9AQ;5/]*-W3!_&Y
M).M)CBFU6H?A&$E&Y]W1!1<[TL;(&9Y:H\_IR5%5UKL:EI]Y<5?BQ_N,XG53
M"!5SG":QBV',.8,HX!1BQEV8!H0@Y/LX397RI4>AS"QV0W!:M6+CK!F7-VL$
MZPF=#JW*@J9$RUB02BPP"%")WW8R-[[V(H*G1%XO?6H/&Q9 RXLWSJKW K5?
M<-VE)0C_Y+%-%*\N<_96G)S5I_1T3L,*12%W4Q]#-Y0-,QGR8!R%,112C%(G
M3OPPTAK8:P6KF46\QQ'(704/6RRE._=P++%)LR;;RL:H!<$79[>>@MGG] [!
M"S! L:M=$$C*#5@T<\HJ^VP5H5O!:=GJ=9ML/"A[M[JX02HU)ILU+C]D5=T$
M:+0K%$XN,+.:Z^ ""?A"-[1WFNIIS\$*P7J*9DAKES=M=P:Y$EUF>=0G5UTN
MF7J*L+V,ZLF'#7M2'"]!VN7'OWG>/=(5PS6%$Q^V>50T=KPX=@/H$1) A!B&
M),8<^M@+,"8!\@*MQF_GHS2SB ]+-/?OLG8XRJ*"HZ6<36F/>>FFA?U2LW&6
MW04]O3,LT)S>@#>F&Z#?D\,:SVPU[C@?H66[>UACX$$+$'LK&U;)_W)UN9T$
M&W/AX070(:D+41(',"&$0^IXB:QTCP*]3IF[I>>^2MB4Q2._ +]DC(FC_@J+
M8[]I:9V6PKW6K$'?\4--(9E1J7F3(&#,T(C[$'5;-=>[A9<MESX@Z*#2^? )
M?2?@ZI_U\^4?):OLY1IH++E8EL'/0@G5X)W\\;TLY=K><G==I-HCJPW)VT\G
MT&'RM!<R$W_UQ'A>UEK.%3#@F)''HP-G,1_(@/BA5V3RNGZ;K^N<EES8!>]X
M^]_KO&^KDV&2K=N^MCEKYKUV+74&?UDA%SNA3V*(H@A!Q+D/8YR(GU",$I^E
MR'.4T@?.1V5NC=9U>-KV=I*V0=','NX'+:]WR*@WQ#J3_^-*:UFNZNFQ'B_0
M(P:N<[!M.;;#H&D\U@YY[M ;_G4Q1JNW)%N.X6:]RK:,9SWCQ8F ^P9F \:/
M?L,M]32SPZR19F=G EBL"YH=1@S;HUE:T>90X*MO=+UAG,G NSS--G77"N@*
MEWF6WU4WO&P\U=9H63D8N5&88A@3%D!$?0H37[B549 0S!@*8R<\?W*P)E9S
M'S3#2;J["T-Q\+18MA=?=(>GM/AXAREX%-):25PO &[;=?T@I+OY1'>NJ)TM
M5/-_%]\839O[^'1C<+6W)V_W]Z1'$@@LVVC=9 &AI3'(AGR;=5:R+D[?P4!E
M0S:J35TV75S?PO_R*%:6F<5573;F0C]NCC@1<UWJ02>BI)EG"HGC4(A=$B(G
MX"F)$E7;_120N6\K6K#J5N!)9DP;TC9(U+P*:"$"" 9 ISUT=:+5C5H;Q)N9
MJT>98,?XG")JQ*P\^>IB!N,4\D-3</)90R.OM2??%/EFT+R9( <['#DP#3T*
M$<&.,-\\#M.$QT18;YSJM;@]"F4A;Y](H)IFTU&F*)I!YY*J:=9T5';P9AA9
M,TJ0+7OC*(QE[8<Q,@_L@=&'S211#JB2_Y>1WR>\EA+^F0MASV2*MOQ#TQ][
M^,'@R56 D>_YC," (6$(^$)V$\(8#"E)'.2%:823U6/3H_5+C<M:36[/PDGG
M2_\2,^7OOX1YT4[>Y#O0%UWK_QZS]@%< \+OLES:9M*Z;X'JJ8;S=@GQ)"7,
M#R")XQBB-(A@'#($N1=@)V A2U"_2U<Y^R[WJ,=KKAWB,F+U&GNCIMX7X[;>
M,= RN9EJ>#5D\@X5T#Z"FQ$0>Q\.W[!W;%AAE*7CY3Q<%CV&K+#MY7%E9U%#
M [.J>-T?D=NIH2QV/>+''J28"P,3X0 FB 70=;PPX4C\#RGYK:-09C8P^ZL,
MW,#6G+1ZG"V*)N:YQ&J:F VXK64YRRS449)L&9E'82QK9(Z1>6!DCCYL)HT_
M%P7[(UNO5RSQ/!Y%7,XO\80EDK@PCM,84H\ZB6"=@R*MV8C]PC/+7 ]&3]BV
M5*O)EPDM>B(U28:V +W$V9+,;)==5$Q>$O-2,@[^;B8,[;59\?!8\GO9D^.)
M7^>T>. ?BJKZR.M/Z2W^UHZU>'D/MQLJ[M+8<1,/8I^Z$+EN#). >M"-***R
M-V\481TQ.A^EF06PO<6G0PQ!UJ (?E@+)'^\ #FOI05?XV^:9Z*%_5 3\&6Y
MK*<:NC2)/09?=PS^T#+X8\M@@>0L9[$][EA20A806E1]V6/@2\5G<67C\F*V
MH?7?L4Q,KY^;.)CLH-?6W*T8]I)8&A2Q'SH017X*$QY3&3=V H=[$:7)*F]2
M'Q6C&^, E<0P:<5P"%99&C_S1YR551>L>%QCRL<O+TRXIJ:T+'#"[ 9+-FJ3
M6:B2!U??:I[+V_(.&]"C SI\+G:Y8++?58^>U>)<!3;8J[H= [9T.:T"X4?J
M9%7>TL]]?R_H*'+>M^][M^&WQ;NL^J=8/4NS?CZ8T$==^[-*HZ^.R=HSVST=
M2KLFD6S#9>_EEVCU!W./F7[#:2/&CJN0)7BJIU1F8Z=6:OLY/#'*<3<"N%BR
M^SGL&&:]G[6.?N>A3L7)1,AN;F'UKGC 6;YR.$W]Q$/0"9T0(I*&D'!?SDL)
M7.*PU(N(4F;[*)29%4]_T,K3MP,,OK:0-5H0G>;1N.:P1KF>>C B6JL7T211
M9_0B.KWV8KV()LD;]B*:?MBT3^5U+HS AT;@/VSKNP/JI)3X'+IN(,M+/0(Q
M=ESHAY20)/"P3S2G&!T#,[-8=CT=!Y -BN8G&#4NFO;(UY--4\H-^EJ.$79&
M>\NCRR[<Y7*,M,-FEZ-/&]9[]Z-^9:O[3X]RZ2ZC,&91D(1. %'@R+LY<73&
M;IS"E".?A!3SP#6;;_X2TLPBVL #10.PDL;EHWCP7GJFM!W&4(T.8]#DFIH3
M;X47FO[[U+3P%HTYRLJGB+4]V?L SNO,Z#Y%[LEIVR=?6+AG3EMT/$@Q;>*-
MM_<X;[&K?N-5S=EUWL88_\ZSNWOQ^Z6P\O$=;VJ992FSK&1N"IE7POCV(X92
MB&@<0>1%$4P8#2'S?)=3+\3"!%^D]8YMRF9672TV3=T/*]9K7 ZJ@C1+@+X;
MELW=U^<UM]A<(QNU![KHVP,,:PK:BZ-:T-MI].H"=-\C.:&@(?H"]&2#CN[C
M'0B^@Y9#<VWG:W<NLD[7OT8#I+FVTUH?I=D0-#O#/_"JXOR3T/J"@/SN@[Q1
MZ4M[G_OP_;L-_\B_U;=_\/43_Z7(Z_MJA8A#Q1$KS'4JFS>QR($X),+%=@+&
MXM1SN>OK'+FFB,Q\0@J!#/4.0F..JIU;2_!)[YAI,9+V?8<3:)"ZV/9>>+Z0
M7A'AS;2Z"_ _')?@4VY1^9_+$TNZVAB-157KN<QZJ0G/7L_0^:#WG&W6_%-Z
M9M%LT\MH%25N&CHTA8'#0H@X)I#(7IZ(8C>(4QS2Q-7R(*RB-[.2.U:S+H1V
M6[)^=?-%MLBF<M!4X\(W2.EV[+2[88I6_JMM@YX.M;T#^O;S+(RR903;16Y9
M2W86QAZ8H_- ,:PP/$P<ZY/&5C&* DR3"+)(*%OD^!&,N>]#QL,D""E/4Q*L
MZJ+&:S4].P)+2VEN(2J+['[JI,Q)U:PB&^&2FG*S1+N>IE+,&+T EW5=9F33
M3K,0]M\-MELOK$"]K;*N$4C+%FU-DWQ0DJ7PBIF47^=/8C^+\ODS_N,7X9&6
M&5XW5[N;Q\>U4#D-F,^\XN43KU;8)SYN6J(C(?PH( XDOHMA2'&2\$#\&VC5
M@6A!GSMUHKOO87*:2XN)GBK08Z6:<IB-07KJ8HO&!1"(@"TF;<I%A\M6<?3X
MV-,21FRPI#?T8"^J28S8\E*WF"VBG^/1V\/"B&DFX7[$#WSEH\#!%#F0RX%1
M"#LQ)%3V)2!>ZB"A4B)?J=_;*0!S7QIW($$/$TB@ZND<1WDRG<AQ+J6:%Q!Z
M1&IE;HQ18I2S<73!Q;(UQL@9YFF,/F=8.2W#TK?BW7:*8IB@-'"1;!U!(")!
M N,T9M )8QZE7H@CJA4(V5M][CA&T\5: M.:G7B<$6K'K#%YFO$!9<KT2Z*/
M46"K%'IO[65+H(^1=5#Z?/0A4Z^W?"Q*<0S*&7([S[M+VPD3&D>^RV#L!L+^
M3<5)A;GL5NKS,/#34!Q@2BG"2M!F%K,M;,#DN#S3287C#%-U@2VQ0=<)[CGP
M8F#@#-E-2B1:\W3'8"WLZRJ0?>CMJKPT4[93=>K*M[O8O?K&2YI5O#IQM]O_
M_:;,*%^%H8.Y&P;0\[$+420.8Q(E(70]0EV/Q3CA6O>KRZ(_LP;J82V4NF1W
M9Q5O+K[;_=+T 122D*J)+*1MGM&6IM%4H_XIT)"V8([1+%NR5"*17>2_KVRA
M639&.R5H'BR^M]S=CT7^U*0P?19J^7U1RI=6+DG3!)$$BM,KAL@/L#C- @;=
MT$,!CA G@?-]).@>0W_FTVS7$NW?_^R&SM_:@H)?\TRW_G_A3;5TD+W:5MD_
MR.QDTV[I$C]NI.4J0^/-LL*_D+2"CMCO863G6;OTW2?)'D7^^SK;9MF8Y=)=
M1[$X\V;R[T7YNSA+Y0CWZL4E&DU]PETG@2CU4UE\YL.$8A]Z"?,CA^$@"(G1
M?>1IF#.?(A*P-(L?R^)./&9Z!3G",\V+1SN<,+YN[/G1(;#$'>,TQ;9O%D<@
MOLY]XC0+3MXB*KQJW$SJD9?U\XWXJM27>:.3'J4R$D!61$9E.6(PQH$C+-.(
M0>*&'%*6NH'K.8&3.BMA?Y-"516,@=/YY@^!JN<B=,";^W7>0VZ:Y6GWDCK-
MM"3TG(BZ0EUZ27/YZL+8=RBDD="=<8@93I!.%I<MEAFD<2W#,#75:8L->CJS
MAWH!&KAM_ZT=(SZ.,,*DJ]8DA?9Z:IT&M71'K4FBC_33FG['L.1G,*J2N*[C
M)D1HOSB,( I3!!,6!M ) S<2FB]Q JPCR*9#5O7E]E:^HC]']1@3U(1SD4FG
M*N-*]<MC3DW!/+_B9>GQER,D'=2EG#V@\DB/J:MOCV*_NMSIZX='V>HRHUVQ
MRRW_5K\16/YNV'].;?&9W8B7'=-DT'V+EK2?7R)FW'%.D9?CTKD(&_5D6)N#
MX*O$"C1H61JF?A9+;+2<4X3X6CWG]!@RTG1.<R&#D8Q-W._77#Q]53T^2GN@
MRY!($/*<D&&8>J$+4>!Q2%)Q@ <)"@DC)/+<0'DFXRDH<Z=!ME%-V2@GJ^4=
MWD:B *Z^W-QHS"P\R:)QW6&-<(- <@5^W5+:V-T6,T>4Z!H;6'CRW>4F%DZA
MOS>R</+A<TM,S:_VVF+%./(2[OER8!K%4,AM# F/Q$\$4=^-8C]@2JWHK&,V
MMWAW>&XO,"!1300@AQ<HY]:=GKN+BO==K[$WFAKH8%O.R<^8LQC5$@NMUZ&>
MB]<KE:!:8N?IZE-; /0=M=N2"3#"',O*!J9LDJ+JAQU[=_8,MAY8TQ-)W8DZ
M2N>TCW0NB7H*YK;$3#8"&5Z-JU*LY>>,D67DQAQ=<#$O98R<H1,R^IR9L?.1
MUW(@WTU9/&6,LS?/OU:R"]%U<SLK]O)2^#5/331E.P0'N6E$*4NA$T1R>C./
M81P0 L,X#7 :Q5[,M4I%]%&864BWD '>@M:<-63 5C4S8UYFZ8F[O%EM)GSV
MV$A[X0>)$,CR'\&.C3ND9IDH9,X32P:" 0*+6@+F#'IYY)^QDN$0M>,-AOJA
MZ0YW<<B$2T4#>8V;A!PF#A%:*4[=@,?"OXT\O6O<<8"S7^3NNFFMFRDWQC<=
M$XS#!$=1S&+(F2/[I[HN3'A 8)"&@>^YKH.Q5IV!/;:93(T[S;0+0"<FUIMP
M3TU7V^.)GEX>Z\CV=H(;^N/<E(BT-:IM'-BR8]B4"#\8L:;VEH$C)"]&&Q_K
MOEB+5S[7N<9(I.-OSRRV[5WN "KXS.M-F6O/-#I!NX)[=#;9F@Z2(<5ZSM$H
M46;NT?$EEW.01DG:<Y'&GS3N;/50Y$U^?AMTOJZJ#6<K0AR.6<1@DL;2^J 1
M3(3A =V (N9(3RC@>M;'"4BSFQUO!R,+VF*Z"F0-Z*;4KOU$L[[N%-?4#D\+
MG-"3S8X%#<2++N_^ K10K;:O&B/+7NNJHU"6;ELU1NJ1EE6CC^L?B5?_K)\O
M_RA9=<G^\3[73M,X\?K<$<*V6*0)CE9 @-Y4=1-!O0#OBZ+."YVHX2D.3)^,
M%HC7$S\%NF=(F)@@T^BP/+7F8J?E!%'#XW+J4?-.D!OQW=]F+W;W\@1YU&$^
M@XX7$8B0ZXOS4AR:L1-13+TT=))4^[P\!FF)\[*!NTL=;O)GJR*MQ1=844*G
MV!4GCN\FL2S^=S!$G#L0L]"%U*=ID$3<#9'6]'<+S#)J&[( JY1MBG,9H&U3
MM+1O(<[2*624*HO=,(]!6;P3Y@BIQ[I@CCUND);U*)QWO'Y;Y-7F05Y=]GUK
MN!?[B4\"F. T@2BF'B2.O!Y),"&<A2%B2O>28T#FSMIHP6HD8)UBQK@TVB)1
M3Q0[B "" =!I:50GFA6T*75L;N9F)WX/VGE,L)1Y-D'46.+9J5>7RSN;0'XO
M[6SJ67U'Y3JO,O'D;<ENBG5&,U[)<KA+5CS6G+U?XSM5EV5RH=EO3AOXH$\$
MZ+%H3ORFQ(]M9&BAPTC=D9GFT+1+8Y4Y>LI'DR_@JT3'DHNC3+:1LS.]^F)N
MCS*A0P=(_27#+IM4Z&DYOH&S=_RQY#1K,S?XXYHW.5(YNWPHRCK[W^;SD_5?
M*\I3&CDXE-5:D3 K8@KC(!7V1NHE?A3[(7?I*N=W$I*:.V +-26Q25JQ&2*H
M+#URU,Q? =ZA"]@ WT:&\ !1S>Z?MC9(S059E.EF/4<'?!ZB> &V2#8L'Z)Y
M 5Y4DU[LEY-:;%MJF7^V.I[:0FO99JF6F7G09]7V^H8)_1M2\7]NQ$)7LN?
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MBC&+#INOF"_U':1H?LZJW]^7G/>-B9M</QZ$L1=0#'WF<XA"G$!AE3DP2%"
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MA2SZ^-R<4\#@BKJWYO8*O1Z6CB04L6@GX'1B;RX;L PX@%0T*9X!2-&Q)!<
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M,:ANKT%S9I?VRS9_0+^L7P1W[@^V=AGL2^K ;$A'AWIQCF7-P)R<L5+ L0U
M3$NAC0[%12,;@ J. QO(JX9XQR]DO5'=]9^WQ3>R$1\%K?9]]]=,[A//-1;9
MS\6V+/^6%X)LUO\C_Y.L\Y]$MBW$/?ESY4>4!*[ B(C$13@)!2(A\9$?Q5$0
M12RF/LAM6.%J9L=2DW;VM&O4#B!@H1WMZSF<Q74*<TF*G=Z]FRMGQR^2M)'B
M6/[9GDMG4/]7#JU9E6[M3XM0RC959PM>V0I/RT(NVU3C"0RSU<6-(RPF!"\_
M2]'5Q0DU%+4=*",IRG5NY!_DE=QWI2\?OA:I/'TI'VN"O[K8U5YV7#$WB)*4
M)XADGD#8"R-$TL!'<2#<)! 18X%6FKD(MW,7K5I^5267;1\?%6B4HNZH7YTC
MNE$*\F^;/]XV7-7'C*)#36W^ZDF2^*ZP59\DA=U_ 1WYO%]>.Z)\']\3YO@[
MMJ^<_D=MV+X:OG!_V O6I:$-I[LY&MQJ$#N_9NV%OS/RNG3@/+_:!T+N!8@:
M#N8I/VRVI;C?_IH_K=5D@?I>+/@2G<92<]<9FU&I-0L*"N-^_5@#9_WZY>ZF
M-QE#VG_-%G#&SX26QKWI# H"%B U=3/+2$.@].:3A";67W:\D)ZP)S.'-%^#
M'S@<Q:Y'D>WUX[:H5.CZ85M6.S?SZS87K\W=^<_/.2]7841=W\L2A*,H1#B3
M_TAHZJ(H2C/!8I'2.-5M&[/!T,P=9<V(.7*0-):2.:?LY92DXU0&C26@7\K*
M!YD^]%A:S;8R=$=RZ+09^D[#BLM>=%;SZ32,.C6G"ZM?_Z!EZ<]@=AJSV.<
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M5!<:, OX;( JZOOY& 9UV<N&PO:.Z'J"--T6]2?>R^(H8=[!E%>XYM]Z?BN
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M\_F7<X3?VL=,*$3#STRM8#1 LCY9 G9A';TVLR-0 QF;\Z^+FJ^.99T^U+Y
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M&X2ZG*]5!95LL.N_#*5QNM'NU$)S![P[^HYDX(>7'WM(08!8=U(=&N&N34T
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MZW4A2'V.2E.*0YI0%'II(@->)O=GCX4HQ7Z01!$A8:H-X=I?>.Y]69VN*EK
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M*.+8C5$8NS()C"(9G7$>(A(3$;# QW&B=:5]>/FY8[)V<J%I'':H"LWHRUA
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MNB*;3W_*8)<W[>^2V+,Z$_[IN?JRK7X7U1U9\Y7O,1)%68"8IRH5KF HC=,
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M6U:6&2)*RX-3;9V6"Z=CX\JI&;EJ.A GE09'20'+;PL\19_PLI@J8(6<0*W
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M2^,JF\%VTH0.33'?5LV#?ZQ+97O91K#6^)K8]L#\%!*)V= 2&Y]IVN4M_(6
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MM(H!, C_K_MM74GZ<UUJXX'T7YK9&TA:4O[ZF+7:'E0(_AV  G(@Y70%U5A
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M<W-IC/I*_?3+#\-OU#^:-O"7'_X/4$L#!!0    ( '&,J%J'?P!.F&X  -!
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MN7?QW4#RO"XZCY?R(,#R^2M.)A?49V&"=,8#.4NEYN-;\%QJT*HPS80P-K7
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MVKUHO#Q=U4]-:U%R/=EQFBHK-3XUW"#P7$,,0R&&=W2L,^N<2BX7DUH_"C]
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MJ]EB^:%L&!TEY:6V#.DDEE@GE##P15I 9VVR:(+'U@T_;Q P$!/5!CV'BW8
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M)1A-^TJQ8B!B%&"X" R-4*&TGG&Q#WV[74:SGP^,;30V )NX>X8H<88IQ2S
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M)J+?D*4_/#ZM]H8&TYV&3M[B-P;:>%EQ*#XS4$8R\,8@R&Q3+DDX[?TA:#V
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M*_#:UTEEQ3 ABN*YLW/T+CG]'I[]@NL0C0P 7/=Y'._'4WRWQ-/%R$4N,>L
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MSK_C8I020RE,HGB_UK%*D2'6/P7);,:(+H;65G8O G^&?@/[(/'.(TMGVAR
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M>6-JU7%$93-C8I<Q>#LM]C/$TOL@Z1X_M:$VAA13KT<F7W=S3#'.&@\F8?7
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M^\4/O^#\E(\*5Y$IYT%@+9:)WH*KA1:"VR"1W)7(6P][VI?&YY3NLP^^'K;
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M,ZRB@(<&+8)09;0SQMC8>>K,1) V_GS;B=:3J>*;#CN[B^^6$2*$M1A@&H9
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M'V0LJQ^3MA'-7$[/B]OC=^_IL.3K%/(?N_<\*ONI9,QI4X#"J-#(7F# B;;
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M&Q( $               @ $     ='AG+3(P,C4P,S,Q+FAT;5!+ 0(4 Q0
M   ( '&,J%KR5#Z(P@P  "6!   0              "  :,) @!T>&<M,C R
M-3 S,S$N>'-D4$L! A0#%     @ <8RH6C:)(O1&'   ]Q(! !0
M     ( !DQ8" '1X9RTR,#(U,#,S,5]C86PN>&UL4$L! A0#%     @ <8RH
M6GJFJV7S.   XH4" !0              ( !"S," '1X9RTR,#(U,#,S,5]D
M968N>&UL4$L! A0#%     @ <8RH6D=7O^LM?@( :WL# !,
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M-P8 ='AG+3(P,C4P,S,Q>&5X,S(R+FAT;5!+!08     "P + -4"   L/ 8
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>txg-20250331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:txg="http://www.10xgenomics.com/20250331"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="txg-20250331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:ProductAndServiceRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:ProductAndServiceRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:LicensingAndRoyaltyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:LicensingAndRoyaltyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">txg:CostOfRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:ProductsAndServicesExcludingGrantRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:ChromiumInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:ChromiumInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:SpatialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:SpatialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:InstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:InstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:ChromiumConsumablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:ChromiumConsumablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:SpatialConsumablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:SpatialConsumablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:ConsumablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:ConsumablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">txg:AmericasExcludingUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">txg:AmericasExcludingUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">txg:AsiaPacificExcludingChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">txg:AsiaPacificExcludingChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">txg:VizgenInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">txg:VizgenInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txg:LicensingAndRoyaltyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
        </entity>
        <period>
            <startDate>2023-11-17</startDate>
            <endDate>2023-11-17</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
        </entity>
        <period>
            <instant>2023-12-20</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txg:TwoThousandsNineteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txg:CompoundAnnualGrowthRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txg:CompoundAnnualGrowthRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txg:CompoundAnnualGrowthRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txg:TotalShareholderReturnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txg:TotalShareholderReturnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txg:TotalShareholderReturnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txg:CompoundAnnualGrowthRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txg:MarketBasedPerformanceAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txg:TotalShareholderReturnMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txg:MarketBasedPerformanceAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txg:MarketBasedPerformanceAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txg:TwoThousandsNineteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txg:TwoThousandsNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txg:TwoThousandsNineteenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txg:TwoThousandsNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txg:TwoThousandsNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txg:TwoThousandsNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">txg:SharesUnderEsppPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">txg:SharesUnderEsppPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-06</startDate>
            <endDate>2025-05-06</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-06</startDate>
            <endDate>2025-05-06</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-06</startDate>
            <endDate>2025-05-06</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">txg:SergeSaxonovMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">txg:SergeSaxonovMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">txg:SergeSaxonovCommonStockPlusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001770787</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">txg:SergeSaxonovMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">txg:SergeSaxonovCarryoverSharesFromPrior10b51PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>txg:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-26">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-27">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-28">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-29">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-30">0001770787</dei:EntityCentralIndexKey>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-252"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-39035</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">10x Genomics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">45-5614458</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">6230 Stoneridge Mall Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Pleasanton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">94588</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">925</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">401-7300</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Class&#160;A common stock, par value $0.00001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">TXG</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-24" unitRef="shares">111092774</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-25" unitRef="shares">12040976</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-31" unitRef="usd">377061000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-32" unitRef="usd">344067000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-4" decimals="-3" id="f-33" unitRef="usd">49844000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-5" decimals="-3" id="f-34" unitRef="usd">49335000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-35" unitRef="usd">52549000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-5" decimals="-3" id="f-36" unitRef="usd">87862000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-37" unitRef="usd">74710000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-5" decimals="-3" id="f-38" unitRef="usd">83107000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">25566000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-40" unitRef="usd">20016000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">579730000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-3" id="f-42" unitRef="usd">584387000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">246087000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-44" unitRef="usd">252648000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">55577000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-46" unitRef="usd">57290000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">4511000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-5" decimals="-3" id="f-48" unitRef="usd">4511000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">15192000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-5" decimals="-3" id="f-50" unitRef="usd">15671000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">2296000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-5" decimals="-3" id="f-52" unitRef="usd">4129000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">903393000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-54" unitRef="usd">918636000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">10068000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-3" id="f-56" unitRef="usd">12909000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">21957000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-58" unitRef="usd">33615000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <txg:AccruedExpensesAndOtherLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-59" unitRef="usd">45483000</txg:AccruedExpensesAndOtherLiabilitiesCurrent>
    <txg:AccruedExpensesAndOtherLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-60" unitRef="usd">41165000</txg:AccruedExpensesAndOtherLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-3" id="f-61" unitRef="usd">20949000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-5" decimals="-3" id="f-62" unitRef="usd">20658000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-63" unitRef="usd">9443000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-64" unitRef="usd">9286000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-65" unitRef="usd">107900000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-66" unitRef="usd">117633000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-67" unitRef="usd">70631000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-68" unitRef="usd">73327000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-69" unitRef="usd">12569000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-70" unitRef="usd">12513000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-71" unitRef="usd">5398000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-5" decimals="-3" id="f-72" unitRef="usd">5029000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-73" unitRef="usd">196498000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-5" decimals="-3" id="f-74" unitRef="usd">208502000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-75" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-76" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-77" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-5" decimals="-3" id="f-78" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-79" unitRef="usd">2000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="-3" id="f-80" unitRef="usd">2000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-3" id="f-81" unitRef="usd">2208665000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-5" decimals="-3" id="f-82" unitRef="usd">2177672000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-83" unitRef="usd">-1501405000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-3" id="f-84" unitRef="usd">-1467047000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-85" unitRef="usd">-367000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-3" id="f-86" unitRef="usd">-493000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-87" unitRef="usd">706895000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-88" unitRef="usd">710134000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-89" unitRef="usd">903393000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-3" id="f-90" unitRef="usd">918636000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-91" unitRef="usd">137823000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-92" unitRef="usd">141005000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-3" id="f-93" unitRef="usd">17060000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-3" id="f-94" unitRef="usd">1000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-95" unitRef="usd">154883000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-3" id="f-96" unitRef="usd">141006000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue contextRef="c-1" decimals="-3" id="f-97" unitRef="usd">49438000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-10" decimals="-3" id="f-98" unitRef="usd">48092000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c-1" decimals="-3" id="f-99" unitRef="usd">105445000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-10" decimals="-3" id="f-100" unitRef="usd">92914000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-1" decimals="-3" id="f-101" unitRef="usd">64245000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-10" decimals="-3" id="f-102" unitRef="usd">68638000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-103" unitRef="usd">89728000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-10" decimals="-3" id="f-104" unitRef="usd">85774000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:LitigationSettlementGain contextRef="c-1" decimals="-3" id="f-105" unitRef="usd">9200000</us-gaap:LitigationSettlementGain>
    <us-gaap:LitigationSettlementGain contextRef="c-10" decimals="-3" id="f-106" unitRef="usd">0</us-gaap:LitigationSettlementGain>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-107" unitRef="usd">144773000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-10" decimals="-3" id="f-108" unitRef="usd">154412000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-109" unitRef="usd">-39328000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-10" decimals="-3" id="f-110" unitRef="usd">-61498000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-3" id="f-111" unitRef="usd">3686000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-10" decimals="-3" id="f-112" unitRef="usd">4736000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-113" unitRef="usd">0</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-10" decimals="-3" id="f-114" unitRef="usd">1000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-115" unitRef="usd">2136000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-10" decimals="-3" id="f-116" unitRef="usd">-1040000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-117" unitRef="usd">5822000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-10" decimals="-3" id="f-118" unitRef="usd">3695000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-119" unitRef="usd">-33506000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-10" decimals="-3" id="f-120" unitRef="usd">-57803000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-121" unitRef="usd">852000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-10" decimals="-3" id="f-122" unitRef="usd">2146000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-123" unitRef="usd">-34358000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-10" decimals="-3" id="f-124" unitRef="usd">-59949000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-125"
      unitRef="usdPerShare">-0.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-126"
      unitRef="usdPerShare">-0.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-10"
      decimals="2"
      id="f-127"
      unitRef="usdPerShare">-0.50</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-10"
      decimals="2"
      id="f-128"
      unitRef="usdPerShare">-0.50</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-129" unitRef="shares">122606091</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-130" unitRef="shares">122606091</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-10" decimals="0" id="f-131" unitRef="shares">119394180</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-10" decimals="0" id="f-132" unitRef="shares">119394180</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-133" unitRef="usd">-34358000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-10" decimals="-3" id="f-134" unitRef="usd">-59949000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-135" unitRef="usd">-20000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-10" decimals="-3" id="f-136" unitRef="usd">136000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-137" unitRef="usd">146000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-10" decimals="-3" id="f-138" unitRef="usd">-163000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-139" unitRef="usd">126000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-10" decimals="-3" id="f-140" unitRef="usd">-27000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-141" unitRef="usd">-34232000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-10" decimals="-3" id="f-142" unitRef="usd">-59976000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="c-11"
      decimals="INF"
      id="f-143"
      unitRef="shares">122291837</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-144" unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-3" id="f-145" unitRef="usd">2177672000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-13" decimals="-3" id="f-146" unitRef="usd">-1467047000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="-3" id="f-147" unitRef="usd">-493000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-148" unitRef="usd">710134000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-15"
      decimals="INF"
      id="f-149"
      unitRef="shares">841913</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-16" decimals="-3" id="f-150" unitRef="usd">422000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-17" decimals="-3" id="f-151" unitRef="usd">422000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-18" decimals="-3" id="f-152" unitRef="usd">30571000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-153" unitRef="usd">30571000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-19" decimals="-3" id="f-154" unitRef="usd">-34358000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-155" unitRef="usd">-34358000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-20" decimals="-3" id="f-156" unitRef="usd">126000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-157" unitRef="usd">126000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="c-21"
      decimals="INF"
      id="f-158"
      unitRef="shares">123133750</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-159" unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-160" unitRef="usd">2208665000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-161" unitRef="usd">-1501405000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-162" unitRef="usd">-367000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-163" unitRef="usd">706895000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c-25"
      decimals="INF"
      id="f-164"
      unitRef="shares">119095362</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-165" unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-166" unitRef="usd">2025890000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-167" unitRef="usd">-1284420000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-168" unitRef="usd">-429000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-169" unitRef="usd">741043000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-30"
      decimals="INF"
      id="f-170"
      unitRef="shares">605487</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-31" decimals="-3" id="f-171" unitRef="usd">1638000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-32" decimals="-3" id="f-172" unitRef="usd">1638000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-33" decimals="-3" id="f-173" unitRef="usd">36129000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-10" decimals="-3" id="f-174" unitRef="usd">36129000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-34" decimals="-3" id="f-175" unitRef="usd">-59949000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-10" decimals="-3" id="f-176" unitRef="usd">-59949000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-35" decimals="-3" id="f-177" unitRef="usd">-27000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-10" decimals="-3" id="f-178" unitRef="usd">-27000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="c-36"
      decimals="INF"
      id="f-179"
      unitRef="shares">119700849</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-3" id="f-180" unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-181" unitRef="usd">2063657000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-182" unitRef="usd">-1344369000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-183" unitRef="usd">-456000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-184" unitRef="usd">718834000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-185" unitRef="usd">-34358000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-10" decimals="-3" id="f-186" unitRef="usd">-59949000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-187" unitRef="usd">31076000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-10" decimals="-3" id="f-188" unitRef="usd">36129000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-189" unitRef="usd">8022000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-10" decimals="-3" id="f-190" unitRef="usd">9194000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-1" decimals="-3" id="f-191" unitRef="usd">1792000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-10" decimals="-3" id="f-192" unitRef="usd">2300000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:OperatingLeaseImpairmentLoss contextRef="c-1" decimals="-3" id="f-193" unitRef="usd">114000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss contextRef="c-10" decimals="-3" id="f-194" unitRef="usd">2454000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-1" decimals="-3" id="f-195" unitRef="usd">-575000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-10" decimals="-3" id="f-196" unitRef="usd">444000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-197" unitRef="usd">-35325000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-10" decimals="-3" id="f-198" unitRef="usd">-23516000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-199" unitRef="usd">-8058000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-10" decimals="-3" id="f-200" unitRef="usd">9937000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-201" unitRef="usd">5530000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-10" decimals="-3" id="f-202" unitRef="usd">2029000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">-2314000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-10" decimals="-3" id="f-204" unitRef="usd">-216000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-205" unitRef="usd">-2547000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-10" decimals="-3" id="f-206" unitRef="usd">4583000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-1" decimals="-3" id="f-207" unitRef="usd">-11745000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-10" decimals="-3" id="f-208" unitRef="usd">-9380000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c-1" decimals="-3" id="f-209" unitRef="usd">347000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c-10" decimals="-3" id="f-210" unitRef="usd">2120000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <txg:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities contextRef="c-1" decimals="-3" id="f-211" unitRef="usd">4329000</txg:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities>
    <txg:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities contextRef="c-10" decimals="-3" id="f-212" unitRef="usd">-12674000</txg:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-213" unitRef="usd">-2631000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-10" decimals="-3" id="f-214" unitRef="usd">-2961000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">360000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-10" decimals="-3" id="f-216" unitRef="usd">249000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-217" unitRef="usd">34351000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-10" decimals="-3" id="f-218" unitRef="usd">-15725000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-219" unitRef="usd">1893000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-10" decimals="-3" id="f-220" unitRef="usd">2910000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities contextRef="c-1" decimals="-3" id="f-221" unitRef="usd">0</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities contextRef="c-10" decimals="-3" id="f-222" unitRef="usd">568000</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-1" decimals="-3" id="f-223" unitRef="usd">0</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-10" decimals="-3" id="f-224" unitRef="usd">12974000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-225" unitRef="usd">-1893000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-10" decimals="-3" id="f-226" unitRef="usd">10632000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-1" decimals="-3" id="f-227" unitRef="usd">422000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-10" decimals="-3" id="f-228" unitRef="usd">1638000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-229" unitRef="usd">422000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-10" decimals="-3" id="f-230" unitRef="usd">1638000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-231" unitRef="usd">114000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-10" decimals="-3" id="f-232" unitRef="usd">-48000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-233" unitRef="usd">32994000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-10" decimals="-3" id="f-234" unitRef="usd">-3503000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-235" unitRef="usd">344067000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-29" decimals="-3" id="f-236" unitRef="usd">359284000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-237" unitRef="usd">377061000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-40" decimals="-3" id="f-238" unitRef="usd">355781000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-239" unitRef="usd">462000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-10" decimals="-3" id="f-240" unitRef="usd">961000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-241" unitRef="usd">398000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-10" decimals="-3" id="f-242" unitRef="usd">1899000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c-1" id="f-243">Description of Business and Basis of Presentation&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization and Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10x Genomics, Inc. (the &#x201c;Company&#x201d;) is a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biological systems at resolution and scale that matches the complexity of biology. The Company&#x2019;s integrated solutions include the Company&#x2019;s Chromium instruments and the Company's Visium CytAssist and Xenium Analyzer, which the Company refers to as &#x201c;Spatial instruments,&#x201d; and the Company&#x2019;s proprietary microfluidic chips, slides, reagents and other consumables for the Company&#x2019;s Chromium, Visium and Xenium solutions, which the Company refers to as &#x201c;consumables.&#x201d; The Company bundles its software with these products to guide customers through the workflow, from sample preparation through analysis and visualization. The Company was incorporated in the state of Delaware in July 2012 and began commercial and manufacturing operations and selling its instruments and consumables in 2015. The Company is headquartered in Pleasanton, California and has wholly-owned subsidiaries in Asia, Europe, Oceania and North America.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements, which include the Company&#x2019;s accounts and the accounts of its wholly-owned subsidiaries, are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). The condensed consolidated balance sheet at December&#160;31, 2024 has been derived from the audited consolidated financial statements of the Company at that date. Certain information and footnote disclosures typically included in the Company&#x2019;s audited consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the Company&#x2019;s financial position, results of operations, comprehensive loss and cash flows for the periods presented, but are not necessarily indicative of the results of operations to be anticipated for any future annual or interim period. All intercompany transactions and balances have been eliminated. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and related notes for the year ended December&#160;31, 2024 included in the Company's Annual Report on Form 10-K filed with the SEC on February&#160;12, 2025 (our &#x201c;Annual Report&#x201d;).&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-244">&lt;div style="margin-top:18pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements, which include the Company&#x2019;s accounts and the accounts of its wholly-owned subsidiaries, are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). The condensed consolidated balance sheet at December&#160;31, 2024 has been derived from the audited consolidated financial statements of the Company at that date. Certain information and footnote disclosures typically included in the Company&#x2019;s audited consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the Company&#x2019;s financial position, results of operations, comprehensive loss and cash flows for the periods presented, but are not necessarily indicative of the results of operations to be anticipated for any future annual or interim period. All intercompany transactions and balances have been eliminated. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-245">Summary of Significant Accounting Policies&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Except as noted below, there were no material changes in the Company&#x2019;s significant accounting policies during the three months ended March&#160;31, 2025. See Note 2 &#x2013; Summary of Significant Accounting Policies to the consolidated financial statements included in the Company&#x2019;s Annual Report for information regarding the Company&#x2019;s significant accounting policies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Products and Services Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates revenue from sales of products, which consist of instruments and consumables, and services. Revenue from product sales is recognized when control of the product is transferred, which is generally upon shipment to the customer. Instrument service agreements, which relate to extended warranties, are typically entered into for a one-year term, following the expiration of the standard one-year warranty period. Revenue for extended warranties is recognized ratably over the term of the extended warranty period as a stand ready performance obligation. Revenue is recorded net of discounts, distributor commissions and sales taxes collected on behalf of governmental authorities. Customers are invoiced generally upon shipment, or upon order for services, and payment is typically due within 30 days. Cash received from customers in advance of product shipment or the provision of services is recorded as a contract liability. The Company&#x2019;s contracts with its customers generally do not include rights of return or a significant financing component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company regularly enters into contracts that include various combinations of products and services which are generally distinct and accounted for as separate performance obligations. The transaction price is allocated to each performance obligation in proportion to its standalone selling price. The Company determines standalone selling price using average selling prices with consideration of current market conditions. If the product or service has no history of sales or if the sales volume is not sufficient, the Company relies upon prices set by management, adjusted for applicable discounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;License and Royalty Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has agreements with third parties that include up-front fees and royalties. Revenue related to the delivery of intellectual property is recognized when the license is delivered to the third parties. Royalty revenue is recognized when the underlying sales occur. If the timing of the reporting of the actual sales from our licensees is after our reporting date, we estimate the royalty revenue receivable at period end and adjust for any changes in estimates in the following period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as a single operating segment. The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;), its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating financial performance. The measures of profitability and significant segment expenses reviewed by the CODM are consistent with the presentation and disclosure in these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts related to the royalty revenue in the condensed consolidated statements of operations for the three months ended March 31, 2024 have been reclassified to conform to the current presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Recently Issued Accounting Pronouncement and Disclosure Rules&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standard Update (&#x201c;ASU&#x201d;) No. 2023-09, Income Taxes (&#x201c;ASU No. 2023-09&#x201d;), which prescribes standardized categories and disaggregation of information in the reconciliation of provision for income taxes, requires disclosure of disaggregated income taxes paid, and modifies other income tax-related disclosure requirements. The updated standard is effective beginning with the Company&#x2019;s fiscal year 2025 annual reporting period. The Company will adopt ASU No. 2023-09 in its fourth quarter of 2025 using a prospective transition method.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses ("ASU 2024-03"), and in January 2025 issued ASU 2025-01, Clarifying the Effective Date ("ASU 2025-01") to provide clarification as to the effective date. ASU 2024-03 requires disaggregated disclosure of income statement expenses. ASU 2024-03 does not change the expense captions currently presented on the income statement; rather it requires disaggregation of certain expense captions into specified categories in disclosures within the footnotes to the financial statements. ASU 2024-03, as amended by ASU 2025-01, is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within fiscal years beginning after December 15, 2027. ASU 2024-03 can be applied on a prospective basis; however, retrospective application is permitted. Early adoption is permitted. As ASU 2024-03 only requires additional disclosure, it will not have a material impact on the Company's financial condition and results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-246">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Products and Services Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates revenue from sales of products, which consist of instruments and consumables, and services. Revenue from product sales is recognized when control of the product is transferred, which is generally upon shipment to the customer. Instrument service agreements, which relate to extended warranties, are typically entered into for a one-year term, following the expiration of the standard one-year warranty period. Revenue for extended warranties is recognized ratably over the term of the extended warranty period as a stand ready performance obligation. Revenue is recorded net of discounts, distributor commissions and sales taxes collected on behalf of governmental authorities. Customers are invoiced generally upon shipment, or upon order for services, and payment is typically due within 30 days. Cash received from customers in advance of product shipment or the provision of services is recorded as a contract liability. The Company&#x2019;s contracts with its customers generally do not include rights of return or a significant financing component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company regularly enters into contracts that include various combinations of products and services which are generally distinct and accounted for as separate performance obligations. The transaction price is allocated to each performance obligation in proportion to its standalone selling price. The Company determines standalone selling price using average selling prices with consideration of current market conditions. If the product or service has no history of sales or if the sales volume is not sufficient, the Company relies upon prices set by management, adjusted for applicable discounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;License and Royalty Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has agreements with third parties that include up-front fees and royalties. Revenue related to the delivery of intellectual property is recognized when the license is delivered to the third parties. Royalty revenue is recognized when the underlying sales occur. If the timing of the reporting of the actual sales from our licensees is after our reporting date, we estimate the royalty revenue receivable at period end and adjust for any changes in estimates in the following period.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ProductWarrantyObligationTerm contextRef="c-4" id="f-247">P1Y</us-gaap:ProductWarrantyObligationTerm>
    <us-gaap:ProductWarrantyObligationTerm contextRef="c-4" id="f-248">P1Y</us-gaap:ProductWarrantyObligationTerm>
    <txg:RevenueFromContractWithCustomerPaymentPeriod contextRef="c-1" id="f-249">P30D</txg:RevenueFromContractWithCustomerPaymentPeriod>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-250">&lt;div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as a single operating segment. The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;), its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating financial performance. The measures of profitability and significant segment expenses reviewed by the CODM are consistent with the presentation and disclosure in these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-251">&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Recently Issued Accounting Pronouncement and Disclosure Rules&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standard Update (&#x201c;ASU&#x201d;) No. 2023-09, Income Taxes (&#x201c;ASU No. 2023-09&#x201d;), which prescribes standardized categories and disaggregation of information in the reconciliation of provision for income taxes, requires disclosure of disaggregated income taxes paid, and modifies other income tax-related disclosure requirements. The updated standard is effective beginning with the Company&#x2019;s fiscal year 2025 annual reporting period. The Company will adopt ASU No. 2023-09 in its fourth quarter of 2025 using a prospective transition method.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses ("ASU 2024-03"), and in January 2025 issued ASU 2025-01, Clarifying the Effective Date ("ASU 2025-01") to provide clarification as to the effective date. ASU 2024-03 requires disaggregated disclosure of income statement expenses. ASU 2024-03 does not change the expense captions currently presented on the income statement; rather it requires disaggregation of certain expense captions into specified categories in disclosures within the footnotes to the financial statements. ASU 2024-03, as amended by ASU 2025-01, is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within fiscal years beginning after December 15, 2027. ASU 2024-03 can be applied on a prospective basis; however, retrospective application is permitted. Early adoption is permitted. As ASU 2024-03 only requires additional disclosure, it will not have a material impact on the Company's financial condition and results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock contextRef="c-1" id="f-253">Other Financial Statement Information&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Available-for-sale Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consisted of the following (in thousands):&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.871%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.945%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.089%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.089%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.802%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.945%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.089%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.089%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.802%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of marketable securities as of March 31, 2025 were all less than one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred no material gross realized gains or losses from available-for-sales debt securities during the three months ended March&#160;31, 2025 or March&#160;31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The available-for-sale debt securities are subject to a periodic impairment review. For investments in an unrealized loss position, the Company determines whether a credit loss exists by considering information about the collectability of the instrument, current market conditions and reasonable and supportable forecasts of economic conditions. The Company recognizes an allowance for credit losses, up to the amount of the unrealized loss when appropriate, and writes down the amortized cost basis of the investment if it is more likely than not that the Company will be required or will intend to sell the investment before recovery of its amortized cost basis. Allowances for credit losses and write-downs are recognized in &#x201c;Other expense, net,&#x201d; and unrealized losses not related to credit losses are recognized in &#x201c;Accumulated other comprehensive loss.&#x201d; There are no allowances for credit losses for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory was comprised of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.181%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.325%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment and machinery &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(131,113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(122,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2025, the Company recorded impairment charges of $0.1&#160;million related to equipment. The impairment charge was triggered by a decision to discontinue an engineering project. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2024, the Company recorded impairment charges of $2.1&#160;million related to computer equipment and software of which $0.3&#160;million, $0.7&#160;million and $1.1&#160;million was classified in cost of revenue, research and development, and selling, general and administrative expenses, respectively, in the condensed consolidated statement of operations. The impairment charge was triggered by a decision to discontinue a productivity engineering project.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Compensation and Related Benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation and related benefits were comprised of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.375%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued bonus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued commissions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and related benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities were comprised of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.181%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties for licensed technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product warranties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Warranties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the reserve for product warranties were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.181%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts charged to cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repairs and replacements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(764)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of period&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue and Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of&#160;March&#160;31, 2025, the aggregate amount of remaining performance obligations related to separately sold extended warranty service agreements or allocated amounts for extended warranty service agreements bundled with sales of instruments was&#160;$33.5 million, of which approximately&#160;$20.9 million&#160;is expected to be recognized to revenue in the next 12 months, with the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;remainder thereafter. The contract liabilities of $33.5 million and $24.1 million as of March&#160;31, 2025 and 2024, respectively, consisted of deferred revenue related to extended warranty service agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following revenue recognized for the periods indicated were included in deferred revenue as of December 31, 2024 and 2023, respectively (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.336%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.246%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents revenue by source for the periods indicated (in thousands). Spatial products include the Company&#x2019;s Visium and Xenium products:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.325%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Chromium&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Spatial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total instruments revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consumables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Chromium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Spatial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total consumables revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Products and services revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;License and royalty revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.325%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Americas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Americas (excluding United States)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Americas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Europe, Middle East and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asia-Pacific&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia-Pacific (excluding China)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Asia-Pacific&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1) Includes license and royalty revenue.   &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;License and Royalty Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2025, the Company settled its worldwide patent litigation with Vizgen, Inc. As part of that settlement, Vizgen has limited rights to certain intellectual property owned or exclusively licensed by the Company. As one part of the settlement, the Company received an upfront payment of $26.0&#160;million and will receive royalties on Vizgen&#x2019;s sales of products covered by the license. The $26.0&#160;million upfront payment was recorded as a $9.2&#160;million gain on settlement and $16.8&#160;million of license and royalty revenue. The amount attributed to the gain on settlement was determined by applying a royalty rate to the Vizgen historical revenues prior to the settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Income (Expense), Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains or losses from foreign currency remeasurement are included in &#x201c;Other income (expense), net&#x201d; in the consolidated statements of operations. The Company recognized foreign currency transaction losses of $1.5 million for the three months ended March&#160;31, 2025, and foreign currency transaction income of $1.0 million for the three months ended March&#160;31, 2024, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="c-1" id="f-254">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consisted of the following (in thousands):&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.871%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.945%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.089%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.089%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.802%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.945%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.089%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.089%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.802%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="c-41" decimals="-3" id="f-255" unitRef="usd">352478000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="c-41" decimals="-3" id="f-256" unitRef="usd">352478000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="c-42" decimals="-3" id="f-257" unitRef="usd">322012000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="c-42" decimals="-3" id="f-258" unitRef="usd">322012000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-43" decimals="-3" id="f-259" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-43" decimals="-3" id="f-260" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-43" decimals="-3" id="f-261" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-43" decimals="-3" id="f-262" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-44" decimals="-3" id="f-263" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-44" decimals="-3" id="f-264" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-44" decimals="-3" id="f-265" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-44" decimals="-3" id="f-266" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-45" decimals="-3" id="f-267" unitRef="usd">49846000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-45" decimals="-3" id="f-268" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-45" decimals="-3" id="f-269" unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-45" decimals="-3" id="f-270" unitRef="usd">49844000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-46" decimals="-3" id="f-271" unitRef="usd">49317000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-46" decimals="-3" id="f-272" unitRef="usd">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-46" decimals="-3" id="f-273" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-46" decimals="-3" id="f-274" unitRef="usd">49335000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-47" decimals="-3" id="f-275" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-47" decimals="-3" id="f-276" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-47" decimals="-3" id="f-277" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-47" decimals="-3" id="f-278" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-48" decimals="-3" id="f-279" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-48" decimals="-3" id="f-280" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-48" decimals="-3" id="f-281" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-48" decimals="-3" id="f-282" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <txg:DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds contextRef="c-4" decimals="-3" id="f-283" unitRef="usd">402324000</txg:DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="-3" id="f-284" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="-3" id="f-285" unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <txg:DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds contextRef="c-4" decimals="-3" id="f-286" unitRef="usd">402322000</txg:DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds>
    <txg:DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds contextRef="c-5" decimals="-3" id="f-287" unitRef="usd">371329000</txg:DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-5" decimals="-3" id="f-288" unitRef="usd">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-5" decimals="-3" id="f-289" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <txg:DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds contextRef="c-5" decimals="-3" id="f-290" unitRef="usd">371347000</txg:DebtSecuritiesAvailableForSaleIncludingMoneyMarketFunds>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss contextRef="c-1" decimals="-5" id="f-291" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss contextRef="c-10" decimals="-5" id="f-292" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-293">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory was comprised of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.181%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves contextRef="c-4" decimals="-3" id="f-294" unitRef="usd">36180000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves contextRef="c-5" decimals="-3" id="f-295" unitRef="usd">38930000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-4" decimals="-3" id="f-296" unitRef="usd">23238000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-5" decimals="-3" id="f-297" unitRef="usd">27441000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-4" decimals="-3" id="f-298" unitRef="usd">15292000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-5" decimals="-3" id="f-299" unitRef="usd">16736000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-300" unitRef="usd">74710000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-5" decimals="-3" id="f-301" unitRef="usd">83107000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-302">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.325%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment and machinery &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(131,113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(122,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-49" decimals="-3" id="f-303" unitRef="usd">36765000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-50" decimals="-3" id="f-304" unitRef="usd">36765000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-51" decimals="-3" id="f-305" unitRef="usd">147235000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-52" decimals="-3" id="f-306" unitRef="usd">147094000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-53" decimals="-3" id="f-307" unitRef="usd">73792000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-54" decimals="-3" id="f-308" unitRef="usd">72498000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-55" decimals="-3" id="f-309" unitRef="usd">15008000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-56" decimals="-3" id="f-310" unitRef="usd">14953000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-57" decimals="-3" id="f-311" unitRef="usd">9745000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-58" decimals="-3" id="f-312" unitRef="usd">9586000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-59" decimals="-3" id="f-313" unitRef="usd">90180000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-60" decimals="-3" id="f-314" unitRef="usd">89567000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-61" decimals="-3" id="f-315" unitRef="usd">4475000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-62" decimals="-3" id="f-316" unitRef="usd">5152000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-317" unitRef="usd">377200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-5" decimals="-3" id="f-318" unitRef="usd">375615000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-319" unitRef="usd">131113000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-320" unitRef="usd">122967000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-321" unitRef="usd">246087000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-322" unitRef="usd">252648000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-63" decimals="INF" id="f-323" unitRef="usd">100000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-64" decimals="INF" id="f-324" unitRef="usd">2100000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-65" decimals="INF" id="f-325" unitRef="usd">300000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-66" decimals="INF" id="f-326" unitRef="usd">700000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-67" decimals="INF" id="f-327" unitRef="usd">1100000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <txg:ScheduleOfAccruedCompensationandRelatedBenefitsTableTextBlock contextRef="c-1" id="f-328">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation and related benefits were comprised of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.417%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.375%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued bonus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued commissions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and related benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</txg:ScheduleOfAccruedCompensationandRelatedBenefitsTableTextBlock>
    <txg:AccruedPayrollAndRelatedCosts contextRef="c-4" decimals="-3" id="f-329" unitRef="usd">6303000</txg:AccruedPayrollAndRelatedCosts>
    <txg:AccruedPayrollAndRelatedCosts contextRef="c-5" decimals="-3" id="f-330" unitRef="usd">2970000</txg:AccruedPayrollAndRelatedCosts>
    <us-gaap:AccruedBonusesCurrent contextRef="c-4" decimals="-3" id="f-331" unitRef="usd">7648000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent contextRef="c-5" decimals="-3" id="f-332" unitRef="usd">21859000</us-gaap:AccruedBonusesCurrent>
    <txg:AccruedCommissionsCurrent contextRef="c-4" decimals="-3" id="f-333" unitRef="usd">3281000</txg:AccruedCommissionsCurrent>
    <txg:AccruedCommissionsCurrent contextRef="c-5" decimals="-3" id="f-334" unitRef="usd">5938000</txg:AccruedCommissionsCurrent>
    <us-gaap:OtherEmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-335" unitRef="usd">4725000</us-gaap:OtherEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherEmployeeRelatedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-336" unitRef="usd">2848000</us-gaap:OtherEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-337" unitRef="usd">21957000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-338" unitRef="usd">33615000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <txg:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock contextRef="c-1" id="f-339">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities were comprised of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.181%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties for licensed technologies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product warranties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</txg:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock>
    <txg:AccruedLegalAndRelatedExpensesCurrent contextRef="c-4" decimals="-3" id="f-340" unitRef="usd">10563000</txg:AccruedLegalAndRelatedExpensesCurrent>
    <txg:AccruedLegalAndRelatedExpensesCurrent contextRef="c-5" decimals="-3" id="f-341" unitRef="usd">6100000</txg:AccruedLegalAndRelatedExpensesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="c-4" decimals="-3" id="f-342" unitRef="usd">4191000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="c-5" decimals="-3" id="f-343" unitRef="usd">7042000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-4" decimals="-3" id="f-344" unitRef="usd">4201000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-5" decimals="-3" id="f-345" unitRef="usd">5315000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent contextRef="c-4" decimals="-3" id="f-346" unitRef="usd">9453000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent contextRef="c-5" decimals="-3" id="f-347" unitRef="usd">8615000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c-4" decimals="-3" id="f-348" unitRef="usd">4775000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c-5" decimals="-3" id="f-349" unitRef="usd">4936000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-350" unitRef="usd">12300000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-351" unitRef="usd">9157000</us-gaap:OtherLiabilitiesCurrent>
    <txg:AccruedExpensesAndOtherLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-352" unitRef="usd">45483000</txg:AccruedExpensesAndOtherLiabilitiesCurrent>
    <txg:AccruedExpensesAndOtherLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-353" unitRef="usd">41165000</txg:AccruedExpensesAndOtherLiabilitiesCurrent>
    <us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock contextRef="c-1" id="f-354">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the reserve for product warranties were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.181%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts charged to cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repairs and replacements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(764)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of period&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock>
    <us-gaap:ProductWarrantyAccrual contextRef="c-5" decimals="-3" id="f-355" unitRef="usd">8615000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrual contextRef="c-29" decimals="-3" id="f-356" unitRef="usd">8116000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrualWarrantiesIssued contextRef="c-1" decimals="-3" id="f-357" unitRef="usd">3965000</us-gaap:ProductWarrantyAccrualWarrantiesIssued>
    <us-gaap:ProductWarrantyAccrualWarrantiesIssued contextRef="c-10" decimals="-3" id="f-358" unitRef="usd">2355000</us-gaap:ProductWarrantyAccrualWarrantiesIssued>
    <us-gaap:ProductWarrantyAccrualPayments contextRef="c-1" decimals="-3" id="f-359" unitRef="usd">3127000</us-gaap:ProductWarrantyAccrualPayments>
    <us-gaap:ProductWarrantyAccrualPayments contextRef="c-10" decimals="-3" id="f-360" unitRef="usd">764000</us-gaap:ProductWarrantyAccrualPayments>
    <us-gaap:ProductWarrantyAccrual contextRef="c-4" decimals="-3" id="f-361" unitRef="usd">9453000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrual contextRef="c-40" decimals="-3" id="f-362" unitRef="usd">9707000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-4" decimals="-5" id="f-363" unitRef="usd">33500000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-68" decimals="-5" id="f-364" unitRef="usd">20900000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="c-69" id="f-365">P12M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:ContractWithCustomerLiability contextRef="c-4" decimals="-5" id="f-366" unitRef="usd">33500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-5" decimals="-5" id="f-367" unitRef="usd">24100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="c-1" id="f-368">&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following revenue recognized for the periods indicated were included in deferred revenue as of December 31, 2024 and 2023, respectively (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.336%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.246%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-1" decimals="-3" id="f-369" unitRef="usd">5857000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-10" decimals="-3" id="f-370" unitRef="usd">3595000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="c-1" id="f-371">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents revenue by source for the periods indicated (in thousands). Spatial products include the Company&#x2019;s Visium and Xenium products:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.325%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Chromium&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Spatial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total instruments revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consumables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Chromium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Spatial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total consumables revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Products and services revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;License and royalty revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-70" decimals="-3" id="f-372" unitRef="usd">5913000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-71" decimals="-3" id="f-373" unitRef="usd">7850000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-72" decimals="-3" id="f-374" unitRef="usd">8902000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-73" decimals="-3" id="f-375" unitRef="usd">17603000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-74" decimals="-3" id="f-376" unitRef="usd">14815000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-75" decimals="-3" id="f-377" unitRef="usd">25453000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-76" decimals="-3" id="f-378" unitRef="usd">84109000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-77" decimals="-3" id="f-379" unitRef="usd">83927000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-78" decimals="-3" id="f-380" unitRef="usd">31247000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-79" decimals="-3" id="f-381" unitRef="usd">26408000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-80" decimals="-3" id="f-382" unitRef="usd">115356000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-81" decimals="-3" id="f-383" unitRef="usd">110335000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-82" decimals="-3" id="f-384" unitRef="usd">7652000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-83" decimals="-3" id="f-385" unitRef="usd">5217000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-386" unitRef="usd">137823000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-387" unitRef="usd">141005000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-3" id="f-388" unitRef="usd">17060000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-3" id="f-389" unitRef="usd">1000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-390" unitRef="usd">154883000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-3" id="f-391" unitRef="usd">141006000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c-1" id="f-392">&lt;div style="margin-top:18pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.325%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Americas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Americas (excluding United States)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Americas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Europe, Middle East and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asia-Pacific&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia-Pacific (excluding China)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Asia-Pacific&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1) Includes license and royalty revenue.</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-84" decimals="-3" id="f-393" unitRef="usd">86818000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-85" decimals="-3" id="f-394" unitRef="usd">75637000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-86" decimals="-3" id="f-395" unitRef="usd">3752000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-87" decimals="-3" id="f-396" unitRef="usd">3993000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-88" decimals="-3" id="f-397" unitRef="usd">90570000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-89" decimals="-3" id="f-398" unitRef="usd">79630000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-90" decimals="-3" id="f-399" unitRef="usd">31895000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-91" decimals="-3" id="f-400" unitRef="usd">34721000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-92" decimals="-3" id="f-401" unitRef="usd">16883000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-93" decimals="-3" id="f-402" unitRef="usd">13924000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-94" decimals="-3" id="f-403" unitRef="usd">15535000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-95" decimals="-3" id="f-404" unitRef="usd">12731000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-96" decimals="-3" id="f-405" unitRef="usd">32418000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-97" decimals="-3" id="f-406" unitRef="usd">26655000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-407" unitRef="usd">154883000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-3" id="f-408" unitRef="usd">141006000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <txg:ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted contextRef="c-98" decimals="-5" id="f-409" unitRef="usd">26000000</txg:ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted>
    <txg:ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted contextRef="c-98" decimals="-5" id="f-410" unitRef="usd">26000000</txg:ProceedsFromLitigationSettlementAndIntellectualPropertyLicenseGranted>
    <us-gaap:LitigationSettlementGain contextRef="c-98" decimals="-5" id="f-411" unitRef="usd">9200000</us-gaap:LitigationSettlementGain>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-99" decimals="-5" id="f-412" unitRef="usd">16800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ForeignCurrencyTransactionGainLossRealizedAfterTax contextRef="c-1" decimals="-5" id="f-413" unitRef="usd">-1500000</us-gaap:ForeignCurrencyTransactionGainLossRealizedAfterTax>
    <us-gaap:ForeignCurrencyTransactionGainLossRealizedAfterTax contextRef="c-10" decimals="-5" id="f-414" unitRef="usd">1000000.0</us-gaap:ForeignCurrencyTransactionGainLossRealizedAfterTax>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-415">Commitments and Contingencies&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Lease Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases office, laboratory, manufacturing, distribution and server space in various locations worldwide. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The payments due under the Company&#x2019;s operating lease liabilities as of March&#160;31, 2025 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Operating&#160;Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 (excluding the three months ended March 31, 2025)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,407)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, noncurrent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes additional information related to operating leases as of March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.325%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company is regularly subject to lawsuits, claims, arbitration proceedings, administrative actions and other legal and regulatory proceedings involving intellectual property disputes, commercial disputes, competition and other matters, and the Company may become subject to additional types of lawsuits, claims, arbitration proceedings, administrative actions, government investigations and legal and regulatory proceedings in the future. As of March&#160;31, 2025, the Company has concluded that a loss is not probable and a contingent liability has not been recorded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bruker (NanoString)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 6, 2021, the Company filed suit against NanoString Technologies, Inc. (&#x201c;NanoString&#x201d;) in the U.S. District Court for the District of Delaware alleging that NanoString&#x2019;s GeoMx Digital Spatial Profiler and associated instruments and reagents infringe U.S. Patent Nos. 10,472,669, 10,662,467, 10,961,566, 10,983,113 and 10,996,219 (the &#x201c;GeoMx Action&#x201d;). On May 19, 2021, the Company filed an amended complaint additionally alleging that the GeoMx products infringe U.S. Patent Nos. 11,001,878 and 11,008,607. On May 4, 2022, the Company filed an amended complaint in the GeoMx Action additionally alleging that the GeoMx products infringe U.S. Patent No. 11,293,917 and withdrawing the Company&#x2019;s claims of infringement of U.S. Patent No. 10,662,467. The Company is seeking, among other relief, injunctive relief and unspecified damages (including attorneys&#x2019; fees) in relation to NanoString&#x2019;s making, using, selling, offering to sell, exporting and/or importing in the United States the GeoMx Digital Spatial Profiler and associated instruments and reagents. NanoString filed its answer to the GeoMx Action on May 18, 2022. A Markman hearing was held on February 17, 2023 and the Court issued its claim construction order on February 28, 2023. On September 7, 2023, the Court issued an order granting the Company&#x2019;s motion for summary judgment that the asserted patents are not invalid for indefiniteness and denying NanoString&#x2019;s motion for summary judgment that the asserted patents are invalid for indefiniteness and lack of written description. On November 17, 2023, a jury found that NanoString willfully infringed the asserted patents and that the asserted patents are valid. The jury awarded the Company more than $31&#160;million in damages, consisting of approximately $25&#160;million in lost profits and approximately $6&#160;million in royalties. Post-trial motions, including the Company&#x2019;s motions for a permanent injunction, ongoing royalties, enhanced damages, attorneys&#x2019; fees and pre- and post-judgment interest, are pending. NanoString filed for bankruptcy protection under Chapter 11 of the United States Bankruptcy Code in the U.S. bankruptcy court in Delaware on February 4, 2024, and the Court&#x2019;s consideration of these post-trial motions was stayed due to the bankruptcy filing. In May 2024, Bruker Corporation (&#x201c;Bruker&#x201d;) acquired certain assets and assumed certain liabilities of NanoString, including the litigation between the Company and NanoString, and the NanoString product lines at issue. On December 23, 2024, the Court denied NanoString&#x2019;s motion for judgement as a matter of law on invalidity, non-infringement and damages, and denied its request for a new trial. The Court granted the Company&#x2019;s motion for permanent injunction, supplemental damages, and pre-judgment and post-judgment interest. On January 31, 2025, Bruker moved to stay the permanent injunction pending appeal. The Court has not ruled on the motion to stay. Due to the uncertainties in collecting the jury award, the Company has not recorded a receivable from NanoString as of March 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 28, 2022, the Company filed a second suit against NanoString in the U.S. District Court for the District of Delaware alleging that NanoString&#x2019;s CosMx Spatial Molecular Imager and associated instruments, reagents and services infringe U.S. Patent Nos. 10,227,639 and 11,021,737 (the &#x201c;CosMx Action&#x201d;). On May 12, 2022, the Company filed an amended complaint in the CosMx Action additionally alleging that the CosMx products additionally infringe U.S. Patent Nos. 11,293,051, 11,293,052 and 11,293,054. NanoString filed its answer to the CosMx Action on May 26, 2022. On March 1, 2023, the Company filed a second amended complaint additionally alleging that the CosMx products infringe U.S. Patent No. 11,542,554. The Company is seeking, among other relief, injunctive relief and unspecified damages (including attorneys&#x2019; fees) in relation to NanoString&#x2019;s making, using, selling, offering to sell, exporting and/or importing in the United States the CosMx Spatial Molecular Imager and associated instruments, reagents and services. NanoString filed its answer to the second amended complaint on March 22, 2023. Discovery is in progress. A Markman hearing was held on January 10, 2024, and the Court issued its claim construction order on February 1, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 1, 2023, NanoString filed a motion in the CosMx Action to add antitrust, unfair competition, tort and contract counterclaims. NanoString seeks, among other relief, injunction relief (including that the Company grant NanoString a license to the patents that the Company asserted against NanoString in the CosMx Action) and unspecified damages (including attorneys&#x2019; fees). On July 10, 2023, the Court denied NanoString&#x2019;s motion for leave to add a contract counterclaim but otherwise granted the motion for leave to amend. On May 24, 2023, NanoString filed a motion to bifurcate its amended counterclaims and a motion for expedited discovery. On June 6, 2023, the Court denied NanoString&#x2019;s motion to bifurcate and granted its motion for expedited discovery. The Company believes NanoString&#x2019;s claims are meritless and intends to vigorously defend itself. Trial is scheduled for August 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 16, 2022, NanoString filed a counterclaim in the CosMx Action alleging that the Company&#x2019;s Visium products infringe U.S. Patent No. 11,377,689 (the &#x201c;689 patent&#x201d;). The Company filed its answer to NanoString&#x2019;s counterclaim in the CosMx Action on August 30, 2022. On November 23, 2022, the Company moved to sever claims relating to NanoString&#x2019;s assertion of the 689 patent and consolidate those claims with the patent case NanoString filed against the Company on October 20, 2022 (discussed below). On January 24, 2023, the Court granted the Company&#x2019;s motion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 20, 2022, NanoString filed suit against the Company in the U.S. District Court for the District of Delaware alleging that the Company&#x2019;s Visium products infringe U.S. Patent No. 11,473,142 (the &#x201c;142 patent&#x201d;), a continuation of the 689 patent (the &#x201c;NanoString Action&#x201d;). NanoString seeks, among other relief, injunctive relief and unspecified damages (including attorneys&#x2019; fees) in relation to the Company&#x2019;s making, using, selling, offering to sell, exporting and/or importing in the United &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;States Visium products and associated instruments, reagents and services. On January 24, 2023, the Court severed NanoString&#x2019;s claims with respect to the 689 patent from the CosMx Action and consolidated those claims with this action. NanoString filed an amended complaint on January 27, 2023. The Company filed an answer to the NanoString Action on February 10, 2023. Discovery is in progress. A Markman hearing was held on January 10, 2024, and the Court issued its claim construction order on February 1, 2024. Trial is scheduled for November 2025. The Company believes NanoString&#x2019;s claims in the NanoString Action are meritless and intends to vigorously defend itself.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 16 and September 25, 2023, the Company filed petitions for inter partes review (&#x201c;IPR&#x201d;) of the 689 patent and the 142 patent, respectively. On February 1, 2024, IPR was instituted for the 689 patent. Oral argument for the 689 IPR took place on March 12, 2025. On September 5, 2024, trial was instituted for the 142 patent. Oral argument for the 142 IPR is scheduled for May 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 30, 2024, NanoString filed a petition for IPR of U.S. Patent No. 11,542,554, which is asserted by the Company against NanoString in the CosMx Action. On August 23, 2024, IPR was instituted for the 554 patent. Oral argument for the 554 IPR is scheduled for May 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 9, 2022, the Company filed suit in the Munich Regional Court in Germany alleging that NanoString&#x2019;s CosMx Spatial Molecular Imager and associated instruments, reagents and services infringe EP Patent No. 2794928B1 (the &#x201c;EP 928 patent&#x201d;) (the &#x201c;Germany CosMx Action&#x201d;). A hearing on infringement was held on March 23, 2023. On May 17, 2023, the Munich Regional Court found that the CosMx products infringe the EP 928 patent and issued a permanent injunction requiring NanoString to stop selling and supplying CosMx instruments and reagents for RNA detection in Germany. The injunction took effect on June 1, 2023. On May 25, 2023, NanoString filed an appeal of the Germany CosMx Action in the Munich Higher Regional Court. A hearing date has not yet been set for this appeal. On October 30, 2023, NanoString requested that the Higher Regional Court temporarily stay enforcement of the injunction pending the appeal. On December 20, 2023, the Higher Regional Court granted NanoString&#x2019;s request conditioned upon NanoString posting a 2.3&#160;million Euro security deposit. The case is currently stayed pending a final legally binding decision on the validity of EP 928.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 29, 2022, NanoString filed a nullity action with the German Federal Patent Court challenging the validity of the EP 928 patent. On February 10, 2023, the Federal Patent Court issued a preliminary opinion upholding the validity of certain claims of the EP 928 patent directed to in situ analysis. On May 7, 2024, the German Federal Patent Court revoked the German part of the EP 928 patent. The Company strongly disagrees with this decision.  On September 9, 2024, the Company appealed the decision to the German Federal Court of Justice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 1, 2023, the Company filed requests for preliminary injunctions in the Munich Local Division of the Unified Patent Court (&#x201c;UPC&#x201d;) alleging that NanoString&#x2019;s CosMx Spatial Molecular Imager and associated instruments, reagents and services for RNA detection infringe the EP 928 patent and EP Patent No. 4108782 (the &#x201c;EP 782 patent&#x201d;). Hearings were held for the EP 782 and EP 928 patents on September 5 and September 19, respectively. On September 19, 2023, the UPC granted the Company&#x2019;s request for the EP 782 patent and issued a preliminary injunction requiring NanoString to stop selling and supplying CosMx instruments and reagents for RNA detection in all 17 UPC member states. On October 10, 2023, the UPC denied the Company&#x2019;s preliminary injunction request for the EP 928 patent. On October 2, 2023, NanoString filed an appeal of the preliminary injunction for the EP 782 patent in the UPC Court of Appeals. A hearing was held before the UPC Court of Appeals on December 18, 2023. The UPC Court of Appeals overturned the preliminary injunction on February 26, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 31 and September 18, 2023 we filed main requests in the Munich Local Division of the UPC alleging that NanoString's CosMx Spatial Molecular Imager and associated instruments, reagents and services for RNA detection infringe the EP 782 and EP 928 patents, respectively. A hearing on the main request for EP 782 is scheduled for September 2025. No hearing has yet been set for the main request with regard to EP 928. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 18, 2023, NanoString filed an opposition in the European Patent Office challenging the validity of the EP 782 patent. In March 2025 the European Patent Office held an oral proceeding and upheld the validity of the claims of the EP 782 patent in an amended form.  On July 27, 2023, NanoString filed a revocation action in the Munich Central Division of the UPC challenging the validity of the EP 928 patent. A hearing in the revocation action took place on September 18, 2024. Following the hearing, the UPC revoked EP 928. The Company strongly disagrees with this decision. On December 17, 2024, the Company appealed the decision to the UPC Court of Appeals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vizgen  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vizgen, Inc. (&#x201c;Vizgen&#x201d;) and the Company were previously engaged in litigation in multiple jurisdictions relating to the Company&#x2019;s Xenium products and Vizgen&#x2019;s MERSCOPE products.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 5, 2025, the Company and Vizgen resolved all outstanding litigation between the two companies. All claims in the litigation have been dismissed with prejudice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Parse&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 24, 2022, the Company filed suit against Parse Biosciences, Inc. (&#x201c;Parse&#x201d;) in the U.S. District Court for the District of Delaware alleging that Parse&#x2019;s Evercode Whole Transcriptomics products and ATAC-seq products infringe U.S. Patent Nos. 10,155,981 (the &#x201c;981 patent&#x201d;), 10,697,013 (the &#x201c;013 patent&#x201d;), 10,240,197 (the &#x201c;197 patent&#x201d;), 10,150,995 (the &#x201c;995 patent&#x201d;), 10,619,207 (the &#x201c;207 patent&#x201d;) and 10,738,357 (the &#x201c;357 patent&#x201d;). The Company seeks, among other relief, injunction relief and unspecified damages (including attorneys&#x2019; fees) in relation to Parse&#x2019;s making, using, selling, offering to sell, exporting and/or importing in the United States Parse&#x2019;s Evercode Whole Transcriptomics products and ATAC-seq products. On October 17, 2022, Parse filed a motion to dismiss alleging that the asserted claims are directed to patent ineligible subject matter. The Court held a hearing on the motion to dismiss on November 22, 2022, and supplemental briefing was submitted on December 15, 2022. On September 14, 2023, the Court denied the motion. Parse filed its answer on October 6, 2023. Discovery is in progress. A Markman hearing was held on February 21, 2024, and the Court issued its claim construction order on May 3, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between April 20 and June 21, 2023, Parse filed petitions for IPR of all of the patents asserted. On October 13, 2023, IPR was instituted on the 981 patent. The PTAB denied institution of Parse&#x2019;s petitions for IPR on the other five asserted patents. On January 2 and 5, 2024, Parse filed rehearing requests with the PTAB for the 197 and 013 patents, respectively. On February 5, 2024, the PTAB instituted IPRs for the 197 and 013 patents on Parse&#x2019;s requests for rehearing. On September 17, 2024, the PTAB found the challenged claims of the 981 patent unpatentable. In February 2025, the PTAB found the challenged claims of the 197 and 013 patents unpatentable. The Company strongly disagrees with these decisions and has appealed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 25, 2025, the Court entered a consent judgment and permanent injunction enjoining Parse from making, using, selling, or offering for sale in the United States, or inducing others to make, use, sell, or offer to sell in the United States, or importing into the United States, for the remaining term of the 992, 207, and 357 patents, any ATAC-seq Method, Composition, or Product, or any other method, composition or product that is not colorably different from the ATAC-seq Methods, Compositions or Products.  The Court stayed trial with respect to the 197, 031, and 981 patents pending the appeal of the IPR decisions on these patents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Curio&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 1, 2023, the Company filed suit against Curio Bioscience, Inc. (&#x201c;Curio&#x201d;) in the U.S. District Court for the District of Delaware alleging that the Curio Seeker Spatial Mapping Kit and associated products and services infringe U.S. Patent Nos. 10,480,022, 10,662,468, 11,001,879, 11,549,138, and 11,761,030. On February 1, 2024, Curio filed a motion to dismiss alleging that the asserted claims are directed to patent ineligible subject matter. The Court denied that motion on May 9, 2024. On May 31 and June 20, 2024, Curio answered the Complaint and filed antitrust and unfair competition counterclaims. The Company filed a motion to dismiss Curio&#x2019;s unfair competition and antitrust counterclaims on July 5, 2024. On February 21, 2025, the Court dismissed all of Curio&#x2019;s unfair competition and antitrust counterclaims with the exception of one counterclaim alleging the lawsuit is objectively baseless. The Company believes Curio&#x2019;s remaining counterclaim is meritless and intends to vigorously defend itself. Trial is scheduled for May 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 4, 2023, the Company filed a request for a preliminary injunction in the Dusseldorf Local Division of the UPC alleging that the Curio Seeker Spatial Mapping Kit and associated products and services infringe EP Patent No. 2697391 (the &#x201c;EP 391 patent&#x201d;). A hearing was held on March 26, 2024. On April 30, 2024, the UPC granted the Company&#x2019;s request and issued a preliminary injunction requiring Curio to stop offering, marketing, using or possessing these Curio Seeker products and services in Germany, France and Sweden. Curio did not appeal the preliminary injunction. On March 25, 2024, the Company filed a main request in the Dusseldorf Local Division of the UPC alleging that the Curio Seeker Spatial Mapping Kit and associated products and services infringe the EP 391 patent. A hearing in the main action is expected in May 2025.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-416">&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The payments due under the Company&#x2019;s operating lease liabilities as of March&#160;31, 2025 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Operating&#160;Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 (excluding the three months ended March 31, 2025)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,407)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, noncurrent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-4" decimals="-3" id="f-417" unitRef="usd">10101000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-4" decimals="-3" id="f-418" unitRef="usd">15371000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-4" decimals="-3" id="f-419" unitRef="usd">15585000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-4" decimals="-3" id="f-420" unitRef="usd">15756000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-4" decimals="-3" id="f-421" unitRef="usd">14329000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <txg:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour contextRef="c-4" decimals="-3" id="f-422" unitRef="usd">26339000</txg:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-4" decimals="-3" id="f-423" unitRef="usd">97481000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-4" decimals="-3" id="f-424" unitRef="usd">17407000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-425" unitRef="usd">80074000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-426" unitRef="usd">9443000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-427" unitRef="usd">70631000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-428" unitRef="usd">80074000</us-gaap:OperatingLeaseLiability>
    <txg:DisclosureOfAdditionalInformationRelatedToOperatingLeasesTableTextBlock contextRef="c-1" id="f-429">&lt;div style="margin-top:18pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes additional information related to operating leases as of March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.325%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</txg:DisclosureOfAdditionalInformationRelatedToOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-430">P6Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-431">P6Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="3" id="f-432" unitRef="number">0.058</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-433" unitRef="number">0.058</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LossContingencyDamagesSoughtValue contextRef="c-100" decimals="-6" id="f-434" unitRef="usd">31000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:GainLossRelatedToLitigationSettlement contextRef="c-100" decimals="-6" id="f-435" unitRef="usd">25000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:PaymentsForRoyalties contextRef="c-100" decimals="-6" id="f-436" unitRef="usd">6000000</us-gaap:PaymentsForRoyalties>
    <us-gaap:SecurityDeposit contextRef="c-101" decimals="-5" id="f-437" unitRef="usd">2300000</us-gaap:SecurityDeposit>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-438">Capital Stock&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025, the number of shares of Class&#160;A common stock and Class&#160;B common stock issued and outstanding were 109,076,917 and 14,056,833, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-102"
      decimals="INF"
      id="f-439"
      unitRef="shares">109076917</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-102"
      decimals="INF"
      id="f-440"
      unitRef="shares">109076917</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-103"
      decimals="INF"
      id="f-441"
      unitRef="shares">14056833</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-103"
      decimals="INF"
      id="f-442"
      unitRef="shares">14056833</us-gaap:CommonStockSharesIssued>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-443">Equity Incentive Plans&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense in the condensed consolidated statement of operations for the periods presented as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.181%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units (&#x201c;RSUs&#x201d;) activity for the three months ended March&#160;31, 2025 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.181%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted&#160;Stock&lt;br/&gt;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant&#160;Date&#160;Fair&#160;Value&lt;br/&gt;(per share)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,493,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,016,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(564,701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(320,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,624,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity for the three months ended March&#160;31, 2025 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock&#160;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,594,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(277,212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96,812)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,220,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2025, the Company granted 561,603 performance stock units (&#x201c;PSUs&#x201d;) under the 2019 Plan to certain members of management which are subject to the achievement of certain performance conditions established by the Company&#x2019;s Compensation Committee of the Board of Directors as described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.73pt"&gt;50% of target PSUs earned will be based on the Company&#x2019;s compound annual growth rate (&#x201c;CAGR&#x201d;) of the Company&#x2019;s Revenue over a two-year performance period from January 1, 2025 to December 31, 2026. Holders may earn from 0% to 200% of the target amount of shares and earned PSUs will then be subject to service-based vesting; and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;ii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:9.96pt"&gt;50% of target PSUs earned will be based on the relative Total Shareholder Return (&#x201c;TSR&#x201d;) of the Company&#x2019;s common stock as compared to the TSR of the members of the Russell 3000 Medical Equipment and Services Sector Index over a three-year performance period from January 1, 2025 to December 31, 2027. Depending on the results relative to the TSR market condition, the holders may earn from 0% to 200% of the target amount of shares which will vest at the end of the performance period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The PSUs will be forfeited if the performance conditions are not achieved at the end of the relative performance periods as described above. The vesting of the PSUs can also be triggered upon certain change in control events or in the event of death or disability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair values of the PSUs relating to CAGR and TSR components were $10.76 and $13.94 per share, respectively. Stock-based compensation expense recognized for these awards was approximately $0.1 million for the three months ended March&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimated the fair values of shares granted under the market-based TSR PSUs using a Monte Carlo simulation model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2024, the Company granted 219,168 PSUs under the 2019 Plan to certain members of management, which are subject to the achievement of certain market-condition and performance-condition goals established by the Company&#x2019;s Compensation Committee of the Board of Directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025, the measurement periods for the 2025 and 2024 PSUs were not completed and the market and performance criteria for the stock awards was not met and therefore no shares vested or became exercisable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2019 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A total of 4,909,589 shares of Class&#160;A common stock were reserved for issuance under the 2019 Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;). The price at which Class A common stock is purchased under the ESPP is equal to 85% of the fair market value of the common stock on the first day of the offering period or purchase date, whichever is lower.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2025 and 2024, no shares of Class A common stock were issued under the ESPP. As of March&#160;31, 2025, there were 3,928,014 shares available for issuance under the ESPP.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="c-1" id="f-444">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense in the condensed consolidated statement of operations for the periods presented as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.181%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-104" decimals="-3" id="f-445" unitRef="usd">2481000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-105" decimals="-3" id="f-446" unitRef="usd">2033000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-106" decimals="-3" id="f-447" unitRef="usd">14106000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-107" decimals="-3" id="f-448" unitRef="usd">16888000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-108" decimals="-3" id="f-449" unitRef="usd">14489000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-109" decimals="-3" id="f-450" unitRef="usd">17208000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-451" unitRef="usd">31076000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-10" decimals="-3" id="f-452" unitRef="usd">36129000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c-1" id="f-453">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units (&#x201c;RSUs&#x201d;) activity for the three months ended March&#160;31, 2025 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.181%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted&#160;Stock&lt;br/&gt;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant&#160;Date&#160;Fair&#160;Value&lt;br/&gt;(per share)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,493,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,016,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(564,701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(320,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,624,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c-5" decimals="INF" id="f-454" unitRef="shares">6493387</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-5"
      decimals="2"
      id="f-455"
      unitRef="usdPerShare">35.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-1" decimals="INF" id="f-456" unitRef="shares">2016004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-457"
      unitRef="usdPerShare">12.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="c-1" decimals="INF" id="f-458" unitRef="shares">564701</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-459"
      unitRef="usdPerShare">47.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="c-1" decimals="INF" id="f-460" unitRef="shares">320043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-461"
      unitRef="usdPerShare">38.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c-4" decimals="INF" id="f-462" unitRef="shares">7624647</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-4"
      decimals="2"
      id="f-463"
      unitRef="usdPerShare">28.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-464">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity for the three months ended March&#160;31, 2025 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock&#160;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,594,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(277,212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96,812)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,220,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-5" decimals="INF" id="f-465" unitRef="shares">4594582</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-466"
      unitRef="usdPerShare">45.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-467" unitRef="shares">277212</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-468"
      unitRef="usdPerShare">1.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-469" unitRef="shares">96812</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-470"
      unitRef="usdPerShare">52.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-471" unitRef="shares">4220558</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-472"
      unitRef="usdPerShare">48.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-110" decimals="0" id="f-473" unitRef="shares">561603</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-111" decimals="2" id="f-474" unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-111" id="f-475">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <txg:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage contextRef="c-112" decimals="2" id="f-476" unitRef="number">0</txg:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage>
    <txg:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage contextRef="c-113" decimals="2" id="f-477" unitRef="number">2</txg:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-114" decimals="2" id="f-478" unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-114" id="f-479">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <txg:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage contextRef="c-115" decimals="2" id="f-480" unitRef="number">0</txg:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage>
    <txg:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage contextRef="c-116" decimals="2" id="f-481" unitRef="number">2</txg:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMultiplierPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-117"
      decimals="2"
      id="f-482"
      unitRef="usdPerShare">10.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-118"
      decimals="2"
      id="f-483"
      unitRef="usdPerShare">13.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c-119" decimals="-5" id="f-484" unitRef="usd">100000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-485">&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimated the fair values of shares granted under the market-based TSR PSUs using a Monte Carlo simulation model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-120" decimals="2" id="f-486" unitRef="number">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-120" decimals="3" id="f-487" unitRef="number">0.040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-120" decimals="2" id="f-488" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-121"
      decimals="INF"
      id="f-489"
      unitRef="shares">219168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-122"
      decimals="INF"
      id="f-490"
      unitRef="shares">4909589</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="c-123" decimals="2" id="f-491" unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="c-124" decimals="0" id="f-492" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="c-125" decimals="0" id="f-493" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-126"
      decimals="INF"
      id="f-494"
      unitRef="shares">3928014</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-495">Net Loss Per Share&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.181%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,220,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,604,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,624,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,578,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares committed under ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,282,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,299,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-496">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.181%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.518%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,220,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,604,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,624,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,578,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares committed under ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,282,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,299,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-127" decimals="0" id="f-497" unitRef="shares">4220558</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-128" decimals="0" id="f-498" unitRef="shares">5604160</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-129" decimals="0" id="f-499" unitRef="shares">7624647</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-130" decimals="0" id="f-500" unitRef="shares">5578818</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-131" decimals="0" id="f-501" unitRef="shares">436873</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-132" decimals="0" id="f-502" unitRef="shares">116883</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-503" unitRef="shares">12282078</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-10" decimals="0" id="f-504" unitRef="shares">11299861</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-505">Subsequent Event&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 6, 2025, to decrease its costs and adjust its organizational structure to align with its strategic priorities, the Company committed to a reduction in force that is expected to result in the termination of approximately 8% of the Company&#x2019;s global workforce. In connection with the reduction in force, the Company currently estimates it will incur between $5.5&#160;million and $6.5&#160;million of costs consisting primarily of cash severance costs which the Company expects to recognize in the second quarter of 2025 and pay by the end of third quarter of 2025. The estimates of costs and expenses that the Company expects to incur in connection with the workforce reduction are subject to a number of assumptions and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the workforce reduction.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent contextRef="c-133" decimals="2" id="f-506" unitRef="number">0.08</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringCharges contextRef="c-134" decimals="-5" id="f-507" unitRef="usd">5500000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-135" decimals="-5" id="f-508" unitRef="usd">6500000</us-gaap:RestructuringCharges>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-1" id="f-509">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-510">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-511">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-136" id="f-512">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 12, 2024, Serge Saxonov, Chief Executive Officer, adopted a Rule 10b5-1 trading arrangement that was intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 35,600 shares of the Company&#x2019;s common stock plus up to 136,000 carryover shares from a prior 10b5-1 plan. The expiration date of the trading arrangement was December 31, 2025. On March 4, 2025, the trading arrangement was terminated at the election of Dr. Saxonov.&lt;/span&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrIndName contextRef="c-136" id="f-513">Serge Saxonov</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-136" id="f-514">Chief Executive Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-136" id="f-515">true</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-137" decimals="0" id="f-516" unitRef="shares">35600</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-138" decimals="0" id="f-517" unitRef="shares">136000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrTerminationDate contextRef="c-136" id="f-518">March 4, 2025</ecd:TrdArrTerminationDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
